<SEC-DOCUMENT>0001628280-22-004101.txt : 20220228
<SEC-HEADER>0001628280-22-004101.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228091144
ACCESSION NUMBER:		0001628280-22-004101
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mersana Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001442836
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38129
		FILM NUMBER:		22684283

	BUSINESS ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-498-0020

	MAIL ADDRESS:	
		STREET 1:		840 MEMORIAL DRIVE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MERSANA THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080813
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mrsn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f,d:54c829abb8e046e0ba4639af9592e947--><html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:mrsn="http://www.mersana.com/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrsn-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xNi0xLTEtMS0xNDM0Mg_b30060a3-52bb-40d6-ab8a-5d87efb69256">0001442836</ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xOC0xLTEtMS0xNDM0Mg_14d1b3ea-ce46-464d-a6a3-37f4d069ee20">2021</ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xOS0xLTEtMS0xNDM0Mg_f83e2399-28c8-4040-b4eb-bc51b3fa154e">FY</ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18yMC0xLTEtMS0xNDM0Mg_3136b473-2503-4c8c-98e2-1bd56c8b486b">false</ix:nonNumeric><ix:nonNumeric contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrsn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3e7551cb27b48f7ae6ca63cb9d0f3a0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7fc42ca8bd44444faceba42910feb1ec_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1b5567939ee84f85a796f7340017d974_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81852bd3e7134038a2f1b0bf58ab6969_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i514791eca1f44909a5e5f94b71ea3a98_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99fce85f8b8644a3b03a21943edd68ed_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5086b7eefe4a4fd9a4cd20e7feb840a8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9be11c24e8ce4dcf855d9e19a0e8605d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1625de5080394e76934616170e525c3e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2263e5f0b5374b6eb63797459412baea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5079a121336542a2ad5e6a69a5d2da56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73784c7eb6bd4fecafcc0ade4d41a8ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e630e58b154d58ada0eb8b3903547b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie614b7c768c042aba10411ce72a641cd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c64af17ca343848603ecfba6316570_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0901ec303026453cb60c34b79bfee33d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01fe62fe6f7e48d490b1f867f9484c23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be31f3383e848e98115c2ab8721f353_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic668054d04aa44eeb592807dc2bc4b8a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08fa6f9dba864472a6d18ffa609a28c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67df1b00583c408f8c9ae48510a0ca54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8074fd8df0f64ee79d269ef09013964b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2978fef777442ca8ce412714c126f1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316531b1bea0420aa2f2b09a689cd4aa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03e3cf73141c45a28882cef716068d1d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47e4c776ea1e49f19f94fa71ab035bad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e856d009884f45bf3990d70080916f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i416501272258413a9fbcffc3613015f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72f092e073f4caea321165cbb01d83d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e7ad9dfbc0149afaf920277bb3301a3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c71214218f46bb9d5a65ebdabaa5e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63559c339ac14a4f808281cc61d2e001_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e350e8b8c7c4fad8a6f1dbcaef3d9c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i57c7504cae894df18aaaa3b793ed4bcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5cd2bc576a64407b348ad9bfc065f8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4fdc5ae4df447da4c58088b9961c67_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1588dcb89e4bfa84977ab490cf0417_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48c7830bb0b0416eb5d577f21baf0aac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97077e4c81a481a8647699765887a0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667df8466ca44fb6a82fd19ed57ff48f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida5a046a9dbb4cc0988324aea0d475c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62083aff246944c9b4984de9c9c1ef1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809dbadb11db4e24afbe3cdcfe4f79d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f98a71f7de2423c9004b46d1a094d47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57bf8dc50aad4550b09f65fd101d5b8e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2289a4965c8d4c269148c6c1a7f94f33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311ddb6991d8496f92c657e71d74c7e1_D20140601-20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-06-01</xbrli:startDate><xbrli:endDate>2014-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb13aee4e814a53a64da4507bad3321_I20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="target"><xbrli:measure>mrsn:target</xbrli:measure></xbrli:unit><xbrli:unit id="milestone"><xbrli:measure>mrsn:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i4af5ca3b68bb4ed7b6a33a6008c3ab69_D20150101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i691905a855ea444a81cdb006aa684830_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9790c299a9564e76a73c4df8750539ba_I20180101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic09d46e0ab9d49a69193af570876fd88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22751430a1af485c87dd79584475d813_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724be6926e0f43708c3842a241f2b234_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic393ee0337764f848b485d8f53c57f94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8719cb8746fc444a8b30ec920ba9e272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a96471c63a400b9ce4997aa4039334_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i266b15fef82f4d77ab6acfccdce49876_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c1155ad2bf48ed93491e3ec3ff0c2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578ab44d714748d09da2b37adc7d98a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c642871deec4bf2ae3f141820fc4f9c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e3153e090a41668aa9d9e117b855f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7616293f91948f28dd309eb148c545e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib939e9ec9abd4ac39881b2e5f6f0a6f4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ce0872b58f0463c95884113a6545230_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf84ce2b240441789956b1e89bcf4595_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0a4b79107a46de82588501551a7baa_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd81097c435142008a0e8197ddc84278_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26419f71b3384c04a3f6605f62bc5c57_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>mrsn:agreement</xbrli:measure></xbrli:unit><xbrli:context id="iccb4e2fad20448bcb47f9ece79c43d47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f3b11dfbc64275ac3f70f6dc51c46b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie83b8c61371748b8a4dad5a60b07f3eb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49b1abd1d2b641b89c50bc6d8090ae6a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8221344b85a746f1bbc5dd99c40db4af_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01be325b8014d11a057d07ade151aab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc721e5fefa54193b4555f316c8c4e98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3cf57eb0c394db486c86ab2341698c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27da38d053440e3a567adb14304e888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ca22aff95e471781a54f27faf5c489_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0a4f6ba5534268909637379ffb82d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66a2e3ad74d845418bc9e56f04eed7ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376e781b4402454fa5e969dd3afdcc1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781aa82fa62448f7922e5f7b324d73f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05eab9496cd948acb8f286ed906bc0da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia64cb818b4e64c72b7ce08b160086366_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife05150f2ac84983998d474cda265a0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ac06dbc12246b49e2a5075fae37c0f_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0db434ef0b14ed0861021376bc27afa_I20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab899b1838874099a8e5ac2ff7777f3b_D20190508-20190508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-08</xbrli:startDate><xbrli:endDate>2019-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4009d30c89524098b6f75ea92a8511f0_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f44c7208fa4c7f961ffd639310b35d_I20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf785a49089f45d398bf851be2b7932a_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2eadf722ff64d92ae9288bc5dfe2b84_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i712f21030d394390afd89dbcc6e8b06c_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096da856c8104fe6ab086e5efc3eec34_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc33cdd85a414f2cb35b3a6e5e998ca2_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i786194604a4b4117b25a3e6b81f087f9_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9ad9876d541413f801749cf53712cf7_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcf2d9fb74094c5991ba27cf6c512eda_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i422c756559014c5d9009424c3496c2ef_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27e84780e10842d2bd65ee2008d484a1_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd180a13515a4868acdde8a30e3a9cd9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8b569721ff344e2aa89e9d46ede08d2_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42af7c89af7b48a79ad2c8608164b77c_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6c994875ee643a9bdf93806ee028002_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursPriorToOctober292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecaffff610841b798a218f5d8f6512a_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursBetweenOctober292022AndOctober292023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c85f701a6a3492b83ae133b0f08ef74_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ea172aa94b48648314fda755ca7392_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:LendersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib909e4352d504cd6b40dc90f0dbdd2b3_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:ThirdPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54e050cde4d9454b8bfc4b3d17c5dc2a_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mrsn:AmortizedInterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:LendersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i649899397fe049798792f393cde3e4cc_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mrsn:AmortizedInterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:ThirdPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b33420048243f9a32ec5f4a1baff18_D20211029-20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrsn:CapitalizedOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-29</xbrli:startDate><xbrli:endDate>2021-10-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f02922d04244f98f6fa502e3378212_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffee20b1411845d4b0b9f086f3c189b9_I20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0c094572df4f53b6e958fe1bcfe81b_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828ebe879492478780a584c32808e4db_D20200501-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37036005f77a435e8823d902b65b4b26_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9e97774b6a4b27bd93e83aa57935c4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338c16ccd7cd41ef810857176b3cb944_I20131231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2013-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c6d26ecc5ca4927bf170e6f70476126_D20191126-20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-26</xbrli:startDate><xbrli:endDate>2019-11-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d00f365edee446b858df5048d05be98_I20191126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1c0f959152f49bbb6f2f1b5870fdd72_D20200302-20200302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-02</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>mrsn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i6e2b696bd2b946689884d6db1dbaebcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e33d28def5e47e48376a78023729e2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2b446a5705439d8204e2db3af84557_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2836cc08d6b440048b685415e74ef94a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcfae73b76f849c2beedf48b3fd3ddb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed739e482d84b91bdcedea1d7aa35da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a2b387a4dd4de5a44607493ebe2f7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica825e7423074dfd9b2d51c5b1e0acfa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737243bf173d4209a6e2039ac6c813f9_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eec540f391a482b8cf41ac59c16c58d_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec75714d1fa4db7ab67c66b6d110b6e_D20170601-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-06-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71270946b0347db9fb2c7e2adb5eb55_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34baed2717f54091a1033f9099b12641_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fac48995f2c4c16a220008833e49a01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c201fa2273b4d5692775bfe687ff519_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaff1344197a4f7f88291b1ff2549f0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90621fb17914192b3cc20226646f468_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c64324e16174923bd142062def84677_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1147f1b66d4b6bae33bea0cccbebbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67789eba647e4e8f9ca09e243889e50e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d675eb3e6d43b4bf7380c997407796_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58196efabc4455dbc9f56d50edcfad0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2375a12808cf4680aa725acb17071871_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace44621dbb84817a2c5f4a3278c74ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b915dd88e74298a6e79a691ceb3e41_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac3651a9b134a21b2606a2b6c456826_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995f53d89db1431783ca696f65ff827c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ac073dc733f464e923ffe588304cf3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b69daa12d7d496a8e30d2f4f904d645_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87d0d7495bf34973b75e45d3a456802f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76db584e2a3847a19b4d09782ea823f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b750e97432649f8902f0c0b2b12632e_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18e0acc3be3c4a918d77e823eeaf9a9b_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1dc96fa4ed842f4aedd626c47454440_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8f204b2f8f47c883a50a6b32629116_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c8751ae82ab48e580bd5035e380db22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16df4d7be5d45f09336d071d6b927ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9166def068646cba741aa6d728d2b9c_I20210405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceExpansionCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a8cc110a0642b68c553e48f18a1285_D20210405-20210405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceExpansionCambridgeMaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a56f442c69248c78859ce174629ab21_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i038ae3a73230483884690b9a78423777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17d87454f6c4db7839bfac2ed9aa926_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c467d1b1b6423e92438fcea0715adb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673a5d42881e4cb3b1331529587e448a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a07a4efd2d24b99831852b517363a51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6461b8d4e239490992a75468dcd510eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jurisdiction"><xbrli:measure>mrsn:jurisdiction</xbrli:measure></xbrli:unit><xbrli:unit id="audit"><xbrli:measure>mrsn:audit</xbrli:measure></xbrli:unit><xbrli:context id="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f43b37474ae4a6eae2f68ccd01a3200_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf265381e7674d2ea77457e88a5120d9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13441f134534f4b8413f2279bfe29f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1b55d99d3a4d06949a1920a27b38ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i705217f95c8147c9a0aef1b16e6593b9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia138aba2a3b3406494fad2a37a13b0ee_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib699aaf9d802436e8631493e14953d6c_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentAndRegulatoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ee2b32513f4e59b994d6020d4f8ef4_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89e4886837f24a38b80b1747ed92ef46_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:SynaffixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6fa9d8c34a04518a93d648eb4c54a81_D20220101-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa034c85dbc456988299ee454032879_D20220101-20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7884cd54894446b89c3403a61b91a97_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001442836</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i54c829abb8e046e0ba4639af9592e947_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEy_458933e5-d883-4908-a432-7ecc34167990">10-K</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAw_4b6b80c2-1137-40b5-a617-d065ade6f4d7">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yMTQ_9a611f80-7233-4fda-b5a0-2455f3c82a0e"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yMTQ_71eddbf8-e55e-407e-b707-9cccf173cf2f">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric>.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA2_94e65d35-f728-4187-adcd-96f0dd9f8ca2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDE1_a877bc77-280c-4f7d-ad0f-5f0fd9885491">001-38129</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA4_53e2ace6-eba3-4915-9df9-d7d9353045d8">Mersana Therapeutics, Inc.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8wLTAtMS0xLTE0MzQy_82bcd39f-5f3f-47cb-a1f6-6edbf07324e2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8wLTItMS0xLTE0MzQy_da4f2f3a-548e-4b4b-bb94-bcaecc6b7977">04-3562403</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfNA_76ba928a-16ef-4160-bf57-bdda1d88ec99">840 Memorial Drive</ix:nonNumeric> <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfNw_ec3263ab-6063-4cd6-810a-649af78d6a16">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfMTE_9b788638-f8b7-4f07-8725-4fd482055dd7">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTItMS0xLTE0MzQy_3b9e688e-a6e9-4eb5-a8ea-d8f27949b0e3">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA5_31e476ee-9b37-4dc3-a318-fb2e2edcb5e7">617</ix:nonNumeric>) <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEw_94e5322a-5778-4710-b364-0054555c6f3c">498-0020</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTAtMS0xLTE0MzQy_7d880790-878f-419a-b1cb-74efd02fbc44">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTEtMS0xLTE0MzQy_bd4c5439-1114-4bfa-851b-b454ccdaad4c">MRSN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTItMS0xLTE0MzQy_a1bac47b-e859-4de7-8339-19aba1a29998">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NONE</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF80Mzk4MDQ2NTE2NjQz_0f2f0267-8d5e-4f80-8f54-82eb0077a564">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAx_acdb2f88-8857-45e6-92eb-ef31f3057094">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMzk4_e14cb182-248a-4289-8829-fff6fcd747f8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMzk5_ae0b8031-82a4-4b25-ac07-b5459b85c0ae">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8wLTAtMS0xLTE0MzQy_7f54c532-affc-4c26-9f84-17f702f714b7">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8xLTMtMS0xLTE0MzQy_2092d6be-30e6-42bd-830b-31ffe720ff82">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8yLTMtMS0xLTE0MzQy_a0bc76a1-b483-453a-b231-013c6ef7588c">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEx_f037ca0a-ffd1-45e9-a4e5-0c06ca1876ec">&#9746;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined by Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDE2_169f730d-6617-4616-abd2-73652ea43f08">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was $<ix:nonFraction unitRef="usd" contextRef="ia3e7551cb27b48f7ae6ca63cb9d0f3a0_I20210630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yOTky_62a09884-18fe-474e-b16b-1c40d738df7a">799,836,646</ix:nonFraction>, based on the last reported sale price of such stock on the Nasdaq Global Select Market as of such date.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;25, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i7fc42ca8bd44444faceba42910feb1ec_I20220225" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMTI5_99082ccc-303d-4a55-90e9-615ccc2ff77b">83,389,806</ix:nonFraction> shares of common stock outstanding at a par value $0.0001 per share.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAz_c22ff07e-06f0-458e-bd7e-6493307dbabb" escape="true">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.732%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_10">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_13">FORWARD LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_13">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_16">ITEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_16">BUSINESS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_16">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_19">ITEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_19">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_19">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_22">ITEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_22">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_22">79</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_25">ITEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_25">PROPERTIES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_25">79</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_28">ITEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_28">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_28">79</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_31">ITEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_31">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_31">79</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_37">ITEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_37">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_37">80</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_40">ITEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_40">[RESERVED]</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_40">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_43">ITEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_43">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_43">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_67">ITEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_67">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_67">93</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_70">ITEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_70">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_70">94</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_154">ITEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_154">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_154">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_157">ITEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_157">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_157">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_160">ITEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_160">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_160">125</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_160">ITEM 9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_160">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_160">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7146825582202">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_7146825582202">126</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_163">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_166">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_166">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_166">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_169">ITEM 11 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_169">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_169">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_172">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_172">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_172">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_175">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_175">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_175">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_178">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_178">PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_178">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_181">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_184">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_184">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_184">128</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_187">ITEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_187">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_187">128</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_190">EXHIBIT INDEX</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_190">129</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_193">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_193">132</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i54c829abb8e046e0ba4639af9592e947_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REFERENCES TO MERSANA</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, the &#8220;Company,&#8221; &#8220;Mersana,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Mersana Therapeutics, Inc. and its consolidated subsidiary, and &#8220;our board of directors&#8221; refers to the board of directors of Mersana Therapeutics, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS AND INDUSTRY DATA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. The words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;on track,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements include, among other things, statements about:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, cost, timing, progress and results of our current and future research and development activities, preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adequacy of our inventory of upifitamab rilsodotin (UpRi) and XMT-1592 to support our ongoing clinical trials, as well as the outcome of planned manufacturing runs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unmet need of ovarian cancer and non-small cell lung cancer;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to quickly and efficiently identify and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance any product candidate into, and successfully complete, clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position, including with respect to our trade secrets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic partnership agreements and our ability to enter into selective strategic partnerships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements, the sufficiency of our current and expected cash resources and our need for additional financing; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the ongoing COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic could adversely affect our preclinical and clinical development efforts, business operations and financial results. The extent of the impact and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the emergence of new variants of the virus, travel restrictions, quarantines, physical distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements contained herein represent our views as of the date of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. We anticipate that subsequent events and developments will cause our views to change. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K may include industry and market data, which we may obtain from our own internal estimates and research, as well as from industry and general publications and research, surveys, and studies conducted by third parties. Industry publications, studies, and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third&#8209;party sources.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to varying degrees of risk and uncertainty. Investors should consider the risks and uncertainties summarized below, as well as the risks and uncertainties discussed in Part I, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Annual Report on Form 10-K. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to the following principal risks and uncertainties:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that we will continue to incur substantial operating losses for the foreseeable future.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a credit facility that places certain restrictions on our operating and financial flexibility.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before, or more successfully than, we do.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We only have two product candidates, upifitamab rilsodotin (UpRi) and XMT-1592, in clinical trials. A failure of any of our product candidates in clinical development could adversely affect our business and may require us to discontinue development of other product candidates based on the same technology.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We can provide no assurance that our clinical product candidates will obtain regulatory approval or that the results of clinical trials will be favorable.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug discovery and development is a complex, time-consuming and expensive process that is fraught with risk and a high rate of failure. We can provide no assurance of the successful and timely development of new antibody drug conjugate, or ADC, products.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to attract and retain senior management and key scientific personnel, we may be unable to successfully develop our product candidates, conduct our clinical trials and commercialize our product candidates.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of our operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely upon patents and other intellectual property rights to protect our technology. We may be unable to protect our intellectual property rights, and we may be liable for infringing the intellectual property rights of others.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20&#160;years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to develop ADCs designed to have improved efficacy, safety and tolerability relative to existing ADC therapies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative platforms, including Dolaflexin and Dolasynthen, delivering our proprietary auristatin DolaLock payload, as well as Immunosynthen, which delivers our novel proprietary stimulator of interferon genes, or STING, agonist ImmunoLock payload, together comprise a highly efficient product engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical studies and clinical trials include first-in-class molecules that target multiple tumor types with high unmet medical need. Our belief is that our novel ADCs may have more favorable safety and efficacy compared to more traditional existing ADCs developed using first-generation technology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled a management team with extensive and relevant experience, including specific ADC experience, from prior work at leading pharmaceutical companies such as Millennium Pharmaceuticals, Inc., Takeda Pharmaceuticals, Inc., Bayer AG, Tesaro, Inc., Vertex Pharmaceuticals Inc., Cubist Pharmaceuticals Inc., Bristol Myers Squibb, Constellation Pharmaceuticals, Inc., Sanofi S.A., GlaxoSmithKline plc, Centocor Inc., Sunovion Pharmaceuticals Inc. and Momenta Pharmaceuticals, Inc. We are supported by our board of directors and scientific advisory board, who offer complementary experience in drug discovery and development, as well as expertise in building public companies, management and business development. We believe that our highly differentiated platforms, together with the team we have assembled, position us well to discover and develop life-changing ADCs for patients fighting cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC technologies and the experience and competencies of our management team to discover and develop promising ADC product candidates and to commercialize cancer therapeutics that address unmet medical needs or provide significant benefit to patients. Key components of our strategy to achieve this goal are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strive to Build UpRi (upifitamab rilsodotin) into a Foundational Medicine in Ovarian Cancer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, upifitamab rilsodotin, which we refer to as UpRi, is a first-in-class Dolaflexin ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and other cancers. We are currently evaluating UpRi in platinum-resistant ovarian cancer in a single-arm registrational trial, which we refer to as UPLIFT, for which we expect to complete enrollment in the third quarter of 2022. We are also conducting a Phase 1/2 umbrella combination trial, which we refer to as UPGRADE. The first combination we are exploring is the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer. We may explore other combinations in the future. We expect to report interim data from UPGRADE in the second half of 2022. In the second quarter of 2022, we expect to initiate enrollment in a randomized placebo-controlled Phase 3 trial, which we refer to as UP-NEXT, to evaluate UpRi as single agent maintenance treatment in patients with platinum-sensitive ovarian cancer that have high NaPi2b expression. Together, data from these trials have the potential to establish the safety and efficacy of UpRi across a wide range of ovarian cancer patients, from those who are platinum-resistant and heavily pre-treated to those in earlier lines of the disease. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strive to Build Out Our Pipeline of Highly Impactful Cancer Medicines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our second clinical candidate, XMT-1592, is a NaPi2b- targeted ADC leveraging our Dolasynthen platform. Our strategy is to explore XMT-1592 as an alternative to UpRi in lung and non-small cell lung adenocarcinoma based on preclinical differentiation. We are conducting a Phase 1 dose exploration trial in patients with ovarian cancer and non-small cell lung cancer, or NSCLC, which we expect to complete in the second half of 2022. Additionally, we are advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, an antigen selectively expressed on tumors in areas of high unmet medical need including breast, endometrial and ovarian cancers. We expect to initiate a phase 1 clinical trial of XMT-1660 in solid tumors in mid-2022. Moreover, we have taken ADCs beyond cytotoxics by developing our Immunosynthen platform which may allow tumor-targeted activation of the innate immune system. XMT-2056, an ADC targeting a novel HER2 epitope that is different from those targeted by currently available HER2 therapies, is our first product candidate based on our Immunosynthen STING-agonist platform. We expect to initiate a Phase 1 clinical trial of XMT-2056 in solid tumors in mid-2022. We believe that each of XMT-1660 and XMT-2056 may provide opportunities in areas of high unmet need including, without limitation, breast cancer and other tumor types.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strive to Build Innovation and Scientific Leadership in ADCs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We intend to establish a leading position in the field of ADCs by continuing to advance platform innovations that further broaden the potential for our ADCs to be first and best in class medicines that deliver clinically meaningful benefit to cancer patients and by pursuing fast-to-market opportunities in areas of high unmet medical need. In addition to the product candidates described above, we also have two earlier stage preclinical candidates, which we refer to as XMT-2068 and XMT-2175, both of which leverage our Immunosynthen platform and target tumor-associated antigens. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Strive to Build Mersana as a Top Employer and Strategic Partner. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We aim to attract and retain talented team members with deep experience in drug discovery, development, manufacturing, and commercialization as well as in general business and administration. Our team is driven by a shared passion to advance therapies that make a significant difference in the lives of cancer patients. We will continue to cultivate the collaborative and passionate workplace culture that has allowed us to advance this mission. We also aim to leverage our technical expertise and experience with respect to our innovative and diversified platforms, Dolaflexin, Dolasynthen and Immunosynthen, to attract and cultivate strategic partnerships that facilitate our ability to bring differentiated product candidates to patients. We have established strategic research and development partnerships with Janssen Biotech, Inc., or Janssen, and Merck KGaA for the development and commercialization of additional ADC product candidates leveraging our proprietary Dolasynthen and Dolaflexin platform technologies against a limited number of targets selected by our partners. We believe the potential of our ADC technologies, supported by our scientific and technical expertise and enabled by our intellectual property strategy, all support our independent and collaborative efforts to discover and develop life-changing ADCs for patients fighting cancer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pipeline is summarized in the chart below:</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20211231_g1.jpg" alt="mrsn-20211231_g1.jpg" style="height:323px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADCs are a validated therapeutic modality in oncology with 11 products approved for use by the Food and Drug Administration, or the FDA, and over 100 being tested in clinical trials. We believe that the field has not yet realized its full potential because first generation ADCs have several limitations and platform innovation has been limited. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of first generation ADCs is to deliver cytotoxic therapy specifically to neoplastic cells while sparing normal tissue. An ADC consists of three components: the antibody, the cytotoxic payload, and a linker to join the two. The antibody portion of the ADC achieves specific targeting by binding to an antigen that ideally has high expression on the surface of the tumor cells, and low expression in healthy tissues. Once the antibody binds to the target, the ADC enters the cell, and the payload is typically released killing the cell. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payload, the drug-to-antibody ratio, or DAR, the linker, and conjugation site of the linker with the antibody all can influence the overall efficacy and tolerability of ADCs. There has been limited innovation in these ADC components since the development of first-generation ADC platforms. We believe optimizing an ADC requires developing payload(s) with optimal properties, varying DAR for a specific target, and optimizing the conjugation site, all of which can contribute to the overall drug-like properties. We believe that our proprietary platforms improve upon first-generation ADC approaches in these aspects and have the potential to advance the field and improve patient outcomes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Technologies and Platforms</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of ADCs is not a one-size-fits-all approach. In fact, a number of diverse factors impact the properties of an ADC, including payload, DAR, site of conjugation and homogeneity. For each target antigen, there may be an optimal combination of these factors. Our novel and highly differentiated platforms are designed to allow us to optimize these properties for a given target and develop ADCs that are designed to best address patient needs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DolaLock Payload</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the cytotoxic payload we use with our Dolaflexin and Dolasynthen platforms as our DolaLock payload. Our DolaLock payload is a proprietary auristatin cytotoxic drug and is a highly potent anti-tubulin agent selectively toxic to rapidly dividing cells. The DolaLock payload has been shown in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preclinical studies to control the bystander effect by locking the cytotoxic drug inside cells after allowing a short period of antigen-independent diffusion throughout the tumor. As the drug diffuses through neighboring cells, the DolaLock payload is metabolized to a form that is still highly potent but is designed to no longer be able to cross the cell membrane, thereby controlling the bystander effect for a potentially safer and more effective cancer therapy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A common mechanism of resistance in cancer is the up-regulation of multi-drug resistance, or MDR, pumps, such as P-glycoproteins, or PgPs, which actively pump drugs out of cancer cells to help them survive. Once metabolized, our DolaLock payload is not a substrate for PgPs, thereby avoiding this resistance mechanism. Our DolaLock payload, with its controlled bystander effect, is designed to enable the creation of ADCs that have the potential of being highly potent, well-tolerated and specifically-targeted cancer therapies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our proprietary auristatin payload has also been shown in preclinical studies to cause immunogenic cell death and to stimulate the immune system through dendritic cell activation. Because of this, we have observed synergy with immuno-oncology agents such as PD-1 inhibitors in preclinical models.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dolaflexin Platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dolaflexin platform was designed to increase the efficacy, safety and tolerability of ADCs. Dolaflexin utilizes our proprietary Fleximer polymer, a biodegradable, highly biocompatible, water-soluble polymer that is able to carry multiple payloads. Instead of direct conjugation to an antibody, payloads are attached through an optimized, cleavable linker to the Fleximer scaffold, which is then conjugated to the antibody through a non-cleavable linker. Our Fleximer polymer has demonstrated dramatically improved drug solubility, pharmacokinetics and immunogenicity, and an increased number of payloads carried by each ADC as compared to other ADC therapies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we believe Dolaflexin has the potential to offer the following benefits relative to first generation ADCs:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Proprietary DolaLock Payload:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Dolaflexin is loaded with our proprietary auristatin cytotoxic drug, which is a highly potent anti-tubulin agent and that is selectively toxic to rapidly dividing cells and has a controlled bystander effect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Higher Drug-to-Antibody Ratio:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Historically, ADCs have been limited to a DAR of 3-4. The Dolaflexin platform can deliver ADCs with DAR of approximately 10, which has enabled ADCs created using this platform to demonstrate greater preclinical efficacy while also maintaining pharmacokinetics and drug-like properties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expanded Range of Addressable Tumor Targets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The higher DAR enabled by Dolaflexin results in a higher amount of cytotoxic drug released into the tumor cell for every ADC that is internalized. As a result, we believe that Dolaflexin ADCs may demonstrate efficacy against tumor targets with lower levels of antigen expression where traditional ADCs have not been effective.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these advantageous characteristics of our Dolaflexin platform provide a substantial opportunity to develop clinically meaningful ADC therapies with potential to address a broader range of cancers than first generation ADC-based approaches. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead clinical candidate, UpRi, is a Dolaflexin ADC that targets NaPi2b. We are currently evaluating UpRi in the UPLIFT and UPGRADE trials and expect to initiate the UP-NEXT trial in the second quarter of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dolasynthen Platform</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Dolasynthen platform enables an iterative approach to designing customized ADCs for a given target while retaining the properties of Dolaflexin, including the use of our proprietary DolaLock payload for a controlled bystander effect. Dolasynthen ADCs consist of a proprietary synthetic scaffold carrying an exact number of DolaLock payloads for precise control of DAR. The Dolasynthen scaffold is then bioconjugated to the antibody in a site-specific manner. The Dolasynthen scaffold has been precisely designed to provide optimal water solubility, charge balance, linker stability and DAR which together offer an opportunity for our ADCs to have superior physicochemical and pharmacokinetic properties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illustrated by our preclinical data, we believe Dolasynthen ADCs have broad therapeutic potential as cancer therapies. Our preclinical data demonstrate the ability of the Dolasynthen platform to generate and identify the optimal ADC for a given target and antibody.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Dolasynthen offers the benefits of Dolaflexin, including the proprietary DolaLock payload, and has the potential to offer the following additional benefits relative to traditional ADCs:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Precise Control of DAR:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The optimal DAR may vary between different targets and antibodies. Dolasynthen uses a proprietary scaffold that allows for precise DARs between 2-24, enabling optimization of the DAR for specific antigens and antibodies.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Site-Specific Bioconjugation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The site of scaffold bioconjugation to an antibody impacts the overall properties of that ADC. Dolasynthen enables site-specific bioconjugation allowing further ADC optimization.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Homogenous ADC Development:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The DAR and antibody bioconjugation is consistent throughout ADCs developed with the Dolasynthen platform allowing for consistent and precise drug delivery to targeted cancer cells.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Increased Hydrophilicity:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The precise optimization of the hydrophilic moiety on Dolasynthen ADCs allows for increased aqueous solubility and enhanced pharmacokinetic properties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second clinical candidate, XMT-1592, is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells. We are conducting a Phase 1 dose exploration trial of XMT-1592 in patients with ovarian cancer and non-small cell lung cancer, NSCLC, adenocarcinoma which we expect to complete in 2022. XMT-1660, our B7-H4-targeted Dolasynthen ADC is currently in investigational new drug, or IND, -enabling studies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ImmunoLock Payload </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the STING agonist that is used as the payload with our Immunosynthen platform as our ImmunoLock Payload. It was designed to have very low cell permeability in order to control delivery and localization of its innate immune-activating effect. STING is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen ADCs carrying the ImmunoLock payload is driven by the targeted activation of the STING pathway in tumor-resident immune cells and in tumor cells, in a target dependent manner. STING pathway activation in both cell types within the tumor provides the potential for enhanced anti-tumor activity with a STING-agonist ADC compared to other innate immune approaches that activate only the immune cells and are not capable of activating the tumor cells.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Immunosynthen Platform</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond the delivery of traditional cytotoxic payloads and into targeted stimulation of the innate immune system. Through the tumor-targeted delivery of a novel STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability posed by the intratumoral or intravenous injection of free (unconjugated) STING agonists. We have generated preclinical data across multiple, diverse targets by creating Immunosynthen ADCs based on a variety of antibodies directed to those targets and evaluating them in a range of tumor models. In each case we have demonstrated significant anti-tumor activity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including complete tumor regressions) after a single low, well-tolerated dose. Additional characterization has demonstrated increased cytokine expression and immune cell infiltration in the tumor microenvironment, as well as the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">induction of immunological memory. We have demonstrated tolerability and characterized the favorable pharmacokinetic profile of Immunosynthen ADCs in non-human primates, after multiple intravenous doses and at exposures significantly higher than those required for robust efficacy in mice.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunosynthen ADCs have been designed to overcome the limitations of free STING agonists and to offer a highly differentiated approach from other innate immune activators due to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Non-Cell Permeable STING Agonist ImmunoLock Payload: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our novel and proprietary payload has very low cell permeability, remaining in the cell to which it is delivered by the antibody, where it can exert its effect.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Enhanced Pharmacokinetic Properties:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The prolonged pharmacokinetics of ADCs and active transport into tumor cells and tumor-resident immune cells can overcome pharmacokinetic and permeability issues of the free agonists, resulting in more robust and sustained activation of the innate immune response in the tumor.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Immunosynthen STING ADCs Provide Targeted Activation in Two Cell Types: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because STING, unlike other innate immune pathways, can be activated in tumor cells and tumor-resident immune cells, target-dependent delivery can result in innate immune activation of both cell types, providing potent and robust anti-tumor responses and the induction of immunological memory.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Together these features have the potential to improve therapeutic index by selectively activating the innate immune system in the tumor environment and minimizing activation in other tissues. We are building a pipeline of Immunosynthen ADC candidates applicable to a broad range of clinical indications. Our first Immunosynthen ADC development candidate, XMT-2056 targets a novel epitope of HER2 and we expect to initiate a Phase 1 clinical trial in mid-2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our product candidates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our platforms to develop a robust pipeline of product candidates with the potential of becoming clinically meaningful cancer therapies. Our pipeline strategy focuses on targets that have been biologically validated (either through ADCs or other modalities), where the advantages of our platforms may lead to clinically superior therapeutic benefits, where we have the potential to achieve first-in-class status, or where fast-to-market opportunities are available. Our lead product candidate, UpRi, is currently being evaluated in the UPLIFT and UPGRADE trials and we expect to initiate the UP-NEXT trial in 2022. Our next product candidate, XMT-1592, is being evaluated in a dose exploration trial. We are also advancing XMT-1660, a B7-H4-targeted Dolasynthen ADC, and XMT-2056, our first Immunosynthen ADC targeting a novel epitope of HER2, both of which are currently in IND-enabling studies. In addition, our partners have multiple ADC product candidates leveraging our Dolaflexin technology in various stages of development.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Upifitamab rilsodotin (UpRi): our NaPi2b-targeted Dolaflexin ADC</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi, a first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. We believe the NaPi2b antigen is broadly expressed in ovarian cancer and other cancers with limited expression in normal tissue. NaPi2b is a member of the SLC34 family of sodium-dependent transporters and plays an important role in maintaining phosphate homeostasis. We initiated a Phase 1/2 clinical trial of UpRi in December 2017 with the primary objectives of determining the recommended phase 2 dose and characterizing the efficacy, safety and tolerability and the secondary objective of assessing the correlation of the NaPi2b biomarker expression and efficacy. The dose escalation portion of the trial established 43 mg/m2 up to a maximum of approximately 80 mg as the maximum tolerated dose. The expansion portion of the trial evaluated two doses, 36 mg/m2 and 43 mg/m2, up to a maximum of 80 mg.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently no tests approved by the FDA to measure NaPi2b expression on tumor cells. Our initial clinical trials have not prospectively identified patients with NaPi2b-expressing tumors, but our development plan for UpRi includes the development of a proprietary immunohistochemistry assay to measure NaPi2b expression in tumors. Based on our retrospective evaluation of tumors collected in the dose escalation and expansion portions of our initial UpRi Phase 1 trial, we believe that high NaPi2b expression is present in approximately two-thirds of ovarian cancer patients. We intend to continue developing our assay in order to confirm the broad prevalence of NaPi2b expression in our target patient populations while correlating those expression levels with the efficacy observed in such patients. We are currently collaborating with a third party to create and obtain regulatory approval for our assay as a commercial companion or complementary diagnostic. We expect to use the assay to evaluate Tumor Proportion Score of greater than or equal to 75% (TPS75) to identify patients with high NaPi2b tumor expression and to help us enrich our data analyses based on biomarker expression.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the course of 2020, we presented early Phase 1 UpRi clinical data, including presentations at the American Society of Clinical Oncology and the European Society for Medical Oncology and at company presentations to investors. These data were from the dose escalation and expansion portions of our UpRi Phase 1 trial, and they demonstrated encouraging clinical activity in heavily-pretreated patients with a safety profile differentiated from those of first generation ADCs. In August 2020, the FDA granted Fast Track Designation for UpRi for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status. In January 2021 and in September 2021, we provided interim clinical data updates from our expansion cohort. The interim data presented in September 2021 was based on approximately 100 ovarian patients for efficacy analysis and an overall group of approximately 200 patients for safety evaluation. All of the data from these patients were from our ongoing Phase 1/2 clinical trial. These data supported UpRi&#8217;s clinically meaningful activity in heavily-pretreated ovarian cancer patients with an objective response rate, or ORR, of approximately 34%, including complete responses, in evaluable patients with high NaPi2b tumor expression. The data also showed that UpRi was generally well tolerated without the severe toxicities commonly seen with other ADCs such as neutropenia, ocular toxicities, or peripheral neuropathy. The most common grade 3 or higher adverse events reported in this heavily pretreated trial population included fatigue and transiently increased aspartate aminotransferase. Other adverse events of clinical interest included infrequent, generally low-grade pneumonitis that generally resolves with dose reduction, delay, discontinuation and treatment with steroids. Based on these safety and efficacy data and our population pharmacokinetics analyses of the overall group of approximately 200 patients administered UpRi as of the data cut off, we determined that the phase 2 recommended dose of UpRi is 36 mg/m2 up to a total dose of approximately 80mg. This is the dose that we are currently evaluating in UPLIFT. In November 2021, we announced that we had completed enrollment of a Phase 1/2 dose escalation cohort of NSCLC adenocarcinoma patients. Based on the data collected from that cohort, we deprioritized further monotherapy development in NSCLC, instead focusing on developing UpRi in ovarian cancer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we initiated UPLIFT which is enrolling patients with platinum-resistant ovarian cancer and with one to four prior lines of therapy, without regard to NaPi2b expression; however, we are confirming the potentially predictive role of the biomarker retrospectively using a novel diagnostic assay to identify patients with high NaPi2b expression. Patients with three to four prior lines of therapy may enroll without prior bevacizumab treatment, accommodating differences in bevacizumab use in early disease. The primary endpoint is ORR in the high NaPi2b patient population and the secondary endpoints are ORR in the overall population, as well as duration of response and safety. UPLIFT is ongoing with sites in the United States, Europe and Australia, and we expect to complete enrollment of approximately 100 patients with NaPi2b high expression and up to 180 patients overall in the third quarter of 2022. If we achieve positive results from UPLIFT, we believe that the trial may enable us to submit a Biologics Licensing Application, or BLA, for UpRi for the treatment of patients with platinum-resistant ovarian cancer with one to four prior lines of therapy, under the FDA's accelerated approval pathway.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we also initiated UPGRADE and began the umbrella trial with an initial evaluation of UpRi combined with carboplatin, a standard platinum chemotherapy used to treat patients with platinum-sensitive ovarian cancer, followed by UpRi monotherapy. The dose escalation portion of UPGRADE is intended to determine the recommended Phase 2 dose of UpRi in combination with carboplatin, and the dose exploration portion of this trial is intended to provide proof of concept for the combination. We expect to report interim data from UPGRADE in the second half of 2022. We believe data from UPGRADE will inform further development of UpRi in combination with other therapies used in platinum-sensitive ovarian cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to initiate UP-NEXT in the second quarter of 2022. The design of UP-NEXT was informed by discussions with the FDA and the Committee for Medicinal Products for Human Use, or CHMP. UP-NEXT could serve as a post-approval confirmatory trial, supporting the expansion of UpRi into earlier lines of therapy. We expect UP-NEXT to enroll platinum-sensitive ovarian cancer patients who have achieved a response or stable disease after platinum therapy. Eligible patients with BRCA mutation must have received prior treatment with poly adenosine diphosphate ribose polymerase, or PARP, inhibitor therapy. Additionally, eligible patients must have high NaPi2b tumor expression. In recognition of the unmet medical need and the lack of a standard of care for these patients, the trial will be randomized against placebo.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-1592: our NaPi2b targeted Dolasynthen ADC</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-1592 was created using our Dolasynthen platform and also targets tumors that express NaPi2b. XMT-1592 comprises the same proprietary NaPi2b antibody and potent auristatin DolaLock payload with controlled bystander effect as in UpRi, with the additional features that our Dolasynthen platform offers, including homogeneity, site-specific bioconjugation and precise DAR. Preclinically, XMT-1592 has shown a differentiated profile particularly in a NSCLC adenocarcinoma model, where data suggested it was four times more efficacious than UpRi, consistent with higher payload delivery to the tumor. Based on these preclinical data, we are exploring XMT-1592 as a potential opportunity in NSCLC adenocarcinoma. XMT-1592 is currently </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being evaluated in Phase 1 dose exploration trial in patients with ovarian cancer and NSCLC adenocarcinoma. We expect to complete dose exploration in the second half of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-1660: our B7-H4-targeted Dolasynthen ADC candidate</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-1660 is our B7-H4-targeted ADC created with our Dolasynthen platform. We believe the expression profile of B7-H4, a cell surface antigen, is well suited for our unique DolaLock payload. B7-H4 can be expressed on tumor cells and on immunosuppressive tumor associated macrophages, or TAMs, which may lead to additional processing of the ADC and more payload in the tumor environment. We believe DolaLock&#8217;s direct cytotoxic effect as well as its immunostimulatory effect through dendritic cell activation and immunogenic cell death are well suited to the biology of the B7-H4 target. We have generated favorable preclinical efficacy data and non-human primate tolerability data with Dolasynthen ADCs targeting B7-H4 with precise DARs of 2 and 6. We selected the DAR6 variant based on this preclinical data. We believe that targeting B7-H4 with XMT-1660 provides significant opportunities for development in areas of high unmet need such as breast cancer, endometrial and ovarian cancer. XMT-1660 is currently in IND-enabling studies, and we expect to initiate Phase 1 dose escalation for XMT-1660 in patients with solid tumors in mid-2022. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">XMT-2056: our First Immunosynthen ADC candidate</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-2056 is our first Immunosynthen STING-agonist ADC. As described above, the therapeutic rationale of an Immunosynthen ADC is to selectively deliver the STING agonist to tumor cells and tumor-resident immune cells in a target-dependent manner, while avoiding delivery to healthy tissues. XMT-2056 is designed to offer a differentiated and complementary therapeutic approach to the treatment of HER2-expressing tumors. XMT-2056 targets a novel HER2 epitope that is distinct from the epitopes targeted by trastuzumab or pertuzumab, providing an opportunity for development as a monotherapy as well as in combination with well-established or investigational anti-HER2 agents. In preclinical studies, XMT-2056 was generally well-tolerated in non-human primate studies with no clinical signs and no adverse findings in clinical pathology or histopathology after single and repeat intravenous doses. XMT-2056 is currently in IND-enabling studies, and we expect to initiate Phase 1 dose escalation for XMT-2056 in patients with solid tumors in mid-2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovarian cancer unmet need and epidemiology</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, ovarian cancer had incidence of approximately 314,000 and caused an estimated 207,000 deaths in 2020. With a U.S. incidence of approximately 21,000 and mortality of 14,000 in 2021 according to the National Cancer Institute Surveillance, Epidemiology and End Results Program, ovarian cancer was the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States. Diagnosis is made histologically, and evaluation is commonly performed following surgical removal of an ovary or fallopian tube or biopsies of the peritoneum. The ovarian cancer standard of care is characterized by initial surgery followed by platinum-containing chemotherapy followed by periods of either observation or maintenance. Nearly 85% of ovarian cancer patients typically relapse following initial treatment.&#160;Subsequent treatment depends on the depth and duration of response to initial platinum treatment. Ovarian cancer patients who progress within six months of completion of platinum-based therapy are considered to have platinum-resistant disease. Unmet medical need is significant for patients with platinum-resistant ovarian cancer as treatment options are mainly limited to single agent chemotherapies such as pegylated liposomal doxorubicin, topotecan and paclitaxel. Multiple Phase 3 trials of single agent chemotherapies in patients with platinum-resistant disease and one to three prior therapies have exhibited an overall response rate of 4-12% and median progression-free survival of 3-4 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With targeted agents approved in platinum-resistant disease increasingly being prescribed in earlier lines of therapy, the unmet need is expected to remain severe. Bevacizumab in combination with chemotherapy is indicated to treat a subset of platinum-resistant ovarian cancer patients with no more than two prior therapies but it is not always well-tolerated and has shown no overall survival benefit. Use of bevacizumab in combination with platinum-containing chemotherapy in the frontline and platinum-sensitive recurrent settings mean an increasing number of platinum-resistant patients are pre-treated with bevacizumab and are not candidates for additional bevacizumab combination treatment. More recently, PARP inhibitors have been approved for heavily-pretreated ovarian cancer including platinum-resistant disease. However, they are predominantly used in a subset of patients with cancers harboring BRCA1 and BRCA2 mutations. Similarly, use of PARP inhibitors in earlier lines of recurrent platinum-sensitive maintenance and more recently frontline maintenance therapy following platinum-based chemotherapy means an increasing number of platinum-resistant patients are pre-treated with PARP inhibitors and are not candidates for additional PARP inhibitor therapy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NSCLC unmet need and epidemiology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, lung cancer had an incidence of approximately 2.2 million and caused an estimated 1.8 million deaths in 2020. With a U.S. incidence of approximately 236,000 new cases and over 130,000 deaths in 2021, lung cancer was the deadliest form of cancer in the United States. The five year survival rate is less than 20% on average.&#160;Approximately 95% of all lung cancers are classified as either small cell lung cancer or NSCLC.&#160;NSCLC can be further divided into squamous or non-squamous. The majority of non-squamous NSCLC is classified as adenocarcinoma. These histological distinctions are important for proper staging, treatment and prognosis. For patients with NSCLC, initial treatment is largely determined by the stage of disease. Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable early-stage NSCLC. Locally-advanced NSCLC is treated by combinations of radiotherapy, immunotherapy, chemotherapy and surgery. The majority of patients present with inoperable disease.&#160;Metastatic NSCLC is managed with systemic chemotherapy and immunotherapy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standard of care is evolving for NSCLC with the introduction of immunotherapies for patients without oncogenic driver mutations and new targeted therapies for patients with EGFR, ALK, ROS-1, NTRK or BRAF mutations. For patients with metastatic disease without oncogenic driver mutations, frontline platinum-based chemotherapy is combined with or, depending on PD-L1 expression status, replaced by, immunotherapy using anti-PD-1 or anti-PD-L1 monoclonal antibodies. For patients with metastatic disease harboring oncogenic driver mutations, several generations of targeted agents are available with different resistance profiles. Frontline therapy is often followed by relapse and recurrence and treatment options for these patients are substantially more limited. The standard of care of docetaxel alone or in combination with targeted agents has an overall response rate of 14-23%, median progression-free survival of 3-4 months and median overall survival of 9-12 months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With PD-1 and PD-L1 inhibitors and next generation targeted therapies moving into frontline, the unmet need in recurrent lung cancer is expected to remain severe.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breast cancer unmet need and epidemiology</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide, breast cancer was the most common cancer with an incidence of approximately 2.3 million and estimated 685,000 deaths in 2020. The U.S. incidence was approximately 282,000 new cases with over 43,600 deaths in 2021. While patients with localized disease typically have a relatively good prognosis, the 5-year survival of patients with distant metastasis is only 29%. There are four main female breast cancer subtypes, which are, in order of prevalence: Hormone Receptor positive (HR+)/ Human Epidermal Growth Factor Receptor 2 negative (HER2-) (&#8220;Luminal A&#8221;), HR-/HER2- (&#8220;Triple Negative&#8221;), HR+/HER2+ (&#8220;Luminal B&#8221;), and HR-/HER2+ (&#8220;HER2-enriched&#8221;). Treatment choice is driven by both subtype and stage of disease. Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable early-stage disease. Some patients receive radiation therapy and/or systemic therapy post-surgery, with treatment choice driven by cancer subtype. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systemic therapy is the mainstay of treatment for metastatic breast cancer. Once again, the treatment choice is determined by cancer subtype and by what treatments patients have received previously. The primary treatment option for patients who are HR+ is endocrine therapy, including aromatase inhibitors. Patients who are HER2+ are usually treated with HER2 targeting agents such as trastuzumab and pertuzumab, among others. Other targeted agents that are used in metastatic breast cancer include CDK4/6 inhibitors, mTOR inhibitors, PARP inhibitors, PIK3CA inhibitor, immunotherapy and ADCs. Patients can also receive chemotherapies, alone or in combination with other agents. In addition, a number of new therapeutic options are under clinical investigation. Despite the availability of these treatment options, outcomes in metastatic breast cancer continue to be poor, and new treatments that improve survival and quality of life are urgently needed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic partnerships</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic partnerships with leading biopharmaceutical companies to advance Dolasynthen and Dolaflexin ADC product candidates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ADC platforms have broad applicability across a number of targets. In February 2022, we entered into a research collaboration and license agreement with Janssen Biotech, Inc., or Janssen, to collaborate on the discovery of Dolasynthen ADCs for up to three antigen targets utilizing Janssen&#8217;s antibodies, with Janssen leading development, manufacturing and commercialization worldwide. We refer to this as the Janssen Collaboration. Our primary objective in entering into the Janssen Collaboration was to collaborate with a leading global pharmaceutical company to further validate the potential of our Dolasynthen platform, to enable novel ADC product candidates, to provide near-term funding and to drive significant long-term value. We have also used strategic partnering to accelerate bringing Dolaflexin ADCs to patients. In 2014, we entered into a collaboration with Merck KGaA for the development and commercialization of ADC product candidates </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilizing Dolaflexin for up to six target antigens; we refer to this as the Merck KGaA Collaboration. In entering into the Merck KGaA Collaboration, our primary objectives were to collaborate with leading pharmaceutical company to further validate the potential of ADC product candidates utilizing Dolaflexin, as well as to provide near-term funding and to drive significant long-term value. Under these collaboration agreements, we own the rights to any improvements to our ADC platform(s). The details of our material existing strategic partnerships are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into the Janssen Collaboration pursuant to which we granted Janssen an exclusive license to use our proprietary Dolasynthen platform and other technology to develop, manufacture and commercialize antibody-drug conjugates directed to up to three targets selected by Janssen. Our responsibilities are to perform bioconjugation activities to create ADCs for Janssen based on antibodies provided by Janssen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also perform certain chemistry, manufacturing and controls development and early stage manufacturing activities for ADCs that Janssen progresses through development, up to and including the manufacturing of clinical drug substance, at Janssen&#8217;s cost. Except with respect to this limited manufacturing, Janssen will be responsible for the further development, manufacturing and commercialization of the ADCs developed under the Janssen Collaboration, including obtaining any necessary regulatory approvals, at Janssen&#8217;s cost.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen Collaboration, we received an upfront payment of $40 million. Certain development and regulatory milestones will also be payable by Janssen for the research programs, including upon certain discovery milestones, initiation of certain clinical trials, and regulatory approval of certain licensed products in certain geographies, with an aggregate total of up to $501 million in the event ADCs directed to all three targets are advanced by Janssen. In the event the ADCs developed by Janssen are commercialized, we are eligible to receive certain commercial milestones for each program upon the achievement of specified aggregate sales thresholds based on all ADCs for an applicable target, with an aggregate total of up to approximately $530 million in the event ADCs directed to all three targets are commercialized by Janssen. In addition, we are eligible to receive tiered royalties at percentages ranging from the mid-single digits to the low-double digits on future net sales of ADCs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Janssen Collaboration will remain in effect, unless earlier terminated, until the expiration of the last-to-expire royalty term for the last ADC. Royalty term means on an ADC-by-ADC and country-by-country basis, the period commencing upon the first commercial sale of an ADC in such country and ending upon the latest to occur of: (a) the date of expiration of the last royalty-bearing patent claim with respect to such ADC in such country; (b) the expiration of regulatory exclusivity for such ADC in such country, if any; and (c) the tenth (10th) anniversary of the first commercial sale of such ADC in such country. Upon the expiration of the royalty term with respect to an ADC in a country, Janssen&#8217;s license becomes a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the relevant platform technology and our interest in any joint technology to develop, manufacture, commercialize and otherwise exploit such ADC in such country.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA Collaboration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, we entered into the Merck KGaA Collaboration under which we formed a strategic partnership with Merck KGaA because of their expertise in oncology drug development. Under this agreement, we are responsible for generating ADC product candidates against Merck KGaA-selected target antigens. Merck KGaA received rights to select up to six target antigens, of which it has selected all six. Merck KGaA is responsible for generating antibodies against the target antigens, and we are responsible for generating Dolaflexin and conjugating this to such antibodies to create the ADC product candidates. With respect to each target antigen selected by Merck KGaA, we granted Merck KGaA an exclusive, worldwide license under certain of our Fleximer ADC-related patents and know-how to develop, manufacture and commercialize ADC product candidates directed to such target antigen. Merck KGaA is then responsible for the further development and commercialization of these ADC product candidates. In addition, if Merck KGaA advances candidates, we are responsible for manufacturing these ADC product candidates for good laboratory practices toxicology studies and Phase 1 clinical trials at Merck KGaA&#8217;s expense and Merck KGaA is responsible for all further manufacture of these ADC product candidates. Merck KGaA is required to pay its own costs in the development, commercialization and manufacture of these ADC product candidates and to reimburse us for our costs incurred in performing our research activities under this agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2021, we have received an upfront payment of $12&#160;million and milestone payments of $3&#160;million under the Merck KGaA Collaboration. If products are successfully developed and commercialized against all six target antigens, we would be entitled to receive future development, regulatory and commercial milestones of up to $777&#160;million. We are entitled to receive tiered royalties in the low- to mid-single digit percentages on net sales of products targeting Merck KGaA&#8217;s target </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antigens during the applicable royalty term if products are successfully developed and commercialized by Merck KGaA under the Merck KGaA Collaboration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Merck KGaA Collaboration will expire upon the expiration of the last royalty term for a product under the agreement in all countries or, if Merck KGaA does not designate any ADC product candidates produced by us under the agreement as preclinical development candidates, upon the expiration of the last-to-expire research program. The royalty term means, on a product-by-product and country-by-country basis, the period commencing upon the first commercial sale of a product and ending upon the later to occur of: (i)&#160;the expiration of the last Mersana patent right that covers or claims the exploitation of such product in such country, or (ii)&#160;10 years from the date of first commercial sale of such product in such country. Upon the expiration of each royalty term for each product on a country-by-country basis, Merck KGaA&#8217;s exclusive license will convert to a perpetual, non-exclusive, royalty-free license with respect to such product in such country. Merck KGaA may terminate the Merck KGaA Collaboration in its entirety or with respect to any target antigen for convenience upon 60&#160;days&#8217; prior written notice. Each party may terminate the Merck KGaA Collaboration in its entirety upon an uncured material breach of the agreement by the other party.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asana Biosciences collaboration agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2012, we entered to a collaboration agreement with Asana Biosciences, or Asana (by assignment from Endo Pharmaceuticals Inc.). Pursuant to the terms of this agreement, we used Asana&#8217;s novel antibodies to develop novel ADCs using our fleximer technology. Asana is responsible for product development, manufacturing and commercialization of any ADC products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic partnerships to access antibodies and develop new platforms to progress our proprietary pipeline</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our focus is to progress our proprietary pipeline of ADCs. For this reason, we have partnered with biotechnology companies that have the capability to generate high quality antibodies or that have existing antibodies that we can license for inclusion in our ADCs. We have also entered into license agreements with biotechnology companies that own certain patent rights and related know-how that enable us to develop new ADC platforms. These strategic partnerships have facilitated the acceleration of our proprietary pipeline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recepta license for the NaPi2b antibody</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, a Brazilian biopharmaceutical company, licensing Recepta&#8217;s NaPi2b antibody for use in UpRi and XMT-1592 and granting Recepta the exclusive right to commercialize UpRi and XMT-1592 in Brazil, which was amended in September 2021. We refer to this as the Recepta License. Under the Recepta License, Recepta granted us an exclusive license and sub-license with respect to certain patents licensed by Recepta from Ludwig Institute for Cancer Research and technology owned by Recepta to develop and exploit products containing Recepta&#8217;s NaPi2b antibody, including UpRi and XMT-1592, worldwide for the diagnosis, prophylaxis and treatment of human cancer. We granted Recepta an exclusive license under our rights in such patents and technology and certain of our ADC-related patents and technology to commercialize any such products developed by us, including UpRi and XMT-1592, in Brazil. We are responsible for using commercially reasonable efforts to develop and commercialize products under the Recepta License globally, with at least one trial site in our Phase 3 clinical trials, and at our own expense in certain major markets. Recepta may conduct development activities in Brazil at its own expense after providing us the opportunity to first conduct such activities at Recepta&#8217;s expense. If a product is successfully developed and commercialized by Recepta in Brazil, we will use diligent efforts to enter into an agreement for the supply of such products to Recepta for sale in Brazil.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Recepta License, we paid Recepta an upfront payment of $1 million during the year ended December 31, 2015 and are obligated to pay Recepta up to $65.5 million in development, regulatory and commercial milestones and tiered royalties in the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term if products are successfully developed and commercialized. Through December&#160;31, 2021, we have incurred $4.0 million and paid $2.8 million in development milestone payments. We are entitled to receive tiered royalties in the low- to&#160;mid-single digit percentages on net sales of products in Brazil until the expiration of the royalty term if products are successfully developed and commercialized. The royalty term means, on a product-by-product and country-by-country basis, the period ending upon the later of (i)&#160;with respect to products commercialized by Mersana, the expiration of the last-to-expire Recepta patent that covers the product in such country (including the term of any applicable supplementary protection certificate) or with respect to products commercialized by Recepta, the expiration of the last-to-expire Mersana patent that covers the product in Brazil (including the term of any applicable supplementary protection certificate) or (ii)&#160;10 years from the date of first commercial sale of such product in such country. Upon the expiration of each royalty term in each country for each applicable product, the exclusive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licenses granted to each party under the agreement will become fully-paid up and royalty-free. The Recepta License will remain in effect until otherwise terminated as set forth below. We may terminate the Recepta License for convenience in its entirety or on a country-by-country basis (except with respect to Brazil) or product-by-product basis upon 180&#160;days&#8217; prior written notice for a termination in its entirety or upon 45&#160;days&#8217; prior written notice for a termination in part. Each party may terminate the Recepta License in its entirety upon bankruptcy or similar proceedings of the other party, upon a patent challenge by the other party or upon an uncured material breach of the agreement by the other party. However, if such breach only relates to one country, the Recepta License may only be terminated with respect to such country.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Synaffix commercial license agreement&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a commercial license agreement with Synaffix B.V., or Synaffix, which we amended and restated in November 2021 to expand our relationship with Synaffix. We refer to the amended and restated agreement as the Synaffix License. Under the Synaffix License, we have the right to develop, manufacture and commercialize ADCs directed to targets using Synaffix&#8217;s proprietary site-specific conjugation technology for up to twelve targets. Through December 31, 2021, we have licensed two targets from Synaffix in connection with our development of XMT-1592 and XMT-1660, for which we have paid $1.5 million in license fees, and $0.8 million in milestone payments. We are required to make milestone payments to Synaffix of up to an aggregate of $28.0 million in development and regulatory milestones and up to $20.0 million in one-time sales milestones based on the achievement of annual sales objectives for each of these two targets. Additionally, we paid upfront fees of $2.5 million at the time of amending and restating the Synaffix License in November 2021, which may be applied to reservation and license fees associated with our selection of the next three targets. Upon licensing any future targets, we will be obligated to pay in the range of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$48.0 mi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llion to $117.0 million for issuance, development, regulatory and one-time sales milestones. We further amended the Synaffix License in February 2022 in connection with the Janssen Collaboration and agreed to pay Synaffix an additional fee of $1.5 million which may be applied to future reservation and license fees, as well as certain portions of potential future development milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commencement of commercial sales of any ADC product directed to a licensed target, if any, we are required to pay to Synaffix tiered royalties in the low-single digit percentages on net sales of the respective products. The Synaffix License remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the Synaffix License covering such product in such country. Upon the expiration of the Synaffix License for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the Synaffix License in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the Synaffix License, subject to a specified notice and cure period, for a breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other party.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate and currently have no plans to establish any current good manufacturing practices, or cGMP, compliant manufacturing facilities. We currently rely, and expect to continue to rely, on external Contract Manufacturing Organizations, or CMOs, for the manufacture of product to support our activities through regulatory approval and commercial manufacturing. We have personnel with pharmaceutical development and manufacturing experience who are responsible for the relationships with our CMOs. In the future, we expect to use these CMOs to manufacture commercial supply of our products, which will require these CMOs to increase scale of production. We do not currently have qualified alternate suppliers in the event the current CMOs that we utilize are unable to scale production for commercial manufacturing. The Dolaflexin, Dolasynthen and Immunosynthen manufacturing processes involve readily available starting materials and use unit operations that are well-precedented in the field of chemical/pharmaceutical production. The current UpRi supply chain utilizes the same vendors that we could use for commercialization. The current XMT-1592 supply chain utilizes the same vendors that we could use for commercialization with the exception of components necessary for the Synaffix bioconjugation technology, where the identification of a commercially capable vendor is ongoing. The current supply chains for XMT-1660 and XMT-2056 have several vendors in common, and based on what we know today, we believe we could use these vendors for commercialization purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, development, testing, manufacture, quality control, packaging, labeling, storage, record-keeping, distribution, import, export, promotion, advertising, marketing, sale, pricing and reimbursement of drug and biologic products are extensively regulated by governmental authorities in the United States and other countries. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory requirements, both pre-approval and post-approval, require the expenditure of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial time and financial resources. The regulatory requirements applicable to biological product development, approval and marketing are subject to change, and regulations and administrative guidance often are revised or reinterpreted by the agencies in ways that may have a significant impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. government regulation of biological products</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA licenses biological products, or biologics, under the Public Health Service Act, or the PHSA, and regulates such products under the Food, Drug and Cosmetic Act, or FDCA. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new biologic in the United States must satisfactorily complete each of the following steps:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">completion of preclinical laboratory tests, animal studies and formulation studies according to good laboratory practices, or GLP, regulations or other applicable regulations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">design of a clinical protocol and submission to the FDA of an IND, which must become effective before human clinical trials may begin and must be updated when certain changes are made;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">approval by an independent institutional review board, or IRB, or ethics committee representing each clinical trial site before each clinical trial may be initiated;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the safety and efficacy of the investigational product for each proposed indication;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">preparation and submission to the FDA of a BLA requesting marketing approval for one or more proposed indications, including payment of application user fees;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">review of the BLA by an FDA advisory committee, where applicable;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the biologic is produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data submitted in support of the BLA; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">FDA review and approval of the BLA, which may be subject to additional post- approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post- approval clinical trials required by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical studies</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The IND and IRB processes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. An IND must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved BLA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial may proceed. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical trial subjects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial data as support for an IND or application for marketing approval. Specifically, the trials must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and re-approve the trial at least annually. The IRB, which must operate in compliance with FDA regulations, must review and approve, among other things, the clinical trial protocol and informed consent information to be provided to trial subjects and must monitor the trial until completed. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board, or DSMB. This group provides authorization as to whether or not a trial may move forward at designated checkpoints based on review of available data from the trial, to which only the DSMB maintains access. Suspension or termination of development during any phase of a clinical trial can occur if the DSMB determines that the participants or patients are being exposed to an unacceptable health risk. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanded access</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or Treatment IND Application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational product for the requested treatment will not interfere with the initiation, conduct or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no obligation for a sponsor to make its investigational products available for expanded access; however, as required by amendments to the FDCA included in the 21st Century Cures Act, or the Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests with respect to product candidates in development to treat serious diseases or conditions, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial for a covered investigational product; or 15 days after the investigational product receives designation from the FDA as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human clinical trials</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before they participate in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. The FDA has issued regulations authorizing a sponsor to transfer certain responsibilities for the conduct of a clinical trial to a contract research organization, or CRO.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional trials may also be required after approval. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are initially conducted in a limited population, which may be healthy volunteers or subjects with the target disease, to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the product candidate&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are typically well-controlled and closely monitored. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken using a larger patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a new biologic product. Such Phase 3 clinical trials are referred to as &#8220;pivotal&#8221; trials. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the trial will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials, typically referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials, such as to verify clinical benefit in the case of products approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting mandatory Phase 4 clinical trials could result in withdrawal of FDA approval for products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology biological product development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health, or NIH. In particular, information related to the product, patient population, phase of investigation, clinical trial sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The NIH&#8217;s Final Rule on registration and reporting requirements for clinical trials became effective in 2017, and both NIH and the FDA have recently signaled the government&#8217;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interactions with FDA during the clinical development program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a development safety update report, or DSUR. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND (Pre-IND meeting), at the end of Phase 2 clinical trial (EOP2 meeting) and before a BLA is submitted (Pre-BLA meeting). Meetings at other times may also be requested. There are three types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-BLA meetings, as well as end of phase meetings such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product, including for example meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing and other regulatory requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other criteria, the sponsor must develop methods </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for testing the identity, strength, quality, and purity of the finished product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric trials</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act, or PREA, applications and certain types of supplements to applications must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. Those plans must contain an outline of the proposed pediatric clinical trial or trials that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric trials along with supporting information. The sponsor and the FDA must reach agreement on a final plan. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial PSP or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors, and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety days after the FDA&#8217;s receipt of the PSP.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited review programs </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Priority review.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerated approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Regenerative advanced therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these expedited programs changes the standards for approval but each may help expedite the development or approval process governing product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Submission and filing of BLAs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, controls, safety updates, patent information, abuse information and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, potency and purity of the biological product to the satisfaction of the FDA. The fee required for the submission and review of an application under the Prescription Drug User Fee Act, or PDUFA, is substantial (for example, for FY2022 this application fee is approximately $3.1 million), and the sponsor of an approved application is also subject to an annual program fee, currently more than $369,000 per eligible prescription product. These fees are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, including where the applicant is a small business submitting its first human therapeutic application for review.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or before whether an application is sufficiently complete to permit substantive review. In pertinent part, FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed until all pertinent information and data have been received&#8221; by the FDA. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#8220;priority review.&#8221; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA goal date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of an application, the FDA will typically submit information requests to the applicant and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications. The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Decisions on BLAs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter. To reach this determination, the FDA must determine that the expected benefits of the proposed product outweigh its potential risks to patients. This assessment is informed by the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the applicant an additional six month extension to respond. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new prescription product, the manufacturer, the approved product and the product&#8217;s manufacturing locations are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and record-keeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe legally available products for unapproved uses or patient populations (i.e., &#8220;off-label uses&#8221;), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a biologic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products, as well as adverse public relations and reputational harm. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new application or supplement, which may require the sponsor to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from adequate and well-controlled clinical trials to demonstrate the product&#8217;s safety and efficacy in the new indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for certain products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market clinical trials requirement to assess new safety risks or imposition of distribution or other restrictions under a REMS program. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential consequences include, among other things:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, untitled letters or other enforcement-related letters or clinical holds on post-approval clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory exclusivity governing biologics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a biological product is licensed for marketing by FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring FDA from approving competing products for certain periods of time. In March 2010, the Patient Protection and Affordable Care Act was enacted in the United States and included the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, the FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30, 2021 and a second product previously approved as a biosimilar was designated as interchangeable in October 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the BPCIA, a manufacturer may submit an application for a product that is &#8220;biosimilar to&#8221; a previously approved biological product, which the statute refers to as a &#8220;reference product.&#8221; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and the proposed biosimilar product in terms of safety, purity and potency. The biosimilar sponsor may demonstrate that its product is biosimilar to the reference product on the basis of data from analytical studies, animal studies and one or more clinical trials to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the FDA to approve a biosimilar product as interchangeable with a reference product, the agency must find not only that the product is biosimilar to the reference product but also that it can be expected to produce the same clinical results as the reference product such that the two products may be switched without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. Following approval of the interchangeable biosimilar product, the FDA may not grant interchangeability status for any second biosimilar until one year after the first commercial marketing of the first interchangeable biosimilar product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reference biological product is granted 12 years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. Even if a product is considered to be a reference product eligible for exclusivity, however, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#8217;s own preclinical data and data from adequate and well&#8209;controlled clinical trials to demonstrate the safety, purity, and potency of their product. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since passage of the BPCIA, many states have passed laws or amendments to laws, which address pharmacy practices involving biosimilar products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the product for the disease or condition will be recovered from sales of the product in the United States.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation qualifies a company for tax credits and potentially market exclusivity for seven years following the date of the product&#8217;s approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests. The product must then go through the review and approval process like any other product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first approved product. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same product for the same disease or condition for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of market exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the disease or condition for which the product has been designated. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drug products that received orphan drug designation before enactment of amendments to the FDCA in 2017 but have not yet been approved by FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; It is unclear how this court decision will be implemented by the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is a type of non&#8209;patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of exclusivity. For biologic products, the six month period may be attached to any existing regulatory exclusivities but not to any patent terms. The conditions for pediatric exclusivity include the FDA&#8217;s determination that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric clinical trials, and the sponsor agreeing to perform, and reporting on, the requested clinical trials within the statutory timeframe. This six&#8209;month exclusivity may be granted if a sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patents that cover the product are extended by six months. Although this is not a patent term extension, it effectively extends the regulatory period during which the FDA cannot approve another application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent term restoration and extension</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, a patent claiming a new product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch&#8209;Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one&#8209;half the time between the effective date of the IND involving human beings and the submission date of the BLA, plus the time between the submission date of the application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Companion diagnostics</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics. According to the guidance, for novel biologics, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the therapeutic product and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostic device on issues related to co-development of the products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND application alone, or both an IND- and IDE-application.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the FDA issued additional guidance which describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple biological oncology products, when appropriate. This guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic products, the companion diagnostic&#8217;s intended use/indications for use should name the specific group of therapeutic products, rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the FDCA, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require pre-notification marketing clearance or approval from the FDA prior to commercial distribution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA previously has required </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare compliance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal Open Payments (or federal &#8220;sunshine&#8221; law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare &amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, or HHS, for re-disclosure to the public, as well as ownership and investment interests held by certain healthcare providers and their immediate family members; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws and regulations prohibiting bribery and corruption such as the Foreign Corrupt Practices Act, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, such as Medicare and Medicaid. Ensuring compliance is time consuming and costly. Similar healthcare laws and regulations exist in the European Union and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform </span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and reimbursement for medical products and other changes to the healthcare system in the United States.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the United States Congress enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, which, among other things, includes changes to the coverage and payment for pharmaceutical products under government healthcare programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. These Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022, a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act, which was signed by President Trump on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden rescinded those orders and issued a new executive order that directs federal agencies to reconsider rules and other policies that limit access to healthcare, and consider actions that will protect and strengthen that access. Under this order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID&#8209;19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the PPACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical prices</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription products from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of products from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs the HHS to create a plan within 45 days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221; On September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b) improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require pharmaceutical manufacturers and other entities in the supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and state data privacy laws</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under HIPAA, the HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, California has enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January 1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, already have passed state privacy laws and other states will likely be considering similar laws in the near future. </span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval and regulation of medical products in the European Union</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products outside of the United States. Whether or not we obtain FDA approval for a product candidate, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the 27-member European Union, before we may commence clinical trials or market products in those countries or areas. In the European Union, our product candidates also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls.</span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the European Union and European Economic Area, or EEA, applying the harmonized regulatory rules for medicinal products, the approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly between countries and jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific clinical site after the applicable ethics committee has issued a favorable opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website: https://eudract.ema.europa.eu.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing authorization in the European Union</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing authorization applications, or MAAs, can be filed either under the so-called centralized or national authorization procedures, albeit through the mutual recognition or decentralized procedure for a product to be authorized in more than one EU Member State.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines Agency, or EMA, that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway, which are part of the EEA. The centralized procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products, advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified diseases, such as HIV/ AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the sponsor in response to questions asked by the Committee for Medicinal Products for Human Use, or the CHMP. Accelerated assessment might be granted by the CHMP in exceptional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Decentralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Using the decentralized procedure, a sponsor may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. The sponsor may choose a member state as the reference member State to lead the scientific evaluation of the application.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Mutual recognition procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the mutual recognition procedure, a medicine is first authorized in one EU Member State (which acts as the reference member state), in accordance with the national procedures of that country. Following this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization produced by the reference member state.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conditional approval</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular circumstances, EU legislation (Article 14&#8211;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new clinical trials and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric trials</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining a marketing authorization in the European Union, sponsors have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine in children is not needed or is not appropriate because (a) the product is likely to be ineffective or unsafe in part or all of the pediatric population; (b) the disease or condition occurs only in adult population; or (c) the product does not represent a significant therapeutic benefit over existing treatments for pediatric population. Before a marketing authorization application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRIME designation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage product development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme, facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance to the sponsor on the overall development and regulatory strategies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Periods of authorization and renewals</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the product on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory requirements after marketing authorization </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The holder of an EU marketing authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation and its related regulations and guidelines which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European Union is also highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, the advertising and promotion of approved products are subject to EU Member States&#8217; laws governing promotion of medicinal products, interactions with clinicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion, which is prohibited in the European Union. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic sponsors from relying on the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization in the European Union during a period of eight years from the date on which the reference product was first authorized in the European Union. The market exclusivity period prevents a successful generic sponsor from commercializing its product in the European Union until ten years have elapsed from the initial authorization of the reference product in the European Union. The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation and exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1) it is intended for the diagnosis, prevention or treatment of a life- threatening or chronically debilitating condition, (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition. The term &#8216;significant benefit&#8217; is defined in Regulation (EC) 847/2000 to mean a clinically relevant advantage or a major contribution to patient care.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten year market exclusivity period, the EMA or the competent authorities of the Member States of the EEA, cannot accept an application for a marketing authorization for a similar medicinal product for the same indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The sponsor will receive a fee reduction for the marketing authorization application if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: (1) the second sponsor can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (2) the sponsor consents to a second orphan medicinal product application; or (3) the sponsor cannot supply enough orphan medicinal product.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric exclusivity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a sponsor obtains a marketing authorization in all EU Member States, or a marketing authorization granted in the centralized procedure by the European Commission, and the trial results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC, or alternatively a one year extension of the regulatory market exclusivity from ten to eleven years, as selected by the marketing authorization holder.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent term extensions</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a product. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained. Although SPCs are available throughout the European Union, sponsors must apply on a country&#8209;by&#8209;country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement and pricing of prescription pharmaceuticals</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments to those in the United States may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, pharmaceutical firms may be required to conduct a clinical trial that compares the cost-effectiveness of the product to other available therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approval of companion diagnostic devices</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medical devices such as companion diagnostics must comply with the General Safety and Performance Requirements, or SPRs, detailed in Annex I of the EU Medical Devices Regulation (Regulation (EU) 2017/745), or MDR which came into force on May 26, 2021 and replaced the previously applicable EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with SPRs and additional requirements applicable to companion medical devices is a prerequisite to be able to affix the CE Mark of Conformity to medical devices, without which they cannot be marketed or sold. To demonstrate compliance with the SPRs, a manufacturer must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent, predictable, and sustainable regulatory framework across the European Union for medical devices.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the regulatory authorities in the European Union also adopted a new In Vitro Diagnostic Regulation, or IVDR, (EU) 2017/746, which will become effective in May 2022. The new regulation will replace the In Vitro Diagnostics Directive (IVDD) 98/79/EC. Manufacturers wishing to apply to a notified body for a conformity assessment of their in vitro diagnostic medical device have until May 2022 to update their Technical Documentation to meet the requirements and comply with the new, more stringent Regulation. Once applicable, the regulation will, among other things: strengthen the rules on placing devices on the market and reinforce surveillance once they are available; establish explicit provisions on manufacturers&#8217; responsibilities for the follow-up of the quality, performance, and safety of devices placed on the market; improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Data Protection Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. Following the withdrawal of the United Kingdom from the European Union, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the regulatory framework in the United Kingdom</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s withdrawal from the European Union took place on January 31, 2020. The European Union and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, which was applied provisionally beginning on January 1, 2021 and which entered into force on May 1, 2021. The Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the European Union and the United Kingdom will form two separate markets governed by two distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the European Union.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect the proprietary technology that we consider important to our business, including pursuing patents that cover our ADC platforms, proprietary compositions of matter, ADC product candidates and methods of using and manufacturing the same, as well as any other relevant inventions and improvements that are considered commercially important to the development of our business. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend significantly on our ability to obtain and maintain patents and other proprietary protection for the technology, inventions and improvements we consider important to our business, and to defend our patents, preserve the confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third parties. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S., international (under Patent Cooperation Treaty, or PCT) and foreign patent applications related to our proprietary technology, inventions and improvements that we consider to be important to the development and implementation of our business. We also believe in protecting our unpatented trade secrets and know-how and continuing our technological innovation to develop our business and to maintain our competitive position.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. In the future, if and when our drug candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each drug and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit from any patent term extension or favorable adjustments to the terms of any of our patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our drug candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may currently own or license or may receive in the future may be challenged, invalidated, circumvented or have the scope of their claims narrowed. For example, we cannot be certain of the priority of inventions covered by pending third party patent applications. If third parties prepare and file patent applications in the United States that also claim technology or therapeutics to which we have rights, we may have to participate in interference proceedings in the USPTO to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us, which is highly unpredictable. In addition, because of the extensive time required for clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any competitive advantage such patent may provide. For more information regarding the risks related to our intellectual property, please see &#8220;Risk factors&#8212;Risks related to our intellectual property.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2022, we owned, in all of our patent portfolios, 22 issued U.S. patents, 13 pending non-provisional U.S. patent applications, five pending provisional U.S. patent applications, 102 issued foreign patents, five pending PCT patent applications and 138 pending foreign patent applications (including four allowed foreign patent applications) in a number of foreign jurisdictions, including, but being not limited to, Argentina, Australia, Brazil, Canada, China, Europe, Eurasia, Gulf Cooperation Council, Hong Kong, Israel, India, Japan, Mexico, Macau, Pakistan, New Zealand, Russia, South Korea, South Africa, and Taiwan. Our 10 issued U.S. patents covering our Fleximer ADC platform are projected to expire in 2032, excluding any additional term for patent term adjustments or patent term extensions; our two issued U.S. patents covering our Dolaflexin </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADC platform are projected to expire in 2034 and 2038, excluding any additional term for patent term adjustments or patent term extensions; our one issued U.S. patent covering our STING agonist payload is projected to expire in 2040, excluding any additional term for patent term adjustments or patent term extensions; our additional nine issued U.S. patents are projected to expire between 2032 and 2037, excluding any additional term for patent term adjustments or patent term extensions; and any patent that may issue from our pending U.S. applications is projected to expire between 2037 and 2042, in each case, excluding any additional term for patent term adjustments or patent term extensions. In addition, we have exclusively in licensed four issued U.S. patents and one issued European patent for the NaPi2b antibody from Recepta, which Recepta licensed from Ludwig Institute for Cancer Research. These in-licensed issued U.S. and European patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody, which is not licensed to us. A patent issuing from this Brazilian patent application is projected to expire in 2029. We have also non-exclusively in-licensed from Synaffix certain patents and patent applications for their proprietary site-specific conjugation technology. These in-licensed Synaffix patents and patent applications are seven issued US patents, four pending non-provisional U.S. patent applications, eight issued foreign patents, one pending PCT patent applications and 14 pending foreign patent applications, in a number of foreign jurisdictions, including, but being not limited to, China, Europe, India, Japan, and Netherlands. These in-licensed issued U.S. and European patents are projected to expire from 2031 to 2040, excluding any additional term for patent term adjustments or patent term extensions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before they are granted. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same product candidate or technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio of our ADC platforms, our ADC product candidates and components thereof and companion diagnostics are summarized below. Some of these portfolios are in very early stages and prosecution has yet to commence on some of the pending patent applications. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the USPTO may be narrowed (sometimes significantly) by the time they issue, if they issue at all. We expect this to be the case with respect to our pending patent applications referred to below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fleximer ADC platform</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our Fleximer ADC platform is directed to compositions of matter for the Fleximer ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Fleximer drug conjugates prior to conjugation with the antibody or antibody fragment and methods of making the same, and compositions of matter for our proprietary auristatin DolaLock compounds and conjugates thereof (e.g., to Fleximer and/or an antibody or antibody fragment). As of January 31, 2022, we owned 10 issued U.S. patents, one pending non-provisional U.S. patent application, 48 issued foreign patents, and four pending foreign patent applications (including one allowed foreign patent application) in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, Russia, South Korea, and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering the Fleximer ADC platform is projected to expire in 2032, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dolaflexin ADC platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our Dolaflexin ADC platform is directed to compositions of matter for the Dolaflexin ADCs, as well as methods of using and making these novel conjugates, compositions of matter for Dolaflexin drug conjugates prior to conjugation with the antibody or antibody fragment and methods of making the same. As of January 31, 2022, we owned two issued U.S. patents, 34 issued foreign patent, and 11 pending foreign patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, South Korea, Mexico, Russia, South Africa and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering Dolaflexin ADC platform is projected to expire in 2034, and any U.S. or foreign patent issuing from the pending applications covering the method of making the Dolaflexin ADC is projected to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UpRi ADC</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for UpRi, our leading NaPi2b ADC product candidate is directed to compositions of matter for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolaflexin platform, as well as methods of using, making these novel conjugates, methods of administration and companion diagnostics. As of January 31, 2021, we owned four pending non-provisional U.S. patent applications (including one allowed U.S. patent application), 37 pending foreign patent applications, and one pending PCT application directed to the composition of matter for UpRi, methods of using and making </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same, companion diagnostics for UpRi ADC and UpRi dosing regimens. We also intend to enter the national/regional phase of the pending PCT patent application in foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, South Korea, Macau, Mexico and South Africa. Any U.S. or foreign patent issuing from the pending applications covering UpRi is projected to expire in 2037, and any U.S. or foreign patent issuing from the pending applications covering UpRi companion diagnostics is projected to expire in 2038, excluding any additional term for patent term adjustments or patent term extensions, and any U.S. or foreign patent issuing from the pending applications covering the UpRi dosing regimens is projected to expire in 2039.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as mentioned above, we have exclusively in licensed four issued U.S. patents and one issued European patent for the novel NaPi2b antibody from Recepta, which Recepta licensed from Ludwig Institute for Cancer Research. These in licensed issued U.S. and European patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody, which is not licensed to us. A patent issuing from this Brazilian patent application is projected to expire in 2029.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dolasynthen ADC platform</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our novel Dolasynthen platform is directed to compositions of matter for the novel scaffold and ADCs thereof, as well as methods of using and making these novel conjugates and scaffolds. As of January 31, 2022, we owned one issued U.S. patent, two pending non-provisional U.S. patent application, 30 pending foreign patent applications. in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, and Taiwan. Any U.S. or foreign patent issuing from the pending applications covering the novel Dolasynthen platform is projected to expire between 2037 and 2039, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XMT-1592 ADC</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for XMT-1592, our other NaPi2b ADC product candidate, is directed to compositions of matter for our novel ADC based on exclusively in licensed NaPi2b antibody and our Dolasynthen platform, as well as methods of using, making, and administration of these novel conjugates. As of January 31, 2022, we owned one pending non-provisional U.S. patent application, three pending foreign patent applications, including Taiwan, and one pending PCT patent application. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, New Zealand, South Africa, Saudi Arabia, and United Arab Emirates. Any U.S. or foreign patent issuing from the pending applications covering XMT-1592 is projected to expire in 2041, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as described above with respect to NaPi2b antibody, we have exclusively in-licensed four issued U.S. patents and one issued European patent for the novel NaPi2b antibody from Recepta, which Recepta licensed from Ludwig Institute for Cancer Research. These in-licensed issued U.S. and European patents are projected to expire in 2029, excluding any additional term for patent term adjustments or patent term extensions. Recepta still owns one pending Brazilian patent application for the NaPi2b antibody, which is not licensed to us. A patent issuing from this Brazilian patent application is projected to expire in 2029. We have also non-exclusively in-licensed from Synaffix certain patents and patent applications for their proprietary site-specific conjugation technology. These in-licensed Synaffix patents and patent applications are seven issued US patents, four pending non-provisional U.S. patent applications, eight issued foreign patents, one pending PCT patent applications and 14 pending foreign patent applications, in a number of foreign jurisdictions, including, but being not limited to, China, Europe, India, Japan, and Netherlands. These in-licensed issued U.S. and European patents are projected to expire from 2031 to 2040, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XMT-1660 ADC </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for XMT-1660, our site-specific B7-H4 ADC product candidate is directed to compositions of matter for our novel ADC based on our novel B7-H4 antibody and our Dolasynthen platform, as well as methods of using, making these novel conjugates and administration of these novel conjugates. As of January 31, 2022, we owned one pending non-provisional U.S. patent application, one pending provisional application, three pending foreign patent applications, including Taiwan, and one pending PCT patent application. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, New Zealand, South Africa, Saudi Arabia, and United Arab Emirates. Any U.S. or foreign patent issuing from the pending applications covering XMT-1660 is projected to expire in 2042, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Immunosynthen ADC platform and XMT-2056</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property portfolio for our novel Immunosynthen platform is directed to compositions of matter for the novel STING agonists and ADCs thereof, including XMT-2056, our Her-2 ADC development candidate that targets a novel epitope of HER2, as well as methods of using and methods of making these novel payloads and ADCs. As of January 31, 2022, we owned one issued U.S. patent, one pending non-provisional U.S. patent applications, five pending foreign patent applications, including Taiwan, and two pending PCT patent applications related to our the novel STING agonists, and one pending non-provisional U.S. patent application, three pending foreign patent applications, including Taiwan, and one pending PCT patent applications related to our Immunosynthen platform. We intend to enter the national/regional phase of the PCT patent applications in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, New Zealand, South Africa, Saudi Arabia, and United Arab Emirates. Any U.S. or foreign patent issuing from the pending applications covering the novel STING agonists is projected to expire between 2040 and 2041, and any U.S. or foreign patent issuing from the pending applications covering the Immunosynthen platform and XMT-2056 is projected to expire in 2041, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above with respect to XMT-2056 as of January 31, 2022, we owned two issued U.S. patent, one pending non-provisional U.S. patent applications, seven issued foreign patent, and 11 pending foreign patent applications (including one allowed foreign patent application), in a number of foreign jurisdictions, including, but not limited to, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Israel, India, Japan, Macau, Mexico, South Korea, New Zealand and Taiwan, directed to the novel Her-2 antibody. Any U.S. or foreign patent issuing from the pending applications covering the novel Her-2 antibody is projected to expire in 2035, excluding any additional term for patent term adjustments or patent term extensions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by executing confidentiality and assignment of inventions agreements with our employees and consultants, which agreements may also include appropriate non-competition and non-solicit agreements depending on level and role, as well as confidentiality agreements with our collaborators and scientific advisors. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty. We cannot guarantee, however, that we will have executed such agreements with all applicable employees and contractors, or that these agreements will afford us adequate protection of our intellectual property and proprietary information rights. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our technology platforms, trade secrets and know-how will over time be disseminated within the industry through independent development and public presentations describing the methodology. For more information regarding the risks associated with our trade secrets, please see &#8220;Risk factors&#8212;Risks related to our intellectual property&#8212;Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries, and the oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary ADC platforms and scientific expertise provide us with competitive advantages, a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions, are actively developing potentially competitive products and technologies. These competitors generally fall within the following categories:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New cancer treatments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Many global pharmaceutical companies, as well as medium and small biotechnology companies, are pursuing new cancer treatments whether small molecules, biologics or ADCs. Any of these treatments could prove to be superior clinically to our products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADC platforms: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Dolaflexin, Dolasynthen, Immunosynthen and other initiatives we have underway are highly differentiated and proprietary, many companies continue to invest in innovation in the ADC field including new payload classes, new conjugation approaches and new targeting moieties. Any of these initiatives could lead to a platform that has superior properties to ours. We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including Daiichi Sankyo, ImmunoGen, Gilead (Immunomedics), Pfizer and SeaGen. These companies or their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partners, including Astellas, AstraZeneca, AbbVie, Genentech/Roche and Takeda, may develop product candidates which compete in the same indications as our current and future product candidates. Multiple companies are also developing immune stimulating ADCs which could compete with our Immunosynthen products, including Bolt Biotherapeutics, Inc., Takeda, and Silverback Therapeutics, Inc. We expect to compete based on our innovative technology and the efficacy, safety and tolerability profile of our ADCs compared to other product candidates but if our ADCs are not demonstrably superior in these respects, we may not be able to compete effectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ovarian cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The first indication that we are targeting for UpRi, our most advanced clinical candidate, is ovarian cancer. There are multiple therapies currently available to treat both newly diagnosed and relapsed ovarian cancer, including platinum agents, non-platinum chemotherapy, PARP inhibitors and bevacizumab. In addition, multiple investigational product candidates are in development to treat these ovarian cancer patients, including the following investigational ADCs: mirvetuximab soravtansine (Immunogen), MORAb-202 (Eisai Co., Ltd. and Bristol Myers Squibb) and STRO-002 (Sutro Biopharma). Our ability to compete effectively with these and other emerging ovarian cancer treatments will depend on our ability to differentiate UpRi from these other therapies based on target patient selection, efficacy and tolerability. If we are unable to effectively differentiate UpRi, this will negatively impact our ability to compete in ovarian cancer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products&#8217; entry. We believe the factors determining the success of our programs will be the efficacy, safety and tolerability of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2022, we had 169 full time employees, including 90 with M.D., Ph.D. or other advanced degrees. Of these full time employees, 128 are engaged in research and development and 41 are engaged in general and administrative activities. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. Our human capital objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees, and focusing on employee well-being and workplace safety. We provide our employees with competitive salaries and bonuses, opportunity for equity ownership, development programs that enable continued learning and growth, and a robust employment package that promotes wellness across all aspects of their lives, including healthcare, retirement planning, and paid time off. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe that fostering diversity, equity, and inclusion is a key element to discovering, developing, and bringing therapies to patients with cancer. As of January 31, 2022, 56% of our global workforce and 40% of our leadership (at the executive director level and above) were female. We strive to build a workforce representative of the communities and patients we serve and to nurture an inclusive culture where all voices are welcomed, heard, and respected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facilities</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 45,000 square feet of office and laboratory space that we lease in the multi-tenant building in which our corporate headquarters are located. Our lease expires in March 2026. We have an option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 2001 as a Delaware corporation. Our principal executive offices are located at 840 Memorial Drive, Cambridge, MA 02139, and our telephone number is 617-498-0020. Our internet site is www.mersana.com. We routinely make available important information free of charge, including copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. We recognize our website as a key channel of distribution to reach public investors and as a means of disclosing material non-public information to comply with our disclosure obligations under SEC Regulation FD. Information contained on our website shall not be deemed incorporated into, or to be part of this Annual Report on Form 10-K, and any website references are not intended to be made through active hyperlinks.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_19"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to development and approval of our ADC product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure of a discovery program or product candidate may occur at any stage of preclinical or clinical development, and, because our and our partner&#8217;s discovery programs and our product candidates are in early stages of preclinical or clinical development, there is a high risk of failure and we or our partners may never succeed in obtaining regulatory approval and generating revenue from such discovery programs or product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early clinical results for UpRi (upifitamab rilsodotin), our lead product candidate, our early preclinical results for XMT-1592 and the early results from preclinical studies or clinical trials of any other current or future product candidates, are not necessarily predictive of the results from our ongoing or future discovery programs, preclinical studies or clinical trials. Promising results in preclinical studies and early encouraging clinical results of a drug candidate may not be predictive of similar results in later-stage preclinical studies or in humans during clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical trials after achieving positive results in earlier stages of clinical development, and we cannot be certain that we will not face similar setbacks. These companies&#8217; setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy events in preclinical or clinical trials, including previously unreported adverse events. Similarly, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates. In addition, clinical trial results for one of our product candidates or for competitor products utilizing similar technology, may raise concerns about the safety or efficacy of other products in our pipeline. If the results of our ongoing or future clinical trials are inconclusive with respect to the efficacy of our product candidates or if we do not meet the clinical endpoints with statistical significance or if there are safety concerns or adverse events associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for our product candidates. For example, patients in our ongoing Phase 1b/2 clinical trial of UpRi have experienced serious adverse events, including without limitation death, pneumonitis, renal impairment, abdominal pain, fatigue, vomiting, sepsis, and pyrexia. We expect that certain patients in ongoing and future clinical trials will experience additional serious adverse events, including those that may result in death, as our product candidates progress through clinical development.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain U.S. Food and Drug Administration (FDA) approval. Even if we, or our collaborators, believe that the results of clinical trials of our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, even if we obtain regulatory approval, that approval may be for indications or patient populations that are not as broad as intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We may also be required to perform additional or unanticipated clinical trials to obtain approval or be subject to additional post-marketing testing requirements to maintain regulatory approval. In addition, regulatory authorities may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy (REMS) program. The failure to obtain timely regulatory approval of product candidates, any product marketing limitations or a product withdrawal would negatively impact our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish interim, top-line or preliminary data from our clinical trials. Positive preliminary data may not be predictive of such trial&#8217;s subsequent or overall results. Interim data from clinical trials that we may complete do not necessarily predict final results and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, we have reported interim data from our ongoing Phase 1b/2 clinical trial of UpRi, but we have not yet reported final data from the trial. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or top-line data we may publish. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only two ADC product candidates, UpRi and XMT-1592, in clinical trials. A failure of any of our product candidates in clinical development would adversely affect our business and may require us to discontinue development of other ADC product candidates based on the same technology.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi and XMT-1592 are currently our only clinical-stage development product candidates. While we have certain other preclinical programs in development and we intend to develop other product candidates, including XMT-1660 and XMT-2056 each for which we plan to submit investigational new drug, or IND, applications in 2022, it will take additional investment and time for such programs to reach the clinical stage of development. In addition, we have other product candidates in our current pipeline that are based on the same platforms as UpRi and XMT-1592. If either product candidate fails in development as a result of any underlying problem with our platforms, then we may be required to discontinue development of the product candidates that are based on the same technologies. If we were required to discontinue development of UpRi or XMT-1592, or if UpRi or XMT-1592 were to fail to receive regulatory approval or were to fail to achieve sufficient market acceptance, we could be prevented from or significantly delayed in achieving profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Events that may delay or prevent successful commencement, enrollment or completion of clinical trials of our product candidates could result in increased costs to us as well as a delay in obtaining, or failure to obtain, regulatory approval, or cause us to suspend or terminate a clinical trial, which could prevent us from commercializing our product candidates on a timely basis, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that clinical trials, including our ongoing and future anticipated additional clinical trials of UpRi, our lead product candidate, and XMT-1592, will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing, and other events may cause us to temporarily or permanently cease a clinical trial. Events that may prevent successful or timely commencement, enrollment or completion of clinical development include, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory agencies on trial design;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching, or failing to reach, agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in obtaining required Institutional Review Board, or IRB, or Ethics Committee, or EC, approval at each clinical trial site;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in recruiting and enrolling suitable patients to participate in clinical trials that meet the criteria of the protocol for the clinical trial;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of a clinical hold by regulatory agencies or IRBs or ECs for any reason, including safety concerns or after an inspection of clinical operations or trial sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by CROs, other third parties or us to adhere to clinical trial requirements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with the FDA&#8217;s good clinical practices, or GCP, or applicable regulatory guidelines in other countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate quantity or quality of a product candidate or other materials necessary to conduct clinical trials, including, for example, delays in the testing, validation, manufacturing or delivery of the product candidates to the clinical sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients not completing participation in a trials or not returning for post-treatment follow-up, including as a result of the ongoing COVID-19 pandemic;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expected or unexpected safety issues, including occurrence of serious adverse events, or SAEs, associated with our product candidates in clinical trials that are viewed as outweighing the product candidate&#8217;s potential benefits or reports may arise from preclinical or clinical testing of other similar cancer therapies that raise safety or efficacy concerns about our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols or submitting additional data; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial; or </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">geopolitical or other events that unexpectedly disrupt, delay or generally interfere in regional or worldwide operations of clinical trial sites, clinical vendors or other operations relevant to the conduct of relevant development activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays, including delays caused by the above factors, can be costly and could negatively affect our ability to complete a clinical trial. If we or our partners are not able to successfully complete clinical trials, we or they will not be able to obtain regulatory approval and will not be able to commercialize our product candidates or our partners&#8217; product candidates based on our technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An inability to enroll sufficient numbers of patients in our clinical trials could result in increased costs and longer development periods for our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials require sufficient patient enrollment, which is a function of many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and nature of the patient population;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity of the disease under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the nature and complexity of the trial protocol, including eligibility criteria for the trial;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of clinical trial sites and the proximity of patients to those sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">standard of care in the diseases under investigation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commitment of clinical investigators to identify eligible patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they are late-stage cancer patients, will not survive the full terms of the clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the ability of our clinical trial sites to continue key activities, such as clinical trial site data monitoring and patient visits, due to limitations on travel imposed or recommended by federal or state governments, employers and others as a result of the COVID-19 pandemic or other worldwide events; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients may be affected by COVID-19 or measures taken in response to the COVID-19 pandemic and are unable to travel to our clinical trial sites.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and future product candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and future product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Challenges in recruiting and enrolling suitable patients to participate in clinical trials that meet the criteria of the protocol could increase costs and result in delays to our current development plan for UpRi, our lead product candidate, XMT-1592 or any other current or future product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates or ADCs developed or commercialized by our competitors may cause undesirable side effects or have other properties that halt their clinical development, delay or prevent regulatory approval of our product candidates or limit their commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by our product candidates or ADCs being developed or commercialized by our partners or competitors could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of subjects and limited duration of exposure, rare and severe side effects of our product candidates or those of our competitors may only be uncovered with a significantly larger number of patients exposed to the drug. SAEs, including death, deemed to be caused by our product candidates or those of our competitors, either before or after receipt of marketing approval, could have a material adverse effect on the development of our product candidates and our business as a whole.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in our ongoing clinical trials have experienced SAEs, including without limitation death, pneumonitis, renal impairment, abdominal pain, fatigue, vomiting, sepsis, and pyrexia. We expect that certain patients in ongoing and future trials will experience additional SAEs, including those that may result in death, as our product candidates progress through clinical development. These or additional undesirable side effects caused by our product candidates or those of our competitors, either before or after receipt of marketing approval, could result in a number of potentially significant negative consequences, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our clinical trials may be put on hold;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">treatment-related side effects could affect patient recruitment for our clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain regulatory approval for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw or limit their approvals of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a contraindication, black box warnings or additional warnings;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may require development of a REMS with Elements to Assure Safe Use as a condition of approval or post-approval;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may decide to remove such product candidates from the marketplace;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase commercialization costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may choose not to develop a potential product candidate, or we may suspend or terminate one or more discovery or preclinical programs or our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time and for any reason, we may determine that one or more of our discovery programs, preclinical programs or product candidates does not have sufficient potential to warrant the allocation of resources toward such program or product candidate. Furthermore, because we have limited financial and personnel resources, we have placed significant focus on the development of our product candidates UpRi and XMT-1592. Accordingly, we may choose not to develop a product candidate or elect to suspend or terminate one or more of our discovery or preclinical programs. If we suspend or terminate a program or product candidate in which we have invested significant resources, we will have expended resources on a program or product candidate that will not provide a full return on our investment. We may also cease developing a product candidate for a particular indication. For example, in November 2021, we determined to cease developing UpRi as a single agent in patients with NSCLC and determined to focus future development on patients with ovarian cancer. As a result, we may have missed an opportunity to have allocated those resources to potentially more productive uses, including existing or future programs or product candidates. If we do not accurately evaluate the commercial potential or target market for a particular future product candidate, we may relinquish valuable rights to future product candidates through collaboration, licensing or other royalty arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our partners may fail to discover and develop additional potential product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our partners&#8217; research programs to identify new product candidates will require substantial technical, financial and human resources, and we or our partners may be unsuccessful in our or their efforts to identify new product candidates. If we or our partners are unable to identify suitable additional product candidates for preclinical and clinical development, our or their ability to develop product candidates and our ability to obtain revenues from commercializing our products or to receive royalties from our partners&#8217; sales of their products in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our financial position and need for additional capital</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses since our inception, we have no products approved for commercial sale and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or sustain profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception. Our net loss was $170.1 million for the year ended December&#160;31, 2021. As of December&#160;31, 2021, we had an accumulated deficit of $450.5 million. We do not know when or whether we will become profitable. To date, we have not commercialized any products and therefore have never generated any revenues from the sale of products, and we do not expect to generate any product revenues in the foreseeable future. Our losses have resulted principally from costs incurred in our discovery and development activities. Our net losses may fluctuate significantly from quarter to quarter and year to year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have devoted most of our financial resources to research and development, including our clinical and preclinical development activities. To date, we have financed our operations primarily with the proceeds from our initial public offering, our follow-on public offerings in 2019 and 2020, the use of our at-the-market, or ATM, equity offering program, and our strategic partnerships. The amount of our future net losses will depend, in part, on the rate of our future expenditures. We have not completed pivotal clinical trials for any product candidate and only have two product candidates in clinical trials. It will be several years, if ever, before we have a product candidate ready for commercialization. Even if we obtain regulatory approval to market a product candidate, our future revenues would depend upon the size of the market or markets in which our product candidates received such approval and our ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product candidates in those markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue clinical development activities for our clinical product candidates UpRi and XMT-1592;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop a diagnostic assay for the NaPi2b biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete IND-enabling studies for our preclinical development candidates XMT-2056 and XMT-1660;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue activities to discover, validate and develop additional product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain marketing approvals for our current and future product candidates for which we complete clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop a sustainable and scalable manufacturing process for our product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address any competing technological and market developments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional research, development and general and administrative personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required by the FDA or any equivalent foreign regulatory authority to perform clinical trials or preclinical trials in addition to those we currently expect to conduct, or if there are any delays in completing the clinical trials of UpRi, XMT-1592, or any other current or future product candidates, our expenses could increase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must succeed in developing our product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may not succeed in these activities, and we may never generate revenue from product sales or strategic partnerships in an amount sufficient to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a credit facility that requires us to comply with certain operating covenants and places restrictions on our operating and financial flexibility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into a Loan and Security Agreement, or the New Credit Facility, with Oxford Finance LLC as the collateral agent and a lender, and SVB as a lender, together, the Lenders. Pursuant to the New Credit Facility, as amended in February 2022, we may borrow up to an aggregate of $100 million, which includes $60 million available immediately, $20 million in a tranche that is subject to meeting certain development milestones, and an additional tranche of $20 million, which is subject to conditional approval from the Lenders. The New Credit Facility is secured by substantially all of our personal property owned or later acquired, excluding intellectual property (but including the right to payments and proceeds from intellectual property), and a negative pledge on intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The New Credit Facility also includes customary representations and warranties, affirmative and negative covenants and conditions to drawdowns, as well as customary events of default. Certain of the customary negative covenants limit our ability, among other things, to incur future debt, grant liens, make investments, make acquisitions, distribute dividends, make certain restricted payments and sell assets, subject in each case to certain exceptions. Our failure to comply with these covenants would result in an event of default under the Loan Agreement and could result in the acceleration of the obligations we owe pursuant to the New Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development or commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents were $177.9 million as of December&#160;31, 2021. We have utilized substantial amounts of cash since our inception and expect that we will continue to expend substantial resources for the foreseeable future developing UpRi, XMT-1592, and any other current or future product candidates. These expenditures may include costs associated with research and development, conducting preclinical studies and clinical trials, potentially obtaining regulatory approvals and manufacturing products, as well as marketing and selling products approved for sale, if any, and potentially acquiring new technologies. In addition, other unanticipated costs may arise. Because the outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates. Our costs will increase if we experience any delays in our clinical trials for UpRi, XMT-1592 or any other current or future product candidates, including delays in enrollment of patients. We also incur costs associated with operating as a public company, hiring additional personnel and expanding our facilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of researching and developing UpRi, XMT-1592 and any other current or future product candidates and conducting preclinical studies and clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and the costs involved in, obtaining regulatory approvals for UpRi, XMT-1592 and any other current or future product candidates if preclinical studies and clinical trials are successful;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing UpRi, XMT-1592 and any other current or future product candidates for clinical trials in preparation for regulatory approval and in preparation for commercialization;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities for UpRi, XMT-1592 and any other current or future product candidates, if any product candidates are approved for sale, including manufacturing, marketing, sales and distribution costs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of, or royalties on, our future products, if any, or products developed by our partners;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing cancer therapies and other adverse market developments; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement for or the cost of developing companion diagnostics and/or complementary diagnostics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had cash and cash equivalents of $177.9 million and, subsequently, we received a $40 million upfront payment under the Janssen Collaboration and $45.6 million of net proceeds received from sales of our common stock under our 2020 ATM. In addition, we currently have the option to borrow $35 million under the New Credit Facility. Taken together, we believe that our current cash and cash equivalents plus the available borrowings under the New Credit Facility will be sufficient to fund our current operating plan commitments into the second half of 2023. However, we have based these estimates on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us and we may need additional funds sooner than planned. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. Our ability to borrow funds under the New Credit Facility is subject to us complying with the applicable covenants at the time we request a drawdown. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or ADC product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our capital need through a variety of means, including through private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of such equity or convertible debt securities may include liquidation or other preferences that are senior to or otherwise adversely affect the rights of our common stockholders. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such as incurring future debt, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness, each of which could adversely impact our ability to conduct our business and execute our operating plan. If we raise additional funds through strategic partnerships with third parties, we may have to relinquish valuable rights to our technologies, including our platforms, or product candidates, or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts for UpRi, XMT-1592, or any other current or future product candidates, or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on specific product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business and financial condition. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through partnering, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our reliance on third parties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture our preclinical and clinical trial product supplies, and we lack the internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient and final drug product must be acceptable to the FDA and other comparable foreign regulatory agencies pursuant to inspections that would be conducted after we submit our marketing application or relevant foreign regulatory submission to the applicable regulatory agency. There can be no assurance that our preclinical and clinical development product supplies will be sufficient, uninterrupted or of satisfactory quality or continue to be available at acceptable prices. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP. We have no direct control over our contract manufacturers&#8217; ability to maintain adequate quality control, quality assurance and qualified personnel. In the event that any of our manufacturers fails to comply with regulatory requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. Our reliance on contract manufacturers also exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may appropriate our trade secrets or other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a delay or inability to initiate or continue clinical trials of product candidates under development;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay in submitting regulatory applications, or delay or failure to receive regulatory approvals, for product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of the cooperation of an existing or future strategic partner;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a requirement to cease distribution or to recall batches of our product candidates; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, adverse publicity, and civil and criminal enforcement and sanctions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or our third-party manufacturers, may be unable to successfully scale-up manufacturing of our ADC product candidates in sufficient quality and quantity, which would delay or prevent us from developing our ADC product candidates and commercializing approved products, if any.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conduct clinical trials of our product candidates and commercialize any approved product candidates, we, or our manufacturing partners, will need to manufacture them in large quantities. We, or our manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We have evaluated which third-party manufacturers to engage for scale-up to commercial supply of our product candidates, including UpRi and XMT-1592, and we have begun to transfer and scale-up certain manufacturing activities. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct preclinical studies and clinical trials for UpRi and XMT-1592 and if such third parties do not properly, timely and successfully perform their obligations to us, we may not be able to obtain regulatory approvals for UpRi, XMT-1592, or any other current or future ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We designed the ongoing clinical trials for UpRi and XMT-1592, and we intend to design any future clinical trials for any future unpartnered product candidates that we may develop if preclinical studies are successful. However, we rely on CROs, clinical sites, investigators and other third parties to assist in managing, monitoring and otherwise carrying out many of these trials. As a result, we have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. These CROs, investigators and other third parties are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. We compete with many other companies for the resources of these third parties. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with whom we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, or complying with cGLP or cGCP, as applicable, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The third parties on whom we rely generally may terminate their engagements at any time, and having to enter into alternative arrangements would delay development and commercialization of our product candidates. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have staffing difficulties;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to comply with contractual obligations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience regulatory compliance issues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undergo changes in priorities or become financially distressed; or</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">form relationships with other entities, some of which may be our competitors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and comparable foreign regulatory authorities require compliance with regulations and standards, including GCP, for designing, conducting, monitoring, recording, analyzing and reporting the results of clinical trials to assure that the data and results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Although we rely, and intend to continue to rely, on third parties to conduct our clinical trials, they are not our employees, and we are responsible for ensuring that each of these clinical trials is conducted in accordance with its general investigational plan, protocol and other requirements. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to untitled and warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their duties under their agreements, if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to clinical trial protocols or to regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, the clinical trials of our product candidates may not meet regulatory requirements. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we or our CROs fail to comply with applicable GCPs or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable, third parties may need to be replaced, we may be subject to negative publicity, fines and civil or criminal sanctions, and preclinical development activities or clinical trials may be extended, delayed, suspended or terminated. If any of these events occur, we may not be able to obtain regulatory approval of our product candidates on a timely basis or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on strategic partnerships with other companies to assist in the research, development and commercialization of our ADC platforms and ADC product candidates. If our existing partners do not perform as expected, this may negatively affect our ability to commercialize our ADC product candidates, generate revenues through technology licensing, or otherwise negatively affect our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established strategic partnerships and intend to continue to establish strategic partnerships with third parties to research, develop and commercialize our platforms and existing and future product candidates. In February 2022, we entered into a collaboration agreement with Janssen Biotech, Inc. for the research, development and commercialization of ADC candidates leveraging our Dolasynthen platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had also entered into a collaboration agreement with Merck KGaA for the development and commercialization of ADC candidates leveraging our Dolaflexin platform. Under these collaborations, we will depend on our partners to design and conduct their clinical trials. As a result, we will not be able to control or oversee the conduct of these programs by our partners and those programs may not be successful, which may negatively impact our business operations. In addition, if any of these partners withdraw support for these programs or proposed products or otherwise impair their development or experience negative results, our business and our product candidates could be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners may terminate their agreements with us for cause under certain circumstances or at will in certain cases and discontinue use of our technologies. In addition, we cannot control the amount and timing of resources our partners may devote to products utilizing or incorporating our technology. Moreover, our relationships with our partners may divert significant time and effort of our scientific staff and management team and require effective allocation of our resources to multiple internal and collaborative projects. Our partners may fail to perform their obligations under the collaboration agreements or may not perform their obligations in a timely manner. If conflicts arise between our partners and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. If any of our partners terminate or breach our agreements with them, or otherwise fail to complete their obligations in a timely manner, it may have a detrimental effect on our financial position by reducing or eliminating the potential for us to receive technology access and license fees, milestones and royalties, reimbursement of development costs, as well as possibly requiring us to devote additional efforts and incur costs associated with pursuing internal development of product candidates. Furthermore, if our partners do not prioritize and commit sufficient resources to programs associated with our product candidates or collaboration product candidates, we or our partners may be unable to commercialize these product candidates, which would limit our ability to generate revenue and become profitable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners may separately pursue competing products, therapeutic approaches or technologies to develop treatments for the diseases targeted by us or our partners. Competing products, either developed by the partners or to which the partners have rights, may result in the withdrawal of partner support for our product candidates. Even if our partners continue their contributions to the strategic partnerships, they may nevertheless determine not to actively pursue the development or commercialization of any resulting products. Additionally, if our partners pursue different clinical or regulatory strategies with their product candidates based on our platforms or technologies, adverse events with their product candidates could negatively affect our product candidates utilizing similar technologies. Any of these developments could harm our product development efforts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To date, we have depended on a small number of partners for a substantial portion of our revenue. The loss of any one of these partners could result in a material decline in our revenue.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic partnerships with a limited number of companies. To date, a substantial portion of our revenue has resulted from payments made under agreements with our strategic partners, and we expect that a portion of our revenue will continue to come from strategic partnerships. The loss of any of our partners, or the failure of our partners to perform their obligations under their agreements with us, including paying license or technology fees, milestone payments, royalties or reimbursements, could have a material adverse effect on our financial performance. Payments under our existing and future strategic partnerships are also subject to significant fluctuations in both timing and amount, which could cause our revenue to fall below the expectations of securities analysts and investors and cause a decrease in our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional strategic partnerships, and if we are not able to establish them on commercially reasonable terms, or maintain them, we may have to alter our development and commercialization plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to strategically evaluate our partnerships and, as appropriate, we expect to enter into additional strategic partnerships in the future, including potentially with major biotechnology or biopharmaceutical companies. We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into strategic partnership agreements related to our product candidates could delay the development and commercialization of such candidates and reduce their competitiveness even if they reach the market. If we are not able to generate revenue under our strategic partnerships when and in accordance with our expectations or the expectations of industry analysts, this failure could harm our business and have an immediate adverse effect on the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to establish and maintain additional strategic partnerships related to our unpartnered product candidates, we will bear all of the risk and costs related to the development of any such product candidate, and we may need to seek additional financing, hire additional employees and otherwise develop expertise, such as regulatory expertise, for which we have not budgeted. If we were not successful in seeking additional financing, hiring additional employees or developing additional expertise, our cash burn rate would increase or we would need to take steps to reduce our rate of product candidate development. This could negatively affect the development of any unpartnered product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to commercialization of our ADC product candidates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future commercial success depends upon attaining significant market acceptance of our ADC product candidates, if approved, among physicians, patients and health care payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for UpRi, XMT-1592, or any other current or future product candidates that we may develop or acquire in the future, the product candidate may not gain market acceptance among physicians, health care payors, patients and the broader healthcare community. Market acceptance of any approved products depends on a number of factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety of the product, as demonstrated in clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the indications for which the product is approved and the label approved by regulatory authorities for use with the product, including any warnings that may be required on the label;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians and patients of the product as a safe and effective treatment;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, safety and efficacy of treatment in relation to alternative treatments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate reimbursement and pricing by third-party payors and government authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Perceptions of any product are influenced by perceptions of competitors&#8217; products that are in the same class of drugs or have a similar mechanism of action. As a result, adverse public perception of our competitors&#8217; products may negatively impact the market acceptance of our product candidates. Market acceptance is critical to our ability to generate significant revenue and become profitable. Any therapeutic candidate, if approved and commercialized, may be accepted in only limited capacities or not at all. If any approved products are not accepted by the market to the extent that we expect, we may not be able to generate significant revenue and our business would suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our drug candidates have not been established with precision. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The precise incidence and prevalence of ovarian cancer and other cancers with NaPi2b expression are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. The total addressable market opportunity for UpRi or XMT-1592 for the treatment of ovarian cancer and non-squamous non-small cell lung cancer with NaPi2b expression will ultimately depend upon, among other things, the diagnosis criteria included in the final label for UpRi or XMT-1592, if our product candidates are approved for sale for these indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients who can be treated with our product candidates may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if and when they are approved.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales and marketing organization or pursue a collaborative arrangement for such sales and marketing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we expect to build a focused sales and marketing infrastructure to market UpRi, XMT-1592, and any other current or future product candidates in the United States and certain foreign jurisdictions, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales, marketing and distribution capabilities and enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute certain of our product candidates outside of the United States or may be unable to do so on terms that are favorable to us. We likely will have limited control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement may be limited or unavailable in certain market segments for our ADC product candidates, which could make it difficult for us to sell our products profitably.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both domestic and foreign markets, sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of our products will be covered by third-party payors, such as government health programs, commercial insurance and managed health care organizations. These third-party payors decide which drugs will be covered and establish reimbursement levels for those drugs. The containment of health care costs has become a priority of foreign and domestic governments as well as private third-party payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability to sell our product candidates profitably. Cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower than anticipated product revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse pricing limitations may hinder our ability to recoup our investment in UpRi, XMT-1592, or any other current or future product candidates, even if such product candidates obtain marketing approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. Further, there is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our products. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our products. In addition, in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly approved drugs, which in turn will put pressure on the pricing of drugs. Manufacturers further may be required to offer price concessions to achieve sales or favorable coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, including member states of the European Union, the pricing of prescription drugs is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In such countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical trial or other trials that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. We cannot be sure that such prices and reimbursement will be acceptable to us or our strategic partners. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of our product candidates in those countries would be negatively affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, and if our competitors develop and market products that are more effective, safer or less expensive than any of our current or future product candidates, our commercial opportunities will be negatively impacted.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. Many third parties compete with us in developing various approaches to cancer therapy. They include pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. Any treatments developed by our competitors could be superior to our product candidates. It is possible that these competitors will succeed in developing technologies that are more effective than our platforms or product candidates or that would render our platforms obsolete, noncompetitive or not economical. We anticipate that we will face increased competition in the future as additional companies enter our market and scientific developments surrounding other cancer therapies continue to accelerate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also aware of multiple companies with ADC technologies that may be competitive to our platforms, including Daiichi Sankyo, ImmunoGen, Gilead (Immunomedics), Pfizer and SeaGen. These companies or their partners, including Astellas, AstraZeneca, AbbVie, Genentech/Roche and Takeda, may develop product candidates which compete in the same indications as our current and future product candidates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Multiple companies are also developing immune stimulating ADC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s which could compete with our Immunosynthen products, including Bolt Biotherapeutics, Inc., Takeda, and Silverback Therapeutics, Inc. We expect to compete on improved efficacy, safety and tolerability compared to other product candidates and if our products are not demonstrably superior in these respects compared to other approved therapeutics, we may not be able to compete effectively. Products we may develop in the future are also likely to face competition from other products and therapies, some of which we may not currently be aware.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approval and marketing than we do. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting royalties for use of technology that they have developed. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, establishing clinical trial sites, recruiting patients and in manufacturing pharmaceutical products and may succeed in discovering, developing and commercializing products in our field before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through strategic partnerships with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, as well as in acquiring technologies complementary to our programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our product candidates are approved and commercialized, we may face competition from biosimilars. The route to market for biosimilars was established with the passage of the Health Care Reform Act in March 2010. The Biologics Price Competition and Innovation Act of 2009, or BPCIA,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">establishes a pathway for the FDA approval of follow-on biologics and provides twelve years data exclusivity for reference products. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Further, since the BPCIA was enacted as part of the overall Health Care Reform Act, current litigation challenges to that Act, discussed more in full below, could impact the validity of the BPCIA. As a result, there still remains significant uncertainty as to the ultimate impact, implementation and regulatory interpretation of the BPCIA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the European Medicines Agency has issued guidelines for approving products through an abbreviated pathway, and biosimilars have been approved in Europe. If a biosimilar version of one of our potential products were approved in the United States or Europe, it could have a negative effect on sales and gross profits of the potential product and our financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our current and potential future product candidates, we believe that our ability to compete effectively and develop products that can be manufactured cost-effectively and marketed successfully will depend on our ability to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our technology platforms;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and maintain intellectual property protection for our technologies and products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required government and other public and private approvals on a timely basis;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize effectively;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain reimbursement for our products in approved indications;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply with applicable laws, regulations and regulatory requirements and restrictions with respect to the commercialization of our products, including with respect to any changed or increased regulatory restrictions; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into additional strategic partnerships to advance the development and commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or protect intellectual property rights related to our technology and ADC product candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain protection with respect to our intellectual property and proprietary technology. We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our platforms and our product candidates, including UpRi and XMT-1592. The patent position of biopharmaceutical companies is generally uncertain because it involves complex legal and factual considerations and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights is highly uncertain. The standards applied by the United States Patent and Trademark Office, or USPTO, and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. In addition, changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The patent prosecution process is expensive, complex and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. We may be unaware of prior art that could be used to invalidate an issued patent or prevent our pending patent applications from issuing as patents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent applications that we own or in-license may fail to result in issued patents, and even if they do issue as patents, such patents may not cover our platforms and product candidates in the United States or in other countries. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. For example, even if patent applications we license or own do successfully issue as patents and even if such patents cover our platforms and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not provide adequate protection or exclusivity for our ADC platform or product candidates, prevent others from designing around our claims or otherwise provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If patent applications we own or have in-licensed with respect to our platforms or our product candidates fail to issue as patents, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could dissuade companies from collaborating with us. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patents or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful development and commercialization of any product candidate. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by the USPTO or a third-party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent and the protection it affords is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, our owned or in-licensed patents protecting such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates might expire before or shortly after such candidates are commercialized. If we encounter delays in obtaining regulatory approvals, the period of time during which we could market a drug under patent protection could be further reduced. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from similar or generic products. The launch of a generic version of one of our products in particular would be likely to result in an immediate and substantial reduction in the demand for our product, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, which could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. These provisions also allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first-to-file provisions, only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any loss of patent protection could have a material adverse impact on our business. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering UpRi, XMT-1592, and any other current or future ADC product candidates could be found invalid or unenforceable if challenged in court or before the USPTO or comparable foreign authority.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering UpRi, XMT-1592, or any other current or future product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be, among other things, an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, lack of written description or non-enablement. Grounds for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we, our licensors, our patent counsel and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Any such loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, strategic partnership or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on license, collaboration and other agreements. We may need to obtain additional licenses from others to advance our research or allow commercialization of our product candidates and it is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. The licensing or acquisition of third party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to use. We also may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our existing licenses and collaboration agreements, including our license with Recepta Biopharma S.A., or Recepta, for intellectual property covering the NaPi2b antibody in UpRi and XMT-1592, and our license with Synaffix B.V., or Synaffix, for intellectual property covering components included in the Dolasynthen platform, impose, and any future licenses, collaborations or other agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, including, in the case of our agreement with Recepta, the license for the rights covering the NaPi2b antibody in UpRi and XMT-1592, and in the case of our agreement with Synaffix, the license for the rights covering components in the Dolasynthen platform. Any of the foregoing could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Disputes may arise regarding intellectual property subject to a licensing, collaboration or other agreements, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation related issues;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inventorship and ownership of inventions and know how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the priority of invention of patented technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering the technology that we license from third parties. For example, pursuant to our license agreement with Recepta, Ludwig Institute for Cancer Research Ltd., a co-owner of the intellectual property, retains control of such activities. Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. If our licensors fail to obtain or maintain such intellectual property, or lose rights to such intellectual property, the rights we have licensed and our exclusivity may be reduced or eliminated and our right to develop and commercialize any of our products that are subject to such licensed rights could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate and our business, financial condition, results of operations and prospects could suffer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property or to defend against intellectual property claims, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors and other third parties may infringe our patents or misappropriate or otherwise violate our owned and in-licensed intellectual property rights. To counter infringement or unauthorized use, litigation or other intellectual property proceedings may be necessary to enforce or defend our owned and in-licensed intellectual property rights, to protect our trade secrets or to determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Such litigation or proceedings can be expensive and time consuming, and any such claims could provoke defendants to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Many of our current and potential competitors have the ability to dedicate substantially greater resources to litigate intellectual property rights than we can and have more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. Even if resolved in our favor, litigation or other intellectual property proceedings could result in substantial costs and diversion of management attention and resources, which could harm our business and financial results.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in a litigation or other proceeding, a court or administrative judge may decide that a patent owned by or licensed to us is invalid or unenforceable, or a court may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. During the course of any patent or other intellectual property litigation or other proceeding, there could be public announcements of the results of hearings, rulings on motions and other interim proceedings or developments and if securities analysts or investors regard these announcements as negative, the perceived value of our product candidates, programs or intellectual property could be diminished. Accordingly, the market price of our common stock may decline. Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement or misappropriation may prevent or delay our development and commercialization efforts.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability and the ability of our strategic partners to develop, manufacture, market and sell product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, reexamination, inter partes review, derivation and post grant review proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing and may develop our product candidates. As the biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we, our customers, licensees or parties indemnified by us are employing their proprietary technology without authorization or have infringed upon, misappropriated or otherwise violated their intellectual property or other rights, regardless of their merit. For example, we may be subject to claims that we are infringing the patent, trademark or copyright rights of third parties, or that our employees have misappropriated or divulged their former employers&#8217; trade secrets or confidential information. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, that we failed to identify. For example, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until issued as patents. Except for certain exceptions, including the preceding exceptions, patent applications in the United States and elsewhere are generally published only after a waiting period of approximately 18 months after the earliest filing, and sometimes not at all. Therefore, patent applications covering our platforms or our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platforms, our product candidates or the use or manufacture of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we believe a third party&#8217;s claims against us are without merit, a court of competent jurisdiction could hold that such third party&#8217;s patent is valid, enforceable and cover aspects of our product candidates, including the materials, formulations, methods of manufacture, methods of analysis, or methods for treatment, in which case, such third party would be able to block our ability to develop and commercialize the applicable technology or product candidate until such patent expired or unless we obtain a license and we may be required to pay such third-party monetary damages, which could be substantial. Such licenses may not be available on acceptable terms, if at all. Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property and it could require us to make substantial licensing and royalty payments. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our technologies or one or more of our product candidates. Defending against claims of patent infringement, misappropriation of trade secrets or other violations of intellectual property could be costly and time consuming, regardless of the outcome. Thus, even if we were to ultimately prevail, or to settle at an early stage, such litigation could burden us with substantial unanticipated costs. In addition, litigation or threatened litigation could result in significant demands on the time and attention of our management team, distracting them from the pursuit of other company business. In the event of a successful claim of infringement against us, in addition to potential injunctive relief, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face a claim of misappropriation if a third party believes that we inappropriately obtained and used trade secrets of such third party. If we are found to have misappropriated a third party&#8217;s trade secrets, we may be prevented from further using such trade secrets, limiting our ability to develop our product candidates, we may be required to obtain a license to such trade secrets which may not be available on commercially reasonable terms or at all and may be non-exclusive, and we may be required to pay damages, which could be substantial. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world where we expect there to be significant markets for our products could be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, our intellectual property license agreements may not always include worldwide rights. For example, certain U.S. and foreign issued patents and patent applications are licensed to us by Recepta on a worldwide basis, except that Recepta retains exclusive rights in such patents and patent applications in Brazil. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our licensed and owned patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing as patents, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our platform technology and discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants and outside scientific advisors, contractors and partners. We cannot guarantee that we have entered into such agreement with each party that may have or have had access to our trade secrets or proprietary technology and processes. Additionally, our confidentiality agreements and other contractual protections may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation. We may not have adequate remedies in the case of a breach of any such agreements, and our trade secrets and other proprietary information could be disclosed to our competitors or others may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, some courts outside and within the United States sometimes are less willing to protect trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our licensors, employees, consultants, advisors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our and our licensors&#8217; employees, including our senior management, consultants or advisors are currently, or previously were, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, including members of our senior management, executed proprietary rights, non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Any of the foregoing may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our owned or in-licensed U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be materially harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and non-U.S. patent agencies. The USPTO and various non-U.S. government agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make ADC products that are similar to any product candidates we may develop or utilize similar ADC-related technology but that are not covered by the claims of the patents that we license or may own in the future;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future strategic partners, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our license partners or current or future strategic partners, might not have been the first to file patent applications covering certain of our or their inventions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may subsequently file a patent covering such intellectual property.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to regulatory approval and other legal compliance matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a biologics licensing application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. Any approval we may be granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions and any of our product candidates that may be approved for marketing in a foreign jurisdiction will be subject to risks associated with foreign operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to market our current product candidates, including UpRi, our lead product candidate, and XMT-1592, each, if approved, in international markets either directly or through partnerships. In order to market and sell our products in the European Union and other foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we fail to comply with applicable non-U.S. regulatory requirements, our target markets will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom is no longer part of the European Single Market and European Union Customs Union. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval is subject to ongoing regulation and could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements, when and if any of our product candidates are approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. In addition, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy. Accordingly, if we receive marketing approval for one or more of our product candidates, we will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we fail to comply with these requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any products could be limited, which could adversely affect our ability to achieve or sustain profitability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic. Violations of the Federal Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on such products, manufacturers or manufacturing processes; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the labeling or marketing of a product; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on distribution or use of a product; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters or untitled letters; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of the products from the market; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall of products; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">damage to relationships with collaborators; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable press coverage and damage to our reputation; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or withdrawal of marketing approvals; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to permit the import or export of our products; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation involving patients using our products. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar restrictions apply to the approval of our products in the European Union. The holder of a marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include compliance with the European Union&#8217;s stringent pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations; the manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory; and the marketing and promotion of authorized drugs, which are strictly regulated in the European Union and are also subject to EU Member State laws.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, in connection with our currently approved products and assuming we, or our collaborators, receive marketing approval for one or more of our product candidates, we, and our collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we, and our collaborators, are not able to comply with post-approval regulatory requirements, our or our collaborators&#8217; ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including but not limited to Breakthrough Therapy, Fast Track and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FDA granted Fast Track Designation for UpRi for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#8217;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#8217;s grant of a marketing authorization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the Securities and Exchange Commission and other government agencies, including from government shut downs, or other disruptions to these agencies&#8217; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the Securities and Exchange Commission, or SEC, and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. As of May 26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently conducting clinical trials for UpRi, and may conduct future clinical trials for our other product candidates at sites outside of the United States, and the FDA may not accept data from trials conducted in such locations or the complexity of regulatory burdens may otherwise adversely impact us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting and we plan to continue to conduct clinical trials outside of the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with GCPs. If the foreign data is the sole basis for a marketing application, then the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful and the FDA must be able to validate the data through an on-site inspection, if necessary. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. If the FDA does not accept the data from any clinical trial that we conduct outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully initiate, enroll and complete a clinical trial in any country outside of the United States is subject to numerous additional risks unique to conducting business in jurisdictions outside the United States, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different local standards for the conduct of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in complying with various and complex import laws and regulations when shipping drug to certain countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of consistency in standard of care from country to country;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished protection of intellectual property in some countries;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange fluctuations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cultural differences in medical practice and clinical research; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in country or regional regulatory requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the COVID-19 pandemic may also have an impact on our ability to successfully conduct trials outside of the United States. For example, we are conducting UPLIFT in countries where clinical trial site staff have been diverted to care for COVID-19 patients and where regulatory authorities are short staffed due to the COVID-19 pandemic. If we have difficulty conducting our clinical trials in jurisdictions outside the United States as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which could have a material adverse effect on our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated approval by the FDA, even if granted for UpRi or any other current or future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek approval of UpRi and any of our other current and future product candidates using the FDA&#8217;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition, generally provides a meaningful advantage over available therapies, and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA or other applicable regulatory agency makes the determination regarding whether a surrogate endpoint is reasonably likely to predict long-term clinical benefit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to seeking such accelerated approval, we will seek feedback from the FDA and otherwise evaluate our ability to seek and receive such accelerated approval. As a condition of approval, the FDA requires that a sponsor of a product receiving accelerated approval perform an adequate and well-controlled post-marketing confirmatory clinical trial or trials. These confirmatory trials must be completed with due diligence and we may be required to evaluate different or additional endpoints in these post-marketing confirmatory trials. These confirmatory trials may require enrollment of more patients than we currently anticipate and will result in additional costs, which may be greater than the estimated costs we currently anticipate. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the FDA will agree with any proposed surrogate endpoints or that we will decide to pursue or submit an BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that, after feedback from FDA, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or under another expedited regulatory designation, there can be no assurance that such submission or application will be accepted or that any expedited review or approval will be granted on a timely basis, or at all.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval of a product candidate approved under the accelerated approval pathway if, for example, the trial required to verify the predicted clinical benefit of our product candidate fails to verify such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug. The FDA may also withdraw approval if other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions of use, we fail to conduct any required post approval trial of our product candidate with due diligence or we disseminate false or misleading promotional materials relating to our product candidate. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidates, or withdrawal of a product candidate, would result in a longer time period for commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate full FDA approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party collaborators are unable to successfully develop and commercialize any required companion diagnostics for our product candidates or engage a third party to do so, or we or they experience significant delays in doing so, we may not realize the full potential of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a companion diagnostic is required for the label for UpRi, our lead product candidate, XMT-1592, or any of our other current or future product candidates, therefore conditioning our ability to market such product candidates on the commercial availability of an approved companion diagnostic, we may seek approval for our validated assay as a companion diagnostic or we may contract with third parties to create and obtain approval for a companion diagnostic. To be successful in developing and commercializing such a companion diagnostic, we need to address a number of scientific, technical and logistical challenges. We have little experience in the development and commercialization of companion diagnostics and may not be successful in developing and commercializing appropriate companion diagnostics to pair with UpRi, XMT-1592, or any of our other current or future product candidates. Companion diagnostics are subject to regulation by the FDA and equivalent foreign regulatory authorities as medical devices and require separate regulatory approval prior to commercialization. Given our limited </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience in developing diagnostics, we may rely in part or in whole on third parties for their design, manufacture and commercialization. We, our collaborators or such third parties may encounter difficulties in developing and obtaining approval for the companion diagnostics, including issues relating to selectivity/specificity, analytical validation, reproducibility or clinical validation. Any delay or failure by us, our collaborators or such third parties to develop or obtain regulatory approval of the companion diagnostics could delay or prevent approval of our product candidates. If we, or any third parties that we may contract with to assist us, are unable to successfully develop and commercialize companion diagnostics for our product candidates, or experience delays in doing so:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the development of UpRi, XMT-1592, and our other current or future product candidates, may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not receive marketing approval if safe and effective use of a product candidate depends on the availability of an companion diagnostic and/or complementary diagnostics and such diagnostic is not commercially available or otherwise approved or cleared by the appropriate regulatory authority; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not realize the full commercial potential of any product candidates that receive marketing approval if, among other reasons, we are unable to appropriately select patients who are likely to benefit from therapy with our products, if approved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, our business would be harmed, possibly materially.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third-party collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our product candidates, if approved. In addition, any diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities, including our interactions with healthcare providers, third party payors, patients and government officials, are, and will continue to be, subject to extensive regulation involving health care, anti-corruption, data privacy and security and consumer protection laws. Failure to comply with applicable laws could result in substantial penalties, contractual damages, reputational harm, diminished revenues and curtailment or restructuring of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities may now or in the future be directly or indirectly subject to various federal and state laws related to health care, anti-corruption, data privacy and security consumer protection. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws include, but are not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing any remuneration, directly or indirectly, to induce, either the referral of an individual for, or the purchasing or ordering of a good or service, for which payment may be made under federal health care programs such as the Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal anti-kickback prohibition known as Eliminating Kickbacks in Recovery Act, enacted in 2018, which prohibits certain payments related to referrals of patients to certain providers (recovery homes, clinical treatment facilities and laboratories) and applies to services reimbursed by private health plans as well as government health care programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal law known as Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program (which may include private health plans) or making false statements relating to healthcare matters;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug marketing, prohibits manufacturers from marketing such products for off-label use and regulates the distribution of samples;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the so-called &#8220;federal sunshine&#8221; law, which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with teaching hospitals, physicians and certain non-physician practitioners to the federal government for re-disclosure to the public;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the privacy, security and breach provisions of HIPAA, which impose obligations on certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) and certain of their &#8220;business associate&#8221; contractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state laws and regulations, including state security breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Foreign Corrupt Practices Act, or FCPA, a United States law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals); and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law analogues of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including private health plans, state privacy laws, state consumer protection laws, and state laws regulating interactions between pharmaceutical manufacturers and healthcare providers, requiring disclosure of such financial interactions or mandating adoption of certain compliance standards, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the regulatory approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the health care laws mentioned above, among other foreign laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable health care laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us to obtain reimbursement for our product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, collectively the ACA. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. These Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022, a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our products or product candidates for which we may obtain regulatory approval or the frequency with which any such product is prescribed or used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts for Jobs Act, or TCJA, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA and therefore because the mandate was repealed as part of the TCJA, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care and consider actions that will protect and strengthen that access.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been incorporated into regulations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the Center for Medicare &amp; Medicaid Services, or CMS, issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed by the Biden administration until January 1, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The order directs the Department of Health and Human Services, or HHS, to create a plan within 45 days to combat &#8220;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, HHS released its plan to reduce pharmaceutical prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; (b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic drugs, and increase transparency; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country and many countries have instituted price ceilings on specific products and therapies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries, including those of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or the EEA, and the processing of personal data that takes place in the EEA, is regulated by the General Data Protection Regulation, or GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we were not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we further expand our operations outside the United States, we will need to dedicate additional resources to comply with U.S. laws regarding international operations and the laws and regulations in each jurisdiction in which we operate and plan to operate. The FCPA prohibits any U.S. individual or business from paying, offering or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries and to devise and maintain an adequate system of internal accounting controls for international operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry because in many countries, hospitals are operated by the government and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Further, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of E.U. Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians in certain E.U. Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual E.U. Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct applicable in the E.U. Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we expand our presence outside of the United States , it will require us to dedicate additional resources to comply with these laws and these laws may preclude us from developing, manufacturing or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our third-party contract manufacturers must comply with environmental, health and safety laws and regulations, and failure to comply with these laws and regulations could expose us to significant costs or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our third-party manufacturers are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations, we could be held liable for any resulting damages and any such liability could exceed our assets and resources. We could also incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, with respect to the operations of our third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal health care programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business and industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our ADC product candidates, conduct our clinical trials and commercialize our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on members of our senior management, including Anna Protopapas, our President and Chief Executive Officer. The loss of the services of any of our senior management could impede the achievement of our research, development and commercialization objectives. Also, each of these persons may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, sales and marketing personnel will also be critical to our success. We conduct our operations at our facility in Cambridge, Massachusetts, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors, may be employed or have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to advance our product candidates through clinical trials and commercialization, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and, if necessary, sales and marketing personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to accomplish these tasks, and our failure to accomplish any of them could prevent us from successfully growing our company or disrupt our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our ADC product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop causes, or is perceived to cause, injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates or products that we may develop;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigations;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to clinical trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We currently carry product liability insurance covering our clinical trials in the amount of $10 million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. In such instance, we might have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are unable to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot be assured that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those of our strategic partners, third-party collaborators or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business, including through material disruptions of our programs or business operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal information technology systems and those of our current or future strategic partners, third party collaborators and other contractors and consultants are vulnerable to service interruptions or security breaches, including from cyber-attacks, computer viruses, ransomware, malware, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If a failure, accident or security breach were to occur and cause interruptions in our operations or the operations of those third parties with which we contract, it could result in a material disruption of our programs and our business operations. We could lose access to our trade secrets or other proprietary information or experience other disruptions, which could require a substantial expenditure of resources to remedy. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in our information systems and networks, including personal information of our employees or others. Outside parties may attempt to penetrate our systems or those of the third parties with which we contract or to coerce or fraudulently induce our employees or employees of such third parties to disclose sensitive information to gain access to our data. The number and complexity of these threats continue to increase over time. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, such risks cannot be eliminated. Furthermore, there can be no assurance that we, or those third parties with which we contract, will promptly detect any such disruption or security breach, if at all. Additionally, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities, our competitive position and the market perception of the effectiveness of our security measures could be harmed, our credibility could be damaged and the further development of our product candidates could be delayed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our common stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our stock price is volatile, our stockholders could incur substantial losses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and may continue to be volatile. During the period from February 25, 2019 to February 25, 2022, the closing price of our common stock ranged from a high of $27.59 per share to a low of $1.45 per share. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this &#8220;Risk Factors&#8221; section, and others beyond our control, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results and timing of preclinical studies and clinical trials of our current or future product candidates, including UpRi and XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials of our competitors&#8217; products;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to adequately protect our trade secrets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms on which we raise additional capital or our ability to raise it;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of any strategic partnership or licensing arrangement;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments, including actions with respect to our products or our competitors&#8217; products;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our financial condition and operating results;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">publication of research reports by securities analysts about us or our competitors or our industry;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions and departures of key personnel;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the passage of legislation or other regulatory developments affecting us or our industry;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us (including pursuant to the pre-funded warrants described below), our insiders or our other stockholders;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">speculation in the press or investment community;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in market conditions for biopharmaceutical stocks; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in general market and economic conditions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market has historically experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. As a result of this volatility, stockholders may not be able to sell their common stock at or above the price for which they paid for their shares. As we operate in a single industry, we are especially vulnerable to these factors to the extent that they affect our industry or our products, or to a lesser extent our markets. Furthermore, as a result of this volatility, we may not be able to maintain compliance with listing requirements of the Nasdaq Stock Market. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exercise significant influence over matters subject to stockholder approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our executive officers, directors and stockholders who own more than 5% of our outstanding common stock, together with their respective affiliates, beneficially owned a significant amount of our common stock, including shares subject to outstanding options and warrants that are exercisable within 60 days after such date. Accordingly, these stockholders, if they act together, could be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of our board of directors and approval of significant corporate transactions. This concentration of ownership could have the effect of entrenching our management or board of directors, delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of us, which in turn could have a material and adverse effect on the fair market value of our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not expect to pay any cash dividends for the foreseeable future.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate that we will pay any cash dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our operations. In addition, our credit facility contains terms and any future debt financing arrangement may contain additional terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our amended and restated certificate of incorporation, our amended and restated by-laws and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. Our amended and restated certificate of incorporation and by-laws include provisions that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">create a classified board of directors whose members serve staggered three-year terms;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that special meetings of our stockholders can be called only by our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholder action by written consent;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that our directors may be removed only for cause;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expressly authorize our board of directors to have discretion to modify, alter or repeal our amended and restated by-laws; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated by-laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation, amended and restated by-laws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses and certain tax credit carryforwards may be subject to certain limitations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, we recorded no income tax benefit for the net operating losses incurred in each year, due to the uncertainty of realizing a benefit from those items. We have incurred net operating losses (NOLs) since our inception. As of December&#160;31, 2021, we have federal NOLs of approximately $403.6 million and state NOLs of approximately $337.1 million. Of the $403.6 million of federal NOLs, $34.1 million expire at various dates through 2037. The remaining $369.4 million of federal NOLs do not expire. The state NOLs will expire at various dates through 2041. As of December&#160;31, 2021, we had Federal and State research and development tax credit carryforwards of approximately $10.1 million and $3.1 million, respectively, which expire at various dates through 2041. Under the 2017 Tax Act, federal NOLs incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs is limited. It is uncertain if and to what extent various states will conform to the 2017 Tax Act. In addition, under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes to offset its post-change income or taxes may be limited. Our past issuances of stock and other changes in our stock ownership may have resulted in ownership changes within the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaning of Section 382 of the Code; accordingly, our pre-change NOLs may be subject to limitation under Section 382. If we determine that we have not undergone an ownership change, the Internal Revenue Service could challenge our analysis, and our ability to use our NOLs to offset taxable income could be limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in ownership changes under Section 382 of the Code further limiting our ability to utilize our NOLs. Our NOLs may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs. We have determined that ownership changes have occurred since our inception and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. We may also have incurred subsequent ownership changes. Furthermore, our ability to utilize our NOLs is conditioned upon our attaining profitability and generating U.S. federal taxable income. We have incurred net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future; thus, we do not know whether or when we will generate the U.S. federal taxable income necessary to utilize our NOLs. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation designates the state or federal courts within the State of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated by-laws, (4) any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or amended and restated by-laws or (5) any other action asserting a claim against us that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Any person or entity that purchases or otherwise acquires any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exclusive forum provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, which provides for exclusive jurisdiction of the federal courts. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act of 1933, as amended, or the Securities Act, inasmuch as Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, provided, that with respect to claims under the Securities Act, our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock and trading volume could decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends, in part, on the research and reports that industry or financial analysts publish about us or our business. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to regularly publish reports on us, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A portion of our total outstanding shares may be sold into the market in the near future, which could cause the market price of our common stock to decline significantly, even if our business is doing well.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a significant number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have registered substantially all shares of common stock that we may issue under our equity compensation plans. These shares can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General risk factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks arising from the outbreaks of disease, such as epidemics or pandemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The widespread infection of COVID-19 in the United States and abroad has caused significant volatility and uncertainty in U.S. and international markets, which could result in a prolonged economic downturn that may disrupt our business, including by adversely affecting our ability to conduct financings on terms acceptable to us, if at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience disruptions that could severely impact our business, preclinical studies and clinical trials, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial materials, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to withdraw from our trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and or patient dosing in our ongoing clinical trials in order to preserve health resources and protect clinical trial participants, which could delay our clinical trials or impact the strength or validity of our clinical trial data. It is unknown how long these pauses or disruptions could continue.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently rely on third parties to, among other things, manufacture raw materials, manufacture our product candidates for our clinical trials, shipping of investigational drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. If any such third party in our supply chain for materials are adversely impacted by restrictions resulting from the coronavirus pandemic, including staffing shortages, raw material supplies, production slowdowns or disruptions in delivery systems, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and conduct our research and development operations.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trials sites and other important agencies and contractors.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees and contractors conducting research and development activities may not be able to access our laboratory for an extended period of time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions. As a result, this could delay timely completion of preclinical activities, including completing IND-enabling studies or our ability to select future development candidates, and initiation of additional clinical trials for other of our development programs</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health regulatory agencies globally may experience disruptions in their operations as a result of the COVID-19 pandemic. The FDA and comparable foreign regulatory agencies may have slower response times or be under-resourced to continue to monitor our clinical trials and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any prolongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development of our product candidates. For example, regulatory authorities may require that we not distribute a product candidate lot until the relevant agency authorizes its release. Such release authorization may be delayed as a result of the COVID-19 pandemic and could result in delays to our clinical trials.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The COVID-19 pandemic may cause the trading prices for our common shares and other biopharmaceutical companies' shares to be highly volatile. As a result, we may face difficulties raising capital through sales of our common shares or such sales may be on unfavorable terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the coronavirus could materially and adversely affect our business and the value of our common shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the coronavirus pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the emergence and severity of new variants of the virus, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19, the timing, availability, efficacy, adoption and distribution of vaccines or other preventative treatments and other actions taken to contain coronavirus or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or the third parties upon whom we depend, may be adversely affected by serious disasters.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any unplanned event, such as a flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power shortage, telecommunication failure or other natural or human-made accident or incident that results in us being unable to fully use our facilities, or the facilities of third parties with which we contract, may have a material and adverse effect on our ability to operate our business and may have significant negative consequences on our financial and operating conditions. Loss of access to these facilities or operations may result in increased costs, delays in the development of our current or future product candidates or the interruption of our business operations for a substantial period of time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the amounts of insurance that we maintain will be sufficient to satisfy any damages and losses in the event a serious disaster or similar event occurs. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs and commercialization efforts may be harmed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic or geopolitical conditions could adversely affect our business, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy, geopolitical considerations and global financial market conditions. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets. We cannot assure stockholders that deterioration of the global credit and financial markets would not negatively impact our stock price, our current portfolio of cash equivalents or investments, or our ability to meet our financing objectives. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. A weak or declining economy, or emerging or actual geopolitical risks could also strain our suppliers and vendors involved in our clinical development activities. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic and geopolitical climate and financial market conditions could adversely impact our business.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_22"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_25"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;PROPERTIES.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Cambridge, Massachusetts. We occupy approximately 45,000 square feet of office and laboratory space that we lease in a multi-tenant building in which our corporate headquarters are located, which lease expires in March 2026. We have an option to extend the lease term for an additional five years thereafter. We believe that this office and laboratory space is sufficient to meet our current needs, and that suitable additional space will be available as and when needed.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_28"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently party to any material legal proceedings. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe we are party to any claim or litigation, the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. </span></div><div id="i54c829abb8e046e0ba4639af9592e947_31"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i54c829abb8e046e0ba4639af9592e947_37"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Information Regarding the Trading of Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;MRSN&#8221; on the Nasdaq Global Select Market. As of February&#160;25, 2022, there were 18 holders of record of shares of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. In addition, our loan and security agreement with Silicon Valley Bank and Oxford Finance LLC contains restrictive covenants that prohibit us, subject to certain exceptions, from paying dividends on our common stock. Any future determination to pay cash dividends will be made at the discretion of our board of directors and will depend on restrictions and other factors our board of directors may deem relevant. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the performance of our common stock to the Nasdaq Composite Index and to the Nasdaq Biotechnology Index from June 28, 2017 (the first date that shares of our common stock were publicly traded) through December&#160;31, 2021, which was the last trading day of the year. The comparison assumes $100 was invested in our common stock and in each of the foregoing indices after the market closed on June 28, 2017, and it assumes reinvestment of dividends, if any. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-top:12pt;text-align:center"><img src="mrsn-20211231_g2.jpg" alt="mrsn-20211231_g2.jpg" style="height:354px;margin-bottom:5pt;vertical-align:text-bottom;width:475px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2021, we granted our chief human resources officer an option to purchase 100,000 shares of our common stock, on April 26, 2021, we granted our chief legal officer an option to purchase 112,500 shares of our common stock, on August 18, 2021, we granted our senior vice president and chief manufacturing officer an option to purchase 112,500 shares of our common stock and on October 27, 2021, we granted our senior vice president, strategic product planning &amp; program leadership an option to purchase 112,500 shares of our common stock, each as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). No underwriters were involved in the foregoing issuances of securities. The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. The recipients either received adequate information about us or had access, through other relationships, to such information.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock option is scheduled to become exercisable as to 25% of the shares underlying the option on the first anniversary of the date of grant, and as to an additional 8.33% of the shares underlying the option at the end of each successive quarter following such date, subject to each recipient&#8217;s continued service. The option granted to our chief human resources officer has an exercise price of $21.67, the option granted to our chief legal officer has an exercise price of $16.98 per share, the option granted to our senior vice president and chief manufacturing officer has an exercise price of $11.56 per share and the option granted to our senior vice president, strategic product planning &amp; program leadership has an exercise price of $8.63 per share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliates Purchasers</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neither we nor any affiliated purchaser or anyone acting on behalf of us or an affiliated purchaser made any purchases of shares of our common stock during the fourth quarter of 2021. </span></div><div id="i54c829abb8e046e0ba4639af9592e947_40"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;[RESERVED]</span></div><div id="i54c829abb8e046e0ba4639af9592e947_43"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of results or developments in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in the Annual Report on Form 10-K, including those risks identified under Part II, Item 1A. Risk Factors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, or SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For our discussion and analysis of the year ended December 31, 2020 compared to the year ended December 31, 2019, please refer to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 26, 2021.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_46"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged over 20&#160;years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable us to develop ADCs designed to have improved efficacy, safety and tolerability relative to existing ADC therapies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our innovative platforms, including Dolaflexin and Dolasynthen, delivering our proprietary auristatin DolaLock payload, as well as Immunosynthen, which delivers our novel proprietary stimulator of interferon genes, or STING, agonist ImmunoLock payload, together comprise a highly efficient product engine that has enabled a robust discovery pipeline for us and our partners. Our ADCs in preclinical studies and clinical trials include first-in-class molecules that target multiple tumor types with high unmet medical need. Our belief is that our novel ADCs may have more favorable safety and efficacy compared to more traditional existing ADCs developed using first-generation technology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leading oncology company by leveraging the potential of our innovative and differentiated ADC technologies and the experience and competencies of our management team to identify, acquire and develop promising ADC product candidates and to commercialize cancer therapeutics that are improvements over existing treatments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UpRi (upifitamab rilsodotin), our first-in-class ADC targeting the sodium-dependent phosphate transport protein NaPi2b, utilizes the Dolaflexin platform to deliver about 10 DolaLock payload molecules per antibody. We believe the NaPi2b antigen is broadly expressed in ovarian cancer and other cancers with limited expression in normal tissue. We are currently evaluating UpRi in platinum-resistant ovarian cancer in a single-arm registrational trial, which we refer to as UPLIFT, for which we expect to complete enrollment in the third quarter of 2022. We are also conducting a Phase 1/2 umbrella combination trial, which we refer to as UPGRADE. The first combination we are exploring is the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer. We may explore other combinations in the future. We expect to report interim data from UPGRADE in the second half of 2022. In the second quarter of 2022, we expect to initiate enrollment in a randomized placebo-controlled Phase 3 trial, which we refer to as UP-NEXT, to evaluate UpRi as single agent maintenance treatment in patients with platinum-sensitive ovarian cancer that have high NaPi2b expression. Together, data from these trials have the potential to establish the safety and efficacy of UpRi across a wide range of ovarian cancer patients, from those who are platinum-resistant and heavily pre-treated to those in earlier lines of the disease.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XMT-1592 was created using our Dolasynthen platform and also targets NaPi2b.&#160;XMT-1592 comprises the same proprietary NaPi2b antibody and auristatin DolaLock payload with controlled bystander effect as in UpRi, with the additional features that our Dolasynthen platform offers, including homogeneity, site-specific bioconjugation and precise drug-to-antibody ratio, or DAR. We are conducting a Phase 1 dose exploration trial of XMT-1592 in patients with ovarian cancer and non-small cell lung cancer, NSCLC, adenocarcinoma, which we expect to complete in the second half of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early-stage programs include XMT-1660, a B7-H4-targeted Dolasynthen ADC, as well as XMT-2056, a STING-agonist ADC developed using our novel Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2, or HER2. Our goal is to rapidly progress these candidates through investigational new drug, or IND, -enabling studies. We expect to initiate a Phase 1 clinical trial of each of XMT-1660 and XMT-2056 in mid-2022. We believe that these development candidates provide significant opportunities in areas of high unmet need such as breast cancer and other tumors. We also have two earlier stage preclinical candidates, which we refer to as XMT-2068 and XMT-2175, both of which leverage our Immunosynthen platform and target tumor-associated antigens.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have established strategic research and development partnerships with Janssen Biotech, Inc., or Janssen, and Merck KGaA for the development and commercialization of additional ADC product candidates leveraging our proprietary Dolasynthen and Dolaflexin platform technologies against a limited number of targets selected by our partners. We believe the potential of our ADC technologies, supported by our scientific and technical expertise and enabled by our intellectual property strategy, all support our independent and collaborative efforts to discover and develop life-changing ADCs for patients fighting cancer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a research collaboration and license agreement with Janssen to collaborate on the discovery and research of Dolasynthen ADCs for up to three antigen targets utilizing Janssen&#8217;s antibodies, with Janssen leading development, manufacturing and commercialization worldwide. We refer to this as the Janssen Collaboration. Upon execution of the agreement we received an upfront payment of $40 million. Our primary objective in entering into the Janssen Collaboration was to collaborate with a leading global pharmaceutical company to further validate the potential of our Dolasynthen platform, to enable the development of novel ADC product candidates, to provide near term non-dilutive funding and to drive significant long-term value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have focused on building our platforms, identifying potential product candidates, producing drug substance and drug product material for use in preclinical studies, conducting preclinical and toxicology studies, manufacturing clinical trial material and conducting clinical trials, establishing and protecting our intellectual property, staffing our company and raising capital. We do not have any products approved for sale and have not generated any revenue from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product sales. We have funded our operations primarily through our strategic partnerships, private placements of our convertible preferred stock, public offerings of our common stock and an at-the-market, or ATM, equity offering program.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant cumulative operating losses. Our net losses were $170.1&#160;million and $88.0 million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $450.5&#160;million. We expect to continue to incur significant expenses and operating losses over the next several years. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue clinical development activities for our clinical product candidates, UpRi, including UPLIFT, UPGRADE and UP-NEXT, and XMT-1592;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue diagnostic development efforts with respect to the NaPi2b biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complete IND-enabling studies and commence clinical trials for our preclinical development candidates XMT-1660 and XMT-2056;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">continue activities to discover, validate and develop additional product candidates, including XMT-2068 and XMT-2175;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;&#160;and</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional research, development and general and administrative personnel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Impact of COVID-19 on Our Business</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">We are continuing to monitor the impact of the coronavirus, or COVID-19, pandemic on our operations and ongoing clinical and preclinical development, as well as discovery efforts. Mitigation activities to minimize COVID-19-related operation disruptions are ongoing and include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are currently enrolling patients at clinical sites in different geographic areas around the world in our ongoing clinical trials, though staffing constraints have become an increasing challenge for the clinical sites with which we work. If staffing challenges persist, we may experience associated delays in trial enrollment. We are in the process of initiating additional clinical sites both inside and outside the United States to increase enrollment, which we believe could also mitigate this potential risk. Consistent with FDA guidance, we allow for remote patient monitoring and remote testing, when reasonably possible. </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">To the best of our knowledge, our contract research and manufacturing partners continue to operate their operations at or near normal levels, though staffing constraints and sourcing of raw and other materials have become an increasing challenge for our vendors. If staffing and/or material sourcing challenges continue, we may experience associated delays in our laboratory, clinical or manufacturing services. We believe we currently have appropriate service support and sufficient inventory of UpRi and XMT-1592 to support our ongoing clinical trials, and we currently expect to have sufficient inventory of XMT-1660 and XMT-2056 to commence Phase 1 clinical trials in 2022. We have planned research, clinical and manufacturing activities to address all currently anticipated future needs. We continue to monitor the research clinical and manufacturing operations of our vendors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted. While the pandemic did not materially affect our financial results and business operations in the year ended December 31, 2021, we are unable to predict the impact that COVID-19 will have on our financial position and operating results in future periods due to numerous uncertainties. Management continues to actively monitor the situation and the possible effects on our financial condition, operations, suppliers, vendors, our workforce and the overall industry. For additional information about risks and uncertainties related to the COVID-19 pandemic that may impact our business, our financial condition or our results of operations, see &#8220;Part I, Item 1A&#8212;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_49"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of products. All of our revenue has been generated from strategic partnerships.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, we entered into an agreement with Merck KGaA for the development and commercialization of ADC product candidates utilizing Fleximer for up to six target antigens. Merck KGaA is responsible for generating antibodies against the target antigens and we are responsible for generating Fleximer and our proprietary payloads and conjugating this to the antibody to create the ADC product candidates. Merck KGaA has the exclusive right to and is responsible for the further development and commercialization of these ADC product candidates. In May 2018, we entered into a supply agreement with Merck KGaA for the supply of materials that could be used for IND-enabling studies and clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, we recognized revenue of an immaterial amount and $0.8 million, respectively, related to the Merck KGaA agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect substantially all of our revenue to be generated from our collaboration agreements with Janssen, Merck KGaA and Asana BioSciences. Given the uncertain nature and timing of clinical development, we cannot predict when or whether we will receive further milestone payments or any royalty payments under these collaborations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information about our revenue recognition policy, see the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include our drug discovery efforts, manufacturing, and the development of our product candidates, which consist of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of funding research and development performed by third parties that conduct research, preclinical activities, manufacturing and clinical trials on our behalf;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory supplies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility costs, including rent, depreciation and maintenance expenses; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">upfront and milestone payments under our third-party licensing agreements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Costs of certain activities, such as manufacturing, preclinical studies and clinical trials, are generally recognized based on an evaluation of the progress to completion of specific tasks. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations and information provided to us by the third parties with whom we contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials and manufacturing costs.&#160;We expect that our future research and development costs will continue to increase over current levels, depending on the progress of our clinical development programs. There are numerous factors associated with the successful development and commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at our current stage of development. Additionally, future commercial and regulatory factors beyond our control may impact our clinical development programs and plans.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our research and development costs have been external costs, which we track on a program-by-program basis following IND submission. We have not historically tracked all of our internal research and development expenses on a program-by-program basis as they are deployed across multiple projects under development. The following table summarizes our external research and development expenses, by program, following IND submission for the years ended December&#160;31, 2021, 2020 and 2019. All external research and development expenses not attributable to the UpRi and XMT-1592 programs are captured within preclinical and discovery costs. These costs relate to XMT-1592 prior to its IND submission in early 2020, as well as our preclinical development candidates XMT-1660, XMT-2056, XMT-2068 and XMT-2175, and additional earlier discovery stage programs and certain unallocated costs. Our internal research and development costs are primarily personnel-related costs, stock-based compensation costs, and facility costs, including depreciation, and lab consumables.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UpRi external costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XMT-1592 external costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,126&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,180&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XMT-1522 external costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preclinical and discovery costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,883&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,013&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,036&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our product candidates is highly uncertain. As such, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development of our product candidates. We are also unable to predict when, if ever, we will generate revenue from commercialization and sale of any of our product candidates that obtain regulatory approval. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of preclinical studies and IND-enabling studies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful enrollment in and completion of clinical trials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing the product candidates, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued acceptable safety profile of the drugs following approval; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to overcome existing and emerging competitive threats to the successful commercialization of our products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development, manufacture or commercialization of any of our product candidates would significantly change the costs, timing and viability associated with the development of that product candidate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other employee-related costs, including stock-based compensation, for personnel in executive, finance, accounting, business development, legal, information technology and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our general and administrative expenses will increase in the future to support continued research and development activities, including increased costs related to the hiring of additional personnel, fees to outside consultants and patent costs, among other expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of interest income earned on cash equivalents and marketable securities. Interest expense is related to borrowings under the credit facilities. These borrowings bear a floating per annum rate interest, as well as a final payment of either 4.25% on the Prior Credit Facility or 5.5% on the New Credit Facility, as defined below, of the amounts drawn, that is being recorded as interest expense over the term through the maturity date using the effective-interest method. Also included in interest expense is the amortization of the deferred financing costs and the accretion of debt discount relating to the credit facilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of&#160;Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2021 and 2020, together with the changes in those items:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Change</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(785)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,986&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(359)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,202)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,060)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,045)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,015)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was less than $0.1 million during the year ended December&#160;31, 2021, compared to $0.8 million during the&#160;year ended December&#160;31, 2020. During the year ended December 31, 2020, we recognized $0.8 million of revenue as a result of the completion of research services associated with a target included in the Merck KGaA Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense was $132.0 million for the year ended December&#160;31, 2021, compared to $67.0 million for the year ended December&#160;31, 2020. The overall increase of $65.0 million was primarily attributable to the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $28.7 million related to manufacturing and clinical development activities for UpRi;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $14.7 million related to preclinical and discovery stage programs including XMT-1660 and XMT-2056;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $10.8 million related to employee compensation (excluding stock-based compensation), primarily due to an increase in headcount supporting the growth of our research and development activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $5.3 million related to manufacturing and clinical development activities for XMT-1592; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of $0.8 million related to other research services and supplies costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increased costs were partially offset by the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $1.3 million related to the favorable resolution of an outstanding payable balance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in research and development expenses increased by $6.0 million primarily as a result of increased headcount.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to increase as we continue our clinical development of UpRi and XMT-1592 and continue to advance our preclinical product candidate pipeline and invest in improvements in our ADC technologies.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased by $15.0 million from $21.9 million for the year ended December&#160;31, 2020 to $36.9 million for the year ended December&#160;31, 2021. The increase in general and administrative expense was primarily attributable to an increase of $4.1 million related to employee compensation (excluding stock-based compensation), related to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase in headcount, and an increase of $5.7 million related to consulting and professional fees. Stock-based compensation increased by $5.1 million also primarily as a result of increased headcount.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense will increase in future periods as we expand our operations. These increases will likely include legal, auditing fees, additional insurance premiums and general compliance and consulting expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net, was $1.2 million for the year ended December&#160;31, 2021 and total other income, net, was $0.1 million for the year ended December&#160;31, 2020. In each period, other expense consisted primarily of interest on our borrowings under the credit facilities, offset by interest income on cash equivalents and short-term marketable securities. For the year ended December 31, 2021, other expense included a $0.4 million loss on extinguishment related to the repayment of the Prior Credit Facility, as defined below.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_55"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations primarily with the proceeds from our initial public offering, our follow-on public offerings in 2019 and 2020, the use of our ATM equity offering program and our strategic partnerships. In July 2018 we established an ATM, or the 2018 ATM, pursuant to which we were able to offer and sell up to $75.0 million of our common stock from time to time at prevailing market prices. During the year ended December 31, 2020, we sold approximately 10.9 million shares of common stock and received net proceeds of $63.0 million under our 2018 ATM. In addition, in June 2020, we sold 9.2 million shares of common stock in a follow-on public offering and received net proceeds of approximately $164.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we terminated the 2018 ATM and established a new ATM, or the 2020 ATM, pursuant to which we are able to sell up to $100.0 million of our common stock from time to time at prevailing market prices. During the year ended December 31, 2021, we sold approximately 4.0 million shares of common stock under the 2020 ATM for net proceeds of $43.1 million. As of December&#160;31, 2021, we had $55.9 million of availability under the 2020 ATM. Subsequent to December&#160;31, 2021 and through February 25, 2022, we sold 9.5 million shares of common stock resulting in net proceeds of $45.6 million under the 2020 ATM offerings. Approximately $9.4 million remains unsold and available for sale under the 2020 ATM. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, we entered into a term loan agreement with Silicon Valley Bank, or SVB, which was subsequently amended on June 29, 2019, August 28, 2020, and August 27, 2021, as amended, the Prior Credit Facility. Pursuant to the Prior Credit Facility we were permitted, subject to certain conditions, to borrow term loans in an aggregate amount of up to $30.0 million, of which $5.2 million were funded upon execution of the 2020 amendment to the Prior Credit Facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we entered into a Loan and Security Agreement, or the New Credit Facility, with Oxford Finance LLC as the collateral agent and a lender, and SVB as a lender, together the Lenders, which was further amended on February 17, 2022. The New Credit Facility provides in aggregate up to $100 million, which includes $60 million available immediately, $20 million in one tranche that is subject to meeting certain development milestones, and an additional tranche of $20 million, which is subject to conditional approval from the Lenders. Upon the closing date, we drew $25 million, of which $5.5 million was used to repay in full the existing balance and satisfy our existing obligations to SVB under the Prior Credit Facility. The New Credit Facility is secured by substantially all of our personal property owned or later acquired, excluding intellectual property (but including the right to payments and proceeds from intellectual property), and a negative pledge on intellectual property, which ensures that the Lender&#8217;s rights to repayment would be senior to the rights of the holders of our common stock in the event of liquidation. Upon entering into the New Credit Facility, we terminated all commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by us to SVB under the Prior Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had cash and cash equivalents of $177.9 million. In addition to our existing cash and cash equivalents, we are eligible to earn milestone and other payments under our collaboration agreements with Janssen, Merck KGaA and Asana. Our ability to earn the milestone payments and the timing of earning these amounts are dependent upon the timing and outcome of our development, regulatory and commercial activities and, as such, are uncertain at this time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the&#160;years ended December&#160;31, 2021, 2020 and 2019:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended<br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(139,988)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(648)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,027&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,293)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76,990)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,743&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $140.0 million for the&#160;year ended December&#160;31, 2021 and primarily consisted of a net loss of $170.1 million adjusted for changes in our net working capital and other non-cash items including stock-based compensation of $18.4 million and depreciation of $0.9 million. Net cash used in operating activities was $74.7 million for the year ended December&#160;31, 2020 and primarily consisted of a net loss of $88.0 million adjusted for non-cash items including stock-based compensation of $7.2 million and depreciation of $1.0 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $0.6&#160;million during the year ended December&#160;31, 2021 compared to net cash provided by investing activities of $37.0&#160;million during the&#160;year ended December&#160;31, 2020. Net cash used in investing activities for the&#160;year ended December&#160;31, 2021 consisted primarily of the purchase of property and equipment. Net cash provided by investing activities for the year ended December&#160;31, 2020 consisted primarily of maturities of marketable securities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $63.6&#160;million during the year ended December&#160;31, 2021 compared to net cash provided by financing activities of $230.4&#160;million during the&#160;year ended December&#160;31, 2020. During the year ended December&#160;31, 2021 cash provided by financing activities consisted primarily of the proceeds from the use of the 2020 ATM of $43.1 million and issuance of debt, net of issuance costs, of $24.0 million under the New Credit Facility, as well as proceeds from exercise of stock options of $1.8 million, partially offset by repayment of debt of $5.5 million to repay the Prior Credit Facility. During the year ended December&#160;31, 2020, cash provided by financing activities consisted primarily of $164.0 million related to the follow-on public offering and the proceeds from the use of the 2018 ATM of $63.0 million, as well as proceeds from exercise of stock options of $3.1 million. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Requirements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our cash expenditures to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of, and seek marketing approval for our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 we had cash and cash equivalents of $177.9 million and, subsequently, we received a $40 million upfront payment under the Janssen Collaboration and $45.6 million of net proceeds received from sales of our common stock under our 2020 ATM. In addition, we currently have the option to borrow $35 million under the New Credit Facility. Taken together, we believe that our current cash and cash equivalents plus the available borrowings under the New Credit Facility will be sufficient to fund our current operating plan commitments into the second half of 2023. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, prioritization and number of our research and development programs;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we obtain;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of securing manufacturing arrangements for clinical and commercial production; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes many&#160;years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve drug sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for many&#160;years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, strategic partnerships and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. We currently have access to the New Credit Facility, as described above, along with funds to potentially be earned in connection with our agreements with Janssen, Merck KGaA and Asana BioSciences, if research and development activities are successful under those agreements. Future additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through additional strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_58"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as of payment due date by period at December&#160;31, 2021:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1 Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1 to 3<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3 to 5<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than<br/>5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease commitments(1)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,916&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,064&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,339&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,513&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations(2)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,416&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,870&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents future minimum lease payments under our non-cancelable operating and finance leases, which expire through February&#160;2024. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents future debt principal plus interest and final payments under the term loan under the New Credit Facility, which is payable in full on October 1, 2026. Refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Notes to Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements in the normal course of business with third parties to assist us with preclinical, clinical, manufacturing, and other products and services for operating purpose. Certain of these agreements include termination rights subject to termination fees or wind down costs. Under such agreements, we are contractually obligated to make certain payments to the parties with whom we contract upon termination, primarily to reimburse them for their unrecoverable outlays incurred prior to cancellation and for wind-down activities. The exact amounts of such obligations are dependent on the timing of termination and the exact terms of the relevant agreement and cannot be reasonably estimated. At December&#160;31, 2021, we had cancellable open purchase orders of $138.7 million in total under agreements for preclinical, clinical, manufacturing, and other products and services for operating purposes. These amounts represent only our estimate of those items for which we had a contractual commitment to pay at December&#160;31, 2021, assuming we would not cancel these agreements. The actual amounts we expect to pay in the future to the third parties under such agreements may differ from the cancellable open purchase order amounts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, we entered into a license agreement with Recepta Biopharma S.A., or Recepta, as amended, for the NaPi2b antibody. We refer to this as the Recepta License. Under the Recepta License, we paid Recepta an upfront payment of $1.0&#160;million and are obligated to pay Recepta up to $65.5&#160;million in development, regulatory and commercial milestones and tiered royalties in the low-single digit percentages on net sales of products outside of Brazil until the expiration of the royalty term. Upon the expiration of each royalty term in each country for each applicable product, the exclusive licenses granted to each party under the Recepta License will become fully-paid up and royalty-free. We have incurred $4.0 million and paid $2.8 million in development milestone payments to date under the Recepta License.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a commercial license agreement with Synaffix B.V., or Synaffix, which we amended and restated in November 2021 to expand our relationship with Synaffix. We refer to the amended and restated agreement as the Synaffix License. Under the Synaffix License, we have the right to develop, manufacture and commercialize ADCs directed to targets using Synaffix&#8217;s proprietary site-specific conjugation technology for up to twelve targets. Through December 31, 2021, we have licensed two targets from Synaffix in connection with our development of XMT-1592 and XMT-1660, for which we have paid $1.5 million in license fees, and $0.8 million in milestone payments. We are required to make milestone payments to Synaffix of up to an aggregate of $28.0 million in development and regulatory milestones and up to $20.0 million in one-time sales milestones based on the achievement of annual sales objectives for each of these two targets. Additionally, we paid upfront fees of $2.5 million at the time of amending and restating the Synaffix License in November 2021, which may be applied to reservation and license fees associated with our selection of the next three targets. Upon licensing any future targets, we will be obligated to pay in the range of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $48.0 mi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llion to $117.0 million for issuance, development, regulatory and one-time sales milestones. We further amended the Synaffix License in February 2022 in connection with the Janssen Collaboration and agreed to pay Synaffix an additional fee of $1.5 million which may be applied to future reservation and license fees, as well as certain portions of potential future development milestones.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commencement of commercial sales of any ADC product directed to a licensed target, if any, we are required to pay to Synaffix tiered royalties in the low-single digit percentages on net sales of the respective products. The Synaffix License remains in effect on a country-by-country and licensed product-by-licensed product basis until the expiration of the last-to-expire valid claim in a patent licensed under the Synaffix License covering such product in such country. Upon the expiration of the Synaffix License for each licensed product in each country, the licenses granted to us for such product in such country will become fully paid-up and perpetual. We may terminate the Synaffix License in its entirety or on a licensed product-by-licensed product basis at any time. Either party may terminate the Synaffix License, subject to a specified notice and cure period, for a breach by the other party of a material provision of the agreement or upon an insolvency-related event experienced by the other party.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgements and Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management's discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. The effects of material revisions in estimates, if any, will be reflected in the financial statements prospectively from the date of change in estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our most critical accounting policies are those relating to revenue recognition and accrued research and development expenses as discussed in the Notes to Consolidated Financial Statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaboration agreements which are within the scope of Accounting Standards Update 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Topic 606, under which we license rights to our technology and certain of our product candidates and perform research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, we perform the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation.&#160;We only apply the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in our arrangements typically consist of license rights to our intellectual property and research and development services.&#160;We also have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, we evaluate the amount of potential payment and the likelihood that the payments will be received.&#160;We utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method better predicts the amount expected to be received.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method.&#160;If it is not probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within our control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;We must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;We utilize key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts we would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance&#160;and related revenue recognition.&#160;If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record the elements of our collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. We consider the guidance in Topic 606 in determining the appropriate treatment for the transactions between us and our collaborative partners and the transactions between us and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, we will recognize our share of the net sales on a gross basis if we are deemed to be the principal in the transactions with customers, or on a net basis if we are instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued expenses as of each balance sheet date. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us&#160;monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in connection with research and development activities for which we have not yet been invoiced.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our expenses related to research and development activities based upon our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed, enrollment of subjects, number of sites activated and the level of effort to be expended in each period.&#160;If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrued or prepaid expense balance accordingly.&#160;Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period.&#160;To date, there have been no material differences from our estimates to the amounts actually incurred. Significant judgement is involved in making the above estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the Notes to Consolidated Financial Statements for a description of recent accounting pronouncements applicable to our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of December&#160;31, 2021, we had cash and cash equivalents of $177.9 million, primarily held in money market mutual funds consisting of U.S. government-backed securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents and marketable securities are invested in U.S. Treasury obligations, commercial paper and corporate bonds. However, we believe that due to the short-term duration of our investment portfolio and low-risk profile of our investments,&#160;an immediate 100 basis points change in interest rates would not have a material effect on the fair market value of our investments portfolio.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The interest rate on our New Credit Facility is sensitive to changes in interest rates. Interest accrues on borrowings under the credit facility at a floating rate equal to the greater of (i) 8.50% and (ii) the prime rate plus 5.25%. We do not currently engage in any hedging activities against changes in interest rates. As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N182Ny9mcmFnOmVkYWMxODkyMzI3MDQ1ZTE4MjhhZWU2MDQwYzJmMWMyL3RleHRyZWdpb246ZWRhYzE4OTIzMjcwNDVlMTgyOGFlZTYwNDBjMmYxYzJfNzE0NjgyNTU4MzY3Ng_8057e5ee-8653-442c-bdfa-a8f3410ee462">25.0</ix:nonFraction> million outstanding under the New Credit Facility and a potential change in the associated interest rates would be immaterial to the results of our operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risks</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently not exposed to market risk related to changes in foreign currency exchange rates, but we may contract with vendors that are located in Asia and Europe and may be subject to fluctuations in foreign currency rates at that time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_73">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (PCAOB ID: <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183MC9mcmFnOjdlNDYwMDMxNTEzNzQ4MzNiNGMxYTVkODI3Zjc0NTRjL3RhYmxlOjY3MGVhZTA2ODIwZjQ3YTM5MmQyNTY5Nzc3OTZlNGU0L3RhYmxlcmFuZ2U6NjcwZWFlMDY4MjBmNDdhMzkyZDI1Njk3Nzc5NmU0ZTRfMS0wLTEtMS0xODE0Ni90ZXh0cmVnaW9uOjdhMTQ1ZWNjYzY5YTQzNmFhYmU2NDVmMWY5YmJiMTFkXzQzOTgwNDY1MTExODY_fda4a4db-8dae-4376-920f-6df26d4e4d78">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_73">95</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_76">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_76">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_79">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_79">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_85">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_85">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_88">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_88">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_91">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i54c829abb8e046e0ba4639af9592e947_91">101</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Mersana Therapeutics, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, and stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrued &amp; Prepaid Clinical Expenses</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As summarized in Note 6 to the consolidated financial statements, the Company&#8217;s accrual for clinical expenses totaled $7.9 million as of December 31, 2021. In addition, the Company&#8217;s Prepaid Expenses and Other Current Assets and Other Assets accounts totaled $13.3 million, which included amounts that were paid in advance of services pursuant to clinical trials as of December 31, 2021. As discussed in Note 2 to the consolidated financial statements, the Company is required to estimate clinical costs incurred and related accruals or remaining prepaid expenses based on certain information, including actual costs incurred or level of effort expended, as provided by its vendors. Payments for such activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accrued and prepaid clinical expenses was complex and judgmental, as the amounts are based on various estimates from third-party vendors, as well as other inputs estimated by members of management, such as, actual costs incurred but not yet billed, estimated project timelines, and the costs associated with these services. Furthermore, due to the duration of the Company&#8217;s ongoing research and development activities and the timing of invoicing received from third parties, the actual amounts incurred are not typically known by the date the financial statements are issued. </span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the controls over the Company&#8217;s process for recording accrued and prepaid clinical expenses. These procedures included controls over management&#8217;s review of inputs used, as well as the completeness and accuracy of the underlying data, in estimating the accrual and prepaid.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the accrued and prepaid clinical expenses, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in the estimates and evaluating the significant assumptions noted above that are used by management to estimate the amounts recorded. We corroborated the progress of research and development activities through discussion with the Company&#8217;s research and development personnel that oversee the research and development projects. We also inspected the Company&#8217;s contracts with third parties and any pending change orders to assess the impact on amounts recorded. Additionally, we reviewed information received by the Company directly from certain sites and other third parties, which included third parties&#8217; estimates of costs incurred to date. We also performed analytical procedures over fluctuations in accrued and prepaid clinical expenses by vendor, study, or other significant work order throughout the period subject to audit and inspected subsequent invoices received from third parties to assess the impact to the accrued and prepaid balances.  </span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183My9mcmFnOjU5YTExNmQ0YmM2NDQxZGJiNWQyMTQ3ZjAzNzEzZWZlL3RleHRyZWdpb246NTlhMTE2ZDRiYzY0NDFkYmI1ZDIxNDdmMDM3MTNlZmVfMjg1ODczMDIzMjk4MjM_c2c94ceb-3e83-49b6-8275-faa532f51631">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2013.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183My9mcmFnOjU5YTExNmQ0YmM2NDQxZGJiNWQyMTQ3ZjAzNzEzZWZlL3RleHRyZWdpb246NTlhMTE2ZDRiYzY0NDFkYmI1ZDIxNDdmMDM3MTNlZmVfMjg1ODczMDIzMjk4MjQ_af2d87ca-d3a7-4198-9a2e-3cf9be5dcc24">Boston, Massachusetts</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMy0xLTEtMS0xNDM0Mg_b5ec9727-375e-493a-a247-24bf81aa37e5">177,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMy0zLTEtMS0xNDM0Mg_bbb55718-89e9-4ea9-ace3-373715a4be2a">255,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNi0xLTEtMS0xNDM0Mg_b8d39333-fb90-468f-b1b5-3b36aa3949dd">10,951</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNi0zLTEtMS0xNDM0Mg_187c18a9-dc8c-4735-a656-8f4ea0da99c7">3,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNy0xLTEtMS0xNDM0Mg_b1b49c7e-516e-4b24-8172-4a24062022be">188,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNy0zLTEtMS0xNDM0Mg_eaad561b-6400-48f3-8b10-7bc911f978f4">258,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOC0xLTEtMS0xNDM0Mg_a1949567-502b-4509-b900-19bbca77608d">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOC0zLTEtMS0xNDM0Mg_a5f8e612-ba1b-4f30-b1fb-097a88fc3159">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOS0xLTEtMS0xNDM0Mg_eaf7f3f0-15c2-4923-a22a-dc7a1dd15b36">12,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOS0zLTEtMS0xNDM0Mg_e5ac401b-57f7-48ff-a69d-a7d4a6eeca7d">10,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTAtMS0xLTEtMTQzNDI_bf597c7c-b3a7-4b0c-bdcb-226a0da9095a">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTAtMy0xLTEtMTQzNDI_5d8b2d69-1ba5-49f3-8580-b2b5a881ec44">2,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTEtMS0xLTEtMTQzNDI_6f3f9d29-0fe6-425d-8d64-0ce451de42a4">206,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTEtMy0xLTEtMTQzNDI_00b2afa5-ed2f-4a8a-b920-14b9de6c217d">273,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTQtMS0xLTEtMTQzNDI_feb52814-ce50-4755-bdfc-051b6c5b6a48">12,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTQtMy0xLTEtMTQzNDI_afaae9ba-2e53-47e1-af82-549a9476bcc4">8,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTUtMS0xLTEtMTQzNDI_cab43154-4090-47e0-9ccf-a5fd65246146">28,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTUtMy0xLTEtMTQzNDI_0015543b-b0d4-49b1-9a5b-93ce12901f13">16,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTYtMS0xLTEtMTQzNDI_b6933404-8536-4a2f-a6d8-6d823fab4e6c">3,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTYtMy0xLTEtMTQzNDI_31f3b4b6-567c-470f-abc6-f4ae950c72f8">3,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTctMS0xLTEtMTQzNDI_2a2a4450-daad-486f-83ad-f608df9c15f4">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTctMy0xLTEtMTQzNDI_00cbfb6a-4d05-4a97-99fe-31531472d4d8">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTktMS0xLTEtMTQzNDI_f80e25a9-82f7-4521-aca2-7f38872f59c6">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTktMy0xLTEtMTQzNDI_2b0b82e2-176c-4aa4-8199-448de8a5bfeb">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjAtMS0xLTEtMTQzNDI_783a73b1-bc61-426b-8084-d84b53812b89">47,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjAtMy0xLTEtMTQzNDI_4829c51f-10b3-45ae-89d4-c114165803ab">30,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjEtMS0xLTEtMTQzNDI_3b2340ee-2b45-48fd-b3d2-083a33697d9e">11,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjEtMy0xLTEtMTQzNDI_a4e42467-67fc-411f-aea6-cb87011c21b6">10,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjItMS0xLTEtMTQzNDI_7a480859-df9f-4f11-938c-53120ac935db">24,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjItMy0xLTEtMTQzNDI_fcfe2112-b221-4f42-99c7-f7412667e7f4">4,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjMtMS0xLTEtMTQzNDI_5b396c75-d40c-4252-9cc3-8b8cf9adddbe">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjMtMy0xLTEtMTQzNDI_207a66f6-b0f2-458a-b05c-323449a07972">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjQtMS0xLTEtMTQzNDI_c19121f9-450e-49b0-894d-28bf4426ce2e">84,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjQtMy0xLTEtMTQzNDI_b28df35c-fb3f-473b-8f3c-6121c5387579">45,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments (Note&#160;13)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjUtMS0xLTEtMTQzNDI_1321e33f-57e6-4f42-ba24-3f54842edc09"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjUtMy0xLTEtMTQzNDI_9d8e0058-8d6f-4b18-8ff6-720d0bf50fb7"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8yMQ_32213049-c535-4a6a-86b2-e56bb358a27f"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8yMQ_598f148e-0237-44e9-99f1-48af4ecb99c4">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8zNQ_80fc022f-b6fa-4186-9704-57f5efbf3b79"><ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8zNQ_cec385f8-527e-44f0-a804-ad54157bbdda">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_2438662d-f377-47f5-b8d6-d66c165bfc16"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_de8b37cc-da18-415e-a54c-3f592a62628c"><ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_e0075950-1ab5-4f9b-b657-38a13ac3d22b"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_fdf6f98c-cbbc-4ab6-a888-970818499daf">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMS0xLTEtMTQzNDI_a0b1c433-4cda-4661-84ac-b6e08a87cd1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMy0xLTEtMTQzNDI_4e7fe15c-b091-44d5-9230-d9a829437150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8xOA_4bfcfeb0-8afd-435f-bcd9-7b39da1b3dd0"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8xOA_957bc2c5-74e6-4917-b7b0-46e2a67c99d3">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8zMg_372042d6-827d-462a-9f1d-f8d6eae0a070"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8zMg_a34993da-9458-4fa9-8adb-020cf07fdef8">175,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV81NA_936d4462-849f-463a-a2ae-36a484db2393"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV81NA_b2be85d6-c8d4-40e3-92d1-6d809aad5095">73,709,056</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV82MQ_ddbadf7d-1f83-4662-808d-aae7c5642da2"><ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV82MQ_f8d26cac-6190-4eff-8abc-2281813b0ffd">68,841,288</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMS0xLTEtMTQzNDI_9d17ffba-d50c-497c-bef8-bf137613324a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMy0xLTEtMTQzNDI_d6a7fd9d-c579-48e8-9b08-09e1e813159c">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjktMS0xLTEtMTQzNDI_0773ec8f-9487-4b66-a19c-fabc62b8f1a9">572,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjktMy0xLTEtMTQzNDI_76b7975f-ae8c-4a12-bf33-0bbd9db3f2a6">508,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzEtMS0xLTEtMTQzNDI_172e66bd-9788-4d88-ba09-e07790af8abf">450,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzEtMy0xLTEtMTQzNDI_f921c547-9b20-4aaf-b8d5-52cd9447ea45">280,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzItMS0xLTEtMTQzNDI_daae871a-df5d-4267-bec2-94ffe49643e8">121,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzItMy0xLTEtMTQzNDI_aa257e92-4298-4d9c-a119-3e837f605764">228,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzMtMS0xLTEtMTQzNDI_f5e11735-c3e1-4d12-9c88-f6cf954ff711">206,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzMtMy0xLTEtMTQzNDI_8796ff47-cddd-4727-a74c-c38fa88729f8">273,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi0xLTEtMS0xNDM0Mg_aba8dc7a-f8d1-40d1-8867-abc3c14d5363">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi0zLTEtMS0xNDM0Mg_cb78efea-45b1-444b-872e-16918e515faa">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi01LTEtMS0xNDM0Mg_265fcbe6-61e6-4f89-92aa-3ad1c8f5f15e">42,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC0xLTEtMS0xNDM0Mg_eff8bd66-6fab-4ee8-83c0-5eb11eed084f">132,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC0zLTEtMS0xNDM0Mg_1d6c733b-1f0f-4e08-8b49-d7840842afe6">67,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC01LTEtMS0xNDM0Mg_8265709d-2f51-4dd1-a8b3-4db50e619b30">55,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS0xLTEtMS0xNDM0Mg_b2eb826d-402c-4421-a088-174ca9676c6a">36,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS0zLTEtMS0xNDM0Mg_25a5e6ef-12f9-47bd-9d44-ed771b3c04ea">21,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS01LTEtMS0xNDM0Mg_42cbeae9-2a38-483e-a327-0069374cbd6e">17,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi0xLTEtMS0xNDM0Mg_ffcc5614-f9b5-4048-9d7c-51738f564e59">168,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi0zLTEtMS0xNDM0Mg_e21f6e9b-7bc0-4f19-9bb4-3c39d17b147d">88,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi01LTEtMS0xNDM0Mg_940d99e1-1d26-40f8-a127-0167722c15dd">72,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC0xLTEtMS0xNDM0Mg_1cb95c7b-261c-4e11-b44d-f34913ca110b">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC0zLTEtMS0xNDM0Mg_4d0071dd-64b7-49d0-a30d-f4346cd46184">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC01LTEtMS0xNDM0Mg_cbd6df39-ff9c-452e-8733-77aea3698deb">2,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS0xLTEtMS0xNDM0Mg_91aac8b0-f711-4079-ba4e-1065e9f5dcd9">1,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS0zLTEtMS0xNDM0Mg_0a954f32-a57d-4d86-8596-f4961bbeae68">359</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS01LTEtMS0xNDM0Mg_15555a8a-25c2-4938-a5dc-4008094dd88a">234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtMS0xLTEtMTQzNDI_5004be2d-29dc-4c3d-8965-3e629e0dfeb4">1,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtMy0xLTEtMTQzNDI_c33bcfd7-8e55-425b-abdd-c52d6abe3007">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtNS0xLTEtMTQzNDI_7d7129a3-7ffe-4c24-aaca-a4580dc6a017">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtMS0xLTEtMTQzNDI_a6c06875-122a-448f-8426-627aacdf0b8d">170,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtMy0xLTEtMTQzNDI_b0fa8af4-dfbe-4a34-8b68-c31d3c73606c">88,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtNS0xLTEtMTQzNDI_da8315e9-2fb5-4e76-b867-80df1a807688">28,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtMS0xLTEtMTQzNDI_e496a9d0-991a-4c82-ad34-f388a9b62274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtMy0xLTEtMTQzNDI_bf952b70-f649-4c2b-9d00-be37a33429bc">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtNS0xLTEtMTQzNDI_eeb9cb15-d4ab-453a-b964-4b8f1a826493">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtMS0xLTEtMTQzNDI_4a393f62-85c7-428c-bd1d-957e26423814">170,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtMy0xLTEtMTQzNDI_305de681-2105-4c2f-a7f3-1e92488d8105">88,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtNS0xLTEtMTQzNDI_2784e70b-8f65-434b-9f13-23f392ead49e">28,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMS0xLTEtMTQzNDI_240f0fe4-2d94-4d2b-820b-b1486d220bed"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMS0xLTEtMTQzNDI_2551dc28-2bcd-4ef0-bfbc-fd540ef37a1a">170,060</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMy0xLTEtMTQzNDI_1537a390-22c5-4cbf-ab67-89d8ffc6e685"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMy0xLTEtMTQzNDI_cfff28a4-2e8d-4aba-a716-454b5e86e0b3">88,045</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtNS0xLTEtMTQzNDI_7236e12e-0509-4a0b-9f8c-c11c48646d23"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtNS0xLTEtMTQzNDI_96f71f33-6011-41f4-8dfd-0106fe71d60a">28,208</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share&#160;attributable to common stockholders &#8212; basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMS0xLTEtMTQzNDI_5ef14567-e30c-47fe-b128-16a73d427473"><ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMS0xLTEtMTQzNDI_bd1b7f3d-1818-4730-8f22-4f9b5d6cdee4">2.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMy0xLTEtMTQzNDI_372a600f-f6fb-4708-8d9c-55f393a1b889"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMy0xLTEtMTQzNDI_cb411d58-0cce-476b-b147-fbaeb202d040">1.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtNS0xLTEtMTQzNDI_a9595224-9e04-433f-a54c-a11f38a7245f"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtNS0xLTEtMTQzNDI_c98ba7f8-267f-44e8-934c-60faaf512fe5">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMS0xLTEtMTQzNDI_3caaf802-2a96-4ea4-b030-32e280851e7d"><ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMS0xLTEtMTQzNDI_73b54f8f-0da9-4b16-951e-3279e65a6073">70,580,949</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMy0xLTEtMTQzNDI_27081e00-9a44-4b00-87d3-cafe021860a6"><ix:nonFraction unitRef="shares" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMy0xLTEtMTQzNDI_7e89d2fa-a552-43aa-bd4f-71a363189b00">61,485,205</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctNS0xLTEtMTQzNDI_45e6b09a-3ad2-4075-9601-9a9a7ecdfca5"><ix:nonFraction unitRef="shares" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctNS0xLTEtMTQzNDI_7eee68d8-e90d-4897-8976-41696fd05011">43,492,113</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.103%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0xLTEtMS0xNDM0Mg_af7f379d-7685-4472-9682-b8aeed624513">23,234,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0zLTEtMS0xNDM0Mg_73f5784d-f02c-44ff-99bc-15bfd9139d2b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81852bd3e7134038a2f1b0bf58ab6969_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi01LTEtMS0xNDM0Mg_21b5ae1e-6bb7-4d12-990a-ffa365a024ad">172,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514791eca1f44909a5e5f94b71ea3a98_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi03LTEtMS0xNDM0Mg_9f0bd979-e1b6-45af-bd67-bd9d9615ef1e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99fce85f8b8644a3b03a21943edd68ed_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi05LTEtMS0xNDM0Mg_b08e1090-f3a4-4b08-a5bd-762fac453ad4">164,166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0xMS0xLTEtMTQzNDI_776472ac-4cb4-41f9-9695-c8224d10ce2a">8,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0wLTEtMS0xNDUzMC90ZXh0cmVnaW9uOjNjNjM5YjQyY2YwYzQyZWY4YjY1ODg1NTFmYTJkMzk3Xzc3_f4c1037a-7665-4f9a-8849-dc633756808e">5,587</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0xLTEtMS0xNDUyNA_9255c3ea-18d5-4858-b8d7-66840e936142">24,437,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0zLTEtMS0xNDUyNA_5db5533b-6479-4196-801f-48b9d0dc7410">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5086b7eefe4a4fd9a4cd20e7feb840a8_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy01LTEtMS0xNDUyNA_92dc9983-bea4-4dfa-931b-71977859265d">92,160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0xMS0xLTEtMTQ1MjQ_8c1652a0-8707-498a-8350-583307176fa5">92,162</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231" decimals="INF" name="mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC0xLTEtMS0xNDM0Mg_6dd2e3bc-8ec8-43fb-8adb-dbb5d53d4b7c">150,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231" decimals="-3" name="mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC01LTEtMS0xNDM0Mg_78597789-14a5-46c8-87f1-c25c1197d7f2">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC0xMS0xLTEtMTQzNDI_95054e5c-91ef-483e-b73f-3b0fec85fb77">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS0xLTEtMS0xNDM0Mg_4aeb6364-617c-4154-bd0d-890b145a7e9c">140,073</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS01LTEtMS0xNDM0Mg_a42817ab-7266-4cb9-8a68-7edc8f27716d">489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS0xMS0xLTEtMTQzNDI_c6555bbc-925b-4afc-9acd-6bb4a3e75d63">489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock in exchange for common stock warrant</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231" decimals="INF" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xLTEtMS0xNDU0Mw_7ecf6966-2cca-46f2-b19e-d69066d29c6b">2,575,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231" decimals="-3" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi01LTEtMS0xNDU0Mw_c325b573-ecc9-4661-83b3-991daa0b3cc8">8,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xMS0xLTEtMTQ1NDM_608fa07a-ec2a-4ec9-a688-e21e726bc90e">8,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock warrant in exchange for retirement of common stock</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy01LTEtMS0xNDU0Mw_8fd547aa-2b8e-4bb6-80c9-dd4f69fa2906">8,986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy0xMS0xLTEtMTQ1NDM_7bbe1bd9-27a5-4fd4-b4bc-a610a8e9eae2">8,986</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi01LTEtMS0xNDM0Mg_1f2c5733-c8e1-4db2-8f5b-2c9307d91dc6">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xMS0xLTEtMTQzNDI_397f9e93-69f8-4d37-bd1a-975acbfee977">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9be11c24e8ce4dcf855d9e19a0e8605d_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy03LTEtMS0xNDM0Mg_7f4c63d2-7722-40b7-b86d-e74fd6bdfc89">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy0xMS0xLTEtMTQzNDI_e1fb6ff7-0c70-4a1d-8e20-6a884bba3bd9">33</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1625de5080394e76934616170e525c3e_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOC05LTEtMS0xNDM0Mg_8e36774c-f51f-4017-9ffc-a26da75faf81">28,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOC0xMS0xLTEtMTQzNDI_bfe81a6e-77c7-4b8b-9ec0-80e615d06bdd">28,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2263e5f0b5374b6eb63797459412baea_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0xLTEtMS0xNDM0Mg_9fcdc777-1456-467b-ac56-059a954e8798">45,388,023</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2263e5f0b5374b6eb63797459412baea_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0zLTEtMS0xNDM0Mg_fb5ea550-fc9c-4ad1-a2df-368d2c117e3d">5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5079a121336542a2ad5e6a69a5d2da56_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS01LTEtMS0xNDM0Mg_b7bcbeef-5957-420f-be7c-1d8458a9c24c">270,662</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73784c7eb6bd4fecafcc0ade4d41a8ac_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS03LTEtMS0xNDM0Mg_2fe1fcf5-37b4-4126-93c8-7fd5b44eb7ab">25</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i90e630e58b154d58ada0eb8b3903547b_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS05LTEtMS0xNDM0Mg_013ef5d6-f724-4a87-a6b8-177ec7bdfe29">192,374</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0xMS0xLTEtMTQzNDI_c6c659b2-27c5-404e-baa5-8cfc71b1004f">78,318</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market transactions, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231" decimals="-3" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMC0xLTEtMTQ1NzYvdGV4dHJlZ2lvbjo2MDJlMDY4MjU1NWE0NDQwYTA2YzhjOGNlYzFlZjExMV8zODQ4MjkwNjk3MzQz_fd9cedaf-dfd6-4327-81e0-daaa76c67888">2,176</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMS0xLTEtMTQ1Nzk_799d16ef-1a1c-4636-979a-6dacd0421afe">10,900,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMy0xLTEtMTQ1Nzk_41d751f6-4a51-4f20-a8ca-e1b373b5ed55">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0901ec303026453cb60c34b79bfee33d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItNS0xLTEtMTQ1Nzk_02ba4eff-70d8-4960-8e07-08b2a147f133">62,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMTEtMS0xLTE0NTc5_82afc4dc-a0ca-41a8-9d73-27aa0b9f0605">62,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231" decimals="-3" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMC0xLTEtMTQ1NzYvdGV4dHJlZ2lvbjpmNTQ1OWYyM2EzNDM0MTIzOTQxNDBjMmFmYzJiNTgxYl83Nw_c04300aa-ff6e-4e06-9561-df50f635d213">10,809</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMS0xLTEtMTQ1Nzk_587b3031-46c7-4d44-92a1-251d07cfb004">9,200,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMy0xLTEtMTQ1Nzk_546ab9b7-a0d6-48ac-99e5-a8f4f27a73d7">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fe62fe6f7e48d490b1f867f9484c23_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtNS0xLTEtMTQ1Nzk_a85d36f5-2e83-432d-a560-36465291004f">163,990</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMTEtMS0xLTE0NTc5_b12f3c08-389d-4f0c-893f-035782ee6b31">163,991</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common stock warrant in exchange for common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231" decimals="INF" name="mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTQtMS0xLTEtMjE0NTI_06c5f9ab-d426-4539-9c65-f060d92fb77e">2,574,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtMS0xLTEtMTQzNDI_5c2409e4-9c52-446f-98d4-d88def90fb4e">697,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtNS0xLTEtMTQzNDI_5f23fabd-3059-4574-83d2-af87e205b7aa">3,138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtMTEtMS0xLTE0MzQy_6ad38378-502b-4c9c-a5be-55132eeac641">3,138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMS0xLTEtMTQzNDI_5ec6232a-09b8-4556-adf8-dda4b02d36d3">80,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItNS0xLTEtMTQzNDI_6bb0da93-6ffa-4933-b38a-ca8a49bc80ea">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMTEtMS0xLTE0MzQy_a4777c38-2cf6-48ac-bb57-cc26ccecae54">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTUtNS0xLTEtMTQzNDI_47201990-d56c-48d7-a598-3f2e9fcdfde2">7,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTUtMTEtMS0xLTE0MzQy_a354aedd-2815-4847-88b2-2d915d354b73">7,172</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1be31f3383e848e98115c2ab8721f353_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTYtNy0xLTEtMTQzNDI_f00f9b3f-7716-4229-a1df-30ad665d6532">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTYtMTEtMS0xLTE0MzQy_f0fd4269-53a6-4e77-9265-16b1655aae15">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic668054d04aa44eeb592807dc2bc4b8a_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTctOS0xLTEtMTQzNDI_d5565661-4ff9-4a07-867e-f06d3fd76129">88,045</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTctMTEtMS0xLTE0MzQy_37c729ad-3eac-4d61-977b-179df1953b3a">88,045</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08fa6f9dba864472a6d18ffa609a28c1_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMS0xLTEtMTQzNDI_7e6b1b3d-c411-4087-8b5a-1eac394a408b">68,841,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08fa6f9dba864472a6d18ffa609a28c1_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMy0xLTEtMTQzNDI_5b2b12fc-8964-445e-9590-dd3874398bc9">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67df1b00583c408f8c9ae48510a0ca54_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtNS0xLTEtMTQzNDI_b8289b3f-2882-4b0c-8b07-e92f2d1561f8">508,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8074fd8df0f64ee79d269ef09013964b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtNy0xLTEtMTQzNDI_25c4cfca-98a4-463b-9810-79c08f2ba014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2978fef777442ca8ce412714c126f1b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtOS0xLTEtMTQzNDI_e5d0258f-1b42-43c4-aeda-013bb1e16de5">280,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMTEtMS0xLTE0MzQy_f7424100-010f-4d09-8ffd-1e1316a7fc61">228,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock from at-the-market transactions, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231" decimals="-3" name="mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpiNTc1N2Y2MDE0YWM0MTg1YWExODk5ZTNkZjdiZGZkNl8zODQ4MjkwNjk3MzIz_535a5ec4-4659-4ad1-b563-23ddfc3e0b05">988</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMS0xLTEtMTQzNDI_3a51a725-9d1e-4b58-817b-b1ae821d3ccd">3,961,074</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i316531b1bea0420aa2f2b09a689cd4aa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktNS0xLTEtMTQzNDI_03e87319-8731-4aad-a0e3-a55ce5d3b3b6">43,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMTEtMS0xLTE0MzQy_a14a384f-c9e2-406d-9158-175415b4002f">43,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItMS0xLTEtMTQzNDI_4276c490-c68b-4d26-91ab-2500b5e872ff">421,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItNS0xLTEtMTQzNDI_dcc06555-5f61-4e9d-a302-f1e3badd0990">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItMTEtMS0xLTE0MzQy_2f28a8cb-8d59-4ccf-a3cc-2d20e2324e35">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted stock units, net of employee tax obligation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMS0xLTEtMTY0MTc_2409980b-99d9-4273-bdf2-a68aa1af5972">407,060</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtNS0xLTEtMjE0NTc_5d22737a-7cba-4cfe-a3cc-cad4311131b8">259</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMTEtMS0xLTIxNDU3_a07d6fd9-4cab-433d-bdf6-3236e28e4ad6">259</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of common stock under ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMS0xLTEtMTQzNDI_fc659516-d9e8-47cc-8ec6-ef845cafe73c">78,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtNS0xLTEtMTQzNDI_2c594a4c-9a96-460d-913c-dcaa1d656fcf">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMTEtMS0xLTE0MzQy_72ab0983-e4b1-4021-9fdd-957070a2faa7">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjQtNS0xLTEtMTQzNDI_72767882-f515-45b5-bb4b-6bf0c2af2c36">18,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjQtMTEtMS0xLTE0MzQy_233f54bd-8b61-4eec-95f4-bf19e1339ea3">18,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e3cf73141c45a28882cef716068d1d_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjYtOS0xLTEtMTQzNDI_f81abba4-336e-4f5f-98c6-f83e209ac307">170,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjYtMTEtMS0xLTE0MzQy_4d86d4e8-559c-4485-ad37-43c2c96dec3c">170,060</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMS0xLTEtMTQzNDI_373d85dc-5b5e-4b21-9d8f-4344649df53c">73,709,056</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMy0xLTEtMTQzNDI_177311ce-e46b-4e6b-921a-777f79847187">7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47e4c776ea1e49f19f94fa71ab035bad_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctNS0xLTEtMTQzNDI_f1de44df-7f3f-4bb1-b5d3-7ce87e3a04ed">572,213</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e856d009884f45bf3990d70080916f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctNy0xLTEtMTQzNDI_05c67784-1541-4eff-96df-7235151d8ab7">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i416501272258413a9fbcffc3613015f6_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctOS0xLTEtMTQzNDI_b0fb1004-7a50-49a5-8a4f-54902677e1c6">450,479</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMTEtMS0xLTE0MzQy_88650035-9852-493b-8849-02269d63a88f">121,741</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy0xLTEtMS0xNDM0Mg_4cf7ad8c-7ad4-4492-9742-66dbb26b373a">170,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy0zLTEtMS0xNDM0Mg_fa496f9b-52ff-4807-b72e-d00153198263">88,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy01LTEtMS0xNDM0Mg_17b705ea-6b37-48f8-80fd-feef84e7ee4a">28,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS0xLTEtMS0xNDM0Mg_9c0f8a9c-1809-4b1d-b7e1-5520f0ab766e">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS0zLTEtMS0xNDM0Mg_c8e1d9a3-d574-45c8-a810-5bc61670f313">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS01LTEtMS0xNDM0Mg_3916eb51-9bdf-41a6-b004-84f533be77b0">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization of premiums and discounts on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy0xLTEtMS0xNDM0Mg_67c06654-1499-4644-a795-9a436693900d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy0zLTEtMS0xNDM0Mg_4a6686e4-c021-4ce0-9ad2-e35a6ce55bcc">86</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy01LTEtMS0xNDM0Mg_e0510809-0052-45aa-8a35-9659a8a5641a">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC0xLTEtMS0xNDM0Mg_a4731134-2905-4595-bdcb-095f8cd474b3">18,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC0zLTEtMS0xNDM0Mg_a8816ba4-362a-4ef1-80c4-4da358e4af37">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC01LTEtMS0xNDM0Mg_a23659cf-66e7-415c-9d9c-3761aa966c2a">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtMS0xLTEtMTQzNDI_9ff1de75-704b-4804-b3ef-6a78d9c12b43">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtMy0xLTEtMTQzNDI_aab1c876-1212-44ac-8a2b-ad53b61f2946">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtNS0xLTEtMTQzNDI_d08fa469-c9ca-4438-8539-8f614c4526c1">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItMS0xLTEtMTQzNDI_b1082b6e-be32-4d60-9b70-31b3d39d09ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItMy0xLTEtMTQzNDI_56455993-3ed3-46eb-a5fb-367669362b3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItNS0xLTEtMTQzNDI_8f13ee99-12f5-4aaf-8b3f-b14ba4a23f21">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtMS0xLTEtMTQzNDI_125d9dd0-3800-4031-a62b-44035e40e37a">2,734</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtMy0xLTEtMTQzNDI_3de746de-a5ff-42cf-a323-63a430a7de70">1,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtNS0xLTEtMTQzNDI_9d59fa72-3010-4d75-8a60-7a4c4dec4a3c">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtMS0xLTEtMTQzNDI_4b8c167e-22a9-4fa8-861e-9d2ae6adc323">718</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtMy0xLTEtMTQzNDI_b8c85bc9-4f66-4fa7-9727-3b20837b7c3e">700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtNS0xLTEtMTQzNDI_ed7f2336-4ad3-4377-ad60-c22586ca1b43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtMS0xLTEtMTQzNDI_8e226c4c-8f12-4dfb-9e75-6c83a2b92dc1">483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtMy0xLTEtMTQzNDI_e6501de7-8793-4c28-9be0-392f4046ff32">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtNS0xLTEtMTQzNDI_8710c371-3079-45e0-b9f6-109cb28c4bdc">3,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtMS0xLTEtMTQzNDI_2f75d3df-9385-4d37-b136-69ee25b96731">12,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtMy0xLTEtMTQzNDI_964e6b36-ead4-4fc0-8547-b1707adc86cb">7,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtNS0xLTEtMTQzNDI_9982cec5-2916-4be2-bfe6-f32ebe06b507">3,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctMS0xLTEtMTQzNDI_f3d858c4-a519-42af-9414-fa550047c3dd">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctMy0xLTEtMTQzNDI_b7dfa449-ff8f-4b05-bb33-88dedb66ee05">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="mrsn:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctNS0xLTEtMTQzNDI_4bf8da17-c65e-4426-b0a2-2dee0c567707">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtMS0xLTEtMTQzNDI_9602e164-538f-4617-8276-352f56bf4b26">1,827</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtMy0xLTEtMTQzNDI_c55b160d-8940-4347-a6d5-e1a3919485ba">1,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtNS0xLTEtMTQzNDI_f3d213e4-e91e-4866-b356-5b2194336eba">1,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktMS0xLTEtMTQzNDI_8036d6ef-f063-48fd-bd9e-3cb64348b5b2">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktMy0xLTEtMTQzNDI_1b680e38-d7e1-41ad-b105-8c1ae76ce74a">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktNS0xLTEtMTQzNDI_6a44e1f4-0af2-49b1-993a-a1e71ec496f3">41,381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMS0xLTEtMTY1Mjc_cac8f5c6-d398-4932-ad70-27b00d492f62">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMy0xLTEtMTY1MzQ_6c3f339e-9dcb-4a6d-98cd-304e5917bf66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtNS0xLTEtMTY1NDE_23530f5d-377d-4342-9d1d-f3a062eaefc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMS0xLTEtMTQzNDI_ef4974b5-591b-43f0-9d8a-25b5387d420e">139,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMy0xLTEtMTQzNDI_119f2993-26bd-4ba1-af7f-1c107a4376cb">74,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtNS0xLTEtMTQzNDI_18150b94-c055-42e1-8a29-21e5e3f306b6">67,744</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtMS0xLTEtMTQzNDI_0f0b4fb2-e168-4b2c-be7f-25110364e588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtMy0xLTEtMTQzNDI_558fc3be-95a4-4f54-9269-3e3791ad64bd">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtNS0xLTEtMTQzNDI_e4c369e4-5b1a-4ecf-90ea-3084ea3b84a7">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtMS0xLTEtMTQzNDI_25c05b06-dbb0-4687-bac0-622d9ba33a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtMy0xLTEtMTQzNDI_23c36f54-1b8a-4def-9047-4f3c54ae7e52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtNS0xLTEtMTQzNDI_e51e89f6-b1db-4ca1-b89e-56f7b3a445d4">53,688</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtMS0xLTEtMTQzNDI_cf371ace-98c5-49e9-99bc-ebc4ea518214">648</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtMy0xLTEtMTQzNDI_d21fec26-ac46-4178-a861-a243c93ee44c">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtNS0xLTEtMTQzNDI_baccc98d-42db-4a97-b53c-e5da2e89358b">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtMS0xLTEtMTQzNDI_094c2415-6666-4736-b7be-b8bd7dea964d">648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtMy0xLTEtMTQzNDI_e39b8d90-a621-47b4-bc85-332602d962ad">37,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtNS0xLTEtMTQzNDI_d4c1172d-ac42-4982-a6ec-6fa2331d14cb">27,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from public offering of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72f092e073f4caea321165cbb01d83d_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktMS0xLTEtMTQzNDI_766e0ada-476f-45e9-9245-f55431e6a558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktMy0xLTEtMTQzNDI_fb072e77-31c4-49f9-a672-1e0cb9d22217">163,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktNS0xLTEtMTQzNDI_4f0b06be-2a4c-4888-bb94-d5dd427d2f78">92,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from use of ATM</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7ad9dfbc0149afaf920277bb3301a3_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtMS0xLTEtMTQzNDI_c2e156fe-8b44-431f-9f5c-658d39b56cf7">43,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c71214218f46bb9d5a65ebdabaa5e0_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtMy0xLTEtMTQzNDI_834b8ff1-0bd4-40ee-8695-c16bfcaf9357">63,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63559c339ac14a4f808281cc61d2e001_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtNS0xLTEtMTQzNDI_db6e28a2-5f80-48ee-b93d-05b9812cb145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItMS0xLTEtMTQzNDI_245a3acd-2c69-4659-89bf-f1036e4c7bfe">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItMy0xLTEtMTQzNDI_6f5586ce-4ee0-4e58-8c3b-a32c37634048">3,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItNS0xLTEtMTQzNDI_54b571fc-ad74-4689-b622-a1069654a4f0">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from purchases of common stock under ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtMS0xLTEtMTQzNDI_012710e2-26f6-4e58-bbfb-c51858d71190">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtMy0xLTEtMTQzNDI_27a74fcd-1798-49c6-9b0a-b167d0647726">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtNS0xLTEtMTQzNDI_e250fc1a-aa30-4fe3-ba9b-129183192649">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of employee tax obligations related to vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMS0xLTEtMTU1Njg_674b3b0e-26a5-4f2b-b70f-e8eb57dcfd96">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMy0xLTEtMTU1Njg_8521d929-99a3-437f-80b1-2faf3b891bac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtNS0xLTEtMTU1Njg_2bcb9f0d-07b3-49d0-91ef-f20d29e98b8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:ProceedsFromDebtNetIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMS0xLTEtMTQzNDI_161c8116-db41-4205-95cb-ca99c69c3d71">24,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="mrsn:ProceedsFromDebtNetIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMy0xLTEtMTQzNDI_514baf6e-d0ae-414f-8f59-774c82945551">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:ProceedsFromDebtNetIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtNS0xLTEtMTQzNDI_9e820ba8-eabe-4522-a0ef-9d75c0c804b9">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctMS0xLTEtMTY1NjY_c93b26dd-4af1-4346-b0e0-83a2731aefee">5,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctMy0xLTEtMTY1NzQ_5b5a5c27-9da2-4997-b0bd-08e27fc43047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctNS0xLTEtMTY1ODY_35cebb4d-3f5c-4698-9c68-6b5a59f2d4e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments under finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtMS0xLTEtMTQzNDI_845bc1f6-ffab-4251-9223-01d21a859271">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtMy0xLTEtMTQzNDI_62e5b2b9-d86e-46dc-a5bf-d81aba5d5f82">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtNS0xLTEtMTQzNDI_4e2a264b-4094-4cc0-a28f-f3a62710ff9b">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtMS0xLTEtMTQzNDI_421bec31-913c-4eef-955b-bb18d18b3d1b">63,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtMy0xLTEtMTQzNDI_18899bff-defb-4cb2-a869-b8e6df1eb3f9">230,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtNS0xLTEtMTQzNDI_a874dbec-9ed5-4644-9f52-7cb521459f68">97,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtMS0xLTEtMTQzNDI_5f9663f5-ba4b-4582-9c21-efa53bb5f6c7">76,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtMy0xLTEtMTQzNDI_6b10a763-d4c6-41af-be6b-80efdc7ed6ba">192,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtNS0xLTEtMTQzNDI_4be1c4cb-9963-484f-a1fb-d8d734fb89a7">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktMS0xLTEtMTQzNDI_93222b07-d294-47a4-ac65-639995016810">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktMy0xLTEtMTQzNDI_d566fcf2-acd2-4f50-bbad-fc2fb3b4cd17">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktNS0xLTEtMTQzNDI_4425abe1-0ba6-420c-b7a1-779a02a35a15">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtMS0xLTEtMTQzNDI_462d841a-371b-4acb-a540-0d214c757a91">178,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtMy0xLTEtMTQzNDI_ed71ab74-8f6a-49ff-9c47-85f50a69ee31">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtNS0xLTEtMTQzNDI_a5856cb5-cce1-4529-9b15-fb1dc265e7a3">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of common stock retired in exchange for issuance of common stock warrant</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtMS0xLTEtMTQzNDI_dd3dee51-41da-4d87-b948-8fb6e09ca55d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtMy0xLTEtMTQzNDI_2a4175fc-b936-4409-a6b4-88246f3bea50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtNS0xLTEtMTQzNDI_58e0ef8c-995d-4e9b-acba-7e6c36decea7">8,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtMS0xLTEtMTQzNDI_505666fc-b116-495f-b06a-33f91351be6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtMy0xLTEtMTQzNDI_e02494b0-169c-4259-8367-9097183cc649">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtNS0xLTEtMTQzNDI_25dfc680-6d0d-4b29-9b92-6af2a62f8b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt financing costs in accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtMS0xLTEtMTQzNDI_8cc755c8-3bce-4f09-b4f7-08918d3f594d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtMy0xLTEtMTQzNDI_908f1c30-edfc-40e9-8d1d-73c677f8984b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtNS0xLTEtMTQzNDI_e2c33bcc-ba6a-491a-a51a-eb15e3811dc2">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctMS0xLTEtMTQzNDI_7a2e5380-a538-4e05-981f-a922dd5bffe4">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctMy0xLTEtMTQzNDI_4b2a2d79-cdf7-4537-bacb-38d76095ee6c">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctNS0xLTEtMTQzNDI_10c08c3a-84b3-4847-a2f3-4b7c84d6c299">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtMS0xLTEtMTQzNDI_1e2279d0-bebb-4cd8-bb6c-a5169a13d42b">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtMy0xLTEtMTQzNDI_a4b7af4f-9305-4cd8-a8cf-25ba331f6ac2">9,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtNS0xLTEtMTQzNDI_81612b99-2652-4946-a14e-1071e6fbe7b5">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for financing lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktMS0xLTEtMTQzNDI_362e8685-accf-4f9a-85aa-cda31fad23eb">609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktMy0xLTEtMTQzNDI_225a8f48-5766-4e4a-95d2-b8aed8309f29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktNS0xLTEtMTQzNDI_979cc30c-1b51-4c50-9d96-7b9cefa718ae">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_91"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i54c829abb8e046e0ba4639af9592e947_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfNDQ0NQ_047a944d-90ba-4bd9-83b0-1b38918dceec" continuedAt="i97680abe4dd44b83936af5fb4a268616" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i97680abe4dd44b83936af5fb4a268616" continuedAt="i2666d38b39c640859cde127b7ba3d44e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged over 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#8217;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering the novel stimulator of interferon genes (STING) agonist ImmunoLock payload, together provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#8217;s clinical candidates include upifitamab rilsodotin (UpRi) and XMT-1592. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lead product candidate, UpRi, is a first-in-class Dolaflexin ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and other cancers. The Company is currently evaluating UpRi in platinum-resistant ovarian cancer in a single-arm registrational trial, referred to as UPLIFT, for which the Company expects to complete enrollment in the third quarter of 2022. The Company is also conducting a Phase 1/2 umbrella combination trial, referred to as UPGRADE. The first combination the Company is exploring is the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer. The Company may explore other combinations in the future. The Company expects to report interim data from UPGRADE in the second half of 2022. In the second quarter of 2022, the Company expects to initiate enrollment in a randomized placebo-controlled Phase 3 trial, referred to as UP-NEXT, to evaluate UpRi as single agent maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer that have high NaPi2b expression.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's second clinical candidate, XMT-1592, is a NaPi2b-targeted ADC leveraging the Dolasynthen platform. The Company is conducting a Phase 1 dose exploration trial in patients with ovarian cancer and non-small cell lung cancer, or NSCLC, which it expects to complete in the second half of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since inception. The Company&#8217;s net loss was $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQzMw_58682e89-fcb7-4fef-aa1e-2718e909b75a">170,060</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQzNw_e5e6eeb9-ec7c-49b1-88f9-e2d43c88d76e">88,045</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQ0NA_8832e105-3eb1-45b9-955c-66c696057a6d">28,208</ix:nonFraction> for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjY0Mw_6ca52c35-3595-4fea-b425-1b7543d9603b">450,479</ix:nonFraction>. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its currently available funds will be sufficient to fund the Company&#8217;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2666d38b39c640859cde127b7ba3d44e">Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.</ix:continuation></span></div><div id="i54c829abb8e046e0ba4639af9592e947_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDM_cd92e6be-065d-4067-ba7e-ab3c11fba0af" continuedAt="i79a7d862f14645daba466136522c3a47" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i79a7d862f14645daba466136522c3a47" continuedAt="i5d55ffe12ad746ea8e4999e9f48d592a"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjI_6c522937-442e-480e-af68-b62e7249538c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTk_12386ac4-48ce-401e-bc9b-6f13086a8a58" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTA_9b6b18cf-9cc9-417b-8d98-68e2a8788e08" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTE_e61a8e46-b0e6-478c-aa8f-3905d6dc2a57" continuedAt="ife93a1755f684d698e2a15e5cee44fff" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical studies, clinical trials and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i5d55ffe12ad746ea8e4999e9f48d592a" continuedAt="ibf03e5333b144c558e4e7f7accbca094"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife93a1755f684d698e2a15e5cee44fff">expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</ix:continuation></span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTc_10472d82-0a99-46c9-8744-fa98b2e75050" continuedAt="i17aa8fcbefa24f89884cd09d8c72c75e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method better predicts the amount of consideration to which the Company will be entitled.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ibf03e5333b144c558e4e7f7accbca094" continuedAt="i478b2073ea6e48d9aa721546d0290b18"><ix:continuation id="i17aa8fcbefa24f89884cd09d8c72c75e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="mrsn:RevenueCollectionPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTExNjc_e0c7139d-80e4-4abf-b033-6a665f2fec5a">30</ix:nonNumeric>-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div></ix:continuation><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDg_a8bf7709-b551-414f-91e3-a05bc5679f83" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also considers the guidance in ASC Topic 606 by analogy in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTg_716db5a9-8839-4a3d-8193-358f3c441abe" continuedAt="icb26d7544922466b8a34a86710f92165" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820), establishes a three-level valuation </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i478b2073ea6e48d9aa721546d0290b18" continuedAt="ide878df1d4994ca895705559d0a644c9"><ix:continuation id="icb26d7544922466b8a34a86710f92165"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div></ix:continuation><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDQ_ddf06593-6fbf-42f7-ad4b-f13fa2d1a996" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDE_aa453887-e181-4c10-a874-ea6808117d2a" escape="true"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDU_c23930a8-619d-4029-bc6d-74bfe08e753d" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi0xLTEtMS0xNDM0Mg_3feeaed5-efad-4af7-af38-29cfe4f08774">255,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi0zLTEtMS0xNDM0Mg_cac51bd5-31c6-4aac-b38d-cdbd9176b4b9">177,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi01LTEtMS0xNDM0Mg_cc0056a0-d272-4073-bf28-a60526b0c74f">62,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi03LTEtMS0xNDM0Mg_4e929421-2b4b-4951-ba35-0bb0feb16aa7">255,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy0xLTEtMS0xNDM0Mg_255c0f49-366f-4a77-8b40-17f2ca44fa70">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy0zLTEtMS0xNDM0Mg_576c473b-c130-43f0-adc0-dd165cda6eef">478</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy01LTEtMS0xNDM0Mg_6d6684f0-8604-44d4-87e2-8191c7273604">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy03LTEtMS0xNDM0Mg_03438108-9249-41ad-b258-ed599cd720f7">321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC0xLTEtMS0xNDM0Mg_23aa74e6-1721-4452-8989-dc431b8d3d04">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC0zLTEtMS0xNDM0Mg_1696b3f1-8fab-435c-bee5-f25b83dbff9a">178,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC01LTEtMS0xNDM0Mg_96374731-0ec6-41c4-b501-c0336f282f5f">62,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC03LTEtMS0xNDM0Mg_9037c322-5e49-4f44-8353-5d8cb37eb318">255,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTI_44103272-6821-4494-a0e5-0406cc59c07c" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5NDI_0f0a99f5-7c8b-4a51-8f65-801fd4025dd8">2,356</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5NDk_7fd00672-c8d5-436a-8db3-e5064030554e">2,153</ix:nonFraction> as of December&#160;31, 2021 and 2020, respectively, comprised of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:RetainageDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5OTY_9528abcc-4fdd-4128-b75f-234c472332c8">1,418</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:RetainageDeposit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwMDM_414f6ecb-fea2-44be-a4cc-49f22176b2e6">1,832</ix:nonFraction>, respectively, held by a service provider, restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwNzI_2938eef7-f583-49e9-b531-722f9dd4d8e2">478</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwNzk_175bbea6-575b-4016-ba6e-552bd2b88289">321</ix:nonFraction>, respectively, held as a security deposit for a standby letter of credit related to a facility lease, and $<ix:nonFraction unitRef="usd" contextRef="i8e350e8b8c7c4fad8a6f1dbcaef3d9c8_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTA5OTUxMTYzMTYyNTQ_271f3e4c-44bc-4c97-b6af-8763e133988b">460</ix:nonFraction> as of December&#160;31, 2021 of deferred financing costs related to the New Credit Facility (as defined below) with Silicon Valley Bank (SVB) and Oxford Financial LLC (Oxford). For additional information regarding the New Credit Facility, please refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTY_5851cbe2-b741-4895-ba2f-364fd2ea3ce0" continuedAt="idfa08cb6b01d44139200ce3e3df43313" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ide878df1d4994ca895705559d0a644c9" continuedAt="i51c0bb0393bb466999e271766465eb91"><ix:continuation id="idfa08cb6b01d44139200ce3e3df43313"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be <ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTkzMzc_91bb8522-ab16-4ff4-a793-5b537642911b">zero</ix:nonFraction> as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit (RSU), at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div></ix:continuation><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDk_e18a48b9-42b4-4081-a26e-4218ea688485" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares outstanding and, for the year ended December 31, 2019, <ix:nonFraction unitRef="shares" contextRef="i57c7504cae894df18aaaa3b793ed4bcf_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMjAxMjU_d84ce66a-c9d9-4b52-bf18-b517a0c96c83">2,575,000</ix:nonFraction> Exchange Warrants (as defined in Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with ASC Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method. For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjM_523cf3be-8af7-475c-aeac-09010990b2a4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5cd2bc576a64407b348ad9bfc065f8d_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi0xLTEtMS0xNDM0Mg_f404ee94-1ad8-49a5-92ad-f95b2d03ad01">8,342,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c4fdc5ae4df447da4c58088b9961c67_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi0zLTEtMS0xNDM0Mg_2cc83417-aaf5-436e-82e4-2df93a5f6c63">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe1588dcb89e4bfa84977ab490cf0417_D20190101-20191231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi01LTEtMS0xNDM0Mg_7f62863c-994b-4876-9110-387caff86bb8">4,720,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48c7830bb0b0416eb5d577f21baf0aac_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy0xLTEtMS0xNDM0Mg_8693e771-a578-4060-a3d0-6d7bef72bc9e">817,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id97077e4c81a481a8647699765887a0a_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy0zLTEtMS0xNDM0Mg_7f9a84d0-7282-43f6-b966-ddf7aad10066">716,767</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i667df8466ca44fb6a82fd19ed57ff48f_D20190101-20191231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy01LTEtMS0xNDM0Mg_d969da79-4c45-467e-aaae-3f6942ba547d">447,336</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida5a046a9dbb4cc0988324aea0d475c4_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC0xLTEtMS0xNDM0Mg_fe00e153-1019-4328-b12f-fd1e4cd6245b">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62083aff246944c9b4984de9c9c1ef1a_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC0zLTEtMS0xNDM0Mg_dee25e4f-5b13-4f4a-93c8-52551a255e1d">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i809dbadb11db4e24afbe3cdcfe4f79d9_D20190101-20191231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC01LTEtMS0xNDM0Mg_ce4ab38d-d270-46c1-9769-c6522697786b">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS0xLTEtMS0xNDM0Mg_9caff05f-b2e6-4ccf-bcd5-f32458d5e5ad">9,199,512</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS0zLTEtMS0xNDM0Mg_546b70c2-d18d-42f4-9a9d-298623a987ae">6,869,189</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS01LTEtMS0xNDM0Mg_e960a2f1-302b-42b0-86ce-723ff0da4c9d">5,207,582</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTM_fb08cb9f-8eeb-4bd8-a432-9e2dc4ef8f87" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjQ_f7402ce2-0619-490c-bacc-8a157ca44755" continuedAt="i1a977c22e4d2493d99cd150ce1095bd6" escape="true">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i1a977c22e4d2493d99cd150ce1095bd6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.380%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f98a71f7de2423c9004b46d1a094d47_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMC0xLTEtMS0xNDM0Mg_0ac2680d-a311-4934-bb76-c1d6fb18449a">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57bf8dc50aad4550b09f65fd101d5b8e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMS0xLTEtMS0xNDM0Mg_e1d7ba5d-26ba-4bd1-8100-ce309ac83b01">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2289a4965c8d4c269148c6c1a7f94f33_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMi0xLTEtMS0xNDM0Mg_5d323dae-795e-437c-a894-cc4dbbeddffc">Shorter of useful life or life of lease</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did <ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_772aec4e-f33c-4a4e-9b2d-5494c64c1f59"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_9fed0a46-4e1a-4409-aff1-ef2d53210028"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_b1fc8652-0522-40ea-9bc8-158d03bbe2e0">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize impairment charges during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i51c0bb0393bb466999e271766465eb91" continuedAt="i9a2cfaeddfe546e583e9bb9a03a4e58a"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDc_b9f25c86-8995-4a62-95b1-169f47029661" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjA_25321502-1ad0-43d5-bc2a-09c4ad8e2336" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjE_942cf43b-fc15-4f8f-9458-bdf7120dc17e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTQ_7e512349-d9f5-4cc0-886b-ce8f0b47083f" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the year ended December&#160;31, 2021, comprehensive loss equaled net loss. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDI_247cc05f-818c-444d-a465-86a39f2e01c0" continuedAt="i3f8782499244475b8a2516b7d599237d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMjY5MzM_ff6eb565-faea-4626-8eea-3a2b80167bc3">no</ix:nonFraction> financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i9a2cfaeddfe546e583e9bb9a03a4e58a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3f8782499244475b8a2516b7d599237d">primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to any significant concentrations of credit risk from these financial instruments.</ix:continuation></span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDY_979c7f12-bd39-49da-aae8-235793f64f9e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE3MjY2_d7912644-7b30-46c2-a232-1bb899c1482f" continuedAt="i2146ba3e42b0488880fab4d14ef613f3" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="i2146ba3e42b0488880fab4d14ef613f3" continuedAt="id501fad90fbb420c8d7ac06c9d0191ec"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a non-refundable technology access fee of $<ix:nonFraction unitRef="usd" contextRef="i311ddb6991d8496f92c657e71d74c7e1_D20140601-20140630" decimals="-3" name="mrsn:CollaborativeArrangementsUpfrontPayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzI5Mw_42f3380c-74e0-4834-8766-a1975899d683">12,000</ix:nonFraction> for the right to develop ADCs directed to <ix:nonFraction unitRef="target" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="INF" name="mrsn:CollaborativeArrangementsExclusiveTargetsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzMzOA_44153a3a-8685-4528-8d16-4ee6acf5ce40">six</ix:nonFraction> exclusive targets over a specified period of time. <ix:nonFraction unitRef="usd" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="-3" name="mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM5Mg_cad9093f-561a-4715-ac9d-b038508d3b5f">No</ix:nonFraction> additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $<ix:nonFraction unitRef="usd" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="-3" name="mrsn:CollaborationArrangementsMaximumAggregateMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEzMDM_baf3fd26-4490-40f8-9f24-784fae96da06">780,000</ix:nonFraction> in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid-single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $<ix:nonFraction unitRef="usd" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1Nzk_9f4e9da1-323a-4671-8ab9-478f50895d6c">84,000</ix:nonFraction>; regulatory milestones $<ix:nonFraction unitRef="usd" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="-3" name="mrsn:CollaborationArrangementsRegulatoryMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MDU_c4c5d0f7-28bf-415a-a55f-729afa93a5b4">264,000</ix:nonFraction>; and sales milestones $<ix:nonFraction unitRef="usd" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="-3" name="mrsn:CollaborationArrangementsSalesMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MzA_73226bca-19be-4c32-a953-4880c7daaeec">432,000</ix:nonFraction>. There are <ix:nonFraction unitRef="milestone" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="INF" name="mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2NDQ_fb8aa75f-54bf-4143-820f-37887089fe54">six</ix:nonFraction> individual development milestones per target, payable upon the completion of various activities, from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are <ix:nonFraction unitRef="milestone" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="INF" name="mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE4NTk_02e94e4d-6c33-4d32-8042-c81d92c2e17b">five</ix:nonFraction> regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are <ix:nonFraction unitRef="milestone" contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630" decimals="INF" name="mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIxMDc_2571e7b0-5149-4d5c-bed4-3e797f25b938">three</ix:nonFraction> individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i4af5ca3b68bb4ed7b6a33a6008c3ab69_D20150101-20191231" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIyNzQ_ee97a38e-46d5-42e6-973c-189728cc31ca">3,000</ix:nonFraction> related to development milestones under the Merck KGaA Agreement. There have been <ix:nonFraction unitRef="usd" contextRef="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIzNTk_6add3ac2-236a-4859-9e7a-6cb175eb7612"><ix:nonFraction unitRef="usd" contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIzNTk_7551842e-22b8-40f7-9f91-10cf03c18f20">no</ix:nonFraction></ix:nonFraction> additional milestone payments in the years ended December&#160;31, 2021 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $<ix:nonFraction unitRef="usd" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="-3" name="mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzI1MzM_c60d7f0e-2f6d-4b3e-bf3c-7f1a10236269">500</ix:nonFraction> on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon <ix:nonNumeric contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231" name="mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzMyNjc_615d8e51-abb2-4a73-8e1b-a212aa9847e2">60</ix:nonNumeric> days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="id501fad90fbb420c8d7ac06c9d0191ec" continuedAt="i3eca22e2375e425ba141d34f7e821963"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC drug substance and clinical GMP drug substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for <ix:nonFraction unitRef="target" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="INF" name="mrsn:CollaborationArrangementsTargetsDesignatedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQ0ODM_1a5b2e10-e7f7-4b9e-9b99-94d23bd0b0ac">six</ix:nonFraction> designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plan for other designated targets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were <ix:nonFraction unitRef="usd" contextRef="i9790c299a9564e76a73c4df8750539ba_I20180101" decimals="-3" name="mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzU1NzE_aa2aca78-a0be-47b5-a73f-76b4bf76bf61">no</ix:nonFraction> milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021 and 2020, the total estimated transaction price for the Merck KGaA Agreement was $<ix:nonFraction unitRef="usd" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzc3MjQ_b41a6e01-4c59-44d5-a1a4-bbb169f07227"><ix:nonFraction unitRef="usd" contextRef="ic09d46e0ab9d49a69193af570876fd88_I20201231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzc3MjQ_e4589cb7-96d7-467b-b8b7-1b59aa0e1aac">21,325</ix:nonFraction></ix:nonFraction>. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQzOTgwNDY1MzM4MDc_221572c0-0e95-4e19-9c88-7eff19347ae2">21,325</ix:nonFraction> was allocated to the performance obligations as follows: approximately $<ix:nonFraction unitRef="usd" contextRef="i22751430a1af485c87dd79584475d813_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgwNjI_5500512f-f253-45b9-9d8e-7ee97a17ff6a">3,941</ix:nonFraction> for each of the license and corresponding research and development services units of account for the first and second designated targets; $<ix:nonFraction unitRef="usd" contextRef="i724be6926e0f43708c3842a241f2b234_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgyMDM_3e11ba97-32aa-4699-8144-5fd1291dad64">3,439</ix:nonFraction> for each of the license and corresponding research and development services units of account for the third and sixth designated target; $<ix:nonFraction unitRef="usd" contextRef="ic393ee0337764f848b485d8f53c57f94_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgzNDI_ed1c94ce-9d15-4040-8d17-68964fae2dc0">3,152</ix:nonFraction> for the license and corresponding research and development services unit of account for the fourth designated target; $<ix:nonFraction unitRef="usd" contextRef="i8719cb8746fc444a8b30ec920ba9e272_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg0NjM_62e083b8-1709-4203-9752-ac16be048911">2,746</ix:nonFraction> for the license and corresponding research and development services unit of account for the fifth designated target; $<ix:nonFraction unitRef="usd" contextRef="i24a96471c63a400b9ce4997aa4039334_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg1ODM_e2dff16a-a6d1-406d-b4c7-f5367488cb51">425</ix:nonFraction> for rights to future technological improvements; and $<ix:nonFraction unitRef="usd" contextRef="i266b15fef82f4d77ab6acfccdce49876_I20211231" decimals="-3" name="mrsn:RevenueTransactionPriceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg2Mzk_675ea284-44f9-44c6-accf-e67bf1ac3f3f">242</ix:nonFraction> for joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i3eca22e2375e425ba141d34f7e821963" continuedAt="if3895872fabb4d40a8a0df7f54dee72c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are <ix:nonNumeric contextRef="if1c1155ad2bf48ed93491e3ec3ff0c2b_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk0NTU_805dcb52-d825-42fe-a767-d4a713f58ea8">10</ix:nonNumeric> and <ix:nonNumeric contextRef="i578ab44d714748d09da2b37adc7d98a6_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk0NjI_e0f64f54-2a55-4140-a302-28a75588608a">5</ix:nonNumeric> years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has completed its research service obligations associated with <ix:nonFraction unitRef="target" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="INF" name="mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk2Njk_e8738756-aecf-46a4-a296-c938d04f8528">four</ix:nonFraction> of the <ix:nonFraction unitRef="target" contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231" decimals="INF" name="mrsn:CollaborationArrangementsTargetsDesignatedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk2Nzk_361cacca-c88d-47d3-8932-a89f0fccc2f4">six</ix:nonFraction> designated targets. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded collaboration revenue of $<ix:nonFraction unitRef="usd" contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3ODY_f82436e4-33e4-495b-90d7-79365d13f3d4">43</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3OTA_f78319bb-5fea-4736-9ba5-d8c130bad3e5">828</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5c642871deec4bf2ae3f141820fc4f9c_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3OTc_4727e48d-844b-47de-8fc9-ebc0f636e2cb">853</ix:nonFraction>, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ie5e3153e090a41668aa9d9e117b855f2_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk5OTU_afaca21a-8dff-48e4-a1ac-6129c89247a1">1,280</ix:nonFraction> related to the Merck KGaA Supply Agreement. There were <ix:nonFraction unitRef="usd" contextRef="ic7616293f91948f28dd309eb148c545e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMDUz_29c2f0b2-381d-41f5-ba2f-68bf6d7776a5"><ix:nonFraction unitRef="usd" contextRef="ib939e9ec9abd4ac39881b2e5f6f0a6f4_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMDUz_8585831b-2243-4016-b0f8-fd707a0448f8">no</ix:nonFraction></ix:nonFraction> amounts recognized during the years ended December&#160;31, 2021 and 2020 related to the Merck KGaA Supply Agreement.&#160;There was <ix:nonFraction unitRef="usd" contextRef="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231" decimals="INF" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMTYy_0b8dadaf-2dd2-4cc1-9e29-a4a462f93d72"><ix:nonFraction unitRef="usd" contextRef="i4ce0872b58f0463c95884113a6545230_I20201231" decimals="INF" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMTYy_c95c19b4-c565-483d-b7d4-04f9cb29faeb">no</ix:nonFraction></ix:nonFraction> balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had recorded $<ix:nonFraction unitRef="usd" contextRef="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMzI5_a1652157-b17b-4eb5-bcf7-40320a38da81">3,944</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4ce0872b58f0463c95884113a6545230_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMzM2_0849524e-e7e3-4e1d-a6bc-1a263834c96f">3,987</ix:nonFraction>, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda XMT-1522 Strategic Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda Pharmaceutical, Inc.'s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon <ix:nonNumeric contextRef="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102" name="mrsn:CollaborationArrangementsDurationToTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzExNDE4_927a96f1-cf96-4b27-87ba-bb9a8a714a88">30</ix:nonNumeric> days&#8217; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of <ix:nonNumeric contextRef="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102" name="mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzExNzgw_78c5389e-4b94-4f77-b6eb-949c909fdf3e">30</ix:nonNumeric> days after the effective termination date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Strategic Research and Development Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of <ix:nonFraction unitRef="target" contextRef="icf84ce2b240441789956b1e89bcf4595_I20160131" decimals="INF" name="mrsn:CollaborativeArrangementsExclusiveTargetsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyMjcx_e4b0ca2c-4e56-4313-a61d-7d8ad6665b3c">seven</ix:nonFraction> exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon <ix:nonNumeric contextRef="i4f0a4b79107a46de82588501551a7baa_D20190102-20190102" name="mrsn:CollaborationArrangementsDurationToTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyNDk5_5e5de1e4-74bf-4b6f-b530-251c3d86dac5">45</ix:nonNumeric> days&#8217; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligations, the Company recognized the remaining deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ifd81097c435142008a0e8197ddc84278_D20190101-20190331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyOTcy_5371913b-f29c-47d2-8513-efb124e55dcd">39,965</ix:nonFraction> related to the termination of the Takeda agreements in the first quarter of 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the termination of the agreements, the Company had identified <ix:nonFraction unitRef="agreement" contextRef="i26419f71b3384c04a3f6605f62bc5c57_I20191231" decimals="INF" name="mrsn:RevenueRemainingPerformanceObligationNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEzMTI4_5d355d52-2da8-4046-be49-8300c1371faf">14</ix:nonFraction> performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="if3895872fabb4d40a8a0df7f54dee72c" continuedAt="id97ac971ed7e47f0bd29037eaf16da6c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were <ix:nonFraction unitRef="agreement" contextRef="iccb4e2fad20448bcb47f9ece79c43d47_I20191231" decimals="INF" name="mrsn:RevenueRemainingPerformanceObligationNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE0Mjk4_9ffa3b75-d5e8-441d-8d86-d89fc6168628">one</ix:nonFraction> performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the year ended December&#160;31, 2019, the Company recorded total revenue of $<ix:nonFraction unitRef="usd" contextRef="ic8f3b11dfbc64275ac3f70f6dc51c46b_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQzOTgwNDY1MzgwMjE_eaaee258-3aae-4f39-9e21-6cb04e3f2efa">39,965</ix:nonFraction> related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. The Company did <ix:nonFraction unitRef="usd" contextRef="ie83b8c61371748b8a4dad5a60b07f3eb_D20200101-20201231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM4NDgyOTA3MjU0OTk_032958f2-ab8e-40fb-9c9a-6e0c8c77cc01"><ix:nonFraction unitRef="usd" contextRef="i49b1abd1d2b641b89c50bc6d8090ae6a_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM4NDgyOTA3MjU0OTk_daed1269-753c-4cd1-bc23-8f842ff058cc">no</ix:nonFraction></ix:nonFraction>t record any revenue under the 2016 Restated Agreement and the XMT-1522 Agreement in the years ended December 31, 2021 and 2020. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the year ended December&#160;31, 2019, the Company was billed approximately $<ix:nonFraction unitRef="usd" contextRef="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1MTg0_88b4e4e2-ea70-4878-b687-18ada7814f0f">200</ix:nonFraction> from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. During the year ended December&#160;31, 2019, the Company billed Takeda $<ix:nonFraction unitRef="usd" contextRef="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231" decimals="-3" name="mrsn:CollaborationArrangementsCostsBilled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1NTgy_6f4f668f-7c23-4a18-bafe-a0e62d359b7e">195</ix:nonFraction> related to ASC 808 costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Assets and Liabilities</span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE3MjY3_b66bd3d3-bde8-40a1-9ee0-7737fd1dec62" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzItMS0xLTEtMTQzNDI_c7400b65-d557-4e83-b6fb-f4edc8960289">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzItNy0xLTEtMTQzNDI_8c4e4a8b-8342-4c07-9a46-d0c0fe818b59">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtMS0xLTEtMTQzNDI_bba8c213-bb0d-4310-aaf7-fdc550752049">3,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityIncrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtMy0xLTEtMTQzNDI_e35e9b51-bb5a-4bb8-b726-4597da788b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtNS0xLTEtMTQzNDI_fbd0f63e-3add-4d51-b239-4ba4137a6abd">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtNy0xLTEtMTQzNDI_6abc2e49-054d-4f67-a741-a82958641dc3">3,944</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzItMS0xLTEtMTQzNDI_5c3b5440-da14-4be7-8f6c-3c17b3b3490c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzItNy0xLTEtMTQzNDI_a55eb6b1-0244-4d67-ade3-abdad2556ce6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtMS0xLTEtMTQzNDI_6edbb288-a1fa-4985-bd48-40694f5135bf">4,815</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityIncrease" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtMy0xLTEtMTQzNDI_e57073ff-04c4-4741-ad55-9f5b9961b002">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="mrsn:ContractWithCustomerLiabilityDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtNS0xLTEtMTQzNDI_dc8fd352-1212-44a7-979f-970bdb2f477b">828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtNy0xLTEtMTQzNDI_a6631364-7fe5-489c-b44c-811b871c90db">3,987</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzMtMS0xLTEtMTQzNDI_df3f51da-5d0c-480a-a06f-3c675ae5329f">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzMtMy0xLTEtMTQzNDI_bd90db1a-33fe-43f8-83b5-d50402ae775d">828</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzQtMS0xLTEtMTQzNDI_689e1296-de8e-4701-9d3f-ded8e0db5f7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzQtMy0xLTEtMTQzNDI_7c8cb84e-e88c-49af-b3a6-b35e9f25704f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i8221344b85a746f1bbc5dd99c40db4af_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTUz_54b3ee56-de5f-461d-9dea-6036de827f34">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia01be325b8014d11a057d07ade151aab_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTU3_afebb587-83f8-4444-99ca-dabb1765bebb">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idc721e5fefa54193b4555f316c8c4e98_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTY0_b39ecfe0-176b-4591-8310-1ee331d7ac7d">25</ix:nonFraction>, respectively, related to these services. The next </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id97ac971ed7e47f0bd29037eaf16da6c">potential milestone the Company is eligible to receive is $<ix:nonFraction unitRef="usd" contextRef="ic3cf57eb0c394db486c86ab2341698c0_I20211231" decimals="-3" name="mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2NDUy_8a8fa1ad-c21c-4c74-943a-f368058f31e3">2,500</ix:nonFraction> upon dosing the fifth patient in a Phase 1 clinical trial by Asana BioSciences. As of December&#160;31, 2021, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</ix:continuation></span></div><div id="i54c829abb8e046e0ba4639af9592e947_106"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDYvZnJhZzphMjI1OTIzYjQzMzc0OTMwOWVjZjc4ZTRiYzI4MzBhMy90ZXh0cmVnaW9uOmEyMjU5MjNiNDMzNzQ5MzA5ZWNmNzhlNGJjMjgzMGEzXzk4MQ_1ad36932-3323-4924-a0e7-42f76122bd11" continuedAt="i1c3284ebde3a44f6bc1e24e932220858" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i1c3284ebde3a44f6bc1e24e932220858"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the carrying value of the Company&#8217;s outstanding borrowing under the Prior Credit Facility and New Credit Facility (as defined below, respectively) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Prior Credit Facility and New Credit Facility are discussed in more detail in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM1Nw_1500a9be-205d-4881-8586-448e95f6bf4c" continuedAt="i8f069256a5d04530acd18ad1e2c1ce2f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i8f069256a5d04530acd18ad1e2c1ce2f"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM1OA_05589634-9cde-4efb-8f4f-ce506adc82c1" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27da38d053440e3a567adb14304e888_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzEtMS0xLTEtMTQzNDI_f0a80d97-96b8-48ab-95c3-ffbbd35d442a">6,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ca22aff95e471781a54f27faf5c489_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzEtMy0xLTEtMTQzNDI_b72fac20-291a-49a7-9ee2-174d09b0602f">6,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0a4f6ba5534268909637379ffb82d1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzItMS0xLTEtMTQzNDI_6480fdb2-9796-4a4f-9c9f-7d6b2d128ba2">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66a2e3ad74d845418bc9e56f04eed7ad_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzItMy0xLTEtMTQzNDI_b8947ecb-19e4-4eec-8f37-f85499bb0f21">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i376e781b4402454fa5e969dd3afdcc1a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzMtMS0xLTEtMTQzNDI_a496578c-909b-4305-b092-610a90c68440">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i781aa82fa62448f7922e5f7b324d73f9_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzMtMy0xLTEtMTQzNDI_2e2db6e2-dff7-435e-8b33-7bd240d7723c">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzQtMS0xLTEtMTQzNDI_75497c60-b7c4-4ef3-b913-e4740c6d2aac">9,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzQtMy0xLTEtMTQzNDI_c15419be-8f6d-45c7-bf4b-9f8388eb4bfe">9,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzUtMS0xLTEtMTQzNDI_5dba44a2-c081-4d4a-aa79-3db7f97954d7">7,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzUtMy0xLTEtMTQzNDI_00a96dea-39cd-499d-b2d6-488b8acbede9">7,635</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzYtMS0xLTEtMTQzNDI_50fd79bb-ac14-48a3-8eb3-6aa9b71b43b5">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzYtMy0xLTEtMTQzNDI_b15508a6-3993-4ce4-b4b7-93927371ba00">1,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded assets under finance leases of $<ix:nonFraction unitRef="usd" contextRef="i05eab9496cd948acb8f286ed906bc0da_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE2NDkyNjc0NDIxMDY_0beb0926-a206-4798-8c86-bc0ff150dff2">609</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia64cb818b4e64c72b7ce08b160086366_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE2NDkyNjc0NDIxMDE_d17b6c66-2cbe-43d1-8418-21a6d1fffa54">0</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="ife05150f2ac84983998d474cda265a0d_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE1MQ_5a44b517-6d01-4488-8d4c-d02fba3c4599">429</ix:nonFraction> as property and equipment during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Financing leases are discussed in more detail in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Depreciation expense for the&#160;years ended December&#160;31, 2021, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzMzMA_93afc0f3-4d45-4ee7-a028-97525524ae71">855</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzMzNA_d2c03948-44ba-4ab9-a1b2-1b81f49830be">1,010</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM0MQ_9178efc0-35d5-4483-acee-0cd75097f693">1,245</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90ZXh0cmVnaW9uOjQyZDYzMDY3MzVkMTRkMTc5ZTVjMDkzODFkY2ViZTdlXzg2_755e32ba-4a4e-4517-898e-5258a94d24b3" continuedAt="i04d79913223e4e7c8c9c69b5d6b562b6" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i04d79913223e4e7c8c9c69b5d6b562b6"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90ZXh0cmVnaW9uOjQyZDYzMDY3MzVkMTRkMTc5ZTVjMDkzODFkY2ViZTdlXzg1_917207bb-b40f-4a05-a976-b839a4c3260d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:AccruedManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzEtMS0xLTEtMTQzNDI_5b395f80-70c2-4a33-a7fc-c76d3527c98a">8,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:AccruedManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzEtMy0xLTEtMTQzNDI_03744c67-d8a6-43aa-a0ef-57d1aaff0ee3">4,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:AccruedClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzItMS0xLTEtMTg3MjE_d6c5dbee-8ede-46c5-8cb8-c01cad312257">7,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:AccruedClinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzItMy0xLTEtMTg3MTY_4323fc11-240f-41c6-a6c5-12172d8d9163">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMjY5OTY_f559e86e-9f1b-442b-b2e4-07282f08b2dd">7,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMjY5OTY_159e9e4e-fa1b-44d2-b697-375a9c676a6e">5,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:AccruedPreclinicalExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMTg3MzM_40792e5b-8727-4823-a808-37769313d3fe">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:AccruedPreclinicalExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMTg3NDc_7bdeb011-4931-4e4b-9c86-628a5a5b00ed">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMTQzNDI_9af6847d-efc7-413a-9317-2bd27ba4fff7">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMTQzNDI_6ebeae15-5cb8-4ad9-8514-4ca335eaf0ee">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzQtMS0xLTEtMTQzNDI_f6b3e07b-c27a-4048-96d8-51e46b65c0ca">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzQtMy0xLTEtMTQzNDI_d8109331-9642-455c-8acb-35075974b6a7">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzUtMS0xLTEtMTQzNDI_a4c73a70-ab41-474e-abb5-68d8642a014f">28,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzUtMy0xLTEtMTQzNDI_a9a42fc2-fe48-48d5-a012-e7b2b49d0e19">16,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_118"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NDg_e893538e-65f0-4496-a8a8-5a6f0ef0c64a" continuedAt="ibfb68fca114a462b80af9876f20b111b" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="ibfb68fca114a462b80af9876f20b111b" continuedAt="iba86f6f124584bbdab9fcec8ca8d4241"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with SVB pursuant to which the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i46ac06dbc12246b49e2a5075fae37c0f_D20190508-20190508" decimals="INF" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzE3OQ_76fa06d7-8526-4929-abe5-7dac6a3f50f5">5,000</ix:nonFraction>. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="if0db434ef0b14ed0861021376bc27afa_I20190508" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4MA_514c3e7a-9f48-4657-9ff3-c7652a57d19a">4.0</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="iab899b1838874099a8e5ac2ff7777f3b_D20190508-20190508" decimals="4" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI5Mg_1faf12d2-f055-4f14-8ee0-6d5847eb4c36">1.50</ix:nonFraction>% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, the Company entered into a second amendment (the Second Amendment) to the Original Agreement with SVB (the Prior Credit Facility). Pursuant to the Second Amendment, the Company drew $<ix:nonFraction unitRef="usd" contextRef="i4009d30c89524098b6f75ea92a8511f0_D20200828-20200828" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDkwMTE_0a8c2bf6-f56f-43f9-bd85-682f8b05ab36">5,200</ix:nonFraction> upon execution of the Second Amendment, the proceeds of which were used to repay the Company&#8217;s existing balance under the Original Agreement and satisfy its obligations to SVB. The Amended Credit Facility accrued interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="ia0f44c7208fa4c7f961ffd639310b35d_I20200828" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzEzMjQ_4ff233ba-3e7b-4289-bc68-aa0ebe0afcd1">4.25</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="idf785a49089f45d398bf851be2b7932a_D20200828-20200828" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzEzMzY_8bc67fb9-ffcc-40d1-b817-f1628488cd40">1.00</ix:nonFraction>% above the Prime Rate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, the Company entered into a loan and security agreement (the New Credit Facility) with SVB and Oxford (Oxford and SVB, together the Lenders). Pursuant to the New Credit Facility, the Company can borrow term loans in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ic2eadf722ff64d92ae9288bc5dfe2b84_I20211029" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODA_c6e04339-8b7f-40c2-8aad-a3ec4d6c230f">100,000</ix:nonFraction>, which includes (i) $<ix:nonFraction unitRef="usd" contextRef="i712f21030d394390afd89dbcc6e8b06c_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_9702f9d0-7c95-4de8-b124-3a51490ca9b6"><ix:nonFraction unitRef="usd" contextRef="i096da856c8104fe6ab086e5efc3eec34_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_a86c0765-522e-4d8c-b20b-d6fc55d98107"><ix:nonFraction unitRef="usd" contextRef="ifc33cdd85a414f2cb35b3a6e5e998ca2_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_cffe05a6-e837-4e2e-9950-e6794b5dbe94">60,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> in up to three principal advances through December 31, 2022, (ii) an additional $<ix:nonFraction unitRef="usd" contextRef="i786194604a4b4117b25a3e6b81f087f9_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4OTg_c9b56969-8c77-4184-837d-e763ba8fac1f">10,000</ix:nonFraction> in one principal advance, if the Company reaches certain development milestone events through December 31, 2022, (iii) an additional $<ix:nonFraction unitRef="usd" contextRef="ic9ad9876d541413f801749cf53712cf7_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MDc_636f0066-c201-4177-b3cd-a6c1530d0475">10,000</ix:nonFraction> in one principal advance, if the Company reaches additional development milestone events through June 30, 2023 and (iv) an additional tranche of $<ix:nonFraction unitRef="usd" contextRef="idcf2d9fb74094c5991ba27cf6c512eda_I20211029" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MTY_6f2ab47d-0189-41bb-805f-50a5e0c8bcf9">20,000</ix:nonFraction>, subject to conditional approval from the Lenders. The Company drew $<ix:nonFraction unitRef="usd" contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MjQ_97c1500a-b3b3-472b-acb5-4d530f9c046c">25,000</ix:nonFraction> upon execution of the New Credit Facility, of which $<ix:nonFraction unitRef="usd" contextRef="i27e84780e10842d2bd65ee2008d484a1_D20211029-20211029" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MzI_b33876a3-c679-425e-8697-48e3f77ba975">5,500</ix:nonFraction> of the proceeds was used to repay the existing balance under the Prior Credit Facility and satisfy its obligations to SVB, resulting in the recording of a $<ix:nonFraction unitRef="usd" contextRef="idd180a13515a4868acdde8a30e3a9cd9_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQzOTgwNDY1MzM1Nzg_fb08b452-cf3d-452d-8135-348cc32e09a5">398</ix:nonFraction> loss on extinguishment, which is presented within interest expense for the year ended December 31, 2021 on the Consolidated Statements of Operations and Comprehensive Loss. Upon entering into the New Credit Facility, the Company terminated all commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by the Company to SVB under the Prior Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The New Credit Facility bears interest at a floating per annum rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="ic8b569721ff344e2aa89e9d46ede08d2_I20211029" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4NTg3MzAyMzQ1NjA2_e4e0fb48-2b7a-46a9-a734-b51ce6455645">8.50</ix:nonFraction>% and (ii) <ix:nonFraction unitRef="number" contextRef="i42af7c89af7b48a79ad2c8608164b77c_D20211029-20211029" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NDA_1e8e866d-2889-4eb6-832b-7f72591f224b">5.25</ix:nonFraction>% above the Prime Rate. Interest is payable monthly in arrears on the first day of each month. The Company is obligated to make interest-only payments through November 1, 2024, followed by equal monthly principal payments and applicable interest through the maturity date of October 1, 2026 (the Maturity Date). If certain development milestones are met, then the interest-only period will be extended to November 1, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to make a final payment to the Lenders equal to <ix:nonFraction unitRef="number" contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029" decimals="4" name="mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzIwOTg_75ada437-cba3-4420-be3a-c114e3b99162">4.25</ix:nonFraction>% of the principal amount of the term loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#8217;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Company&#8217;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) <ix:nonFraction unitRef="number" contextRef="ic6c994875ee643a9bdf93806ee028002_D20211029-20211029" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI2MTU_5d4ae6fd-5109-41dd-8357-8bb8039cdb7c">3.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs on or prior to the first anniversary of the funding date of such term loan, (b) <ix:nonFraction unitRef="number" contextRef="i9ecaffff610841b798a218f5d8f6512a_D20211029-20211029" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI3MjY_e8f1bd1b-179e-4990-bee6-8fb0be293a61">2.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs after the first anniversary of the funding date of such term loan but on or prior to the second anniversary of the funding date of such term loan, or (c) <ix:nonFraction unitRef="number" contextRef="i3c85f701a6a3492b83ae133b0f08ef74_D20211029-20211029" decimals="3" name="mrsn:DebtInstrumentPrepaymentFeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4NjY_fcc672c5-045e-44ea-a95a-7227c967e2d8">1.0</ix:nonFraction>% of the term loans then extended to the Company if the prepayment occurs after the second anniversary of the funding date of such term loan but before the Maturity Date. The New Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The restrictive covenants include, among others, requirements relating to the Company&#8217;s ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payment obligations under the New Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#8217;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon the Lenders' demand and shall accrue interest at an additional rate of <ix:nonFraction unitRef="number" contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029" decimals="3" name="mrsn:DebtInstrumentAdditionalRateInEventOfDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQyNzA_435b8b52-2462-4732-ba4f-e52f08c13afc">5.0</ix:nonFraction>% per annum of the past due amount outstanding. As of December&#160;31, 2021, the Company was in compliance with all covenants under the New Credit Facility. As such, as of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="iba86f6f124584bbdab9fcec8ca8d4241"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the New Credit Facility, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQ2Mjg_d4763217-a896-459e-ae32-ebe81143b4cb">958</ix:nonFraction> in costs, of which $<ix:nonFraction unitRef="usd" contextRef="ia0ea172aa94b48648314fda755ca7392_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NTI_c67c8acd-7446-4916-9ff6-f1c6cea6c7e4">210</ix:nonFraction> was paid to Lenders and $<ix:nonFraction unitRef="usd" contextRef="ib909e4352d504cd6b40dc90f0dbdd2b3_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NTc_870abcf4-3bb5-45ee-aa28-a77c69d02a5c">748</ix:nonFraction> was paid to third parties. Certain costs were recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method, which was comprised of $<ix:nonFraction unitRef="usd" contextRef="i54e050cde4d9454b8bfc4b3d17c5dc2a_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQ3NzQ_2f40c09c-d473-4186-958c-0f2c93bb9a87">151</ix:nonFraction> of the costs paid to the Lenders and $<ix:nonFraction unitRef="usd" contextRef="i649899397fe049798792f393cde3e4cc_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NjI_61add7fc-3312-4677-bb87-a18f422b126b">273</ix:nonFraction> of the costs paid to third parties. The remaining costs of $<ix:nonFraction unitRef="usd" contextRef="ib1b33420048243f9a32ec5f4a1baff18_D20211029-20211029" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NDc_e38859b6-bb20-4bd5-aca6-9bf39d2ae7d4">533</ix:nonFraction> were capitalized in other assets related to the Company's right to borrow additional amounts from the Lenders in the future and amortized to interest expense over the relevant draw period on a straight-line basis.</span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NDk_2f2015ab-f5ab-439a-a3f6-0523aaccb345" escape="true"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i89f02922d04244f98f6fa502e3378212_D20200828-20200828" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUxMDE_941c4dfc-c133-4f3d-8e0d-31af407bef5a">25,000</ix:nonFraction> outstanding under the New Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzEtMS0xLTEtMTQzNDI_8057e5ee-8653-442c-bdfa-a8f3410ee462">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzItMS0xLTEtMTQzNDI_cb5eb2b5-eeec-4a40-b5d7-4c305fc83a73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:DebtInstrumentCarryingAmountNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzMtMS0xLTEtMTQzNDI_24dc66a9-0862-4501-a169-07eb4fda76b1">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzQtMS0xLTEtMTQzNDI_1e566276-33af-4a8a-b300-a6cfbe4bf8ff">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzUtMS0xLTEtMTQzNDI_8e09c9f3-686d-4df3-b277-72ebe047e1eb">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzYtMS0xLTEtMTQzNDI_62ad3188-180d-438f-b0f8-bc5ebf39b46f">24,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NTA_d65f5f0b-8034-44c2-b0fe-3c7483255e39" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzAtMS0xLTEtMTQzNDI_5033c9b3-4cbc-40db-84fc-71d4ba4356c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzEtMS0xLTEtMTQzNDI_054a0d53-f163-4db8-862a-ad26bc441c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzItMS0xLTEtMTQzNDI_d9e80b63-73ca-4970-ba19-eeeecab52036">2,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzMtMS0xLTEtMTQzNDI_73e1b09c-b7d6-4b18-9875-737a94fe1203">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzQtMS0xLTEtMTgxMDI_50d2eb2c-695b-43e6-ba04-fdb1098943b8">10,417</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzQtMS0xLTEtMTQzNDI_0a2eac52-b1f6-463b-936e-aabe852aa43b">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUzMjE_1ba92941-c50d-438e-82b7-2f8634cfdfb5">797</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpenseDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUzMjg_8fcdfb13-4d3b-449b-ab46-d57605dc683b">340</ix:nonFraction>, respectively, of interest expense related to the Prior Credit Facility and New Credit Facility, as applicable.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_124"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM3NzI_ee70766e-9ef0-4461-abc5-815f34d181ba" continuedAt="icd09250681c546e19f4958e2d95b9b1c" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="icd09250681c546e19f4958e2d95b9b1c" continuedAt="ic4d42b6fcd6844189a546ad0390600de"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had <ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4Xzcx_24f6a0f1-3cd1-4758-9a28-e65712c58815">25,000,000</ix:nonFraction> shares of authorized preferred stock. <ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzExMg_af035335-77ca-4ae6-afa1-acc34bd4f859">No</ix:nonFraction> shares of preferred stock have been issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-market equity offering program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $<ix:nonFraction unitRef="usd" contextRef="iffee20b1411845d4b0b9f086f3c189b9_I20180731" decimals="INF" name="mrsn:StockIssuanceProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM0NQ_18407370-e571-425f-aa1e-f7d07c2898bf">75,000</ix:nonFraction> of its common stock from time to time at prevailing market prices. During the year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTU1Mjg_799d16ef-1a1c-4636-979a-6dacd0421afe">10,900,599</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTkzNDM_f640e079-6332-4a69-ab6f-24934cda8769">62,976</ix:nonFraction> through the 2018 ATM. In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $<ix:nonFraction unitRef="usd" contextRef="i2c0c094572df4f53b6e958fe1bcfe81b_I20200531" decimals="INF" name="mrsn:StockIssuanceProgramAuthorizedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4Xzg4NA_eb539018-64d0-4ef5-a122-ad89831f17d4">100,000</ix:nonFraction> of its common stock from time to time at prevailing market prices. As of December&#160;31, 2021, the Company had sold <ix:nonFraction unitRef="shares" contextRef="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTU0OTk_3a51a725-9d1e-4b58-817b-b1ae821d3ccd">3,961,074</ix:nonFraction> shares of common stock and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i828ebe879492478780a584c32808e4db_D20200501-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM4NDgyOTA3MDQxNDM_4906b50e-9a43-441b-8c0b-d22f3e136686">43,087</ix:nonFraction> under the 2020 ATM.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ic4d42b6fcd6844189a546ad0390600de"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on offering</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="i37036005f77a435e8823d902b65b4b26_D20200601-20200630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzEwNzA_5d7f7a50-4f3f-428f-931a-9dab470d1590">9,200,000</ix:nonFraction> shares of common stock, in an underwritten public offering price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f9e97774b6a4b27bd93e83aa57935c4_I20200630" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzExNTU_83a4973d-c746-435d-b4e5-a759e9035c17">19.00</ix:nonFraction> per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $<ix:nonFraction unitRef="usd" contextRef="i37036005f77a435e8823d902b65b4b26_D20200601-20200630" decimals="-3" name="mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzEyNzk_af7fc92d-ca56-4eb0-b92b-78bb835af8de">163,990</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase <ix:nonFraction unitRef="shares" contextRef="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231" decimals="INF" name="mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE0MTc_54549fc0-0140-4e1f-b646-a98604edb05d">129,491</ix:nonFraction> shares of common stock. The warrants have a $<ix:nonFraction unitRef="usdPerShare" contextRef="i338c16ccd7cd41ef810857176b3cb944_I20131231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE0NjQ_9633e068-0c54-4906-b578-3334dedf283a">0.05</ix:nonFraction> per share exercise price and a contractual life of <ix:nonNumeric contextRef="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231" name="mrsn:ContractualLifeOfWarrants" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE1MTg_e0b2bfde-b633-44af-8160-bc1913db4307">10</ix:nonNumeric> years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2021 and 2020 there were warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE2NjY_42d490d2-bc47-4b26-aa0b-a4e8c3acabb5"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE2NjY_700de3e4-b165-4ec2-9972-312538d19181">39,474</ix:nonFraction></ix:nonFraction> shares of common stock. During the year ended December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="mrsn:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE3MzA_9b9613af-e1be-448d-92ad-8b60840312ae">no</ix:nonFraction> exercises of warrants in exchange for shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of <ix:nonFraction unitRef="shares" contextRef="i5c6d26ecc5ca4927bf170e6f70476126_D20191126-20191126" decimals="INF" name="mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzIwNDY_b1be402e-8ff2-4afc-a5f1-caec5008d7b4">2,575,000</ix:nonFraction> shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7d00f365edee446b858df5048d05be98_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzIxMzc_df6448e3-b5f8-4e52-8f13-9261eb3ed866">2,575,000</ix:nonFraction> shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d00f365edee446b858df5048d05be98_I20191126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzI0MDQ_69dd45a4-8278-4e9d-83e5-2f975ac69d6d">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of <ix:nonFraction unitRef="shares" contextRef="ic1c0f959152f49bbb6f2f1b5870fdd72_D20200302-20200302" decimals="INF" name="mrsn:WarrantsExercisedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzMzOTU_99745d4c-eb3e-4506-83e8-a2c842cbadfe">2,574,971</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231" decimals="INF" name="mrsn:NumberOfVotesPerCommonShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM0ODM_ef2aed3a-c8fd-4a78-8350-7ea04bbe46ca">one</ix:nonFraction> vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors of the Company (the Board).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020 there were <ix:nonFraction unitRef="shares" contextRef="i6e2b696bd2b946689884d6db1dbaebcc_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM2NTM_263fd154-d0ec-47f2-8428-09817751600c">9,199,512</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6e33d28def5e47e48376a78023729e2b_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM2NjA_a57dafc6-68d6-416a-ba99-0a0c11df8146">6,869,189</ix:nonFraction> shares of common stock, respectively, reserved for the exercise of outstanding stock options and warrants.</span></div><div style="margin-top:12pt;text-align:justify"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM3NzE_1daca46c-d809-476d-94d0-0bd31e9ed537" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff2b446a5705439d8204e2db3af84557_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzEtMS0xLTEtMTQzNDI_22923bad-4834-45f0-a364-f7903d9a15f6">8,342,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2836cc08d6b440048b685415e74ef94a_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzEtMy0xLTEtMTQzNDI_fb56be5c-a7a0-47ca-a6a2-ef41fa6134f4">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcfae73b76f849c2beedf48b3fd3ddb2_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzItMS0xLTEtMTQzNDI_625703f7-6246-4bf4-a5a5-84381d4033a6">817,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ed739e482d84b91bdcedea1d7aa35da_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzItMy0xLTEtMTQzNDI_b1ccc8cf-6c2b-40cc-8097-ea51dc2e5113">716,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9a2b387a4dd4de5a44607493ebe2f7c_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzMtMS0xLTEtMTQzNDI_38f6c525-efc3-4d51-8864-33f5ef308d9d">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica825e7423074dfd9b2d51c5b1e0acfa_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzMtMy0xLTEtMTQzNDI_4e2219a4-505a-4fbb-8e6d-3c977da2e4bc">39,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzUtMS0xLTEtMTQzNDI_d1619932-ebc2-4219-9ac5-931be61f8ab2">9,199,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzUtMy0xLTEtMTQzNDI_985bca9c-c1c7-4cdc-83b8-b713a31a2e80">6,869,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTY_db945089-435a-4dc8-bbaa-bc72164a7dd1" continuedAt="i43d1fd8e896e4f8787c7544a7972b328" escape="true">Stock Options</ix:nonNumeric></span></div><ix:continuation id="i43d1fd8e896e4f8787c7544a7972b328" continuedAt="i773f0cc4f3b8465e82a795f70af5c222"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2017, there were <ix:nonFraction unitRef="shares" contextRef="i737243bf173d4209a6e2039ac6c813f9_I20170630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzc0_68b6f19d-a788-4455-bbe9-24104beeb7a2">3,141,625</ix:nonFraction> options outstanding under the Company&#8217;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations or forfeitures of options granted under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i773f0cc4f3b8465e82a795f70af5c222" continuedAt="i8e966dcbc2094a79a904a1c60c9bca69"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 the Company&#8217;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to <ix:nonFraction unitRef="shares" contextRef="i3eec540f391a482b8cf41ac59c16c58d_I20170630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQ3MQ_1d868701-4488-4173-9165-8cc1247cbea8">2,255,000</ix:nonFraction> shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, RSUs or other stock-based awards. The number of shares of common stock issuable under the Plan cumulatively increases annually by <ix:nonFraction unitRef="number" contextRef="i5ec75714d1fa4db7ab67c66b6d110b6e_D20170601-20170630" decimals="2" name="mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzc3Mw_937d8fae-a0d1-45a2-8d77-36dc8ff25cff">4</ix:nonFraction>% of the outstanding shares or such lesser amount determined by the Board. The terms of the awards made under the Plan are determined by the Board, subject to the provisions of the Plan. In January 2021, the number of shares of common stock issuable under the 2017 Plan was increased by <ix:nonFraction unitRef="shares" contextRef="ia71270946b0347db9fb2c7e2adb5eb55_D20210101-20210131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQzOTgwNDY1MjMzNTI_577020aa-e50f-4911-abb7-33410b345bd7">2,753,651</ix:nonFraction> shares. As of December&#160;31, 2021 there were <ix:nonFraction unitRef="shares" contextRef="i34baed2717f54091a1033f9099b12641_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk2MA_29ad4810-b0be-4c95-b0bc-df4054fc09f3">1,308,183</ix:nonFraction> shares available for future issuance under the Plan. During the year ended December&#160;31, 2021, the Company granted to employees <ix:nonFraction unitRef="shares" contextRef="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzcxNDY4MjU1OTU3ODk_f3e8c098-2683-4125-a5b5-88e2d65d852a">715,716</ix:nonFraction> RSUs and options to purchase <ix:nonFraction unitRef="shares" contextRef="i1fac48995f2c4c16a220008833e49a01_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzMzNTM1MTA0NjY4NzUw_4f8ab782-eebf-45a4-9132-8492c6cd0906">2,870,720</ix:nonFraction> shares of common stock under the 2017 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, both with respect to incentive stock options and nonqualified stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally <ix:nonNumeric contextRef="i2c201fa2273b4d5692775bfe687ff519_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNDE0_9b94a362-0735-459a-af7f-c903e8520ed4">four years</ix:nonNumeric>. Options granted under the Plan expire no later than <ix:nonNumeric contextRef="iaaff1344197a4f7f88291b1ff2549f0c_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNDQx_5327764b-a627-4d45-9eb3-f860a04373c8">10</ix:nonNumeric> years from the date of grant. Options under the 2007 Plan were granted at an exercise price established by the Board (or a committee thereof) that was not less than the fair market value of the underlying common stock on the date of grant and subject to such vesting provisions determined by the Board (or a committee thereof). The Board may accelerate vesting or otherwise adjust the terms of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants to its employees, upon approval by the Board, options to purchase shares of common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The securities are issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the options granted under the 2017 Plan. As of December&#160;31, 2021 there were options to purchase <ix:nonFraction unitRef="shares" contextRef="if90621fb17914192b3cc20226646f468_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzY1OTcwNjk3NzM4MDU_209f9303-ae48-454c-8029-64866370fedd">757,500</ix:nonFraction> shares of common stock granted as inducement awards outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option activity</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTg_3be02eb6-f0cb-4625-aea8-f6f6c8d1080e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtMS0xLTEtMTQzNDI_b020107d-70d1-4429-9ba9-18500e772f4e">6,112,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtMy0xLTEtMTQzNDI_ce58eef8-a2d1-4eda-80c8-99e65e2e71d9">7.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtNS0xLTEtMTQzNDI_a25828be-6c57-4a6c-9adb-b2680eddd781">7.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtNy0xLTEtMTQzNDI_51102fd6-3050-425c-a7bd-cd7365efb5fa">114,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzItMS0xLTEtMTQzNDI_91f57f6c-f39c-46cc-a22e-afc77508f76b">3,308,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzItMy0xLTEtMTQzNDI_b664e1e4-6c55-45ce-98a5-2131acf15780">16.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzMtMS0xLTEtMTQzNDI_4a0112b4-b72d-4ac2-a81a-98440e0dbdd6">421,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzMtMy0xLTEtMTQzNDI_0e70fe12-c550-4189-b81a-0e6607d446ce">4.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzQtMS0xLTEtMTQzNDI_1ad7cb62-4b4a-4668-86ed-e54d8384a371">657,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzQtMy0xLTEtMTQzNDI_c5419526-21a6-48d1-9d38-fe3bb5a8ca2b">11.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtMS0xLTEtMTQzNDI_01b12bc6-d732-49a2-85f2-2021a2a02356">8,342,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtMy0xLTEtMTQzNDI_fd5e2833-1129-4118-af02-ee10934d7b3d">11.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtNS0xLTEtMTQzNDI_c1abf0ac-e4dd-4e7c-b51f-5e587508c87d">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtNy0xLTEtMTQzNDI_f6aafb64-9901-4d16-abfc-fa0e1c4cbd15">8,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtMS0xLTEtMjI5NTI_e82c4530-fd8e-4364-ab7f-9f20084e0c6a">8,342,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtMy0xLTEtMjI5NTI_4a132ac5-38e6-412e-9ce1-30ff4c16a46c">11.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtNS0xLTEtMjI5NTI_18539dd6-6b09-4407-8f07-b7b305d46be9">7.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtNy0xLTEtMjI5NTI_8cf4cd1c-b9c9-43fd-bc4c-6e5740505966">8,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctMS0xLTEtMTQzNDI_a1004141-a27f-458b-b2c0-3a1651f0ea24">3,997,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctMy0xLTEtMTQzNDI_950154b9-6a57-43b8-a4fa-f562084e9cef">7.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctNS0xLTEtMTQzNDI_599af6f8-a93d-4f56-853d-6135b03d06b1">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctNy0xLTEtMTQzNDI_13a5aa44-e567-4520-86ad-5d95d53d3d2d">7,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MTI_15c698b1-2b77-45d8-873a-1c529e5d3982">11.71</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MTY_4ef398f3-6c0c-47ab-bb60-1c65325888cf">7.99</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MjM_c07d5c52-9c3e-4aaa-aaff-da200cd77711">2.47</ix:nonFraction> per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyNzg_a2c966db-d78d-47e8-9388-45399009e1a3">4,299</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyODM_1a6c2034-f0e5-4cb7-9f66-8445b3279c3d">11,147</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyOTI_a2aa0de3-641e-44d2-a6e8-8407cc9deb7c">202</ix:nonFraction>, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from the exercise of stock options was $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MDQ_0d9f59db-b813-4251-a6f0-c7665d58ec29">1,837</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MDg_caad72e0-bc25-4100-bac4-4ebba8ac56e4">3,138</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MTU_13530c97-7c84-4210-b09c-5c362c9c80a2">175</ix:nonFraction> for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i8e966dcbc2094a79a904a1c60c9bca69" continuedAt="ic59727f4ed8741e98188d393ccd4e626"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically issues RSUs with a service condition to certain officers and other employees that typically vest between <ix:nonNumeric contextRef="i1c64324e16174923bd142062def84677_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzEwNDQ1MzYwNDc1NzAw_e796f0f3-2613-43da-b656-78956a295043">one year</ix:nonNumeric> and <ix:nonNumeric contextRef="i0e1147f1b66d4b6bae33bea0cccbebbb_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzEwNDQ1MzYwNDc1NzA4_35b15461-f830-4789-bbbf-019e183044be">four years</ix:nonNumeric> from the grant date.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTk_bd37ebdd-0664-4f65-98a4-107391d02d6f" escape="true"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtMS0xLTEtMTQzNDI_2a7fee7f-1b96-4987-ab15-f28bca3dc18a">716,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtMy0xLTEtMTQzNDI_1d7b2d12-ee80-4afe-9519-dc40efb807e4">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtNS0xLTEtMTQzNDI_35a9bb5b-b495-4eb4-9816-669ffa94580b">19,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtNy0xLTEtMTQzNDI_2d2a82fa-37ec-41b0-9ab2-08172177e118">6.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzItMS0xLTEtMTQzNDI_f3e8c098-2683-4125-a5b5-88e2d65d852a">715,716</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzItNy0xLTEtMTQzNDI_884ac588-884a-4a46-83c6-4c72f19c2214">18.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzMtMS0xLTEtMTQzNDI_c6a8fabb-30fe-4560-b749-dfa9a7337b9a">419,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzMtNy0xLTEtMTQzNDI_913186d4-1af9-42d5-966d-774a2adc3a96">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzQtMS0xLTEtMTQzNDI_aaa49bab-8639-429d-b7d3-317d10d553e6">195,538</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzQtNy0xLTEtMTQzNDI_7cf84cb4-e9ae-4eaf-9a84-aeef29ca2941">12.34</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtMS0xLTEtMTQzNDI_f637e3d8-9e2f-4f3f-a68a-4ce6076badb5">817,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtMy0xLTEtMTQzNDI_45c5e87b-52f7-44a7-b999-3b8a9f52ebd0">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtNS0xLTEtMTQzNDI_1721a456-4d86-4838-bece-182a0cf3dda5">5,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtNy0xLTEtMTQzNDI_5ea4da04-cf84-4908-b003-b1cc2e3bc52b">15.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019, was $<ix:nonFraction unitRef="usd" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNDQ_5574f653-0420-4685-8791-aebc731c5ec9">5,790</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNTM_736a6688-b03c-402d-8acb-01dd5902ecb3">0</ix:nonFraction>, and, $<ix:nonFraction unitRef="usd" contextRef="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNjQ_80f275a2-94a0-4008-809f-1281292b78b7">0</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for all stock-based awards to employees and non-employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date for awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.</span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTM_4a71cf74-b463-4e29-9d91-b40eaed71bca" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItMS0xLTEtMTQzNDI_7c36b616-0a1f-41d0-ab6a-4ac93b6bfafe">14,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d675eb3e6d43b4bf7380c997407796_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItMy0xLTEtMTQzNDI_9674eba4-347f-4d43-a2bc-110553384a17">5,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58196efabc4455dbc9f56d50edcfad0_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItNS0xLTEtMTQzNDI_6d8cd394-396f-4446-9970-5f3701bae6e5">4,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtMS0xLTEtMTQzNDI_0de3e10a-0b3e-43fd-ac8a-139908161c11">3,522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtMy0xLTEtMTQzNDI_41291ce8-d803-4923-83a1-5dc9e7a1e648">1,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtNS0xLTEtMTQzNDI_69045eb4-4eb3-450f-8902-11eb2b8d7004">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtMS0xLTEtMTQzNDI_aac25174-161a-4a3e-9e56-8d8241a3f8d5">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2375a12808cf4680aa725acb17071871_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtMy0xLTEtMTQzNDI_b280e712-1f43-4283-8515-17a892ddf289">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace44621dbb84817a2c5f4a3278c74ab_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtNS0xLTEtMTQzNDI_ad934838-fcb9-40e3-a8e8-8eed8c75c175">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtMS0xLTEtMTQzNDI_50fc8701-0749-44a4-88a5-97f746d8cbd4">18,409</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtMy0xLTEtMTQzNDI_84f9d7f8-5aa9-4735-8554-178619897789">7,172</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtNS0xLTEtMTQzNDI_22f8ab0a-fb1c-4fd4-bab4-8cc8133bafe7">4,872</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTc_3684b3d5-af63-4971-b221-f54c7e94f671" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b915dd88e74298a6e79a691ceb3e41_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItMS0xLTEtMTQzNDI_05a44bd2-fa39-4afa-92e7-6dc54b971f30">9,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ac3651a9b134a21b2606a2b6c456826_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItMy0xLTEtMTQzNDI_c972ab3e-9341-4257-8367-b809f6c6b74e">3,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995f53d89db1431783ca696f65ff827c_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItNS0xLTEtMTQzNDI_eae440b7-edb1-46d9-8290-16a31fbea483">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac073dc733f464e923ffe588304cf3a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtMS0xLTEtMTQzNDI_2e44b8ba-3d2f-4546-8d9b-10309fce794d">8,425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b69daa12d7d496a8e30d2f4f904d645_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtMy0xLTEtMTQzNDI_bab3e27f-dc6e-4521-a631-4efe8e6b1d27">3,331</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87d0d7495bf34973b75e45d3a456802f_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtNS0xLTEtMTQzNDI_2efc9d52-76dd-495c-9b75-b4f106557dd3">2,627</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtMS0xLTEtMTQzNDI_967a8ddc-8593-4d14-9b54-6a3afbefdd33">18,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtMy0xLTEtMTQzNDI_6c6bc5c3-e00e-4c8f-8fff-b498ee6589a5">7,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtNS0xLTEtMTQzNDI_5113296e-2039-46a9-bb0c-66bef542d8fa">4,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i76db584e2a3847a19b4d09782ea823f8_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM5NTY_40ff9469-c121-44db-9110-977425d5b33b">38,958</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM5NjM_25734405-8054-4ae1-8f2a-6b587b4a3a11">9,929</ix:nonFraction> of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQxMzg_696ccbbe-656f-4a20-84c5-55be129f3f23">2.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQxNDU_81b3ce00-ed63-4763-9b08-88f82d67b3eb">2.8</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ic59727f4ed8741e98188d393ccd4e626"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTI_f76d174c-f77d-41b5-bf21-1b0069491802" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItMS0xLTEtMTQzNDI_4be74895-3984-408d-a327-d7afeff34520">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItMy0xLTEtMTQzNDI_77cc33cd-696c-4b9b-9a94-150956883df3">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItNS0xLTEtMTQzNDI_c0bc6528-ebaf-48fb-b40a-9639f2bb04f7">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtMS0xLTEtMTQzNDI_3ffa9b0c-e685-4395-ac4f-ff0c51259e00">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtMy0xLTEtMTQzNDI_7f9a05bd-7762-4ec1-a786-3d1c2f13e6d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtNS0xLTEtMTQzNDI_f775af91-8790-49d7-ac1c-ca79384335a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtMS0xLTEtMTQzNDI_fbbcf68c-b8f6-4721-b500-f9d707ad1a67">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtMy0xLTEtMTQzNDI_f7bae689-12ee-4426-9f03-893befad94bc">6.05</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtNS0xLTEtMTQzNDI_2b9ebadd-83f5-4dc6-ae5d-8e10103a0a5e">5.99</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtMS0xLTEtMTQzNDI_f30c1653-9975-4868-9810-8a1114cf19a8">82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtMy0xLTEtMTQzNDI_689f2175-2cca-4952-9220-ffa3031ec19f">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtNS0xLTEtMTQzNDI_35f2c9fc-e403-4565-8598-ed301ac948a2">74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility for the Company&#8217;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. <ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQ1OTc_aba376b3-63cf-4aa0-974d-615da4fc946b">No</ix:nonFraction> dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i1b750e97432649f8902f0c0b2b12632e_I20171231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUyNTk_b3fce34a-7143-4782-b666-a54c78412b87">225,000</ix:nonFraction> shares of common stock for issuance under the 2017 ESPP, plus an annual increase, to be added as of January 1st of each year, equal to the least of (i) <ix:nonFraction unitRef="shares" contextRef="i18e0acc3be3c4a918d77e823eeaf9a9b_D20170101-20171231" decimals="INF" name="mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNTQ2_097c3656-a888-44ca-85f8-09e27fe8dbe0">450,000</ix:nonFraction> shares of common stock; (ii) <ix:nonFraction unitRef="number" contextRef="id1dc96fa4ed842f4aedd626c47454440_D20170101-20171231" decimals="2" name="mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM4NDgyOTA3MTM3NTY_8c5852f6-93ab-4678-8af7-dcffe6b86df1">one</ix:nonFraction> percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December 31st; and (iii) the number of shares of common stock determined by the Board on or prior to such date for such year, up to maximum of <ix:nonFraction unitRef="shares" contextRef="i8c8f204b2f8f47c883a50a6b32629116_I20171231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNTM1_ca8ee364-936c-4363-8199-1941dd58dbab">4,725,000</ix:nonFraction> shares of common stock in the aggregate. During the years ended December&#160;31, 2021 and 2020 the Company issued <ix:nonFraction unitRef="shares" contextRef="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUzNzE_43b9662b-df86-422a-9cd3-37bde62b35c6">78,253</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i2375a12808cf4680aa725acb17071871_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUzNzg_ac67a3e4-979f-46a9-b4f2-6f0c4b8e7e12">80,267</ix:nonFraction> shares, respectively, under the 2017 ESPP. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i0c8751ae82ab48e580bd5035e380db22_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU0NDU_5a3eeff2-40ae-47ba-9cde-5acc64cbaaa9">566,565</ix:nonFraction> shares available for issuance.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDI_54fe8d61-d52f-4b93-8121-e4cf4fc75387" continuedAt="i5bef3a6131ec4c1da20d3cfaba9b8805" escape="true"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDI_6a2fcbcb-33a8-4f6b-a4e1-cff7bcbaa479" continuedAt="ia6397d5625aa4052bb46539efe592ffc" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i5bef3a6131ec4c1da20d3cfaba9b8805" continuedAt="ic5f5b04476124b569318d53924c1cb1c"><ix:continuation id="ia6397d5625aa4052bb46539efe592ffc" continuedAt="i18644f15b8024f92a3c7e5a49cae7335"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office and lab space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease (the Office Lease) to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the Office Lease for an additional <ix:nonNumeric contextRef="id16df4d7be5d45f09336d071d6b927ad_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODAx_38c4fbdd-d832-4334-8217-d316696e7cb9">five years</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional office space in its existing building for <ix:nonNumeric contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODEx_bd6dcd5e-b83e-498e-8e8a-a7a796103acd">five years</ix:nonNumeric>, beginning July 1, 2021, and committed the Company to lease payments of $<ix:nonFraction unitRef="usd" contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzAzMDM_5133a878-9204-4a81-a9fc-934415a24890">4,983</ix:nonFraction> over that period (the Expansion Lease). In connection with the Expansion Lease, the Company increased the balance of the security deposit by increasing the standby letter of credit for the benefit of its landlord by $<ix:nonFraction unitRef="usd" contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3Xzk4OTU2MDQ2NjY5NjI_d2a3b9d3-9af5-4de5-a0a7-e72a9e2ee8ed">157</ix:nonFraction>. The Expansion Lease also provided the Company with a tenant improvement allowance of $<ix:nonFraction unitRef="usd" contextRef="id7a8cc110a0642b68c553e48f18a1285_D20210405-20210405" decimals="-3" name="mrsn:OperatingLeaseTenantImprovementAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzA2MTc_add1cc58-7403-442c-9c70-832d4ada924c">51</ix:nonFraction>. Independent from the option under the Office Lease, the Company has an option to extend the lease term of the Expansion Lease for an additional <ix:nonNumeric contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzA3NjY_d93f733a-0899-4757-85c3-18215ae46580">five years</ix:nonNumeric>. The Company&#8217;s exercise of the options to extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use (ROU) asset and liability and are reflected as an expense in the period incurred.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="ic5f5b04476124b569318d53924c1cb1c" continuedAt="i3cbb7f0df4784047a4fb46cffb20b5e5"><ix:continuation id="i18644f15b8024f92a3c7e5a49cae7335" continuedAt="i81d5161bf50a452e9eab47e07d646d2c"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the signing of the Expansion Lease in April 2021, the Company recorded an increase of $<ix:nonFraction unitRef="usd" contextRef="i2a56f442c69248c78859ce174629ab21_D20210401-20210630" decimals="-3" name="mrsn:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM2ODE_870d587b-515a-41dd-9833-552398328dd1"><ix:nonFraction unitRef="usd" contextRef="i2a56f442c69248c78859ce174629ab21_D20210401-20210630" decimals="-3" name="mrsn:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM2ODE_b0a82c62-7d30-435e-963a-a5a4e40a9c8e">3,783</ix:nonFraction></ix:nonFraction> to its ROU asset and lease liabilities in the second quarter of 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM5NDE_39d6b765-1c07-4500-9226-828ce84452c3">478</ix:nonFraction> in connection with the Office Lease and Expansion Lease as of December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:SecurityDeposit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3Njk1NjM_831bface-a09e-4705-ab76-148aaba7fefd">321</ix:nonFraction> in connection with the Office Lease as of December&#160;31, 2020, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has remaining finance lease terms of <ix:nonNumeric contextRef="i038ae3a73230483884690b9a78423777_I20211231" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODI5_d22e3924-0739-4b50-b878-444b77874e12">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="if17d87454f6c4db7839bfac2ed9aa926_I20211231" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODQ5_b29a2b6f-62cc-4141-ae8c-e70c747f736f">five years</ix:nonNumeric> for certain equipment, some of which include options to purchase at fair value. For the year ended December&#160;31, 2021, the Company recorded assets under finance leases of $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzQ1OTQ_8cf150d4-93da-42d6-9f82-8b4858902475">609</ix:nonFraction> as property and equipment.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDE_532e28b4-4a52-458c-ab2d-88db780ae4c3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItMS0xLTEtMTQzNDI_53a4deaf-233c-4f27-a3b8-7fdf7f9ee104">3,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItMy0xLTEtMTQzNDI_a5c30611-ca59-4faf-a051-36cd208ed1f8">2,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItNS0xLTEtMjAzMjA_d2074cbc-f655-49d7-bd79-986461dad14e">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtMS0xLTEtMTQzNDI_aa8554fb-2fae-4c9f-8917-b139559516d5">169</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtMy0xLTEtMTQzNDI_a19e2764-6adb-470e-a670-8bcd705457f7">101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtNS0xLTEtMjAzMTI_cde5f335-5a80-4ec5-880d-1c5cccc0f812">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtMS0xLTEtMTQzNDI_558512b6-679e-4292-8e41-81f04bd25742">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtMy0xLTEtMTQzNDI_06fb56f6-b25b-40fd-a0ff-a9fd91f9b67a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtNS0xLTEtMjAzMTI_0f16067b-078a-4b55-9682-229c3c85e241">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctMS0xLTEtMTQzNDI_a36ed8ab-4f74-4def-9617-ef820b7ca3fb">197</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="mrsn:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctMy0xLTEtMTQzNDI_32b82b35-5bfe-4b78-b765-d02076ecc1a1">122</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="mrsn:FinanceLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctNS0xLTEtMjAzMTI_e1d84e54-8463-4d36-87ce-1c51e4c51c85">95</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDU_09bba9d2-d5b8-4184-9ca1-1f8273ca7c07" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzMtMS0xLTEtMTQzNDI_52644c4f-2b63-459f-9db2-48a1fe952513">12,889</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzMtMy0xLTEtMTQzNDI_1741773f-a811-4de0-907e-863ab9ea7aa5">10,936</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzQtMS0xLTEtMTQzNDI_195d62ef-cc9e-4b32-bf3a-487bfe07536e">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzQtMy0xLTEtMTQzNDI_556df544-566a-48ce-b180-34544dbdc013">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzUtMS0xLTEtMTQzNDI_43d31e92-3a69-4e64-b045-6f75c7926f3a">11,247</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzUtMy0xLTEtMTQzNDI_abb19c10-95f8-45a2-9ec3-56576a444756">10,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzgtMS0xLTEtMTQzNDI_21b82d14-5515-45ef-887c-5d25c23f8194">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzgtMy0xLTEtMTQzNDI_dd23f968-cc05-48ae-b163-ff257dd87ec4">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzktMS0xLTEtMTQzNDI_c6ed6544-f447-4402-a80a-d20cb91b7023">345</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzktMy0xLTEtMTQzNDI_266bf7a3-1d7f-4f9a-b830-6c7af518e6ea">176</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">Other liabilities, current</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTEtMS0xLTE0MzQy_7e74fce8-dcbe-4f8d-899f-73e2ec22e2e4">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTMtMS0xLTE0MzQy_92f46d93-a2f9-4016-9691-c8ab5ca92ee8">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">Other liabilities</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTEtMS0xLTE0MzQy_5aa72b0b-6b0f-459b-8670-3f5962735c83">449</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTMtMS0xLTE0MzQy_40d12ad0-6a99-4988-a8e0-0a602b6759e8">174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE0LTEtMS0xLTE0MzQy_cd50fd95-7760-4e04-9424-2b38db00285a">4.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE0LTMtMS0xLTE0MzQy_b0d0ab82-d096-4720-a026-9be94523ed54">5.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE1LTEtMS0xLTE0MzQy_9336db64-0e38-4516-b7c7-f0a10eda3ccc">4.0</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE1LTMtMS0xLTE0MzQy_63de183a-c911-43e2-acd7-e7628c703cea">2.9</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE4LTEtMS0xLTE0MzQy_b862adc0-00fb-4026-913d-ca6ae89043d4">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE4LTMtMS0xLTE0MzQy_c9a416a0-9226-4b48-a774-040e5db4ea2b">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE5LTEtMS0xLTE0MzQy_ac39b9a3-4fa3-4553-8457-14b436209fab">5.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE5LTMtMS0xLTE0MzQy_4b66fd60-9e06-4f55-95f1-4445cab043a8">6.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i3cbb7f0df4784047a4fb46cffb20b5e5"><ix:continuation id="i81d5161bf50a452e9eab47e07d646d2c"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDQ_19eb36c0-5c29-4e3a-9602-c613279b8b37" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzMtMS0xLTEtMTQzNDI_b40761d5-3b18-41fc-a3bf-d68c12a22bbc">3,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzMtMy0xLTEtMTQzNDI_e19508c0-11df-4349-8f29-17ecd2e4a29f">2,394</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzQtMS0xLTEtMTQzNDI_b02fd481-13dd-455b-941e-fcd28cd69a35">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzQtMy0xLTEtMTQzNDI_2121ee49-ca81-4508-ac64-57f8032c4177">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzUtMS0xLTEtMTQzNDI_370766ed-ecf7-4a10-b5a5-6c3a10cbbb12">215</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzUtMy0xLTEtMTQzNDI_491522b8-8182-41cc-8da0-d89b27a8390b">116</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NTI_db5ed081-c8d1-42f4-95fd-499f11049886">3,390</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NTY_6a88a3c4-af8e-4bf0-b055-e81277a91ef5">2,644</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NjM_ef70ad79-20d6-4f8d-8da9-2d533167f959">2,160</ix:nonFraction> for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDM_84c7e229-f38a-496d-9d5f-5294411722fe" escape="true"><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDY_ad044661-329c-439c-ac31-dec7d453381c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzEtMS0xLTEtMTQzNDI_48b7f8f7-9b39-424a-8f2b-5ba645c41ed9">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzEtMy0xLTEtMTQzNDI_85c83164-5bb1-4790-bcc1-8c0496a09a00">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzItMS0xLTEtMTQzNDI_b829861f-ab23-4023-b8fe-3c8196475452">3,909</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzItMy0xLTEtMTQzNDI_9a1024d3-ef1b-456d-84a5-76a8cc0a59a6">262</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzMtMS0xLTEtMTQzNDI_6433be4c-9710-45e7-a62f-f2810df141e0">4,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzMtMy0xLTEtMTQzNDI_287ab145-38f7-4973-a916-524cf358377b">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzQtMS0xLTEtMTQzNDI_9433d7fe-9d0c-44ba-98f5-f1b30d717487">4,147</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzQtMy0xLTEtMTQzNDI_a8d31172-c02c-455e-a69f-cec63c1b0d1d">48</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzUtMS0xLTEtMTQzNDI_2cf158e5-4c9c-43bf-84a3-51347339fd22">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzUtMy0xLTEtMTQzNDI_5fd73d13-9742-458a-99d5-3a0dbc41bcc9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzYtMS0xLTEtMTQzNDI_d171aa8f-3c52-4452-8faf-ce77257323b1">17,188</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzYtMy0xLTEtMTQzNDI_8c10c049-b689-4af8-8941-5503f4266ac3">728</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzctMS0xLTEtMTQzNDI_75660788-2901-4202-a8c8-e6c598b98d5c">3,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzctMy0xLTEtMTQzNDI_4ecddfc8-8503-46cb-aa36-8ed9591f50d8">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzgtMS0xLTEtMTQzNDI_58ae3f3d-e79c-46f8-a67b-a81087e3b007">13,550</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzgtMy0xLTEtMTQzNDI_5b63e05f-9169-4355-9408-c5ccdcf0dfa2">688</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i54c829abb8e046e0ba4639af9592e947_136"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTY_fb105612-acd8-4100-935f-5026b7287de6" continuedAt="ie43d85ee968645408de39a14dde96748" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ie43d85ee968645408de39a14dde96748" continuedAt="i8c95aaaadd3c49c2bd2a0551a235d097"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_054b904d-95cb-40a2-8c2f-635f2c44766f"><ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_2338ea19-ca21-41a4-aa4b-8960e19765a0"><ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_de02c164-3dda-462e-b8c5-3726b9732f9e">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.</span></div><ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTg_78b1a79f-0efe-461f-945d-0cbd75332366" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2021, 2020 and 2019 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:62.296%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtMS0xLTEtMTQzNDI_7fbb007a-9707-4c96-9a11-ad16ddf45d12">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtMy0xLTEtMTQzNDI_2be0c066-50c0-47b9-83d6-260231385c7d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtNS0xLTEtMTQzNDI_77b18511-96f6-46e2-b178-410eb62d4347">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItMS0xLTEtMTQzNDI_df18c395-6e15-4476-b5a9-af02546a8809">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItMy0xLTEtMTQzNDI_919fcf49-f29d-45ed-b403-10736a4e543d">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItNS0xLTEtMTQzNDI_e5806561-ed91-48e5-baa9-5857d9ef61d5">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtMS0xLTEtMTQzNDI_4844e090-dfad-43b3-a89d-2baca91e6ec2">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtMy0xLTEtMTQzNDI_35527001-aff0-4110-a602-3807e99a88c6">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtNS0xLTEtMTQzNDI_08bea209-e460-4931-b2e5-705db37fc81f">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtMS0xLTEtMTQzNDI_3c7923ac-e19f-4494-9066-018ad88ecaa4">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtMy0xLTEtMTQzNDI_dcbdb5c6-62b2-44b3-89cd-5dd3ae32f940">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtNS0xLTEtMTQzNDI_82679329-127b-4018-81da-2d07bdbc7542">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtMS0xLTEtMTQzNDI_b87e605f-568a-4140-a529-baf78ce65d3a">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtMy0xLTEtMTQzNDI_20884c4b-b252-4d59-9b29-87a8ff75c94e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtNS0xLTEtMTQzNDI_7e71fd65-9bd6-48f5-95ba-731c6e1b47a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctMS0xLTEtMTQzNDI_e9f9cc9f-03a1-484d-bced-4a9e8c9fb27a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctMy0xLTEtMTQzNDI_73158a97-31c5-497a-9243-6567f755a368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctNS0xLTEtMTQzNDI_5ef83722-45fa-475e-8d75-e1692e24e0a1">53.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtMS0xLTEtMTQzNDI_f5fcf5b0-1fee-4d9d-b3c4-468c87bedd73">31.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtMy0xLTEtMTQzNDI_c78a5651-b77b-4f25-9aca-90f50df848a8">32.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtNS0xLTEtMTQzNDI_c3ba6204-e356-4461-b11b-11f667089e43">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktMS0xLTEtMTQzNDI_34b28509-465f-4c0e-a46e-1491d4c66cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktMy0xLTEtMTQzNDI_f868978a-237f-4caa-af99-e638f9c11c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktNS0xLTEtMTQzNDI_4cd3c1d9-6aa7-4d97-a4c6-18c483a511cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i8c95aaaadd3c49c2bd2a0551a235d097" continuedAt="i4afff2089d2f4b7383ad964b0a6767c1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTc_18053b82-948b-4c5b-a453-3c6bd348ac5c" continuedAt="i35f604f8eb904e6e806e173058c60993" escape="true">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020 are as follows:</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i35f604f8eb904e6e806e173058c60993"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzItMS0xLTEtMTQzNDI_6b60fe61-c450-4fee-8f0b-a9be5321a1a4">106,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzItMy0xLTEtMTQzNDI_72c3da67-2370-4c08-b219-86b833b6fdc7">64,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzMtMS0xLTEtMTQzNDI_00cf6355-8f8c-420e-bfa0-6ab7b6b34b05">12,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzMtMy0xLTEtMTQzNDI_8f74bf17-a34f-42b7-b01d-4cfccaedf3ca">5,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzQtMS0xLTEtMTQzNDI_8b2c15af-bc9f-4fd1-be98-9d305a2487d2">6,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzQtMy0xLTEtMTQzNDI_36b7b942-3c3c-4801-b524-da57df8a2f50">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzUtMS0xLTEtMTQzNDI_e29d90c1-90ba-47fb-830e-e4e373d296c5">3,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzUtMy0xLTEtMTQzNDI_ade4f6b5-7d76-4ebd-87c4-6b864b0d4a21">3,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:DeferredTaxAssetsLicensedTechnology" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzYtMS0xLTEtMTQzNDI_37a1b97e-9e28-442f-99b8-9f0e333cd959">2,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:DeferredTaxAssetsLicensedTechnology" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzYtMy0xLTEtMTQzNDI_cb18c7f4-1bc6-4dda-a3fc-d5b775a0f4a6">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzctMS0xLTEtMTQzNDI_b6a995d0-871f-49fa-a5bc-44c6fa5afee6">1,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzctMy0xLTEtMTQzNDI_b85179e0-a715-4ffd-9a2e-7737a4bef538">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="mrsn:DeferredTaxAssetsDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzgtMS0xLTEtMTQzNDI_59c78c97-4ed3-432d-b4f2-0584354a2d2c">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="mrsn:DeferredTaxAssetsDepreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzgtMy0xLTEtMTQzNDI_a76f4b26-268c-4b50-982a-154850db75ac">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEwLTEtMS0xLTE0MzQy_0a5414f9-f5a7-4f8a-9249-df9e45c0d2d8">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEwLTMtMS0xLTE0MzQy_1a84fdd3-8056-414e-8e7b-89a0aa6e533a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzExLTEtMS0xLTE0MzQy_9106907e-0242-4214-97c4-c1a6b08e6b0d">133,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzExLTMtMS0xLTE0MzQy_e105727b-2331-4131-a866-8fc9581ba3bd">80,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEyLTEtMS0xLTE0MzQy_bf988841-53de-49b5-ad90-a6bddeae30fa">130,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEyLTMtMS0xLTE0MzQy_2fa859d6-eeaf-4659-b07f-ef7664897692">77,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEzLTEtMS0xLTE0MzQy_915a87f3-e87a-49fc-98bf-498f6c3c9546">3,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEzLTMtMS0xLTE0MzQy_074024f7-77bc-4aec-9eb1-af4e1d265e90">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE1LTEtMS0xLTE0MzQy_636db9be-c5c8-43e5-8c6f-42633a67fed4">3,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE1LTMtMS0xLTE0MzQy_0ff8a08c-33ff-405c-b3e3-310acb9e90a0">2,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE2LTEtMS0xLTE0MzQy_d0156bfa-3e68-493d-ac9f-763a9b69e58d">3,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE2LTMtMS0xLTE0MzQy_6e1f7458-c830-46e3-8280-1f65d4b44da7">2,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE3LTEtMS0xLTE0MzQy_28c97e38-9429-4472-b27f-c71df08481f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE3LTMtMS0xLTE0MzQy_20d0722b-1e25-48d9-b766-ae533a537974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2021, the Company had Federal and State net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzgzMw_f961a954-34ec-42b0-b50e-ba7e421ea1a2">403,579</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i673a5d42881e4cb3b1331529587e448a_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzg0MA_089aebc1-5f48-45af-8977-f3416336bd18">337,057</ix:nonFraction>, respectively. Of the $<ix:nonFraction unitRef="usd" contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzY1OTcwNjk3NzczMTE_f961a954-34ec-42b0-b50e-ba7e421ea1a2">403,579</ix:nonFraction> of Federal net operating loss carryforwards, $<ix:nonFraction unitRef="usd" contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231" decimals="-3" name="mrsn:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzkxMw_bb91c7e2-c9ab-4214-8c45-548e15333269">34,149</ix:nonFraction> expire at various dates through 2037. The remaining $<ix:nonFraction unitRef="usd" contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231" decimals="-3" name="mrsn:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzk2OA_1aad3432-70b4-4c49-b3f4-9cbacc116760">369,430</ix:nonFraction> of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2041. At December&#160;31, 2021, the Company had Federal and State research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i3a07a4efd2d24b99831852b517363a51_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzEyMTk_1516c36e-8dc5-4145-a3ee-8050213f8f0e">10,077</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6461b8d4e239490992a75468dcd510eb_I20211231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzEyMjY_d69175a1-2130-42eb-ba1f-b32efc089c72">3,061</ix:nonFraction>, respectively, which expire at various dates through 2041.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE2ODE_4a240a48-d985-41f8-8b49-e2395a9d9343">130,051</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE2ODg_d01d98c9-87c8-430a-8c1e-1145d5ef5cb7">77,375</ix:nonFraction> at December&#160;31, 2021 and December&#160;31, 2020, respectively. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE3NTY_e5919326-da83-4f7e-a4e3-4b3ba04ac4d2">52,676</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE3NzY_55e294a7-8869-4b2c-94e2-99bc2b8e8dae">28,468</ix:nonFraction> during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the Company&#8217;s net operating losses generated during the periods, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="i4afff2089d2f4b7383ad964b0a6767c1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzM4MzU_982eb52a-0fad-4a22-8c1a-ddd1c36a778a"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzM4MzU_e5f53326-8eb5-4545-be4a-00bf7a09989f">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2021 and 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ2NzY_0e2ff762-4e9a-4d21-9a65-391dbbce6d13"><ix:nonFraction unitRef="usd" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ2NzY_391e89ae-91f5-4ddb-9a0d-c59167bd46ac">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States federal tax jurisdiction and <ix:nonFraction unitRef="jurisdiction" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="mrsn:IncomeTaxesNumberOfStateJurisdictions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ4MzI_f71e4353-fd6c-48d5-8c6d-dc1960db332c">four</ix:nonFraction> state jurisdictions. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2021, 2020 and 2019. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2017, although carryforward attributes that were generated prior to tax&#160;year 2017 may still be adjusted upon examination to the extent utilized in a future period. There are <ix:nonFraction unitRef="audit" contextRef="i1b5567939ee84f85a796f7340017d974_I20211231" decimals="INF" name="mrsn:IncomeTaxesNumberOfAuditsInProgress" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyNDg_bcb7524b-1808-46a9-801b-99fd5789e1c1">no</ix:nonFraction> federal or state audits currently in progress.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_139"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzg2Mg_ab49d2d2-bd29-4d92-85ec-1c6ed1032e0c" continuedAt="i2346e0ffe0a74b71b87fab3244e55392" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2346e0ffe0a74b71b87fab3244e55392">The Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="mrsn:DefinedContributionPlanEligibleAgeToParticipate" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzIzMw_e0c0890a-6a1e-4e6f-9cac-743c3495c6ed">21</ix:nonNumeric> are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to <ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="2" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzM0Mw_4634748c-7313-4229-8ba9-c6cb3ec1292c">95</ix:nonFraction>% of eligible pay on a pre&#8211;tax basis up to the federal annual limits. For the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#8217; contributions at <ix:nonFraction unitRef="number" contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU0Mg_fe73d255-8482-4d85-bec6-216a0cf6bd0a">50</ix:nonFraction>% on the first <ix:nonFraction unitRef="number" contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU1OA_8b7f5e15-791e-48cd-97c6-2e493feaf7f2">6</ix:nonFraction>% up to $<ix:nonFraction unitRef="usd" contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU2Nw_c325ab87-212d-4342-b6d5-749d1db504b0">6</ix:nonFraction>. For the period from August 1, 2019 to December&#160;31, 2020 and for the year ended December&#160;31, 2021, the Company matched the employees&#8217; contributions at <ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzY5MQ_096059c8-1b21-4c7f-bb07-f2d501c6ef58"><ix:nonFraction unitRef="number" contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzY5MQ_7bb95192-faa4-4fa7-a8dc-e82743952aef">100</ix:nonFraction></ix:nonFraction>% on the first <ix:nonFraction unitRef="number" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcwNw_0c5b26a4-64cb-460b-80ca-5f6d011fb91b"><ix:nonFraction unitRef="number" contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcwNw_88d0c689-7f24-4eda-9859-891c4a724dda">4</ix:nonFraction></ix:nonFraction>% up to $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcxNg_33e7b732-dc40-49b4-94e5-054548e144a0"><ix:nonFraction unitRef="usd" contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231" decimals="-3" name="mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcxNg_ce5f2793-3ef1-46c9-ba24-d3207eeac829">7</ix:nonFraction></ix:nonFraction>. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, the Company recorded expense of $<ix:nonFraction unitRef="usd" contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc4Nw_9b7bd53a-77d5-4795-bfcf-8ba300938c2c">764</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc5MQ_82d31fc6-42a2-432b-b217-bc767f740c30">486</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc5OA_8c938d57-949d-4dbf-8e7c-19af028b94d2">404</ix:nonFraction>, respectively, related to its contribution to its 401(k)&#160;Plan.</ix:continuation></span></div><div id="i54c829abb8e046e0ba4639af9592e947_142"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:CommitmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzQzNQ_c8b206f1-173f-4187-963c-1c045cf2d975" continuedAt="i1642f6875f2e4ee096543448b5629dc4" escape="true">Commitments</ix:nonNumeric></span></div><ix:continuation id="i1642f6875f2e4ee096543448b5629dc4"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded research and development expense related to non-refundable license payments of $<ix:nonFraction unitRef="usd" contextRef="id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE3OA_6742fb3e-0b6b-4e83-a600-d0ba655e3d99">3,075</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i6f43b37474ae4a6eae2f68ccd01a3200_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE4Mg_2b98dfa0-f070-439a-85b1-0bc0f51202f5">250</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="ibf265381e7674d2ea77457e88a5120d9_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE5MA_4d6ffce2-933a-412f-99c7-8232615c739c">750</ix:nonFraction>, respectively. Further development milestones of $<ix:nonFraction unitRef="usd" contextRef="ib13441f134534f4b8413f2279bfe29f0_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzIzOA_04282dc4-7459-403e-bc09-36975a4d7a59">2,125</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i9c1b55d99d3a4d06949a1920a27b38ba_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzI0Mg_67db200a-02ea-42cd-a639-a49629f3925c">750</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i705217f95c8147c9a0aef1b16e6593b9_D20190101-20191231" decimals="-3" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzI0OQ_5a0ac685-6d88-4ef8-b89e-c5fd3ad1c8da">600</ix:nonFraction>, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these consolidated financial statements for the Company&#8217;s future obligations related to leases as of December&#160;31, 2021.</span></div></ix:continuation><div id="i54c829abb8e046e0ba4639af9592e947_148"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzM4NDgyOTA3MTU2MjE_79ae84c2-568d-4ae9-b12e-478f16ec22bc" continuedAt="i393a31eeda05475698760a6957776fb0" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i393a31eeda05475698760a6957776fb0" continuedAt="id1b82b51f1e545bb868e496060914798"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Research Collaboration and License Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into the Janssen Collaboration pursuant to which the Company granted Janssen an exclusive license to use the Company's proprietary Dolasynthen platform and other technology to develop, manufacture and commercialize ADCs directed to up to three targets selected by Janssen. The Company is responsible for performing bioconjugation activities to create ADCs for Janssen based on antibodies provided by Janssen. The Company will also perform certain chemistry, manufacturing and controls development and early stage manufacturing activities for ADCs that Janssen progresses through development, up to and including the manufacturing of clinical drug substance, at Janssen&#8217;s cost. Except with respect to this limited manufacturing, Janssen will be responsible for the further development, manufacturing and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div><div style="margin-top:2pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics,&#160;Inc.</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to consolidated financial statements</span></div><div style="text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(continued)</span></div></div><ix:continuation id="id1b82b51f1e545bb868e496060914798"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of the ADCs developed under the Janssen Collaboration, including obtaining any necessary regulatory approvals, at Janssen&#8217;s cost.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia138aba2a3b3406494fad2a37a13b0ee_D20220201-20220228" decimals="-3" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MDg_fa8481fa-e953-45bf-ba3f-d4ae74d6579b">40,000</ix:nonFraction> in February 2022. The Company is eligible to receive development and regulatory milestones with an aggregate total of $<ix:nonFraction unitRef="usd" contextRef="ib699aaf9d802436e8631493e14953d6c_I20220228" decimals="-3" name="mrsn:CollaborationArrangementsMaximumAggregateMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MTY_a91d64eb-ad19-45f1-9bfb-eb38ae31bfcf">501,000</ix:nonFraction>, if licensed products directed to all three Targets are advanced by Janssen. The Company is also eligible to receive commercial milestones with an aggregate total of $<ix:nonFraction unitRef="usd" contextRef="ic7ee2b32513f4e59b994d6020d4f8ef4_I20220228" decimals="-3" name="mrsn:CollaborationArrangementsMaximumAggregateMilestones" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MjU_d390a157-1b1d-4d2b-86f0-2a2ae9673a51">530,000</ix:nonFraction> in the event of commercialization of three Targets by Janssen and tiered royalties based on mid-single digits to low-double digits on future net sales of licensed ADCs </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Janssen Collaboration will continue in effect until the date on which the royalty term and all payment obligations with respect to all licensed ADCs in all countries have expired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Other Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company amended the Commercial License and Option Agreement with Synaffix B.V. (Synaffix) in connection with the Janssen Collaboration, and agreed to pay Synaffix a non-refundable execution fee of $<ix:nonFraction unitRef="usd" contextRef="i89e4886837f24a38b80b1747ed92ef46_D20220202-20220202" decimals="-3" name="mrsn:CollaborationAgreementNonrefundableExecutionFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MzQ_5eaf1600-ce10-4ee5-9f9b-e845b8960e55">1,500</ix:nonFraction> which will be applied against future target license fees or development milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further in connection with the Janssen Collaboration, on February 17, 2022, the Company amended the New Credit Facility described in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements. Pursuant to this amendment the Company has agreed to replace the tranche B term loan and the tranche C term loan with a single combined term loan tranche in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2NDE_de98a891-dcee-4a68-a2a5-e62acd599806">20,000</ix:nonFraction>. Also, the combined term loan tranche will now be available any time on or prior to June 30, 2023, within <ix:nonNumeric contextRef="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217" name="mrsn:LineOfCreditFacilityTrancheAvailabilityDuration" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzM4NDgyOTA3MTI0NzU_331d0b07-391c-483c-8f96-e6cbe9e09eb0">90</ix:nonNumeric> days of the Company achieving both of the prior tranche B and tranche C term loan milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2021 and through February 25, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="ib6fa9d8c34a04518a93d648eb4c54a81_D20220101-20220225" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2MzQ1_178a6330-ebb2-4644-a3d5-8f6d78d00c76">9,493,776</ix:nonFraction> shares of common stock resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5fa034c85dbc456988299ee454032879_D20220101-20220225" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2NDAx_e3222023-91ca-46e2-9443-a20bad28b0f7">45,579</ix:nonFraction> from ATM offerings, with substantial participation from existing long-term investors. Approximately $<ix:nonFraction unitRef="usd" contextRef="ie7884cd54894446b89c3403a61b91a97_I20220225" decimals="-3" name="mrsn:SaleOfStockRemainingAmountUnsoldAndAvailableForSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2NTA1_cc9ca653-e5b8-4594-be6d-c249dce76978">9,414</ix:nonFraction> remains unsold and available for sale under the 2020 ATM.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_157"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and (2) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2021, the end of the period covered by this Annual Report on Form 10-K. Based upon such evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles, or GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control &#8212; Integrated Framework. Based on our assessment, our management has concluded that, as of December&#160;31, 2021, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2021 has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their report which is included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended December&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Mersana Therapeutics, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited Mersana Therapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Mersana Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2021 consolidated financial statements of the Company and our report dated February 28, 2022 expressed an unqualified opinion thereon.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 28, 2022</span></div><div id="i54c829abb8e046e0ba4639af9592e947_160"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Inducement Stock Incentive Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2022, our Board of Directors adopted, upon recommendation of the compensation committee of our Board of Directors, or the Committee, the 2022 Inducement Stock Incentive Plan, or the Inducement Plan, to be effective immediately. The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and other stock-based awards, collectively, the stock awards, with respect to an aggregate of 2,000,000 shares of our common stock (subject to adjustment as provided in the Inducement Plan). Awards under the Inducement Plan may only be granted to persons who (a) were not previously our employee or director or (b) are commencing employment with us following a bona fide period of non-employment, in either case as an inducement material to the individual&#8217;s entering into employment with us and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). A complete copy of the Inducement Plan is attached hereto as Exhibit 10.28 to this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2022, our Board of Directors adopted, upon recommendation of the Committee, the nonstatutory stock option agreement and the restricted stock unit agreement for use in the grant of stock options and restricted stock units pursuant to the Inducement Plan. All stock options under the Inducement Plan shall be nonstatutory stock options. A complete copy of the forms of nonstatutory stock option agreement and the restricted stock unit agreement are attached hereto as Exhibits 10.30 and 10.29, respectively, to this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">At-the-market Equity Offering Program</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 28, 2022, we entered into a Sales Agreement, or Sales Agreement, with Cowen and Company, LLC, or Cowen, under which we may issue and sell shares of common stock, from time to time, having an aggregate offering price of up to $100.0 million. Sales of common stock through Cowen may be made by any method that is deemed an &#8220;at the market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Cowen has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell our shares of common stock based upon our instructions. We are not obligated to make any sales of our common stock under the Sales Agreement. Any sales under the Sales Agreement will be made pursuant to our registration statement on Form S-3 (File No 333-260895), which became effective on November 18, 2021, and pursuant to a prospectus supplement relating to such offering to be filed with the Securities and Exchange Commission.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_7146825582202"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i54c829abb8e046e0ba4639af9592e947_166"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We post our Code of Business Conduct and Ethics, which applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, in the &#8220;Corporate Governance&#8221; sub-section of the &#8220;Investors &amp; Media&#8221; section (https://ir.mersana.com) of our corporate website https://mersana.com/. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_169"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 11&#160;will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated here by reference.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_172"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_175"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_178"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item 14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2022 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i54c829abb8e046e0ba4639af9592e947_184"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a list of the consolidated financial statements included herein, see Index to the Consolidated Financial Statements in this Annual Report on Form 10-K, which is incorporated into this Item by reference.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statement Schedules</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No financial statement schedules have been submitted because they are not required or are not applicable or because the information required is included in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the Exhibit Index immediately before the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></div><div id="i54c829abb8e046e0ba4639af9592e947_187"></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT&#160;INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description&#160;of&#160;Exhibit</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d1.htm">Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, File No. 001-38129, filed on July 10, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465917044267/a17-17109_1ex3d2.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K, File No. 001-38129, filed on July 10, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-4_1.htm">Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-4_2.htm">Third Amended and Restated Investor Rights Agreement, dated as of June 15, 2016, by and among Mersana Therapeutics, Inc. and the Stockholders listed therein (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000110465919068163/tm1924038d1_ex4-1.htm">Form of Exchange Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form 8-K, File No. 001-38129, filed on November 27, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020001726/mrsn-20191231ex44aee8769.htm">Description of Registrant&#8217;s Common Stock (incorporated by reference to Exhibit 4.4 to the Company's Form 10-K, File No. 001-38129, filed on February 28, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_1.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_2.htm">Commercial Lease, dated February 24, 2009, between Mersana Therapeutics, Inc. and Rivertech Associates II, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex101321160.htm">Seventh Lease Extension and Modification Agreement to the Lease Between Rivertech Associates II LLC and Mersana Therapeutics, Inc., dated March 10, 2020, by and between Mersana Therapeutics, Inc. and Rivertech Associates II LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on May 8, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001442836/000162828021009717/exhibit10110-qfy2021q1.htm">Eighth Lease Modification Agreement to the Lease Between Rivertech Associates II LLC and Mersana Therapeutics, Inc., effective as of April 5, 2021, by and between Mersana Therapeutics, Inc. and Rivertech Associates II LLC. (incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q, File No. 001-38129, filed on May 10, 2021).</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001442836/000162828021009717/exhibit10110-qfy2021q1.htm"> </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_4.htm">Collaboration and Commercial License Agreement, dated June 23, 2014, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_5.htm">Amendment 1 to the Collaboration and Commercial License Agreement, dated June 1, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_6.htm">Amendment 2 to the Collaboration and Commercial License Agreement, dated August 12, 2016, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_7.htm">Amendment 3 to the Collaboration and Commercial License Agreement, dated February 28, 2017, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837018007081/mer-20180630ex10176898a.htm">Amendment 4 to Collaboration and Commercial License Agreement dated May 15, 2018, by and between Mersana Therapeutics, Inc. and Merck KGaA (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on August 14, 2018).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_8.htm">License, Development and Commercialization Agreement, dated July 9, 2015, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837019010082/mrsn-20190930ex101faeead.htm">First Amendment to the License, Development and Commercialization Agreement, dated August 19, 2019, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on November 6, 2019).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021022420/exhibit10110-q2021q3.htm">Second Amendment to the License, Development and Commercialization Agreement, dated September 28, 2021, by and between Mersana Therapeutics, Inc. and Recepta Biopharma S.A. (incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q, File No. 001-38129, filed on November 9, 2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_9.htm">Agreement Regarding LICR Technology, dated July 9, 2015, by and between Ludwig Institute for Cancer Research, Recepta Biopharma S.A. and Mersana Therapeutics, Inc. (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101410kfy2021.htm">Loan and Security Agreement, dated October 29, 2021, by and between Oxford Finance LLC, Silicon Valley Bank and Mersana Therapeutics, Inc. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101510kfy2021.htm">Amended and Restated Commercial License and Option Agreement, dated November 23, 2021, by and between Synaffix B.V. and Mersana Therapeutics, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_16.htm">Amended and Restated&#160;Offer&#160;Letter, by and between Mersana Therapeutics, Inc. and Anna Protopapas, dated March 17, 2017 (incorporated by reference to Exhibit 10.16 to the Company's Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021009717/exhibit10210-qfy2021q1.htm">Offer Letter, by and between Mersana Therapeutics, Inc. and Arvin Yang, dated November 5, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021009717/exhibit10210-qfy2021q1.htm"> (incorporate by reference to Exhi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021009717/exhibit10210-qfy2021q1.htm">bit 10.2 to the Company's Form 10-Q, File No. 001-38129, filed on May 10, 2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000155837020005892/mrsn-20200331ex1032c0f0b.htm">Offer Letter, by and between Mersana Therapeutics, Inc. and Brian DeSchuytner, dated June 10, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Form 10-Q, File No. 001-38129, filed on May 8, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021009717/exhibit10310-qfy2021q1.htm">Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Michael Kaufman, dated March 8, 2017 (incorporated by reference to Exhibit 10.3 to the Company's Form 10-Q, File No. 001-38129, filed on May 10, 2021). </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_18.htm">Amended and Restated Offer Letter, by and between Mersana Therapeutics, Inc. and Timothy B. Lowinger, dated March 8 (incorporated by reference to Exhibit 10.18 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_19.htm">2007 Stock Incentive Plan, as amended (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_20.htm">Form of Incentive Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917003762/a2232278zex-10_21.htm">Form of Nonqualified Stock Option under the 2007 Stock Incentive Plan (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Form S-1, File No. 333-218412, filed on June 1, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_22.htm">2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.22 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_23.htm">Form of Incentive Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_24.htm">Form of Nonqualified Stock Option under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.24 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000162828021016000/exhibit10110-q2021q2.htm">Form of Restricted Stock Unit under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Form 10-Q, File No. 333-38129, filed on August 6, 2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102810kfy2021.htm">2022 Inducement Stock Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102910kfy2021.htm">Form of Inducement Restricted Stock</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102910kfy2021.htm"> Unit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102910kfy2021.htm"> under </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102910kfy2021.htm">the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102910kfy2021.htm">2022 Inducement Stock Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit103010kfy2021.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit103010kfy2021.htm">Non-statutory Stock Option under the 2022 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit103010kfy2021.htm">Inducement Stock Incentive Plan</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_25.htm">2017 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.25 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.32&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1442836/000104746917004050/a2232415zex-10_26.htm">2017 Cash Bonus Plan (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Form S-1/A, File No. 333-218412, filed on June 16, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit21110kfy2021q4.htm">Subsidiaries of Mersana Therapeutics, Inc.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit23110kfy2021q4.htm">Consent of Ernst&#160;&amp; Young&#160;LLP.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31110kfy2021q4.htm">Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by Chief Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31210kfy2021q4.htm">Certification pursuant to Section 302 of Sarbanes Oxley Act of 2002 by </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31210kfy2021q4.htm">Chief</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit31210kfy2021q4.htm"> Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1**</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32110kfy2021q4.htm">Certification of periodic financial report pursuant to Section 906 of Sarbanes Oxley Act of 2002 by Chief Executive Officer and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32110kfy2021q4.htm">Chief</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit32110kfy2021q4.htm"> Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial and related information from Mersana Therapeutics, Inc.&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, formatted in Inline eXtensible Business Reportable Language (iXBRL) includes: (i) the Consolidated Balance Sheet; (ii) the Consolidated Statement of Operations and Comprehensive Loss; (iii) the Consolidated Statement of Changes in Stockholders' Equity; (iv) the Consolidated Statement of Cash Flows; and, (v) Notes to Consolidated Financial Statements.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2021, formatted in Inline XBRL (contained in Exhibit 101).</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="i54c829abb8e046e0ba4639af9592e947_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i54c829abb8e046e0ba4639af9592e947_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mersana Therapeutics, Inc.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Anna Protopapas</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anna Protopapas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ANNA PROTOPAPAS</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anna Protopapas</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;BRIAN DESCHUYTNER</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer (Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian DeSchuytner</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ASHISH MANDELIA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Controller (Principal Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ashish Mandelia</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;DAVID MOTT</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Mott</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;KRISTEN HEGE</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristen Hege, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ANDREW A. F. HACK</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Andrew A. F. Hack, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;LAWRENCE M. ALLEVA</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lawrence M. Alleva</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;WILLARD H. DERE, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Willard H. Dere, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;MARTIN H. HUBER, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin H. Huber, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ALLENE M. DIAZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allene M. Diaz</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>2
<FILENAME>exhibit101410kfy2021.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i184a70b5647542429a0a947fe963dd54_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.14</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks demote omissions.</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LOAN AND SECURITY AGREEMENT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THIS LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (as the same may from time to time be amended, modified, supplemented or restated, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) dated as of October 29, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA&#160; 22314</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oxford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as collateral agent (in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 275 Grove Street, Suite 2-200, Newton, MA 02466 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SVB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and MERSANA THERAPEUTICS, INC., a Delaware corporation with offices located at 840 Memorial Drive, Cambridge, MA 02139 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders.  The parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ACCOUNTING AND OTHER TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounting terms not defined in this Agreement shall be construed in accordance with GAAP.  Calculations and determinations must be made in accordance with GAAP.  Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section&#160;13.  All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.  All references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are United States Dollars, unless otherwise noted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LOANS AND TERMS OF PAYMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1&#160;&#160;&#160;&#160;Promise to Pay.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Term A Draw Period, to make term loans to Borrower in an aggregate amount of up to Sixty Million Dollars ($60,000,000.00) to be disbursed in an amount equal to Twenty-Five Million Dollars ($25,000,000.00) on the Effective Date according to each Lender&#8217;s Term A Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto, with the remaining Thirty-Five Million Dollars ($35,000,000.00) available to be disbursed, upon Borrower&#8217;s request, in up to three (3) additional single advances according to each Lender&#8217;s Term&#160;A Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (such term loans on the Effective Date and thereafter are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;A Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Each disbursement of Term A Loans after the Effective Date shall be in an aggregate amount of at least Five Million Dollars ($5,000,000.00) and, unless the entire remaining amount of the Term A Loan Commitment will be disbursed at such disbursement, in a denomination that is a whole number multiple of Five Million Dollars ($5,000,000.00).  After repayment, no Term&#160;A Loan may be re-borrowed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement and upon Borrower&#8217;s request, the Lenders agree, severally and not jointly, during the Term B Draw Period, to make term loans to Borrower in an aggregate amount equal to Ten Million Dollars ($10,000,000.00) and disbursed in a single advance according to each Lender&#8217;s Term&#160;B Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;B Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  After repayment, no Term&#160;B Loan may be re-borrowed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement and upon Borrower&#8217;s request, the Lenders agree, severally and not jointly, during the Term C Draw Period, to make term loans to Borrower in an aggregate amount equal to Ten Million Dollars ($10,000,000.00) and disbursed in a single advance according to each Lender&#8217;s Term&#160;C Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;C Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  After repayment, no Term&#160;C Loan may be re-borrowed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders may, in their sole discretion, agree to make term loans to Borrower prior to the Amortization Date in an aggregate amount equal to Twenty Million Dollars ($20,000,000.00) in a single advance and, if made, according to a commitment schedule to be provided by the Lenders prior to the Funding Date of such term loans (such term loans are hereinafter referred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;D Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;D Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;&#59; each Term&#160;A Loan, Term&#160;B Loan, Term C Loan or Term D Loan is hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term&#160;A Loans, the Term&#160;B Loans, the Term C Loans and the Term D Loans are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  After repayment, no Term&#160;D Loan may be re-borrowed.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Repayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Borrower shall make monthly payments of interest only commencing on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.  Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof.  Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon&#58; (1) the amount of such Lender&#8217;s Term&#160;Loan, (2) the effective rate of interest, as determined in Section&#160;2.3(a), and (3) a repayment schedule equal to (y) twenty-four (24) months if the Amortization Date is November 1, 2024 and (z) twelve (12) months if the Amortization Date is November 1, 2025.  All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date.  Each Term&#160;Loan may only be prepaid in accordance with Sections 2.2(c)&#160;and 2.2(d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Mandatory Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Lenders, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of&#58; (i)&#160;all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii)&#160;the Final Payment, (iii)&#160;the Prepayment Fee, plus (iv) all other Obligations that are due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts. Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect of the Term Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Prepayment of Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Borrower shall have the option at any time to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i)&#160;provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, and (ii)&#160;pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A)&#160;all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, Borrower shall also have the option to prepay part of the Term Loans advanced by the Lenders under this Agreement at any time, provided Borrower (i) shall make no more than two (2) prepayments during the life of this Agreement, (ii) provides written notice of its election to prepay the Term Loans at least ten (10) days prior to such prepayment, (iii) prepays such part of the Term Loans in a denomination that is not less than Ten Million Dollars ($10,000,000.00) or, if in excess thereof, in integral whole number multiples of One Million Dollars ($1,000,000.00), and (iv) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) the portion of outstanding principal of such Term Loans plus all accrued and unpaid interest thereon through the prepayment date, (B) the applicable Final Payment, and (C) all other Obligations that are then due and payable, including Lenders&#8217; Expenses and interest at the Default Rate with respect to any past due amounts, (D) the applicable Prepayment Fee with respect to the portion of such Term Loans being prepaid, and (E) a portion of any fee that would have otherwise been due pursuant to Section 2.2(d)(i). For the purposes of clarity, any partial prepayment shall be applied pro-rata to all outstanding amounts under each Term Loan, and shall be applied pro-rata within each Term Loan tranche to reduce amortization payments under Section 2.2(b) on a pro-rata basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of Interest on the Credit Extensions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Subject to Section&#160;2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per annum rate equal to the Basic Rate, determined by Collateral Agent on the Funding Date of the applicable Term Loan and monthly thereafter, which interest shall be payable monthly in arrears in accordance with Sections 2.2(b)&#160;and 2.3(e). Interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding under such Term Loan through and including the day on which such Term Loan is paid in full.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a floating per annum rate equal to the rate that is otherwise applicable thereto plus five percentage points (5.00%) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Payment or acceptance of the increased interest rate provided in this Section&#160;2.3(b)&#160;is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">360-Day Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Interest shall be computed on the basis of a three hundred sixty (360) day year, and the actual number of days elapsed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Debit of Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Collateral Agent and each Lender may debit (or ACH) any deposit accounts, maintained by Borrower or any of its Subsidiaries, including the Designated Deposit Account, for principal and interest payments or any other amounts Borrower owes Collateral Agent or the Lenders under the Loan Documents when due.  Any such debits (or ACH activity) shall not constitute a set-off. Without limiting the foregoing, Collateral Agent and each Lender shall use commercially reasonable efforts to notify Borrower for the reasons of debiting of any amounts (other than principal and interest payments) debited from Borrower's deposit accounts in respect of this Agreement after such debt has been made&#59; provided, however, failure to provide such notice shall not be considered a breach of any provision hereof by Collateral Agent or any Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to the respective Lender to which such payments are owed, at such Lender&#8217;s office in immediately available funds on the date specified herein. Unless otherwise provided, interest is payable monthly on the Payment Date of each month.  Payments of principal and&#47;or interest received after 2&#58;00 p.m. Eastern time are considered received at the opening of business on the next Business Day.  When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses, indemnities and reimbursements, shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4&#160;&#160;&#160;&#160;Secured Promissory Notes.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), and shall be repayable as set forth in this Agreement.  Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender&#8217;s Secured Promissory Note, an appropriate notation on such Lender&#8217;s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may be) the receipt of such payment.  The outstanding amount of each Term Loan set forth on such Lender&#8217;s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender&#8217;s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to make payments of principal of or interest on any Secured Promissory Note when due.  Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5&#160;&#160;&#160;&#160;Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower shall pay to Collateral Agent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Facility Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A non-refundable facility fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), to be shared between the Lenders pursuant to their respective Commitment Percentages, due and payable as follows&#58; (i) with respect to the Term A Loans made by the Lenders on the Effective Date, One Hundred Twenty-Five Thousand Dollars ($125,000.00), which shall be fully earned and due and payable on the Effective Date, and (ii) with respect to each Term Loan made by the Lenders after the Effective Date, an amount equal to the product of (A) one half of one percent (0.50%) and (B) the original principal amount of such Term Loan, which shall be fully earned and due and payable on the Funding Date of such Term Loan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Final Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Prepayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All Lenders&#8217; Expenses (including reasonable and documented out-of-pocket attorneys&#8217; fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Effective Date, when due&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Borrower has paid to Collateral Agent a deposit of &#91;**&#93; Dollars ($&#91;**&#93;) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), to initiate Collateral Agent&#8217;s and Lenders&#8217; due diligence review and documentation process.  The Good Faith Deposit will be used to pay Lenders&#8217; Expenses due on the Effective Date, with the balance, if any, towards the Facility Fee due under Section 2.5(a) hereof&#59; provided, however, Borrower shall be responsible for the entire amount of Lenders&#8217; Expenses payable under Section 2.5(d) hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6&#160;&#160;&#160;&#160;Withholding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Payments received by the Lenders from Borrower hereunder will be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any governmental authority (including any interest, additions to tax or penalties applicable thereto, collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires Borrower to make any withholding or deduction from any such payment or other sum payable hereunder to the Lenders, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction, each Lender receives a net sum equal to the sum which it would have received had no withholding or deduction been required and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority&#59; provided, however, Borrower shall not be required to pay any additional amount to any Lender with respect to Excluded Taxes.  Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such withholding payment&#59; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower.  The agreements and obligations of Borrower contained in this Section&#160;2.6 shall survive the termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On the date of this Agreement, each Lender shall deliver to Borrower a complete and properly executed IRS Form W-9.  If any assignee of a Lender&#8217;s rights under Section 12.1 of this Agreement is not a &#8220;United States Person&#8221; as defined in Section 7701(a)(30) of the U.S. Internal Revenue Code (&#8220;Non-U.S. Lender&#8221;), such Non-U.S. Lender shall, upon becoming party to this Agreement, deliver to Borrower a complete and properly executed IRS Form W-8BEN-E (or W-8BEN, as applicable), W-8ECI or W-8IMY, as appropriate, or any successor form prescribed by the IRS, certifying that such Non-U.S. Lender is entitled to an exemption from U.S. withholding tax on interest and other amounts payable under this Agreement.  Notwithstanding the foregoing, (i) Borrower shall not be required to pay any additional amount to any Non-U.S. Lender hereunder if such Non-U.S. Lender fails or is unable to deliver the forms, certificates or other evidence described in the preceding sentence, unless such Non-U.S. Lender&#8217;s failure or inability to deliver such forms is the result of any change in any applicable law, treaty or governmental rule, or any change in the interpretation thereof after such Non-U.S. Lender became a party to this Agreement and (ii) Borrower shall not be required to pay any additional amount to any Non-U.S. Lender hereunder with respect to taxes imposed under Sections 1471 through 1474 of the U.S. Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with) and any current or future regulations or official interpretations thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CONDITIONS OF LOANS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1&#160;&#160;&#160;&#160;Conditions Precedent to Initial Credit Extension.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Each Lender&#8217;s obligation to make a Term&#160;A Loan is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;original Loan Documents, each duly executed by Borrower and each Subsidiary, as applicable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;duly executed original Control Agreements with respect to any Collateral Accounts maintained by Borrower or any of its Subsidiaries which require a Control Agreement pursuant to Section 6.6&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;duly executed original Secured Promissory Notes in favor of each Lender according to its Term&#160;A Loan Commitment Percentage in respect of the Term A Loans made by such Lender on the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;subject to the Post Closing Letter, the certificate(s) for the Shares of Mersana Securities, together with Assignment(s) Separate from Certificate, duly executed in blank&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the Operating Documents and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent agency) of Borrower&#8217;s and such Subsidiaries&#8217; jurisdiction of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">organization or formation and each jurisdiction in which Borrower and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;a completed Perfection Certificate for Borrower and each of its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;the Annual Projections, for the current calendar year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;duly executed original officer&#8217;s certificate for Borrower and each Subsidiary that is a party to the Loan Documents, relating to the Operating Documents, corporate authorizations and other matters, in a form acceptable to Collateral Agent and the Lenders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;certified copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;subject to the Post Closing Letter, a landlord&#8217;s consent executed in favor of Collateral Agent in respect of all of Borrower&#8217;s and each Subsidiaries&#8217; leased locations&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;subject to the Post Closing Letter, a bailee waiver executed in favor of Collateral Agent in respect of each third party bailee with respect to locations in the United States where Borrower or any Subsidiary maintains Collateral having a book value in excess of Three Million Dollars ($3,000,000.00)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;a duly executed legal opinion of counsel to Borrower dated as of the Effective Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;evidence satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section&#160;6.5 hereof are in full force and effect, together with appropriate evidence showing loss payable and&#47;or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Lenders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;a payoff letter from Silicon Valley Bank in respect of the Existing Indebtedness&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;evidence that (i)&#160;the Liens securing the Existing Indebtedness will be terminated and (ii)&#160;the documents and&#47;or filings evidencing the perfection of such Liens, including without limitation any financing statements and&#47;or control agreements, have or will, concurrently with the initial Credit Extension, be terminated&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section&#160;2.5 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2&#160;&#160;&#160;&#160;Conditions Precedent to all Credit Extensions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  The obligation of each Lender to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;receipt by (i) the Lenders of an executed Disbursement Letter in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> attached hereto&#59; and (ii) SVB of an executed Loan Payment&#47;Advance Request Form in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> attached hereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the representations and warranties in Section&#160;5 hereof shall be true, accurate and complete in all material respects on the date of the Disbursement Letter (and the Loan Payment&#47;Advance Request Form) and on the Funding Date of each Credit Extension&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension.  Each Credit Extension is Borrower&#8217;s representation and warranty on that date that the representations and warranties in Section&#160;5 hereof are true, accurate and complete in all material respects&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;in such Lender&#8217;s sole but reasonable discretion, there has not been any Material Adverse Change&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes, in number, form and content acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section&#160;2.5 hereof&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;with respect to the Term B Loans only, in such Lender&#8217;s sole discretion, the &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3&#160;&#160;&#160;&#160;Covenant to Deliver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower agrees to deliver to Collateral Agent and the Lenders each item required to be delivered to Collateral Agent under this Agreement as a condition precedent to any Credit Extension.  Borrower expressly agrees that a Credit Extension made prior to the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by Collateral Agent or any Lender of Borrower&#8217;s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in each Lender&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4&#160;&#160;&#160;&#160;Procedures for Borrowing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan, Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 2&#58;00 p.m. Eastern time five (5) Business Days prior to the date the Term Loan is to be made.  Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to the Lenders by electronic mail or facsimile a completed Disbursement Letter (and the Loan Payment&#47;Advance Request Form, with respect to SVB) executed by a Responsible Officer or his or her designee.  The Lenders may rely on any telephone notice given by a person whom a Lender reasonably believes is a Responsible Officer or designee.  On the Funding Date, each Lender shall credit and&#47;or transfer (as applicable) to the Designated Deposit Account, an amount equal to its Term Loan Commitment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CREATION OF SECURITY INTEREST</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1&#160;&#160;&#160;&#160;Grant of Security Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof.  Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to have priority to Collateral Agent&#8217;s Lien.  If Borrower shall acquire a commercial tort claim (as defined in the Code) with a value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00), Borrower, shall promptly notify Collateral Agent in a writing signed by Borrower, as the case may be, of the general details thereof (and further details as may be required by Collateral Agent) and grant to Collateral Agent, for the ratable benefit of the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrower acknowledges that it previously has entered, and&#47;or may in the future enter, into Bank Services Agreements with Bank.  Regardless of the terms of any Bank Services Agreement, Borrower agrees that any amounts Borrower owes Bank thereunder shall be deemed to be Obligations hereunder and that it is the intent of Borrower and Bank to have all such Obligations secured by the first priority perfected security interest in the Collateral granted herein (subject only to Permitted Liens that may have superior priority to Bank&#8217;s Lien in this Agreement).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If this Agreement is terminated, Collateral Agent&#8217;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) are repaid in full in cash.  Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) and at such time as the Lenders&#8217; obligation to make Credit Extensions has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower.  In the event (x) all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement), except for Bank Services, are satisfied in full, and (y) this Agreement is terminated, Bank shall terminate the security interest granted herein upon Borrower providing cash collateral acceptable to Bank in its good faith business judgment for Bank Services, if any.  In the event such Bank Services consist of outstanding Letters of Credit, Borrower shall provide to Bank cash collateral in an amount equal to (x)&#160;if such Letters of Credit are denominated in Dollars, then one hundred five percent (105.00%)&#59; and (y)&#160;if such Letters of Credit are denominated in a Foreign Currency, then one hundred ten percent (110.00%), of the Dollar Equivalent of the face amount of all such Letters of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit plus all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in its good faith business judgment), to secure all of the Obligations relating  to such  Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2&#160;&#160;&#160;&#160;Authorization to File Financing Statements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent&#8217;s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&#8217;s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.3&#160;&#160;&#160;&#160;Pledge of Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby pledges, assigns and grants to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted in connection therewith, and all other cash and non-cash proceeds of the foregoing, as security for the performance of the Obligations.  On the Effective Date, or, to the extent not certificated as of the Effective Date, within ten (10) days of the certification of any Shares, the certificate or certificates for the Shares will be delivered to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by Borrower.  To the extent required by the terms and conditions governing the Shares, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares.  Upon the occurrence and during the continuance of an Event of Default hereunder, Collateral Agent may effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and cause new (as applicable) certificates representing such securities to be issued in the name of Collateral Agent or its transferee.  Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Shares.  Unless an Event of Default shall have occurred and be continuing, Borrower shall be entitled to exercise any voting rights with respect to the Shares and to give consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would be inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of such terms.  All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrower represents and warrants to Collateral Agent and the Lenders as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1&#160;&#160;&#160;&#160;Due Organization, Authorization&#58; Power and Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower and each of its Subsidiaries is duly existing and in good standing as a Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change.  In connection with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate signed by an officer of Borrower or such Subsidiary (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).  Borrower represents and warrants that (a)&#160;Borrower and each of its Subsidiaries&#8217; exact legal name is that which is indicated on its respective Perfection Certificate and on the signature page of each Loan Document to which it is a party&#59; (b)&#160;Borrower and each of its Subsidiaries is an organization of the type and is organized in the jurisdiction set forth on its respective Perfection Certificate&#59; (c)&#160;each Perfection Certificate accurately sets forth each of Borrower&#8217;s and its Subsidiaries&#8217; organizational identification number or accurately states that Borrower or such Subsidiary has none&#59; (d)&#160;each Perfection Certificate accurately sets forth Borrower&#8217;s and each of its Subsidiaries&#8217; place of business, or, if more than one, its chief executive office as well as Borrower&#8217;s and each of its Subsidiaries&#8217; mailing address (if different than its chief executive office)&#59; (e)&#160;except as may be set forth on its Perfection Certificate, Borrower and each of its Subsidiaries (and each of its respective predecessors) have not, in the past five (5) years, changed its jurisdiction of organization, organizational structure or type, or any organizational number assigned by its jurisdiction&#59; and (f)&#160;all other information set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries, is accurate and complete (it being understood and agreed that Borrower and each of its Subsidiaries may from time to time update certain information in the Perfection Certificates (including the information set forth in clause (d)&#160;above) after the Effective Date to the extent Borrower is permitted by one or more specific provisions in this Agreement or any other Loan Document&#59; such updated Perfection Certificates subject to the review and approval of Collateral Agent unless such facts, events or circumstances being updated first arose or occurred after the Effective Date and do not constitute a breach, default, or Event of Default under this Agreement or any other Loan Document.  If Borrower or any of its Subsidiaries is not now a Registered Organization but later becomes one, Borrower shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person&#8217;s organizational identification number within five (5) Business Days of receiving such organizational identification number.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is a party have been duly authorized, and do not (i)&#160;conflict with any of Borrower&#8217;s or such Subsidiaries&#8217; organizational documents, including its respective Operating Documents, (ii)&#160;contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii)&#160;contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or such Subsidiary, or any of their property or assets may be bound or affected, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except for filings with the Securities and Exchange Commission which do not require any consent by any Governmental Authority, such Governmental Approvals which have already been obtained and are in full force and effect or are being obtained pursuant to Section&#160;6.1(b), or filings required to perfect the security interest granted herein) or (v) constitute an event of default under any material agreement by which Borrower or any of such Subsidiaries, or their respective properties, is bound.  Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.2&#160;&#160;&#160;&#160;Collateral.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower and each of its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien under the Loan Documents, free and clear of any and all Liens except Permitted Liens, and neither Borrower nor any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent in connection herewith with respect of which Borrower or such Subsidiary has given Collateral Agent notice and taken such actions as are necessary to give Collateral Agent a perfected security interest therein to the extent required under this Agreement. The Accounts are bona fide, existing obligations of the Account Debtors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;On the Effective Date, and except as disclosed on the Perfection Certificate (i)&#160;the Collateral is not in the possession of any third party bailee (such as a warehouse), and (ii)&#160;no such third party bailee possesses components of the Collateral in excess of Five Hundred Thousand Dollars ($500,000.00).  None of the components of the Collateral (other than (1) inventory in transit, and (2) laptops (and related electronic computer equipment) and mobile phones) shall be maintained at locations other than as disclosed in the Perfection Certificates on the Effective Date or as permitted pursuant to Section&#160;6.11.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;All unexpired Inventory is in all material respects of good quality, free from material defects, and all unexpired Inventory held out for sale is in all material respects of marketable quality.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to solely own, free and clear of all Liens other than Permitted Liens.  Except as noted on the Perfection Certificates, in connection with the Permitted License Amendment Transaction, or as otherwise disclosed pursuant to the terms of this Agreement (to the extent Borrower is permitted to take such action resulting in the applicable update by one or more specific provisions of this Agreement), neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i)&#160;prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower&#8217;s or such Subsidiaries&#8217; interest in such material license or other material agreement or any other property, or (ii)&#160;for which a default under or termination of could interfere with Collateral Agent&#8217;s or any Lender&#8217;s right to sell any Collateral.  Borrower shall promptly (and in any event within ten (10) Business Days) provide written notice to Collateral Agent and each Lender of Borrower or any of its Subsidiaries entering into or becoming bound by any material license or other material agreement with respect to which Borrower or any Subsidiary is the licensee (other than over-the-counter software that is commercially available to the public).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.3&#160;&#160;&#160;&#160;Litigation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Except as disclosed (i)&#160;on the Perfection Certificates, or (ii)&#160;in accordance with Section&#160;6.9 hereof, there are no actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than Two Hundred Fifty Thousand Dollars ($250,000.00).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.4&#160;&#160;&#160;&#160;No Material Deterioration in Financial Condition&#59; Financial Statements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries (subject to normal year-end adjustments to reflect the non-cash impact of accounting for stock compensation or other non-cash equity items and the absence of footnotes) as of the dates and for the periods presented.  There has not been any material deterioration in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;8</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.5&#160;&#160;&#160;&#160;Solvency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower is Solvent, and Borrower and each of its Subsidiaries, taken as a whole, is Solvent.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6&#160;&#160;&#160;&#160;Regulatory Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Neither Borrower nor any of its Subsidiaries is an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its Subsidiaries is a &#8220;holding company&#8221; or an &#8220;affiliate&#8221; of a &#8220;holding company&#8221; or a &#8220;subsidiary company&#8221; of a &#8220;holding company&#8221; as each term is defined and used in the Public Utility Holding Company Act of 2005.  Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change.  Neither Borrower&#8217;s nor any of its Subsidiaries&#8217; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#8217;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None of Borrower, any of its Subsidiaries, or any of Borrower&#8217;s or its Subsidiaries&#8217; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i)&#160;in violation of any Anti-Terrorism Law, (ii)&#160;engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti-Terrorism Law, or (iii)&#160;is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.7&#160;&#160;&#160;&#160;Investments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities except for Permitted Investments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8&#160;&#160;&#160;&#160;Tax Returns and Payments&#59; Pension Contributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower and each of its Subsidiaries has timely filed or have timely obtained extensions for filing all required tax returns and reports, and Borrower and each of its Subsidiaries, has timely paid all foreign, federal, state, and local Taxes owed by Borrower and such Subsidiaries, in all jurisdictions in which Borrower or any such Subsidiary is subject to Taxes, including the United States, unless (a) such Taxes are being contested in accordance with the following sentence or (b) in the case of state or local Taxes, if such Taxes do not, individually or in the aggregate, exceed Fifty Thousand Dollars ($50,000.00).  Borrower and each of its Subsidiaries, may defer payment of any contested Taxes, provided that Borrower or such Subsidiary, (a)&#160;in good faith contests its obligation to pay the Taxes by appropriate proceedings promptly and diligently instituted and conducted, (b)&#160;notifies Collateral Agent in writing of the commencement of, and any material development in, the proceedings, and (c)&#160;posts bonds or takes any other steps required to prevent the Governmental Authority levying such contested Taxes from obtaining a Lien upon any of the Collateral that is other than a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.&#8221;  Neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower&#8217;s or such Subsidiaries&#8217;, prior tax years which could result in additional Taxes becoming due and payable by Borrower or its Subsidiaries in excess of Fifty Thousand Dollars ($50,000.00), except to the extent that such Taxes are being contested in accordance with the immediately preceding sentence.  Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.9&#160;&#160;&#160;&#160;Use of Proceeds.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes. A portion of the proceeds of the Term&#160;A Loans shall be used by Borrower to repay the Existing Indebtedness in full on the Effective Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;9</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.10&#160;&#160;&#160;&#160;Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower has full power and authority to create a first lien on the Shares and no disability or contractual obligation exists that would prohibit Borrower from pledging the Shares pursuant to this Agreement.  To Borrower&#8217;s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares.  The Shares have been and will be duly authorized and validly issued, and are fully paid and non-assessable.  To Borrower&#8217;s knowledge, the Shares are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of no reasonable grounds for the institution of any such proceedings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.11&#160;&#160;&#160;&#160;Full Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  No written representation, warranty or other statement of Borrower or any of its Subsidiaries in any certificate or written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading in light of the circumstances under which they were made (it being recognized that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.12&#160;&#160;&#160;&#160;Definition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Knowledge.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;  For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower&#8217;s knowledge or awareness, to the &#8220;best of&#8221; Borrower&#8217;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of the Responsible Officers.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">AFFIRMATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrower shall, and shall cause each of its Subsidiaries to, do all of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.1&#160;&#160;&#160;&#160;Government Compliance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Maintain its and all its Subsidiaries&#8217; legal existence and good standing in their respective jurisdictions of organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change.  Comply with all laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject, the noncompliance with which could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Obtain and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries of their respective businesses and obligations under the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Lenders, in all of the Collateral.  Borrower shall promptly notify Collateral Agent of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries and unless otherwise requested by Collateral Agent, on or before the next Reporting Date, provide copies to Collateral Agent of such material Governmental Approvals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2&#160;&#160;&#160;&#160;Financial Statements, Reports, Certificates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Deliver to each Lender&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;as soon as available, but no later than forty-five (45) days after the last day of each fiscal quarter, a company prepared consolidated and consolidating balance sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such quarter certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;as soon as available, but no later than one hundred twenty (120) days after the last day of Borrower&#8217;s fiscal year or within five (5) days of filing with the SEC, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion (provided that such unqualified opinion may contain going concern explanatory language as it relates to Borrower&#8217;s cash levels) on the financial statements from Ernst &#38; Young LLP or another an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;as soon as available after approval thereof by Borrower&#8217;s Board of Directors, but no later than thirty (30) days after the last day of each of Borrower&#8217;s fiscal years,&#160;Borrower&#8217;s annual financial projections for the entire current fiscal year as approved by Borrower&#8217;s Board of Directors, which such annual financial projections shall be set forth in a quarter-by-quarter format (such annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;&#59; provided that, any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;10</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">revisions to the Annual Projections approved by Borrower&#8217;s Board of Directors shall be delivered to Collateral Agent and the Lenders no later than seven (7) Business Days after such approval)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;within five (5) days of delivery, copies of all statements, reports and notices made available to Borrower&#8217;s security holders or holders of Subordinated Debt&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Within five (5) Business Days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission, </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;prompt notice of (y) in the event that Borrower is no longer subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, prompt notice of any material change to the capitalization table of Borrower, and (z) any amendments of the Operating Documents of Borrower or any of its Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;prompt notice of any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;as soon as available, but no later than thirty (30) days after the last day of each month, copies of the month-end account statements for each Collateral Account maintained by Borrower or its Subsidiaries, which statements may be provided to Collateral Agent and each Lender by Borrower or directly from the applicable institution(s)&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;other information as reasonably requested by Collateral Agent or any Lender.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, notices or documents required to be delivered pursuant to the terms hereof (to the extent any such information or documents are included in materials otherwise filed with the SEC) may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date on which (i) Borrower posts such documents, or provides a link thereto, on Borrower&#8217;s website on the internet at Borrower&#8217;s website address, or (ii) on which such documents are posted on Borrower&#8217;s behalf on the website of the Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;No later than thirty (30) days after the last day of each month, deliver to each Lender, a duly completed Compliance Certificate signed by a Responsible Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Keep proper books of record and account in accordance with GAAP in all material respects, in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities.  Borrower shall, and shall cause each of its Subsidiaries to, allow, at the sole cost of Borrower (once in any given fiscal year unless an Event of Default has occurred and is continuing, in which case all such visits or inspections shall be at the cost of the Borrower), Collateral Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any of its books and records, and to conduct a collateral audit and analysis of its operations and the Collateral.  Such audits shall be conducted no more often than once every year unless (and more frequently if) an Event of Default has occurred and is continuing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3&#160;&#160;&#160;&#160;Inventory&#59; Returns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Keep all unexpired Inventory in all material respects in good condition, free from material defects, and keep all unexpired Inventory held out for sale in all material respects in marketable condition.  Returns and allowances between Borrower, or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower&#8217;s, or such Subsidiary&#8217;s, customary practices as they exist at the Effective Date.  Borrower must promptly notify Collateral Agent and the Lenders of all returns, recoveries, disputes and claims that involve more than Five Hundred Thousand Dollars ($500,000.00), individually or in the aggregate, in any calendar year. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.4&#160;&#160;&#160;&#160;Taxes&#59; Pensions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Timely file or obtain extensions for filing and require each of its Subsidiaries to timely file, all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely pay, all foreign, federal, state, and local Taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, except for (i) deferred payment of any Taxes contested pursuant to the terms of Section&#160;5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and (ii) any failure to timely pay or file state or local Taxes in an amount, individually or in the aggregate, in excess of Fifty Thousand Dollars ($50,000.00), and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;11</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.5&#160;&#160;&#160;&#160;Insurance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Keep Borrower&#8217;s and its Subsidiaries&#8217; business and the Collateral insured for risks and in amounts standard for companies in Borrower&#8217;s and its Subsidiaries&#8217; industry and location and as Collateral Agent may reasonably request.  Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Lenders.  All property policies shall have a lender&#8217;s loss payable endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as additional insured.  The Collateral Agent shall be named as lender loss payee and&#47;or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral Agent, that it will give the Collateral Agent thirty (30) days prior written notice (or ten (10) days prior written notice in the event of cancellation for non-payment) before any such policy or policies shall be materially altered or canceled.  At Collateral Agent&#8217;s request, Borrower shall deliver certified copies of policies and evidence of all premium payments.  Proceeds payable under any policy shall, at Collateral Agent&#8217;s option, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.  Notwithstanding the foregoing, (a)&#160;so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to Five Hundred Thousand Dollars ($500,000.00) with respect to any loss, but not exceeding Five Hundred Thousand Dollars ($500,000.00), in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property&#59; provided that any such replaced or repaired property (i)&#160;shall be of better, equal or like value as the replaced or repaired Collateral and (ii)&#160;shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b)&#160;after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.  If Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section&#160;6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and&#47;or any Lender may make, at Borrower&#8217;s expense, all or part of such payment or obtain such insurance policies required in this Section&#160;6.5, and take any action under the policies Collateral Agent or such Lender deems prudent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.6&#160;&#160;&#160;&#160;Operating Accounts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Maintain all of Borrower&#8217;s and its Subsidiaries&#8217; (excluding Mersana Securities) Collateral Accounts that are operating accounts or hold excess cash with Bank or its Affiliates&#59; provided, however, that all Collateral Accounts (other than Excluded Accounts) of Borrower shall be maintained in accounts which are subject to a Control Agreement in favor of Collateral Agent.  Borrower shall also conduct all of its primary banking with Bank and Bank&#8217;s Affiliates, including, without limitation, cash management, letters of credit and business credit cards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Borrower shall provide Collateral Agent five (5) days&#8217; prior written notice before Borrower or any of its Subsidiaries establishes any Collateral Account (other than Excluded Accounts) after the Effective Date at or with any Person other than Bank or its Affiliates.  In addition, for each Collateral Account that Borrower or any Guarantor, at any time maintains, Borrower or such Guarantor shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral Agent&#8217;s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account, which Control Agreement may not be terminated without prior written consent of Collateral Agent.  The provisions of the previous sentence shall not apply to Collateral Accounts (i) exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&#8217;s, or any of its Subsidiaries&#8217;, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates, (ii) held by Mersana Securities, or (iii) subject to a lien permitted by clauses (k), (n) and (o) of &#8220;Permitted Liens&#8221; for all such Collateral Accounts at any time ((i) through (iii) collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Excluded Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Neither Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Sections 6.6(a)&#160;and (b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;At all times Borrower shall maintain unrestricted (other than restrictions in favor of Collateral Agent and the Lenders) cash in one or more Collateral Accounts subject to Control Agreements in favor of Collateral Agent in an aggregate amount of not less than an amount equal to the lesser of (a) one hundred five percent (105.00%) of the outstanding Obligations and (b) the amount of Borrower&#8217;s and all of its Subsidiaries&#8217; (including Mersana Securities) total consolidated cash.  Bank may restrict withdrawals or transfers by or on behalf of Borrower that would violate this Section 6.6(d), regardless of whether an Event of Default exists at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7&#160;&#160;&#160;&#160;Protection of Intellectual Property Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower and each of its Subsidiaries shall&#58; (a)&#160;use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;12</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property that is material to Borrower&#8217;s business&#59; (b)&#160;promptly advise Collateral Agent in writing upon becoming aware of any material infringement by a third party of its Intellectual Property&#59; and (c)&#160;not allow any Intellectual Property material to Borrower&#8217;s business to be abandoned, forfeited or dedicated to the public without Collateral Agent&#8217;s prior written consent.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.8&#160;&#160;&#160;&#160;Litigation Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Commencing on the Effective Date and continuing through the termination of this Agreement, make available to Collateral Agent and the Lenders, at reasonable times and upon reasonable notice, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&#8217;s officers, employees and agents and Borrower&#8217;s Books, to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute or defend any third-party suit or proceeding instituted by or against Collateral Agent or any Lender, and which is with respect to any Collateral or relating to Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.9&#160;&#160;&#160;&#160;Notices of Litigation and Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower will give prompt written notice to Collateral Agent and the Lenders of any litigation or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of Two Hundred Fifty Thousand Dollars ($250,000.00) or more or which could reasonably be expected to have a Material Adverse Change.  Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in any event within three (3) Business Days) upon Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Collateral Agent and the Lenders of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.10&#160;&#160;&#160;&#160;&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.11&#160;&#160;&#160;&#160;Landlord Waivers&#59; Bailee Waivers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  In the event that Borrower or any of its Subsidiaries, after the Effective Date, intends to add any new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, in each case pursuant to Section&#160;7.2, then Borrower or such Subsidiary will provide prior written notice thereof to Collateral Agent, and, in the event that the new location is the chief executive office of the Borrower or such Subsidiary or the Collateral at any such new location is valued in excess of Three Million  Dollars ($3,000,000.00) in the aggregate and located in the United States, such bailee or landlord, as applicable, must execute and deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent prior to the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.12&#160;&#160;&#160;&#160;Creation&#47;Acquisition of Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  In the event Borrower, or any of its Subsidiaries creates or acquires any Subsidiary (including, without limitation, pursuant to a Division), Borrower shall provide prior written notice to Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably required by Collateral Agent or any Lender to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto)&#59; and Borrower (or its Subsidiary, as applicable) shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security interest in the Shares of each such newly created Subsidiary. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.13&#160;&#160;&#160;&#160;Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral Agent&#8217;s Lien in the Collateral or to effect the purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Deliver to Collateral Agent and Lenders, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to Borrower&#8217;s business or otherwise could reasonably be expected to have a Material Adverse Change.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NEGATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrower shall not, and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.1&#160;&#160;&#160;&#160;Dispositions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Convey, sell, lease, transfer, assign, or otherwise dispose of (including, without limitation, pursuant to a Division) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), or permit any of its Subsidiaries to Transfer, all or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;13</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">part of its business or property, except for Transfers (a)&#160;of Inventory in the ordinary course of business&#59; (b)&#160;of worn out, surplus or obsolete Equipment&#59; (c)&#160;in connection with Permitted Liens, Permitted Investments and&#160;Permitted Licenses&#59; (d) from any Subsidiary of Borrower to Borrower, or between or among co-Borrowers or secured Guarantors hereunder&#59; (e) of cash and Cash Equivalents in connection with transactions in the ordinary course of business that (i) are approved by Borrower&#8217;s Board of Directors (to the extent Board approval is required by Borrower&#8217;s policies or other organizational documents), (ii) are customary for the Borrower&#8217;s industry and (iii) not otherwise prohibited hereunder&#59; (f) mandated destruction of pre-clinical and clinical trial supplies&#59; and (g) other Transfers of property, other than Intellectual Property, having a book value not exceeding Five Hundred Thousand Dollars ($500,000.00) in the aggregate during any fiscal year. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.2&#160;&#160;&#160;&#160;Changes in Business, Management, Ownership, or Business Locations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (a)&#160;Engage in or permit any of its Subsidiaries to engage in any business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related or incidental thereto&#59; (b)&#160;liquidate or dissolve&#59; or (c)&#160;(i)&#160;any Key Person shall cease to be actively engaged in the management of Borrower unless written notice thereof is provided to Collateral Agent within ten (10) days of such change, or (ii)&#160;consummate any transaction or series of related transactions in which the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than forty nine percent (49%) of the voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions (other than by the sale of Borrower&#8217;s equity securities in a public offering, a private placement of public equity or to venture capital or institutional investors so long as Borrower identifies to Collateral Agent the venture capital investors or institutional investors prior to the closing of the transaction).  Borrower shall not, without at least ten (10) days&#8217; prior written notice to Collateral Agent&#58; (A)&#160;add any new offices or business locations, including warehouses, except in accordance with the provisions of Section 6.11&#59; (B) change its jurisdiction of organization, (C)&#160;change its organizational structure or type, (D) change its legal name, or (E)&#160;change any organizational number (if any) assigned by its jurisdiction of organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3&#160;&#160;&#160;&#160;Mergers or Acquisitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person (including, without limitation, pursuant to a Division). A Subsidiary may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a &#8220;co-Borrower&#8221; hereunder or has provided a secured Guaranty of Borrower&#8217;s Obligations hereunder) or with (or into) Borrower provided Borrower is the surviving legal entity, and as long as no Event of Default is occurring prior thereto or arises as a result therefrom. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4&#160;&#160;&#160;&#160;Indebtedness.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.5&#160;&#160;&#160;&#160;Encumbrance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens that are permitted by the terms of this Agreement to have priority over Collateral Agent&#8217;s Lien), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent, for the ratable benefit of the Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any of Borrower&#8217;s or such Subsidiary&#8217;s Intellectual Property, except as is otherwise permitted in Section&#160;7.1 hereof and the definition of &#8220;Permitted Liens&#8221; herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6&#160;&#160;&#160;&#160;Maintenance of Collateral Accounts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Maintain any Collateral Account except pursuant to the terms of Section&#160;6.6 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.7&#160;&#160;&#160;&#160;Distributions&#59; Investments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (a)&#160;Pay any dividends (other than (i) dividends payable solely in capital stock and (ii) dividends by any Subsidiary of Borrower to Borrower) or make any distribution or payment in respect of or redeem, retire or purchase any capital stock (other than (i) repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements, stockholder rights plans, director or consultant stock option plans, or similar plans, provided such repurchases pursuant to this clause (i) and clause (iv) below do not exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate per fiscal year, (ii) convert any of its convertible securities into other securities pursuant to the terms of such convertible securities or otherwise in exchange thereof, (iii) pay de minimis amounts of cash in lieu of fractional shares upon conversion of convertible securities or upon any stock split or consolidation, provided such cash amounts do not exceed Fifty Thousand Dollars ($50,000.00) in the aggregate per fiscal year, (iv) make purchases of capital stock or options to acquire such capital stock with the proceeds received from a substantially concurrent issuance of capital stock or convertible securities, provided such repurchases pursuant to this clause (iv) and clause (i) above exceed Two Hundred Fifty Thousand Dollars ($250,000.00) in the aggregate per fiscal year, and (v) make purchases of capital stock in connection with (1) the exercise of stock options or stock appreciation rights or (2) the satisfaction of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;14</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">withholding tax obligations&#59; in each case, by way of cashless (or, &#8220;net&#8221;) exercise) or (b)&#160;directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.8&#160;&#160;&#160;&#160;Transactions with Affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or any of its Subsidiaries, except for (a)&#160;transactions that are in the ordinary course of Borrower&#8217;s or such Subsidiary&#8217;s business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an arm&#8217;s length transaction with a non-affiliated Person, (b)&#160;Subordinated Debt or equity investments by Borrower&#8217;s investors in Borrower or its Subsidiaries, (c) reasonable and customary compensation and benefit arrangements (including the granting of options or other equity compensation arrangements) and any indemnification arrangements with employees, officers, directors or consultants entered into in the ordinary course of business and approved by Borrower&#8217;s Board of Directors to the extent required by Borrower&#8217;s organizational documents, and (d) transactions permitted by Section 7.1(d), the second sentence of Section 7.3, clause (i) of the definition of Permitted Indebtedness, and clauses (f) and (g) of the definition of Permitted Investments. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.9&#160;&#160;&#160;&#160;Subordinated Debt.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (a)&#160;Make or permit any payment on any Subordinated Debt, except under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or (b)&#160;amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof, except to the extent expressly permitted under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject, or adversely affect the subordination thereof to Obligations owed to the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.10&#160;&#160;&#160;&#160;Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Become an &#8220;investment company&#8221; or a company controlled by an &#8220;investment company&#8221;, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose&#59; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur&#59; fail to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change, or permit any of its Subsidiaries to do so&#59; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of Borrower or any of its Subsidiaries, including any such liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.11&#160;&#160;&#160;&#160;Compliance with Anti-Terrorism Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Collateral Agent hereby notifies Borrower and each of its Subsidiaries that pursuant to the requirements of Anti-Terrorism Laws, and Collateral Agent&#8217;s policies and practices, Collateral Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which information includes the name and address of Borrower and each of its Subsidiaries and their principals and such other information that will allow Collateral Agent to identify such party in accordance with Anti-Terrorism Laws.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Borrower and each of its Subsidiaries shall immediately notify Collateral Agent if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a)&#160;is convicted on, (b)&#160;pleads </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> to, (c)&#160;is indicted on, or (d)&#160;is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate to, directly or indirectly, (i)&#160;conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii)&#160;deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti-Terrorism Law, or (iii)&#160;engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">EVENTS OF DEFAULT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any one of the following shall constitute an event of default (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) under this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1&#160;&#160;&#160;&#160;Payment Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower fails to (a)&#160;make any payment of principal or interest on any Credit Extension on its due date, or (b)&#160;pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;15</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the date of acceleration pursuant to Section&#160;9.1 (a)&#160;hereof).  During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2&#160;&#160;&#160;&#160;Covenant Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.11 (Landlord Waivers&#59; Bailee Waivers), 6.12 (Creation&#47;Acquisition of Subsidiaries) or 6.13 (Further Assurances) or Borrower violates any covenant in Section&#160;7&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Borrower, or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section&#160;8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within fifteen (15) days after the occurrence thereof&#59; provided, however, that if the default cannot by its nature be cured within the fifteen (15) day period or cannot after diligent attempts by Borrower be cured within such fifteen (15) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period).  Grace periods provided under this Section&#160;shall not apply, among other things, to financial covenants or any other covenants set forth in subsection (a)&#160;above&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3&#160;&#160;&#160;&#160;Material Adverse Change.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  A Material Adverse Change occurs&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.4&#160;&#160;&#160;&#160;Attachment&#59; Levy&#59; Restraint on Business.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;(i)&#160;The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity under control of Borrower or its Subsidiaries on deposit with any Lender or any Lender&#8217;s Affiliate or any bank or other institution at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii)&#160;a notice of lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i)&#160;and (ii)&#160;hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise)&#59; provided, however, no Credit Extensions shall be made during any ten (10) day cure period&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;(i)&#160;any material portion of Borrower&#8217;s or any of its Subsidiaries&#8217; assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii)&#160;any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting any part of its business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.5&#160;&#160;&#160;&#160;Insolvency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (a)&#160;Borrower or any of its Subsidiaries is or becomes Insolvent&#59; (b)&#160;Borrower or any of its Subsidiaries begins an Insolvency Proceeding&#59; or (c)&#160;an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within forty-five (45) days (but no Credit Extensions shall be made while Borrower or any Subsidiary is Insolvent and&#47;or until any Insolvency Proceeding is dismissed)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.6&#160;&#160;&#160;&#160;Other Agreements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  There is a default in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Five Hundred Thousand Dollars ($500,000.00) or that could reasonably be expected to have a Material Adverse Change&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.7&#160;&#160;&#160;&#160;Judgments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least Five Hundred Thousand Dollars ($500,000.00) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated, or unstayed for a period of ten (10) days after the entry thereof (provided that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or decree)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8&#160;&#160;&#160;&#160;Misrepresentations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and&#47;or Lenders or to induce Collateral Agent and&#47;or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;16</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9&#160;&#160;&#160;&#160;Subordinated Debt.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  A default or breach occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of Borrower or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any terms of such agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.10&#160;&#160;&#160;&#160;Guaranty.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (a)&#160;Any Guaranty terminates or ceases for any reason to be in full force and effect&#59; (b)&#160;any Guarantor does not perform any obligation or covenant under any Guaranty&#59; (c)&#160;any circumstance described in Sections 8.3, 8.4, 8.5, 8.7, or 8.8 occurs with respect to any Guarantor, or (d)&#160;the liquidation, winding up, or termination of existence of any Guarantor&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.11&#160;&#160;&#160;&#160;Governmental Approvals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> such revocation, rescission, suspension, modification or non-renewal has resulted in or could reasonably be expected to result in a Material Adverse Change&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.12&#160;&#160;&#160;&#160;Lien Priority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens which are permitted to have priority in accordance with the terms of this Agreement&#59; provided that such circumstance is not due to Collateral Agent&#8217;s failure to file an appropriate continuation financing statement, amendment financing statement or initial financing statement&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.13&#160;&#160;&#160;&#160;Delisting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The shares of common stock of Borrower are delisted from NASDAQ Capital Market because of failure to comply with continued listing standards thereof or due to a voluntary delisting which results in such shares not being listed on any other nationally recognized stock exchange in the United States having listing standards at least as restrictive as the NASDAQ Capital Market.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">RIGHTS AND REMEDIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rights and Remedies.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Upon the occurrence and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required Lenders shall,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">without notice or demand, do any or all of the following&#58; (i)&#160;deliver notice of the Event of Default to Borrower, (ii)&#160;by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section&#160;8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii)&#160;by notice to Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders (but if an Event of Default described in Section&#160;8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Section&#160;9.1(a)&#160;above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">without notice or demand, to do any or all of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;foreclose upon and&#47;or sell or otherwise liquidate, the Collateral&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;apply to the Obligations any (a)&#160;balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or (b)&#160;any amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower&#59; and&#47;or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a)&#160;and (b)&#160;above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;17</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable, notify any Person owing Borrower money of Collateral Agent&#8217;s security interest in such funds, and verify the amount of such account&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;make any payments and do any acts it considers necessary or reasonable to protect the Collateral and&#47;or its security interest in the Collateral.  Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates.  Collateral Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral Agent&#8217;s rights or remedies&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and&#47;or advertise for sale, the Collateral.  Collateral Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower&#8217;s and each of its Subsidiaries&#8217; labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent&#8217;s exercise of its rights under this Section&#160;9.1, Borrower&#8217;s and each of its Subsidiaries&#8217; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;place a &#8220;hold&#8221; on any account maintained with Collateral Agent or the Lenders and&#47;or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;demand and receive possession of Borrower&#8217;s Books&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or any of its Subsidiaries&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;subject to clauses 9.1(a)&#160;and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;for any Letters of Credit, demand that Borrower (i)&#160;deposit cash with Bank in an amount equal to (x)&#160;if such Letters of Credit are denominated in Dollars, then one hundred five percent (105.00%)&#59; and (y)&#160;if such Letters of Credit are denominated in a Foreign Currency, then one hundred ten percent (110.00%), of the Dollar Equivalent of the aggregate face amount of all Letters of Credit remaining undrawn (plus all interest, fees, and costs due or to become due in connection therewith (as estimated by Bank in its good faith business judgment)), to secure all of the Obligations relating to such Letters of Credit, as collateral security for the repayment of any future drawings under such Letters of Credit, and Borrower shall forthwith deposit and pay such amounts, and (ii)&#160;pay in advance all letter of credit fees scheduled to be paid or payable over the remaining term of any Letters of Credit&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ix)&#160;&#160;&#160;&#160;terminate any FX&#160;Contracts.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any provision of this Section&#160;9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section&#160;9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.  As used in the immediately preceding sentence, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exigent Circumstance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any event or circumstance that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of the Collateral.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.2&#160;&#160;&#160;&#160;Power of Attorney.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney-in-fact, exercisable upon the occurrence and during the continuance of an Event of Default, to&#58; (a)&#160;endorse Borrower&#8217;s or any of its Subsidiaries&#8217; name on any checks or other forms of payment or security&#59; (b)&#160;sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any invoice or bill of lading for any Account or drafts against Account Debtors&#59; (c)&#160;settle and adjust disputes and claims about the Accounts directly with Account Debtors, for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;18</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">amounts and on terms Collateral Agent determines reasonable&#59; (d)&#160;make, settle, and adjust all claims under Borrower&#8217;s insurance policies&#59; (e)&#160;pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same&#59; and (f)&#160;transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits.  Borrower hereby appoints Collateral Agent as its lawful attorney-in-fact to sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any documents necessary to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to make Credit Extensions hereunder.  Collateral Agent&#8217;s foregoing appointment as Borrower&#8217;s or any of its Subsidiaries&#8217; attorney in fact, and all of Collateral Agent&#8217;s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and Collateral Agent&#8217;s and the Lenders&#8217; obligation to provide Credit Extensions terminates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.3&#160;&#160;&#160;&#160;Protective Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section&#160;6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders&#8217; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral.  Collateral Agent will make reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter.  No such payments by Collateral Agent are deemed an agreement to make similar payments in the future or Collateral Agent&#8217;s waiver of any Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.4&#160;&#160;&#160;&#160;Application of Payments and Proceeds.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a)&#160;Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b)&#160;the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied&#58; first, to the Lenders&#8217; Expenses&#59; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts)&#59; third, to the principal amount of the Obligations outstanding&#59; and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents.  Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct.  In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category.  Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation &#8220;ratably,&#8221; &#8220;proportionally&#8221; or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise.  Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&#8217;s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower.  Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date&#59; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent.  If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender&#8217;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders&#8217; claims.  To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis.  If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent&#8217;s security interest therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.5&#160;&#160;&#160;&#160;Liability for Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for&#58; (a)&#160;the safekeeping of the Collateral&#59; (b)&#160;any loss or damage to the Collateral&#59; (c)&#160;any diminution in the value of the Collateral&#59; or (d)&#160;any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;19</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">act or default of any carrier, warehouseman, bailee, or other Person.  Borrower bears all risk of loss, damage or destruction of the Collateral.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.6&#160;&#160;&#160;&#160;No Waiver&#59; Remedies Cumulative.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Failure by Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith.  No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given.  The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative.  Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity.  The exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent&#8217;s or any Lender&#8217;s waiver of any Event of Default is not a continuing waiver.  Collateral Agent&#8217;s or any Lender&#8217;s delay in exercising any remedy is not a waiver, election, or acquiescence.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7&#160;&#160;&#160;&#160;Demand Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NOTICES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All notices, consents, requests, approvals, demands, or other communication (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Communication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered&#58; (a)&#160;upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid&#59; (b)&#160;upon transmission, when sent by facsimile or electronic mail transmission&#59; (c)&#160;one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid&#59; or (d)&#160;when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.  Any of Collateral Agent, Lender or Borrower may change its mailing address, facsimile number, or email address by giving the other party written notice thereof in accordance with the terms of this Section&#160;10.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;20</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:77.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.948%"><tr><td style="width:1.0%"></td><td style="width:32.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Borrower&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERSANA THERAPEUTICS, INC.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840 Memorial Drive</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cambridge, MA 02139 </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Legal Department</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;**&#93; </font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WILMER CUTLER PICKERING HALE AND DORR LLP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1225 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street, Suite 2600</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denver, CO 80202</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Chalyse Robinson</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; (720) 274-3133</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; chalyse.robinson&#64;wilmerhale.com</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If to Collateral Agent&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 South Union Street&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suite 300&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandria, VA&#160; 22314</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attention&#58; Legal Department</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; &#91;**&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;**&#93;</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a copy to</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 Grove Street, Suite 2-200</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Newtown, MA 02466</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Lauren Cole</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; &#91;**&#93;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; &#91;**&#93;</font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DLA PIPER LLP (US)</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Street, NW</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington, DC 20004</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Attn&#58; Eric E. Eisenberg</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fax&#58; (202) 799-5211</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Email&#58; eric.eisenberg&#64;us.dlapiper.com </font></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York law governs the Loan Documents without regard to principles of conflicts of law.  Borrower, Lenders and Collateral Agent each submit to the exclusive jurisdiction of the State and Federal courts in the City of New York, Borough of Manhattan.  NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND THE LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL AGENT AND THE LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT&#8217;S AND THE LENDERS&#8217; RIGHTS AGAINST BORROWER OR ITS PROPERTY.  Borrower expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court.  Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section&#160;10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower&#8217;s actual receipt thereof or three (3) days after deposit in the U.S. mails, first class, registered or certified mail return receipt requested, proper postage prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, COLLATERAL AGENT, AND THE LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;21</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EACH PARTY TO ENTER INTO THIS AGREEMENT.  EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1&#160;&#160;&#160;&#160;Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> This Agreement binds and is for the benefit of the successors and permitted assigns of each party.  Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&#8217;s and each Lender&#8217;s prior written consent (which may be granted or withheld in Collateral Agent&#8217;s and each Lender&#8217;s discretion, subject to Section&#160;12.6).  The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such sale, transfer, assignment, negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or grant of a participation, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Lender Transfer&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> all or any part of, or any interest in, the Lenders&#8217; obligations, rights, and benefits under this Agreement and the other Loan Documents&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require.  Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender Transfer (other than a Lender Transfer in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency&#59; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to a Lender&#8217;s own financing or securitization transactions) shall be permitted, without Borrower&#8217;s consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.2&#160;&#160;&#160;&#160;Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) harmless against&#58;  (a)&#160;all obligations, demands, claims, and liabilities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) asserted by any other party in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by the Loan Documents&#59; and (b)&#160;all losses or Lenders&#8217; Expenses incurred, or paid by Indemnified Person in connection with&#59; related to&#59; following&#59; or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral Agent, and&#47;or the Lenders and Borrower (including reasonable and documented attorneys&#8217; fees and expenses), except for Claims and&#47;or losses directly caused by such Indemnified Person&#8217;s  gross negligence or willful misconduct.  Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the reasonable and documented fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.3&#160;&#160;&#160;&#160;Time of Essence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Time is of the essence for the performance of all Obligations in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.4&#160;&#160;&#160;&#160;Severability of Provisions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.5&#160;&#160;&#160;&#160;Correction of Loan Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Collateral Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties&#59; provided that, the Collateral Agent and the Lenders provide Borrower with at least five (5) days prior written notice of such correction.  In the event of any objection by Borrower to such correction, such correction shall be made solely by an amendment singed by Collateral Agent, Lenders and Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.6&#160;&#160;&#160;&#160;Amendments in Writing&#59; Integration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  (a)&#160;No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;22</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to any departure by Borrower or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&#8217;s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender&#8217;s written consent&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral Agent&#8217;s written consent or signature&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment)&#59; (C) change the definition of the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; or the percentage of Lenders which shall be required for the Lenders to take any action hereunder&#59; (D) release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder)&#59; (E) amend, waive or otherwise modify this Section&#160;12.6 or the definitions of the terms used in this Section&#160;12.6 insofar as the definitions affect the substance of this Section&#160;12.6&#59; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement&#59; (G) amend any of the provisions of Section&#160;9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder&#59; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations&#59; or (I)&#160;amend any of the provisions of Section&#160;12.10.  It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the provisions of the foregoing clauses (i), (ii)&#160;and (iii)&#160;are subject to the provisions of any interlender or agency agreement among the Lenders and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Other than as&#160;expressly provided for in Section&#160;12.6(a)(i)-(iii), Collateral Agent may, if requested by the Required Lenders, from time to time&#160;designate covenants in this Agreement less restrictive by notification to a representative of Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.7&#160;&#160;&#160;&#160;Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.8&#160;&#160;&#160;&#160;Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  All covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied.  Without limiting the foregoing, except as otherwise provided in Section&#160;4.1, the grant of security interest by Borrower in Section&#160;4.1 shall survive until the termination of all Bank Services Agreements.  The obligation of Borrower in Section&#160;12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section&#160;12.9 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.9&#160;&#160;&#160;&#160;Confidentiality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  In handling any confidential information of Borrower and its Subsidiaries, the Lenders and Collateral Agent shall exercise the same degree of care that it exercises for their own proprietary information, but disclosure of information may be made&#58; (a)&#160;subject to the terms and conditions of this Agreement, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;23</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">to the Lenders&#8217; and Collateral Agent&#8217;s Subsidiaries or Affiliates, or in connection with a Lender&#8217;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; (b)&#160;to prospective transferees (other than those identified in (a)&#160;above) or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Collateral Agent shall, except upon the occurrence and during the continuance of an Event of Default, obtain such prospective transferee&#8217;s or purchaser&#8217;s agreement to the terms of this provision or to similar confidentiality terms)&#59; (c)&#160;as required by law, regulation, subpoena, or other order&#59; (d)&#160;to Lenders&#8217; or Collateral Agent&#8217;s regulators or as otherwise required in connection with an examination or audit&#59; (e)&#160;as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents&#59; and (f)&#160;to third party service providers of the Lenders and&#47;or Collateral Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less restrictive than those contained herein. Confidential information does not include information that either&#58; (i)&#160;is in the public domain or in the Lenders&#8217; and&#47;or Collateral Agent&#8217;s possession when disclosed to the Lenders and&#47;or Collateral Agent, or becomes part of the public domain after disclosure to the Lenders and&#47;or Collateral Agent&#59; or (ii)&#160;is disclosed to the Lenders and&#47;or Collateral Agent by a third party, if the Lenders and&#47;or Collateral Agent does not know that the third party is prohibited from disclosing the information.  Collateral Agent and the Lenders may use confidential information for any purpose relating to the administration of this Agreement, including, without limitation, for the development of client databases, reporting purposes, and market analysis, in each case on an aggregated basis without any identifying information regarding the Borrower or its Subsidiaries.  The provisions of the immediately preceding sentence shall survive the termination of this Agreement.  The agreements provided under this Section&#160;12.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section&#160;12.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.10&#160;&#160;&#160;&#160;Public Announcement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Notwithstanding anything else herein to the contrary, Borrower hereby agrees that Collateral Agent and each Lender may, with Borrower&#8217;s consent (such consent not to be unreasonably withheld or delayed), make a public announcement of the transactions contemplated by this Agreement, and may publicize the same on its company website, in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower&#8217;s name, tradenames, logos, and any information related to the transactions to the extent such information is not confidential.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.11&#160;&#160;&#160;&#160;Right of Set Off.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including a Collateral Agent affiliate) or in transit to any of them.  At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.  ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.12&#160;&#160;&#160;&#160;Silicon Valley Bank as Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Collateral Agent hereby appoints Silicon Valley Bank (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SVB</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) as its agent (and SVB hereby accepts such appointment) for the purpose of perfecting Collateral Agent&#8217;s Liens in assets which, in accordance with Article 8 or Article 9, as applicable, of the Code can be perfected by possession or control, including without limitation, all deposit accounts maintained at SVB.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.13&#160;&#160;&#160;&#160;Cooperation of Borrower.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  If necessary, Borrower agrees to (i)&#160;execute any documents (including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section&#160;12.1, (ii)&#160;make Borrower&#8217;s management available to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions (which meetings shall be conducted during normal business hours and upon reasonable prior written no more often than twice every twelve months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request. Subject to the provisions of Section&#160;12.9, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment (other than, in the absence of the occurrence and continuance of an Event of Default, a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent), any and all information in such Lender&#8217;s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender&#8217;s credit evaluation of Borrower prior to entering into this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;24</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1&#160;&#160;&#160;&#160;Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  As used in this Agreement, the following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;account&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Account Debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;account debtor&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person&#8217;s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person&#8217;s managers and members.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, November 1, 2024&#59; provided, however, if Borrower achieves the Term C Milestone, then the Amortization Date with respect to all Term Loans shall automatically be extended to November 1, 2025.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Annual Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;6.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Anti-Terrorism Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are any laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any (i)&#160;investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business or (ii)&#160;any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (i)&#160;and that, with respect to each of the preceding clauses (i)&#160;and (ii), is administered or managed by (a)&#160;a Lender, (b)&#160;an Affiliate of a Lender or (c)&#160;a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bank Services</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are any products, credit services, and&#47;or financial accommodations previously, now, or hereafter provided to Borrower or any of its Subsidiaries by Bank or any Bank Affiliate, including, without limitation, any letters of credit, cash management services (including, without limitation, merchant services, direct deposit of payroll, business credit cards, and check cashing services), interest rate swap arrangements, and foreign exchange services as any such products or services may be identified in Bank&#8217;s various agreements related thereto (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bank Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, with respect to each Term Loan, the per annum rate of interest (based on a year of three hundred sixty (360) days) equal to the greater of (a) eight and one half of one percent (8.50%) and (b)&#160;(i) the Prime Rate on the last Business Day of the month that immediately precedes the month in which the interest will accrue, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (ii) five and one quarter of one percent (5.25%).  Notwithstanding the foregoing, the Basic Rate for the Term Loans for the period from the Effective Date through and including October 31, 2021 shall be eight and one half of one percent (8.50%).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biologics License Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an application for licensure of a biological product submitted to the FDA under 42 U.S.C. &#167; 262(k) for permission to introduce, or deliver for introduction, a biologic product into interstate commerce.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Blocked Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">is any Person&#58;  (a)&#160;listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b)&#160;a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c)&#160;a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;a Person that commits, threatens or conspires to commit or supports &#8220;terrorism&#8221; as defined in Executive Order No. 13224, or (e)&#160;a Person that is named a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221; on the most current list published by OFAC or other similar list.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Borrower&#8217;s Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are Borrower&#8217;s or any of its Subsidiaries&#8217; books and records including ledgers, federal, and state tax returns, records regarding Borrower&#8217;s or its Subsidiaries&#8217; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are (a)&#160;marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition&#59; (b)&#160;commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &#38; Poor&#8217;s Ratings Group or Moody&#8217;s Investors Service, Inc.&#59; (c)&#160;certificates of deposit maturing no more than one (1) year after issue provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent (unless such account is an Excluded Account)&#59; and (d) money market funds at least ninety-five percent (95.00%) of the assets of which constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition.  For the avoidance of doubt, the direct purchase by Borrower or any of its Subsidiaries of any Auction Rate Securities, or purchasing participations in, or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by Borrower or any of its Subsidiaries shall be conclusively determined by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this Agreement governing Permitted Investments.  Notwithstanding the foregoing, Cash Equivalents does not include and Borrower, and each of its Subsidiaries, are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">auction rate security (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Auction Rate Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are defined in Section&#160;12.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York&#59; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern&#59; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &#8220;Code&#8221; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any and all properties, rights and assets of Borrower described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, Oxford, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commodity Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;commodity account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Communication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is that certain certificate in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;26</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a)&#160;any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable&#59; (b)&#160;any obligations for undrawn letters of credit for the account of that Person&#59; and (c)&#160;all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices&#59; but &#8220;Contingent Obligation&#8221; does not include endorsements in the ordinary course of business.  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith&#59; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any control agreement entered into among the depository institution at which Borrower or any of its Subsidiaries maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities Account or a Commodity Account, Borrower and such Subsidiary, and Collateral Agent pursuant to which Collateral Agent obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any Term Loan or any other extension of credit by Collateral Agent or Lenders for Borrower&#8217;s benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.3(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;deposit account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Designated Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is Borrower&#8217;s deposit account, account number ending with &#91;**&#93; maintained with Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Disbursement Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is that certain form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Division</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, in reference to any Person which is an entity, the division of such Person into two (2) or more separate Persons, with the dividing Person either continuing or terminating its existence as part of such division, including, without limitation, as contemplated under Section 18-217 of the Delaware Limited Liability Company Act for limited liability companies formed under Delaware law, or any analogous action taken pursuant to any other applicable law with respect to any corporation, limited liability company, partnership or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollar Equivalent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, at any time, (a)&#160;with respect to any amount denominated in Dollars, such amount, and (b)&#160;with respect to any amount denominated in a Foreign Currency, the equivalent amount therefor in Dollars as determined by Bank at such time on the basis of the then-prevailing rate of exchange in San Francisco, California, for sales of the Foreign Currency for transfer to the country issuing such Foreign Currency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;$&#8221; each mean lawful money of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in the preamble hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is (i)&#160;a Lender, (ii)&#160;an Affiliate of a Lender, (iii)&#160;an Approved Fund and (iv) any commercial bank, savings and loan association or savings bank or any other entity which is an &#8220;accredited investor&#8221; (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard &#38; Poor&#8217;s Rating Group and a rating of Baa2 or higher from Moody&#8217;s Investors Service, Inc. at the date that it becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each case of clauses (i)&#160;through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition of any withholding or similar taxes&#59; provided that notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include, unless an Event of Default has occurred and is continuing, (i)&#160;Borrower or any of Borrower&#8217;s Affiliates or Subsidiaries or (ii)&#160;a direct competitor of Borrower or a vulture hedge fund, each as determined by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;27</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral Agent.  Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender&#8217;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is all &#8220;equipment&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Lender, any Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes imposed as a result of such Lender being organized under the laws of, or having its principal office or its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or that are imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such Tax (other than connections arising solely from such Lender becoming a party to this Agreement and performing its obligations and receiving payments under such Agreement). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Existing Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the indebtedness of Borrower to Silicon Valley Bank in the aggregate principal outstanding amount as of the Effective Date of approximately Five Million Two Hundred Thousand Dollars ($5,200,000) pursuant to that certain Loan and Security Agreement, dated as of May 9, 2019, entered into by and between Silicon Valley Bank and Borrower, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.5(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal Reserve Bank of New York&#8217;s Website</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the website of the Federal Reserve Bank of New York at&#160;http&#58;&#47;&#47;www.newyorkfed.org, or any successor source.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of (a)&#160;the Maturity Date, or (b)&#160;the acceleration of any Term Loan, or (c)&#160;the prepayment of a Term Loan pursuant to Section&#160;2.2(c)&#160;or (d), equal to the original principal amount of any funded Term Loan being repaid, multiplied by the Final Payment Percentage, payable to Lenders in accordance with their respective Pro Rata Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Final Payment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is four and one quarter of one percent (4.25%).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means lawful money of a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is a Subsidiary that is not an entity organized under the laws of the United States or any territory thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Funding Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FX&#160;Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any foreign exchange contract by and between Borrower and Bank under which Borrower commits to purchase from or sell to Bank a specific amount of Foreign Currency on a specified date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;28</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Intangibles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are all &#8220;general intangibles&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section 2.5(e).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governmental Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any Person providing a Guaranty in favor of Collateral Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is (a)&#160;indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b)&#160;obligations evidenced by notes, bonds, debentures or similar instruments, (c)&#160;capital lease obligations, and (d)&#160;Contingent Obligations.  Notwithstanding anything to the contrary herein and strictly for the purposes of clause (c) of the definition of Indebtedness and for no other purpose, any obligations of a Person that are or would have been treated as operating leases or capital leases for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February 25, 2016 of an Accounting Standards Update (Topic 842) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) shall continue to be accounted for as operating leases or capital leases (whether or not such operating lease obligations or capital lease obligations, as applicable, were in effect on such date) notwithstanding the fact that such obligations are required in accordance with the ASU (on a prospective or retroactive basis or otherwise) to be treated as capitalized lease obligations in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;12.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insolvency Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Insolvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means not Solvent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all of Borrower&#8217;s or any Subsidiary&#8217;s right, title and interest in and to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;its Copyrights, Trademarks and Patents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how, operating manuals&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;any and all source code&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;29</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;any and all design rights which may be available to Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is all &#8220;inventory&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of any Person&#8217;s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance, payment or capital contribution to any Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is each of Borrower&#8217;s (i)&#160;Chief Executive Officer, who is Anna Protopapas as of the Effective Date, (ii) the principal financial officer, who is Brian C. DeSchuytner as of the Effective Date, and (iii) the principal scientific officer, who is Timothy B. Lowinger, PhD as of the Effective Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any one of the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are the Persons identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> hereto and each assignee that becomes a party to this Agreement pursuant to Section&#160;12.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are all audit fees and expenses, costs, and expenses (including reasonable and documented out-of-pocket attorneys&#8217; fees and expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Collateral Agent and&#47;or the Lenders in connection with the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> is a standby or commercial letter of credit issued by Bank upon request of Borrower based upon an application, guarantee, indemnity, or similar agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are, collectively, this Agreement, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, each Loan Payment&#47;Advance Request Form and any Bank Services Agreement, the Post Closing Letter, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement&#59; all as amended, restated, or otherwise modified.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loan Payment&#47;Advance Request Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is that certain form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;B-2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is (a)&#160;a material impairment in the perfection or priority of Collateral Agent&#8217;s Lien in the Collateral or in the value of such Collateral&#59; (b)&#160;a material adverse change in the business, operations or condition (financial or otherwise) of either (i) Borrower or (ii) Borrower and its Subsidiaries, taken as a whole&#59; or (c)&#160;a material impairment of the prospect of repayment of any portion of the Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, for each Term Loan, October 1, 2026.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mersana Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Mersana Securities Corp., a corporation organized under the laws of the Commonwealth of Massachusetts and a Subsidiary of Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are all of Borrower&#8217;s obligations to pay when due any debts, principal, interest, Lenders&#8217; Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes the Lenders now or later, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;30</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents, or otherwise, including, without limitation, all obligations relating to letters of credit (including reimbursement obligations for drawn and undrawn letters of credit), cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and&#47;or Collateral Agent, and the performance of Borrower&#8217;s duties under the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OFAC Lists</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and&#47;or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are, for any Person, such Person&#8217;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#8217;s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a)&#160;if such Person is a corporation, its bylaws in current form, (b)&#160;if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c)&#160;if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">) calendar day of each calendar month, commencing on December 1, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Borrower&#8217;s Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Indebtedness existing on the Effective Date and disclosed on the Perfection Certificate(s)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Subordinated Debt&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;unsecured Indebtedness to trade creditors incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i)&#160;the aggregate outstanding principal amount of all such Indebtedness does not exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time and (ii)&#160;the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&#8217;s business&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;other unsecured Indebtedness in an aggregate amount outstanding at any time not to exceed &#91;**&#93; Dollars ($&#91;**&#93;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Indebtedness between or among co-Borrowers or secured Guarantors hereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Indebtedness consisting of Investments under clause (f) of the definition of &#8220;Permitted Investments&#8221;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Indebtedness relating to insurance premium financing arrangements, not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) outstanding at any time&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;31</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;any obligations owing with respect to corporate credit cards or merchant services in an aggregate amount outstanding at any time not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time outstanding&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;Indebtedness in respect of letters of credit, bank guarantees, bonds and similar instruments issued for the account of the Borrower or any Subsidiary in the ordinary course of business supporting obligations under (A) workers&#8217; compensation, unemployment insurance and other social security laws and (B) bids, trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and obligations of a like nature&#59; in an aggregate amount for (A) and (B) not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;Indebtedness of either Borrower and its respective Subsidiaries arising from the honoring by a bank or other financial institution of a check, draft or similar instrument in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;Indebtedness representing deferred compensation, severance, pension and health and welfare retirement benefits or the equivalent thereof to current and former employees of either Borrower or its Subsidiaries incurred in the ordinary course of business or in connection with Permitted Investments, not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) in the aggregate in any fiscal year&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a)&#160;through (n)&#160;above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower, or its Subsidiary, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Investments disclosed on the Perfection Certificate(s) and existing on the Effective Date&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;(i)&#160;Investments consisting of cash and Cash Equivalents held in Borrower&#8217;s Collateral Accounts that are maintained in accordance with Section 6.6 of this Agreement, and (ii)&#160;any other Investments permitted by Borrower&#8217;s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Investments consisting of Collateral Accounts in which Collateral Agent has a perfected security interest to the extent required by Section 6.6&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Investments in connection with Transfers permitted by Section&#160;7.1&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;Investments (i) by Borrower in Mersana Securities so long as no Event of Default has occurred and is continuing or would result from such Investments (ii) by Borrower in Subsidiaries (other than Mersana Securities) not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) in the aggregate in any fiscal year, (iii) between or among co-Borrowers or secured Guarantors hereunder, and (iv) by Subsidiaries in Borrower&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;Investments consisting of (i)&#160;travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii)&#160;loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower&#8217;s Board of Directors&#59; not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) in the aggregate for (i) and (ii) in any fiscal year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business&#59; provided that this paragraph (i) shall not apply to Investments of Borrower in any Subsidiary&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Investments in joint ventures or strategic alliances in the ordinary course of Borrower&#8217;s business consisting of the non-exclusive licensing of technology, the development of technology or the providing of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;32</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">technical support&#59; provided that any cash Investments by Borrower or its Subsidiaries for such Investments do not exceed &#91;**&#93; Dollars ($&#91;**&#93;) in the aggregate in any fiscal year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;the formation or acquisition of Subsidiaries after the Effective Date, subject to compliance with Section 6.12 of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;other Investments not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) in the aggregate in any fiscal year. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are (A) licenses of over-the-counter software that is commercially available to the public, and (B) non-exclusive and exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that, with respect to each such license described in clause (B), (i)&#160;no Event of Default has occurred or is continuing at the time of such license&#59; (ii)&#160;the license constitutes an arms-length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property&#59; (iii)&#160;in the case of any exclusive license, (x) Borrower delivers three (3) days&#8217; prior written notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral Agent and the Lenders copies of the final executed licensing documents in connection with the exclusive license promptly upon consummation thereof, and (y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United States (other than the Permitted License Transaction, which may be a worldwide exclusive license)&#59; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or any of its Subsidiaries are paid to a Deposit Account that is governed by a Control Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted License Amendment Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an amendment of that certain Commercial License and Option Agreement between Borrower and Synaffix B.V. dated as of January 3, 2019 pursuant to which Borrower licenses additional Intellectual Property from Synaffix B.V. and&#47;or its Affiliates so long as (a) such amendment is entered into within thirty (30) days of the effective date of the Permitted License Transaction, (b) no Event of Default has occurred or is continuing at the time of entering into such amendment, and (c) the aggregate amount of upfront payments paid by Borrower to Synaffix B.V. and&#47;or its Affiliates pursuant to such amendment does not exceed Ten Million Dollars ($10,000,000.00). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted License Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a collaboration and worldwide exclusive license agreement between Borrower and Johnson &#38; Johnson or its Affiliates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">J&#38;J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Borrower will apply its proprietary technology platforms to up to three (3) antibody targets identified and provided by J&#38;J and for which Borrower will receive at least Twenty Million Dollars ($20,000,000.00) in upfront cash proceeds.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; are&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Liens existing on the Effective Date and disclosed on the Perfection Certificates or  arising under this Agreement and the other Loan Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Liens for taxes, fees, assessments or other government charges or levies, either (i)&#160;not due and payable or (ii)&#160;being contested in good faith and for which Borrower maintains adequate reserves on its Books, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the Treasury Regulations adopted thereunder&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Liens securing Indebtedness permitted under clause (e)&#160;of the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,&#8221; provided that (i)&#160;such Liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20)&#160;days after the, acquisition, lease, repair, improvement or construction of, such property financed or leased by such Indebtedness and (ii)&#160;such Liens do not extend to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Liens of materialmen, mechanics, carriers, warehousemen, suppliers, landlords or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed &#91;**&#93; Dollars ($&#91;**&#93;), and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;33</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Liens to secure payment of workers&#8217; compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;leases or subleases of real property granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), and leases, subleases, non-exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent or any Lender a security interest therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;banker&#8217;s liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection with Borrower&#8217;s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section&#160;6.6&#160;hereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;Liens arising from judgments (or appeal or other surety bonds relating to such judgments), decrees or attachments in circumstances not constituting an Event of Default under Section&#160;8.4 or 8.7&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Liens consisting of Permitted Licenses&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Liens in favor of customs and revenue authorities in the ordinary course of business, to secure payment of customs duties in connection with the importation of goods&#59; provided, however, the aggregate amount of such payments so secured at any given time shall not exceed &#91;**&#93; Dollars ($&#91;**&#93;) and such Liens shall be restricted to the goods imported in connection with which such payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;deposits to secure the performance of leases entered into in the ordinary course of business and not representing an obligation for borrowed money so long as (i) each such deposit is made at the commencement of a lease or its renewal when there is no underlying default under such lease and (ii) the aggregate amount of all such outstanding deposits does not exceed &#91;**&#93; Dollars ($&#91;**&#93;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)&#160;&#160;&#160;&#160;easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and other similar Liens affecting Borrower&#8217;s owned real property not interfering in any material respect with the ordinary course of Borrower&#8217;s business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)&#160;&#160;&#160;&#160;Liens granted in the ordinary course of business in connection with the financing of insurance premiums securing Indebtedness permitted by clause (j) of the definition of &#8220;Permitted Indebtedness&#8221; and not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)&#160;&#160;&#160;&#160;Liens solely on cash collateral pledged to secure Indebtedness in respect of corporate credit cards permitted pursuant to clause (k) of the definition of &#8220;Permitted Indebtedness&#8221; and not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(o)&#160;&#160;&#160;&#160;deposits to secure Indebtedness permitted by clause (l) of the definition of &#8220;Permitted Indebtedness&#8221; and not to exceed &#91;**&#93; Dollars ($&#91;**&#93;) at any time&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(p)&#160;&#160;&#160;&#160;Liens incurred in the extension, renewal or refinancing of the Indebtedness secured by Liens described in (a) through (o), but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness may not increase.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Post Closing Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is that certain Post Closing Letter dated as of the Effective Date by and between Collateral Agent and Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prepayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;34</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;for a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term Loan, three percent (3.00%) of the principal amount of such Term Loan prepaid&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the second anniversary of the Funding Date of such Term Loan, two percent (2.00%) of the principal amount of the Term Loans prepaid&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan and prior to the Maturity Date, one percent (1.00%) of the principal amount of the Term Loans prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the rate of interest per annum from time to time published in the money rates section of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> or any successor publication thereto as the &#8220;prime rate&#8221; then in effect&#59; provided that if such rate of interest, as set forth from time to time in the money rates section of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">The Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, becomes unavailable for any reason as determined by Collateral Agent, the &#8220;Prime Rate&#8221; shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal amount of all Term Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registered Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;registered organization&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8220;Relevant Governmental Body&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">means the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York or any successor thereto.&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reporting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date of the next Compliance Certificate is delivered or required to delivered pursuant to Section 6.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) have not assigned or transferred any of their interests in their Term Loan, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loan, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loan, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance of the Term Loan and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion of its Term Loan, (B) each assignee or transferee of an Original Lender&#8217;s interest in the Term Loan, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C) any Person providing financing to any Person described in clauses (A) and (B) above&#59; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to such financing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Requirement of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any of the President, Chief Executive Officer, Treasurer or principal financial officer of Borrower acting alone.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Secured Promissory Note Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender and credits made thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is any &#8220;securities account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;35</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower or Borrower&#8217;s Subsidiary, in any Subsidiary. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, with respect to any Person&#58; the fair salable value of such Person&#8217;s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of such Person&#8217;s liabilities&#59; such Person is not left with unreasonably small capital after the transactions in this Agreement&#59; and such Person is able to pay its debts (including trade debts) as they mature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subordinated Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and&#47;or its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between Collateral Agent, Borrower, and&#47;or any of its Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent and the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term A Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the period commencing on the Effective Date and ending on the earlier of (i)&#160;December 31, 2022 and (ii)&#160;the occurrence of an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the period commencing on the date of the occurrence of the Term B Milestone and ending on the earliest of (i)&#160;the date that is ninety (90) days after the occurrence of the Term B Milestone, (ii) December 31, 2022 and (iii)&#160;the occurrence of an Event of Default&#59; provided, however, that the Term B Draw Period shall not commence if on the date of the occurrence of the Term B Milestone an Event of Default has occurred and is continuing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term B Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Borrower&#8217;s delivery to Collateral Agent and Lenders of evidence, satisfactory to Collateral Agent and Lenders in their reasonable discretion, that Borrower has &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is the period commencing on the date of the occurrence of the Term C Milestone and ending on the earliest of (i)&#160;the date that is ninety (90) days after the occurrence of the Term C Milestone, (ii) June 30, 2023 and (iii)&#160;the occurrence of an Event of Default&#59; provided, however, that the Term C Draw Period shall not commence if on the date of the occurrence of the Term C Milestone an Event of Default has occurred and is continuing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term C Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means Borrower&#8217;s delivery to Collateral Agent and Lenders of evidence, satisfactory to Collateral Agent and Lenders in their sole but reasonable discretion, that Borrower &#91;**&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.2(a)(iv)&#160;hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.2(a)(i) hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.2(a)(ii)&#160;hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.2(a)(iii)&#160;hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;D Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;2.2(a)(iv)&#160;hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule&#160;1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the aggregate amount of such commitments of all Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; is defined in Section&#160;7.1.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;36</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i184a70b5647542429a0a947fe963dd54_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, the parties hereto have caused this Agreement to be executed as of the Effective Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERSANA THERAPEUTICS, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Brian DeSchuytner&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Brian DeSchuytner&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">   Chief Financial Officer&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">COLLATERAL AGENT AND LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">  &#47;s&#47; Colette H. Featherly&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Colette H. Featherly&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Senior Vice President&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> &#47;s&#47; Lauren Cole&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Lauren Cole&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> Director&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:76.32pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Loan and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i184a70b5647542429a0a947fe963dd54_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SCHEDULE&#160;1.1<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Lenders and Commitments</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term&#160;A Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$60,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term B Loans</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$10,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term C Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$10,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr><tr style="height:13pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.37pt;padding-right:1.37pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate (all Term Loans)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lender</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Term Loan Commitment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SILICON VALLEY BANK</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000,000.00</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$80,000,000.00</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00%</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>3
<FILENAME>exhibit101510kfy2021.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i19fa76fd6320467dbe22d0f095a77383_1"></div><div style="min-height:92.16pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.15</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONFIDENTIAL</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTION COPY</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED COMMERCIAL LICENSE AND OPTION AGREEMENT<br><br><br>BETWEEN<br><br><br>SYNAFFIX B.V.<br><br><br>AND<br><br><br>MERSANA THERAPEUTICS, INC.<br><br><br>DATED AS OF JANUARY 3, 2019, </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AS AMENDED AND RESTATED ON 22 NOVEMBER 2021</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i19fa76fd6320467dbe22d0f095a77383_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 1 DEFINITIONS&#160;&#160;&#160;&#160;1</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 2 LICENSES, SUPPLY AND TECHNOLOGY TRANSFER&#160;&#160;&#160;&#160;14</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Non-Exclusive License and Research License&#160;&#160;&#160;&#160;14</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Option Right and Non-Exclusive License for Additional Targets&#160;&#160;&#160;&#160;15</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93; Products.&#160;&#160;&#160;&#160;18</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sublicenses&#160;&#160;&#160;&#160;19</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Manufacturing&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Supply Agreement&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tech Transfer&#160;&#160;&#160;&#160;20</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Contract Manufacturing&#160;&#160;&#160;&#160;22</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Target Substitution.&#160;&#160;&#160;&#160;22</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agent&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Other Rights&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Bankruptcy&#160;&#160;&#160;&#160;24</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 3 PAYMENTS&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Initial Target License Issuance Fee&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Additional Target License Issuance Fee&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amendment Fee.&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Development Milestone Payments&#160;&#160;&#160;&#160;25</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sales Milestone Payments&#160;&#160;&#160;&#160;27</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment of Royalties&#160;&#160;&#160;&#160;29</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Payment Method&#160;&#160;&#160;&#160;30</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Currency Conversion&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Late Payment Interest&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Records&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taxes&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Audit Rights&#160;&#160;&#160;&#160;31</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 4 PRODUCT ACTIVITIES&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Diligence&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Annual Reports&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responsibilities&#160;&#160;&#160;&#160;32</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regulatory Matters&#160;&#160;&#160;&#160;33</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 5 INTELLECTUAL PROPERTY&#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ownership of Remodeled Antibodies&#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Improvements&#160;&#160;&#160;&#160;34</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Other Intellectual Property&#160;&#160;&#160;&#160;35</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patent Maintenance and Prosecution&#160;&#160;&#160;&#160;35</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patent Term Extensions&#160;&#160;&#160;&#160;35</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Licensed Patents and Licensed Know-How Enforcement and Defense&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Defense of Infringement Claims of Licensed Technology&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cooperation&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 6 CONFIDENTIALITY&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidentiality Obligations&#160;&#160;&#160;&#160;36</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permitted Usage&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Terms of Agreement&#160;&#160;&#160;&#160;37</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Permitted Publications&#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Public Announcements&#160;&#160;&#160;&#160;38</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 7 REPRESENTATIONS, WARRANTIES AND COVENANTS&#160;&#160;&#160;&#160;39</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">General&#160;&#160;&#160;&#160;39</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representations and Covenants of MERSANA&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representations of SNFX&#160;&#160;&#160;&#160;40</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Covenants of SNFX&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">DISCLAIMER&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 8 INDEMNIFICATION&#59; INSURANCE&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification by MERSANA&#160;&#160;&#160;&#160;41</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Indemnification by SNFX&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Procedure&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Insurance&#160;&#160;&#160;&#160;42</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 9 LIMITATION OF LIABILITY&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LIMITATION&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 10 TERM AND TERMINATION&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Term&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Termination&#160;&#160;&#160;&#160;43</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effect of Expiration or Termination&#160;&#160;&#160;&#160;44</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE 11 GENERAL PROVISIONS&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Entire Agreement&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Modification&#59; Waiver&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Further Assurances&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Force Majeure&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Assignments&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance by Affiliates&#160;&#160;&#160;&#160;46</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Relationship of the Parties&#160;&#160;&#160;&#160;47</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Third Party Beneficiaries&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">No Use of Names&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notices&#160;&#160;&#160;&#160;47</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dispute Resolution&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Submission to Court for Resolution&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Governing Law&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Headings&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Severability&#160;&#160;&#160;&#160;48</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equitable Relief&#160;&#160;&#160;&#160;49</font></div><div style="margin-bottom:6pt;padding-left:72pt;padding-right:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.17.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Counterparts&#160;&#160;&#160;&#160;49</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AMENDED AND RESTATED COMMERCIAL LICENSE AND OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Amended and Restated Commercial License and Option Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CLOA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is effective as of November 22, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between Synaffix B.V., with an office at Pivot Park Oss, Noord-Brabant, Kloosterstraat 9, 5349 AB, Oss, The Netherlands (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SNFX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Mersana Therapeutics, Inc., with an office at 840 Memorial Drive, Cambridge, Massachusetts 02139, USA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MERSANA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  SNFX and MERSANA are each referred to herein by name or, individually, as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or, collectively, as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; This CLOA amends and restates in its entirety that certain Commercial License and Option Agreement, dated as of January 3, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between the Parties (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to Section 11.2 thereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">BACKGROUND</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> SNFX Controls (as defined below) the Licensed Technology (as defined below)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, SNFX desires to grant to MERSANA a non-exclusive license, and MERSANA desires to receive from SNFX a non-exclusive license, to the Licensed Technology to Develop, Manufacture, Commercialize and otherwise Exploit Products against Licensed Targets (each as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, SNFX granted such non-exclusive license to MERSANA in accordance with, and pursuant to, the terms and conditions of the Original Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Parties wish to amend and restate the Original Agreement as set forth in this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in consideration of the foregoing and the mutual covenants and agreements provided herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, SNFX and MERSANA hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 1<br>DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As used in this CLOA, capitalized terms shall have the meanings indicated in this Article 1 or as specified elsewhere in this CLOA&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Target Substitution Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(b). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Target Substitution Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party, any Person that, directly or indirectly, through one (1) or more intermediaries, controls, is controlled by, or is under common control with such Party.  For purposes of this Section 1.1, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) the direct or indirect ownership of fifty percent (50%) or more of the voting securities entitled to elect the directors or management of the entity, or (b) the ability to otherwise control the management thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party escrow agent appointed by SNFX from time to time who shall confidentially maintain a list of Unavailable Targets.  On the Effective Date, the Agent is Prof. Jean-Paul Vulli&#233;ty, Partner at Lalive Avocats, 35, Rue de la Mairie, P.O. Box 6569, 1211Geneva 6, Switzerland, having an email address at jpvulliety&#64;lalive.law. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agent Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Antibody</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Antibody-Drug Conjugates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ADC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a biopharmaceutical molecule for targeted therapy, consisting of either &#91;**&#93; and in each case ((i) and (ii)) is linked, via chemical linker(s), to one or more molecules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.12.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a day on which national banks located in the Commonwealth of Massachusetts and the Netherlands are open for commercial banking business other than a Saturday or Sunday.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Calendar Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a three (3) month period beginning on January 1, April 1, July 1 or October 1 of any Calendar Year, except that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last Calendar Quarter of the Term shall end upon the expiration or termination of this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Calendar Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) for the first Calendar Year, the period commencing on the Effective Date and ending on December 31 of the year during which the Effective Date occurs, (b) for the last Calendar Year, the period commencing on January 1 of the last year of the Term, and ending on the last day of the Term, and (c) each interim period of twelve (12) months commencing on January 1 and ending on December 31.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a clinical investigation in human subjects that has been approved by a Regulatory Authority and is intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of a Product, or to identify any adverse reactions to a Product, or to study absorption, distribution, metabolism, or excretion of a Product with the objective of ascertaining its safety, activity or efficacy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities of marketing, promoting, distributing, offering for sale or selling a Product in the Field in the Territory, including, for example, marketing, branding, pricing, distribution, sales, obtaining health insurance reimbursement coverage, market research, business analytics, pharmacovigilance and medical affairs activities, pre-commercial launch market development activities conducted in anticipation of Regulatory Approval to sell or market the Product, seeking Pricing Approval for the Product (if applicable), preparing advertising and promotional materials, sales force training, and all interactions and correspondence with a Regulatory Authority regarding Clinical Trials commenced following Regulatory Approval.  When used as a verb, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to engage in Commercialization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) with respect to the efforts to be expended by a Party with respect to any objective other than Developing, Manufacturing, Commercializing or otherwise Exploiting a Product, such reasonable, diligent, and good faith efforts as such Party would normally use to accomplish a similar objective under similar circumstances&#59; and (b) with respect to any objective relating to Developing, Manufacturing, Commercializing or otherwise Exploiting a Product by a Party, that level of efforts and resources </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that such Party would normally devote to the performance of such activities for a product owned by it, which is of a similar commercial potential at a similar stage in its lifecycle, in each case taking into account issues of safety and efficacy, product profile, the proprietary position, the then-current competitive environment for such product and the likely timing of such product&#8217;s entry into the market, the pricing and launching strategy for such product, the regulatory environment and status of such product, and any other relevant factors, including other scientific, technical and commercial factors. For clarity, Commercially Reasonable Efforts will not mean that a Party guarantees that it will actually accomplish the applicable task or objective.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all information, including technical, scientific and other information, Know-How, invention disclosures, patent applications, trade secrets, knowledge, technology, means, methods, processes, practices, proprietary materials, formulas, instructions, skills, techniques, procedures, specifications, data, results and other material, pre-clinical and clinical trial results, and any tangible embodiments of any of the foregoing, and any scientific, manufacturing, marketing and business plans, any financial and personnel matters relating to a Party or its present or future products, sales, suppliers, customers, employees, investors or business, that has been disclosed by or on behalf of such Party or such Party&#8217;s Affiliates to the other Party or the other Party&#8217;s Affiliates, in any manner, whether orally, visually, or in tangible form, either in connection with the discussions and negotiations pertaining to this CLOA or in the course of performing this CLOA. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to any information, material or Intellectual Property Right not in the public domain, possession of the right, whether directly or indirectly, by a Party or its Affiliates, of the ability, whether by sole or joint ownership, license or otherwise (other than by operation of the licenses and other grants in this CLOA) to grant the right to access or use, or to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such information, material or Intellectual Property Right, as applicable, without violating the terms of any agreement or other arrangement with any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cover</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covered</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Patent in a country, that the Development, Manufacture or Commercialization of a Product in such country would, but for the ownership of or grant of a license to such Patent, infringe a Valid Claim of such Patent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means to discover, research or otherwise develop a process, compound or product, including conducting non-clinical, pre-clinical and clinical research and development activities, including toxicology, pharmacology and other pre-clinical development efforts, test method development and stability testing, process development, formulation development, delivery system development, quality assurance and quality control development, process and manufacturing scale-up and other manufacturing activities related to developing a product, statistical analysis, clinical pharmacology, clinical studies (including Clinical Trials and pre-approval studies), regulatory affairs, and Regulatory Approval and clinical study regulatory activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EMA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the European Medicines Agency and any successor agency thereto.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all countries that are officially recognized as member states of the European Union as of the Effective Date (which shall for the purposes of this CLOA include the United Kingdom even after it has ceased to be a member of the EU), Norway, Switzerland and all countries that are officially added into and recognized as member states of the European Union after the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean for SNFX, the Chief Executive Officer of SNFX (or such individual&#8217;s designee), and, for MERSANA, the Chief Executive Officer of MERSANA (or such individual&#8217;s designee).  If either position is vacant or either position does not exist, then the individual having the most nearly equivalent position (or such individual&#8217;s designee) shall be deemed to be the Executive Officer of the relevant Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exploit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means make, have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FD&#38;C Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;301, et seq.), as amended, together with any rules, regulations and requirements promulgated thereunder (including any amendments, additions, supplements, extensions and modifications thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.27&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.28&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the therapeutic use of antibody-drug conjugates in all human conditions, diseases and disorders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.29&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Target Verification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.30&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product in any country in the Territory, the first sale of such Product by MERSANA or its Affiliates or Sublicensees to a Third Party in such country for which monetary value has been received following, if required by Law to sell such Product, Regulatory Approval and Pricing Approval, but excluding the sale of any Product for use in any Clinical Trial or for compassionate, named patient (paid or unpaid) use.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.31&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Clinical Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the then-current standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory Authorities or Law in the relevant jurisdiction.  In the United States, GCP shall be based on Good Clinical Practices established through FDA guidances (including Guideline for Good Clinical Practice &#8211; ICH Harmonized Tripartite Guideline (ICH E6)), and, outside the United States, GCP shall be based on Guideline for Good Clinical Practice &#8211; ICH Harmonized Tripartite Guideline (ICH E6), as each may be amended or updated from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.32&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Laboratory Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the United States), as may be amended or updated from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.33&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Manufacturing Practices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all applicable then-current standards relating to manufacturing practices for fine chemicals, intermediates, bulk products or finished pharmaceutical products, including (a) all applicable requirements detailed in the FDA&#8217;s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211 and &#8220;The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products,&#8221; as each may be amended or updated from time to time, and (b) all applicable Laws promulgated by any Regulatory Authority having jurisdiction over the manufacture of any Product, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.34&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any regional, central, multi- or supra-national, federal, state, provincial, municipal or local court, commission, council or governmental, regulatory or administrative body, board, bureau, branch, agency, instrumentality, authority or tribunal, division or any subdivision thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.35&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any discovery, invention, idea, contribution, method, finding, trade secret, or improvement, whether or not patentable, and all intellectual property therein, that is conceived, reduced to practice, or otherwise Developed by or on behalf of a Party or its Affiliates, in the course of Developing or Manufacturing a Product for a Licensed Target under this CLOA and the Supply Agreement, that is, subject to Section 5.2, a modification, improvement, alteration or enhancement to the Licensed Technology or MERSANA Technology, as applicable. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.36&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">IND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) in the United States, an Investigational New Drug Application, as defined in the FD&#38;C Act, filed with the FDA that is required to be filed with the FDA before conducting a Clinical Trial (including all supplements and amendments that may be filed with respect to the foregoing), and (b) any foreign counterpart of the foregoing (such as a Clinical Trial Application in the EU).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.37&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the first Target selected by MERSANA as of the Effective Date, identified as SLC34A2, with a common name of Sodium-dependent phosphate transport protein 2B, and with a UniProtKB&#47;Swiss-Prot number of O95436.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.38&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.39&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target Substitution Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.40&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target Substitution Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.9(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.41&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Patents, copyrights, database rights, Know-How, and similar rights of any type (excluding trademarks) under the Laws of any Governmental Entity, including all applications, registrations, extensions and renewals relating to any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.42&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.2(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.43&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Improvement Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Patent that claims or discloses any discovery, invention, idea, contribution, method, finding, trade secret or improvement included in a Joint Improvement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.44&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all technical information and other technical subject matter, proprietary methods, ideas, concepts, formulations, discoveries, inventions, devices, technology, trade secrets, compositions, designs, formulae, know-how, show-how, specifications, drawings, techniques, results, data, processes, methods, procedures, designs and regulatory correspondence and information (including pharmacological, toxicological, pre-clinical, clinical and manufacturing test data, manufacturing protocols, analytical methods and data, quality control data and process validation), whether or not patentable, including any tangible embodiments of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.45&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Party or its Affiliates, the good faith understanding of the facts and information in possession of an executive officer of, or in-house legal counsel of, or in-house patent agents employed by, such Party or its Affiliates after (a) inquiry of in-house employees with relevant knowledge and outside legal counsel and (b) reasonable investigation of the relevant internal records of a Party. For purposes of this definition, an &#8220;executive officer&#8221; shall mean any person in the position of vice president, senior vice president, president or chief executive officer of a Party or any of its Affiliates.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.46&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, individually and collectively, any and all laws, statues, ordinances, orders, rules, rulings, directives and regulations (including written governmental interpretations thereof, the guidance related thereto, or the application thereof) of any kind whatsoever of any Governmental Entity or Regulatory Authority, and any judicial, governmental, or administrative order, judgement, decree, or ruling, within the applicable jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.47&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.48&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each of the license fees referred to in Sections 3.1 and 3.2 hereof, and &#8220;License Fees&#8221; means all such license fees collectively.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.49&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all Know-How, including the Know-How listed on Schedule 2 hereof, but only to the extent (a) Controlled by SNFX or any of its Affiliates as of the Effective Date or at any time during the Term, and (b) reasonably necessary or useful to Develop, Manufacture, Commercialize or otherwise Exploit an antibody-drug conjugate obtained by &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.50&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means those Patents Controlled by SNFX or any of its Affiliates as of the Effective Date or at any time during the Term, including those Patents listed in Schedule 1 attached hereto, that are reasonably necessary or useful to Develop, Manufacture, Commercialize or otherwise Exploit an antibody-drug conjugate obtained by &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.51&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.52&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Licensed Know-How and the Licensed Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.53&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.54&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.55&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Major Market Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each of &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.56&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all operations necessary or appropriate to make, test, release, package, store, label, supply and ship a Product, in accordance with applicable packaging, controls, industry standards, GMPs, applicable Laws, and the Product&#8217;s specifications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.57&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Processes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.58&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.59&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Material Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MTA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Materials Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by and between the Parties with an effective date of November 17, 2017, as amended by that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Materials Transfer Agreement Amendment #1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> dated as of August 22, 2018, and as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">further amended by that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Materials Transfer Agreement Amendment #2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> dated as of December 30, 2018, that are attached to this CLOA as Exhibit A through Exhibit C, respectively. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.60&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MERSANA Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.61&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MERSANA Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means MERSANA&#8217;s proprietary technology used for the creation, identification, Development, Manufacture, Commercialization or other Exploitation of antibody-drug conjugates, including, but not limited to, linkers and payloads. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.62&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Mutual Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Mutual Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by and between the Parties with an effective date of October 14, 2015, as amended by that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Confidential Disclosure Agreement Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with an effective date of October 13, 2018.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.63&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Drug Application,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; as defined in the FD&#38;C Act and applicable regulations promulgated thereunder by the FDA and all amendments and supplements thereto filed with the FDA, or the equivalent application filed with any Regulatory Authority, including all documents, data, and other information concerning Product, which are necessary for gaining Regulatory Approval to market and sell Product in the relevant jurisdiction. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.64&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the gross amounts invoiced for a Product by MERSANA, its Affiliates and their respective Sublicensees for sales or other disposition of such Product to a Third Party purchaser, less the following to the extent that the following are directly incurred with respect to a Product, or allocated specifically to a Product in accordance with generally accepted accounting principles consistently applied across the books and records of MERSANA, its Affiliates and their respective Sublicensees, as applicable&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">  </font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">customer, trade, quantity and cash discounts actually allowed with respect to such sales which effectively reduce the selling price and are appropriately deducted from sales under appropriate accounting principles, consistently applied&#59; <br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">rejected goods, damaged or defective goods, recalls, returns, rebates, field destroys, reimbursements, chargebacks and other allowances actually allowed with respect to such sales&#59;<br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">retroactive price reductions that are actually allowed or granted&#59;<br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">deductions to the gross invoice price of Product imposed by Regulatory Authorities or other Governmental Entities&#59; </font></div><div><font><br></font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sales (such as VAT or its equivalent) and excise taxes, other consumption taxes, and customs duties (excluding any taxes paid on the income from such sales) to the extent the selling Person is not otherwise entitled to a credit or a refund for such taxes or duties&#59;<br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a reasonable reserve for non-collectable receivables related to Product (provided that, such amounts shall not exceed two percent (2%) of Net Sales in a given Calendar Year and that if such amounts are later collected, they shall be included in Net Sales in the Calendar Quarter of collection)&#59; and </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">charges for packing, freight, shipping and insurance (to the extent separately stated on the invoice).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent that MERSANA, its Affiliates and its Sublicensees receive consideration other than or in addition to cash upon the sale or disposition of a Product to a Third Party </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchaser, Net Sales for such Product shall be calculated based on the average price of such Product sold for cash during the period based on the quantity of Product sold. The Parties agree that such price, less any cash consideration received with respect to a Product, reflects the fair market value of any non-cash consideration received with respect to such Product. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any Products for which no monetary consideration is received that are used for promotional or advertising purposes, used for free samples, or otherwise distributed to patients unable to purchase the same (including patients in Clinical Trials or compassionate use programs) shall not be included in Net Sales. Donations for charity reasons (to avoid doubt, for which no monetary consideration is received) shall also not be included in Net Sales.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any Product is sold as part of a Combination Product (as defined below), the Net Sales for such Product shall be determined by multiplying the applicable Net Sales of the Product (as determined without the application of this paragraph) by the fraction, A&#47;(A+B), where A is the average per unit sale price of the Product component of the Combination Product when sold separately as a stand-alone product in finished form in the country in which the Combination Product is sold and B is the average per unit sale of the other active ingredients contained in the Combination Product when sold separately as stand-alone products in finished form in the country in which the Combination Product is sold, in each case during the applicable royalty reporting period in accordance with Section 3.6(b) or, if sales of such stand-alone products did not occur in such country in the applicable period, then in the most recent royalty reporting period in which such sales of such stand-alone products occurred in such country. If such average sale prices cannot be determined, Net Sales shall be mutually agreed upon by the Parties based on the relative fair market value of each component, such agreement not to be unreasonably withheld. As used herein, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any pharmaceutical product that consists of a Product as well as one or more other active therapeutic ingredients, other than an active therapeutic ingredient conjugated to such Product. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.65&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.66&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.67&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.2(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.68&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.69&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(5).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.70&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.71&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all national, regional and international&#58; (a) patents and pending patent applications (including provisional patent applications)&#59; (b) patent applications filed from the foregoing or from an application claiming priority to the foregoing, including all provisional applications, converted provisionals, continuations, continuations-in-part, continued prosecution, divisional and substitute applications, renewals, continued prosecution applications and all patents granted thereon&#59; (c) patents-of-addition, revalidations, reissues, reexaminations and extensions or restorations (including any supplementary protection certificates and the like) by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof&#59; (d) inventor&#8217;s certificates, utility models, petty patents, innovation patents and design patents&#59; (e) other forms of government-issued rights substantially similar to any of the foregoing, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing&#59; and (f) United States and foreign counterparts of any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.72&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any individual, corporation, partnership, association, joint-stock company, trust, unincorporated organization or government or political subdivision thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.73&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 1 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) both a Phase 1a Trial and a Phase 1b Trial, or (b) a single trial that may contain elements of both a Phase 1a Trial and a Phase 1b Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 1a Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a compound, the principal purpose of which is a preliminary determination of safety, pharmacokinetics, and pharmacodynamic parameters in healthy individuals or patients, as described in 21 C.F.R. 312.21(a), or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 1b Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a compound, the principal purpose of which is a further determination of safety and pharmacokinetics (including exploration of trends of a biomarker-based or clinical endpoint-based efficacy relationship to dose which are not designed to be statistically significant) of the compound whether or not in combination with concomitant treatment after an initial Phase 1a Clinical Trial, prior to commencement of Phase 2 Trials or Phase 3 Trials, and which provides (itself or together with other available data) sufficient evidence of safety to be included in filings for a Phase 2 Trial or a Phase 3 Trial with Regulatory Authorities, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.74&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 2 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a product in any country that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate evidence of clinical safety and effectiveness for a particular indication or indications in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.75&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Phase 3 Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a product in any country that would satisfy the requirements of U.S. 21 C.F.R. Part 312.21(c) and is intended to (a) establish that the product is safe and efficacious for its intended use, (b) define contraindications, warnings, precautions and adverse reactions that are associated with the product in the dosage range to be prescribed, and (c) support Regulatory Approval for such product, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.76&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pivotal Clinical Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Clinical Trial of a product on a sufficient number of subjects that, prior to commencement of the trial, satisfies both of the following ((a) and (b))&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such trial is designed to establish that such product has an acceptable safety and efficacy profile for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support Regulatory Approval of such product, or a similar clinical study prescribed by the FDA, EMA or other applicable Regulatory Authority&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">such trial is a registration trial sufficient for filing an application for a Regulatory Approval for such product in the U.S. or another country or some or all of an extra-national territory, as evidenced by (i) an agreement with or statement from the FDA, the EMA or other applicable Regulatory Authority on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA, EMA or other applicable Regulatory Authority, for such registration trial. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.77&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#8220;Preferentially Binds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, &#91;**&#93;. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.78&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pricing Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, in a country where a Governmental Entity authorizes reimbursement for, or approves or determines pricing for, biopharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.79&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any product comprising or consisting of an ADC that Preferentially Binds a Licensed Target that uses or incorporates MERSANA Technology and (a) which uses or comprises the Licensed Technology&#59; or (b) which is Covered by any Valid Claim of the Licensed Patents. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.80&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prosecute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to Patents, the filing for, prosecuting, responding to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings (including conducting or participating in interference and oppositions) filed by Third Parties against, and maintaining, Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.81&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a country or jurisdiction within the Territory, final regulatory approval (excluding Pricing Approval) required for the Manufacture and Commercialization of a Product for a disease or condition in accordance with the Laws of such country or jurisdiction. In the United States, its territories and possessions, Regulatory Approval means approval of a NDA, Biologics License Application or an equivalent by the FDA. In the EU, Regulatory Approval means marketing authorization from the EMA.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.82&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any national (e.g., the FDA), supranational (e.g., the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Entity in any jurisdiction of the world involved in the granting of Regulatory Approval or Pricing Approval for biopharmaceutical products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.83&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Documentation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means all submissions to Regulatory Authorities and other Governmental Entities, including for Clinical Trials, preclinical trials, tests, and biostudies, relating to a Product, including all INDs, NDAs, Biologics License Application, Regulatory Approvals and Pricing Approvals, as well as all correspondence with Governmental Entities (registration and licenses, pricing and reimbursement correspondence, regulatory drug lists, advertising and promotion documents), adverse event files, complaint files, Manufacturing records and inspection reports.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.84&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Party&#8217;s Affiliates and its and their officers, directors, employees, contractors, agents (including internal and external legal counsel and accountants) and advisors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.85&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(7).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.86&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(5).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.87&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(7).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.88&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(7).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.89&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, on a Product-by-Product and country-by-country basis, the period beginning on the First Commercial Sale of such Product in such country and ending on the expiration, cessation of enforceability or abandonment of the last Valid Claim in all Licensed Patents that Cover such Product in such country.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.90&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.5.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.91&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.92&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.93&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Third Party to whom MERSANA or its Affiliate enters into a Sublicense Agreement hereunder to Develop, Manufacture, Commercialize, or otherwise Exploit a Product, but excluding wholesalers and other physical distributors.  For the avoidance of doubt, if MERSANA sells to a wholesaler or other physical distributor, such sale to such wholesaler or distributor shall be deemed a sale for purposes of calculating Net Sales hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.94&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.95&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.96&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.97&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SNFX Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.98&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the supply agreement to be negotiated and agreed upon between the Parties, the key terms of which are attached as Schedule 3 hereto. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.99&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (a) a specific protein as defined by its UniProtKB&#47;Swiss-Prot number (including any glyco or lipoprotein or carbohydrate), and any unique fragment, peptide, epitope or isoform thereof, and any naturally occurring allelic variant or splice variants thereof, that are encoded by the same gene (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Antigen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or (b) &#91;**&#93;.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.100&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Approval Request Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.2(b)(1).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.101&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tech Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.102&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.103&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.2(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.104&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 2.4(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.105&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.106&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Three-way Mutual Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">3-Way Mutual Non-Disclosure Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> by and between the Parties and Me Jean-Paul Vulliety (escrow agent) with an effective date of August 2, 2018, as amended by that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Confidential Disclosure Agreement Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with an effective date of November 29, 2018 and that certain </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Confidential Disclosure Agreement Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> with an effective date of January 31, 2019, that are attached to this CLOA as Exhibit D and Exhibit E, respectively, and that the Parties intend shall be further amended within &#91;**&#93; of the Amendment Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.107&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any Person other than SNFX, MERSANA or any Affiliate of either SNFX or MERSANA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.108&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Unavailable Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Target &#91;**&#93; any Target for which (a) SNFX or any of its Affiliates has granted an exclusive license or an exclusive option to a license, that in either case has not expired or terminated, to a Third Party to Develop, Manufacture, Commercialize and otherwise Exploit a product (i) against the Target, or (ii) against a &#91;**&#93; Antigen &#91;**&#93;, in each case ((i) and (ii)) to the extent such exclusive license or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">exclusive option would conflict with the grant of rights with respect to such Target to MERSANA hereunder prior to the date Agent sends notice of Final Target Verification (as defined herein), the date of the Initial Target Substitution Notice or the date of the Additional Target Substitution Notice, as applicable, to MERSANA, (b) SNFX has notified the Agent that it has exclusively reserved for itself or its Affiliates such Target (without, for the avoidance of doubt, any obligation to conduct Development activities with respect to such Target)&#59;  provided that the number of such reserved Targets shall not exceed four (4) at any given time and SNFX will not substitute any such reserved Target more than one (1) time per Calendar Quarter, or (c) SNFX has initiated a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> program for Development of a product against the Target, for which SNFX has approved a research plan, has identified an antibody-drug conjugate or other product against such Target to be used in such program, and has commenced activities to make an antibody-drug conjugate or other product against such Target, and in the case of clause (a), (b) or (c), SNFX has provided written notice thereof to Agent prior to the date Agent sends notice of Final Target Verification to MERSANA, the date of the Initial Target Substitution Notice or the date of the Additional Target Substitution Notice, as applicable. For the avoidance of doubt, &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.109&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Patent in a country, any claim of an (a) issued patent that has not (i) been held unpatentable, unenforceable or invalid by a court or other Governmental Entity of competent jurisdiction in a decision that is not appealed or is unappealable, or (ii) expired, irretrievably lapsed or been abandoned, revoked, admitted to be invalid or unenforceable through reissue, dedicated to the public or disclaimed, or (b) application for a Patent that (i) has been pending for less than &#91;**&#93; years and is being prosecuted in good faith and has not been cancelled, withdrawn or abandoned or (ii) has not been admitted to be invalid or unenforceable through reissue, reexamination, or disclaimer, and which is not subject to an interference claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.110&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the context of this CLOA otherwise requires&#58;  (a) words of any gender include each other gender&#59; (b) words using the singular or plural number also include the plural or singular number, respectively&#59; (c) the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">hereof,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">herein,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">hereby</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and derivative or similar words refer to this entire CLOA&#59; (d) the terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Article,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; refer to the specified Article, Section or Exhibit of this CLOA&#59; and (e) the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">including without limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">but not limited to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#59; (f) the words &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">shall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; have the same meaning, (g) the word &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or&#8221;, and (h) all references to monetary amounts are to United States of America currency (U.S. Dollars).  Whenever this CLOA refers to a number of days, such number shall refer to calendar days. The preamble to this CLOA and the descriptive headings of Articles and Sections are inserted solely for convenience of reference and are not intended as complete or accurate descriptions of the content of this CLOA or of such Articles or Sections.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 2<br>LICENSES, SUPPLY AND TECHNOLOGY TRANSFER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.1.&#160;&#160;&#160;&#160;Non-Exclusive License and Research License. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the Term and thereafter as provided in Sections 10.3(a)(2) and 10.3(a)(3) and in accordance with the terms and conditions of this CLOA, SNFX, on behalf of itself and its Affiliates, shall grant and does hereby grant to MERSANA and its Affiliates a non-exclusive, transferable only in accordance with Section 11.5, royalty-bearing right and license, with the right to grant sublicenses (through multiple tiers) only in accordance with Section 2.4, to and under the Licensed Technology to Develop, Manufacture, Commercialize and otherwise Exploit Products that are, in each case, against the Initial Target, in the Field in the Territory. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX, on behalf of itself and its Affiliates, shall grant and does hereby grant to MERSANA and its Affiliates a non-exclusive, transferable only in accordance with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.5, royalty-free right and license, with the right to grant sublicenses (through multiple tiers) solely to Third Parties acting on MERSANA&#8217;s behalf and in accordance with Section 2.4, to use the Materials (as defined herein) supplied pursuant to Section 2.6 to conduct internal research and perform or have performed Manufacturing activities for such research for the purpose of determining whether to exercise an Option right hereunder (i) after confirmation that a Target is not an Unavailable Target, (ii) after reservation of such Target (including payment of the applicable Reservation Fee for such Target) pursuant to Section 2.2(b)(7), and (iii) during the corresponding Reservation Period for such Target. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.2.&#160;&#160;&#160;&#160;Option Right and Non-Exclusive License for Additional Targets</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">At any time on or after the Effective Date and until the Option Term expiration date set forth below in this Section 2.2(a) for each Option, MERSANA shall have &#91;**&#93; options (represented by &#91;**&#93; (inclusive), and each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to obtain a non-exclusive license under the Licensed Technology for Products against an additional Target (i.e., &#91;**&#93;) in the Field, in the Territory, provided however, that each such additional Target selected for an Option is not an Unavailable Target on the day that the Agent provides notice of Final Target Verification (as defined below) to MERSANA for such Target. On an Option-by-Option basis, each Option may be exercised from the Effective Date until the corresponding Option Term expiration date provided below (as applied to each Target, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for such Target), and the Option right for each of &#91;**&#93; will expire on the corresponding Option Term expiration date shown below if such Option right remains unexercised on such expiration date. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:44.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Number</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Option Term Expiration Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During any applicable Option Term, MERSANA may exercise its reservation rights and Option rights for the corresponding Target set forth in Section 2.2(a) as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA shall send a written notice to the Agent identifying the Target &#91;**&#93; it wishes to confirm is not an Unavailable Target or reserve for the purpose of the grant of a License under Section 2.2(c) of this CLOA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Approval Request Notice&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;**&#93; days after its receipt of the Target Approval Request Notice, the Agent shall verify, and confirm in writing to MERSANA and SNFX, whether each requested Target is an Unavailable Target and, if a Target is an Unavailable Target, whether the Unavailable Target is an Unavailable Target as a result of clause (b) or clause (c) of Section 1.108.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the proposed Target is an Unavailable Target, MERSANA will not have exhausted any of its rights to designate another Target and the above procedure may be repeated by MERSANA until such a notice is made with respect to a Target that is not an Unavailable Target&#59; and provided, further, that such process shall not extend or otherwise alter the Option Term specified for any given Target as set forth in Section 2.2(a). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Target requested by MERSANA is not an Unavailable Target, the Agent shall confirm in writing to MERSANA that the Target is available for the grant of a License within &#91;**&#93; days after its receipt of the Target Approval Request Notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Final Target Verification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Following the date the Agent sends a Final Target Verification notice to MERSANA, SNFX shall not take any action that would result in a Target becoming an Unavailable Target (i) during the &#91;**&#93; period in Section 2.2(b)(5), (ii) during the applicable Reservation Period (as defined below, if applicable) if MERSANA reserves such Target pursuant to the Target reservation process set forth in Sections 2.2(b)(5) and 2.2(b)(7), including paying the applicable Reservation Fee, or (iii) if MERSANA provides an Option Notice (as defined below), during the &#91;**&#93; that MERSANA has to pay the respective License Fee (if any) under Section 2.2(b)(6). MERSANA shall not provide any additional Target Approval Request Notices in any Calendar Quarter &#91;**&#93; after Agent has confirmed in writing to MERSANA &#91;**&#93; in such Calendar Quarter that a &#91;**&#93; is not an Unavailable Target and is available for the grant of a License. For clarity, &#91;**&#93; in any particular Calendar Quarter described above, MERSANA shall not be limited in the number of times it provides a Target Approval Request Notice, and Agent shall not be limited in the number of times it processes a Target Approval Request Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within &#91;**&#93; Days after receiving such Final Target Verification, MERSANA may provide written notification to SNFX of its right to either (i) in respect of Options &#91;**&#93; (inclusive) and Options &#91;**&#93; (inclusive) only, reserve the Target subject to Section 2.2(b)(7) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or (ii) in respect of Options &#91;**&#93; (inclusive), exercise the Option right under this Section 2.2(b) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and in the case of either (i) or (ii), the Reservation Notice or Option Notice (as applicable) shall indicate the identity of the Target &#91;**&#93;, which shall be specified by its common name(s) and UniProtKB&#47;Swiss-Prot number(s).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With respect to each Option Notice, within &#91;**&#93; days after MERSANA provides SNFX with such Option Notice, and following receipt of a written invoice, MERSANA shall pay the appropriate License Fee to SNFX, as set forth in Section 3.2, with respect to such Target.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(7)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During the applicable Option Terms, MERSANA may, with respect to each of Options &#91;**&#93; (inclusive) and Options &#91;**&#93; (inclusive), exercise its right to reserve a Target that is not an Unavailable Target (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reserved Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) pursuant to a Reservation Notice, for a period of up to &#91;**&#93; months each (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that, (A) MERSANA may unreserve a Reserved Target at any time upon written notice to SNFX, with the Reservation Period for such Reserved Target being deemed to expire on the date of such written notice&#59; and (B) if the Option Term has expired in respect of an Option without any Target being reserved in accordance with this Section 2.2(b)(7), MERSANA&#8217;s right to reserve a Target with respect to such Option shall also expire. With respect to any Reserved Target, SNFX shall not take any action that would result in such Target becoming an Unavailable Target during the applicable Reservation Period. MERSANA shall pay to SNFX a one-time non-refundable reservation issuance fee for each Reserved Target (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reservation Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the following </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amounts, as applicable&#58; (i) &#91;**&#93; U.S. Dollars (U.S. $&#91;**&#93;) for each of Option &#91;**&#93;&#59; and (ii) &#91;**&#93; U.S. Dollars (U.S. $&#91;**&#93;) for each of Options &#91;**&#93; (inclusive)&#59; which shall be payable within &#91;**&#93; days after MERSANA provides SNFX with a Reservation Notice for such Target, and following receipt of a written invoice from SNFX. If MERSANA subsequently elects to exercise its Option right under this Section 2.2(b) for a Reserved Target during the Reservation Period, then MERSANA shall provide an Option Notice and pay the remainder of the License Fee owed pursuant to the procedures set forth in Section 2.2(b)(6)&#59; provided that the Reservation Fee(s) previously paid by MERSANA in relation to such Option shall be deducted from the License Fee owed by MERSANA under Section 3.2 for such Target. If MERSANA does not subsequently elect to exercise its Option right under this Section 2.2(b) for a Reserved Target during the Reservation Period, then the Reservation Fee paid by MERSANA for such Reserved Target shall be deemed to be final, nonrefundable and non-creditable against any other payments owed by MERSANA to SNFX.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Only upon MERSANA exercising its Option right for a given Target by (i) obtaining Final Target Verification for such Target, (ii) providing its Option Notice for such Target, and (iii) making payment of the appropriate License Fee (if applicable), shall the Option right of MERSANA be considered fully exercised with respect to such Target whereby, during the Term and thereafter as provided in Section 10.3(a)(2), and in accordance with the terms and conditions of this CLOA, SNFX, on behalf of itself and its Affiliates, shall grant and does hereby grant to MERSANA and its Affiliates a non-exclusive, transferable only in accordance with Section 11.5, royalty-bearing right and license, with the right to grant sublicenses (through multiple tiers) only in accordance with Section 2.4, to and under the Licensed Technology to Develop, Manufacture, Commercialize and otherwise Exploit Products that are, in each case, against such Target, in the Field in the Territory (each such grant, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and each such Target, including the Initial Target, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall be solely responsible for the Agent&#8217;s performance of its obligations under this CLOA and SNFX shall be liable for any breach by the Agent of any such obligation or any error or omission of or by the Agent in performing such obligations related to (i) the correct assessment and reservation of each Target&#59; (ii) adherence to the timelines, both (i) and (ii) as set forth in Section 2.2(b) and in Section 2.9, and (iii) Agent&#8217;s confidentiality obligations in the Three-Way Mutual Non-Disclosure Agreement (or any similar three-way confidentiality agreement with an Agent entered into pursuant to Section 2.10). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For clarity, except as expressly provided herein, SNFX grants no other right or license, including any rights or licenses to the Licensed Technology or any other Intellectual Property Rights not otherwise expressly granted herein.  Notwithstanding anything to the contrary in this CLOA and without limitation of any rights granted or reserved to SNFX pursuant to any other term or condition of this CLOA, SNFX hereby expressly retains, on behalf of itself and its Affiliates and sublicensees, all rights in and to the Licensed Technology, including with respect to the Licensed Target, to Develop, Manufacture, Commercialize and otherwise Exploit products inside and outside the Field throughout the Territory and nothing in this CLOA shall be deemed or construed to in any way to restrict any such exploitation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of the Amendment Date, MERSANA shall be deemed to have exercised its Option right under Option &#91;**&#93; with respect to the Target identified in a certain letter agreement signed by the Parties as of the Amendment Date, and such Target shall be a Licensed Target that is Licensed pursuant to Section 2.2(c). &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.3.&#160;&#160;&#160;&#160;&#91;**&#93; Products.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> For the avoidance of doubt, if MERSANA is developing, or desires to develop, a Product containing a &#91;**&#93; ADC against a Target &#91;**&#93; and wishes to reserve such Target pursuant to Section 2.2(b)(7) or exercise its Option pursuant to Section 2.2(c), MERSANA shall designate the Target &#91;**&#93; for the Target verification process set out in Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2(b). Provided such Target is not an Unavailable Target, and subject to MERSANA exercising its rights in accordance with the procedure in Section 2.2(b)(7) or Section 2.2(c) (as applicable), the corresponding Reserved Target and Licensed Target &#91;**&#93; selected by MERSANA. In addition and for clarity, and in each case subject to Section 7.5(a)&#58; (a) where MERSANA or its Sublicensee Develops, Manufactures, Commercializes and otherwise Exploits a Product comprising a &#91;**&#93; ADC under a License (i.e. the Licensed Target is a Target &#91;**&#93;, SNFX shall not be prevented from (i) granting exclusive and non-exclusive licenses to products that are directed to any &#91;**&#93; of such Licensed Target only&#59; (ii) granting exclusive and non-exclusive licenses to products that are directed to any individual Antigen of such Licensed Target and one (1) or more Antigens not included in such Licensed Target&#59; or (iii) granting non-exclusive licenses to products that are directed &#91;**&#93; in such Licensed Target (but not exclusive licenses to &#91;**&#93; covered by such Licensed Target)&#59; and (b) where the Licensed Target &#91;**&#93; in accordance with this Section 2.3, neither MERSANA nor its Sublicensees shall be permitted to Develop, Commercialize or otherwise Exploit a Product &#91;**&#93; under the License to such Licensed Target, unless such Antigen is also, &#91;**&#93;, a Licensed Target under this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.4.&#160;&#160;&#160;&#160;Sublicenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The rights and licenses granted pursuant to Section 2.1 and Section 2.2 include the right to grant sublicenses (through multiple tiers) to Third Parties pursuant to a written sublicense agreement (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicense Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that (a) MERSANA or its Affiliate may only enter into Sublicense Agreements with respect to Licensed Targets, and with respect to any specific Licensed Target, only after the corresponding License Fee for such Licensed Target has been paid to SNFX&#59; (b) MERSANA shall provide SNFX with a copy of each such Sublicense Agreement granted under this Section 2.4, and any amendment thereto, within thirty (30) days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following execution thereof, it being understood and agreed to by SNFX that commercially sensitive information may be redacted from such copies to the extent such information is not necessary to verify compliance hereunder, and the terms, conditions and existence of such Sublicense Agreement and amendments thereto shall be deemed the Confidential Information of MERSANA&#59; (c) any such Sublicense Agreement and amendments thereto shall be consistent with and subject to the terms and conditions of this CLOA&#59; (d) MERSANA shall remain fully responsible to SNFX for the performance of its Sublicensee(s) with respect to MERSANA&#8217;s obligations under the terms of this CLOA&#59; and (e) MERSANA shall reserve the right under each Sublicense Agreement to conduct an audit of its Sublicensee in a comparable manner to Section 3.12. MERSANA shall remain obligated to make all payments due to SNFX under the terms of this CLOA with respect to the activities of its Sublicensees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If SNFX delivers a notice of termination to MERSANA pursuant to any of Sections 10.2(b), 10.2(c) or 10.2(d) (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), SNFX will grant, and hereby grants, an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to each Sublicensee (that is not (i) at the time of such termination, in material breach of its Sublicense Agreement, or (ii) the party challenging a Licensed Patent in respect of Section 10.2(d)) to enter into a license agreement directly with SNFX with respect to Products against any Licensed Targets that are also within the scope of such Sublicensee&#8217;s sublicense from MERSANA under the Licensed Technology, as of the date of the Termination Notice (such Licensed Targets, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Targets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Each Sublicensee may exercise its Sublicensee Option by providing a written notice to SNFX within &#91;**&#93; from the date the Termination Notice is given (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  If a Sublicensee exercises the Sublicensee Option prior to the expiration of the Sublicensee Option Period, SNFX and such Sublicensee shall enter into a license agreement directly with each other (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">New License Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on substantially the same terms and conditions as those set forth in this CLOA, including license scope, territory, duration of license grant and financial terms&#59; provided that, for the avoidance of doubt, SNFX shall not be required to agree to any terms in such New License Agreement that impose any obligations on SNFX that are not in this Agreement.  On a Sublicensee-by-Sublicensee basis, this CLOA will not be deemed to be terminated with respect </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to any Products against the Sublicensee Targets for the purposes of the Sublicense Agreement (but, for clarity, MERSANA and its Affiliates shall not have any rights in respect of Products against such Sublicensee Targets under this CLOA following MERSANA&#8217;s receipt of the Termination Notice, except as expressly provided in this CLOA (including Section 10.3(c))), until&#58; (1) if Sublicensee does not exercise the Sublicensee Option during the Sublicensee Option Period, the expiration of the Sublicensee Option Period&#59; or (2) if Sublicensee exercises the Sublicensee Option during the Sublicensee Option Period, the date when the New License Agreement is fully executed and is in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.5.&#160;&#160;&#160;&#160;Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise set forth in this Article 2, MERSANA shall, with the exception of activities under the Supply Agreement, be solely responsible for the cost and performance of Manufacturing and supplying, or having Manufactured and supplied, Products for Development, Commercialization and other Exploitation in the Territory.  In this role, MERSANA shall have the right, in its sole discretion, to identify and manage CMOs (as defined below), as well as lead all supply chain management and quality control activities. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.6.&#160;&#160;&#160;&#160;Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Parties shall use Commercially Reasonable Efforts to negotiate and execute the Supply Agreement consistent with the terms set forth herein and in Schedule 3 attached hereto within sixty (60) days following the Effective Date. Pursuant to such Supply Agreement, SNFX will Manufacture and supply, or have Manufactured and supplied by one or multiple CMOs, for MERSANA batches of certain proprietary components of the Licensed Technology &#91;**&#93; for the Manufacture of Products (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in such quantities and at such times as reasonably requested by MERSANA for any pre-clinical activities and Phase 1 Trial of a Product and for use of the Materials in exercising the rights granted under Section 2.1(b).  The Supply Agreement shall contain such additional terms that are reasonable and customary for similar supply agreements entered into by biopharmaceutical companies, including customary quality terms. If requested by MERSANA, the Parties shall use good faith efforts to enter into a mutually-agreeable quality agreement on customary terms. In the event that the Parties are not able to execute the Supply Agreement (and quality agreement, if applicable) by the date that is &#91;**&#93; days after the Effective Date, the Parties shall engage an independent expert mutually agreed upon by both Parties, the costs of which shall be equally shared by the Parties, and each Party shall submit to such expert, within &#91;**&#93; days of the selection of the expert, all applicable materials and information regarding the open areas of dispute in the Supply Agreement, and the expert shall provide its determination on such open areas within &#91;**&#93; days thereafter, which determination shall be binding on the Parties. The Parties acknowledge and agree that, as of the Amendment Date, the Parties have entered into a Supply Agreement which shall be deemed to have satisfied the terms of this Section 2.6 while such Supply Agreement is in effect. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.7.&#160;&#160;&#160;&#160;Tech Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA shall have the right, at any time after the Effective Date, to require SNFX to effect a transfer to MERSANA, or any Affiliate or CMO designated by MERSANA, of SNFX&#8217;s Know-How relating to the then-current process for the Manufacture of the Materials or the bioconjugation and Manufacture of remodeled antibodies using the Licensed Technology (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Processes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as is necessary and useful to enable MERSANA to implement the Manufacturing Processes at facilities designated by MERSANA (such transfer, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tech Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). SNFX shall provide, and shall use Commercially Reasonable Efforts to cause its CMOs to provide (including by using Commercially Reasonable Efforts to negotiate contractual obligations for such CMOs to do so under agreements entered into following the Effective Date), the reasonable assistance requested by MERSANA to enable MERSANA (or its Affiliates or designated CMOs, as applicable) to implement the Manufacturing Processes at the facilities designated by MERSANA.  If requested by MERSANA, such assistance shall include facilitating the entering into of agreements with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable CMOs relating to the Manufacture of the Materials and the bioconjugation and Manufacture of the remodeled antibodies using the Licensed Technology.  Without limitation to the foregoing, in connection with each Tech Transfer&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall make available, and shall use Commercially Reasonable Efforts to cause its CMOs to make available (including by using Commercially Reasonable Efforts to negotiate contractual obligations for such CMOs to do so under agreements entered into following the Effective Date), to MERSANA (or its Affiliates or designated CMOs, as applicable) from time to time as MERSANA may reasonably request, all Manufacturing-related Know-How relating to the Manufacturing Processes, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to materials to be used and control methods, that are reasonably necessary or useful to enable MERSANA (or its Affiliates or designated CMOs, as applicable) to use and practice the Manufacturing Processes&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall cause all appropriate employees and representatives of SNFX and its Affiliates to meet with, and shall use Commercially Reasonable Efforts to cause all appropriate employees and representatives of its CMOs to meet with (including by using Commercially Reasonable Efforts to negotiate contractual obligations for such CMOs to do so under agreements entered into following the Effective Date), employees or representatives of MERSANA (or its Affiliates or designated CMOs, as applicable) at the applicable Manufacturing facility at mutually convenient times to assist with the working up and use of the Manufacturing Processes and with the training of MERSANA&#8217;s personnel (or its Affiliates&#8217; or designated CMOs&#8217; personnel, as applicable) to the extent reasonably necessary or useful to enable MERSANA (or its Affiliates or designated CMOs, as applicable) to use and practice the Manufacturing Processes&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall provide, and shall use Commercially Reasonable Efforts to cause its CMOs to provide (including by using Commercially Reasonable Efforts to negotiate contractual obligations for such CMOs to do so under agreements entered into following the Effective Date), such other assistance as MERSANA (or its Affiliates or designated CMOs, as applicable) may reasonably request to enable MERSANA (or its Affiliates or designated CMOs, as applicable) to use and practice the Manufacturing Processes and otherwise to Manufacture the Materials and to perform bioconjugation and Manufacture the remodeled antibodies using the Licensed Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA shall pay to CMOs all verifiable costs incurred directly as a result of performing the Tech Transfer and pay to SNFX all verifiable, out-of-pocket costs and labor &#91;**&#93; incurred directly as a result of performing the Tech Transfer. MERSANA shall make such payment within &#91;**&#93; days following SNFX or a CMO providing MERSANA with an invoice and reasonable supporting documentation (including receipts) therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the foregoing, in the event that SNFX makes any modification, improvement, alteration or enhancement relating to the Manufacture of the Materials or the bioconjugation or Manufacture of the remodeled antibodies using the Licensed Technology after completion of the activities set forth under this Section 2.7, SNFX shall promptly disclose such Improvement to MERSANA, and shall, at MERSANA&#8217;s request, perform technology transfer with respect to such Improvement in the same manner as provided in this Section 2.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Access to Tech Transfer assistance and consultation shall be requested and coordinated through a single contact person to be designated by SNFX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.8.&#160;&#160;&#160;&#160;Contract Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Where SNFX, at its discretion, for any activities under the Supply Agreement, outsources the manufacture of any Materials to Third Party manufacturing organization(s) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), SNFX shall ensure that all contracts for the manufacture of Materials with such CMOs comply with the terms and conditions of this CLOA and the Supply Agreement&#59; provided, however, that SNFX&#8217;s right to use any such CMO is subject to (i) the Manufacturing Process for the Material implemented by such CMO being consistent with the regulatory standards applicable to the conduct of pre-clinical studies and Phase 1 Trials and (ii) MERSANA&#8217;s approval of such CMO after conducting a satisfactory audit, such approval not to be unreasonably withheld or delayed.  For avoidance of doubt, a satisfactory audit includes an audit where all identified deficiencies have been resolved or otherwise accepted by MERSANA. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the activities conducted under 2.7(a), up to &#91;**&#93; and upon not less than &#91;**&#93; prior written notice, SNFX will permit MERSANA or its designee, and to the extent it has the right to do so, cause its CMOs to permit MERSANA or its designee, to inspect and audit the parts of its facility, or its CMOs&#8217; facility where the Manufacture of the Materials is carried out in order to assess SNFX&#8217;s or its CMOs&#8217; compliance with the Supply Agreement (and any quality agreement), and to discuss any related technical issues with SNFX&#8217;s or its CMOs&#8217; management personnel.  SNFX shall, and shall direct its CMOs, to the extent it has the right to do so, to reasonably cooperate with each inspection by making all necessary information in SNFX&#8217;s or its CMOs&#8217; possession available to MERSANA or its designee for a reasonable amount of time to permit MERSANA or its designee to conduct such inspection. All of the forgoing inspections and audits shall be at MERSANA&#8217;s sole cost and expense.  SNFX shall further provide MERSANA with copies of any audit findings of its CMOs promptly following the performance of an audit by SNFX of any CMO of SNFX&#59; provided that, if required under the applicable agreement, SNFX shall use Commercially Reasonable Efforts to obtain such CMO&#8217;s consent to provide such reports.  In the event that any issues are identified in any audit by MERSANA or its designee, SNFX shall, within thirty (30) days after it receives notice of such identified issues, provide a written explanation thereof to MERSANA, including a corrective action plan that has been implemented to address such issues. SNFX shall take such actions as may be necessary to correct all identified issues in a timely manner and SNFX shall advise MERSANA periodically (and at such times as MERSANA may otherwise reasonably request) in writing of progress being made, as well as when such issues have been corrected. MERSANA shall not be liable for any costs or expenses incurred by SNFX to correct such deficiencies of SNFX&#8217;s or its CMOs&#8217; Manufacturing Processes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.9.&#160;&#160;&#160;&#160;Target Substitution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In respect of the Licensed Targets for Option &#91;**&#93; (inclusive) &#91;**&#93;, MERSANA shall have the right to substitute &#91;**&#93; of such Licensed Targets only, at any time prior to the earlier of (a) &#91;**&#93; such Licensed Target&#59; or (b) &#91;**&#93; such Licensed Target (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target Substitution Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), &#91;**&#93;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If MERSANA is interested in exercising the Initial Target Substitution Right, it shall notify SNFX and the Agent thereof without disclosing the new Target (such new Target, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proposed Initial Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and such notice, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target Substitution Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall separately specify to Agent the Proposed Initial Target and the Licensed Target to be substituted. SNFX shall cause the Agent to notify MERSANA within &#91;**&#93; thereafter whether the Proposed Initial Target is an Unavailable Target or not. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Proposed Initial Target is an Unavailable Target, the substitution right shall not be deemed to be exercised and Agent shall notify MERSANA thereof. In such case, MERSANA may thereafter exercise its Initial Target Substitution Right to substitute the same or different Licensed Target (as long as it is a Licensed Target for any of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Options &#91;**&#93; (inclusive)) with a different Proposed Initial Target in accordance with this Section 2.9(a), provided that the Initial Target Substitution Right has not expired.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Proposed Initial Target is not an Unavailable Target, then MERSANA may exercise the Initial Target Substitution Right by providing written notice thereof to SNFX within &#91;**&#93; of receiving notice that the Proposed Initial Target is not an Unavailable Target, following which the substituted existing Licensed Target specified in Section 2.9(a)(1) shall cease to be a Licensed Target and shall become a Terminated Target (unless, for clarity, MERSANA subsequently exercises its Option right or Target substitution right with respect to such former Licensed Target and a different Option) and such Proposed Initial Target shall be deemed a Licensed Target hereunder. For clarity, during such &#91;**&#93; period, the Proposed Initial Target shall not be reserved for MERSANA and SNFX shall have no obligation to ensure that such Proposed Initial Target does not become an Unavailable Target during such &#91;**&#93; period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In respect of any Reserved Targets and Licensed Targets for Option &#91;**&#93; (inclusive) &#91;**&#93;, MERSANA shall have the right, with respect to each such Option, to either (i) substitute the Reserved Target for such Option (if any) at any time during the Reservation Period for such Reserved Target, or (ii) substitute the Licensed Target for such Option (if any) at any time prior to the earlier of (a) &#91;**&#93; such Licensed Target&#59; or (b) &#91;**&#93; such Licensed Target (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Target Substitution Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). For clarity, if MERSANA has already exercised its Additional Target Substitution Right with respect to the Reserved Target for an Option, MERSANA will no longer have an Additional Target Substitution Right with respect to the Licensed Target for the same Option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If MERSANA is interested in exercising the Additional Target Substitution Right, it shall notify SNFX and the Agent thereof without disclosing the new Target (such new Target, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Proposed Additional Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#8221; and such notice, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Target Substitution Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and shall separately specify to Agent the Proposed Additional Target and the Reserved Target or Licensed Target (as applicable) to be substituted. SNFX shall cause the Agent to notify MERSANA within &#91;**&#93; thereafter whether the Proposed Additional Target is an Unavailable Target or not. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Proposed Additional Target is an Unavailable Target, the substitution right shall not be deemed to be exercised and Agent shall notify MERSANA thereof. In such case, MERSANA may thereafter exercise its Additional Target Substitution Right for such Option with a different Proposed Additional Target in accordance with this Section 2.9(b), provided that the Additional Target Substitution Right for such Option has not expired.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If the Proposed Additional Target is not an Unavailable Target, then MERSANA may exercise the Additional Target Substitution Right for such Option by providing written notice thereof to SNFX within &#91;**&#93; of receiving notice that the Proposed Additional Target is not an Unavailable Target &#91;**&#93;, following which the substituted existing Reserved Target or Licensed Target (as applicable) specified in Section 2.9(b)(1) shall cease to be a Reserved Target or Licensed Target (as applicable) and shall become a Terminated Target (unless, for clarity, MERSANA subsequently exercises its Target reservation right, Option right or Target substitution right with respect to such former Licensed Target and a different Option) and such Proposed Additional Target shall be deemed a Reserved Target or Licensed Target (as applicable) hereunder. For clarity, during such &#91;**&#93; period, the Proposed Additional Target shall not be reserved for MERSANA and SNFX shall have no obligation to ensure that such Proposed Additional Target does not become an Unavailable Target during such &#91;**&#93; period. In addition, such &#91;**&#93; period with respect to the substitution of a Reserved Target shall not extend the Option Term in respect of any applicable Option. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.10.&#160;&#160;&#160;&#160;Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX shall ensure that (a) an Agent (such Agent not to be a director, officer or employee of either Party or its Affiliates) has been appointed to perform the activities under this Agreement applicable to an Agent, at all times during the period starting from the Effective Date until the expiration of each Option Term and the expiration of MERSANA&#8217;s right to substitute a Target in accordance with Section 2.9 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agent Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (b) at all times during the Agent Term, SNFX and such then-current Agent are parties to a three-way confidentiality agreement with MERSANA, which includes terms which prohibit the Agent from disclosing to SNFX any Targets in a Target Approval Request Notice, Initial Target Substitution Notice or Additional Target Substitution Notice from MERSANA, until and unless MERSANA has provided a Reservation Notice, Option Notice or a notice to exercise its Initial Target Substitution Right under Section 2.9(a) or to exercise its Additional Target Substitution Right under Section 2.9(b), as applicable, with respect to such Target.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.11.&#160;&#160;&#160;&#160;No Other Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX and MERSANA each acknowledges and agrees that, except as expressly granted under this CLOA, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or otherwise, by either Party to the other Party.  All rights with respect to other Intellectual Property Rights that are not specifically granted herein are reserved.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.12.&#160;&#160;&#160;&#160;Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All rights and licenses granted under or pursuant to this CLOA, including amendments hereto, are, and will otherwise be deemed to be, for purposes of Section 365(n) of 11 U.S.C. Section 101, et. seq. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under Paragraph 101(35A) of the Bankruptcy Code, and any comparable Law of a relevant jurisdiction.  The Parties agree that MERSANA shall retain and may fully exercise all of its rights and elections under applicable Law. The Parties further agree that, in the event of the commencement of bankruptcy proceeding by or against SNFX, MERSANA shall be entitled to a complete duplicate of (or complete access to, as appropriate) any Licensed Technology which at that date is known to be useful or necessary for the Development, Manufacture, Commercialization and other Exploitation of any Products against a Licensed Target throughout the Territory and all embodiments of such Licensed Technology&#59; and the same, if not already in MERSANA&#8217;s possession, will be promptly delivered to MERSANA (a) upon any such commencement of a bankruptcy proceeding, upon MERSANA&#8217;s written request therefor (which request must identify the specific Licensed Technology), unless SNFX (or trustee on behalf of SNFX) elects within &#91;**&#93; days to continue to perform all of its obligations under this CLOA or (b) if not delivered under (a) above, upon rejection of this CLOA by or on behalf of SNFX, upon written request therefor by MERSANA.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 3<br>PAYMENTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.1.&#160;&#160;&#160;&#160;Initial Target License Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In partial consideration of the rights and licenses granted by SNFX hereunder, MERSANA shall pay to SNFX a one-time non-refundable and non-creditable license issuance fee for the license granted hereunder with respect to the Initial Target of Seven Hundred and Fifty Thousand U.S. Dollars (U.S. $750,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Target License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within &#91;**&#93; days after the Effective Date following receipt of a written invoice from SNFX. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.2.&#160;&#160;&#160;&#160;Additional Target License Issuance Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In partial consideration of the rights and licenses granted by SNFX hereunder, MERSANA shall pay to SNFX on a Licensed Target-by-Licensed Target basis (other than with respect to the Initial Target) a one-time (for each Licensed Target) non-refundable and non-creditable license issuance fee of &#91;**&#93; (each license issuance fee for a Licensed Target, together with the Initial Target License Fee, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">License Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon the issuance of each License for additional Target for which MERSANA exercises its Option rights under Section 2.2, except that no such License Fee shall be payable in respect of the Licensed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Targets for Option &#91;**&#93; (inclusive) if MERSANA exercises its Option rights under Section 2.2 in respect of such Targets.  Each License Fee owed under this Section 3.2 shall be paid within &#91;**&#93; days after MERSANA provides SNFX with an Option Notice in accordance with Section 2.2(b)(5) following receipt of a written invoice from SNFX. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.3.&#160;&#160;&#160;&#160;Amendment Fee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In partial consideration of the additional rights and licenses granted by SNFX as of the Amendment Date, MERSANA shall pay to SNFX a one-time non-refundable and non-creditable deal expansion fee of three million U.S. Dollars (U.S. $3,000,000.00) within &#91;**&#93; after the Amendment Date following receipt of a written invoice from SNFX. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.4.&#160;&#160;&#160;&#160;Development Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In further consideration of the rights and licenses granted by SNFX hereunder, MERSANA shall pay to SNFX on a Licensed Target-by-Licensed Target basis the one-time (for each Licensed Target), non-refundable and non-creditable milestone payments set forth below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon the first achievement by MERSANA or its Affiliates or Sublicensees of each of the corresponding events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Development Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). MERSANA shall notify SNFX pursuant to Section 11.10 within &#91;**&#93; days after achievement of the applicable Development Milestone Event and shall pay the corresponding Development Milestone Payment within &#91;**&#93; days after receipt of SNFX&#8217;s invoice therefor. For clarity, each Development Milestone Payment set forth below shall be due and payable one time only for each Licensed Target (regardless of the number of Products or indications to achieve any such Development Milestone Event for such Licensed Target) and the Development Milestone Payment amount is determined as shown in the table based upon the Development Milestone Event and the date on which the License Fee was paid for such Licensed Target. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Number</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Event</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">If License Fee for the Licensed Target Paid On or Before &#91;**&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">If License Fee for the Licensed Target Paid On or After &#91;**&#93; but on or before &#91;**&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Development Milestone Payment</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">If License Fee for the Licensed Target Paid On or After &#91;**&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First dosing of a patient in the first Phase 1 Trial of a Product against the applicable Licensed Target.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$750,000</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, upon the &#91;**&#93;, MERSANA shall pay to SNFX a one-time, non-refundable and non-creditable Development Milestone Payment of &#91;**&#93; dollars ($&#91;**&#93;). MERSANA shall notify SNFX pursuant to Section 11.10 within &#91;**&#93; after achievement of such event &#91;**&#93; and shall pay such corresponding Development Milestone Payment within &#91;**&#93; after receipt of SNFX&#8217;s invoice therefor.  </font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties understand and agree that, if MERSANA or its Affiliates or Sublicensees is able to accelerate the Development of a Product such that one or more Clinical Trials that would have represented a Development Milestone Event (as defined immediately above) can be omitted, the corresponding omitted clinical-stage Development Milestone Payment(s) shall still be paid in full by MERSANA to SNFX at the time that the next payable Development Milestone Payment is paid.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, the Development Milestone Payment amounts set forth in this Section 3.3 for any Licensed Target for which the corresponding License Fee was paid on or before &#91;**&#93; will be reduced by &#91;**&#93;, but only for such Licensed Target.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.5.&#160;&#160;&#160;&#160;Sales Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In further consideration of the rights and licenses granted by SNFX hereunder, MERSANA shall pay to SNFX on a Licensed Target-by-Licensed Target basis the one-time (for each Licensed Target), non-refundable and non-creditable milestone payments set forth below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sales Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) upon the first achievement by MERSANA or its Affiliates or Sublicensees of each of the corresponding events (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sales Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). MERSANA shall notify SNFX pursuant to Section 11.10 within &#91;**&#93; days after achievement of the applicable Sales Milestone Event and shall pay the corresponding Sales Milestone Payment within &#91;**&#93; days after receipt of SNFX&#8217;s invoice therefor. For clarity, each Sales Milestone Payment set forth below shall be due and payable one time only for each Licensed Target (regardless of the number of Products or indications to achieve any such Sales Milestone Event for each such Licensed Target).  All such notices issued from MERSANA to SNFX hereunder shall be accompanied by a written statement setting forth in reasonable detail the calculation thereof.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Event</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Payment (Initial Target and Licensed Targets for Option &#91;**&#93; (inclusive))</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Sales Milestone Payment (Licensed Targets for Option &#91;**&#93; (inclusive))</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.6.&#160;&#160;&#160;&#160;Payment of Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In further consideration of the rights and licenses granted by SNFX hereunder, during the Royalty Term, MERSANA shall pay to SNFX on a Licensed Target-by-Licensed Target basis, the following royalties&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in respect of the Initial Target and each of the Licensed Targets for Option &#91;**&#93; (inclusive), if any&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales less than &#91;**&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93; and less than &#91;**&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in respect of each of the Licensed Targets for Option &#91;**&#93; (inclusive), if any&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales less than &#91;**&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93; and less than &#91;**&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93; and less than &#91;**&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;&#91;**&#93; of Net Sales in a Calendar Year in the Territory of Products against such Licensed Target sold by MERSANA, its Affiliates and Sublicensees for that portion of such Net Sales greater than or equal to &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA shall&#58; (a) within &#91;**&#93; days following the end of each Calendar Quarter in which a royalty payment accrues, provide to SNFX a report, on a Licensed Target-by-Licensed Target basis, for each country in the Territory in which sales of Product occurred in the Calendar Quarter covered by such statement, specifying for such Calendar Quarter&#58; the number of Products sold&#59; the gross sales and Net Sales&#59; the royalties payable, including an accounting of itemized deductions taken in the calculation of Net Sales in accordance with MERSANA&#8217;s normal practices used to prepare its audited financial statements for internal and external reporting purposes and in accordance with GAAP&#59; the applicable exchange rate to convert foreign currency to U.S. Dollars under Section 3.8&#59; and the royalty calculation and royalties payable in U.S. Dollars, and (b) make the royalty payments owed to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX hereunder in accordance with such royalty report in arrears, within &#91;**&#93; days from the end of each Calendar Quarter in which such payment accrues.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary, the royalties under this Section 3.6 shall be payable by MERSANA with respect to each Product on a country-by-country basis in the Territory solely during the Royalty Term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Payments on Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA shall be responsible for paying any amounts due to Third Parties under any agreement between MERSANA and such Third Party in connection with the Development, Manufacture or Commercialization of Product throughout the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.7.&#160;&#160;&#160;&#160;Payment Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All payments made by MERSANA under this CLOA shall be made in U.S. Dollars, and such payments shall be made by check or wire transfer to&#58; </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, SNFX may designate another bank account in writing&#59; provided that such other account information is provided to MERSANA at least thirty (30) days prior to any such payment becoming due hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.8.&#160;&#160;&#160;&#160;Currency Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that Products are sold in any country in the Territory in currencies other than U.S. Dollars, Net Sales shall be calculated by MERSANA in accordance with U.S. generally accepted accounting principles, consistently applied.  Net Sales in currencies other than U.S. Dollars shall be converted into U.S. Dollars using MERSANA&#8217;s standard conversion methodology for its own financial reporting. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.9.&#160;&#160;&#160;&#160;Late Payment Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any payment due and payable to SNFX under the terms and conditions of this CLOA, including any royalty payment, made by MERSANA after the date such payment is due and payable shall bear interest as of the day after the date such payment was due and payable and shall continue to accrue such interest until such payment is made at a rate equal to the lesser of either (a) &#91;**&#93; above the prime rate as reported by Citibank, New York, New York, as of the date such payment was due and payable, or (b) the maximum rate permitted by applicable Law. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.10.&#160;&#160;&#160;&#160;Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Product-by-Product basis, following the First Commercial Sale of such Product and thereafter during the Term, MERSANA shall maintain, and shall cause its Affiliates and Sublicensees to maintain, complete and accurate records sufficient to enable accurate calculation of royalties and other payments due SNFX hereunder.  Such records and books of account shall be preserved by MERSANA for a period of &#91;**&#93; years after the end of the period covered by such records and books of account, which obligation shall survive termination of this CLOA.  MERSANA must direct its Affiliates and Sublicensees to provide reports and keep records in a manner consistent with this Section 3.10.  MERSANA shall provide reports received from any Affiliates and Sublicensees to SNFX with its applicable payments hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.11.&#160;&#160;&#160;&#160;Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA may withhold from any payment made to SNFX under this CLOA any tax liability of SNFX required to be withheld by MERSANA under the Laws of the United States or any other country or jurisdiction where MERSANA has Commercialized Products.  If any tax is required by Law to be withheld by MERSANA, MERSANA shall provide SNFX receipts or other evidence of such withholding and payment to the appropriate tax authorities on a timely basis following such tax payment.  Each Party agrees to cooperate with the other Party in claiming refunds or exemptions from such deductions or withholdings under any relevant agreement or treaty which is in effect.  The Parties shall discuss applicable mechanisms for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">minimizing such taxes to the extent possible in compliance with applicable Law.  In addition, the Parties shall cooperate in accordance with applicable Law to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other similar taxes) in connection with this CLOA, provided that MERSANA shall be responsible for the payment of all such indirect taxes associated with the Manufacture and Commercialization of Product and shall not deduct any such indirect tax amounts from the payments due SNFX under this CLOA. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.12.&#160;&#160;&#160;&#160;Audit Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  On a Product-by-Product basis, following the First Commercial Sale of such Product, MERSANA shall permit an independent certified public accountant of internationally recognized standing designated by SNFX and reasonably acceptable to MERSANA, to have access, no more than &#91;**&#93; during the Term and no more than &#91;**&#93; following the termination of this CLOA, during regular business hours and upon at least &#91;**&#93; days written notice, to MERSANA&#8217;s records and books to the extent necessary to determine the accuracy of Net Sales reported, and payments made, by MERSANA to SNFX within the &#91;**&#93; period immediately preceding such an audit.  The independent public accountant shall disclose to SNFX only (a) the accuracy of Net Sales reported and the basis for royalty and other payments made to SNFX under this CLOA and (b) the difference, if any, such reported and paid amounts vary from amounts determined as a result of the audit.  If such examination results in a determination that Net Sales or payments have been misstated, over or under paid amounts due shall be paid promptly to the appropriate Party.  If Net Sales are understated by greater than &#91;**&#93;, the fees and expenses of such accountant shall be paid by MERSANA&#59; otherwise the fees and expenses of such accountant shall be paid by SNFX.  All matters reviewed by such independent public accountant shall be deemed Confidential Information of MERSANA subject to Article 6.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 4<br>PRODUCT ACTIVITIES</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.1.&#160;&#160;&#160;&#160;Diligence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA, directly or through one or more of its Affiliates or Sublicensees, will use Commercially Reasonable Efforts to Develop, Manufacture, Commercialize, and otherwise Exploit at least one Product against each Licensed Target in each Major Market Country. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to the obligation under Section 4.1(a), MERSANA shall file an IND with the FDA for one (1) Product within &#91;**&#93; of the Effective Date. In the event that MERSANA does not file an IND with the FDA for one (1) Product within such &#91;**&#93; period, then, if this CLOA has not been terminated prior to such date, MERSANA shall pay &#91;**&#93; to SNFX as SNFX&#8217;s sole remedy for MERSANA&#8217;s failure to so file such an IND.  For the avoidance of doubt, MERSANA&#8217;s obligations under this Section 4.1(b) shall have been fully satisfied and shall not apply to any other Product upon MERSANA either filing an IND with the FDA for one (1) Product within &#91;**&#93; of the Effective Date or paying &#91;**&#93; to SNFX as set forth in this clause (b).  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.2.&#160;&#160;&#160;&#160;Annual Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No later than January 31 of each year commencing on the Effective Date and ending, on a Product-by-Product basis, at the end of the applicable Royalty Term, MERSANA shall submit a written report to SNFX covering the preceding Calendar Year.  Each report will summarize MERSANA&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; significant activities related to the Development and Commercialization of at least one Product against each Licensed Target and the status of Clinical Trials and applications for Regulatory Approval necessary for Exploiting such Products. Such reports will be deemed MERSANA&#8217;s Confidential Information in accordance with Article 6. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.3.&#160;&#160;&#160;&#160;Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise set forth in this CLOA, MERSANA shall be solely responsible for the Development, Manufacturing, Commercialization and Exploitation of all Products in the Field in the Territory.  MERSANA shall bear &#91;**&#93; of all costs and expenses associated with the Development, Manufacturing, Commercialization and Exploitation of Products.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.4.&#160;&#160;&#160;&#160;Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As between the Parties, MERSANA will (i) be solely responsible for, and will solely own, all applications for Regulatory Approval and Pricing Approval with respect to a Product and (ii) have the sole right and responsibility to file all INDs and make all other filings with the Regulatory Authorities, and to otherwise seek all Regulatory Approvals and Pricing Approvals for the Products, in the Territory, as well as to conduct all correspondence and communications with Regulatory Authorities regarding such matters. Upon the Effective Date with respect to the Initial Target, and upon MERSANA exercising its Option right for a Licensed Target (other than the Initial Target) in accordance with Section 2.2(c) during the Term and thereafter as provided in Section 10.3(a)(2), SNFX, on behalf of itself and its Affiliates, shall grant and does hereby grant to MERSANA and its Affiliates a non-exclusive, transferable in accordance with Section 11.5, &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) and any foreign counterpart of such regulation, with the right to grant such a Right of Reference to Sublicensees hereunder (through multiple tiers), to and under all data contained in any Regulatory Documentation Controlled by SNFX that is necessary or useful to Develop, Manufacture, Commercialize or otherwise Exploit a Product in the Field in the Territory, and SNFX shall provide a signed statement to this effect, if requested by MERSANA, in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any analogous applicable Law recognized outside of the United States). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall provide MERSANA with reasonable cooperation and assistance in connection with regulatory activities for each Product at MERSANA&#8217;s sole cost and expense, including (i) reasonable assistance in preparing filings and submissions necessary to obtain and maintain Regulatory Approval and Pricing Approval (if applicable) for each Product, (ii) responding to reasonable requests by MERSANA for additional Regulatory Documentation (and information and clinical data contained therein) related to such Product, and (iii) providing other technical information in SNFX&#8217;s Control that is necessary or useful for MERSANA in connection with any application for Regulatory Approval or Pricing Approval for a Product&#59; provided that SNFX&#8217;s cooperation is subject to MERSANA&#8217;s reimbursement of any reasonable out-of-pocket costs incurred by SNFX and &#91;**&#93;.  Further, such access shall be requested and coordinated through a single contact person to be designated by SNFX.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA shall be responsible for ensuring, at its sole expense, that the Development, Manufacturing, Commercialization and other Exploitation of all Products in the applicable jurisdiction within the Territory are in compliance with applicable Laws in all material respects, including all rules and regulations promulgated by applicable Regulatory Authorities.  Specifically and without limiting the foregoing, MERSANA shall be responsible for filing all compliance filings, certificates and safety reporting for the Products required by applicable Law at its sole expense in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MERSANA shall be responsible for taking all actions related to adverse event reporting and other regulatory obligations that are legally required of the holder of a Regulatory Approval application, license, registration or authorization under applicable Law.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 5<br>INTELLECTUAL PROPERTY </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.1.&#160;&#160;&#160;&#160;Ownership of Remodeled Antibodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge and agree that MERSANA is and will be the sole and exclusive owner of all right, title and interest in and to any Intellectual Property Rights to the extent related to any remodeled antibody against a Licensed Target for which the License Fee has been paid, and that are conceived, generated, Developed or reduced to practice under this CLOA or the Supply Agreement that is derived from an antibody Controlled by MERSANA. For the avoidance of doubt, MERSANA will be the sole and exclusive owner of all right, title and interest in and to any Intellectual Property Rights related to any Products conceived, generated, Developed or reduced to practice under this CLOA or the Supply Agreement that are derived from a remodeled antibody against a Licensed Target for which the License Fee has been paid, whether or not MERSANA Controls the intellectual property related to the antibody included in any such Product. Further, for the avoidance of doubt, SNFX will be the sole and exclusive owner of all right, title and interest in and to any Licensed Technology used, or any Improvements to the Licensed Technology that are not specific to a remodeled antibody against a Licensed Target for which the License Fee has been paid.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.2.&#160;&#160;&#160;&#160;Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 5.2(c), any Improvements to the Licensed Technology conceived, generated, Developed or reduced to practice solely by or on behalf of either Party or jointly by or on behalf of both Parties shall be exclusively owned by SNFX or its designee&#59; provided that, with respect to any Improvements to the Licensed Technology conceived, generated, developed or reduced to practice by or on behalf of MERSANA individually or jointly with SNFX, such Improvements shall only be owned by SNFX or its designee pursuant to this Section 5.2(a) to the extent that the applicable Licensed Technology has been disclosed to MERSANA, or, in the case of Patents and Patent applications, that have been published. Subject to the preceding sentence, MERSANA shall assign, and does hereby assign to SNFX or its designee, all of MERSANA&#8217;s right, title and interest in and to any such Improvements to the Licensed Technology including all Intellectual Property Rights therein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 5.2(c), any Improvements to the MERSANA Technology conceived, generated, Developed or reduced to practice solely by or on behalf of either Party or jointly by or on behalf of both Parties shall be exclusively owned by MERSANA or its designee&#59; provided that, with respect to any Improvements to the MERSANA Technology conceived, generated, developed or reduced to practice by or on behalf of SNFX individually or jointly with MERSANA, such Improvements shall only be owned by MERSANA or its designee pursuant to this Section 5.2(b) to the extent that the applicable MERSANA Technology has been disclosed to SNFX or, in the case of Patents and Patent application, that have been published. Subject to the preceding sentence, SNFX shall assign, and does hereby assign to MERSANA or its designee, all of SNFX&#8217;s right, title and interest in and to any such Improvements to the MERSANA Technology including all Intellectual Property Rights therein.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any Improvement that is an Improvement to both the Licensed Technology and the MERSANA Technology conceived, generated, developed or reduced to practice solely by or on behalf of either Party or jointly by or on behalf of both Parties in the course or performing or exercising rights under this CLOA or the Supply Agreement (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Improvement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall be jointly owned by SNFX and MERSANA or their respective designee (other than any Improvements that are specific to the remodeled antibodies, which shall be solely owned by MERSANA pursuant to Section 5.1), and each of SNFX and MERSANA or their respective designee shall have, and does hereby have an undivided joint ownership interest in all rights, title, and interest worldwide in and to such Joint Improvement and all Intellectual Property Rights therein, effective immediately upon the conception or reduction to practice thereof. In accordance with the foregoing, SNFX hereby assigns an undivided joint ownership interest in and to such Joint Improvement to MERSANA, and MERSANA hereby assigns an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">undivided joint ownership interest in and to such Joint Improvement to SNFX. Each Party shall have the right to practice, license and sublicense (through multiple tiers), or otherwise Exploit any Joint Improvement without the consent of or accounting to the other Party. In the event that any Joint Improvement is conceived, generated, developed or reduced to practice hereunder, the Parties shall promptly meet to discuss and determine whether to seek Patent protection thereon. If the Parties decide to seek Patent protection for any Joint Improvement, the Parties will mutually agree on the preparation, filing, prosecution and maintenance of any Joint Improvement Patent using Patent counsel that is reasonably acceptable to both Parties. The Parties shall timely discuss in good faith an enforcement strategy (including the allocation of costs) with respect to any Joint Improvement Patent and the allocation between the Parties of responsibility for enforcement of Joint Improvement Patents. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.3.&#160;&#160;&#160;&#160;Other Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth above in this Article 5, all other Intellectual Property Rights invented, conceived, generated, developed or reduced to practice solely by or on behalf of either Party or jointly by or on behalf of both Parties in the course or performing or exercising rights under this CLOA or the Supply Agreement will be owned by the Party that invented, conceived, generated, developed or reduced to practice such Intellectual Property Rights, the determination of which will be made in accordance with applicable Law in the United States.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.4.&#160;&#160;&#160;&#160;Patent Maintenance and Prosecution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX shall, at its sole expense and within its sole discretion, prepare, file, prosecute and maintain the Licensed Patents and be responsible for any related interference, re-issuance, re-examination and other opposition proceedings&#59; provided that SNFX shall provide MERSANA with drafts of any filings that use MERSANA&#8217;s data prior to their submission in sufficient time to allow MERSANA the reasonable opportunity to review, consider and substantively comment thereon.  SNFX may abandon any Licensed Patent or Licensed Patent claims in SNFX&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.5.&#160;&#160;&#160;&#160;Patent Term Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX shall have the sole right, but not the obligation, to seek, in SNFX&#8217;s name, patent term extensions, adjustments, restorations, or supplementary protection certificates under applicable Law for the Licensed Patents in the Territory&#59; it being understood and agreed that, if SNFX seeks a patent term extension, then MERSANA agrees to perform, at SNFX&#8217;s request and sole expense, any reasonable measures required by applicable Law for SNFX to obtain such extension.  SNFX, its agents and attorneys will give due consideration to all suggestions and comments of MERSANA regarding any such activities, including the choice of which Licensed Patent to apply term extensions to, but in the event of a disagreement between the Parties, SNFX shall have the final decision making authority.  For clarity, (a) any such extended Licensed Patent will remain included in the definition of Valid Claim for purposes of extending the Term and (b) SNFX shall have the right, in its sole discretion, to abandon such Licensed Patent at any time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.6.&#160;&#160;&#160;&#160;Licensed Patents and Licensed Know-How Enforcement and Defense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If either Party becomes aware of an infringement by a Third Party of any Licensed Technology in the Territory, whether or not within the Field or with respect to a Licensed Target, it shall notify the other Party as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">soon as practicable.  Upon notice of an infringement by a Third Party of any Licensed Technology, SNFX shall have the sole right (but not the obligation) at its sole cost to take the appropriate steps to enforce or defend any Licensed Patents in the Field against Third Parties.  Any settlements, damages or other monetary awards relating to such infringement or violation by a Third Party of any Licensed Patent recovered by SNFX pursuant to a suit, action or proceeding brought pursuant to this Section 5.6 will be retained by SNFX.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.7.&#160;&#160;&#160;&#160;Defense of Infringement Claims of Licensed Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 8.1, in the event that a Third Party institutes a claim against a Party in the Territory during the Term, alleging that the Development, Manufacture, Commercialization or Exploitation of the Products </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Territory in accordance with this CLOA infringes or misappropriates the Intellectual Property Rights of such Third Party, then such Party shall immediately provide the other Party with written notice of such claim along with the related facts in reasonable detail. MERSANA shall have the first right, but not the obligation, at its sole cost and expense, and through counsel of its choosing, to assume direction and control of the defense and settlement of any such claim brought against MERSANA, or, subject to any Third Party obligations, any such claim brought against SNFX&#59; provided that it shall not&#58; (a) settle or otherwise compromise any such claims brought against SNFX that would materially adversely affect SNFX&#59; or (b) assert a claim or counterclaim against such Third Party based on the Licensed Technology, without the written consent of SNFX, such consent not to be unreasonably withheld or delayed.  Without limiting the foregoing, MERSANA shall not settle any such claims brought against SNFX unless such settlement involves only the payment of money and includes a complete and unconditional release of SNFX from all liability with respect thereto.  SNFX shall assist and cooperate in connection with the defense of such claim upon MERSANA&#8217;s reasonable request and at the sole cost and expense of MERSANA. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.8.&#160;&#160;&#160;&#160;Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In any suit, proceeding or dispute involving the infringement of any of the Licensed Patents in the Field or misappropriation of any of the Licensed Know-How in the Field, the Parties shall provide each other with reasonable cooperation, and, upon the request and at the expense of the Party bringing suit, the other Party shall make available to the Party bringing suit, at reasonable times and under appropriate conditions, all reasonable and relevant personnel, records, papers, information, samples, specimens, and the like in its possession.  Notwithstanding any other provision of this Article 5, neither Party shall make any settlements of any suit, proceeding or action relating to an infringement of the Licensed Patents in the Field or misappropriation of any of the Licensed Know-How in the Field that would materially adversely affect the other Party or materially adversely affect the rights and licenses granted hereunder without first obtaining such other Party&#8217;s prior written consent, such consent not to be unreasonably withheld or delayed.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 6<br>CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.1.&#160;&#160;&#160;&#160;Confidentiality Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees that, during the Term and for &#91;**&#93; years thereafter, all Confidential Information of the other Party shall be maintained in confidence, and shall not be used for any purpose other than the purposes expressly permitted by this CLOA, and, subject to Section 6.2, shall not be disclosed to any Third Party.  The Mutual Non-Disclosure Agreement shall terminate as of the Effective Date and the provisions of this Article 6 and this CLOA shall supersede the Mutual Non-Disclosure Agreement in all respects, and all &#8220;Confidential Information&#8221; (as defined in the Mutual Non-Disclosure Agreement) exchanged by the Parties thereunder shall be deemed to be Confidential Information hereunder and be subject only to the provisions of this Article 6 and CLOA as of and after the Effective Date.  The foregoing obligations will not apply to any portion of Confidential Information to the extent that it can be established by competent proof that such portion of the Confidential Information&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">was already known to the recipient or its Representatives, other than under an obligation of confidentiality, at the time of disclosure&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">was generally available to the public or was otherwise part of the public domain at the time of its disclosure to the recipient or its Representatives&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">became generally available to the public or otherwise becomes part of the public domain after its disclosure and other than through any act or omission of the recipient in breach of this CLOA&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">was subsequently lawfully disclosed to the recipient or its Representatives by a Third Party other than in contravention of a confidentiality obligation of such Third Party to the disclosing party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.2.&#160;&#160;&#160;&#160;Permitted Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party may use and disclose the Confidential Information of the other Party, in accordance with this CLOA, as follows&#58; (a) to its Representatives who have a need to know such Confidential Information to perform such Party&#8217;s obligations under this CLOA and who are bound by obligations of confidentiality no less strict than those contained in this CLOA (other than the term of such confidentiality obligations, which shall be customary for the applicable situation), (b) to exercise rights granted to or retained by such Party&#59; (c) in connection with the Prosecution or enforcement of Licensed Patents or Improvements, in accordance with this CLOA&#59; or (d) in connection with prosecuting or defending litigation, complying with applicable governmental regulations, filing for, obtaining and maintaining Regulatory Approvals and Pricing Approvals, or as otherwise required by Law, but provided that if a Party is required by Law to make any disclosure of the other Party&#8217;s Confidential Information, it will give reasonable advance notice to the other Party of such disclosure requirement (if legally permitted), it will disclose only for the sole purpose of and solely to the extent required by such Law, and it will use its reasonable efforts to secure confidential treatment of such portion of the Confidential Information required to be disclosed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.3.&#160;&#160;&#160;&#160;Terms of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The terms of this CLOA shall be the Confidential Information of both Parties, and subject to the terms of this Article 6.  Notwithstanding the foregoing, either Party may make a disclosure of the terms of this CLOA&#58; (a) to any bona fide financial advisors, accountants, investors, potential acquirers, or, in the case of MERSANA, potential sublicensees who have undertaken substantive negotiation of a Sublicense Agreement with MERSANA in good faith and are bound in writing to maintain the confidentiality of such disclosure to the same extent required of the Parties hereunder, (b) if required by applicable Law, or (c) as otherwise permitted pursuant to Section 6.5. A Party will give the other Party written notice of any required disclosure under (b) above (if legally permitted), which notice shall, to the extent reasonably practicable, be given a reasonable period of time in advance of such required disclosure.  In the event either Party is required to file this CLOA with the U.S. Securities and Exchange Commission or any comparable non-U.S. Governmental Entity, such Party shall apply for confidential treatment of this CLOA to the fullest extent permitted by applicable Law, shall provide the other Party a copy of the confidential treatment request a reasonable enough time in advance of its filing to attempt to give the other Party a meaningful opportunity to comment thereon, and shall incorporate in such confidential treatment request any reasonable comments of the other Party (if reasonably practicable).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.4.&#160;&#160;&#160;&#160;Permitted Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event MERSANA desires to publish or present any information with respect to the Licensed Technology, MERSANA shall provide SNFX with a copy of such proposed publication or presentation no less than twenty (20) days prior to its intended submission for publication or public disclosure. SNFX shall respond in writing promptly and in no event later than ten (10) days after receipt of the proposed material, with one or more of the following&#58; (a) comments on the proposed material, which MERSANA shall consider in good faith&#59; (b) a specific statement of concern, based upon the need to seek Patent protection or to block publication or public disclosure if SNFX reasonably determines that the proposed disclosure includes intellectual property that should be maintained as a trade secret to protect any Licensed Technology, in which event MERSANA agrees not to submit such publication or make such presentation that contains such information for at least forty-five (45) days in order for SNFX to have the opportunity to seek Patent protection for any material in such publication or presentation which it believes is patentable&#59; (c) an identification of SNFX&#8217;s Confidential Information that is contained in the material reviewed, which MERSANA shall remove, if </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">requested by SNFX&#59; or (d) an identification of any SNFX trade secret that is contained in the material reviewed and which SNFX desires to maintain as a trade secret, which MERSANA shall remove, if requested by SNFX.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The contents of any publication or presentation that has been reviewed and approved by SNFX may be re-released by MERSANA without a requirement for re-approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX shall be expressly prohibited from publishing or presenting any information with respect to the MERSANA Technology or any Product without MERSANA&#8217;s prior written consent, which may be withheld in its sole discretion. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.5.&#160;&#160;&#160;&#160;Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that the press release attached hereto as Exhibit F regarding the existence of this CLOA will be issued upon execution of this CLOA on the Effective Date. The Parties further agree that the press release attached hereto as Exhibit G regarding the amendment and expansion of this CLOA will be issued by SNFX within &#91;**&#93; of the Amendment Date. Additional public announcements or press releases regarding this CLOA may be issued by either Party at any other time pending approval of the public announcement or press release content by both Parties, such approval not to be unreasonably withheld. Neither Party shall make any subsequent public announcement concerning this CLOA or the terms hereof not previously made public without the prior written approval of the other Party, such consent not to be unreasonably withheld or delayed by such other Party, with regard to the form, content, and precise timing of such announcement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 7<br>REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.1.&#160;&#160;&#160;&#160;General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party represents and warrants, and covenants (as applicable), to the other Party, that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Effective Date and the Amendment Date, it is duly organized, validly existing and in good standing under the Laws of its jurisdiction of incorporation or organization and has all requisite power and authority to conduct its business and engage in the transactions provided for in this CLOA&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Effective Date and the Amendment Date, the execution, delivery and performance by it of this CLOA, and the consummation by it of the transactions contemplated hereby, have been duly authorized and approved by all necessary corporate or equivalent action on its part.  This CLOA has been duly executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency or other laws relating to or affecting creditors&#8217; rights generally&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Effective Date and the Amendment Date, the execution, delivery and performance by it of this CLOA, and the consummation by it of the transactions contemplated hereby, do not and will not&#58;  (i) violate any applicable Laws&#59; (ii) conflict with, or result in the breach of any provision of, its certificate or articles of incorporation, bylaws or equivalent organizational documents&#59; (iii) result in the creation of any lien or encumbrance of any nature upon any property being transferred or licensed by it pursuant to this CLOA&#59; or (iv) violate, conflict with, result in the breach or termination of, or constitute a default under (or event which, with notice, lapse of time or both, would constitute a default under), any permit, contract, agreement or other obligation or restriction to which it is a party or by which any of its properties or businesses are bound&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the Effective Date and the Amendment Date, no authorization, consent or approval of, or notice to or filing with, any Regulatory Authority is required for the execution, delivery and performance by it of this CLOA (excluding approvals of Regulatory Authorities as contemplated herein)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">where this CLOA refers to an action or obligation to be undertaken by a Party&#8217;s Affiliates, such Party will cause such Affiliates, during the Term, to undertake such obligations or other actions, and such Party will be responsible and liable for any acts or omissions by its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it shall not use, during the Term, any employee or consultant who has been debarred by any Regulatory Authority, or, to the best of such Party&#8217;s Knowledge, is the subject of debarment proceedings by a Regulatory Authority&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">it will maintain throughout the Term all permits, licenses, registrations, and other forms of authorizations and approvals from any Governmental Entity that are necessary or required to be obtained or maintained by such Party in order for such Party to execute and deliver this CLOA and to perform its obligations hereunder in a manner which complies with all applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.2.&#160;&#160;&#160;&#160;Covenants of MERSANA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA hereby covenants that, during the Term, it shall, and shall direct its Affiliates and Sublicensees to, perform all of its obligations under this CLOA, and shall comply in all material respects with all applicable Laws in the Development, Manufacture and Commercialization of the Product.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.3.&#160;&#160;&#160;&#160;Representations of MERSANA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. On a Licensed Target-by-Licensed Target basis, MERSANA hereby represents and warrants to SNFX that, to its Knowledge, as of the date that the License with respect to a Licensed Target is granted, the Antibody or Antibodies that MERSANA intends to incorporate, as of such date, into each Product against such Licensed Target &#91;**&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.4.&#160;&#160;&#160;&#160;Representations of SNFX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX hereby represents and warrants to MERSANA, as of the Effective Date and the Amendment Date, and, except as stated otherwise, on each separate date that MERSANA receives a license to a Licensed Target pursuant to Section 2.2(c), except as may be set forth in a disclosure schedule delivered by SNFX to MERSANA on each such date, that&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX or its Affiliates are the sole and exclusive owner(s) of the Licensed Technology, all of which is, except for &#91;**&#93;, free and clear of any liens, charges or encumbrances, and, except for any Patents disclosed by SNFX to MERSANA in writing prior to each such date, to SNFX&#8217;s Knowledge, neither SNFX nor any of its Affiliates have infringed any Patents or misappropriated any Know-How of a Third Party in connection with Developing the Licensed Technology.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for any Patents disclosed by SNFX to MERSANA in writing prior to each such date, to SNFX&#8217;s Knowledge, the practice of the Licensed Technology in the manner contemplated by this CLOA and disclosed by MERSANA to SNFX as of the Effective Date does not infringe any Patents or misappropriate any Know-How of a Third Party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX or its Affiliates have complied in all material respects with all applicable Laws with respect to the filing, prosecution and maintenance of the Licensed Patents, paid all maintenance and annuity fees with respect to the Licensed Patents, and no dispute regarding inventorship has been alleged or threatened with respect to the Licensed Patents&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except for the pending oppositions filed against &#91;**&#93;, there are no actual, pending or, to SNFX&#8217;s Knowledge, alleged or threatened, adverse actions, suits, claims, interferences, re-examinations, oppositions, inventorship challenges or formal governmental investigations involving the Licensed Technology by or against SNFX or any of its Affiliates, in each case that are in or before any Governmental Entity&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Schedule 1 includes a complete and correct list of the Licensed Patents, as of the Effective Date, necessary or useful for MERSANA to Develop, Manufacture, Commercialize or otherwise Exploit Products as contemplated herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX or its Affiliates have and will have the full right, power and authority to grant all of the right, title and interest in the licenses and other rights granted or to be granted to MERSANA, its Affiliates or Sublicensees under this CLOA&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the execution, delivery and performance by SNFX of this CLOA and its compliance with the terms and provisions hereof does not and will not violate or result in a breach of or default under any binding obligation or agreement of SNFX existing as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.5.&#160;&#160;&#160;&#160;Covenants of SNFX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SNFX covenants that it will not, during the Term, undertake any obligation, or grant any right, license, interest or lien, that conflicts with its obligations, or the rights and licenses granted to MERSANA, under the terms of this CLOA, or impairs the rights granted by SNFX to MERSANA under the terms of this CLOA. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Where this CLOA refers to an action or obligation to be undertaken by the Agent, SNFX will cause the Agent, during the Term, to undertake such obligations or other actions, and SNFX will be responsible and liable for any acts or omissions by the Agent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.6.&#160;&#160;&#160;&#160;DISCLAIMER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT AS PROVIDED IN THIS ARTICLE 7, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT TO THE SUBJECT MATTER OF THIS CLOA, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, AND ALL WARRANTIES AND CONDITIONS OF THE VALIDITY OF THE LICENSED PATENTS OR NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.  THIS SECTION 7.6 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#8217;s OBLIGATIONS UNDER ARTICLE 8.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 8<br>INDEMNIFICATION&#59; INSURANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1.&#160;&#160;&#160;&#160;Indemnification by MERSANA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA shall indemnify, hold harmless, and defend SNFX and its Representatives (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SNFX Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Third Party claims, suits, losses, liabilities, damages, costs, fees and expenses (including reasonable attorneys&#8217; fees) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) finally awarded to a Third Party by a court of competent jurisdiction or agreed to in a settlement approved by MERSANA that results from any claim made or brought against a SNFX Indemnitee by or on behalf of such Third Party, and subject to Section 8.3, any direct out-of-pocket costs and expenses (including reasonable attorneys&#8217; fees) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) incurred by a SNFX Indemnitee while investigating or conducting the defense of such Third Party claim, in any such case, solely to the extent such claim is directly based on or directly arises out of (a) the breach by MERSANA of any representation, warranty or covenant contained in this CLOA, (b) the negligence or willful misconduct of MERSANA or its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Representatives or Sublicensees in connection with the performance of MERSANA&#8217;s obligations in this CLOA, (c) any actual violation by MERSANA of applicable Laws in the Development, Manufacture, Commercialization or Exploitation of any Product, (d) the Development, Manufacturing or Commercialization of a Product by MERSANA or its Affiliates or Sublicensees (including product liability) in the Territory, or (e) the Development, Manufacture, Commercialization or Exploitation of any Product that infringes any Patent or misappropriates any Know-How owned or possessed by any Third Party (except to the extent no such infringement or misappropriation would occur but for the practice of the Licensed Technology)&#59; provided, however, that such indemnification right shall not apply to any Losses or Litigation Costs for which SNFX is obligated to indemnify MERSANA under Section 8.2. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.2.&#160;&#160;&#160;&#160;Indemnification by SNFX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX shall indemnify, hold harmless, and defend MERSANA and its Representatives (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">MERSANA Indemnitees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from and against any and all Losses finally awarded to a Third Party by a court of competent jurisdiction or agreed to in a settlement approved by SNFX that result from any claim made or bought against an MERSANA Indemnitee by or on behalf of such Third Party, and subject to Section 8.3, any Litigation Costs incurred by a MERSANA Indemnitee while investigating or conducting the defense of such Third Party claim, in any such case, solely to the extent such claim is directly based on or directly arises out of (a) the breach by SNFX of any representation, warranty or covenant contained in this CLOA, (b) the negligence or willful misconduct of SNFX or its Representatives, licensees or sublicensees in connection with the performance of SNFX&#8217;s obligations in this CLOA, (c) any actual violation by SNFX of applicable Laws in its performance of its obligations in this CLOA, or (d) any action or omission of the Agent in performing its obligations under or in connection with this CLOA&#59; provided, however, that such indemnification right shall not apply to any Losses or litigation costs for which MERSANA is obligated to indemnify SNFX under Section 8.1.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.3.&#160;&#160;&#160;&#160;Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of any such claim against any MERSANA Indemnitee or SNFX Indemnitee (individually, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such Indemnitee shall promptly notify the other Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in writing of the claim and the Indemnifying Party shall manage and control, at its sole expense, the defense of the claim and its settlement&#59; provided that the failure to so notify promptly shall not relieve the Indemnifying Party of its obligations under this Article 8 except to the extent of the actual prejudice suffered by such Indemnifying Party as a result of such failure.  The Indemnitee shall cooperate with the Indemnifying Party and may, at its option and expense, be represented in and participate in any such action or proceeding.  The Indemnifying Party shall not be liable for any settlements, litigation costs or expenses incurred by any Indemnitee without the Indemnifying Party&#8217;s written authorization.  Notwithstanding the foregoing, if the Indemnifying Party believes that any of the exceptions to its obligation of indemnification of the Indemnitees set forth in Section 8.1 or Section 8.2 may apply, the Indemnifying Party shall promptly notify the Indemnitees, which shall then have the right to be represented in any such action or proceeding by separate counsel at their expense&#59; provided that the Indemnifying Party shall be responsible for payment of such expenses if the Indemnitees are ultimately determined to be entitled to indemnification from the Indemnifying Party.  The Indemnifying Party shall not effect any settlement of any such claims without the consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed, unless such settlement involves only the payment of money and includes a complete and unconditional release of the Indemnitee from all liability with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.4.&#160;&#160;&#160;&#160;Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party shall procure and maintain insurance, or shall self-insure, in each case, in a manner adequate to cover its obligations hereunder and consistent with normal business practices of prudent companies similarly situated at all times during which any Product is being Developed, Manufactured, Commercialized or otherwise Exploited hereunder.  Each Party shall procure insurance or self-insure at its own expense.  Such insurance does not create a limit on either Party&#8217;s liability with respect to its indemnification obligations under this Article 8.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Party shall provide the other Party with written evidence of such insurance or self-insurance upon request.  Each Party shall provide the other Party with written notice at least &#91;**&#93;&#160;days before the cancellation or non-renewal of such insurance.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 9<br>LIMITATION OF LIABILITY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.1.&#160;&#160;&#160;&#160;LIMITATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  EXCEPT FOR ANY LOSSES THAT RESULT FROM A BREACH OF THE CONFIDENTIALITY OBLIGATIONS IN ARTICLE 6 OR ARE SUBJECT TO INDEMNIFICATION UNDER ARTICLE 8, OR LIABILITY THAT IS THE CONSEQUENCE OF GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE SAME), HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY ARISING OUT OF THIS CLOA, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, AND WHETHER OR NOT SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.  THIS ARTICLE 9 SHALL NOT BE CONSTRUED TO LIMIT EITHER PARTY&#8217;S OBLIGATIONS UNDER ARTICLE 8.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 10<br>TERM AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1.&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This CLOA shall commence on the Effective Date and, on a country-by-country and Licensed Target-by-Licensed Target basis, and, unless earlier terminated pursuant to this Article 10, shall remain in effect until the last to expire of any Royalty Term for each Product against a Licensed Target in such country (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.2.&#160;&#160;&#160;&#160;Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;For Convenience</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  MERSANA shall have the right, at any time, to terminate this CLOA in its entirety or on a Licensed Target-by-Licensed Target basis (in the event of termination of this CLOA on a Licensed Target-by-Licensed Target basis pursuant to this Section 10.2(a) or Section 10.2(b), each such terminated Licensed Target, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Terminated Target</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by providing not less than &#91;**&#93; days&#8217; prior written notice to SNFX of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;For Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If either Party shall at any time breach any material term, condition or agreement herein, and shall fail to have cured any such default or breach within &#91;**&#93; days (or &#91;**&#93; days if such default or breach is the non-payment of any amounts due hereunder) (such period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) after receipt of written notice thereof by the other Party, then the other Party may, at its option, terminate this CLOA upon written notice to the other Party&#59; provided that, in the event such an uncured breach by either Party relates only to one or more, but not all, of the Licensed Targets, the non-breaching Party shall only have the right to terminate this CLOA with respect to such Licensed Target(s)&#59; provided further, that the non-breaching Party shall have the right to terminate this CLOA in its entirety in the event that such an uncured breach by the other Party relates to at least &#91;**&#93; of the Licensed Targets&#59; provided further, that if a breach is unrelated to any payment obligations hereunder and cannot be cured within the Notice Period but the breaching Party commences actions to cure such breach within the Notice Period, the Notice Period will be extended for an additional &#91;**&#93; days so long as the breaching Party thereafter diligently continues such actions&#59; and provided further that if either Party initiates a dispute resolution procedure under Section 11.11 to resolve the dispute for which termination is being sought during the Notice Period, the Notice Period will be tolled and the termination will become effective only if such breach remains uncured for &#91;**&#93; days after the final resolution of the dispute through such dispute resolution procedure (or, if </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the breach is unrelated to any payment obligations hereunder and cannot be cured within such &#91;**&#93; day period after such final resolution, such period to cure such breach will be extended for a subsequent &#91;**&#93; day period so long as the breaching Party diligently continues such actions to cure such breach).  Any termination of this CLOA under this Section 10.2 shall not, however, prejudice the right of the Party who terminates this CLOA to recover any payment due at the time of such termination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;For Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Either Party may terminate this CLOA  (i) immediately upon written notice to the other Party in the event the other Party is insolvent or initiates a voluntary proceeding under any applicable bankruptcy Law or code&#59; or (ii) immediately upon written notice to the other Party in the event the other Party becomes the subject of an involuntary proceeding under any applicable bankruptcy Law or code and such proceeding is not dismissed or stayed within &#91;**&#93; days of its commencement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  SNFX may terminate this CLOA in its entirety upon &#91;**&#93; days&#8217; written notice to MERSANA in the event MERSANA, or any of its Affiliates or Sublicensees, challenges in a legal or administrative proceeding the validity or enforceability of a Valid Claim of any Licensed Patent (except as (i) required under a court order or subpoena or (ii) a defense against a claim, action or proceeding asserted by SNFX against MERSANA or any of its Affiliates or Sublicensees)&#59; provided that any such termination shall not become effective if (A) such action has been withdrawn before the end of the aforementioned notice period or (B) in the event that the challenging party is a Sublicensee of MERSANA, MERSANA terminates such Sublicensee&#8217;s Sublicense Agreement to the challenged Licensed Patent before the end of the aforementioned notice period. In addition, if the Valid Claim of a Licensed Patent is upheld, MERSANA shall reimburse SNFX for its reasonable legal costs and expenses incurred in defending any such challenge.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.3.&#160;&#160;&#160;&#160;Effect of Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;Rights and Obligations Upon Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon expiration or termination of this CLOA, neither Party shall have any further rights or obligations hereunder in the Territory with respect to the Terminated Targets or under this CLOA in its entirety, as applicable, except pursuant to any provisions hereunder that expressly survive such expiration or termination (including, for the avoidance of doubt, this Section 10.3).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon the date of expiration (but not earlier termination) of each Royalty Term with respect to all Products with respect to a Licensed Target in a country, the rights and licenses granted by SNFX or its Affiliates to MERSANA and its Affiliates under this CLOA to Develop, Manufacture, Commercialize and otherwise Exploit Products against such Licensed Target in the Field throughout the Territory shall convert to irrevocable, perpetual, non-exclusive, royalty-free, fully paid-up, freely transferable, non-terminable rights and licenses, with the right to grant sublicenses (through multiple tiers), with no further obligation to SNFX. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any termination by MERSANA pursuant to Sections 10.2(b) or 10.2(c), the rights and licenses granted by SNFX or its Affiliates to MERSANA and its Affiliates under this CLOA to Develop, Manufacture, Commercialize and otherwise Exploit Products against a Licensed Target in the Field throughout the Territory shall convert to irrevocable, perpetual, non-exclusive, freely transferable, non-terminable rights and licenses, with the right to grant sublicenses (through multiple tiers), subject to the continued payment by MERSANA of all amounts due to SNFX pursuant to Article 3 during the applicable Royalty Term in a country&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of any termination by SNFX pursuant to Sections 10.2(b), 10.2(c), or 10.2(d) or MERSANA terminates pursuant to Section 10.2(a), as of the effective date of such termination of this CLOA&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;this CLOA and all rights and licenses granted to MERSANA under Sections&#160;2.1, 2.2 and 4.4(a) shall terminate with respect to the Terminated Targets or with respect to all Licensed Targets, as applicable, and all such applicable rights in the Licensed Technology shall revert to SNFX&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;except as required for a Party to exercise its rights or fulfill its obligations under this Section 10.3, each Party shall return to the other Party or destroy (at the disclosing Party&#8217;s option) and cease using all Confidential Information of the other Party (including, for the avoidance of doubt, the Licensed Know-How and all copies thereof) that are solely related to the Terminated Targets or with respect to all Confidential Information if this CLOA is terminated in its entirety, as applicable&#59; provided, however, each Party may retain one (1) copy of such Confidential Information for archival purposes.  Each Party shall confirm in writing to the other Party that all such Confidential Information, except one (1) copy for archival purposes, has been returned to the other Party.  Notwithstanding the foregoing, the obligation to return Confidential Information shall not cover information that is required to be retained by applicable Law or information maintained on routine computer system backup tapes, disks or other backup storage devices as long as such backed-up information is not used, disclosed or otherwise recovered from such backup devices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Accrued Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Termination of this CLOA for any reason will be without prejudice to any rights that will have accrued to the benefit of a Party prior to such termination.  Such termination will not relieve a Party from accrued payment obligations or from obligations which are expressly indicated to survive termination of this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of Sections 2.1(a) (to the extent set forth in Section 10.3(a)(2) and 10.3(a)(3)), 2.2(d)(3), 2.4(b), 2.11, 2.12, 5.1, 5.2, 5.3, 10.3 and Article 1, Article 3 (to the extent set forth in Section 10.3(a)(3)), Article 6, Article 7, Article 8, Article 9 and Article 11 shall survive expiration or termination of this CLOA for the period so specified, if any, or for perpetuity.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ARTICLE 11<br>GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.1.&#160;&#160;&#160;&#160;Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties acknowledge that this CLOA, together with the exhibits and schedules attached hereto, sets forth the entire agreement and understanding of the Parties as to the subject matter hereof, and supersedes all prior and contemporaneous discussions, agreements and writings in respect hereto, except for the Material Transfer Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which shall remain in full force and effect between SNFX and MERSANA, and the Three-way Mutual Non-Disclosure Agreement which shall remain in full force and effect between SNFX, MERSANA and Me Jean-Paul Vulliety.  To the extent there is any conflict or ambiguity between this CLOA and the Material Transfer Agreement (or any amendments thereto that may be agreed in the future between the Parties), this CLOA shall control.  To the extent there is any conflict or ambiguity between this CLOA and the Three-way Mutual Non-Disclosure Agreement (or any amendments thereto that may be agreed in the future between the parties thereto), the Three-way Mutual Non-Disclosure Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.2.&#160;&#160;&#160;&#160;Modification&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No waiver, modification, amendment or alteration of any provision of this CLOA will be valid or effective unless made in writing and signed by each of the Parties.  The failure of a Party to enforce any rights or provisions of the CLOA shall not be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">construed to be a waiver of such rights or provisions, or a waiver by such Party to thereafter enforce such rights or provisions or any other rights or provisions hereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.3.&#160;&#160;&#160;&#160;Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each Party agrees to execute, acknowledge, and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the express provisions of this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.4.&#160;&#160;&#160;&#160;Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither Party shall be held responsible for any delay or failure in performance hereunder caused by strikes, embargoes, unexpected government requirements, civil or military authorities, acts of God, earthquake, terrorism, or by the public enemy or other causes reasonably beyond such Party&#8217;s control and without such Party&#8217;s fault or negligence&#59; provided that the affected Party notifies the unaffected Party as soon as reasonably possible, and resumes performance hereunder as soon as reasonably possible following cessation of such force majeure event.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.5.&#160;&#160;&#160;&#160;Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A Party shall not have the right to assign, by operation of law or otherwise, any of its rights or obligations under this CLOA without the prior written consent of the other Party, which consent shall not be unreasonably withheld, except that either Party may assign or transfer this CLOA in its entirety, without the written consent of the other Party, (a) to any successor in interest that acquires all or substantially all of the business or assets of a Party or that portion of the business or assets of such Party pertaining to the subject matter of this CLOA (whether by merger, reorganization, acquisition, consolidation, sale or otherwise) or (b) to its Affiliate&#59; provided that any permitted assignee will assume all rights and obligations of its assignor under this CLOA. Any assignment not in accordance with this Section 11.5 will be null and void. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.6.&#160;&#160;&#160;&#160;Performance by Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties recognize that each may perform some or all of its obligations under this CLOA through its Affiliates or may exercise some or all of its rights under this CLOA through its Affiliates&#59; provided, however, that each Party shall remain responsible and be the guarantor of the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this CLOA in connection with such performance.  In particular and without limitation, all Affiliates of a Party that receive Confidential Information of the other Party pursuant to this CLOA shall be governed and bound by all obligations set forth in Article 6.  Each Party will prohibit all of its Affiliates from taking any action that such Party is prohibited from taking under this CLOA as if such Affiliates were parties to this CLOA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.7.&#160;&#160;&#160;&#160;Relationship of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties shall perform their obligations under this CLOA as independent contractors and nothing in this CLOA is intended or will be deemed to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties.  Neither Party will have any right, power or authority to assume, create, or incur any expense, liability, or obligation, express or implied, on behalf of the other.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.8.&#160;&#160;&#160;&#160;No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except for the rights to indemnification provided for under Article 8 above, all rights, benefits and remedies under this CLOA are solely intended for the benefit of MERSANA and SNFX, and except for such rights to indemnification expressly provided pursuant to Article 8, no Third Party shall have any rights whatsoever to&#58;  (a)&#160;enforce any obligation contained in this CLOA&#59; (b)&#160;seek a benefit or remedy for any breach of this CLOA&#59; or (c)&#160;take any other action relating to this CLOA under any legal theory, including actions in contract, tort (including negligence, gross negligence and strict liability), or as a defense, setoff or counterclaim to any action or claim brought or made by the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.9.&#160;&#160;&#160;&#160;No Use of Names</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise required under applicable Law or permitted under this CLOA, neither Party will use the name, logo or trademark of the other Party or any of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">its Affiliates or any of its or their Sublicensees in its advertising, press releases or marketing or promotional materials without the prior written consent of such other Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.10.&#160;&#160;&#160;&#160;Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice, request, delivery, approval or consent required or permitted to be given under this CLOA will be in writing and will be deemed to have been sufficiently given if delivered in person (in which case, it will be effective upon delivery), transmitted by facsimile, if facsimile number is provided below (receipt verified&#59; in which case, it will be effective upon delivery), by express courier service (signature required&#59; in which case, it will be effective two days after being deposited with such courier service), or transmitted by email, if email is provided below (receipt verified&#59; in which case, it will be effective upon delivery) to the Party to which it is directed.</font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to SNFX&#58;&#160;&#160;&#160;&#160;Synaffix B.V.</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Industrielaan 63 <br>5349 AE, Oss<br>The Netherlands</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;p.vandesande&#64;synaffix.com<br>Attention&#58;  &#160;&#160;&#160;&#160;CEO <br>With copy to&#58; &#160;&#160;&#160;&#160;legal&#64;synaffix.com</font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:144pt;text-indent:-108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to MERSANA&#58;&#160;&#160;&#160;&#160;Mersana Therapeutics<br>840 Memorial Drive</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, Massachusetts 02139 USA</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58; (617) 498-0109</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; &#91;**&#93;</font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Legal Department</font></div><div style="padding-left:108pt;text-indent:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">With a copy to&#58; </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ropes &#38; Gray LLP</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">800 Boylston Street</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Boston, MA 02199</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Marc Rubenstein</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Fax&#58; (617) 235-0706</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; marc.rubenstein&#64;ropesgray.com</font></div><div><font><br></font></div><div style="padding-left:144pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.11.&#160;&#160;&#160;&#160;Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this CLOA (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall first be presented to the Parties&#8217; respective Executive Officers for resolution.  If the Parties are unable to resolve a given Dispute pursuant to this Section 11.11 after discussions between the Executive Officers within ten (10) days after referring such Dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter in accordance with Section 11.12.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.12.&#160;&#160;&#160;&#160;Submission to Court for Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 11.11, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this CLOA, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts.  The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this CLOA in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.  Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 11.10 shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">effective service of process for any action, suit or proceeding brought against it under this CLOA in any such court.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.13.&#160;&#160;&#160;&#160;Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This CLOA and all questions regarding its validity or interpretation, or the performance or breach of this CLOA, shall be governed by and construed and enforced in accordance with the laws of the State of New York and the Federal laws of the United States of America, without reference to conflicts of laws principles. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.14.&#160;&#160;&#160;&#160;Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The article, section and subsection headings contained herein are for the purposes of convenience only and are not intended to define or limit the contents of the articles, sections or subsections to which such headings apply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.15.&#160;&#160;&#160;&#160;Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  When possible, each provision of this CLOA will be interpreted in such manner as to be effective and valid under applicable Law, but, if any provision of this CLOA is held to be prohibited by or invalid under applicable Law, such provision will be ineffective but only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or of this CLOA.  The Parties will make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.16.&#160;&#160;&#160;&#160;Equitable Relief.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in this CLOA will deny any Party the right to seek injunctive or other equitable relief from a court of competent jurisdiction in the context of prospective irreparable harm. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.17.&#160;&#160;&#160;&#160;Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This CLOA may be executed in two (2) or more counterparts (including by facsimile or electronic signature), each of which shall be deemed an original and all of which together shall constitute one instrument. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Signature Page Follows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table></div><div><font><br></font></div></div></div><div id="i19fa76fd6320467dbe22d0f095a77383_7"></div><hr style="page-break-after:always"><div style="min-height:86.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Parties have executed this CLOA in duplicate originals by their duly authorized representatives as of the Amendment Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SYNAFFIX B.V.</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERSANA THERAPEUTICS, INC.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SNFX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">MERSANA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8221;)</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Peter van de Sande&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Brian DeSchuytner&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Peter van de Sande&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Brian DeSchuytner&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Executive Officer&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> November 23, 2021&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> Chief Financial Officer&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">November 22, 2021&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:82.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>4
<FILENAME>exhibit102810kfy2021.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie6a98db5a03241988fc636c509099827_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.28</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERSANA THERAPEUTICS, INC.<br>2022 INDUCEMENT STOCK INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">DEFINED TERMS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following terms, when used in the Plan (as defined below), have the meanings and are subject to the provisions set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Rules&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  Financial Accounting Standards Board Accounting Standards Codification Topic 718, or any successor provision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The Compensation Committee, except with respect to such matters that are not delegated to the Compensation Committee by the Board (whether pursuant to committee charter or otherwise).  The Compensation Committee (or the Board acting with a majority of the Independent Directors), with respect to such matters over which they retain authority under the Plan or otherwise), to the extent permitted by applicable law and subject to any requirements under the Nasdaq Stock Market Rules, may delegate (i) to one or more of its members (or one or more other members of the Board, including the full Board) such of its duties, powers and responsibilities as it may determine&#59; provided that the grant of any Award under the Plan must be approved by the Company&#8217;s Independent Directors in order to comply with the exemption from the stockholder approval requirement for &#8220;inducement grants&#8221; provided under Nasdaq Stock Market Rule 5635(c)(4)&#59;  or (ii) to one or more officers of the Company the power to grant Awards to the extent permitted by Section 152 or 157(c) of the Delaware General Corporation Law, provided that the Compensation Committee (or Board, acting with a majority of the Independent Directors) shall fix the terms of the Awards to be granted by such officers, the maximum number of shares subject to Awards that the officers may grant and the time period in which such Awards may be granted, and, provided, further that no officer shall be authorized to grant Awards to any &#8220;executive officer&#8221; of the Company (as defined by Rule 3b-7 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or to any &#8220;officer&#8221; of the Company (as defined by Rule 16(a)-1(f) under the Exchange Act.   For purposes of the Plan, the term &#8220;Administrator&#8221; will include the Board, the Compensation Committee, the Independent Directors, and the officer or officers delegated authority under the Plan to the extent of such delegation, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Any or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Stock Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">SARs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Restricted Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Unrestricted Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Stock Units, including Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Performance Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Awards (other than Awards described in (1) through (6) above) that are convertible into or otherwise based on Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The Board of Directors of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  In the case of any Participant who is party to an employment or severance-benefit agreement that contains a definition of &#8220;Cause,&#8221; the definition set forth in such agreement applies with respect to such Participant for purposes of the Plan for so long as such agreement is in effect.  In every other case, &#8220;Cause&#8221; means, as determined by the Administrator, (i) a substantial failure of the Participant to perform the Participant&#8217;s duties and responsibilities to the Company or any of its subsidiaries or substantial negligence in the performance of such duties and responsibilities&#59; (ii) the commission by the Participant of a felony or a crime involving moral turpitude&#59; (iii) the commission by the Participant of theft, fraud, embezzlement, material breach of trust or any material act of dishonesty involving the Company or any of its subsidiaries&#59; (iv) a significant violation by the Participant of the code of conduct of the Company or any of its subsidiaries of any material policy of the Company or any of its subsidiaries, or of any statutory or common law duty of loyalty to the Company or any of its subsidiaries&#59; (v) material breach of any of the terms of the Plan or any Award made under the Plan, or of the terms of any other agreement between the Company or any of its subsidiaries and the Participant&#59; or (vi) other conduct by the Participant that could be expected to be harmful to the business, interests or reputation of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The U.S. Internal Revenue Code of 1986, as from time to time amended and in effect, or any successor statute as from time to time in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Mersana Therapeutics, Inc., a Delaware corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Any of (i) a consolidation, merger or similar transaction or series of related transactions, including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in the acquisition of all or substantially all of the Company&#8217;s then-outstanding common stock by a single person or entity or by a group of persons and&#47;or entities acting in concert&#59; (ii) a sale or transfer of all or substantially all the Company&#8217;s assets&#59; or (iii) a dissolution or liquidation of the Company.  Where a Covered Transaction involves a tender offer that is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the Covered Transaction will be deemed to have occurred upon consummation of the tender offer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Adoption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The date the Plan was adopted by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A member of the Board who is not an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.19pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Any person who is employed by the Company or any of its subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.53pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  As of a particular date, (i) the closing price for a share of Stock reported on the Nasdaq Stock Market (or any other national securities exchange on which the Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the immediately preceding date on which a closing price was reported or (ii) in the event that the Stock is not traded on a national securities exchange, the fair market value of a share of Stock determined by the Administrator consistent with the rules of Section 409A to the extent applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Independent Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58; the Company&#8217;s independent directors (as defined in Nasdaq Stock Market Rule 5605(a)(2).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Statutory Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A Stock Option that is not intended to be an &#8220;incentive stock option&#8221; within the meaning of Section 422. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A person who is granted an Award under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  An Award subject to Performance Criteria.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Criteria</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Specified criteria, other than the mere continuation of Service or the mere passage of time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award.  A Performance Criterion and any targets with respect thereto need not be based upon an increase, a positive or improved result or avoidance of loss.  Performance Criterion may include an objectively determinable measure or objectively determinable measures of performance relating to any, or any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Administrator specifies)&#58;  sales&#59; revenues&#59; assets&#59; expenses&#59; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis&#59; return on equity, investment, capital or assets&#59; one or more operating ratios&#59; borrowing levels, leverage ratios or credit rating&#59; market share&#59; capital expenditures&#59; cash flow&#59; stock price&#59; stockholder return&#59; sales of particular products or services&#59; customer acquisition or retention&#59; acquisitions and divestitures (in whole or in part)&#59; joint ventures and strategic alliances&#59; spin-offs, split-ups and the like&#59; reorganizations&#59; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings&#59; or strategic business criteria, consisting of one or more objectives based on&#58;  meeting specified market penetration or value added, product development or introduction (including, without limitation, any clinical trial accomplishments, regulatory or other filings or approvals, or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third-party collaborations), manufacturing or process development, legal compliance or risk reduction,  patent application or issuance goals or any other metric determined by the Administrator.  The Administrator may at any time provide that one or more of the Performance Criteria applicable to such Award will be adjusted to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable Performance Criterion or Criteria or may waive the Performance Criteria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.86pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  The Mersana Therapeutics, Inc. 2022 Inducement Stock Incentive Plan, as from time to time amended and in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.53pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Stock subject to restrictions requiring that it be redelivered or offered for sale to the Company if specified service or performance-based conditions are not satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(u)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:16.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A Stock Unit that is, or as to which the delivery of Stock or cash in lieu of Stock is, subject to the satisfaction of specified performance or other vesting conditions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A right entitling the holder upon exercise to receive an amount (payable in cash or in shares of Stock of equivalent value) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the base value from which appreciation under the SAR is to be measured.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(w)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:14.86pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Section 409A of the Code and the regulations thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Section 422</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Section 422 of the Code and the regulations thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:17.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  A Participant&#8217;s employment or other service with the Company or any of its subsidiaries.  Service will be deemed to continue, unless the Administrator otherwise determines at the time of grant of an Award or thereafter, so long as the Participant is employed by, or otherwise is providing services to, the Company or any of its subsidiaries.  If a Participant&#8217;s employment or other service relationship is with any subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant&#8217;s Service will be deemed to have terminated when the entity ceases to be a subsidiary of the Company unless the Participant transfers Service to the Company or any of its remaining subsidiaries.  Notwithstanding the foregoing, in construing the provisions of any Award relating to the payment of &#8220;nonqualified deferred compensation&#8221; (subject to Section 409A) upon a termination or cessation of Service, references to termination or cessation of employment, separation from service, retirement or similar or correlative terms will be construed to require a &#8220;separation from service&#8221; (as that term is defined in Section 1.409A-1(h) of the Treasury Regulations) from the Company and from all other corporations and trades or businesses, if any, that would be treated as a single &#8220;service recipient&#8221; with the Company under Section 1.409A-1(h)(3) of the Treasury Regulations.  The Company may, but need not, elect in writing, subject to the applicable limitations under Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a &#8220;separation from service&#8221; has occurred.  Any such written election will be deemed a part of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Common stock of the Company, par value $0.0001 per share.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(aa)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:11.52pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  An option entitling the holder to acquire shares of Stock upon payment of the exercise price.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ab)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:10.85pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash measured by the value of Stock in the future.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ac)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Unrestricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;&#58;  Stock not subject to any restrictions under the terms of the Award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">PURPOSE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan provides for the grant of Awards consisting of, or based on, Stock.  The purposes of the Plan are to attract, retain and reward persons who are expected to make important contributions to the Company with an inducement material for such persons to enter into employment with the Company and its subsidiaries, to incentivize them to generate stockholder value, to enable them to participate in the growth of the Company and to align their interests with the interests of the Company&#8217;s stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ADMINISTRATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan&#59; determine eligibility for and grant Awards&#59; determine, modify or waive the terms and conditions of any Award&#59; determine the form of settlement of Awards (whether in cash, shares of Stock, other Awards, or other property)&#59; prescribe forms, rules and procedures relating to the Plan and Awards&#59; and otherwise do all things necessary or desirable to carry out the purposes of the Plan.  Determinations of the Administrator made under the Plan are conclusive and bind all persons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">LIMITS ON AWARDS UNDER THE PLAN</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt;text-decoration:underline">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to adjustment as provided in Section 7(b), the maximum number of shares of Stock that may be delivered in satisfaction of Awards under the Plan is 2,000,000 shares of Stock.  For purposes of this Section 4(a), shares of Stock shall not be treated as delivered under the Plan unless and until, and to the extent, they are actually issued and delivered to a Participant.  Without limiting the generality of the foregoing, shares of Stock withheld by the Company in payment of the exercise price or purchase price of an Award or in satisfaction of tax withholding requirements with respect to an Award and shares of Stock underlying any portion of an Award that is settled or that expires, becomes unexercisable, terminates or is forfeited to or repurchased by the Company, in each case, without the delivery of Stock shall not be treated as delivered in satisfaction of Awards under the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.85pt;text-decoration:underline">Type of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Stock delivered by the Company under the Plan may be authorized but unissued Stock or previously issued Stock acquired by the Company.  No fractional shares of Stock will be delivered under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">ELIGIBILITY AND PARTICIPATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Awards under the Plan may only be granted to persons who (a) were not previously an Employee or Director of the Company or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case as an inducement material to the individual&#8217;s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). For the avoidance of doubt, neither consultants nor advisors shall be eligible to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">RULES APPLICABLE TO AWARDS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt;text-decoration:underline">All Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Award Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall determine the terms of all Awards, subject to the limitations provided herein.  By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an Award, the Participant will be deemed to have agreed to the terms of the Award and the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(2), no Awards may be transferred other than by will or by the laws of descent and distribution.  During a Participant&#8217;s lifetime, except as the Administrator otherwise expressly provides in accordance with the third sentence of this Section 6(a)(2), SARs and NSOs may be exercised only by the Participant.  The Administrator may permit the transfer of Awards, subject to applicable securities and other laws and such limitations as the Administrator may impose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Vesting, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall determine the time or times at which an Award vests or becomes exercisable and the terms on which a Stock Option or SAR remains exercisable.  Without limiting the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, regardless of any adverse or potentially adverse tax or other consequences resulting from such acceleration.  Unless the Administrator expressly provides otherwise, however, the following rules will apply if a Participant&#8217;s Service ceases&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Except as provided in (B) and (C) below, immediately upon the cessation of the Participant&#8217;s Service each Stock Option and SAR that is then held by the Participant or by the Participant&#8217;s permitted transferees, if any, will cease to be exercisable and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">will terminate and all other Awards that are then held by the Participant or by the Participant&#8217;s permitted transferees, if any, to the extent not already vested will be forfeited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">Subject to (C) and (D) below, all vested and unexercised Stock Options and SARs held by the Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Service, to the extent then exercisable, will remain exercisable for the lesser of (i) a period of three months or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(3), and will thereupon immediately terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Subject to (D) below, all vested and unexercised Stock Options and SARs held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Service due to his or her death, to the extent then exercisable, will remain exercisable for the lesser of (i) the one-year period ending with the first anniversary of the Participant&#8217;s death or (ii) the period ending on the latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(3), and will thereupon immediately terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">All Stock Options and SARs (whether or not vested or exercisable) held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Service will immediately terminate upon such cessation of Service if the termination is for Cause or occurs in circumstances that in the determination of the Administrator would have constituted grounds for the Participant&#8217;s Service to be terminated for Cause.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Recovery of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may provide in any case that any outstanding Award (whether or not vested or exercisable) and the proceeds from the exercise or disposition of any Award or Stock acquired under any Award will be subject to forfeiture and disgorgement to the Company, with interest and other related earnings, if the Participant to whom the Award was granted violates (i) a non-competition, non-solicitation, confidentiality or other restrictive covenant by which he or she is bound or (ii) any Company policy applicable to the Participant that provides for forfeiture or disgorgement with respect to incentive compensation that includes Awards under the Plan.  In addition, the Administrator may require forfeiture and disgorgement to the Company of any outstanding Award and the proceeds from the exercise or disposition of any Award or Stock acquired under any Award, with interest and other related earnings, to the extent required by law or applicable stock exchange listing standards, including, without limitation, Section 10D of the Exchange Act, and any applicable Company policy.  Each Participant, by accepting or being deemed to have accepted an Award under the Plan, agrees to cooperate fully with the Administrator, and to cause any and all permitted transferees of the Participant to cooperate fully with the Administrator, to effectuate any forfeiture or disgorgement required hereunder.  Neither the Administrator nor the Company nor any other person, other than the Participant and his or her permitted transferees, if any, will be responsible for any adverse tax or other consequences to a Participant or his or her permitted transferees, if any, that may arise in connection with this Section 6(a)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The delivery, vesting and retention of Stock, cash or other property under an Award are conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the Award.  The Administrator shall prescribe such rules for the withholding of taxes with respect to any Award as it deems necessary.  The Administrator may hold back shares of Stock from an Award or permit a Participant to tender previously owned shares of Stock in satisfaction of tax withholding requirements (but not in excess of the maximum withholding amount consistent with the award being subject to equity accounting treatment under the Accounting Rules).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Dividend Equivalents, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may provide for the payment of amounts (on terms and subject to conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock subject to an Award whether or not the holder of such Award is otherwise entitled to share in the actual dividend or distribution in respect of such Award.  Any entitlement to dividend equivalents or similar entitlements will be established and administered either consistent with an exemption from, or in compliance with, the requirements of Section 409A.  Dividends or dividend equivalent amounts payable in respect of Awards that are subject to restrictions may be subject to such limits or restrictions as the Administrator may impose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Rights Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing in the Plan may be construed as giving any person the right to be granted an Award or to continued Service with the Company or any of its subsidiaries, or any rights as a stockholder except as to shares of Stock actually issued under the Plan.  The loss of existing or potential profit in Awards will not constitute an element of damages in the event of termination of Service for any reason, even if the termination is in violation of an obligation of the Company or any of its subsidiaries to the Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(8)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Coordination with Other Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Awards under the Plan may be granted in tandem with other Awards under the Plan or awards made under other compensatory plans or programs of the Company or any of its subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(9)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">Without limiting the generality of Section 11(b) hereof, each Award will contain such terms as the Administrator determines and will be construed and administered, such that the Award either qualifies for an exemption from the requirements of Section 409A or satisfies such requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">If a Participant is deemed on the date of the Participant&#8217;s termination of Service to be a &#8220;specified employee&#8221; within the meaning of that term under Section 409A(a)(2)(B), then, with regard to any payment that is considered nonqualified deferred compensation under Section 409A, to the extent applicable, payable on account of a &#8220;separation from service&#8221;, such payment will be made or provided on the date that is the earlier of (i) the expiration of the six-month period measured from the date of such &#8220;separation from service&#8221; and (ii) the date of the Participant&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Upon the expiration of the Delay Period, all payments delayed pursuant to this Section 6(a)(9)(B) (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such delay) will be paid on the first business day following the expiration of the Delay Period in a lump sum and any remaining payments due under the Award will be paid in accordance with the normal payment dates specified for them in the applicable Award agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">For purposes of Section 409A, each payment made under this Plan will be treated as a separate payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(10)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.02pt;text-decoration:underline">Press Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Promptly following the grant of an Award hereunder, the Company must disclose in a press release the material terms of the grant, the number of shares of Stock involved, and, if required by law or the Nasdaq Stock Market Rules, the identity of the Participant. Each Participant, by accepting an Award, consents to the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.85pt;text-decoration:underline">Stock Options and SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">NSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each Stock Option granted pursuant to the Plan will an NSO.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Time and Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless the Administrator expressly provides otherwise, no Stock Option or SAR will be deemed to have been exercised until the Administrator receives notice of exercise in a form acceptable to the Administrator that is signed by the appropriate person and accompanied by any payment required under the Award.  Any attempt to exercise a Stock Option or SAR by any person other than the Participant (or a permitted transferee) will not be given effect unless the Administrator has received such evidence as it may require that the person exercising the Award has the right to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The exercise price (or the base value from which appreciation is to be measured) of each Award requiring exercise must be no less than 100% of the Fair Market Value of the Stock subject to the Award, determined as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Payment of Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Where the exercise of an Award is to be accompanied by payment, payment of the exercise price must be by cash or check acceptable to the Administrator or, if so permitted by the Administrator and if legally permissible, (i) through the delivery of previously acquired unrestricted shares of Stock, or the withholding of unrestricted shares of Stock otherwise deliverable upon exercise, in either case, that have a Fair Market Value equal to the exercise price&#59; (ii) through a broker-assisted exercise program acceptable to the Administrator&#59; (iii) by other means acceptable to the Administrator&#59; or (iv) by any combination of the foregoing permissible forms of payment.  The delivery of previously acquired shares in payment of the exercise price under clause (i) above may be accomplished either by actual delivery or by constructive delivery through attestation of ownership, subject to such rules as the Administrator may prescribe.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Maximum Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The maximum term of Stock Options and SARs must not exceed 10 years from the date of grant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Repricing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except in connection with a corporate transaction involving the Company (which term includes, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split-up, spin-off, combination, or exchange of shares) or as otherwise contemplated by Section 7 below, the Company may not, without obtaining stockholder approval, (i) amend the terms of outstanding Stock Options or SARs to reduce the exercise price or base value of such Stock Options or SARs&#59; (ii) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an exercise price or base value that is less than the exercise price or base value of the original Stock Options or SARs&#59; or (iii) cancel outstanding Stock Options or SARs that have an exercise price or base value greater than the Fair Market Value of a share of Stock on the date of such cancellation in exchange for cash or other consideration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">EFFECT OF CERTAIN TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt;text-decoration:underline">Mergers, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise expressly provided in an Award agreement or by the Administrator, the following provisions will apply in the event of a Covered Transaction&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Assumption or Substitution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Covered Transaction is one in which there is an acquiring or surviving entity, the Administrator may provide for (i) the assumption or continuation of some or all outstanding Awards or any portion thereof or (ii) the grant of new awards in substitution therefor by the acquiror or survivor or an affiliate of the acquiror or survivor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Cash-Out of Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 7(a)(5) below, the Administrator may provide for payment (a &#8220;cash-out&#8221;), with respect to some or all Awards or any portion thereof, equal in the case of each affected Award or portion thereof to the excess, if </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any, of (i) the Fair Market Value of one share of Stock times the number of shares of Stock subject to the Award or such portion, over (ii) the aggregate exercise or purchase price, if any, under the Award or such portion (in the case of a SAR, the aggregate base value above which appreciation is measured), in each case on such payment terms (which need not be the same as the terms of payment to holders of Stock) and other terms, and subject to such conditions, as the Administrator determines&#59; provided, however, for the avoidance of doubt, that if the per share exercise or purchase price (or base value) of an Award is equal to or greater than the Fair Market Value of one share of Stock, the Award may be cancelled with no payment due hereunder or otherwise in respect of such Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Acceleration of Certain Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section 7(a)(5) below, the Administrator may provide that any Award requiring exercise will become exercisable, in full or in part, and&#47;or that the delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including Restricted Stock Units and Performance Awards to the extent consisting of Stock Units) will be accelerated, in full or in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the Administrator, following exercise of the Award or the delivery of the shares, as the case may be, to participate as a stockholder in the Covered Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination of Awards upon Consummation of Covered Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as the Administrator may otherwise determine in any case, each Award will automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited) immediately upon consummation of the Covered Transaction, other than (i) any Award that is assumed or substituted pursuant to Section 7(a)(1) above and (ii) any Award that by its terms, or as a result of action taken by the Administrator, continues following the Covered Transaction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Additional Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any share of Stock and any cash or other property delivered pursuant to Section 7(a)(2) or Section 7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if any, as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction.  For purposes of the immediately preceding sentence, a cash-out under Section 7(a)(2) above or an acceleration under Section 7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other vesting condition.  In the case of Restricted Stock that does not vest and is not forfeited in connection with the Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to such restrictions as the Administrator deems appropriate to carry out the intent of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.85pt;text-decoration:underline">Changes in and Distributions with Respect to Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Basic Adjustment Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of a stock dividend, stock split or combination of shares (including a reverse stock split), recapitalization or other change in the Company&#8217;s capital structure that constitutes an equity restructuring within the meaning of the Accounting Rules, the Administrator shall make appropriate adjustments to the maximum number of shares of Stock specified in Section 4(a) that may be issued under the Plan, and shall make appropriate adjustments to the number and kind of shares of stock or securities underlying Awards then outstanding or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other provision of Awards affected by such change.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Certain Other Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may also make adjustments of the type described in Section 7(b)(1) above to take into account distributions to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">stockholders other than those provided for in Section 7(a) and 7(b)(1), or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in the operation of the Plan and the requirements of Section 409A, to the extent applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt;text-decoration:underline">Continuing Application of Plan Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  References in the Plan to shares of Stock will be construed to include any stock or securities resulting from an adjustment pursuant to this Section 7.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">LEGAL CONDITIONS ON DELIVERY OF STOCK</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction from shares of Stock previously delivered under the Plan until&#58;  (i) the Company is satisfied that all legal matters in connection with the issuance and delivery of such shares have been addressed and resolved&#59; (ii) if the outstanding Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered have been listed or authorized to be listed on such exchange or system upon official notice of issuance&#59; and (iii) all conditions of the Award have been satisfied or waived.  The Company may require, as a condition to the exercise of an Award or the delivery of shares of Stock under an Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law.  Any Stock required to be issued to Participants under the Plan will be evidenced in such manner as the Administrator may deem appropriate, including book-entry registration or delivery of stock certificates.  In the event that the Administrator determines that stock certificates will be issued to Participants under the Plan, the Administrator may require that certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer applicable to such Stock, and the Company may hold the certificates pending lapse of the applicable restrictions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards&#59; provided, however, that except as otherwise expressly provided in the Plan the Administrator may not, without the Participant&#8217;s consent, alter the terms of an Award so as to affect materially and adversely the Participant&#8217;s rights under the Award, unless the Administrator expressly reserved the right to do so at the time the Award was granted.   Any amendments to the Plan will be conditioned upon stockholder approval only to the extent, if any, such approval is required by law (including the Code) or applicable stock exchange requirements, as determined by the Administrator.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">OTHER COMPENSATION ARRANGEMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The existence of the Plan or the grant of any Award will not affect the Company&#8217;s right to award a person bonuses or other compensation in addition to Awards under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting or being deemed to have accepted an Award under the Plan, each Participant waives any right to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in connection therewith, and agrees that any such action, proceedings or counterclaim will be tried before a court and not before a jury.  By accepting or being deemed to have accepted an Award under the Plan, each Participant certifies that no officer, representative, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or attorney of the Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers.  Notwithstanding anything to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to agree to submit disputes arising under the terms of the Plan or any Award made hereunder to binding arbitration or as limiting the ability of the Company to require any eligible individual to agree to submit such disputes to binding arbitration as a condition of receiving an Award hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.85pt;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in the Plan, neither the Company, nor any of its subsidiaries, nor the Administrator, nor any person acting on behalf of the Company, any of its subsidiaries, or the Administrator, will be liable to any Participant, to any permitted transferee, to the estate or beneficiary of any Participant or any permitted transferee, or to any other holder of an Award by reason of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Section 409A or by reason of Section 4999 of the Code, or otherwise asserted with respect to the Award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">ESTABLISHMENT OF SUB-PLANS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Administrator may at any time and from time to time establish one or more sub-plans under the Plan (for local-law compliance purposes or other administrative reasons determined by the Administrator) by adopting supplements to the Plan containing, in each case, such limitations on the Administrator&#8217;s discretion under the Plan, and such additional terms and conditions, as the Administrator deems necessary or desirable.  Each supplement so established will be deemed to be part of the Plan but will apply only to Participants within the group to which the supplement applies (as determined by the Administrator).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">GOVERNING LAW</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:17.52pt;text-decoration:underline">Certain Requirements of Corporate Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Awards will be granted and administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Stock is listed or entered for trading, in each case as determined by the Administrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:16.85pt;text-decoration:underline">Other Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as otherwise provided by the express terms of an Award agreement, under a sub-plan described in Section 12 or as provided in Section 13(a) above, the domestic substantive laws of the Commonwealth of Massachusetts govern the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of or based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:18.2pt;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  By accepting an Award, each Participant will be deemed to (i) have submitted irrevocably and unconditionally to the jurisdiction of the federal and state courts located within the geographic boundaries of the United States District Court for the District of Massachusetts for the purpose of any suit, action or other proceeding arising out of or based upon the Plan or any Award&#59; (ii) agree not to commence any suit, action or other proceeding arising out of or based upon the Plan or an Award, except in the federal and state courts located within the geographic boundaries of the United States District Court for the District of Massachusetts&#59; and (iii) waive, and agree not to assert, by way of motion as a defense or otherwise, in any such suit, action or proceeding, any claim that he or she is not subject personally to the jurisdiction of the above-named courts that his or her property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of the suit, action or proceeding is improper or that the Plan or an Award or the subject matter thereof may not be enforced in or by such court.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- 12 -</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>5
<FILENAME>exhibit102910kfy2021.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6b86534febbf45f09b187937fe56eba5_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.29</font></div></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of RSUs&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">MERSANA THERAPEUTICS, INC. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2022 INDUCEMENT STOCK INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) evidences a grant of restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by Mersana Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to the individual named above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant to and subject to the terms of the Mersana Therapeutics, Inc. 2022 Inducement Stock Incentive Plan (as from time to time amended and in effect, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Except as otherwise defined herein, all capitalized terms used herein have the same meanings as in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In consideration of the employment services to be rendered to the Company by the Grantee and as an inducement material for the Grantee to enter into employment with the Company, the Company grants to the Grantee on the date set forth above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the number of RSUs set forth above, giving the Grantee the conditional right to receive, with respect to each RSU granted hereunder, without payment and pursuant to and subject to the terms and conditions set forth in this Agreement and in the Plan, one share of Stock (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), subject to adjustment pursuant to Section 7 of the Plan in respect of transactions occurring after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The RSUs are granted to the Grantee pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4), as an inducement that is material to the Grantee&#8217;s entering into employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting&#59; Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Unless earlier terminated, forfeited, relinquished or expired, the RSUs will vest as to &#91;25% of the shares on each of the first &#91;four&#93; anniversaries of the Vesting Commencement Date (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, subject to Grantee's continued Service through such Vesting Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If the Grantee's Service ceases for any reason, except as expressly provided for in any agreement between the Grantee and the Company or any of its subsidiaries, the RSUs, to the extent not then vested, will be immediately forfeited.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Delivery of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to Section 4 below, the Company shall, as soon as practicable upon the vesting of any RSUs subject to this Agreement (but in no event later than 30 days following a Vesting Date), effect delivery of the Shares with respect to such vested RSUs to the Grantee (or, in the event of the Grantee's death, to the person to whom the Award has passed by will or the laws of descent and distribution). No Shares will be issued pursuant to this Agreement unless and until all legal requirements applicable to the issuance or transfer of such Shares have been complied with to the satisfaction of the Administrator.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeiture&#59; Recovery of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Vesting to be specified based on grant terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.29</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The RSUs, and the proceeds from the issuance or disposition of the Shares, will be subject to forfeiture and disgorgement to the Company, with interest and related earnings, if at any time the Grantee is not in compliance with all applicable provisions of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;By accepting, or being deemed to have accepted, the RSUs, the Grantee expressly acknowledges and agrees that his or her rights, and those of any permitted transferee of the RSUs, including the right to any Shares or proceeds from the disposition thereof, are subject to Section 6(a)(4) of the Plan (including any successor provision). Nothing in the preceding sentence may be construed as limiting the general application of Section 7 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The RSUs may not be transferred except as expressly permitted under Section 6(a)(2) of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee expressly acknowledges and agrees that the Grantee's rights hereunder, including the right to be issued Shares in settlement of the RSUs subject to this Agreement, are subject to the Grantee's satisfaction of all taxes required to be withheld, if any. At such time as the Grantee is not aware of any material nonpublic information about the Company or the Stock, and the Grantee is not otherwise prevented from doing so under the Company&#8217;s Insider Trading Policy, the Grantee shall execute the instruction set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Durable Automatic Sale Instruction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) as the means of satisfying such tax obligation. If the Grantee does not execute the Durable Automatic Sale Instruction prior to an applicable vesting date, then the Grantee agrees that if under applicable law the Grantee will owe taxes at such vesting date on the portion of the award of RSUs then vested, the Company shall be entitled to immediate payment from the Grantee of the amount of any tax required to be withheld by the Company. The Company shall not deliver any shares of Stock to the Grantee until it is satisfied that all required withholdings have been made.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effect on Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This grant of the RSUs will not give the Grantee any right to be retained in the Service of the Company or any of its subsidiaries, affect the right of the Company or any of its subsidiaries to terminate the Grantee's Service at any time, or affect any right of the Grantee to terminate his or her Service with the Company at any time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by reference. A copy of the Plan as in effect on the Date of Grant has been furnished or made available to the Grantee. By accepting, or being deemed to have accepted, all or any part of the RSUs, the Grantee agrees to be bound by the terms of the Plan and this Agreement. In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.29</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Schedule A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Durable Automatic Sale Instruction</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Durable Automatic Sale Instruction is being delivered to Mersana Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by the undersigned on the date set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby acknowledge that the Company has granted, or may in the future from time to time grant, to me restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) under the Company&#8217;s equity incentive plans as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge that upon the vesting dates applicable to any such RSUs, I will have compensation income equal to the fair market value of the shares of the Company&#8217;s common stock subject to the RSU that vest on such date and that the Company is required to withhold income and employment taxes in respect of that compensation income on the applicable vesting date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I desire to establish a process to satisfy such withholding obligation in respect of all RSUs that have been, or may in the future be, granted by the Company to me through an automatic sale of a portion of the shares of the Company&#8217;s common stock that would otherwise be issued to me on each applicable vesting date, such portion to be in an amount sufficient to satisfy such withholding obligation, with the proceeds of such sale delivered to the Company in satisfaction of such withholding obligation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I understand that the Company has arranged for the administration and execution of its equity incentive plans and the sale of securities by plan participants thereunder pursuant to an Internet-based platform administered by a third party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Agent&#8217;s designated brokerage partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon any vesting of my RSUs from and after the date of this Durable Automatic Sale Instruction, I hereby appoint the Agent (or any successor administrator) to automatically sell such number of shares of the Company&#8217;s common stock issuable with respect to my RSUs that vest as is sufficient to generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding obligations with respect to the income recognized by me upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall receive such net proceeds in satisfaction of such tax withholding obligation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby appoint the Chief Executive Officer, the Chief Financial Officer, the Chief Legal Officer and the Treasurer, and any of them acting alone and with full power of substitution, to serve as my attorneys in fact to arrange for the sale of shares of common stock in accordance with these durable automatic sale instructions. I agree to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares of common stock pursuant to these durable automatic sale instructions.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By signing below, I hereby represent to the Company that, as of the date hereof, I am not aware of any material nonpublic information about the Company or its common stock and that I am not prohibited from entering into these durable automatic sale instructions by the Company&#8217;s insider trading policy or otherwise. I have structured these automatic sale instructions to constitute a &#8220;binding contract&#8221; relating to the sale of common stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.29</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grantee</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>6
<FILENAME>exhibit103010kfy2021.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if42eafaba4f8451b8b1739a8e4eda663_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.30</font></div><div style="margin-bottom:0.12pt;text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Number of Shares of Stock subject to the Stock Option&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exercise Price Per Share&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">$&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Vesting Commencement Date</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;&#9679;&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">MERSANA THERAPEUTICS, INC.<br>2022 INDUCEMENT STOCK INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">NON-STATUTORY STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) evidences a stock option granted by the Company to the individual named above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Optionee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to and subject to the terms of the Mersana Therapeutics, Inc. 2022 Inducement Stock Incentive Plan (as from time to time amended and in effect, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Meaning of Certain Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.  The following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58;  In the event of the Optionee&#8217;s death, the beneficiary named in the written designation (in a form acceptable to the Administrator) most recently filed with the Administrator by the Optionee prior to the Optionee&#8217;s death and not subsequently revoked, or, if there is no such designated beneficiary, the executor or administrator of the Optionee&#8217;s estate.  An effective beneficiary designation will be treated as having been revoked only upon receipt by the Administrator, prior to the Optionee&#8217;s death, of an instrument of revocation in a form acceptable to the Administrator.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Option Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;&#58;  The Optionee or, if at the relevant time the Stock Option has passed to a Beneficiary, the Beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Grant of Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In consideration of the employment services to be rendered to the Company by the Optionee and as an inducement material for the Optionee to enter into employment with the Company, the Company grants to the Optionee on the date set forth above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) an option (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to purchase, pursuant to and subject to the terms set forth in this Agreement and in the Plan, up to the number of shares of Stock set forth above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), with an exercise price per Share as set forth above, in each case, subject to adjustment pursuant to Section 7 of the Plan in respect of transactions occurring after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Stock Option evidenced by this Agreement is a non-statutory option (that is, an option that does not qualify as an incentive stock option under Section 422 of the Code) and is granted to the Optionee pursuant to the inducement grant exception under Nasdaq Stock Market Rule 5635(c)(4), as an inducement that is material to the Optionee&#8217;s entering into employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Vesting&#59; Method of Exercise&#59; Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">vest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as used herein with respect to the Stock Option or any portion thereof means to become exercisable and the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">vested</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as applied to any outstanding Stock Option means that the Stock Option is then exercisable, subject, in each case, to the terms of the Plan.  &#91;Unless earlier terminated, forfeited, relinquished or expired, the Stock Option will vest as to 25% of the Shares underlying such Stock Option upon the first anniversary of the Vesting Commencement Date, and as to 6.25% of the Shares underlying such Stock Option on the last day of each three month period thereafter, in each case, with the number of Shares that vest on any such date being rounded down to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the nearest whole share and the Stock Option becoming vested as to 100% of the Shares on the fourth anniversary of the Vesting Commencement Date&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, subject, in each case, to the Optionee remaining in continuous Service from the date of this Agreement through such vesting date.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Exercise of the Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No portion of the Stock Option may be exercised until such portion vests.  Each election to exercise any vested portion of the Stock Option will be subject to the terms and conditions of the Plan and must be in written or electronic form acceptable to the Administrator, signed (including by electronic signature) by the Option Holder (or in such other form as is acceptable to the Administrator).  Each such written or electronic exercise election must be received by the Company at its principal office or by such other party as the Administrator may prescribe and be accompanied by payment in full of the exercise price as provided in the Plan.  The latest date on which the Stock Option or any portion thereof may be exercised is the 10th anniversary of the Date of Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Final Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and, if not exercised by such date, the Stock Option or any remaining portion thereof will thereupon immediately terminate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Cessation of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If the Optionee&#8217;s Service ceases, except as expressly provided for in an employment or other individual agreement between the Optionee and the Company or its Affiliate, the Stock Option, to the extent not already vested, will be immediately forfeited, and any vested portion of the Stock Option that is then outstanding will be treated as provided in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Forfeiture&#59; Recovery of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Stock Option, and the proceeds from the exercise or disposition of the Stock Option or the Shares, will be subject to forfeiture and disgorgement to the Company, with interest and related earnings, if at any time the Optionee is not in compliance with all applicable provisions of this Agreement and the Plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">By accepting, or being deemed to have accepted, the Stock Option, the Optionee expressly acknowledges and agrees that his or her rights, and those of any permitted transferee of the Stock Option, under the Stock Option, including the right to any Stock acquired under the Stock Option or proceeds from the disposition thereof, are subject to Section 6(a)(4) of the Plan (including any successor provision).  Nothing in the preceding sentence may be construed as limiting the general application of Section 8 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Nontransferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Stock Option may not be transferred except as expressly permitted under Section 6(a)(2) of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The exercise of the Stock Option will give rise to &#8220;wages&#8221; subject to withholding.  The Optionee expressly acknowledges and agrees that the Optionee&#8217;s rights hereunder, including the right to be issued Shares upon exercise, are subject to the Optionee promptly paying to the Company in cash or by check (or by such other means as may be acceptable to the Administrator) all taxes required to be withheld.  No Shares will be issued pursuant to the exercise of the Stock Option unless and until the person exercising the Stock Option has remitted to the Company an amount in cash sufficient to satisfy any federal, state, or local withholding tax requirements, or has made other arrangements satisfactory to the Company with respect to such taxes.  The Optionee authorizes the Company and its subsidiaries to withhold such amount from any amounts otherwise owed to the Optionee, but nothing in this sentence may be construed as relieving the Optionee of any liability for satisfying his or her obligation under the preceding provisions of this Section.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Effect on Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Neither the grant of the Stock Option, nor the issuance of Shares upon exercise of the Stock Option, will give the Optionee any right to be retained in the employ or service of the Company or any of its subsidiaries, affect the right of the Company or any of its subsidiaries to </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Vesting to be specified based on terms of grant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">terminate the Optionee&#8217;s Service at any time, or affect any right of the Optionee to terminate his or her Service at any time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Provisions of the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is subject in its entirety to the provisions of the Plan, which are incorporated herein by reference.  A copy of the Plan as in effect on the Date of Grant has been furnished or made available to the Optionee.  By accepting, or being deemed to have accepted, all or any part of the Stock Option, the Optionee agrees to be bound by the terms of the Plan and this Agreement.  In the event of any conflict between the terms of this Agreement and the Plan, the terms of the Plan will control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Optionee acknowledges and agrees that (i) this Agreement may be executed in two or more counterparts, each of which will be an original and all of which together will constitute one and the same instrument, or, alternatively, may be acknowledged electronically in the Company&#8217;s designated electronic equity management system, (ii) this Agreement may be executed and exchanged using facsimile, portable document format (PDF) or electronic signature, which, in each case, will constitute an original signature for all purposes hereunder, and (iii) such signature by the Company will be binding against the Company and will create a legally binding agreement when this Agreement is countersigned by the Optionee.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#91;Signature page follows.&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><div id="if42eafaba4f8451b8b1739a8e4eda663_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company, by its duly authorized officer, and the Optionee have executed this Agreement as of the Date of Grant.</font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">MERSANA THERAPEUTICS, INC.</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreed and Accepted&#58;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;Optionee&#8217;s Name&#93;</font></td><td colspan="6" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Signature page to Non-Statutory Stock Option Agreement</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>exhibit21110kfy2021q4.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iba568656984344ed8b2ae509de35ec19_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Registrant</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:44.337%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State of Incorporation or Organization</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mersana Securities Corp.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>exhibit23110kfy2021q4.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id771e6c764894161a5ab42123aed01eb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 23.1</font></div></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-260895) of Mersana Therapeutics, Inc. and in the related Prospectus,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-3 No. 333-238140) of Mersana Therapeutics, Inc. and in the related Prospectus,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-255975) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and Inducement Stock Option Awards,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236775) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan,</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-230159) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan, </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-222845) pertaining to the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-219388) pertaining to the Mersana Therapeutics, Inc. 2007 Stock Incentive Plan, as amended, the Mersana Therapeutics, Inc. 2017 Stock Incentive Plan and the Mersana Therapeutics, Inc. 2017 Employee Stock Purchase Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our report dated February&#160;28, 2022, with respect to the consolidated financial statements of Mersana Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Mersana Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mersana Therapeutics, Inc. for the year ended December&#160;31, 2021.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">                                                                                                                            </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Boston, Massachusetts </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;28, 2022</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>exhibit31110kfy2021q4.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7fdc406132554ed4881f978dd73fc091_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Anna Protopapas, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anna Protopapas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anna Protopapas<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>exhibit31210kfy2021q4.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i91dba363458e45cabe10361fb6ca78ec_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian&#160;DeSchuytner, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Mersana Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report), that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian&#160;DeSchuytner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Brian DeSchuytner<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>exhibit32110kfy2021q4.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i16cf9e1858634840b445f0c58df96034_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Annual Report on Form 10-K of Mersana Therapeutics, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the company, hereby certifies, pursuant to Section&#160;1350 of Chapter 63 of Title 18, United States Code, that to the best of her or his knowledge&#58;</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anna Protopapas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anna Protopapas<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 28, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian&#160;DeSchuytner</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian DeSchuytner<br>Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>mrsn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrsn="http://www.mersana.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.mersana.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrsn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.mersana.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.mersana.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails">
        <link:definition>2407403 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesOtherAssetsDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails">
        <link:definition>2408404 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails">
        <link:definition>2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetlosspershareDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails">
        <link:definition>2410406 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
        <link:definition>2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRisksDetails" roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails">
        <link:definition>2412408 - Disclosure - Summary of Significant Accounting Policies - Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.mersana.com/role/CollaborationAgreements">
        <link:definition>2113103 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.mersana.com/role/CollaborationAgreementsTables">
        <link:definition>2314302 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsNarrativeDetail" roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail">
        <link:definition>2415409 - Disclosure - Collaboration Agreements - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsNarrativeDetail_1" roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail_1">
        <link:definition>2415409 - Disclosure - Collaboration Agreements - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsContractAssetsandLiabilitiesDetails" roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.mersana.com/role/FairValueMeasurements">
        <link:definition>2117104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.mersana.com/role/PropertyandEquipment">
        <link:definition>2118105 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.mersana.com/role/PropertyandEquipmentTables">
        <link:definition>2319303 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails">
        <link:definition>2420411 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.mersana.com/role/AccruedExpenses">
        <link:definition>2121106 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedexpensesTables" roleURI="http://www.mersana.com/role/AccruedexpensesTables">
        <link:definition>2322304 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.mersana.com/role/AccruedExpensesDetails">
        <link:definition>2423412 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.mersana.com/role/Debt">
        <link:definition>2124107 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.mersana.com/role/DebtTables">
        <link:definition>2325305 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.mersana.com/role/DebtNarrativeDetails">
        <link:definition>2426413 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtComponentsDetails" roleURI="http://www.mersana.com/role/DebtComponentsDetails">
        <link:definition>2427414 - Disclosure - Debt - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtFuturepaymentsDetails" roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails">
        <link:definition>2428415 - Disclosure - Debt - Future payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.mersana.com/role/StockholdersEquity">
        <link:definition>2129108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.mersana.com/role/StockholdersEquityTables">
        <link:definition>2330306 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.mersana.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2431416 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockDetails" roleURI="http://www.mersana.com/role/StockholdersEquityCommonStockDetails">
        <link:definition>2432417 - Disclosure - Stockholders' Equity - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptions" roleURI="http://www.mersana.com/role/StockOptions">
        <link:definition>2133109 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsTables" roleURI="http://www.mersana.com/role/StockOptionsTables">
        <link:definition>2334307 - Disclosure - Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsNarrativeDetails" roleURI="http://www.mersana.com/role/StockOptionsNarrativeDetails">
        <link:definition>2435418 - Disclosure - Stock Options - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsActivityUnderStockOptionPlanDetails" roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails">
        <link:definition>2436419 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsRestrictedStockUnitsDetails" roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails">
        <link:definition>2437420 - Disclosure - Stock Options - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsStockBasedCompensationExpenseDetails" roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails">
        <link:definition>2438421 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockOptionsFairValueAssumptionsDetails" roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails">
        <link:definition>2439422 - Disclosure - Stock Options - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.mersana.com/role/Leases">
        <link:definition>2140110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.mersana.com/role/LeasesTables">
        <link:definition>2341308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.mersana.com/role/LeasesNarrativeDetails">
        <link:definition>2442423 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2443424 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalbalancesheetinformationDetails" roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails">
        <link:definition>2444425 - Disclosure - Leases - Supplemental balance sheet information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalcashflowinformationDetails" roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails">
        <link:definition>2445426 - Disclosure - Leases - Supplemental cash flow information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureminimumleasepaymentsDetails" roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails">
        <link:definition>2446427 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureminimumleasepaymentsDetails_1" roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1">
        <link:definition>2446427 - Disclosure - Leases - Future minimum lease payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.mersana.com/role/IncomeTaxes">
        <link:definition>2147111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.mersana.com/role/IncomeTaxesTables">
        <link:definition>2348309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.mersana.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2449428 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationDetails" roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails">
        <link:definition>2450429 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofdeferredtaxassetsDetails" roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails">
        <link:definition>2451430 - Disclosure - Income Taxes - Components of deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNetoperatinglosscarryforwardsDetails" roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails">
        <link:definition>2452431 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxcreditcarryforwardDetails" roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails">
        <link:definition>2453432 - Disclosure - Income Taxes - Tax credit carryforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesValuationallowanceDetails" roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails">
        <link:definition>2454433 - Disclosure - Income Taxes - Valuation allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.mersana.com/role/EmployeeBenefitPlan">
        <link:definition>2155112 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2456434 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitments" roleURI="http://www.mersana.com/role/Commitments">
        <link:definition>2157113 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsLicenseagreementsDetails" roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails">
        <link:definition>2458435 - Disclosure - Commitments - License agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.mersana.com/role/SubsequentEvents">
        <link:definition>2159114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.mersana.com/role/SubsequentEventsDetails">
        <link:definition>2460436 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrsn_WarrantsExercisedInPeriod" abstract="false" name="WarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LeasesLineItems" abstract="true" name="LeasesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsRegulatoryMilestones" abstract="false" name="CollaborationArrangementsRegulatoryMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" abstract="false" name="CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_JanssenMember" abstract="true" name="JanssenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CapitalizedOtherAssetsMember" abstract="true" name="CapitalizedOtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_JointResearchCommitteeServicesMember" abstract="true" name="JointResearchCommitteeServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" abstract="true" name="PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" abstract="false" name="CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" abstract="false" name="FinalPaymentAsPercentageOfOriginalPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrsn_A2017ESPPMember" abstract="true" name="A2017ESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" abstract="false" name="SaleOfStockRemainingAmountUnsoldAndAvailableForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborativeArrangementsExclusiveTargetsNumber" abstract="false" name="CollaborativeArrangementsExclusiveTargetsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_OfficeSpaceExpansionCambridgeMaMember" abstract="true" name="OfficeSpaceExpansionCambridgeMaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_IncomeTaxesNumberOfAuditsInProgress" abstract="false" name="IncomeTaxesNumberOfAuditsInProgress" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheThreeMember" abstract="true" name="NewCreditFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" abstract="false" name="CollaborationArrangementsDevelopmentMilestonesPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LesseeOperatingLeasesAbstract" abstract="true" name="LesseeOperatingLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsTargetsDesignatedNumber" abstract="false" name="CollaborationArrangementsTargetsDesignatedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_DebtInstrumentPrepaymentFeePercent" abstract="false" name="DebtInstrumentPrepaymentFeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrsn_FinanceLeasesMember" abstract="true" name="FinanceLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ThirdPartiesMember" abstract="true" name="ThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_WarrantsAndShareBasedPaymentsMember" abstract="true" name="WarrantsAndShareBasedPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDurationToTermination" abstract="false" name="CollaborationArrangementsDurationToTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" abstract="false" name="CollaborationArrangementsPriorWrittenTerminationNoticeDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_ContractualLifeOfWarrants" abstract="false" name="ContractualLifeOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" abstract="false" name="FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" abstract="false" name="ClassOfWarrantOrRightSharesExchangedForWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_AccruedClinicalExpensesCurrent" abstract="false" name="AccruedClinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_DefinedContributionPlanEligibleAgeToParticipate" abstract="false" name="DefinedContributionPlanEligibleAgeToParticipate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram2018ATMMember" abstract="true" name="AtMarketEquityOfferingProgram2018ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ExistingCreditFacilityMember" abstract="true" name="ExistingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgramMember" abstract="true" name="AtMarketEquityOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_SynaffixMember" abstract="true" name="SynaffixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualCommercialMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_StockIssuanceProgramAuthorizedAmount" abstract="false" name="StockIssuanceProgramAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AmortizedInterestExpenseMember" abstract="true" name="AmortizedInterestExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_AmendedCreditFacilityMember" abstract="true" name="AmendedCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LeasesTable" abstract="true" name="LeasesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheOneMember" abstract="true" name="NewCreditFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_DebtCovenantPeriodAxis" abstract="true" name="DebtCovenantPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborativeArrangementsUpfrontPayment" abstract="false" name="CollaborativeArrangementsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" abstract="true" name="AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" abstract="false" name="StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_SupplyAgreementMerckKgaaMember" abstract="true" name="SupplyAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" abstract="false" name="MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIncentivePlan2007Member" abstract="true" name="StockIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheSixMember" abstract="true" name="NewCreditFacilityTrancheSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" abstract="false" name="StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_OperatingLeaseTenantImprovementAllowance" abstract="false" name="OperatingLeaseTenantImprovementAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" abstract="true" name="DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheFiveMember" abstract="true" name="NewCreditFacilityTrancheFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheFourMember" abstract="true" name="NewCreditFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_RightsToFutureTechnologicalImprovementsMember" abstract="true" name="RightsToFutureTechnologicalImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LendersMember" abstract="true" name="LendersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" abstract="true" name="CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" abstract="false" name="CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_DevelopmentAndRegulatoryMember" abstract="true" name="DevelopmentAndRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsLicensedTechnology" abstract="false" name="DeferredTaxAssetsLicensedTechnology" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" abstract="false" name="LineOfCreditFacilityTrancheAvailabilityDuration" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_ProceedsFromDebtNetIssuanceCosts" abstract="false" name="ProceedsFromDebtNetIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" abstract="false" name="CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" abstract="false" name="StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_DebtCovenantPeriodDomain" abstract="true" name="DebtCovenantPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_NewCreditFacilityTrancheTwoMember" abstract="true" name="NewCreditFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" abstract="true" name="ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_StockIncentivePlan2017Member" abstract="true" name="StockIncentivePlan2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_InducementAwardProgramMember" abstract="true" name="InducementAwardProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LimitedServicesMember" abstract="true" name="LimitedServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_AtMarketEquityOfferingProgram2020ATMMember" abstract="true" name="AtMarketEquityOfferingProgram2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_DebtInstrumentCarryingAmountNoncurrent" abstract="false" name="DebtInstrumentCarryingAmountNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" abstract="false" name="LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrsn_AccruedManufacturingExpensesCurrent" abstract="false" name="AccruedManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" abstract="true" name="ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" abstract="false" name="ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mrsn_RevenueRemainingPerformanceObligationNumber" abstract="false" name="RevenueRemainingPerformanceObligationNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_FinanceLeaseTotalCostAbstract" abstract="true" name="FinanceLeaseTotalCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_ContractWithCustomerLiabilityIncrease" abstract="false" name="ContractWithCustomerLiabilityIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" abstract="false" name="CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" abstract="false" name="CollaborationArrangementsMilestonePaymentReceivableNextMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_RevenueTransactionPriceAmount" abstract="false" name="RevenueTransactionPriceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LicenseAgreementUpfrontPaymentsMember" abstract="true" name="LicenseAgreementUpfrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsMaximumAggregateMilestones" abstract="false" name="CollaborationArrangementsMaximumAggregateMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_ComputerEquipmentAndOfficeEquipmentMember" abstract="true" name="ComputerEquipmentAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_DebtInstrumentAdditionalRateInEventOfDefault" abstract="false" name="DebtInstrumentAdditionalRateInEventOfDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrsn_LesseeFinanceLeasesAbstract" abstract="true" name="LesseeFinanceLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_CollaborationAgreementsAbstract" abstract="true" name="CollaborationAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_DeferredTaxAssetsDepreciation" abstract="false" name="DeferredTaxAssetsDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" abstract="true" name="LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" abstract="true" name="ChangeInContractAssetsAndLiabilitiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" abstract="false" name="DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_RevenueCollectionPeriod" abstract="false" name="RevenueCollectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrsn_IncomeTaxesNumberOfStateJurisdictions" abstract="false" name="IncomeTaxesNumberOfStateJurisdictions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_NumberOfVotesPerCommonShare" abstract="false" name="NumberOfVotesPerCommonShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrsn_CollaborationAgreementNonrefundableExecutionFee" abstract="false" name="CollaborationAgreementNonrefundableExecutionFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_PrepaymentOccursPriorToOctober292022Member" abstract="true" name="PrepaymentOccursPriorToOctober292022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsDevelopmentMilestones" abstract="false" name="CollaborationArrangementsDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_OfficeSpaceCambridgeMaMember" abstract="true" name="OfficeSpaceCambridgeMaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsSalesMilestones" abstract="false" name="CollaborationArrangementsSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" abstract="false" name="StockIssuanceDiscountsAndCommissionsOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_NewCreditFacilityMember" abstract="true" name="NewCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_LeasesSupplementalCashFlowInformationAbstract" abstract="true" name="LeasesSupplementalCashFlowInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrsn_AccruedPreclinicalExpensesCurrent" abstract="false" name="AccruedPreclinicalExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" abstract="true" name="PrepaymentOccursBetweenOctober292022AndOctober292023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrsn_ContractWithCustomerLiabilityDecrease" abstract="false" name="ContractWithCustomerLiabilityDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_CollaborationArrangementsCostsBilled" abstract="false" name="CollaborationArrangementsCostsBilled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrsn_LicenseAgreementMilestonePaymentsMember" abstract="true" name="LicenseAgreementMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>mrsn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3dcc21db-c755-4c3f-8ccd-871909890cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b3033c4-09eb-49c9-a42d-b1099d7a0d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3dcc21db-c755-4c3f-8ccd-871909890cf8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7b3033c4-09eb-49c9-a42d-b1099d7a0d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a07dbce-60f1-49dc-82b9-4fb8e3ef9c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3dcc21db-c755-4c3f-8ccd-871909890cf8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a07dbce-60f1-49dc-82b9-4fb8e3ef9c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_952587a9-a9b9-4f73-8f6f-cb3784c730c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:to="loc_us-gaap_AccountsPayableCurrent_952587a9-a9b9-4f73-8f6f-cb3784c730c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_20f92b74-94ca-4da2-837b-adda8108af0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_20f92b74-94ca-4da2-837b-adda8108af0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1780c5b1-7668-413d-bcbc-23bda9997db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1780c5b1-7668-413d-bcbc-23bda9997db5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_afb010aa-ae92-4348-9b01-d704aea8d082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_afb010aa-ae92-4348-9b01-d704aea8d082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a855f433-eb9d-4578-9155-4d134fb5a415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d0ff36fa-07b1-4561-a429-9ee81120bfe7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a855f433-eb9d-4578-9155-4d134fb5a415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3f91535c-48f8-4592-9b67-55b4e76b094c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a6627d9-4e99-4885-9427-a249a2942e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f91535c-48f8-4592-9b67-55b4e76b094c" xlink:to="loc_us-gaap_LiabilitiesCurrent_5a6627d9-4e99-4885-9427-a249a2942e71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9bd415e9-e0c7-4b95-b3a2-6386bd7fbf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f91535c-48f8-4592-9b67-55b4e76b094c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9bd415e9-e0c7-4b95-b3a2-6386bd7fbf3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cbc7dad9-74f6-44b9-bc2d-4114d2b2191d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f91535c-48f8-4592-9b67-55b4e76b094c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cbc7dad9-74f6-44b9-bc2d-4114d2b2191d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ee7d8d61-56fc-4f02-a4db-b629cb77517f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3f91535c-48f8-4592-9b67-55b4e76b094c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ee7d8d61-56fc-4f02-a4db-b629cb77517f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1eee0f63-0645-4bc5-9c87-c21f21f72d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4a29ff44-abff-49e5-b989-cca74755742e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1eee0f63-0645-4bc5-9c87-c21f21f72d23" xlink:to="loc_us-gaap_AssetsCurrent_4a29ff44-abff-49e5-b989-cca74755742e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_21fe612c-a646-478e-bef2-092bcf0f2dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1eee0f63-0645-4bc5-9c87-c21f21f72d23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_21fe612c-a646-478e-bef2-092bcf0f2dae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcfe12ac-1bc1-4d56-9f07-49e5d6c1b992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1eee0f63-0645-4bc5-9c87-c21f21f72d23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcfe12ac-1bc1-4d56-9f07-49e5d6c1b992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2fb61ac7-b1c1-47b6-94a2-16ee26019359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1eee0f63-0645-4bc5-9c87-c21f21f72d23" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2fb61ac7-b1c1-47b6-94a2-16ee26019359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b2daaf6-df99-47e8-9744-cd48b3edad73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3f3e5949-48e8-4e23-94d3-e6ca28938ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b2daaf6-df99-47e8-9744-cd48b3edad73" xlink:to="loc_us-gaap_CommonStockValue_3f3e5949-48e8-4e23-94d3-e6ca28938ab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3688e829-805e-4961-a108-266132ff1809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b2daaf6-df99-47e8-9744-cd48b3edad73" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3688e829-805e-4961-a108-266132ff1809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f012fdd-e628-4603-9a4a-ac2b319abc63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b2daaf6-df99-47e8-9744-cd48b3edad73" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f012fdd-e628-4603-9a4a-ac2b319abc63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6bcaec8f-8abf-4a33-a161-680277e1cf07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b2daaf6-df99-47e8-9744-cd48b3edad73" xlink:to="loc_us-gaap_PreferredStockValue_6bcaec8f-8abf-4a33-a161-680277e1cf07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5c4b3f4-1966-4b55-b58e-26f6d21ee91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3aa716b9-c8d6-43cc-b9a4-fefbfa243832" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5c4b3f4-1966-4b55-b58e-26f6d21ee91a" xlink:to="loc_us-gaap_Liabilities_3aa716b9-c8d6-43cc-b9a4-fefbfa243832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_839f2c37-e2de-4c85-a644-7a8de910183d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5c4b3f4-1966-4b55-b58e-26f6d21ee91a" xlink:to="loc_us-gaap_StockholdersEquity_839f2c37-e2de-4c85-a644-7a8de910183d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7e6ac4db-f9aa-4369-a2ba-15c3a9d49e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b5c4b3f4-1966-4b55-b58e-26f6d21ee91a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7e6ac4db-f9aa-4369-a2ba-15c3a9d49e02" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0a1d967a-9537-4b26-b68e-1c5e934ed27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87674811-646a-4042-ae74-bc6a90f6b310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0a1d967a-9537-4b26-b68e-1c5e934ed27e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87674811-646a-4042-ae74-bc6a90f6b310" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bfc81be7-0a47-4927-b675-99e2767ccf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0a1d967a-9537-4b26-b68e-1c5e934ed27e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bfc81be7-0a47-4927-b675-99e2767ccf3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d76bfd29-df50-41cb-9da6-e3e10abad8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_045cc0f2-9fe4-43b3-bb99-669cc8fe1665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d76bfd29-df50-41cb-9da6-e3e10abad8b9" xlink:to="loc_us-gaap_InterestExpense_045cc0f2-9fe4-43b3-bb99-669cc8fe1665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_facf3450-e7c7-4df9-879f-9b79d3d84738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_d76bfd29-df50-41cb-9da6-e3e10abad8b9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_facf3450-e7c7-4df9-879f-9b79d3d84738" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a68830a-44c3-497c-a7a5-a060dc6e8ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e70406a-0c3a-410c-8a93-3c5e9076e6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a68830a-44c3-497c-a7a5-a060dc6e8ff5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1e70406a-0c3a-410c-8a93-3c5e9076e6f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bf46105f-a505-404f-870d-035cff4e6191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5a68830a-44c3-497c-a7a5-a060dc6e8ff5" xlink:to="loc_us-gaap_NetIncomeLoss_bf46105f-a505-404f-870d-035cff4e6191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74c39007-b00c-40d5-81de-ecdf5d8e81bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d48efca-3cd8-4ab1-b599-767bfd27d235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74c39007-b00c-40d5-81de-ecdf5d8e81bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2d48efca-3cd8-4ab1-b599-767bfd27d235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7de54ed7-fb3e-47f7-870c-a3a77cf547fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74c39007-b00c-40d5-81de-ecdf5d8e81bc" xlink:to="loc_us-gaap_OperatingExpenses_7de54ed7-fb3e-47f7-870c-a3a77cf547fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_85708b5c-f07e-452c-bc7c-415c1a3eb8db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74c39007-b00c-40d5-81de-ecdf5d8e81bc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_85708b5c-f07e-452c-bc7c-415c1a3eb8db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8dde7c-13a0-472b-bad8-ea65ea8d5a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5dda3f9-80b5-4370-bb76-d19950210421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8dde7c-13a0-472b-bad8-ea65ea8d5a5b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d5dda3f9-80b5-4370-bb76-d19950210421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_000a1310-c5f6-403d-a89b-2bb72c0972e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8dde7c-13a0-472b-bad8-ea65ea8d5a5b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_000a1310-c5f6-403d-a89b-2bb72c0972e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3c536bfc-fc5a-4c3c-ad4c-7a135279d055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8dde7c-13a0-472b-bad8-ea65ea8d5a5b" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_3c536bfc-fc5a-4c3c-ad4c-7a135279d055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ca339d9-66bc-4488-b6bf-8c22cd7b1a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ca339d9-66bc-4488-b6bf-8c22cd7b1a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_72b4846e-8809-4a52-bd72-d491c0aeaeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_72b4846e-8809-4a52-bd72-d491c0aeaeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_f1832595-2b89-43b7-bdf4-4f7b8664400e" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_f1832595-2b89-43b7-bdf4-4f7b8664400e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_38273691-5651-405a-9d34-7ddecdc226ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_RepaymentsOfDebt_38273691-5651-405a-9d34-7ddecdc226ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4daa9dfa-ebf9-458d-97f6-d9a250878e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4daa9dfa-ebf9-458d-97f6-d9a250878e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8ce65e44-4111-467f-9956-f6f5d245c04d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8ce65e44-4111-467f-9956-f6f5d245c04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ba5ecaac-7fd5-485d-ac8f-bfe4ac999100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_af425a27-fd44-4cce-b137-cbf16536454d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ba5ecaac-7fd5-485d-ac8f-bfe4ac999100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4df5f0bd-8c1e-477c-9530-3ebb68b79d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4df5f0bd-8c1e-477c-9530-3ebb68b79d8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ee7722d6-1cde-41c0-a3ed-a5e2a0c64b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_ProfitLoss_ee7722d6-1cde-41c0-a3ed-a5e2a0c64b61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8fdfb1d5-0a05-44ad-bac7-a4fb696947b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8fdfb1d5-0a05-44ad-bac7-a4fb696947b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73a64119-fec0-4d1b-ad20-f952a66d326c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73a64119-fec0-4d1b-ad20-f952a66d326c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ad9e3e22-2b46-46ad-a809-246634ca8d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ad9e3e22-2b46-46ad-a809-246634ca8d57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_36aed8f0-0835-4533-b82e-9bc00af306cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_36aed8f0-0835-4533-b82e-9bc00af306cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_90b0a8e9-2891-4d0f-b65b-65d8b2bab62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_90b0a8e9-2891-4d0f-b65b-65d8b2bab62a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cf27757f-8511-453b-822b-4a4f4f4cea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_cf27757f-8511-453b-822b-4a4f4f4cea8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_a0bd803f-62dd-4dae-bdc9-ed3e9051b2ba" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_a0bd803f-62dd-4dae-bdc9-ed3e9051b2ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_207ec559-b4aa-4306-923b-909818f38e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_ShareBasedCompensation_207ec559-b4aa-4306-923b-909818f38e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ad3fbc7a-3d38-4777-b4d8-fe38832c1bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_ad3fbc7a-3d38-4777-b4d8-fe38832c1bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f9fa3eb8-fa82-4655-b09b-059eacd4e68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f9fa3eb8-fa82-4655-b09b-059eacd4e68b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aa955b76-6549-46d4-a72f-8ea0c164cccf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aa955b76-6549-46d4-a72f-8ea0c164cccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_faa1ecba-528b-4d39-b8bc-38b863ffa1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_48e6e687-1834-485e-a74c-0e795af34e99" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_faa1ecba-528b-4d39-b8bc-38b863ffa1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7744137-0997-4c4d-afb9-3e66e91a5753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c233e49-f6aa-4d70-9d35-1747bc7c2855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7744137-0997-4c4d-afb9-3e66e91a5753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9c233e49-f6aa-4d70-9d35-1747bc7c2855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffa77946-8d2d-4e91-b879-833c39e42c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7744137-0997-4c4d-afb9-3e66e91a5753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ffa77946-8d2d-4e91-b879-833c39e42c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f39e049b-6ddc-4efa-9137-4f50e3b44ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d7744137-0997-4c4d-afb9-3e66e91a5753" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f39e049b-6ddc-4efa-9137-4f50e3b44ee1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f999ca8-959f-40f2-bae2-70f35053e376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3eacdfe1-7ba8-4b21-8ed7-d81cd4ba9fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f999ca8-959f-40f2-bae2-70f35053e376" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3eacdfe1-7ba8-4b21-8ed7-d81cd4ba9fb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_102c5d65-0049-4808-a7cb-ca202b4b5219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f999ca8-959f-40f2-bae2-70f35053e376" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_102c5d65-0049-4808-a7cb-ca202b4b5219" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_aff7be16-b3ea-47a8-bc12-04c1be35765d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit_4fdec4ba-e0f6-4d21-b7ec-abf10668b180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_aff7be16-b3ea-47a8-bc12-04c1be35765d" xlink:to="loc_us-gaap_RetainageDeposit_4fdec4ba-e0f6-4d21-b7ec-abf10668b180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_c62d9610-918c-4c7f-99fe-9f5cb98d92b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_aff7be16-b3ea-47a8-bc12-04c1be35765d" xlink:to="loc_us-gaap_SecurityDeposit_c62d9610-918c-4c7f-99fe-9f5cb98d92b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_11d7b186-5c8f-4516-b5c6-ad4e80bfd17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_aff7be16-b3ea-47a8-bc12-04c1be35765d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_11d7b186-5c8f-4516-b5c6-ad4e80bfd17e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_1cb9dfcf-17a6-4e89-b36e-2e98a12a9584" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_04b0aaf4-2b98-4bd7-af2c-d62ef4eceae3" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_1cb9dfcf-17a6-4e89-b36e-2e98a12a9584" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_04b0aaf4-2b98-4bd7-af2c-d62ef4eceae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_d435ddfc-0e23-4921-a805-043e1103eae7" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_1cb9dfcf-17a6-4e89-b36e-2e98a12a9584" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_d435ddfc-0e23-4921-a805-043e1103eae7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_3df9e40a-fb73-446b-937c-8a41027979ac" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_1cb9dfcf-17a6-4e89-b36e-2e98a12a9584" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_3df9e40a-fb73-446b-937c-8a41027979ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_dcb63aab-feba-4005-b41a-5dc52e32839d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cf3306f8-3b85-4bf3-a25e-5572dd93626b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_dcb63aab-feba-4005-b41a-5dc52e32839d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_cf3306f8-3b85-4bf3-a25e-5572dd93626b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2f0f877c-cda2-4255-b5b6-a60f47e21ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_dcb63aab-feba-4005-b41a-5dc52e32839d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2f0f877c-cda2-4255-b5b6-a60f47e21ef4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedClinicalExpensesCurrent_c6093e8e-95b9-4215-8a07-5bb2087e738f" xlink:href="mrsn-20211231.xsd#mrsn_AccruedClinicalExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_mrsn_AccruedClinicalExpensesCurrent_c6093e8e-95b9-4215-8a07-5bb2087e738f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_73e33a60-0cc7-4154-9430-2fc581e1124d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_73e33a60-0cc7-4154-9430-2fc581e1124d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalExpensesCurrent_392d0959-2d42-4183-b794-abf542c44a4b" xlink:href="mrsn-20211231.xsd#mrsn_AccruedPreclinicalExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_mrsn_AccruedPreclinicalExpensesCurrent_392d0959-2d42-4183-b794-abf542c44a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d7d200c6-c589-411c-a30c-5e99c59c712d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d7d200c6-c589-411c-a30c-5e99c59c712d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0e2da5e8-2235-4462-8b66-c0be99455e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0e2da5e8-2235-4462-8b66-c0be99455e4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedManufacturingExpensesCurrent_584a19ce-638f-4aed-843c-a5f381dd2a59" xlink:href="mrsn-20211231.xsd#mrsn_AccruedManufacturingExpensesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_ee115c70-4e28-4502-8c96-baae35a1fbca" xlink:to="loc_mrsn_AccruedManufacturingExpensesCurrent_584a19ce-638f-4aed-843c-a5f381dd2a59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_22a1ee3f-04a5-470d-81ea-a9e27939d9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6a94d036-8f55-4454-aba0-cfd74801b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_22a1ee3f-04a5-470d-81ea-a9e27939d9e3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6a94d036-8f55-4454-aba0-cfd74801b31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_48a605d9-5f46-410a-8909-f801e5efcd68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_22a1ee3f-04a5-470d-81ea-a9e27939d9e3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_48a605d9-5f46-410a-8909-f801e5efcd68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_068cd32b-6e29-4aad-b542-5859aeff664f" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_22a1ee3f-04a5-470d-81ea-a9e27939d9e3" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_068cd32b-6e29-4aad-b542-5859aeff664f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f0799f66-0138-4bf3-8829-a1a890f7daa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_7cff852d-9092-416f-8412-be4f57cc2a6e" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f0799f66-0138-4bf3-8829-a1a890f7daa4" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_7cff852d-9092-416f-8412-be4f57cc2a6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_8a27aafe-96ed-40b5-91d3-4d2d68d95585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f0799f66-0138-4bf3-8829-a1a890f7daa4" xlink:to="loc_us-gaap_LongTermDebtCurrent_8a27aafe-96ed-40b5-91d3-4d2d68d95585" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtFuturepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_aa7cabe0-28ca-4f97-bb64-e66f6b1d7a02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_aa7cabe0-28ca-4f97-bb64-e66f6b1d7a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_26cbd47d-7cce-4a8c-8d94-b62510c51f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_26cbd47d-7cce-4a8c-8d94-b62510c51f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_845615d9-00ff-478a-a90f-8a1fe071af91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_845615d9-00ff-478a-a90f-8a1fe071af91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d7e2fdf9-4d3b-46c5-857e-cf48cadaa187" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d7e2fdf9-4d3b-46c5-857e-cf48cadaa187" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a5a515e-954b-41d9-a23d-338dedf92670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_042eb135-fb3a-4ab9-8af9-3a323c97a768" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7a5a515e-954b-41d9-a23d-338dedf92670" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost_3462629a-fddb-4927-88c7-e75dd95aa472" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_eb9f5265-3c04-45e0-8eaf-a1067893c716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_FinanceLeaseCost_3462629a-fddb-4927-88c7-e75dd95aa472" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_eb9f5265-3c04-45e0-8eaf-a1067893c716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9f8815c9-864f-4ceb-bf7c-879943aca2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrsn_FinanceLeaseCost_3462629a-fddb-4927-88c7-e75dd95aa472" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9f8815c9-864f-4ceb-bf7c-879943aca2fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesFutureminimumleasepaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f2b71c8c-3bf9-4a08-b9cf-9e1d07f092b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f2b71c8c-3bf9-4a08-b9cf-9e1d07f092b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_00c4a693-2814-4b2e-9512-4d9d433dca53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_00c4a693-2814-4b2e-9512-4d9d433dca53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a6694939-6d0f-49bc-a403-89fb776cd0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a6694939-6d0f-49bc-a403-89fb776cd0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_16ad0e3b-689e-484c-9310-3d58098a434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_16ad0e3b-689e-484c-9310-3d58098a434b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c0f7ff54-244b-4efc-bef1-c81ff3265981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_824c2014-1b73-4cbf-b659-6db8a55add3c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c0f7ff54-244b-4efc-bef1-c81ff3265981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd7664a-04e4-4e1a-9e8a-1d4f1e0b895f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5e358a6-2a7d-4611-b42f-b8ae666c5131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd7664a-04e4-4e1a-9e8a-1d4f1e0b895f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a5e358a6-2a7d-4611-b42f-b8ae666c5131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b770aba8-6d58-4b53-840a-39838fd34a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8bd7664a-04e4-4e1a-9e8a-1d4f1e0b895f" xlink:to="loc_us-gaap_OperatingLeaseLiability_b770aba8-6d58-4b53-840a-39838fd34a2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesFutureminimumleasepaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_42b4a5c3-8a05-49ab-a26e-d84f7be1ae6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_42b4a5c3-8a05-49ab-a26e-d84f7be1ae6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84d9c118-ca98-40b1-bde7-f8d17044e3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_84d9c118-ca98-40b1-bde7-f8d17044e3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_943ac685-5746-449e-bbaa-1efe196048a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_943ac685-5746-449e-bbaa-1efe196048a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b078f1cf-37a1-424b-b159-992c59e60d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b078f1cf-37a1-424b-b159-992c59e60d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3147dd6f-c4d1-41b5-bc5e-1f05ce2aa57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_198b2515-8a97-4995-b056-bc6517a365ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3147dd6f-c4d1-41b5-bc5e-1f05ce2aa57e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5b2426b4-49eb-434f-836e-74ad8f61dd39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_47b6c813-8f59-4d7a-9015-a2cc1cea0534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5b2426b4-49eb-434f-836e-74ad8f61dd39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_47b6c813-8f59-4d7a-9015-a2cc1cea0534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_475adaa2-9f55-4992-9d88-35010ab7f396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_5b2426b4-49eb-434f-836e-74ad8f61dd39" xlink:to="loc_us-gaap_FinanceLeaseLiability_475adaa2-9f55-4992-9d88-35010ab7f396" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_c88fdf01-422e-4217-a900-e61f3a646d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_c88fdf01-422e-4217-a900-e61f3a646d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4da8e3c7-1bb0-44f3-95b2-598266f82102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4da8e3c7-1bb0-44f3-95b2-598266f82102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_372f8b84-aa7b-4ae4-ac56-11c051689574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_372f8b84-aa7b-4ae4-ac56-11c051689574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8888cb1e-a5a2-470e-a46c-db3be4516970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_8888cb1e-a5a2-470e-a46c-db3be4516970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e11aaf1-ead9-4922-9b95-cfe94dd504aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_0e11aaf1-ead9-4922-9b95-cfe94dd504aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0dc41e5c-47e5-45ab-9a53-105fa78721c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_0dc41e5c-47e5-45ab-9a53-105fa78721c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_507a8d71-fced-48bc-a8e9-1fb728bfc584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5ca2c542-7f69-4341-9b41-360f8893b99b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_507a8d71-fced-48bc-a8e9-1fb728bfc584" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:calculationLink xlink:role="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a49585c5-6fb4-4e14-af10-ebefdf6f4dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a49585c5-6fb4-4e14-af10-ebefdf6f4dbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b9e27ba2-7e81-4a8f-8669-e8fb82092db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_b9e27ba2-7e81-4a8f-8669-e8fb82092db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_90464f1d-55ea-4ce6-9436-3b723f0fd6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_90464f1d-55ea-4ce6-9436-3b723f0fd6af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology_936fc17a-cd58-48d3-99af-a266e0e7ef25" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_mrsn_DeferredTaxAssetsLicensedTechnology_936fc17a-cd58-48d3-99af-a266e0e7ef25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_caecb142-12f6-4d65-bd19-ecd4705f6a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_caecb142-12f6-4d65-bd19-ecd4705f6a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_22f9cb70-b6de-46d1-bcee-53eb9350be35" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_22f9cb70-b6de-46d1-bcee-53eb9350be35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation_c69668fb-3ada-4031-86d0-bd60fabddf42" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_mrsn_DeferredTaxAssetsDepreciation_c69668fb-3ada-4031-86d0-bd60fabddf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_32a34518-afdc-4029-8ca2-8ab6170de7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8c957973-3bd6-416f-ba1e-f7068121e8f7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_32a34518-afdc-4029-8ca2-8ab6170de7c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_faef2c99-6ed3-432a-8d75-4c01bee7363d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_62652edc-e3a3-4de1-9754-6f6d21a002a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_faef2c99-6ed3-432a-8d75-4c01bee7363d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_62652edc-e3a3-4de1-9754-6f6d21a002a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f1df46ee-8ab0-49bf-983a-3f5554f27f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_faef2c99-6ed3-432a-8d75-4c01bee7363d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f1df46ee-8ab0-49bf-983a-3f5554f27f79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e796c7bb-ae6f-4076-96cb-100af2be6bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3a0f2f41-dd79-4da3-853e-57dc967661ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e796c7bb-ae6f-4076-96cb-100af2be6bbd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3a0f2f41-dd79-4da3-853e-57dc967661ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d98f0739-6855-44f3-8421-094c3877368a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_44002bac-2f2c-4b0f-ad41-6dc29c7f457f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d98f0739-6855-44f3-8421-094c3877368a" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_44002bac-2f2c-4b0f-ad41-6dc29c7f457f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_94a0c326-411f-4383-adf0-e877f8ea171f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d98f0739-6855-44f3-8421-094c3877368a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_94a0c326-411f-4383-adf0-e877f8ea171f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>mrsn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ie3ef6c686045440f9391661521df8fbd_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03683a00-1a28-4d9c-aeb3-7eafd2660752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_SharesOutstanding_03683a00-1a28-4d9c-aeb3-7eafd2660752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c79b2851-4695-4f10-a04d-6e1bfca90268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockholdersEquity_c79b2851-4695-4f10-a04d-6e1bfca90268" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca267d8-9271-4d77-ae45-b4e6d541a605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca267d8-9271-4d77-ae45-b4e6d541a605" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_636b3bf7-66f5-4e55-9834-7bb30badf747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_636b3bf7-66f5-4e55-9834-7bb30badf747" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_9ac623ef-6077-4d59-bc85-efa5676abf64" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_9ac623ef-6077-4d59-bc85-efa5676abf64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_1804edce-d342-4c20-bc72-ad7b33f25a99" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_1804edce-d342-4c20-bc72-ad7b33f25a99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2bf63db4-3222-4af2-8e9d-da1fc8b831be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2bf63db4-3222-4af2-8e9d-da1fc8b831be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_75a802ac-5f58-4013-8a96-22e9b446119a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_75a802ac-5f58-4013-8a96-22e9b446119a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_6aa96da3-2fb3-425c-b38f-70b24d93c39b" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_6aa96da3-2fb3-425c-b38f-70b24d93c39b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_575be2f0-5384-4202-8ce1-40adcd5f7155" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_575be2f0-5384-4202-8ce1-40adcd5f7155" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ba2c78ff-0ced-4e3b-960e-120b1a63eaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ba2c78ff-0ced-4e3b-960e-120b1a63eaac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_a3bba5f7-ec21-48a0-bdb8-d0f56f2fcfc1" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_a3bba5f7-ec21-48a0-bdb8-d0f56f2fcfc1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a327768d-109e-49b5-b5ae-4014d1779598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a327768d-109e-49b5-b5ae-4014d1779598" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a92cfabb-4315-4b82-a5d5-db2059ce9c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a92cfabb-4315-4b82-a5d5-db2059ce9c29" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c71e839a-4c89-4c53-b408-8e3a584fdda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c71e839a-4c89-4c53-b408-8e3a584fdda3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3fa5e937-3d31-4fc5-b413-9144712d034b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3fa5e937-3d31-4fc5-b413-9144712d034b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3e89142d-4ff2-4f5d-a091-ec848739d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3e89142d-4ff2-4f5d-a091-ec848739d49f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3df537e2-b4fe-4664-8340-59ed1c22ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3df537e2-b4fe-4664-8340-59ed1c22ef9a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7f1b643-b5bd-467b-8fd2-8b6bd467a702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_NetIncomeLoss_a7f1b643-b5bd-467b-8fd2-8b6bd467a702" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03149592-2838-4909-84c8-d9aee41a30b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_138bc815-4e77-4bcf-8ccb-0c2c4a1ae53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:to="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f91d8539-ff25-4f03-aeed-0a5b841fd26d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:to="loc_us-gaap_EquityComponentDomain_f91d8539-ff25-4f03-aeed-0a5b841fd26d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:to="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84d50b60-0370-4685-9df9-814e22825935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_CommonStockMember_84d50b60-0370-4685-9df9-814e22825935" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2eb22a3d-9047-43ad-894e-dc6865c4e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2eb22a3d-9047-43ad-894e-dc6865c4e1d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34ef8a76-b536-45a3-987a-4e363e1b5caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34ef8a76-b536-45a3-987a-4e363e1b5caa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fbf2b288-86f0-41c4-a8e1-b7f2591a6197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_RetainedEarningsMember_fbf2b288-86f0-41c4-a8e1-b7f2591a6197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df30dde5-b24a-412f-80f2-8f04c1ad9c53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_df30dde5-b24a-412f-80f2-8f04c1ad9c53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_7da208b3-1759-4efb-973b-84c8672bd308" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_7da208b3-1759-4efb-973b-84c8672bd308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_a55f6107-ce83-4fb6-885f-49d510335507" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_PublicStockOfferingMember_a55f6107-ce83-4fb6-885f-49d510335507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_677e27d9-17e4-4273-af29-9bbaeed75664" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_677e27d9-17e4-4273-af29-9bbaeed75664" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i0dfa30e895df4d248bacf9ed9de997ec_ConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_a97b8aa2-a3fa-4893-b85e-c9d027d8e772" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_a97b8aa2-a3fa-4893-b85e-c9d027d8e772" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_546bb134-82cc-42df-9e4e-321042453569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_546bb134-82cc-42df-9e4e-321042453569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d31a5a6b-0966-450b-b882-e7f28af845cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d31a5a6b-0966-450b-b882-e7f28af845cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_cc8ce661-f471-4dd9-ac00-2aefd8ba3985" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_cc8ce661-f471-4dd9-ac00-2aefd8ba3985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_a5ddb395-7c0a-4589-80b1-1ac8360faaf9" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_PublicStockOfferingMember_a5ddb395-7c0a-4589-80b1-1ac8360faaf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_9dc6a18d-fa37-4251-9778-4e8fd21631cf" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_9dc6a18d-fa37-4251-9778-4e8fd21631cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47328e78-fd3e-40f7-ade4-7f70096ea7c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:to="loc_us-gaap_EquityComponentDomain_47328e78-fd3e-40f7-ade4-7f70096ea7c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:to="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a9fe4381-9189-422e-bae7-658b76c019bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:to="loc_us-gaap_CommonStockMember_a9fe4381-9189-422e-bae7-658b76c019bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_52193ba2-299b-485d-a038-9f70b7e80c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_52193ba2-299b-485d-a038-9f70b7e80c4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="id78bb8ed4ade419f86fb2f88655c4bf2_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8f9fdd91-5508-44dc-8262-4a9466df1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:to="loc_us-gaap_ProfitLoss_8f9fdd91-5508-44dc-8262-4a9466df1eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d3b1912d-7dc4-4d21-9a55-e114e3b441cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d3b1912d-7dc4-4d21-9a55-e114e3b441cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e7373dfb-723d-4881-bdc7-067479d69435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e7373dfb-723d-4881-bdc7-067479d69435" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_72abc4bb-2062-4911-b2d5-727c9617d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_ShareBasedCompensation_72abc4bb-2062-4911-b2d5-727c9617d30a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9b012c33-c8ee-42fe-a0fc-019380033e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9b012c33-c8ee-42fe-a0fc-019380033e57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_417a8fd6-aa6e-44ab-bead-fdaca5e469f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_417a8fd6-aa6e-44ab-bead-fdaca5e469f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf8ff480-6bba-49e6-a087-daa0eb94d740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf8ff480-6bba-49e6-a087-daa0eb94d740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_051c726e-8612-4c80-9e6f-2908acd7808f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_051c726e-8612-4c80-9e6f-2908acd7808f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1f917778-4847-46a2-a111-47f3412ba075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1f917778-4847-46a2-a111-47f3412ba075" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_571a6b94-9e03-46ad-aa78-ce0f4012abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_571a6b94-9e03-46ad-aa78-ce0f4012abb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_299952c7-01f2-4be0-89d5-1a58f356029f" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_299952c7-01f2-4be0-89d5-1a58f356029f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_095b9cfa-f9a0-45ed-9f46-ab3ed21851ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_095b9cfa-f9a0-45ed-9f46-ab3ed21851ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_895388c1-a926-4218-bb24-3b058bbe99e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_895388c1-a926-4218-bb24-3b058bbe99e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e7a5c92a-27d2-4850-a035-9bd95b804368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e7a5c92a-27d2-4850-a035-9bd95b804368" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7633ee4-300e-402e-8f3b-e8a7677789a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7633ee4-300e-402e-8f3b-e8a7677789a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e4f8908d-fbc2-4694-8a0e-602197391091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e4f8908d-fbc2-4694-8a0e-602197391091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96a91858-f794-4cba-9c77-fc4db3c5987a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96a91858-f794-4cba-9c77-fc4db3c5987a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_039f9334-57f7-43de-9280-720d5bfaf6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_039f9334-57f7-43de-9280-720d5bfaf6a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8354fc-a888-4c5e-b804-6629246f41c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8354fc-a888-4c5e-b804-6629246f41c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a47c6e2-5a7e-4877-95cd-a656d9c78dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a47c6e2-5a7e-4877-95cd-a656d9c78dda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a824bd45-d26d-49c7-8c9d-b544cf2d4e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a824bd45-d26d-49c7-8c9d-b544cf2d4e96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_662bfd01-bb16-43a3-be00-2c758bac6f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_662bfd01-bb16-43a3-be00-2c758bac6f2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76ce433b-573b-4fff-a60c-59e5c2850b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76ce433b-573b-4fff-a60c-59e5c2850b63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_1b19ecdd-2f93-43f0-bdac-abd9f0030804" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_1b19ecdd-2f93-43f0-bdac-abd9f0030804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_6518054e-c1fd-4a5a-b938-fe75a249439c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_RepaymentsOfDebt_6518054e-c1fd-4a5a-b938-fe75a249439c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f431bed5-0d37-46ab-a5ea-b0d7824c07b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f431bed5-0d37-46ab-a5ea-b0d7824c07b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2812afde-8b98-445e-b495-da4f0aca0e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2812afde-8b98-445e-b495-da4f0aca0e01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_73a4a472-35c1-4a4d-98b2-ae6b8f0dd359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_73a4a472-35c1-4a4d-98b2-ae6b8f0dd359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e133d57-5e9c-40d0-8ed2-7825011b2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e133d57-5e9c-40d0-8ed2-7825011b2d84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f96f12f-0860-4031-a344-9f2f30b355b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_79694dec-6d5b-424a-9e50-93ffe9a1814b" xlink:href="mrsn-20211231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_79694dec-6d5b-424a-9e50-93ffe9a1814b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4bfc38a8-57c7-47d1-bc0c-ca7b44ab8018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4bfc38a8-57c7-47d1-bc0c-ca7b44ab8018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8bb3134c-e1eb-42bf-bc4d-744c74d7c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8bb3134c-e1eb-42bf-bc4d-744c74d7c57a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2fd1cef6-5f54-4161-868b-c8850fb56ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_InterestPaidNet_2fd1cef6-5f54-4161-868b-c8850fb56ed1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd1b116d-3d41-499a-a8ad-27a6a9188292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd1b116d-3d41-499a-a8ad-27a6a9188292" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_228272d5-d77c-4806-8b8e-88c501959c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_228272d5-d77c-4806-8b8e-88c501959c82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_d3e0c351-d1f8-4507-9f16-f505c0668aa8" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:to="loc_mrsn_PublicStockOfferingMember_d3e0c351-d1f8-4507-9f16-f505c0668aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgramMember_5e481807-df05-4d87-83c4-00f131cc08f2" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:to="loc_mrsn_AtMarketEquityOfferingProgramMember_5e481807-df05-4d87-83c4-00f131cc08f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="extended" id="i0a41082b2efa4f6a955adee25b60f262_SummaryofSignificantAccountingPoliciesOtherAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_67de999c-7757-4a90-bbf5-5e99678627c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_67de999c-7757-4a90-bbf5-5e99678627c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:to="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:to="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bcb1258f-5ebc-4f94-97a2-8087f6463a85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:to="loc_us-gaap_CreditFacilityDomain_bcb1258f-5ebc-4f94-97a2-8087f6463a85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:to="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_43afa7bf-8f8e-4688-8284-9f0b3bc44889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:to="loc_us-gaap_LineOfCreditMember_43afa7bf-8f8e-4688-8284-9f0b3bc44889" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:to="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityMember_29d3230c-45d1-4a8d-9e4a-07e6cc099c34" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:to="loc_mrsn_NewCreditFacilityMember_29d3230c-45d1-4a8d-9e4a-07e6cc099c34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesNetlosspershareDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails" xlink:type="extended" id="i23f5ffc446394ec5a4d60a8ea447abcf_SummaryofSignificantAccountingPoliciesNetlosspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96561991-d272-4a38-8f32-a906233061ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96561991-d272-4a38-8f32-a906233061ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09b2fd43-4ac4-4397-9e3a-60d001394aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09b2fd43-4ac4-4397-9e3a-60d001394aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_348e2479-5301-484b-9963-4482b620f466_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:to="loc_us-gaap_EquityComponentDomain_348e2479-5301-484b-9963-4482b620f466_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:to="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_f679e24e-068c-4a2c-b4fb-86ffd5730191" xlink:href="mrsn-20211231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:to="loc_mrsn_ExchangeWarrantsMember_f679e24e-068c-4a2c-b4fb-86ffd5730191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf8a01f7-5d45-4667-89cf-8e28a84068ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cf8a01f7-5d45-4667-89cf-8e28a84068ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_283e29f4-b547-4a5f-a4a8-6e4ddd760c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_283e29f4-b547-4a5f-a4a8-6e4ddd760c45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_889b50ce-c977-4ee7-8b2b-379e7769930c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_889b50ce-c977-4ee7-8b2b-379e7769930c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6078e3d4-49e6-4aad-ab81-1862f89a4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_WarrantMember_6078e3d4-49e6-4aad-ab81-1862f89a4b46" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended" id="i0b47fabbf09441e0bcc00b1061dc9541_SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b1d7b3c3-9811-490b-9a33-a4351f917564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b1d7b3c3-9811-490b-9a33-a4351f917564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_c4208655-e29b-48b8-bbbb-dacec3388868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_c4208655-e29b-48b8-bbbb-dacec3388868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a73dd0b0-5ae7-4c76-8ac8-5905daeda3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_AssetImpairmentCharges_a73dd0b0-5ae7-4c76-8ac8-5905daeda3df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f159fcf-66ce-4f5f-b453-5f57e21c5d06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f159fcf-66ce-4f5f-b453-5f57e21c5d06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_603cb22d-4143-4438-b7c5-ac80cf32b189" xlink:href="mrsn-20211231.xsd#mrsn_ComputerEquipmentAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_603cb22d-4143-4438-b7c5-ac80cf32b189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_c17bb4b3-1058-428b-8ee4-e5db2402923b" xlink:href="mrsn-20211231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_mrsn_LaboratoryEquipmentMember_c17bb4b3-1058-428b-8ee4-e5db2402923b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4f6c3028-b309-4b61-aa29-cb7d51d981f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4f6c3028-b309-4b61-aa29-cb7d51d981f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="extended" id="i03dd7e0560044815bcdc5d30622267a2_CollaborationAgreementsNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:href="mrsn-20211231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:href="mrsn-20211231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:href="mrsn-20211231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21013ac6-c6e8-4346-8738-f449d86ad1e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21013ac6-c6e8-4346-8738-f449d86ad1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:href="mrsn-20211231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1f1fb1b-516d-4fec-8512-3fdce1731112_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:to="loc_srt_ProductsAndServicesDomain_c1f1fb1b-516d-4fec-8512-3fdce1731112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:to="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:href="mrsn-20211231.xsd#mrsn_LimitedServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:href="mrsn-20211231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:href="mrsn-20211231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81fc58b8-7a16-4340-962a-fa7a8a795223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81fc58b8-7a16-4340-962a-fa7a8a795223" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail_1" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsNarrativeDetail_1"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail_1" xlink:type="extended" id="i1ee7e95513c346e4a533c59ce3fbf05f_CollaborationAgreementsNarrativeDetail_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:href="mrsn-20211231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:href="mrsn-20211231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:href="mrsn-20211231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21013ac6-c6e8-4346-8738-f449d86ad1e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_21013ac6-c6e8-4346-8738-f449d86ad1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:href="mrsn-20211231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1f1fb1b-516d-4fec-8512-3fdce1731112_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:to="loc_srt_ProductsAndServicesDomain_c1f1fb1b-516d-4fec-8512-3fdce1731112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:to="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:href="mrsn-20211231.xsd#mrsn_LimitedServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:href="mrsn-20211231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:href="mrsn-20211231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended" id="i8a4886f654e044fca1bbd5e1ba189a52_PropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2a9aff40-c605-4aea-86e6-610d89df70cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2a9aff40-c605-4aea-86e6-610d89df70cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_62644943-fea6-4570-92d6-92d9e7a7dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_62644943-fea6-4570-92d6-92d9e7a7dda5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b018f464-abef-4e0e-ac1e-83a3a7b31b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b018f464-abef-4e0e-ac1e-83a3a7b31b53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7ee70740-cc67-4076-a666-dafb3157e0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7ee70740-cc67-4076-a666-dafb3157e0f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f984facf-75b2-477e-a073-cfecf0674ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_Depreciation_f984facf-75b2-477e-a073-cfecf0674ab1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b295af87-b621-4607-b025-19a8e8ea9b88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b295af87-b621-4607-b025-19a8e8ea9b88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_21150188-6db4-4bc7-8ccb-8fb9e6f82b35" xlink:href="mrsn-20211231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_LaboratoryEquipmentMember_21150188-6db4-4bc7-8ccb-8fb9e6f82b35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c4336dd5-dcee-4205-bf94-1fd014429aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c4336dd5-dcee-4205-bf94-1fd014429aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_3df8b425-4b50-470d-a2d8-6710391db97c" xlink:href="mrsn-20211231.xsd#mrsn_ComputerEquipmentAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_3df8b425-4b50-470d-a2d8-6710391db97c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeasesMember_86093004-e1bc-4871-8834-6a15ad62fe26" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_FinanceLeasesMember_86093004-e1bc-4871-8834-6a15ad62fe26" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="extended" id="i0bc5dc4f10884864bd80d14fd9c64da4_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_d6a3475c-0769-406b-a89c-36a699ef72fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_d6a3475c-0769-406b-a89c-36a699ef72fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bd794004-a4eb-4075-a46c-57026085f295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bd794004-a4eb-4075-a46c-57026085f295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3b0104af-9e67-4fd7-b8cd-262cf329a908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3b0104af-9e67-4fd7-b8cd-262cf329a908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e2c5c514-e6fb-476f-8988-b27e1f5f41a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e2c5c514-e6fb-476f-8988-b27e1f5f41a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e14caaf8-1dc5-48f8-9c58-9ddc0e28674c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e14caaf8-1dc5-48f8-9c58-9ddc0e28674c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_aad3b5fd-b30f-4c53-a7ce-d51f2bdacc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_aad3b5fd-b30f-4c53-a7ce-d51f2bdacc9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f48d673a-8e67-4377-80a6-a671e3300e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f48d673a-8e67-4377-80a6-a671e3300e69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_f472835f-4db6-4789-879f-05e4c4169ffd" xlink:href="mrsn-20211231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_f472835f-4db6-4789-879f-05e4c4169ffd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent_81d1ce24-0508-480a-9e21-0d6183be8aa6" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_DebtInstrumentPrepaymentFeePercent_81d1ce24-0508-480a-9e21-0d6183be8aa6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_bfff1b2b-8d72-4651-8b4f-369e843e4149" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_bfff1b2b-8d72-4651-8b4f-369e843e4149" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d91e6c2-cd39-455e-8057-328313c3b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d91e6c2-cd39-455e-8057-328313c3b6e9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_727cc523-7781-4db8-a9ae-5f3afa9e491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_InterestExpenseDebt_727cc523-7781-4db8-a9ae-5f3afa9e491c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0580acdd-03f9-423a-87a6-8c20d3b4269e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0580acdd-03f9-423a-87a6-8c20d3b4269e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember_0e2b6e1b-fb64-4bf6-abb4-2a1e1aad5a42" xlink:href="mrsn-20211231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_ExistingCreditFacilityMember_0e2b6e1b-fb64-4bf6-abb4-2a1e1aad5a42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember_1eaf428a-be50-49ac-b8a4-192f76c4f001" xlink:href="mrsn-20211231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_AmendedCreditFacilityMember_1eaf428a-be50-49ac-b8a4-192f76c4f001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityMember_0fedd8df-aeb1-460f-a6ef-211f98a016c4" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityMember_0fedd8df-aeb1-460f-a6ef-211f98a016c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheOneMember_28a72138-9bd6-4fd7-8ce2-c76497a1e8ea" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheOneMember_28a72138-9bd6-4fd7-8ce2-c76497a1e8ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheTwoMember_d1db897b-fe9f-418c-bbc3-7f48a65dfffa" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheTwoMember_d1db897b-fe9f-418c-bbc3-7f48a65dfffa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheThreeMember_261685d8-695c-4a47-aaaa-be93e69f55d1" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheThreeMember_261685d8-695c-4a47-aaaa-be93e69f55d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFourMember_a9dbe1d0-53c2-462b-9eeb-f19e73d3cecd" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheFourMember_a9dbe1d0-53c2-462b-9eeb-f19e73d3cecd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFiveMember_3ba857e5-ecc7-46a4-a414-2dc2a51c7f1d" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheFiveMember_3ba857e5-ecc7-46a4-a414-2dc2a51c7f1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheSixMember_82e1f5f7-b41e-4710-9b4d-4c8041347295" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheSixMember_82e1f5f7-b41e-4710-9b4d-4c8041347295" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_592f7559-d79e-4afd-8db5-f2db95f423c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:to="loc_us-gaap_VariableRateDomain_592f7559-d79e-4afd-8db5-f2db95f423c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:to="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c61f75cd-6076-458c-b891-aced4ccdaed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:to="loc_us-gaap_PrimeRateMember_c61f75cd-6076-458c-b891-aced4ccdaed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38e672c5-8f50-46b5-9a38-326fdffb52d2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:to="loc_srt_RangeMember_38e672c5-8f50-46b5-9a38-326fdffb52d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:to="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8667cb58-ee61-4fbb-a429-4915c8a86cda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:to="loc_srt_MinimumMember_8667cb58-ee61-4fbb-a429-4915c8a86cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e9a1b211-c60f-4247-8874-13958e7b67e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:to="loc_us-gaap_CreditFacilityDomain_e9a1b211-c60f-4247-8874-13958e7b67e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:to="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bfbc0a0d-1aac-44c6-a02f-5417ccf81238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:to="loc_us-gaap_LineOfCreditMember_bfbc0a0d-1aac-44c6-a02f-5417ccf81238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_49617a55-b887-45f3-ad23-86636d181e71_default" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_49617a55-b887-45f3-ad23-86636d181e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToOctober292022Member_0fe70558-1d01-4048-afb5-5ebc3f2adc18" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursPriorToOctober292022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursPriorToOctober292022Member_0fe70558-1d01-4048-afb5-5ebc3f2adc18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_11f84a68-deba-4420-991d-316fbefd4579" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_11f84a68-deba-4420-991d-316fbefd4579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_2b7b1f5f-c3c4-4588-aed8-68f3331471a8" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_2b7b1f5f-c3c4-4588-aed8-68f3331471a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fe11fe69-73d4-42b0-a8fd-c96958443a79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:to="loc_us-gaap_RelatedPartyDomain_fe11fe69-73d4-42b0-a8fd-c96958443a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:to="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LendersMember_f13ca06c-bc7e-491e-9dbc-7e1c48cb8571" xlink:href="mrsn-20211231.xsd#mrsn_LendersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:to="loc_mrsn_LendersMember_f13ca06c-bc7e-491e-9dbc-7e1c48cb8571" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ThirdPartiesMember_67c65fe9-6160-4e2f-baf0-6a795e85d650" xlink:href="mrsn-20211231.xsd#mrsn_ThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:to="loc_mrsn_ThirdPartiesMember_67c65fe9-6160-4e2f-baf0-6a795e85d650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_26a89a47-ed5c-470b-a836-18bd163a6a7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_26a89a47-ed5c-470b-a836-18bd163a6a7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmortizedInterestExpenseMember_1395c2b5-a3d8-43cd-a806-87c6b988206f" xlink:href="mrsn-20211231.xsd#mrsn_AmortizedInterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:to="loc_mrsn_AmortizedInterestExpenseMember_1395c2b5-a3d8-43cd-a806-87c6b988206f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CapitalizedOtherAssetsMember_b320c387-b7a7-4ad0-8b17-fa681f8b6c25" xlink:href="mrsn-20211231.xsd#mrsn_CapitalizedOtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:to="loc_mrsn_CapitalizedOtherAssetsMember_b320c387-b7a7-4ad0-8b17-fa681f8b6c25" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i4f17187afc2445eea80c62a86a5ff256_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7fc2871a-e38e-46af-b8ea-323d006fc846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7fc2871a-e38e-46af-b8ea-323d006fc846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1baa44f3-fc33-47f7-8f81-cee297dbbb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1baa44f3-fc33-47f7-8f81-cee297dbbb78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount_28c112d2-1ff9-4d25-9b37-05793186a7c3" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_StockIssuanceProgramAuthorizedAmount_28c112d2-1ff9-4d25-9b37-05793186a7c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c4884dd-2177-48d2-8ad8-afc89fed0800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c4884dd-2177-48d2-8ad8-afc89fed0800" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb8b697e-394a-4c61-9d48-901f16571e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb8b697e-394a-4c61-9d48-901f16571e4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_48a6e93c-634d-47df-8a4a-bf204282e134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_48a6e93c-634d-47df-8a4a-bf204282e134" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_e85e6e23-b008-47ec-9ca9-ccca51cb3e65" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_e85e6e23-b008-47ec-9ca9-ccca51cb3e65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_85ed80da-6576-42de-b752-17ffdde6ad5b" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_85ed80da-6576-42de-b752-17ffdde6ad5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ce105675-92e7-403c-81c4-3148049b75ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ce105675-92e7-403c-81c4-3148049b75ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractualLifeOfWarrants_184da42b-544e-41a7-8462-f9941529ebea" xlink:href="mrsn-20211231.xsd#mrsn_ContractualLifeOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ContractualLifeOfWarrants_184da42b-544e-41a7-8462-f9941529ebea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5fd38329-a6cb-46fb-8e81-6c3aa24e04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5fd38329-a6cb-46fb-8e81-6c3aa24e04c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_97f7f964-b6dd-4ba2-88eb-fa80292c59ec" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_97f7f964-b6dd-4ba2-88eb-fa80292c59ec" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f9e37483-942a-4244-b76b-efce9dd95057" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f9e37483-942a-4244-b76b-efce9dd95057" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_95b28837-e718-491a-961e-3d68dd1911ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_95b28837-e718-491a-961e-3d68dd1911ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod_92ac98a8-bff9-49a7-a4d1-1af54c25edc0" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_WarrantsExercisedInPeriod_92ac98a8-bff9-49a7-a4d1-1af54c25edc0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare_55e90f02-0fd2-4aac-b62c-3023757d2321" xlink:href="mrsn-20211231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_NumberOfVotesPerCommonShare_55e90f02-0fd2-4aac-b62c-3023757d2321" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_26b75ca9-230d-424a-b676-940c3d738c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_26b75ca9-230d-424a-b676-940c3d738c6b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b5edee3-f573-4da6-a931-d876589e584c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3b5edee3-f573-4da6-a931-d876589e584c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_6ca23973-61dd-4a94-ba0b-e496358e55e5" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_6ca23973-61dd-4a94-ba0b-e496358e55e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_f40723e2-5903-46e5-8880-b1b965fa9ee7" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_f40723e2-5903-46e5-8880-b1b965fa9ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_2eab4b27-4131-4f0c-acf4-fc6fe4c31aff" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_PublicStockOfferingMember_2eab4b27-4131-4f0c-acf4-fc6fe4c31aff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2c1373eb-b360-4650-a375-f8cdbe3670ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:to="loc_us-gaap_EquityComponentDomain_2c1373eb-b360-4650-a375-f8cdbe3670ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:to="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d3b92360-ff05-43c8-8d97-4bc60d782ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_us-gaap_CommonStockMember_d3b92360-ff05-43c8-8d97-4bc60d782ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6effa451-c8c2-445f-b84e-8db56e4809dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6effa451-c8c2-445f-b84e-8db56e4809dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_8f294857-8b47-429f-8796-615ccf9d2c86" xlink:href="mrsn-20211231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_mrsn_ExchangeWarrantsMember_8f294857-8b47-429f-8796-615ccf9d2c86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_59a949a1-2d15-4f86-826c-578dad275c7c" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_59a949a1-2d15-4f86-826c-578dad275c7c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquityCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended" id="ibfcc03633f1b4574bb376439213a08b2_StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_07f3755a-0975-4c53-bbb4-86a777a32071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_07f3755a-0975-4c53-bbb4-86a777a32071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_30f4adce-2262-42e4-a2ae-7ab075f8bafa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:to="loc_us-gaap_EquityComponentDomain_30f4adce-2262-42e4-a2ae-7ab075f8bafa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:to="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_6725138a-c9d0-47cb-a9d5-c5dfffdb0f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_6725138a-c9d0-47cb-a9d5-c5dfffdb0f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_be4853d4-cb29-4d4c-a310-22f807cb7861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:to="loc_us-gaap_WarrantMember_be4853d4-cb29-4d4c-a310-22f807cb7861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:to="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_795b0052-7cb6-4d68-b791-d952a4fc086e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_795b0052-7cb6-4d68-b791-d952a4fc086e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_90d17b53-55bb-4a7a-a3db-3ddf52b5949d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_90d17b53-55bb-4a7a-a3db-3ddf52b5949d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d4a3028-1602-497e-95a0-801df91f92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d4a3028-1602-497e-95a0-801df91f92d4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsNarrativeDetails" xlink:type="extended" id="i331e5a09541e463692e358817fcb5324_StockOptionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99fdb82d-a49b-4d0d-b979-c4639076a584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99fdb82d-a49b-4d0d-b979-c4639076a584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d0f59939-feea-48ad-80bf-be77129e28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d0f59939-feea-48ad-80bf-be77129e28b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_2cf25233-aa8d-43a4-be87-f6729c318ffe" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_2cf25233-aa8d-43a4-be87-f6729c318ffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a234444-ca5c-4dd8-ac2d-d5d3e905695e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a234444-ca5c-4dd8-ac2d-d5d3e905695e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0a42814a-20ba-41fe-b8ed-d97e0b1343a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0a42814a-20ba-41fe-b8ed-d97e0b1343a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60607d30-9485-4509-84c0-46d8b84d9020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60607d30-9485-4509-84c0-46d8b84d9020" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4f5c4b88-139a-4c5e-8c97-6f597f11d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4f5c4b88-139a-4c5e-8c97-6f597f11d36b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aba6d5c5-81e0-48c3-973c-1f47bcf76f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aba6d5c5-81e0-48c3-973c-1f47bcf76f89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23d75fef-0713-4eba-928e-7ba4522d4644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23d75fef-0713-4eba-928e-7ba4522d4644" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff66cd5c-df02-42fb-af6c-b631121fd30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff66cd5c-df02-42fb-af6c-b631121fd30f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32cbb640-4abb-463b-bdac-a8dc1129c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32cbb640-4abb-463b-bdac-a8dc1129c72b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b29f5291-9024-4d66-836b-3532beae9317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b29f5291-9024-4d66-836b-3532beae9317" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_effbfde0-0ef3-4ae7-9fef-c801204ba5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_effbfde0-0ef3-4ae7-9fef-c801204ba5f0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ffb63d5f-c408-4134-b131-6d64eb6ca353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ffb63d5f-c408-4134-b131-6d64eb6ca353" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_55339941-e59d-4f70-8f71-92af5eee546e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_55339941-e59d-4f70-8f71-92af5eee546e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1a15381-3f71-4ce5-a2c6-8756583530f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1a15381-3f71-4ce5-a2c6-8756583530f8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_628969d4-62ef-4bf9-bae0-78741a41f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_628969d4-62ef-4bf9-bae0-78741a41f07b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_31793da9-d8e1-44b0-b7f5-72ddb96621e0" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_31793da9-d8e1-44b0-b7f5-72ddb96621e0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2b761af5-1fcc-4012-9248-cf2e7d914561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2b761af5-1fcc-4012-9248-cf2e7d914561" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a02a024e-9c6d-4977-8978-271cd3a89cc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:to="loc_us-gaap_PlanNameDomain_a02a024e-9c6d-4977-8978-271cd3a89cc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:to="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member_a3c5206c-d9a0-4692-b4b0-11e054e3c360" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_StockIncentivePlan2007Member_a3c5206c-d9a0-4692-b4b0-11e054e3c360" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member_001ecf92-efe9-4415-b8d1-0e3843148a73" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_StockIncentivePlan2017Member_001ecf92-efe9-4415-b8d1-0e3843148a73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember_21a2252c-dfc7-40d4-b539-0e89bd765d30" xlink:href="mrsn-20211231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_InducementAwardProgramMember_21a2252c-dfc7-40d4-b539-0e89bd765d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_A2017ESPPMember_f2b8080f-2eb9-4173-a3ff-8afb03b698ec" xlink:href="mrsn-20211231.xsd#mrsn_A2017ESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_A2017ESPPMember_f2b8080f-2eb9-4173-a3ff-8afb03b698ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13feebc3-684a-4963-9fd3-1c3335900fe8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13feebc3-684a-4963-9fd3-1c3335900fe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8be91860-2d1f-4ae4-baf8-e8a63684d294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_EmployeeStockMember_8be91860-2d1f-4ae4-baf8-e8a63684d294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3dc1144-8191-4a84-9232-e834bfa32565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3dc1144-8191-4a84-9232-e834bfa32565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a3333c8c-aaa5-4f5b-be55-0f9fa600b18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a3333c8c-aaa5-4f5b-be55-0f9fa600b18c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b9177ce-ccc4-4612-8bc0-6b40bf521a44_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:to="loc_srt_RangeMember_7b9177ce-ccc4-4612-8bc0-6b40bf521a44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:to="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1ff74b8-2bdc-4c19-8772-ced08fa6b4ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:to="loc_srt_MaximumMember_d1ff74b8-2bdc-4c19-8772-ced08fa6b4ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ae4555d1-1e38-483c-afec-1e8ed1350506" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:to="loc_srt_MinimumMember_ae4555d1-1e38-483c-afec-1e8ed1350506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e1982904-cc03-4dc6-8306-bc0fbbb1d348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:to="loc_us-gaap_ClassOfStockDomain_e1982904-cc03-4dc6-8306-bc0fbbb1d348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:to="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d00e8eb9-e320-460e-9db6-4cef8d80030a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:to="loc_us-gaap_CommonStockMember_d00e8eb9-e320-460e-9db6-4cef8d80030a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="extended" id="i19cf2dae30dd4122b63fcd7467a938e4_StockOptionsRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1169083-fc28-46b5-a99e-1e87fb39f6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1169083-fc28-46b5-a99e-1e87fb39f6b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bd8005ea-cbd6-4661-b167-423181672955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bd8005ea-cbd6-4661-b167-423181672955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20c9c9d6-0f15-4d6f-8e8d-f344580bbb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20c9c9d6-0f15-4d6f-8e8d-f344580bbb53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e72a1ba7-f6da-40bc-b93c-45653a9cb50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e72a1ba7-f6da-40bc-b93c-45653a9cb50a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14a64659-9a17-479f-8eb2-30838abd4614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97178692-23ef-4ea0-ab8f-4917ca7091f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97178692-23ef-4ea0-ab8f-4917ca7091f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b838ee0e-401a-4662-a391-ab0275419fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b838ee0e-401a-4662-a391-ab0275419fb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_021553ce-bbfc-40c6-be6e-4028af3c0b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_021553ce-bbfc-40c6-be6e-4028af3c0b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7f9c93d1-7f6b-4e23-8429-25ab15165cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7f9c93d1-7f6b-4e23-8429-25ab15165cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5550b12f-8bac-4cbe-ac4a-11a14f1d7722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5550b12f-8bac-4cbe-ac4a-11a14f1d7722" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_36150caf-cfd2-4b6b-8cae-6d4bc7ebda50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_36150caf-cfd2-4b6b-8cae-6d4bc7ebda50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9101d9db-c461-4d16-853b-bbaa64f41f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:to="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0818495-89a9-4246-afb8-b61c521c28f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b0818495-89a9-4246-afb8-b61c521c28f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_28db4ad6-de32-455e-9a30-4e0d0f478445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_28db4ad6-de32-455e-9a30-4e0d0f478445" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="extended" id="iec5b23c6311c4f36af8fea2b7c07d9b3_StockOptionsStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f8672f70-ade1-4c2a-bbe5-aa16f7a5ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f8672f70-ade1-4c2a-bbe5-aa16f7a5ff9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_881a3fb7-689c-459a-930a-2bc6473f5100_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_881a3fb7-689c-459a-930a-2bc6473f5100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4563993d-5785-42d5-b02d-3e59bf488e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4563993d-5785-42d5-b02d-3e59bf488e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8d32852-e2f5-4703-a82c-a0722908e71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8d32852-e2f5-4703-a82c-a0722908e71d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:to="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c22c52ab-3f2a-4ae6-ae96-c08d1471083a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c22c52ab-3f2a-4ae6-ae96-c08d1471083a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ccf0440-e5a6-4752-a2be-e86992301aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ccf0440-e5a6-4752-a2be-e86992301aa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e19b3ef-08c1-4c73-b5f2-ab1cbbf17249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e19b3ef-08c1-4c73-b5f2-ab1cbbf17249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_48905b33-da9f-48f6-a12e-2de59596a171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_EmployeeStockMember_48905b33-da9f-48f6-a12e-2de59596a171" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/LeasesNarrativeDetails" xlink:type="extended" id="id0e4a4dd45e241e0a237391ec0e0fa67_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:href="mrsn-20211231.xsd#mrsn_LeasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d7fd5846-31b1-4460-af21-f6dec5953e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d7fd5846-31b1-4460-af21-f6dec5953e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78c2e353-dcf6-40ee-ac18-07ebc2186294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78c2e353-dcf6-40ee-ac18-07ebc2186294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e685e845-710e-440d-ae85-f2d5aad5be80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_OperatingLeaseLiability_e685e845-710e-440d-ae85-f2d5aad5be80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_f386ba1f-8102-470d-a9a0-3d9cb4751c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_SecurityDeposit_f386ba1f-8102-470d-a9a0-3d9cb4751c06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLeaseTenantImprovementAllowance_873eb0c8-b318-48c1-9be3-75f9b0e88f64" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLeaseTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_OperatingLeaseTenantImprovementAllowance_873eb0c8-b318-48c1-9be3-75f9b0e88f64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9219a134-4d40-4a7d-b841-3a5a777e343a" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9219a134-4d40-4a7d-b841-3a5a777e343a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_30b884d6-3292-47b6-ab2f-c26afd6775ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_30b884d6-3292-47b6-ab2f-c26afd6775ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5038a1ee-5ffc-4a58-b308-df61475ea337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5038a1ee-5ffc-4a58-b308-df61475ea337" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f9cc1d4b-4806-4eaf-8404-9ac0dd2f7962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LeaseCost_f9cc1d4b-4806-4eaf-8404-9ac0dd2f7962" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_83cb3456-ea23-4593-b62a-c802a2bfc650" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_83cb3456-ea23-4593-b62a-c802a2bfc650" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:href="mrsn-20211231.xsd#mrsn_LeasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c438c897-4157-42c0-a83c-c6ac9dc6528d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c438c897-4157-42c0-a83c-c6ac9dc6528d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember_64226532-3a5c-4cef-99da-b92f5953c99c" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:to="loc_mrsn_OfficeSpaceCambridgeMaMember_64226532-3a5c-4cef-99da-b92f5953c99c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember_02a1c142-c5f3-46f5-9087-394948e153fa" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceExpansionCambridgeMaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:to="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember_02a1c142-c5f3-46f5-9087-394948e153fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:to="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a937ed73-0605-40a1-803a-a83000332906_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:to="loc_srt_RangeMember_a937ed73-0605-40a1-803a-a83000332906_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:to="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_10f7e49f-57f0-47ea-a4a0-c39c6c2afdf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:to="loc_srt_MinimumMember_10f7e49f-57f0-47ea-a4a0-c39c6c2afdf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ddebc12-68aa-4869-9dcf-b997ea9d94dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:to="loc_srt_MaximumMember_6ddebc12-68aa-4869-9dcf-b997ea9d94dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesNetoperatinglosscarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="extended" id="if5a998d9bc0a463c9d8d4160449a2ca0_IncomeTaxesNetoperatinglosscarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_88fa10e9-df63-4a78-853a-a8b084bc231c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_88fa10e9-df63-4a78-853a-a8b084bc231c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_8846d1e4-90df-4bae-87a9-4880232d9349" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_8846d1e4-90df-4bae-87a9-4880232d9349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_ca636e44-7db6-4289-9657-47b7ce79e9e3" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_ca636e44-7db6-4289-9657-47b7ce79e9e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_366926cc-8643-45a9-9dbb-cf3b9cb0edff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_366926cc-8643-45a9-9dbb-cf3b9cb0edff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5bb7a80c-1ff0-4fc5-aa6c-5e9b91c5c064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:to="loc_us-gaap_DomesticCountryMember_5bb7a80c-1ff0-4fc5-aa6c-5e9b91c5c064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a3b6099e-5302-44b2-b833-8bc78ae75344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a3b6099e-5302-44b2-b833-8bc78ae75344" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesTaxcreditcarryforwardDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="extended" id="i2cd4e35ce68b428eab95a35469ae70bf_IncomeTaxesTaxcreditcarryforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_b1cdce8d-cced-4691-b17f-86203c462cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_b1cdce8d-cced-4691-b17f-86203c462cc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0280a038-8d24-4793-884c-10a153fb65c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0280a038-8d24-4793-884c-10a153fb65c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e7a68f86-52eb-419e-9e19-83b1ae02d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:to="loc_us-gaap_DomesticCountryMember_e7a68f86-52eb-419e-9e19-83b1ae02d2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bc728cdd-4042-4a6d-9e81-41e2d4c774ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bc728cdd-4042-4a6d-9e81-41e2d4c774ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0962125f-766b-4e0b-8d59-57e3f2be88f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0962125f-766b-4e0b-8d59-57e3f2be88f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_1b9bed91-2de0-498b-9f93-1fbe6faec742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:to="loc_us-gaap_ResearchMember_1b9bed91-2de0-498b-9f93-1fbe6faec742" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CommitmentsLicenseagreementsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="extended" id="ieb168f68ec914b40b0d7f6e0e6b86b46_CommitmentsLicenseagreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_07224d9e-8e84-4a58-9e3d-1e083d245924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_07224d9e-8e84-4a58-9e3d-1e083d245924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b5cc7352-e9e0-4c43-82cf-f48f5efb8341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_b5cc7352-e9e0-4c43-82cf-f48f5efb8341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_4849e299-def9-4a72-8f37-c8275bd2f632" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:to="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_4849e299-def9-4a72-8f37-c8275bd2f632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember_ffc2b6ce-fcc2-42cd-8536-5fd0a16843fb" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:to="loc_mrsn_LicenseAgreementMilestonePaymentsMember_ffc2b6ce-fcc2-42cd-8536-5fd0a16843fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.mersana.com/role/SubsequentEventsDetails" xlink:type="extended" id="i40b32d5cd1214667a349df3f9f8fc66f_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_67341b57-ff9e-4764-8a9f-a9e18ee2760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_ProceedsFromCollaborators_67341b57-ff9e-4764-8a9f-a9e18ee2760c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_5d0bfa63-72a9-4190-851f-2e7910bb19fc" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_5d0bfa63-72a9-4190-851f-2e7910bb19fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee_0c07ddad-133f-49e8-b5e7-5fba08a11993" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementNonrefundableExecutionFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee_0c07ddad-133f-49e8-b5e7-5fba08a11993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a4a19cca-6003-4e99-a77a-a0c84e21b433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a4a19cca-6003-4e99-a77a-a0c84e21b433" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_b1c5a436-5558-4117-bae5-952b3f7700ea" xlink:href="mrsn-20211231.xsd#mrsn_LineOfCreditFacilityTrancheAvailabilityDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_b1c5a436-5558-4117-bae5-952b3f7700ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78ebabfc-4f36-4df6-9d87-d752f656232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78ebabfc-4f36-4df6-9d87-d752f656232d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a672c564-5935-42fb-865c-9dd8a263befd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a672c564-5935-42fb-865c-9dd8a263befd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_c514d118-793e-4040-a781-a456db7d96ee" xlink:href="mrsn-20211231.xsd#mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_c514d118-793e-4040-a781-a456db7d96ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b5275b39-20e2-4121-9cfb-590a18f7a8c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b5275b39-20e2-4121-9cfb-590a18f7a8c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ac57dc00-f44f-4cf6-b06e-25a87c604c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:to="loc_us-gaap_SubsequentEventMember_ac57dc00-f44f-4cf6-b06e-25a87c604c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_20b6664e-cdef-43c1-82da-46103d13dbf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:to="loc_us-gaap_CreditFacilityDomain_20b6664e-cdef-43c1-82da-46103d13dbf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:to="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_f75de44c-f627-4ca5-9aee-20a58304cb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:to="loc_us-gaap_LineOfCreditMember_f75de44c-f627-4ca5-9aee-20a58304cb20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f38963e7-5c3c-4088-9479-57b5a9bbb6dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f38963e7-5c3c-4088-9479-57b5a9bbb6dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_db38b99b-a18e-4c30-825d-850a9aae9bc8" xlink:href="mrsn-20211231.xsd#mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:to="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_db38b99b-a18e-4c30-825d-850a9aae9bc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentAndRegulatoryMember_45d8b7e9-1d5b-4fc1-a3c4-17d1d46c9e2e" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentAndRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:to="loc_mrsn_DevelopmentAndRegulatoryMember_45d8b7e9-1d5b-4fc1-a3c4-17d1d46c9e2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CommercialMember_16642536-2b68-446e-8a6c-9e3bafd6d46f" xlink:href="mrsn-20211231.xsd#mrsn_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:to="loc_mrsn_CommercialMember_16642536-2b68-446e-8a6c-9e3bafd6d46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:to="loc_us-gaap_RelatedPartyDomain_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:to="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JanssenMember_e57de7ca-1750-4145-a8b4-687be388af21" xlink:href="mrsn-20211231.xsd#mrsn_JanssenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:to="loc_mrsn_JanssenMember_e57de7ca-1750-4145-a8b4-687be388af21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SynaffixMember_0656d543-7823-49c5-9fc2-cdca3e5f4b77" xlink:href="mrsn-20211231.xsd#mrsn_SynaffixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:to="loc_mrsn_SynaffixMember_0656d543-7823-49c5-9fc2-cdca3e5f4b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ebd96eb7-83f0-4115-8ea0-287839adea4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:to="loc_us-gaap_EquityComponentDomain_ebd96eb7-83f0-4115-8ea0-287839adea4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:to="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00e25db3-c028-4c72-86d3-ac11b0bd7583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:to="loc_us-gaap_CommonStockMember_00e25db3-c028-4c72-86d3-ac11b0bd7583" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_722ea644-2820-49fc-a356-d7cf0dd719f8" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_722ea644-2820-49fc-a356-d7cf0dd719f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>mrsn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_a5bac0e9-f999-49c8-91ea-8385857d1206_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e2f9399e-721e-4980-9475-046b436f15af_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_df33de8b-f219-4368-8ea8-4b6e91910ad4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax computed at federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_054fcda8-c34e-43fc-8340-a0802c8cf610_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0a1025c8-35ef-46cc-a1c9-c690748aed03_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of employee tax obligation (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bd21f796-57ea-41fa-ae46-cb42045156ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_94313bf7-b50d-47cc-a9ae-5cc0c25a5c9d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_23a532ff-f3c4-457d-b067-63cf41533cec_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2f3bf21c-024a-4680-889c-0fe0a275dd0a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8d92c6e6-add5-4560-a080-3c100b645473_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_aee2ad6c-7d49-44d3-9d2c-08159207b064_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_89bad441-b57e-4c69-81d6-fdf257b7d795_terseLabel_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3ade6c9b-95fc-4162-bb4a-6f1a5aa61911_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a4d1096b-c099-4e46-a9c7-e6bcc1bf04ce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5a281d8-8909-4034-a984-2f1cd60ddbbd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3036336c-7d06-43c5-8f5e-30f255a3afb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_44f5dc6d-8638-4e61-9c3b-9e28b387cd8b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_1f0d7afb-7d24-46b8-8dbc-ae75a1b55001_terseLabel_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_label_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract Assets And Liabilities [Roll Forward]</link:label>
    <link:label id="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_documentation_en-US" xlink:label="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract Assets And Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:href="mrsn-20211231.xsd#mrsn_ChangeInContractAssetsAndLiabilitiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:to="lab_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_51457664-861e-43da-9ef5-76dc697773f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated future payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ad4c6164-8504-4e4f-afd2-04d50abe9955_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0486f791-9423-4d55-9585-e559c764a286_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_dbbd97f8-c14c-46c8-9c58-25429aad6524_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5cdcdcab-f701-4c1c-8b46-6d04f61dc54d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_aa48fdbf-4fb5-4885-b507-3349230ab001_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the balances of our contract assets and liabilities and recognized revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7269a480-c1c8-4c22-9266-7649727501e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9d3251d3-78b5-4d47-9b39-e153471551f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_790b6ba3-fc82-4ee9-bafd-bb8c00a62eb0_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued as a result of the exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_435bd6a8-e2f8-43d9-92a1-66b91060f6b6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e356b1c8-81e0-4319-bc75-908607916208_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d0f95261-036e-4934-bc4b-f57829f59a77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3da3334d-050c-4d6b-97d0-ec22d6a86344_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_62b73fbd-5f8a-4621-adf2-2b82d6e7bd56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c2a6bca2-d4ec-4991-8a48-ab175fa9513b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_A2017ESPPMember_bed505da-13f4-44ef-9816-ec2f777bcd73_terseLabel_en-US" xlink:label="lab_mrsn_A2017ESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_mrsn_A2017ESPPMember_label_en-US" xlink:label="lab_mrsn_A2017ESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP [Member]</link:label>
    <link:label id="lab_mrsn_A2017ESPPMember_documentation_en-US" xlink:label="lab_mrsn_A2017ESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_A2017ESPPMember" xlink:href="mrsn-20211231.xsd#mrsn_A2017ESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_A2017ESPPMember" xlink:to="lab_mrsn_A2017ESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_16609aa7-f8b5-4c4f-943d-507bbd30ed6d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6821a28a-3597-4b10-a361-e5ba6fa50fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_01d10b3c-119e-4cb6-be52-5154e37de722_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f6988b24-853e-4b7d-8b0d-ceaf5d8c00f6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_9535cc01-3d6e-4287-86fe-17d006a666a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_4f4f5264-fb0a-4b8e-8bd3-09f50eed9a28_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next potential milestone payment eligible to receive</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Milestone Payment Receivable, Next Milestone</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the next potential milestone the company will be eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:to="lab_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_1ae8f073-b578-42c7-8fd8-3fdb49190ff1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_dc22e7a7-c20d-4960-bd3c-9c6c40dbe779_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_77fa9a8f-f2f8-4464-8d53-cf6690470619_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_cd1bc815-5a54-4a52-a9ad-ceb12ab6a602_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future principal payments</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_09981f2a-3fad-43be-b534-18781e5abe70_terseLabel_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, additions</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_label_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Increase</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityIncrease_documentation_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityIncrease" xlink:href="mrsn-20211231.xsd#mrsn_ContractWithCustomerLiabilityIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractWithCustomerLiabilityIncrease" xlink:to="lab_mrsn_ContractWithCustomerLiabilityIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_30cad603-677b-46a7-9836-05406f9148d3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_aa271e9e-a0b2-41b7-9875-09c78faa9355_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_79673a82-190f-47ba-9606-9f7718fb35ff_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_a2e62541-7803-4236-82ac-b64bf98d076b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceAbstract" xlink:to="lab_us-gaap_ValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b99c47ad-0031-4e7f-afec-6e43c11b5dd1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts included in the contract liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_cba09375-6726-469a-8db3-596804fbe974_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b806d563-5759-4580-bfaf-b4ac489cf49f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d30f0e77-3019-477c-b445-77ad01755a4f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a506de26-cf5c-4f80-b430-6439c6633450_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_6f405c4b-2efc-4e04-9743-4005b28e2b3c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_16c10201-4649-4862-af01-316f011dff04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0a72ddd3-14a3-4005-94b3-afb083980713_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_50f4f3a6-57c4-4f0d-b42d-d179c916dc53_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Between October 29, 2022 and October 29, 2023</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Between October 29, 2022 and October 29, 2023 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Between October 29, 2022 and October 29, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:to="lab_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_4687e6d5-0b9f-4e90-966c-a07811163483_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_03f8997a-9977-4d6d-8844-6f5d50e23e73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c277465-adf7-4b5a-9787-a46f208f04cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4db6e93f-76ed-4bda-ad03-5f9e5118fe94_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_07427c37-80f4-436b-9591-a89b46b55d5b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_39ede7de-caa3-43e2-8571-037ca98bfa6a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f37d50ae-4e42-4436-b29a-be43338f6014_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5c067f79-3f0a-4fc9-a544-c79e5fa6bb91_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_12a3332a-8e01-4c8d-bfad-0ee4c01feaf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carry-forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_73d3752a-cfa3-40f4-a8fc-4e17e44eabce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_77b9d5c8-f59e-410a-a706-e668a1796dc2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_db06c491-6aae-46e5-ae36-6ce76f991b3c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for financing lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fa1d847c-cbcb-4102-8cde-29b092a28436_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20553726-628b-44a5-8070-161ff245f26e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_561d820d-0fa2-40b6-adaa-38f64e80cd10_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrant in exchange for common stock (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares Of Common Stock Warrants In Exchange For Common Stock Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during period and exercise of common stock warrant in exchange for common stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d6343407-fa1d-4ec7-9194-ba46753c4248_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_812c8d8f-f10e-42c4-a6d7-e75f0d4e0876_terseLabel_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock issuance, net of issuance costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_label_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:to="lab_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d753caae-a1e8-4ed8-a206-ad0452c34ecc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a1865a06-cdb1-4e53-b46b-7549bd24a301_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210f27bb-b871-480d-9f4f-a4c4bbc994fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e4f6978c-67e5-4a98-aa5b-164034ef733e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_cbc8787a-efb7-412b-92e9-7404f34f6ae6_negatedLabel_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Assets</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_mrsn_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_6346763d-604b-4d61-934d-e7de732d5d20_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d6af8d1f-2cf3-4d1c-ab5d-886fd1b5c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability, noncurrent, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_3e6c2a37-95a4-482f-8172-95f5b6b98e40_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AccruedClinicalExpensesCurrent_fa00eb72-9f4d-4b9a-a764-e1d10b621759_terseLabel_en-US" xlink:label="lab_mrsn_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical expenses</link:label>
    <link:label id="lab_mrsn_AccruedClinicalExpensesCurrent_label_en-US" xlink:label="lab_mrsn_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Expenses Current</link:label>
    <link:label id="lab_mrsn_AccruedClinicalExpensesCurrent_documentation_en-US" xlink:label="lab_mrsn_AccruedClinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedClinicalExpensesCurrent" xlink:href="mrsn-20211231.xsd#mrsn_AccruedClinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AccruedClinicalExpensesCurrent" xlink:to="lab_mrsn_AccruedClinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_89f4df4d-b3fe-4764-9ebc-6bc6d662b62a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_94503a9b-6411-461d-9138-ee6045342145_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_3dad5223-2c55-4e82-aa87-ee541f7bc822_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares, Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f63782c8-7816-48a0-b9ac-a817795c4487_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_31f38a83-c898-4415-b453-612c58045eb3_terseLabel_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_label_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements, Exclusive Targets, Number</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:to="lab_mrsn_CollaborativeArrangementsExclusiveTargetsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_135c595e-ad63-4af6-be63-f16e0368ef9b_terseLabel_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_label_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility [Member]</link:label>
    <link:label id="lab_mrsn_AmendedCreditFacilityMember_documentation_en-US" xlink:label="lab_mrsn_AmendedCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember" xlink:href="mrsn-20211231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedCreditFacilityMember" xlink:to="lab_mrsn_AmendedCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5182b8aa-4051-40a9-9d91-cc5b9aa06feb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_fbc7a9ca-41d3-4ad9-80d3-c33aaa4901eb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d01f5cef-584c-458d-bf70-986a79a14dab_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_7ac8d787-a797-40f9-aa8f-c8ca90bb1f5a_terseLabel_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Not Received, Included in Estimated Transaction Price</link:label>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_label_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Not Received, Included in Estimated Transaction Price</link:label>
    <link:label id="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_documentation_en-US" xlink:label="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of milestone payments, which had not been received, included in the estimated transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:href="mrsn-20211231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:to="lab_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_52bf3b9a-f94a-479e-97e0-42fb9fc2d83b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_eb353441-b69e-4264-bf42-52378dcf8684_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFourMember_dec73f0e-e855-4083-9615-2cc6775c921b_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Four</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFourMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFourMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheFourMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4719c87c-7d65-4c1d-9060-75dc6ef0bc1f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_795523ba-bbcc-44db-b088-db4822cfe0e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant components of net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f0583b74-1cbc-476c-a9cf-41c078757812_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_57911f1a-b00d-432c-8ac3-2041e679836f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8eda328-606f-414b-9d29-8eceebc92011_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_33191e46-735d-4afb-bcc0-f770386ee316_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At market equity offering program (2018 ATM)</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2018 ATM) [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market equity offering program to offer and sell common stock from time to time at prevailing market prices.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram2018ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_8a230e7d-9c48-4e9d-a59e-0fafa16f1eba_terseLabel_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term:</link:label>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:href="mrsn-20211231.xsd#mrsn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_mrsn_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_82e65f56-d55e-4a87-88d6-2a1eb8ed31aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_8c62ae91-dcc7-4152-8343-6cc3ee1b1829_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_66c4b8fc-0a1c-41c7-9dd2-de087ef4d103_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_514f271e-693a-4b48-8580-9daf8574a246_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_40811c02-247e-4473-b2ed-04f0270f45ef_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensed technology</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Licensed Technology</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLicensedTechnology_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:to="lab_mrsn_DeferredTaxAssetsLicensedTechnology" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9fc3c312-970e-40af-800b-9db0cb2da4db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d8a11373-5ddb-4d60-9529-38b71e704926_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders &#8212; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ab396862-872a-445d-b6f0-09e4eb34c34a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from purchases of common stock under ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f99355e0-dd5b-4beb-983c-35e09e997357_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_f3579662-c05f-4143-a0fe-77195d864096_terseLabel_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful life of property and equipment</link:label>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</link:label>
    <link:label id="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="mrsn-20211231.xsd#mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="lab_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityMember_bb012689-c4ec-4632-9b66-af21dd666371_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityMember" xlink:to="lab_mrsn_NewCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b08fd70a-d9dc-4a8c-80f8-e07c3252ebe0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f60f221a-d5c1-465e-b216-56fe7cb5d9ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_99083fbc-26a6-495f-883b-7db2e13a9dbf_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_b34f7cbc-8500-4b27-adeb-dc8bc9b146d9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_c709d64e-26a0-4342-9213-fe47b5dcb183_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASC 808 costs billed to Takeda</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Costs Billed</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsCostsBilled_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of costs billed during the period under terms of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsCostsBilled" xlink:to="lab_mrsn_CollaborationArrangementsCostsBilled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0c4cb045-2cdd-4302-bc6b-2a9502e2651a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_4c0ac7fe-1654-4b49-a7ec-b0130e4d7a88_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit expenses</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fb35b4fb-7b95-4df6-b33e-40d6ba00bbef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToOctober292022Member_fd213999-2194-4696-be8b-afa62e229776_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Prior To October 29, 2022</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToOctober292022Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Prior To October 29, 2022 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursPriorToOctober292022Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs Prior To October 29, 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursPriorToOctober292022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:to="lab_mrsn_PrepaymentOccursPriorToOctober292022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_86b51cd4-d713-41b3-9c04-b13ed2b48cdc_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of shared development costs following effective termination date</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Shared Development Costs Effective Following Termination Date, Period</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:to="lab_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_8f28d080-eca4-4dc9-9795-943831e4d859_negatedLabel_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_label_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired During Period, Exchanged for Common Stock Warrant, Value</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_documentation_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity impact of the value of stock that has been retired in exchange for common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:to="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f880cc71-0a02-45ba-9c86-f663c4e25784_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinanceLeasesMember_4ef1d183-0ced-420b-9969-7f779e2f0245_terseLabel_en-US" xlink:label="lab_mrsn_FinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_mrsn_FinanceLeasesMember_label_en-US" xlink:label="lab_mrsn_FinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases [Member]</link:label>
    <link:label id="lab_mrsn_FinanceLeasesMember_documentation_en-US" xlink:label="lab_mrsn_FinanceLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeasesMember" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinanceLeasesMember" xlink:to="lab_mrsn_FinanceLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_9e92c5b3-7361-47de-9986-bb5ecdd1d8d2_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA Agreement and Merck KGaA supply agreement</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement And Supply Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA and the Supply Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_592fbf53-8b48-4deb-815d-ff86ac7bfdec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units, net of employee tax obligation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d866404f-81b9-471d-bb6c-f4f81f3eca70_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_250316c8-516a-4d64-9fff-bb4f6170271c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_b1b3ce48-2264-4756-8f50-5910865c42a0_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_56acd608-648f-4c7c-b078-3132f157e1cd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheOneMember_d3cc8ce7-439c-4315-be4d-b26a5843d264_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche One</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheOneMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche One [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheOneMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheOneMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7758e2a3-6ca7-4c80-837d-d189d2fd1329_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b4aa5d7e-ebb8-4801-bd60-13e0ec0d91bd_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_663f2cfa-7aab-479d-bc5f-67970c6ec1bb_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheThreeMember_6e33fdc6-1cb4-4a33-8ff6-139446d6f5fb_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Three</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheThreeMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheThreeMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheThreeMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_79867cd3-744f-4ffc-953f-d0b99dd7905a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bb4c25f9-c4ca-4081-a202-7759d50f76cd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_08441c29-3523-48a5-acb3-919fd079a6b7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_cf848c81-21a8-4784-92b6-1ba2e2c72473_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_fb1bfc4a-1efa-434a-b6c2-629d508ba31e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_33ca60b7-a2c6-4586-a85b-531e92d6d99f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_991d055b-d5cc-4179-bf90-bacb34c81ae0_verboseLabel_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_label_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance, Discounts And Commissions On Transaction</link:label>
    <link:label id="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_documentation_en-US" xlink:label="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and commissions deducted from cash proceeds received on stock transaction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:to="lab_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_ac2c31e2-a16f-465e-9703-936f8e8fdab6_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time until agreement terminated</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Duration to Termination</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDurationToTermination_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDurationToTermination" xlink:to="lab_mrsn_CollaborationArrangementsDurationToTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c5d13873-da57-4c8e-b753-fd0cd68b4403_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d90004e2-4b96-44ea-809d-da9326685046_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of ownership shift</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_72b5fa99-17b6-4265-8cee-baae0f3ad2d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_70b92acd-ff53-4a80-8723-d3d65f89d32f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_df95844a-7fe7-43d4-9eed-e3103f7b340d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_504e1627-e753-4cf6-bf9c-a7ca74615e6d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0461bd28-863b-48a5-930a-16f2695e5805_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_be21e06f-39c4-44dd-ad6a-83cb79456fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_0e76b36a-99ca-40de-b767-bd4567aeee2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_23a1f0c0-2946-4b45-925a-e5bf415b26b1_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM)</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM) [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program (2020 ATM)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgram2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cff100cc-6aa1-4ec6-9602-0491182da818_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_68c7caf4-2932-4745-aac6-15204c0a8db1_terseLabel_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares exchanged for warrants (in shares)</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_label_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Shares Exchanged for Warrants</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_documentation_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common shares exchanged for warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:to="lab_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OperatingLeaseTenantImprovementAllowance_68e16f4b-39b3-4ab4-8a76-1cad4af19f19_terseLabel_en-US" xlink:label="lab_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_mrsn_OperatingLeaseTenantImprovementAllowance_label_en-US" xlink:label="lab_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Tenant Improvement Allowance</link:label>
    <link:label id="lab_mrsn_OperatingLeaseTenantImprovementAllowance_documentation_en-US" xlink:label="lab_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLeaseTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:to="lab_mrsn_OperatingLeaseTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_255d62d8-0e86-4801-b991-334d031b5da5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_48b0ea1b-8377-4822-94f8-5352942b3a03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4bd7946a-9569-451b-94ab-8dfa8d2ad9d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_da8c3fc9-213c-4de9-9cd8-0877d1ee6e8b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_ab497488-1763-4260-9f61-d6b27663eb77_terseLabel_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs After October 29, 2023 but Before October 1, 2026</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_label_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs After October 29, 2023 but Before October 1, 2026 [Member]</link:label>
    <link:label id="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_documentation_en-US" xlink:label="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Occurs After October 29, 2023 but Before October 1, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:to="lab_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheSixMember_b3a2d114-ae8c-485d-8079-85b9f2bb5d92_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Six</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheSixMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Six [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheSixMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheSixMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheSixMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_40d2db4f-b8de-4ef2-90d6-ebf70a750137_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ef5db593-cb52-4247-be9d-4ab546c445ae_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_18f34369-2262-47fc-9092-9de925f665f2_terseLabel_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, transaction price, amount</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_label_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Transaction Price, Amount</link:label>
    <link:label id="lab_mrsn_RevenueTransactionPriceAmount_documentation_en-US" xlink:label="lab_mrsn_RevenueTransactionPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount" xlink:href="mrsn-20211231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueTransactionPriceAmount" xlink:to="lab_mrsn_RevenueTransactionPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_38d179e9-f664-40ab-bdb2-10615687cf28_terseLabel_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Domain]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_label_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Domain]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodDomain_documentation_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtCovenantPeriodDomain" xlink:to="lab_mrsn_DebtCovenantPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1a283327-7b48-499e-8c49-162046565ff8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_0fb95cee-a9c0-4b2e-a984-284e82861ecd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_4ab52301-be4a-4799-9362-7a1dd87a58f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule for number of common stock reserved for exercise of outstanding stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_10fce3e2-dcee-487c-907e-6b855af9941f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_dfd65356-c1cd-488f-a58e-cca0fbaf55fa_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt financing costs, net of accretion</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_6387cc6a-1940-43f9-a88f-77622e8027ab_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, fourth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Four [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for fourth target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_bfc2832f-375a-4257-9c07-bac9ea3e1408_terseLabel_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billing term</link:label>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_label_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Collection Period</link:label>
    <link:label id="lab_mrsn_RevenueCollectionPeriod_documentation_en-US" xlink:label="lab_mrsn_RevenueCollectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which entity receives payment upon billing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueCollectionPeriod" xlink:href="mrsn-20211231.xsd#mrsn_RevenueCollectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueCollectionPeriod" xlink:to="lab_mrsn_RevenueCollectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_be807860-c293-4535-b656-06d7a89ef23a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_ef6672b0-1f40-4ee0-9f85-f9c45efaa8d1_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional rate in event of default</link:label>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_label_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Additional Rate in Event of Default</link:label>
    <link:label id="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the additional percentage of rate in event of default under debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:to="lab_mrsn_DebtInstrumentAdditionalRateInEventOfDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e3eedc3c-9580-47f8-aaef-0b28d0b3669f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_4cae80da-00d3-488c-b923-a2479d0cd87d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a46caf2f-9027-4f9a-a9da-20c25ddb7aa0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_fd6cd97e-120f-45b4-a5a9-b1752ae158c4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1d19adb3-b858-4f14-977e-92793a781bb7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e275d7b2-5685-42e4-a871-6d93fcc0a426_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_616ea5b3-e313-4118-812d-752863f0ba55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_ea9d264c-27d3-4d76-aa37-5b6cf66784fa_terseLabel_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_label_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements, Upfront Payment</link:label>
    <link:label id="lab_mrsn_CollaborativeArrangementsUpfrontPayment_documentation_en-US" xlink:label="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of upfront payment received during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:to="lab_mrsn_CollaborativeArrangementsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9e6b3247-ce26-4f25-beae-a6b3ca976afa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5f8b259b-066b-409e-9d3a-4c1d98e8cd5d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1545c30e-7341-40c0-9d7e-423b0472c144_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4dfb0b56-8d89-4bfb-bf72-93bb4df5669c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f0f5045e-40de-4511-8f47-250571263c15_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_412f8e39-3e0f-48c6-b194-2c9ac0b1c852_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_9de9a477-4f62-4c11-9293-0653884cdd0c_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Sales Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsSalesMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum sales milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsSalesMilestones" xlink:to="lab_mrsn_CollaborationArrangementsSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_19dc0907-12c6-4930-a029-0da95f2e02e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_29f65fa1-c84a-40d9-9ef0-b6aec8e3ff16_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_9c13047a-a2c8-48f0-a583-e11e09faa1a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_a7bdf2d8-14ec-4220-be2d-eb20bfbc764f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3cc402a7-3c41-493c-890c-6c6e3578d390_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_3fd5bbda-2f79-44df-adec-9a7b79d89e4d_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior written notice for termination period</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Prior Written Termination Notice, Duration</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:to="lab_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_c38b87d0-cc41-49bb-86fe-293c16e7d35c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payments</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation, Share-based Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:to="lab_us-gaap_DeferredCompensationShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8bcd08ac-a963-4de3-b5c1-1fc0385b098b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6e2000ac-48fa-4900-a5e5-ddc2fc6a65d8_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1a1b19ae-5f29-4bf7-9b4b-c727ab723270_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties related to uncertain tax position</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e0857511-42af-44d8-8af8-138c5b58f7f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_4bd87ada-6d92-4a40-8ab7-4d952ac52dff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt financing costs in accrued expenses</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ce13a6de-12b2-4cf8-9b0d-7833aa2922d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e88cdfc6-7fa3-4874-ba79-18eaaafed31b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ca1a36c9-f345-4a20-8554-5216e96a2849_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesTable_173f9843-8362-4836-a6ca-5c10a41df127_terseLabel_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_mrsn_LeasesTable_label_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Table]</link:label>
    <link:label id="lab_mrsn_LeasesTable_documentation_en-US" xlink:label="lab_mrsn_LeasesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable" xlink:href="mrsn-20211231.xsd#mrsn_LeasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesTable" xlink:to="lab_mrsn_LeasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_153ae1ff-0679-4b96-8f3a-5d797e487326_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d0d4e685-618a-48d7-96c6-5f0a9b999fb7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_63bfc22d-ecd9-48ef-b7ac-96c05649f408_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d564a9ab-ef3a-4ea9-91f5-b6a0a437a66f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_80f2295a-5d54-45bf-a4b1-2691adbf090b_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_mrsn_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_93e3e96f-57ce-4992-a1b3-ac01d4e61e01_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 175,000,000 shares authorized; 73,709,056 and 68,841,288&#160;shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_77cec481-40b6-47a0-94f6-254793298072_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_423f6ceb-1ea8-41e2-8a4d-267a71e0f9a9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_8bb3dfaa-77ba-4541-9275-6689e662633d_terseLabel_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount employer contributes per employee</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_label_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Employer Contribution Per Employee, Amount</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_documentation_en-US" xlink:label="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual amount the employer contributes per employee to a defined contribution plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:href="mrsn-20211231.xsd#mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:to="lab_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LendersMember_6956862f-63bc-4ed8-9aec-e406bdadcc2b_terseLabel_en-US" xlink:label="lab_mrsn_LendersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders</link:label>
    <link:label id="lab_mrsn_LendersMember_label_en-US" xlink:label="lab_mrsn_LendersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders [Member]</link:label>
    <link:label id="lab_mrsn_LendersMember_documentation_en-US" xlink:label="lab_mrsn_LendersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LendersMember" xlink:href="mrsn-20211231.xsd#mrsn_LendersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LendersMember" xlink:to="lab_mrsn_LendersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3150c800-c674-4fe6-9dd6-819ebf89fac3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period of unrecognized stock compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_72e7c5af-4187-4100-88ec-102bf42d8f9b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_435f657b-2e90-47c6-892d-ae270d1bc780_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_88a90adc-1a0e-4e86-a7b7-117098134899_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments (Note&#160;13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_f3624f4f-746b-42de-8643-853850fcdd12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_deb28c0a-f857-4f3f-91cd-10fd072530ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_e35d3cf9-cf4e-404d-b182-65ed47ba7337_terseLabel_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_label_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Depreciation</link:label>
    <link:label id="lab_mrsn_DeferredTaxAssetsDepreciation_documentation_en-US" xlink:label="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DeferredTaxAssetsDepreciation" xlink:to="lab_mrsn_DeferredTaxAssetsDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_97790d2a-4ffa-4f7f-81bc-5a7f592a9bee_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_301e1d28-6f12-4f57-ab0d-19eb37eecf0e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_265babb4-5827-4458-8a8d-5c2207ac3cf4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instruments with off-balance sheet risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_efc1f173-b432-46a8-9388-06559975ba9d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_1e5096a9-693a-4cb4-83cb-6fa12901a494_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLineItems_label_en-US" xlink:label="lab_dei_AuditorLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLineItems" xlink:to="lab_dei_AuditorLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_64512936-05cf-4a32-9886-851cc4474d8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted average assumptions for estimating fair value of option awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_799fcff7-daa3-40e2-89ec-c00ab0c3d824_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_59a6e0b3-3398-4a7a-8678-d57e9d3d13b5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6ad0e760-1674-444a-80e2-59d9cfe901b1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmortizedInterestExpenseMember_3ab6ee42-3be8-4bc5-884a-6b2fb155613f_terseLabel_en-US" xlink:label="lab_mrsn_AmortizedInterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Interest Expense</link:label>
    <link:label id="lab_mrsn_AmortizedInterestExpenseMember_label_en-US" xlink:label="lab_mrsn_AmortizedInterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Interest Expense [Member]</link:label>
    <link:label id="lab_mrsn_AmortizedInterestExpenseMember_documentation_en-US" xlink:label="lab_mrsn_AmortizedInterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmortizedInterestExpenseMember" xlink:href="mrsn-20211231.xsd#mrsn_AmortizedInterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmortizedInterestExpenseMember" xlink:to="lab_mrsn_AmortizedInterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a66850dd-0055-471a-bec6-a02c3dfb5dd0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_279cafbd-050c-4b95-9ce8-566896016210_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, liability, current, statement of financial position</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_3c68d89d-1dca-40f1-9962-a0010bb5cefa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_07ff68fe-47b7-444a-b3d4-1427ce10bdd5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_84193194-16f3-42f3-b91d-538bb43e7a16_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_aebc33b3-e2e4-48b9-865f-4c5c946257ba_verboseLabel_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of state jurisdictions in which entity files income tax returns</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_label_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes, Number of State Jurisdictions</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions_documentation_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of state jurisdictions in which entity files income tax returns.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:href="mrsn-20211231.xsd#mrsn_IncomeTaxesNumberOfStateJurisdictions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:to="lab_mrsn_IncomeTaxesNumberOfStateJurisdictions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_8615beb1-ea9e-4790-947c-dcc24c62ff03_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9b04a464-93c7-4a5e-b819-b37064e78e55_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_df1051b1-e7d3-4ae3-b400-20a77c6d2702_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_f2758dc2-93f3-4f6b-aab9-dc20b74e0335_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of development milestone payment received</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones Payment Received</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the development milestone payment received by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_e46114f6-5e92-4d15-858a-bcec1166e1df_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_label_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAgreementMilestonePaymentsMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:to="lab_mrsn_LicenseAgreementMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b12d73de-dabe-4160-8be7-e1520b04880c_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_b115c8aa-dc5d-46e8-9466-a67be5680a6b_totalLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_e4e11ca5-0ad1-449d-a365-c674b1f74a10_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Maximum Aggregate Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:to="lab_mrsn_CollaborationArrangementsMaximumAggregateMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_0d4e210c-8f74-4fd3-8fd2-d36402038422_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next potential development milestone payment eligible to receive</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones Payment Receivable, Next Milestone</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the next potential development milestone the company will be eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_56203201-6c5a-4ab3-a517-6fbf6da66ed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d42fcad3-220c-4bd7-a170-f40f8f29a8d4_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7ee4d7c6-5964-442f-a456-bb99d9517780_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_b43ddd3b-6f94-4070-a205-9074e6503ff1_terseLabel_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and share-based payment awards</link:label>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_label_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Share Based Payments [Member]</link:label>
    <link:label id="lab_mrsn_WarrantsAndShareBasedPaymentsMember_documentation_en-US" xlink:label="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and share-based payment awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:to="lab_mrsn_WarrantsAndShareBasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_801dc7ea-3e84-401b-9e7a-d18ea8210d17_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_711ffc04-7d9c-4ea3-a695-fa12da4146bb_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_fd9624ec-12f5-4291-898c-6a90c9e42c1c_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_label_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Leases [Abstract]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingLeasesAbstract_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeasesAbstract" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract" xlink:to="lab_mrsn_LesseeOperatingLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_4c059dc0-8d49-4db5-b2ba-81a4aec653bf_terseLabel_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract_documentation_en-US" xlink:label="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Supplemental Cash Flow Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:href="mrsn-20211231.xsd#mrsn_LeasesSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:to="lab_mrsn_LeasesSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8a7852f5-7eb6-458f-ae16-e71c90ff48a7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_fb68a0be-1347-4dda-a68a-760b7c295d90_terseLabel_en-US" xlink:label="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended New Credit Facility, Combined Tranche Four and Five</link:label>
    <link:label id="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_label_en-US" xlink:label="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended New Credit Facility, Combined Tranche Four and Five [Member]</link:label>
    <link:label id="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_documentation_en-US" xlink:label="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended New Credit Facility, Combined Tranche Four and Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:href="mrsn-20211231.xsd#mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:to="lab_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_PublicStockOfferingMember_9acdfd6c-9edd-47f1-bd43-6b802927eb98_terseLabel_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_mrsn_PublicStockOfferingMember_label_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_mrsn_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_mrsn_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_PublicStockOfferingMember" xlink:to="lab_mrsn_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_48e82ea0-e8e9-4258-930a-a9a8a4e6e1ff_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_9f5c60c0-6f6d-4017-84fc-b0ade774fa38_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a4ead2f6-baef-4252-a583-831e81cc0059_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f7704b78-ba44-4584-b5b1-20b40686d606_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_88301a2a-c017-499b-8bed-9a76b266a5d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_48a2cb67-d538-459f-8705-30d7252566f2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_3ffe04f9-8aab-476b-9493-64cb948cfdc9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_cf536930-6872-41e0-a323-2698b4ee36a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_450b71b9-6a75-40c4-b422-814beac9adc6_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental balance sheet information related to leases</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_label_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Lease, Supplemental Balance Sheet Information [Table Text Block]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of supplemental balance sheet information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:to="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f84a413a-02c5-4763-a993-41066055b112_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_eae818a8-ac5b-44ba-ab48-efb4bcd8f607_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5bcf7e73-9207-4cd5-b454-7da66edf65ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_bde8521d-69a7-4e91-9e4f-03a0bc6fb50b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9ed264a0-38a7-4463-a3a3-4d2c925ee9a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d37945fd-60e4-4596-8e96-cf0e4a2e88dc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_147111d5-92c3-4b02-92ca-b2dda0cc7751_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_9f97bb44-0978-4905-ace4-18b703003199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_8073bb7f-17ba-4f6c-b522-35884a8f0ffe_terseLabel_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche availability duration (in days)</link:label>
    <link:label id="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_label_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Tranche Availability Duration</link:label>
    <link:label id="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_documentation_en-US" xlink:label="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period within which the term loan tranche will be available after achieving the tranche loan milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:href="mrsn-20211231.xsd#mrsn_LineOfCreditFacilityTrancheAvailabilityDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:to="lab_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_ba2ab79d-8c9e-458b-9254-ea71c0a5b0bb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2c70dc3f-28b5-450b-92dd-baa245b14afc_terseLabel_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in ROU asset</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1ad8de79-0fdb-4e1c-b285-b8248242bfef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0dc72402-ee86-4dcb-a202-fd88db8432c7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_1110cff6-8719-4953-a61e-9b84a4c5a1f0_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_a6892c61-aded-47cd-829f-94ddcbd7238d_terseLabel_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XMT-1522 agreement</link:label>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_label_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Collaboration And Commercial License Agreement Takeda [Member]</link:label>
    <link:label id="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_documentation_en-US" xlink:label="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:to="lab_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheTwoMember_101bad76-8fbb-42df-bbfd-567727970b48_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Two</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheTwoMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheTwoMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheTwoMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_d4f86634-202b-4c98-999d-78a54d0729c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_67133c26-23ba-432e-afaa-128d5c958a6a_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt, net of current portion</link:label>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_label_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount, Noncurrent</link:label>
    <link:label id="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:to="lab_mrsn_DebtInstrumentCarryingAmountNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_4edfdb5a-6e8f-4efa-8b52-1f57f2d48f2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_203a112b-09ee-4f21-ac9a-3d70273f75af_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Regulatory Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsRegulatoryMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:to="lab_mrsn_CollaborationArrangementsRegulatoryMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5b950167-b7f9-4762-9555-f0bd9d09e984_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_b5bf0e69-1352-4d06-b474-2b80c25786b0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f726cf7b-3ec5-41d1-b6fb-ed3e774b7f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_8811d581-7e2d-416a-b527-9a4edc2f7510_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock unit activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280ecf36-ec3c-476b-9fa8-a36d22bc8e88_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock into which warrants may be converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_23570a83-7f3b-4491-99a1-9b5596e5309d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_5952ca21-ff37-472f-971d-3e5567b37f03_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_1fca3320-192e-4aca-aad8-26db96c28379_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana BioSciences</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_label_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Commercial License Agreement Asana Bio Sciences [Member]</link:label>
    <link:label id="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_documentation_en-US" xlink:label="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Collaboration and Commercial License Agreement with Asana BioSciences, an existing partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:to="lab_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_f49aaf4d-24fd-4ce9-a0d2-2ccd8448664b_terseLabel_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases:</link:label>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_label_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Abstract]</link:label>
    <link:label id="lab_mrsn_LesseeFinanceLeasesAbstract_documentation_en-US" xlink:label="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeFinanceLeasesAbstract" xlink:href="mrsn-20211231.xsd#mrsn_LesseeFinanceLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract" xlink:to="lab_mrsn_LesseeFinanceLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_43de6dc2-456a-4f09-a9d9-fce82732c925_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_4127a2b8-5ce7-4942-84d7-7a01023ceea0_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_label_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementsAbstract_documentation_en-US" xlink:label="lab_mrsn_CollaborationAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAgreementsAbstract" xlink:to="lab_mrsn_CollaborationAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e59b476-1295-425c-ac0b-3ae6dbbb735f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_fc2ef5b6-ef56-4865-b726-d2b083bd3fc6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_9134626d-7237-4226-b6cb-59b5c21d4e99_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_da3f07ac-f1c9-4c03-b760-06cf4c786a7b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_b67e21d4-3759-4013-8e1b-f647d1f268a4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88a57af0-7c1d-478f-a10a-5113543e471d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fe939ea4-04bb-4589-b786-46479bc6783c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_732d1250-43b4-4d5e-93e5-8b28e4a8373e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_360a9aa2-423b-466e-9f3e-135426dbb397_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0fa16300-8fb0-4f2d-a3e2-0c2c945f30f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9a7e446a-de7b-4a22-abfa-73ab04b065af_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0964b3b7-1c8b-4aab-ba3d-2202d03448cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_62ce48f7-0a98-414c-b6fc-cf449b2f9a2b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f6cc9e66-0267-4b38-9406-3680e200259a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_b15aa3d5-fce0-4906-aa87-fc0c699d6fb8_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, fifth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Five [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for fifth target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_af152187-03ef-4ad2-bbe5-4f0ac8b23298_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b01da8bf-4b71-4290-b77f-1b15e89dcc36_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_3598791e-2574-4281-9d77-8fa6b79f1be1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4fc54f1e-212f-4a41-ae6e-f40f38ceebbb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carry forwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_423a38f9-a073-46ca-a45e-9c04e31d1551_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3a5cb86c-a0fe-48ba-a1b7-d935b3f8abbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_85572963-c125-4ddf-b0f8-2a285f84ca50_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_2b6e9abf-e7df-4bb2-81f1-91411173f4a1_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual development milestones per target</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Development Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual development milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_167cd035-d877-4bce-a60a-def4185a86e6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_14f2c237-0821-4cdb-aadc-c763900bad44_terseLabel_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_label_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised In Period</link:label>
    <link:label id="lab_mrsn_WarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_mrsn_WarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WarrantsExercisedInPeriod" xlink:to="lab_mrsn_WarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_be349df3-edc3-46ed-ac56-8ee22de23c21_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_dd18394f-295e-4d93-aedb-1b6b3babf4c9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1c3e0d25-e00a-4e46-8125-abe16aa32325_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_dcd8a989-aa17-460f-9f78-e664fc5547fe_terseLabel_en-US" xlink:label="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares available for sale</link:label>
    <link:label id="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_label_en-US" xlink:label="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Remaining Amount Unsold and Available for Sale</link:label>
    <link:label id="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_documentation_en-US" xlink:label="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares of common stock available for sale under the program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:href="mrsn-20211231.xsd#mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:to="lab_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5ce6e331-4907-4071-8bc5-834c772cb3ae_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_37750007-1e5e-4389-af4d-e07df1c980cd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under ESPP</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_64192ea7-f7ad-438b-9316-1339dc3e5f58_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CapitalizedOtherAssetsMember_84345533-c131-4faf-af5d-2798baa3691e_terseLabel_en-US" xlink:label="lab_mrsn_CapitalizedOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Other Assets</link:label>
    <link:label id="lab_mrsn_CapitalizedOtherAssetsMember_label_en-US" xlink:label="lab_mrsn_CapitalizedOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Other Assets [Member]</link:label>
    <link:label id="lab_mrsn_CapitalizedOtherAssetsMember_documentation_en-US" xlink:label="lab_mrsn_CapitalizedOtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CapitalizedOtherAssetsMember" xlink:href="mrsn-20211231.xsd#mrsn_CapitalizedOtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CapitalizedOtherAssetsMember" xlink:to="lab_mrsn_CapitalizedOtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_5e9ccc6b-dfc6-4d83-8540-0dd58e25b214_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6c04c534-2333-4d88-be73-c4baf8d61583_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk and Off-balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6f2a1f87-5ad8-4e6e-a8e3-8db01d239347_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e5631518-b420-457c-b163-fc1a2cf8a1c2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_4aa39dae-abd2-433a-a591-7724e72f39ad_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_b641f21c-7e32-4db8-ac9d-12cbc5505499_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related research and development services, including phase 1 development and transfer certain materials and know how</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services And Development And Transfer [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related research and development services, including Phase 1 development and transfer certain materials and know how related to the Company's manufacturing processes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_6d5bca3a-673c-4f88-895d-8990b08a1517_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_91bab794-982b-499e-bde1-e664f85d284d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b165f01f-57fc-4ea0-9e05-7ba87d70c387_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual commercial milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Commercial Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual commercial milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4fee3622-0dd6-436e-a28b-210a37727491_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6f9ae06a-d0c1-4b56-9180-2fe65256f819_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_d43ca818-2b94-48c0-bc52-544c9df1f729_terseLabel_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label>
    <link:label id="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in operating lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_4b82aaa6-52f6-4e47-876e-11e2d75ea2f7_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual regulatory milestones per target</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement Individual Regulatory Milestones Target Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual regulatory milestones per target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:to="lab_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3847cc8f-ddd9-4254-958e-46b4e10b979c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AccruedPreclinicalExpensesCurrent_8e86c528-b3bb-40f1-bcac-af7751450c21_terseLabel_en-US" xlink:label="lab_mrsn_AccruedPreclinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical expenses</link:label>
    <link:label id="lab_mrsn_AccruedPreclinicalExpensesCurrent_label_en-US" xlink:label="lab_mrsn_AccruedPreclinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical Expenses Current</link:label>
    <link:label id="lab_mrsn_AccruedPreclinicalExpensesCurrent_documentation_en-US" xlink:label="lab_mrsn_AccruedPreclinicalExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalExpensesCurrent" xlink:href="mrsn-20211231.xsd#mrsn_AccruedPreclinicalExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AccruedPreclinicalExpensesCurrent" xlink:to="lab_mrsn_AccruedPreclinicalExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_d850e83a-f0b4-48df-b49a-ffc3d2f7b666_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b9140e61-11aa-4306-9bcb-f06ab467ac61_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_07634804-6035-4d83-b4fd-1f7b006b8a5d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_69b17c1f-7051-4332-b0a3-1efce94cd216_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5dff7106-d8f9-4f18-84ef-5d8eed2848b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of common stock under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_191be0d9-e225-4318-8253-d23825ec93f2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_6efa5b9e-adc7-47e0-b139-3a0463c551b4_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_3fbb41cf-b8e9-435d-8704-81ffdc1fa39f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage employer matches of the employee's percentage contribution matched</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_cae5798a-ed34-4634-873a-95cc37d8bf95_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0110baa7-29a3-4af4-868d-c9c7eaaba4c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_c51dfab8-88b0-4bce-a4c0-075f15ea9892_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_663ed80a-976b-4864-a985-c470adf2e89c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9193e760-f824-409b-b334-e72903dc851c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_cdd21c65-30a4-4929-8281-2c0cbed2b58c_terseLabel_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space, Cambridge, MA, Leased</link:label>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_label_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Cambridge Ma [Member]</link:label>
    <link:label id="lab_mrsn_OfficeSpaceCambridgeMaMember_documentation_en-US" xlink:label="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space in Cambridge, MA under operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OfficeSpaceCambridgeMaMember" xlink:to="lab_mrsn_OfficeSpaceCambridgeMaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_44d2fe72-fe87-45a8-a34b-db145f0f3a7f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_549e5bc5-022b-4556-9168-39617ccdc85f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_e7bb3f61-7cbf-43a1-ad0f-a057f2fdba35_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_df824095-6603-4701-96af-420b0c6273b1_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants (in shares)</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_label_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Options and Warrants Exercised</link:label>
    <link:label id="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_documentation_en-US" xlink:label="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock issued as a result of the exercise of stock options and warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:to="lab_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2161afb4-e311-4819-bffa-c16e3d6bfff0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_f4586541-0bf2-4530-a5a0-b3a11185d83d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_8cd70140-7ef7-4b0e-9cc2-5765e83d0b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from the exercise of stock options (in dollars)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_953ebd79-0eb8-4b9c-b5c5-d1212541cbf6_terseLabel_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of supplemental cash flow information related to leases</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating And Finance Lease, Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:label id="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of supplemental cash flows information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="lab_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ed5cb9d6-3a6a-4589-81ab-58404ae59e83_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7d57013d-cce6-416c-be1e-a309df1fc8a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_79d56f67-78f9-44b9-aa9e-a898b06bdad0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_59880d23-a7fd-4a25-be94-cf80b8b7262e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_81206a55-f859-47b6-8b3d-a29ce33da0e5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e0eb0a60-7ceb-4418-b8cb-f7976b09f16c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2ae41f15-324e-430a-a835-697b88e99ae5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ed94e0de-7b66-4b18-a037-154933679167_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a4be9503-b9cb-4145-aab6-832adec1a160_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c27c3e78-691e-440b-a8dd-ad34f926b3bf_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_3823fab0-acb0-441e-8f61-ea98a9bd805f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9f96e3e6-0416-47d6-a326-bec299bb4299_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_f3b5b05f-1cce-4edc-a487-427a0479947c_negatedLabel_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock in exchange for common stock warrant (in shares)</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_label_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired During Period, Exchanged For Common Stock Warrant, Shares</link:label>
    <link:label id="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_documentation_en-US" xlink:label="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock that have been retired in exchange for common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:to="lab_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_72efb655-4548-46c7-b66b-53a9869a5d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7c13a73b-4f69-4305-afc0-72a38077c9a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting for Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5a73c12d-acf7-46bb-9583-96f1f6a59dd9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock warrant in exchange for retirement of common stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1e43ef72-b295-4220-91e7-090c20d2d118_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_e87e0580-49e0-47e2-a2b9-e83ac0c3dbf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_JanssenMember_9f8026ec-24d8-4080-a14e-4d675b9cc668_terseLabel_en-US" xlink:label="lab_mrsn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_mrsn_JanssenMember_label_en-US" xlink:label="lab_mrsn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen [Member]</link:label>
    <link:label id="lab_mrsn_JanssenMember_documentation_en-US" xlink:label="lab_mrsn_JanssenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JanssenMember" xlink:href="mrsn-20211231.xsd#mrsn_JanssenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_JanssenMember" xlink:to="lab_mrsn_JanssenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_aa132868-2900-4306-bdb4-c508df2d0d4c_terseLabel_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of shares authorized to be offered and sold</link:label>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_label_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Program, Authorized Amount</link:label>
    <link:label id="lab_mrsn_StockIssuanceProgramAuthorizedAmount_documentation_en-US" xlink:label="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of common stock shares authorized to be issued under the program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:to="lab_mrsn_StockIssuanceProgramAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_744358ef-8cf7-472c-b240-60a93630a641_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit for security deposit</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_df87b6c8-9ace-45ff-a19c-58d8a25d016f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_98913426-fadf-4f87-8915-f986cea0d50b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8a74ce5d-5a3d-4293-beee-10262fcc60b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8cd8debb-09b5-460d-8dec-d152d618f1aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_0c350c08-ba14-4a3d-b3de-4fdb23ca2638_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term-debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7d05eeb3-a62d-4a04-b953-89d6ba0b4285_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7f58f579-6570-4ad2-8711-f64d90644201_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_cba9382a-6879-4916-b516-677b68e05264_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b20074c5-a8a4-481c-8ef7-6d0e3df6f6d0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c837e03d-8a74-41e7-86b0-17c5983eeaad_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_d6059164-52c0-45bb-9f80-912be26ded24_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_ae4f64f4-82eb-47ab-82c5-6f9f53f8f407_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_d8d077cf-b001-4997-bd23-a44581567c83_terseLabel_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment fee percentage</link:label>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_label_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Prepayment Fee Percent</link:label>
    <link:label id="lab_mrsn_DebtInstrumentPrepaymentFeePercent_documentation_en-US" xlink:label="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of prepayment fee under debt instrument.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:to="lab_mrsn_DebtInstrumentPrepaymentFeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995cee06-2185-4ad0-86a0-9bcac966a2d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_800f3490-a96b-4ad5-a243-6242f854cf1c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20109369-87eb-4e87-9c19-6e15dfa21fa5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_a118fd03-e542-4a83-897a-dd997cab45a2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_3ef08618-3edd-4c19-950f-12942681550e_terseLabel_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate:</link:label>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_mrsn_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageDiscountRateAbstract" xlink:href="mrsn-20211231.xsd#mrsn_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract" xlink:to="lab_mrsn_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainageDeposit_81449aab-7442-4470-825f-7230bb188504_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainageDeposit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held by service provider</link:label>
    <link:label id="lab_us-gaap_RetainageDeposit_label_en-US" xlink:label="lab_us-gaap_RetainageDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retainage Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainageDeposit" xlink:to="lab_us-gaap_RetainageDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_ecefbbf9-d5f0-4d86-9aaa-29a7e2f4015f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2710cf8f-39df-467d-b1fb-884349b9cb7e_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c604757a-bc48-4700-9f9a-f460177b2cbf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_18bac328-9538-4041-b19c-733b2fac0ce0_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5bedade0-8ed5-482e-95ab-ddb82ee81e9e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_24b3b90e-aef4-49d5-8115-c4ce5e21a280_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgramMember_7e6065de-0627-4cd1-860a-9fcba2f3aa92_terseLabel_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgramMember_label_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program [Member]</link:label>
    <link:label id="lab_mrsn_AtMarketEquityOfferingProgramMember_documentation_en-US" xlink:label="lab_mrsn_AtMarketEquityOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At Market Equity Offering Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgramMember" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AtMarketEquityOfferingProgramMember" xlink:to="lab_mrsn_AtMarketEquityOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_95c89992-ba8a-4eef-891d-0de77e6d34ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_4a3d090c-c2b6-4c51-ab32-bec4a411de8e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ec3f0ba3-3ce3-4ebb-96fe-f75ee0f19d48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense by award type</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6127c4ab-d7c0-4e11-970d-8744b63d6237_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_5083d84f-acba-4dda-929b-4954ac60e420_terseLabel_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares into which warrant issued during period may be converted</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_label_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Securities Called by Warrants or Rights, Number Issued</link:label>
    <link:label id="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_documentation_en-US" xlink:label="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:to="lab_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0daa0046-85ab-41fc-a91e-ab2862ba7b4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d17b297f-6c64-4a51-9dc6-943293e50359_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_5e649efc-4bc1-4e5b-9f88-f7f1d92f61a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_83d03da8-a2cd-47d4-ad06-b2d5b5e47cce_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5db30c41-46d8-472d-85da-123e5306bff1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities, current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_f9f7b543-6f80-4960-8af0-ee6c7a30e624_terseLabel_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common share</link:label>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_label_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Common Share</link:label>
    <link:label id="lab_mrsn_NumberOfVotesPerCommonShare_documentation_en-US" xlink:label="lab_mrsn_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of votes for each shares held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare" xlink:href="mrsn-20211231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NumberOfVotesPerCommonShare" xlink:to="lab_mrsn_NumberOfVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a40285d-d4b5-4200-aecc-97328a46c0e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5b19be4d-21a2-4534-aca9-0f6568b10af8_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2b1a5bab-1ffe-4b09-90e2-595f26c8471c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_7800b91c-d055-40e9-8913-26080533a0c2_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_f64a162c-8835-48ef-98a9-cf3f9772e3cc_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Development Milestones</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsDevelopmentMilestones_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum development milestone amount the company is entitled to receive under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:to="lab_mrsn_CollaborationArrangementsDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_490b12e9-044d-485e-bf2b-10a631293b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9961b79a-f7d5-4bf5-a4ca-d17e4e84fd16_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dabac199-d754-4fad-bad0-9c6038b29677_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36cfa2f2-99c0-4f64-ba25-e8debb229944_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_64e6693b-bfc2-4327-9708-7119c50386b7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_083fd287-9978-4ce3-8e55-5b99d6e1421e_terseLabel_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Restated Tokeda agreement and XMT-1522 agreement</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_label_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement And Development Collaboration And Commercial License Agreement Takeda [Member]</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_documentation_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited. Also includes the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:to="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_ec8e8f58-d87d-417b-91c5-5b0375ca28cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c50c13e4-d45a-4cfc-8ae2-d03cf6dec88d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense as reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_ade73c8e-5859-4e3f-830a-5843be8d066b_terseLabel_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint research committee services</link:label>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_label_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Research Committee Services [Member]</link:label>
    <link:label id="lab_mrsn_JointResearchCommitteeServicesMember_documentation_en-US" xlink:label="lab_mrsn_JointResearchCommitteeServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents joint research committee services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember" xlink:href="mrsn-20211231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_JointResearchCommitteeServicesMember" xlink:to="lab_mrsn_JointResearchCommitteeServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_903503bc-4c26-419a-bc47-eb7509d3f300_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_f9e05014-fead-4358-a758-f7b18d3969bb_terseLabel_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, deductions</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_label_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Decrease</link:label>
    <link:label id="lab_mrsn_ContractWithCustomerLiabilityDecrease_documentation_en-US" xlink:label="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityDecrease" xlink:href="mrsn-20211231.xsd#mrsn_ContractWithCustomerLiabilityDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractWithCustomerLiabilityDecrease" xlink:to="lab_mrsn_ContractWithCustomerLiabilityDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5d1198b1-6384-4650-8897-a4364e2125ea_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_647fc2ec-43dc-431b-a8c2-0458d0361364_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6c6f0712-a82f-4b5e-8436-c655d96c243b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d04268c6-35da-4889-b671-fb6b1fbd14d6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e8bb69a5-37c3-454a-b77d-5740b220f446_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_40f87a30-4312-4711-91a3-477ed8f0ef95_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_4c0f23a0-108f-42f9-b79a-89b66fefd882_terseLabel_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_label_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Number</link:label>
    <link:label id="lab_mrsn_RevenueRemainingPerformanceObligationNumber_documentation_en-US" xlink:label="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:href="mrsn-20211231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:to="lab_mrsn_RevenueRemainingPerformanceObligationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6770c45a-c313-4674-ac45-5283d8d75062_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_7a7d6f1f-f2fe-4794-b69d-edd1494af8c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_65702f5a-a031-45ff-a657-ec200cea82bf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_acd1132c-356b-4fd7-8f06-b787bcb41d75_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2fb18e0f-27e4-4c92-96ec-7225c0210f12_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7b6f62be-7dd2-4938-b436-a29c74cba49c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_08b03c19-fc77-4950-8c89-72e6f1d3096c_terseLabel_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual life of warrants</link:label>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_label_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Life of Warrants</link:label>
    <link:label id="lab_mrsn_ContractualLifeOfWarrants_documentation_en-US" xlink:label="lab_mrsn_ContractualLifeOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The contractual life of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractualLifeOfWarrants" xlink:href="mrsn-20211231.xsd#mrsn_ContractualLifeOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ContractualLifeOfWarrants" xlink:to="lab_mrsn_ContractualLifeOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember_f39bef25-0bf1-4ee4-b579-4de33278c868_terseLabel_en-US" xlink:label="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Expansion Cambridge Ma</link:label>
    <link:label id="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember_label_en-US" xlink:label="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Expansion Cambridge Ma [Member]</link:label>
    <link:label id="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember_documentation_en-US" xlink:label="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Expansion Cambridge Ma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceExpansionCambridgeMaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:to="lab_mrsn_OfficeSpaceExpansionCambridgeMaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_df74247a-b11b-4956-b23e-fc7e8b9afa18_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ThirdPartiesMember_35c678ff-6867-4d10-9d64-08d2916197c3_terseLabel_en-US" xlink:label="lab_mrsn_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties</link:label>
    <link:label id="lab_mrsn_ThirdPartiesMember_label_en-US" xlink:label="lab_mrsn_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties [Member]</link:label>
    <link:label id="lab_mrsn_ThirdPartiesMember_documentation_en-US" xlink:label="lab_mrsn_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ThirdPartiesMember" xlink:href="mrsn-20211231.xsd#mrsn_ThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ThirdPartiesMember" xlink:to="lab_mrsn_ThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_18d75b6a-978a-4c01-a611-a49ad5f29215_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_e66da118-f948-4c42-bdd8-4e0042a2e10e_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized in the period from:</link:label>
    <link:label id="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Asset and Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:to="lab_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fea7849d-5b60-4eb2-8d6c-f606fd6aa7db_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_68a2efef-94a2-46dd-aa1d-28f3f24a57a6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4a9ce5d0-33a9-45f3-8efb-49b768e4756c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_4da06cb3-2ec9-4c3d-8a5c-273fb61200df_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_184f55a1-e4bd-4f58-b951-f3e3bc2fe4cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_8a8b2b3a-32e5-4442-b662-de98c4354e16_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_8c713ddd-7e73-4d85-a191-f98c95c50258_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_d852e9d3-9cdd-4033-9398-79f472f9a2a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_eddf3cd1-c065-49f7-bee8-137955dc8c5e_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_32fc038b-ae9d-49b8-94a8-6f9a5dd5bbbd_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_40963a0f-c488-4211-a935-9b52f3137701_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_b693e866-312f-43da-8660-9ae8c77a4fa8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders &#8212; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_26eb5266-8533-4bdb-9220-9a0351f5372b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_5871aadb-9f2b-44bb-a63e-30c418c1b647_terseLabel_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of federal or state audits in progress</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_label_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes, Number of Audits in Progress</link:label>
    <link:label id="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress_documentation_en-US" xlink:label="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of federal and (or) state audits in progress.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:href="mrsn-20211231.xsd#mrsn_IncomeTaxesNumberOfAuditsInProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:to="lab_mrsn_IncomeTaxesNumberOfAuditsInProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_de84507b-ce28-478c-8770-5edc58fe50bc_terseLabel_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative annual increase in number of shares issuable, percentage</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_label_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Outstanding Stock Maximum, Cumulative Annual Increase</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_documentation_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:to="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember_cec5cf4c-e859-4974-a3cb-447bed198a42_terseLabel_en-US" xlink:label="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and office equipment</link:label>
    <link:label id="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember_label_en-US" xlink:label="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Office Equipment [Member]</link:label>
    <link:label id="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to computer equipment and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:href="mrsn-20211231.xsd#mrsn_ComputerEquipmentAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:to="lab_mrsn_ComputerEquipmentAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0f4eeacd-23b1-4444-9b39-cee7ef32e19a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9884533e-3a7e-4703-92d6-e2f12830d700_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_718c7d0a-c298-4de4-95ea-0b404cbb6ee8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_bf95b1aa-5e10-4513-a185-e8a3f4a82239_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_da949b91-0b6c-45ef-8ad3-102e8e5125cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance at end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_99044114-57ce-4712-b6d9-eed39c1d4fbb_terseLabel_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt, net of issuance costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_label_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Debt, Net Issuance Costs</link:label>
    <link:label id="lab_mrsn_ProceedsFromDebtNetIssuanceCosts_documentation_en-US" xlink:label="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow (outflow) during the period from borrowings in aggregate debt. Includes proceeds from short-term and long-term debt and delayed cash payments of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:to="lab_mrsn_ProceedsFromDebtNetIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_35817e59-6c9f-4b1b-b0f6-cae243db7b29_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments</link:label>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_label_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAgreementUpfrontPaymentsMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:to="lab_mrsn_LicenseAgreementUpfrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_26386c00-3dea-414f-84d7-6bbf8eeb88a2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_be6d15a1-f808-43f8-b707-1889b4ebda6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e211255c-c266-4270-a585-903c2291cb88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_946f64cd-72fa-4843-a613-93d402a3ed8f_terseLabel_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Plan</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_label_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2017 [Member]</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2017Member_documentation_en-US" xlink:label="lab_mrsn_StockIncentivePlan2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to 2017 Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIncentivePlan2017Member" xlink:to="lab_mrsn_StockIncentivePlan2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_534378b9-a957-49b7-945e-6068d257d909_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of income tax rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b21ce6de-9b37-415e-a346-4bbfb7219896_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of future minimum payments on finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_39ed6d3d-986a-4ab1-883f-887d83ef19b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LimitedServicesMember_811fafc8-3363-4c19-b3f7-ae0c3afa2c74_terseLabel_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited services</link:label>
    <link:label id="lab_mrsn_LimitedServicesMember_label_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Services [Member]</link:label>
    <link:label id="lab_mrsn_LimitedServicesMember_documentation_en-US" xlink:label="lab_mrsn_LimitedServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember" xlink:href="mrsn-20211231.xsd#mrsn_LimitedServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LimitedServicesMember" xlink:to="lab_mrsn_LimitedServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee_db049abf-cdfc-4c8f-bd00-34fc5796e13d_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Nonrefundable Execution Fee</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee_label_en-US" xlink:label="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Nonrefundable Execution Fee</link:label>
    <link:label id="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee_documentation_en-US" xlink:label="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of non-refundable execution fee to be paid as part of a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementNonrefundableExecutionFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:to="lab_mrsn_CollaborationAgreementNonrefundableExecutionFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_02ccb3db-1ef6-4983-8b42-02daceae9003_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_f89cded5-258e-4572-a10f-77151376db26_terseLabel_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual increase (in shares)</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_label_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award Maximum Annual Increase Shares</link:label>
    <link:label id="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_documentation_en-US" xlink:label="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares that may be added annually to the plan on the first day of the fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:to="lab_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_d57dd223-58bd-4148-be5c-62ed4d0dc58c_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, first and second targets</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Targets One And Two [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for the first and second designated targets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_c4a98309-9937-4e39-8fd9-f9b481dfa98b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_44900a62-9a5e-40c6-9afc-c210e2f6c027_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e5b79048-cc25-4433-9a22-9f86eaac1bc3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_7d65b351-a7d5-40b6-ac37-347d89415cb4_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional fees receivable when target is designated and commercial license to target is granted</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Additional Payment to Obtain a Development and Commercial License</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:to="lab_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6a9e2e3a-d6aa-4524-b5c0-9565bb96b1f2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinanceLeaseCost_9761fb0b-9ca9-4ec9-bcd1-14413fccacfb_totalLabel_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_mrsn_FinanceLeaseCost_label_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_mrsn_FinanceLeaseCost_documentation_en-US" xlink:label="lab_mrsn_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of finance lease cost recognized by lessee for lease contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinanceLeaseCost" xlink:to="lab_mrsn_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bc757efc-9319-46db-96a5-95e1fc108527_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_dad5da66-6fc2-4280-af29-6078a754d247_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d79baa38-f09b-4abd-9431-2a0a043b2523_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f5d0512b-93fb-4873-8b11-412e2ccdd1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_5f38827d-bce3-45bd-8ff0-0c135525faed_terseLabel_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Axis]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_label_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period [Axis]</link:label>
    <link:label id="lab_mrsn_DebtCovenantPeriodAxis_documentation_en-US" xlink:label="lab_mrsn_DebtCovenantPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DebtCovenantPeriodAxis" xlink:to="lab_mrsn_DebtCovenantPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_031c9a77-2036-4cfd-ac4d-66a991b88783_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of service obligations completed of designated targets</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:to="lab_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6b8b1af8-739c-4885-957e-eb361319bc97_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_376c844a-0ad0-4e9c-9e96-ef07d335221f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_166c8d5b-362a-4c73-89b7-b14b91a6b5ac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_20f5a1ca-7a1e-4eea-b2ee-5c6be986b4bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_fea57381-ad02-48fa-8cf1-634f91cbd115_terseLabel_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck KGaA supply agreement</link:label>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_label_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Agreement Merck Kgaa [Member]</link:label>
    <link:label id="lab_mrsn_SupplyAgreementMerckKgaaMember_documentation_en-US" xlink:label="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the Supply Agreement with Merck KGaA.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember" xlink:href="mrsn-20211231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_SupplyAgreementMerckKgaaMember" xlink:to="lab_mrsn_SupplyAgreementMerckKgaaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_SynaffixMember_37d4ec3c-dd06-42bf-a31d-0f74a633f4d4_terseLabel_en-US" xlink:label="lab_mrsn_SynaffixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix</link:label>
    <link:label id="lab_mrsn_SynaffixMember_label_en-US" xlink:label="lab_mrsn_SynaffixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix [Member]</link:label>
    <link:label id="lab_mrsn_SynaffixMember_documentation_en-US" xlink:label="lab_mrsn_SynaffixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synaffix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SynaffixMember" xlink:href="mrsn-20211231.xsd#mrsn_SynaffixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_SynaffixMember" xlink:to="lab_mrsn_SynaffixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0360d37c-2830-4eb8-b2eb-094fa5dd1871_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_cef3f201-d229-4468-b4e2-f3b388f9a903_terseLabel_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_label_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_mrsn_StockIncentivePlan2007Member_documentation_en-US" xlink:label="lab_mrsn_StockIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to 2007 Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_StockIncentivePlan2007Member" xlink:to="lab_mrsn_StockIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_534cb901-8d2b-4a65-b453-c2436ac7b501_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_44c1f26c-0523-4ecb-9aa9-ea5a200619f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cf87c190-cadd-482d-9e02-7f0b7c18f103_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_44b6ae63-8753-41c5-86a7-6ed9ed437876_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_95d6a644-d1c3-4b26-9508-9e3f4e70ea23_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_ecf2ca53-41df-44ac-ac4f-261e8a2ba11e_terseLabel_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights to future technological improvements</link:label>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_label_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rights To Future Technological Improvements [Member]</link:label>
    <link:label id="lab_mrsn_RightsToFutureTechnologicalImprovementsMember_documentation_en-US" xlink:label="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents rights to future technological improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:href="mrsn-20211231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:to="lab_mrsn_RightsToFutureTechnologicalImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d4abb146-6e75-445f-bad9-bcb469048015_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_fb70e490-7c6e-4f70-8cd7-a35d3b71be08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1013b14a-1e61-4264-903c-53338aa5f2dc_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_7ced1814-2c13-493d-8043-fccac45b5db5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3a1bd372-2db2-42a4-aaf3-4438429a40b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2d69dec2-c574-4d9e-8111-96579ea5fd6d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LeasesLineItems_3e333f57-c055-40c6-bcd5-cdea35edf715_terseLabel_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_mrsn_LeasesLineItems_label_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Line Items]</link:label>
    <link:label id="lab_mrsn_LeasesLineItems_documentation_en-US" xlink:label="lab_mrsn_LeasesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems" xlink:href="mrsn-20211231.xsd#mrsn_LeasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LeasesLineItems" xlink:to="lab_mrsn_LeasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2ae6c0ba-ca9e-43c4-a822-810b26ca748f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_2ccc0a8c-52bd-4227-97d5-865d3d1f0e14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion related to final payment</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_bb513d2d-b24d-4ca7-be84-7625251893d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_63b46b4b-77a8-44ce-9f33-fd16be9690b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_21c49f47-3178-478c-a19f-102d0d1f9ae9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_2e3ba767-f63e-44f1-9ab0-b3481d190158_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_405962b9-64bb-4fb7-b5ee-60a9c94de751_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b44a2050-fae2-4adc-9fa7-1d1e7607e18e_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_c5b03da8-fab3-4f21-acd0-22eb3bcee06a_terseLabel_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards not subject to expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_78e8c12a-b97b-42b3-bde3-6fcccaa7c570_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in Total operating expenses</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_d53e129d-9022-43b4-b14d-0913744e6157_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_492b87ca-5b8d-4bc5-a2d4-f589a9ed2de4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_fc276011-483c-4298-aa4a-9c5e285bd9d4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a640dc2a-e34c-4cc8-889b-ce0c17632923_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_bcd15907-3818-4333-b560-ee09833fdb79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_71a2d4b5-dc05-47af-bfc5-8ec9fff9dd95_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_58196cc6-4437-4768-bb83-528d3c9ec48d_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_55107297-8fa4-41d2-bd98-94836a043407_terseLabel_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Restated Tokeda agreement</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_label_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement [Member]</link:label>
    <link:label id="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_documentation_en-US" xlink:label="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:to="lab_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_5de4241e-58e7-496c-a8f6-758243b79509_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization of premiums and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_c191badd-c70c-4cc7-9e0f-e463f4ee5859_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements, estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23463d60-c833-45ca-914b-9b6660e953c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_afd63ec8-1a19-4a26-9a01-c823c7fbadb8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a09bc20-ae2f-48b8-9558-e4c2c4f2ec9a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash per statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_15ce9745-3bf6-44ba-a61d-764d873ca4f1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e7b4ec68-7587-4406-9072-fdc639118655_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_db34632f-0498-4d2e-9a57-fdf61d3a0503_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_1c0fa148-f395-4cd8-8539-6196d2f7ae3d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11d76466-5c5e-4202-8e4c-af7d5a00e85f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_70075356-eee2-48bc-84bd-afc4f79d0bde_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DevelopmentAndRegulatoryMember_62dc8d2f-bccc-4fd4-940d-bf63058e916b_terseLabel_en-US" xlink:label="lab_mrsn_DevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory</link:label>
    <link:label id="lab_mrsn_DevelopmentAndRegulatoryMember_label_en-US" xlink:label="lab_mrsn_DevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory [Member]</link:label>
    <link:label id="lab_mrsn_DevelopmentAndRegulatoryMember_documentation_en-US" xlink:label="lab_mrsn_DevelopmentAndRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentAndRegulatoryMember" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentAndRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DevelopmentAndRegulatoryMember" xlink:to="lab_mrsn_DevelopmentAndRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_9bc7ffcc-35e8-40f9-b159-e66af1097d6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_a6032309-aec3-4ba3-8efb-02981b8da309_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_be6a4fff-d892-4901-814e-8fdd9601dca6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bf20fb6e-a4b9-490a-9d70-0f69daaae0ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_5d6eb5ad-5527-4305-81ee-ce4e153bde9b_terseLabel_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets designated</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_label_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements, Targets Designated, Number</link:label>
    <link:label id="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber_documentation_en-US" xlink:label="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of targets designated as of balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:to="lab_mrsn_CollaborationArrangementsTargetsDesignatedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_fc354a8c-beb7-4be6-8ba5-ed17c07c4011_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c488e93f-0925-43ea-b9ad-231a1ff2ea34_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8d04414f-ee04-464c-8164-ab6a87c47db0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d53c1057-3753-4bbf-ace6-bc62d67122d3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2dcc4583-212d-439f-888c-4978931c521c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a746c402-9352-447a-b341-376a81ad3057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_951e194f-56da-4cd6-9875-170f297b6656_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_56bdfc2f-55d4-4d06-8ace-6264aca9383e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bab3bcf4-3e2e-4a34-8e6b-e892058c1602_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spread (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_71953607-7adb-42fd-9c5a-9763757d1186_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_AccruedManufacturingExpensesCurrent_8c74eda4-bd7e-40fa-837b-7ab302d1cc12_terseLabel_en-US" xlink:label="lab_mrsn_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued manufacturing expenses</link:label>
    <link:label id="lab_mrsn_AccruedManufacturingExpensesCurrent_label_en-US" xlink:label="lab_mrsn_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Manufacturing Expenses Current</link:label>
    <link:label id="lab_mrsn_AccruedManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_mrsn_AccruedManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedManufacturingExpensesCurrent" xlink:href="mrsn-20211231.xsd#mrsn_AccruedManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_AccruedManufacturingExpensesCurrent" xlink:to="lab_mrsn_AccruedManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_5a0178a7-efad-414c-8c33-13dd2b509512_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_367c514c-6f4f-428c-8dd1-68af6db0b243_terseLabel_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of common stock retired in exchange for issuance of common stock warrant</link:label>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_label_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Common Stock Retired in Exchange For Issuance of Common Stock Warrant</link:label>
    <link:label id="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_documentation_en-US" xlink:label="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of common stock retired in exchange for issuance of common stock warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:href="mrsn-20211231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:to="lab_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_31ecbfe9-5c38-4550-9319-6c17d85c74c6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_5b867a69-523f-44f4-a607-7be8d719c571_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_87902ecc-c63b-4544-b185-bd386edff4d4_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_11d6ab0b-db44-4304-a957-e36cc9b6dd47_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_839d1a15-17b2-4a8d-ae02-c14ec379c38c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0bbb4527-446c-4272-8ade-724e536f4c10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_19c87c76-2f70-4835-8429-404b0224b894_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab21bc1f-5d0e-4984-9150-aa021190c714_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_aa738482-80ee-43a5-9931-dcc5437d2822_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c9c51d81-56d3-405f-b13f-8d288885933b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_afe0a06d-8a94-4dbe-94f0-861a7a1a77b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3777b38c-9844-43c4-959b-d1d46986a466_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c8818b92-0c1e-4544-a696-7f512450bf0f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42e0fee3-4e6f-4506-934a-d2f81dd17da0_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b8eecff3-227c-42e8-912c-3f79bd1aef93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fbb7986f-bad3-4705-aef3-48ba364bdc76_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1b15531b-dab6-49cf-9c00-0b1401dc4cea_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_1d202126-b0ff-40e5-a537-6e3edc2097db_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_00a3f8e7-b03e-4270-b6f0-04f97642dab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of employee tax obligations related to vesting of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFiveMember_193bdf77-af43-473f-abd0-f9220c27db2d_terseLabel_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Five</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFiveMember_label_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Five [Member]</link:label>
    <link:label id="lab_mrsn_NewCreditFacilityTrancheFiveMember_documentation_en-US" xlink:label="lab_mrsn_NewCreditFacilityTrancheFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Credit Facility, Tranche Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFiveMember" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_NewCreditFacilityTrancheFiveMember" xlink:to="lab_mrsn_NewCreditFacilityTrancheFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_fc3b9d4b-2e77-4991-bd62-bea50be51338_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a540046a-72f1-4d08-9798-223476bab9a7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_d5c3b0a6-19e3-4a24-90cb-149d55a92180_terseLabel_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility</link:label>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_label_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility [Member]</link:label>
    <link:label id="lab_mrsn_ExistingCreditFacilityMember_documentation_en-US" xlink:label="lab_mrsn_ExistingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember" xlink:href="mrsn-20211231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ExistingCreditFacilityMember" xlink:to="lab_mrsn_ExistingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6f81caad-516f-448a-8dd0-035c7b71538b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a61f8492-fb9d-4463-b1b5-350d70e1733e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Options, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6738e871-143a-48d0-aad6-e863f4d3bfac_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_1539bee1-dc8b-419e-a978-492f1b4ee119_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_34a1ee37-048e-4b86-80c0-27d477b59716_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_56ad09c8-37b3-44af-a2fe-b0f191cb5b2e_terseLabel_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment as percentage of original principal amount</link:label>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_label_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment as Percentage of Original Principal Amount</link:label>
    <link:label id="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_documentation_en-US" xlink:label="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the final payment as percentage of original principal amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:href="mrsn-20211231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:to="lab_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_23195a31-39a2-4367-bef8-326e57c439ab_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_43386bd2-a054-4ab1-bc89-6c5fa4b3c333_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_821ec512-c7de-4dc0-abdb-145e2c28fd38_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_09059ac2-667b-4300-bd33-f0b9de2bdf77_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_2c08db3a-5ca4-446c-a08e-6e498e83250a_terseLabel_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label id="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_mrsn_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_4703622f-6847-40cb-b95d-4969d3d549a4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_InducementAwardProgramMember_ba2da521-b77d-470b-9043-a6d90c54f40f_terseLabel_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program</link:label>
    <link:label id="lab_mrsn_InducementAwardProgramMember_label_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program [Member]</link:label>
    <link:label id="lab_mrsn_InducementAwardProgramMember_documentation_en-US" xlink:label="lab_mrsn_InducementAwardProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Award Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember" xlink:href="mrsn-20211231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_InducementAwardProgramMember" xlink:to="lab_mrsn_InducementAwardProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_03da2065-ca06-4bb0-858e-55c746922a3c_terseLabel_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_label_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Total Cost [Abstract]</link:label>
    <link:label id="lab_mrsn_FinanceLeaseTotalCostAbstract_documentation_en-US" xlink:label="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Total Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseTotalCostAbstract" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeaseTotalCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract" xlink:to="lab_mrsn_FinanceLeaseTotalCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_330ea84e-026f-47a1-904f-50ae2f2a2cc2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f50c8150-c78f-4b13-935a-de96a82034a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_d5b87a73-430d-4287-8991-818b99ac9c20_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_664c1d19-d6fc-4c07-be14-46668a675f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_ba514af9-466f-4f10-8b4c-3720b591d9a0_terseLabel_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible age to participate</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_label_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligible Age to Participate</link:label>
    <link:label id="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate_documentation_en-US" xlink:label="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum age for employees to be eligible to participate in defined contribution plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:href="mrsn-20211231.xsd#mrsn_DefinedContributionPlanEligibleAgeToParticipate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:to="lab_mrsn_DefinedContributionPlanEligibleAgeToParticipate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_CommercialMember_4258f7c2-7830-40d1-8ea1-85cfe994b3eb_terseLabel_en-US" xlink:label="lab_mrsn_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_mrsn_CommercialMember_label_en-US" xlink:label="lab_mrsn_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_mrsn_CommercialMember_documentation_en-US" xlink:label="lab_mrsn_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CommercialMember" xlink:href="mrsn-20211231.xsd#mrsn_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_CommercialMember" xlink:to="lab_mrsn_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_d5724b62-44f6-4ea5-b9c2-c487dc22ac48_terseLabel_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and corresponding research and development services, third and sixth target</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_label_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Related Research And Development Services Target Three And Six [Member]</link:label>
    <link:label id="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_documentation_en-US" xlink:label="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the license and corresponding research and development services for third and sixth designated target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:to="lab_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_8981d2b3-ec45-4fd1-9a0a-75d5fdce8fce_terseLabel_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants</link:label>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_label_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_mrsn_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_mrsn_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security, two, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount with an exercise price of $0.0001 per share. Referred to as the "Exchange Warrants".</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember" xlink:href="mrsn-20211231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_ExchangeWarrantsMember" xlink:to="lab_mrsn_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_221f463c-5e55-4adf-9233-e78177ebfa5d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e0ddfae4-f7a4-4405-8a31-0c0792514e7e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_9a3d003f-a6dc-438a-a483-d27e6f09becf_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_a175f9b6-2430-48a5-944e-fc59700eb3e5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_7a399c46-66db-4a12-8b89-94cf36cd604d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution by employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_f212c818-5db4-48a1-b739-b882ee719457_terseLabel_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_mrsn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_mrsn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember" xlink:href="mrsn-20211231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrsn_LaboratoryEquipmentMember" xlink:to="lab_mrsn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e2449666-b4d1-4d3d-9f2d-3264121332b8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_58a13b01-9510-4600-88a4-12f5241eaba6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Options, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>mrsn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:425dd8b9-aa24-4fab-a4e9-225438dbf20c,g:846580ec-79da-4d10-a138-b2ce8d67ce3f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mersana.com/role/Cover" xlink:type="simple" xlink:href="mrsn-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_86c5e025-97e0-420f-9e98-b7113b4653fd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentType_86c5e025-97e0-420f-9e98-b7113b4653fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_5ea6f8c4-8ca1-4e70-80e2-d75c6bbaacf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentAnnualReport_5ea6f8c4-8ca1-4e70-80e2-d75c6bbaacf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c192041a-4d95-42f2-8a40-e5acf72adcf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentPeriodEndDate_c192041a-4d95-42f2-8a40-e5acf72adcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_04126081-a804-4c00-902b-d2b6ecb8cdff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_CurrentFiscalYearEndDate_04126081-a804-4c00-902b-d2b6ecb8cdff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3b675bd4-a665-45db-a4c4-cd06441c3a7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentTransitionReport_3b675bd4-a665-45db-a4c4-cd06441c3a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_356b7041-8dc8-4c84-9a22-3298e3f51d2a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityFileNumber_356b7041-8dc8-4c84-9a22-3298e3f51d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c53f5727-2da3-4e56-81c3-8ad806967331" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityRegistrantName_c53f5727-2da3-4e56-81c3-8ad806967331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ccc82cbc-a292-4ece-a4cf-635ea166ed2f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ccc82cbc-a292-4ece-a4cf-635ea166ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_96e3bb73-1619-40ad-a072-1e127f86c455" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityTaxIdentificationNumber_96e3bb73-1619-40ad-a072-1e127f86c455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_796e62c5-aa90-436b-9ca8-772af3708209" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityAddressAddressLine1_796e62c5-aa90-436b-9ca8-772af3708209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_51e46e24-a2f0-40c0-9343-9ae4bb71bd01" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityAddressCityOrTown_51e46e24-a2f0-40c0-9343-9ae4bb71bd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1797f866-0b59-4346-9e39-b701622b35b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityAddressStateOrProvince_1797f866-0b59-4346-9e39-b701622b35b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3b22ce1c-b7c3-4326-adbf-16ecb64453da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityAddressPostalZipCode_3b22ce1c-b7c3-4326-adbf-16ecb64453da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0d8dba73-7838-46ec-b7c5-cc6c864633a4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_CityAreaCode_0d8dba73-7838-46ec-b7c5-cc6c864633a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_df5af628-8df7-4c2a-81aa-f9a67fe80e63" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_LocalPhoneNumber_df5af628-8df7-4c2a-81aa-f9a67fe80e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_58ba2f98-5f2e-4660-8978-2c4a2af62118" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_Security12bTitle_58ba2f98-5f2e-4660-8978-2c4a2af62118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c722f97a-fb18-417e-bc0c-9266135e7050" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_TradingSymbol_c722f97a-fb18-417e-bc0c-9266135e7050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d1ae8374-9afc-4c4c-91dd-bfd5ce6a034b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_SecurityExchangeName_d1ae8374-9afc-4c4c-91dd-bfd5ce6a034b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c5567a15-828c-477a-a190-4c9884bfa97d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c5567a15-828c-477a-a190-4c9884bfa97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_fe28b21f-79db-4d6e-9a80-2c14e44becd8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityVoluntaryFilers_fe28b21f-79db-4d6e-9a80-2c14e44becd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e3709e64-e4da-412f-96d2-77df62b6e074" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityCurrentReportingStatus_e3709e64-e4da-412f-96d2-77df62b6e074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ab628979-cbc7-47fc-9d55-2c0446da6a8a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityInteractiveDataCurrent_ab628979-cbc7-47fc-9d55-2c0446da6a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_39ba5dde-1c0a-4d3e-8a0e-e8ab145adc00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityFilerCategory_39ba5dde-1c0a-4d3e-8a0e-e8ab145adc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_46acba77-9d43-44a6-bd89-729a8973d66f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntitySmallBusiness_46acba77-9d43-44a6-bd89-729a8973d66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6b917aff-19df-4e06-a2c1-bbef9cb97445" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityEmergingGrowthCompany_6b917aff-19df-4e06-a2c1-bbef9cb97445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_95bde6c6-d67e-4b60-9c36-914fd2943b34" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_IcfrAuditorAttestationFlag_95bde6c6-d67e-4b60-9c36-914fd2943b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_24018f97-4dc5-425c-a366-3b4491a56814" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityShellCompany_24018f97-4dc5-425c-a366-3b4491a56814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7c215d88-54e5-4531-9d08-2f2b05106856" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityPublicFloat_7c215d88-54e5-4531-9d08-2f2b05106856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8c5d099c-cc18-4e6a-913e-23345bebaccc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8c5d099c-cc18-4e6a-913e-23345bebaccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7ffea0aa-68a9-4817-9894-9412bfc57dfa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_7ffea0aa-68a9-4817-9894-9412bfc57dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_65a0340d-c3bb-421b-97ab-62e5d46d394e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_EntityCentralIndexKey_65a0340d-c3bb-421b-97ab-62e5d46d394e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_80ff09ca-0e37-40a2-8c66-bb0f7f4c2a60" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentFiscalYearFocus_80ff09ca-0e37-40a2-8c66-bb0f7f4c2a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_fd421dd4-c915-4495-828f-8c2058559127" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_fd421dd4-c915-4495-828f-8c2058559127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e545c2bb-6cbc-4de5-ac9c-29c6aed4a976" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_22fa6009-1878-4185-a41a-4c3d201d27c4" xlink:to="loc_dei_AmendmentFlag_e545c2bb-6cbc-4de5-ac9c-29c6aed4a976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AuditInformation" xlink:type="simple" xlink:href="mrsn-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLineItems_aa22ade8-c1e2-44d1-9c45-ec99079966bc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_1da76eff-2716-4a80-8f14-ec5042a1b0bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_aa22ade8-c1e2-44d1-9c45-ec99079966bc" xlink:to="loc_dei_AuditorName_1da76eff-2716-4a80-8f14-ec5042a1b0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_f34d26b1-668a-4096-8152-79c82ea5f96f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_aa22ade8-c1e2-44d1-9c45-ec99079966bc" xlink:to="loc_dei_AuditorLocation_f34d26b1-668a-4096-8152-79c82ea5f96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_cf682a3b-53cb-4180-acd7-5d2a713d7fbc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AuditorLineItems_aa22ade8-c1e2-44d1-9c45-ec99079966bc" xlink:to="loc_dei_AuditorFirmId_cf682a3b-53cb-4180-acd7-5d2a713d7fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_05f13605-2db0-43fc-bf24-9f173d41307e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05f13605-2db0-43fc-bf24-9f173d41307e" xlink:to="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_977287e4-dab8-406f-9c21-933167d90043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_977287e4-dab8-406f-9c21-933167d90043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e73089a7-ecac-4d24-af2f-1e4e44552640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_977287e4-dab8-406f-9c21-933167d90043" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e73089a7-ecac-4d24-af2f-1e4e44552640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_827dfa97-4e04-4f1a-b701-d1ef1b2d8f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_977287e4-dab8-406f-9c21-933167d90043" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_827dfa97-4e04-4f1a-b701-d1ef1b2d8f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_31e40423-d0ff-4d52-828c-993a9aff6e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_977287e4-dab8-406f-9c21-933167d90043" xlink:to="loc_us-gaap_AssetsCurrent_31e40423-d0ff-4d52-828c-993a9aff6e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1f7cb6b2-6547-4d2e-a1c9-ae8b04f48538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1f7cb6b2-6547-4d2e-a1c9-ae8b04f48538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f49a6dea-6f6d-408a-be8e-0fb3a2248362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f49a6dea-6f6d-408a-be8e-0fb3a2248362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_867ef771-d1ba-4158-8c85-d452c885c6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_867ef771-d1ba-4158-8c85-d452c885c6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6418f618-73d5-4dbd-8b09-6c0b14d96c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e9f0361e-2c42-4b21-82a3-12e1ada005fa" xlink:to="loc_us-gaap_Assets_6418f618-73d5-4dbd-8b09-6c0b14d96c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c5bb6a7b-f08d-44b6-8ff6-cd929bfdb7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05f13605-2db0-43fc-bf24-9f173d41307e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c5bb6a7b-f08d-44b6-8ff6-cd929bfdb7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c5bb6a7b-f08d-44b6-8ff6-cd929bfdb7a6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2926fd74-a368-447d-b38e-9f1ecf824b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_AccountsPayableCurrent_2926fd74-a368-447d-b38e-9f1ecf824b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dbb16f74-3452-41ba-92ec-3aece5c8f57b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_dbb16f74-3452-41ba-92ec-3aece5c8f57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7e7c0f79-3999-4ae3-924d-7f95de9dd0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7e7c0f79-3999-4ae3-924d-7f95de9dd0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55f759c4-0c8d-4297-b818-05dc5b73681f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55f759c4-0c8d-4297-b818-05dc5b73681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5eb9da34-ee88-498d-80ed-d8ee3a1a1add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5eb9da34-ee88-498d-80ed-d8ee3a1a1add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_39fdb184-fa50-47d4-901c-077b81f7e376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_LiabilitiesCurrent_39fdb184-fa50-47d4-901c-077b81f7e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5f728c6-9223-4277-a1d6-c2cd21897893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5f728c6-9223-4277-a1d6-c2cd21897893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_405ba7bd-7054-40b9-919b-4cbc192e6209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_405ba7bd-7054-40b9-919b-4cbc192e6209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4b6196f4-366a-4aca-a694-943c5fb703a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4b6196f4-366a-4aca-a694-943c5fb703a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5fa2c983-41f8-4d7f-b488-945706f364d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_Liabilities_5fa2c983-41f8-4d7f-b488-945706f364d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5ccabf79-d3fe-48bb-a8b1-ce2d53f403f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0e05b6a6-76e2-4db8-9487-997150cba6d0" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5ccabf79-d3fe-48bb-a8b1-ce2d53f403f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c5bb6a7b-f08d-44b6-8ff6-cd929bfdb7a6" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_01979451-af46-4ecf-85b6-b6b96732d3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:to="loc_us-gaap_PreferredStockValue_01979451-af46-4ecf-85b6-b6b96732d3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c16b8709-491f-4bad-88a7-1394b6a404a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:to="loc_us-gaap_CommonStockValue_c16b8709-491f-4bad-88a7-1394b6a404a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_39076b74-5bc5-4b4a-ba64-8ef99cf8fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_39076b74-5bc5-4b4a-ba64-8ef99cf8fdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d365421-ec7c-4e4c-8807-a43f76afd016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1d365421-ec7c-4e4c-8807-a43f76afd016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0fad314-2c52-4381-89d9-35ddba2d8fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2ae63719-1f17-414d-b730-8af91af13dc8" xlink:to="loc_us-gaap_StockholdersEquity_c0fad314-2c52-4381-89d9-35ddba2d8fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6fd3c116-5f23-4bb6-9fb5-754bed0e647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c5bb6a7b-f08d-44b6-8ff6-cd929bfdb7a6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6fd3c116-5f23-4bb6-9fb5-754bed0e647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bcbbbfa5-d045-435e-82fd-a394f1a47a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bcbbbfa5-d045-435e-82fd-a394f1a47a28" xlink:to="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_38f6678a-359d-4df5-82c5-57d6233d63ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_38f6678a-359d-4df5-82c5-57d6233d63ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_869260ae-6d9a-4ea0-89aa-819cb7b21d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_869260ae-6d9a-4ea0-89aa-819cb7b21d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_69de0516-539c-419b-a229-5b2563444b45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_PreferredStockSharesIssued_69de0516-539c-419b-a229-5b2563444b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ebe1a00a-9ca4-401a-b37a-28bd97a2bc0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ebe1a00a-9ca4-401a-b37a-28bd97a2bc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d9c262f-8e51-4ab7-8130-257d653c2c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9d9c262f-8e51-4ab7-8130-257d653c2c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dc37ed22-3320-4b7f-aff2-44252d646ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dc37ed22-3320-4b7f-aff2-44252d646ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_99addb2d-9f35-45cc-9da0-ebde11b6cfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_CommonStockSharesIssued_99addb2d-9f35-45cc-9da0-ebde11b6cfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b45196dd-e93f-47be-9cef-78b5a8803d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_cc3b2a34-270a-491b-a2af-f0436c99da29" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b45196dd-e93f-47be-9cef-78b5a8803d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd9a61c-f1e9-48ca-8fed-2a3ed5f306ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd9a61c-f1e9-48ca-8fed-2a3ed5f306ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_298db8f2-b594-4f70-aaff-f74e72c50e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_OperatingExpensesAbstract_298db8f2-b594-4f70-aaff-f74e72c50e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6784736b-9729-4b18-8a38-0e9b38d314c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_298db8f2-b594-4f70-aaff-f74e72c50e3e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6784736b-9729-4b18-8a38-0e9b38d314c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_415a4dc2-822d-458f-a257-968f80ef8257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_298db8f2-b594-4f70-aaff-f74e72c50e3e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_415a4dc2-822d-458f-a257-968f80ef8257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3d2e7da6-5910-4818-a5b1-4fe27b98c896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_298db8f2-b594-4f70-aaff-f74e72c50e3e" xlink:to="loc_us-gaap_OperatingExpenses_3d2e7da6-5910-4818-a5b1-4fe27b98c896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_352040b4-78f4-4c9e-8412-e04b961c9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_352040b4-78f4-4c9e-8412-e04b961c9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_93096ed7-9d7c-442a-bc74-fc5edc7d9cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_352040b4-78f4-4c9e-8412-e04b961c9f88" xlink:to="loc_us-gaap_InvestmentIncomeInterest_93096ed7-9d7c-442a-bc74-fc5edc7d9cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_33caac41-240e-4099-a9e4-ed36c1204b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_352040b4-78f4-4c9e-8412-e04b961c9f88" xlink:to="loc_us-gaap_InterestExpense_33caac41-240e-4099-a9e4-ed36c1204b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_496c1c77-f311-4077-bc69-bccb0d7eaa96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_352040b4-78f4-4c9e-8412-e04b961c9f88" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_496c1c77-f311-4077-bc69-bccb0d7eaa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5473a410-30ff-4b02-b681-53dac78a2ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_NetIncomeLoss_5473a410-30ff-4b02-b681-53dac78a2ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_85a172aa-f31a-4b6e-a072-75111f93c558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_85a172aa-f31a-4b6e-a072-75111f93c558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e080629d-45ab-41c1-bd7c-5a5de75d58d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_85a172aa-f31a-4b6e-a072-75111f93c558" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e080629d-45ab-41c1-bd7c-5a5de75d58d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b2d3700d-5655-4ae2-89bc-3268b26255c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b2d3700d-5655-4ae2-89bc-3268b26255c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_dc65f3ee-ba22-4a2b-904d-6be8e9f703d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_dc65f3ee-ba22-4a2b-904d-6be8e9f703d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3f863856-9183-4dde-aff4-37ccaf9fc29f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3f863856-9183-4dde-aff4-37ccaf9fc29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b23dd8d1-ba7d-4086-8616-f1aa96ba4502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_EarningsPerShareBasic_b23dd8d1-ba7d-4086-8616-f1aa96ba4502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_06a1b57d-ccde-4a8e-a203-56a9db8a1b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_EarningsPerShareDiluted_06a1b57d-ccde-4a8e-a203-56a9db8a1b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87419c58-79f0-4958-a26b-9c80ac9e5cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_87419c58-79f0-4958-a26b-9c80ac9e5cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18c3f8b3-c38a-442b-8460-6379e5f5a03e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f34e4d65-ca09-4ddf-a03b-803a0fea4fce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18c3f8b3-c38a-442b-8460-6379e5f5a03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8d0deae3-2a4e-4a14-8896-b1c0630c3c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8d0deae3-2a4e-4a14-8896-b1c0630c3c03" xlink:to="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f91d8539-ff25-4f03-aeed-0a5b841fd26d" xlink:to="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_84d50b60-0370-4685-9df9-814e22825935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_CommonStockMember_84d50b60-0370-4685-9df9-814e22825935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2eb22a3d-9047-43ad-894e-dc6865c4e1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2eb22a3d-9047-43ad-894e-dc6865c4e1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34ef8a76-b536-45a3-987a-4e363e1b5caa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34ef8a76-b536-45a3-987a-4e363e1b5caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_fbf2b288-86f0-41c4-a8e1-b7f2591a6197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_75951012-a7d7-47d3-8ec9-e177ffeba2e9" xlink:to="loc_us-gaap_RetainedEarningsMember_fbf2b288-86f0-41c4-a8e1-b7f2591a6197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_df30dde5-b24a-412f-80f2-8f04c1ad9c53" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_7da208b3-1759-4efb-973b-84c8672bd308" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_7da208b3-1759-4efb-973b-84c8672bd308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_a55f6107-ce83-4fb6-885f-49d510335507" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_PublicStockOfferingMember_a55f6107-ce83-4fb6-885f-49d510335507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_677e27d9-17e4-4273-af29-9bbaeed75664" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_91184e1e-8fd5-4c6d-9b60-4047ab6ad41b" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_677e27d9-17e4-4273-af29-9bbaeed75664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e58f3d9-6e8d-4512-a0e2-bf8773550c51" xlink:to="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8ff8d8a3-75c7-46eb-a992-644995cff0ce" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03683a00-1a28-4d9c-aeb3-7eafd2660752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_SharesOutstanding_03683a00-1a28-4d9c-aeb3-7eafd2660752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c79b2851-4695-4f10-a04d-6e1bfca90268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockholdersEquity_c79b2851-4695-4f10-a04d-6e1bfca90268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca267d8-9271-4d77-ae45-b4e6d541a605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2ca267d8-9271-4d77-ae45-b4e6d541a605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_636b3bf7-66f5-4e55-9834-7bb30badf747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_636b3bf7-66f5-4e55-9834-7bb30badf747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_9ac623ef-6077-4d59-bc85-efa5676abf64" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised_9ac623ef-6077-4d59-bc85-efa5676abf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_1804edce-d342-4c20-bc72-ad7b33f25a99" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised_1804edce-d342-4c20-bc72-ad7b33f25a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2bf63db4-3222-4af2-8e9d-da1fc8b831be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2bf63db4-3222-4af2-8e9d-da1fc8b831be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_75a802ac-5f58-4013-8a96-22e9b446119a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition_75a802ac-5f58-4013-8a96-22e9b446119a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_6aa96da3-2fb3-425c-b38f-70b24d93c39b" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares_6aa96da3-2fb3-425c-b38f-70b24d93c39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_575be2f0-5384-4202-8ce1-40adcd5f7155" xlink:href="mrsn-20211231.xsd#mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue_575be2f0-5384-4202-8ce1-40adcd5f7155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ba2c78ff-0ced-4e3b-960e-120b1a63eaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_ba2c78ff-0ced-4e3b-960e-120b1a63eaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_a3bba5f7-ec21-48a0-bdb8-d0f56f2fcfc1" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised_a3bba5f7-ec21-48a0-bdb8-d0f56f2fcfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a327768d-109e-49b5-b5ae-4014d1779598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a327768d-109e-49b5-b5ae-4014d1779598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a92cfabb-4315-4b82-a5d5-db2059ce9c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a92cfabb-4315-4b82-a5d5-db2059ce9c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c71e839a-4c89-4c53-b408-8e3a584fdda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c71e839a-4c89-4c53-b408-8e3a584fdda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3fa5e937-3d31-4fc5-b413-9144712d034b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3fa5e937-3d31-4fc5-b413-9144712d034b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3e89142d-4ff2-4f5d-a091-ec848739d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_3e89142d-4ff2-4f5d-a091-ec848739d49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3df537e2-b4fe-4664-8340-59ed1c22ef9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3df537e2-b4fe-4664-8340-59ed1c22ef9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7f1b643-b5bd-467b-8fd2-8b6bd467a702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_NetIncomeLoss_a7f1b643-b5bd-467b-8fd2-8b6bd467a702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03149592-2838-4909-84c8-d9aee41a30b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_SharesOutstanding_03149592-2838-4909-84c8-d9aee41a30b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_138bc815-4e77-4bcf-8ccb-0c2c4a1ae53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_fb2846ab-9ee6-4ba3-896a-9fa14056fc91" xlink:to="loc_us-gaap_StockholdersEquity_138bc815-4e77-4bcf-8ccb-0c2c4a1ae53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_44d392cf-8f21-4277-b37b-18efdfe70482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_44d392cf-8f21-4277-b37b-18efdfe70482" xlink:to="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1989b8bc-5cae-4ffa-b6e7-a3e6fe385e1d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_cc8ce661-f471-4dd9-ac00-2aefd8ba3985" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_cc8ce661-f471-4dd9-ac00-2aefd8ba3985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_a5ddb395-7c0a-4589-80b1-1ac8360faaf9" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_PublicStockOfferingMember_a5ddb395-7c0a-4589-80b1-1ac8360faaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_9dc6a18d-fa37-4251-9778-4e8fd21631cf" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_59d0bc90-de78-489b-a6d7-0ca9c35c9d03" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_9dc6a18d-fa37-4251-9778-4e8fd21631cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_47328e78-fd3e-40f7-ade4-7f70096ea7c6" xlink:to="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a9fe4381-9189-422e-bae7-658b76c019bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:to="loc_us-gaap_CommonStockMember_a9fe4381-9189-422e-bae7-658b76c019bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_52193ba2-299b-485d-a038-9f70b7e80c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4a3b3ecf-46f7-42d3-aa24-a65476d9c6ff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_52193ba2-299b-485d-a038-9f70b7e80c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f17f1ce6-1918-41b8-a437-1938921a6550" xlink:to="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_a97b8aa2-a3fa-4893-b85e-c9d027d8e772" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction_a97b8aa2-a3fa-4893-b85e-c9d027d8e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_546bb134-82cc-42df-9e4e-321042453569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_546bb134-82cc-42df-9e4e-321042453569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d31a5a6b-0966-450b-b882-e7f28af845cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19752200-5d12-40da-9916-08c5145b3d04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d31a5a6b-0966-450b-b882-e7f28af845cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="mrsn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a5ceb9cd-5051-466a-a6d5-8a31f755f448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a5ceb9cd-5051-466a-a6d5-8a31f755f448" xlink:to="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_43c1be6d-2b52-4179-9cf1-20c7ee0ccd25" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_d3e0c351-d1f8-4507-9f16-f505c0668aa8" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:to="loc_mrsn_PublicStockOfferingMember_d3e0c351-d1f8-4507-9f16-f505c0668aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgramMember_5e481807-df05-4d87-83c4-00f131cc08f2" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5acac982-13e3-4c1e-8d4f-668179852578" xlink:to="loc_mrsn_AtMarketEquityOfferingProgramMember_5e481807-df05-4d87-83c4-00f131cc08f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a2cc16c2-e8b8-45bc-b772-5b6160585328" xlink:to="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8f9fdd91-5508-44dc-8262-4a9466df1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:to="loc_us-gaap_ProfitLoss_8f9fdd91-5508-44dc-8262-4a9466df1eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_19e5d805-96c9-4b50-9033-3eb07d582676" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d3b1912d-7dc4-4d21-9a55-e114e3b441cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d3b1912d-7dc4-4d21-9a55-e114e3b441cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e7373dfb-723d-4881-bdc7-067479d69435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_e7373dfb-723d-4881-bdc7-067479d69435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_72abc4bb-2062-4911-b2d5-727c9617d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_ShareBasedCompensation_72abc4bb-2062-4911-b2d5-727c9617d30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_9b012c33-c8ee-42fe-a0fc-019380033e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_9b012c33-c8ee-42fe-a0fc-019380033e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_417a8fd6-aa6e-44ab-bead-fdaca5e469f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_417a8fd6-aa6e-44ab-bead-fdaca5e469f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf8ff480-6bba-49e6-a087-daa0eb94d740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bf8ff480-6bba-49e6-a087-daa0eb94d740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_051c726e-8612-4c80-9e6f-2908acd7808f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_051c726e-8612-4c80-9e6f-2908acd7808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1f917778-4847-46a2-a111-47f3412ba075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_1f917778-4847-46a2-a111-47f3412ba075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_571a6b94-9e03-46ad-aa78-ce0f4012abb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_571a6b94-9e03-46ad-aa78-ce0f4012abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_299952c7-01f2-4be0-89d5-1a58f356029f" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseAssets_299952c7-01f2-4be0-89d5-1a58f356029f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_095b9cfa-f9a0-45ed-9f46-ab3ed21851ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_095b9cfa-f9a0-45ed-9f46-ab3ed21851ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_895388c1-a926-4218-bb24-3b058bbe99e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_895388c1-a926-4218-bb24-3b058bbe99e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e7a5c92a-27d2-4850-a035-9bd95b804368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_14274732-ae93-4b66-8385-b361afa58430" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e7a5c92a-27d2-4850-a035-9bd95b804368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7633ee4-300e-402e-8f3b-e8a7677789a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ed07e392-f30c-4de3-b2f0-f9df75345dad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7633ee4-300e-402e-8f3b-e8a7677789a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e4f8908d-fbc2-4694-8a0e-602197391091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e4f8908d-fbc2-4694-8a0e-602197391091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96a91858-f794-4cba-9c77-fc4db3c5987a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_96a91858-f794-4cba-9c77-fc4db3c5987a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_039f9334-57f7-43de-9280-720d5bfaf6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_039f9334-57f7-43de-9280-720d5bfaf6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8354fc-a888-4c5e-b804-6629246f41c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5df4a463-61ca-40aa-b0f9-7c21231031fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0e8354fc-a888-4c5e-b804-6629246f41c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a47c6e2-5a7e-4877-95cd-a656d9c78dda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4a47c6e2-5a7e-4877-95cd-a656d9c78dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a824bd45-d26d-49c7-8c9d-b544cf2d4e96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a824bd45-d26d-49c7-8c9d-b544cf2d4e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_662bfd01-bb16-43a3-be00-2c758bac6f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_662bfd01-bb16-43a3-be00-2c758bac6f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76ce433b-573b-4fff-a60c-59e5c2850b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_76ce433b-573b-4fff-a60c-59e5c2850b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_1b19ecdd-2f93-43f0-bdac-abd9f0030804" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromDebtNetIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_mrsn_ProceedsFromDebtNetIssuanceCosts_1b19ecdd-2f93-43f0-bdac-abd9f0030804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_6518054e-c1fd-4a5a-b938-fe75a249439c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_RepaymentsOfDebt_6518054e-c1fd-4a5a-b938-fe75a249439c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_f431bed5-0d37-46ab-a5ea-b0d7824c07b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_f431bed5-0d37-46ab-a5ea-b0d7824c07b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2812afde-8b98-445e-b495-da4f0aca0e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dc898b54-bc55-40ad-a636-4bbc8e42b2fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2812afde-8b98-445e-b495-da4f0aca0e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_73a4a472-35c1-4a4d-98b2-ae6b8f0dd359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_73a4a472-35c1-4a4d-98b2-ae6b8f0dd359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e133d57-5e9c-40d0-8ed2-7825011b2d84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e133d57-5e9c-40d0-8ed2-7825011b2d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f96f12f-0860-4031-a344-9f2f30b355b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1f96f12f-0860-4031-a344-9f2f30b355b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_245ec37f-04ec-48f8-9acd-e9cdec45ceef" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_79694dec-6d5b-424a-9e50-93ffe9a1814b" xlink:href="mrsn-20211231.xsd#mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant_79694dec-6d5b-424a-9e50-93ffe9a1814b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4bfc38a8-57c7-47d1-bc0c-ca7b44ab8018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_4bfc38a8-57c7-47d1-bc0c-ca7b44ab8018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8bb3134c-e1eb-42bf-bc4d-744c74d7c57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_8bb3134c-e1eb-42bf-bc4d-744c74d7c57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2fd1cef6-5f54-4161-868b-c8850fb56ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_InterestPaidNet_2fd1cef6-5f54-4161-868b-c8850fb56ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd1b116d-3d41-499a-a8ad-27a6a9188292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bd1b116d-3d41-499a-a8ad-27a6a9188292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_228272d5-d77c-4806-8b8e-88c501959c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b0b6d64c-6500-4438-a2d0-8b9b45eade20" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_228272d5-d77c-4806-8b8e-88c501959c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="mrsn-20211231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c071b99c-d5f9-461c-93dc-822fd51e2aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2f9bd21f-dd8a-4bdc-b98e-55bb6eb04ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c071b99c-d5f9-461c-93dc-822fd51e2aca" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2f9bd21f-dd8a-4bdc-b98e-55bb6eb04ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9fe47f22-0caf-4108-86ec-47676525244f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_735a68b4-fb18-44dd-8495-a35d87abe678" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9fe47f22-0caf-4108-86ec-47676525244f" xlink:to="loc_us-gaap_NetIncomeLoss_735a68b4-fb18-44dd-8495-a35d87abe678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109d8dd1-4aef-44ea-9b0b-92f4b132bb1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9fe47f22-0caf-4108-86ec-47676525244f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_109d8dd1-4aef-44ea-9b0b-92f4b132bb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0f0f3cbe-4954-4f4b-a59a-ee15c976ea81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_caf5a27c-8b3e-463f-976e-7733da016275" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0f0f3cbe-4954-4f4b-a59a-ee15c976ea81" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_caf5a27c-8b3e-463f-976e-7733da016275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_8cd25dab-ebec-465e-a0ed-3cf10afae64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_8cd25dab-ebec-465e-a0ed-3cf10afae64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f30ce47e-2189-4cd8-8d49-dd1edf32a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_UseOfEstimates_f30ce47e-2189-4cd8-8d49-dd1edf32a5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e057e1b4-6c27-47b8-9048-f3c945ff9264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_e057e1b4-6c27-47b8-9048-f3c945ff9264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1528f786-15de-48c0-883d-ef57eb65fd64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1528f786-15de-48c0-883d-ef57eb65fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1eead8de-c38b-428e-ac08-f353856276a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1eead8de-c38b-428e-ac08-f353856276a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_fef947be-17a7-42ae-93b5-947826fbb8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_fef947be-17a7-42ae-93b5-947826fbb8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bc002a3c-af34-427f-812e-f05a658c6025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bc002a3c-af34-427f-812e-f05a658c6025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9f35f989-f687-4b0d-bc7a-da74a9114a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9f35f989-f687-4b0d-bc7a-da74a9114a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_afeea0f5-84c4-48d7-97c2-0cf6c3dd38d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_afeea0f5-84c4-48d7-97c2-0cf6c3dd38d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8fe71b00-8861-4284-9c92-5d782717cbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8fe71b00-8861-4284-9c92-5d782717cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_4bbeb71a-4806-4678-8b4d-dbf723a77419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_4bbeb71a-4806-4678-8b4d-dbf723a77419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1ccd3074-02b1-454a-86f9-b911f6236aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1ccd3074-02b1-454a-86f9-b911f6236aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_25375ba8-81d7-4568-b760-4aee1c7554a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_25375ba8-81d7-4568-b760-4aee1c7554a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_6e373fb4-7d12-44ee-bb48-85b64ca8e34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_6e373fb4-7d12-44ee-bb48-85b64ca8e34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_eff86a12-9421-4c3b-9cc5-8f861cca2295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_eff86a12-9421-4c3b-9cc5-8f861cca2295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bb44c256-33e8-4da9-9369-08843ea2887a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_bb44c256-33e8-4da9-9369-08843ea2887a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e0ae2c94-7afa-4286-b123-e9288e3229d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e0ae2c94-7afa-4286-b123-e9288e3229d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb98a0c4-595b-490c-8231-df090c6a2869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_03786f06-d20c-448b-b363-b517f730249a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb98a0c4-595b-490c-8231-df090c6a2869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da68f1f3-b9d0-4ebb-9201-66a4f41e794f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8f7b8860-775e-4389-9361-2cf1cb7f33ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da68f1f3-b9d0-4ebb-9201-66a4f41e794f" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8f7b8860-775e-4389-9361-2cf1cb7f33ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f0d244ad-9315-4cde-bcfd-23a8726cfd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da68f1f3-b9d0-4ebb-9201-66a4f41e794f" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f0d244ad-9315-4cde-bcfd-23a8726cfd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_be7bbcce-c88a-412c-bfd5-1ec783e3e252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da68f1f3-b9d0-4ebb-9201-66a4f41e794f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_be7bbcce-c88a-412c-bfd5-1ec783e3e252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_23d7e1d7-6d4e-47f1-8ece-abdab0796941" xlink:href="mrsn-20211231.xsd#mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da68f1f3-b9d0-4ebb-9201-66a4f41e794f" xlink:to="loc_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_23d7e1d7-6d4e-47f1-8ece-abdab0796941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1b97dd83-0b0a-42c4-9d75-2383045240fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueCollectionPeriod_ca1f6d31-986f-4c39-afae-9126fec4afa6" xlink:href="mrsn-20211231.xsd#mrsn_RevenueCollectionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1b97dd83-0b0a-42c4-9d75-2383045240fe" xlink:to="loc_mrsn_RevenueCollectionPeriod_ca1f6d31-986f-4c39-afae-9126fec4afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_55f49ed0-5c2f-49ba-a865-07bec5fcbf09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04869ad6-4722-451f-b5cc-0d1d8389374a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55f49ed0-5c2f-49ba-a865-07bec5fcbf09" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04869ad6-4722-451f-b5cc-0d1d8389374a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0cfe631-25e8-4809-9f39-2387e3a8b474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04869ad6-4722-451f-b5cc-0d1d8389374a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a0cfe631-25e8-4809-9f39-2387e3a8b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4262f94e-5cee-453e-b367-67fff3584c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04869ad6-4722-451f-b5cc-0d1d8389374a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4262f94e-5cee-453e-b367-67fff3584c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39abaedb-75ba-493c-b326-d8ab0728fec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_04869ad6-4722-451f-b5cc-0d1d8389374a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_39abaedb-75ba-493c-b326-d8ab0728fec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9fd48ce-a945-4797-8382-5f48c3b37b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_43822f4b-1061-4755-bffc-579d22eecc28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9fd48ce-a945-4797-8382-5f48c3b37b6c" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_43822f4b-1061-4755-bffc-579d22eecc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e80be425-f02f-4042-bc83-faad1bb3a3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_43822f4b-1061-4755-bffc-579d22eecc28" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e80be425-f02f-4042-bc83-faad1bb3a3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainageDeposit_56fb1042-65b9-426b-b38c-132d4879a41b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainageDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_43822f4b-1061-4755-bffc-579d22eecc28" xlink:to="loc_us-gaap_RetainageDeposit_56fb1042-65b9-426b-b38c-132d4879a41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_c2f2bc08-2411-4838-897e-2f27e306620e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsAbstract_43822f4b-1061-4755-bffc-579d22eecc28" xlink:to="loc_us-gaap_SecurityDeposit_c2f2bc08-2411-4838-897e-2f27e306620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9fd48ce-a945-4797-8382-5f48c3b37b6c" xlink:to="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:to="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_bcb1258f-5ebc-4f94-97a2-8087f6463a85" xlink:to="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_43afa7bf-8f8e-4688-8284-9f0b3bc44889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7278a0da-be44-4b33-8ce1-ce231a72ae74" xlink:to="loc_us-gaap_LineOfCreditMember_43afa7bf-8f8e-4688-8284-9f0b3bc44889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:to="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6d1cbe3b-5dda-4fc3-9ffc-82603a8e256a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityMember_29d3230c-45d1-4a8d-9e4a-07e6cc099c34" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cadab3da-701b-4f1b-b35a-4e4e094c7bf5" xlink:to="loc_mrsn_NewCreditFacilityMember_29d3230c-45d1-4a8d-9e4a-07e6cc099c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4a3b05f2-8543-4955-92ee-e4e04b6bc48e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_67de999c-7757-4a90-bbf5-5e99678627c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_700919dd-769d-4ca8-a02d-ba3a1ba0085f" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_67de999c-7757-4a90-bbf5-5e99678627c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6505f35b-c625-4563-ae46-a543ff7ab026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e99d45a7-3e33-4d64-b740-56e4cd89035a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6505f35b-c625-4563-ae46-a543ff7ab026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e99d45a7-3e33-4d64-b740-56e4cd89035a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesNetlosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1d04eb2-d76b-44ad-9c29-443e0fc12e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1d04eb2-d76b-44ad-9c29-443e0fc12e58" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_348e2479-5301-484b-9963-4482b620f466" xlink:to="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_f679e24e-068c-4a2c-b4fb-86ffd5730191" xlink:href="mrsn-20211231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_31ddf241-f7e7-4441-bca0-4ee98a036545" xlink:to="loc_mrsn_ExchangeWarrantsMember_f679e24e-068c-4a2c-b4fb-86ffd5730191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cf8a01f7-5d45-4667-89cf-8e28a84068ff" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_283e29f4-b547-4a5f-a4a8-6e4ddd760c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_283e29f4-b547-4a5f-a4a8-6e4ddd760c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_889b50ce-c977-4ee7-8b2b-379e7769930c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_889b50ce-c977-4ee7-8b2b-379e7769930c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6078e3d4-49e6-4aad-ab81-1862f89a4b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2c19ed16-0dbe-4df3-a510-7882a00357c7" xlink:to="loc_us-gaap_WarrantMember_6078e3d4-49e6-4aad-ab81-1862f89a4b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_ec16e94e-90bf-4da5-90f9-ded9898d0197" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96561991-d272-4a38-8f32-a906233061ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_17bf3c22-8bbc-4150-ad1d-5b78d330475f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_96561991-d272-4a38-8f32-a906233061ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09b2fd43-4ac4-4397-9e3a-60d001394aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e797cab-3625-42a8-8409-0d3bb2f5f65f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_09b2fd43-4ac4-4397-9e3a-60d001394aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12fbf58b-92c8-411a-abe3-30559995d359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12fbf58b-92c8-411a-abe3-30559995d359" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4f159fcf-66ce-4f5f-b453-5f57e21c5d06" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_603cb22d-4143-4438-b7c5-ac80cf32b189" xlink:href="mrsn-20211231.xsd#mrsn_ComputerEquipmentAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_603cb22d-4143-4438-b7c5-ac80cf32b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_c17bb4b3-1058-428b-8ee4-e5db2402923b" xlink:href="mrsn-20211231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_mrsn_LaboratoryEquipmentMember_c17bb4b3-1058-428b-8ee4-e5db2402923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4f6c3028-b309-4b61-aa29-cb7d51d981f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4245ba14-6faa-4858-91c9-fe9d6167c60d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4f6c3028-b309-4b61-aa29-cb7d51d981f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1d6242d7-ff86-4173-9aca-ff55a6548397" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b1d7b3c3-9811-490b-9a33-a4351f917564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b1d7b3c3-9811-490b-9a33-a4351f917564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_c4208655-e29b-48b8-bbbb-dacec3388868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_c4208655-e29b-48b8-bbbb-dacec3388868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a73dd0b0-5ae7-4c76-8ac8-5905daeda3df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dacf4960-dcd2-422c-9925-71eb4c287d72" xlink:to="loc_us-gaap_AssetImpairmentCharges_a73dd0b0-5ae7-4c76-8ac8-5905daeda3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SummaryofSignificantAccountingPoliciesRisksDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a9fb522-f197-4956-b0f2-d3958a1b74bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_8d2dd573-2cce-4d3a-82ba-ecbb6edab9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a9fb522-f197-4956-b0f2-d3958a1b74bf" xlink:to="loc_us-gaap_RisksAndUncertaintiesAbstract_8d2dd573-2cce-4d3a-82ba-ecbb6edab9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_fa916fa5-09cd-4a0f-a28d-2d7a5f6f85a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_8d2dd573-2cce-4d3a-82ba-ecbb6edab9b5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_fa916fa5-09cd-4a0f-a28d-2d7a5f6f85a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreements" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreements"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_5b27325c-e3e4-4974-be17-8d35208ed9e8" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a76c0e96-24f7-4fc7-99bb-238faeff2050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_5b27325c-e3e4-4974-be17-8d35208ed9e8" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a76c0e96-24f7-4fc7-99bb-238faeff2050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_71686a52-3e80-4091-bb1a-d4688b64237f" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_022429bd-3306-493c-a096-10e2e1d3aa74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_71686a52-3e80-4091-bb1a-d4688b64237f" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_022429bd-3306-493c-a096-10e2e1d3aa74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_3d7ca960-0b72-4dea-a4e8-e67758f26783" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_3d7ca960-0b72-4dea-a4e8-e67758f26783" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_21013ac6-c6e8-4346-8738-f449d86ad1e7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember_373d9590-0e98-42fc-9074-6ca9a6988e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember_3133ae3f-9a2d-4bc3-94bc-774e1202359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_ed0728fb-2ad1-4a7e-a8b8-7aa83503d459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember_6a418326-c015-4dca-9bb3-13a1673ce6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:href="mrsn-20211231.xsd#mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember_e8e73c18-90ff-4d8d-94ba-3da2fd7a4ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember_37f6f6e8-da65-47c3-8186-e820242288aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:href="mrsn-20211231.xsd#mrsn_SupplyAgreementMerckKgaaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40f92614-a6b4-4d6a-a46b-e879878ef4c0" xlink:to="loc_mrsn_SupplyAgreementMerckKgaaMember_736c3014-6943-4fc4-902c-69a9383ae0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c1f1fb1b-516d-4fec-8512-3fdce1731112" xlink:to="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember_f65eff0c-d76f-4150-a96c-ba6be7d757c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:href="mrsn-20211231.xsd#mrsn_LimitedServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LimitedServicesMember_f8418323-34b6-4d47-9b89-62cacee5641f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember_4957100b-abd7-4330-bd2a-f7bc951bab84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember_419e76b9-b5ff-434f-853e-b39068185f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember_a36e510c-65a6-4048-be33-24e6370c058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember_444fa84b-a6e7-452d-976b-f270422b7886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:href="mrsn-20211231.xsd#mrsn_RightsToFutureTechnologicalImprovementsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_RightsToFutureTechnologicalImprovementsMember_f6ddbdf0-3b8b-4661-825c-4089ee59d9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:href="mrsn-20211231.xsd#mrsn_JointResearchCommitteeServicesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_442acd78-c984-40cb-8092-7c9aaf3093cb" xlink:to="loc_mrsn_JointResearchCommitteeServicesMember_528173f2-84f7-4d97-ba0b-634e506fe29a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81fc58b8-7a16-4340-962a-fa7a8a795223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_81fc58b8-7a16-4340-962a-fa7a8a795223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f6568c5c-27f7-4373-832d-b379e2132a4a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsUpfrontPayment_ccda227a-4b35-4c2f-ac20-65217dd40b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:href="mrsn-20211231.xsd#mrsn_CollaborativeArrangementsExclusiveTargetsNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborativeArrangementsExclusiveTargetsNumber_05da26a3-3cd2-4393-b8dd-176ce183e9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense_e3db44ed-ee49-4a97-8a69-81dbad037e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_f8ac62d9-9ad3-4da9-9b87-2678bec63b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestones"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestones_60a7d404-4850-48b2-af7e-44ec5f04fea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsRegulatoryMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsRegulatoryMilestones_5ddc547e-7f11-4cff-acae-49a6366d2e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSalesMilestones"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSalesMilestones_b80ad963-90fe-490f-871a-be0496bc8876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber_de7bd799-e289-4ee6-8c5e-b6591618c067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber_d5c1f4b9-7bf2-4411-b39d-7c52a34a8663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber_b16271c0-dcd2-4efc-9b5e-2330b1e3812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived_26e9eb1d-714f-440f-8bee-b18da98165df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone_1d2e5391-629a-48a5-81a0-03bc3ed90083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration_ea01c6bb-dbae-4aab-9f80-db5d7a1a8b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedNumber_7d4571ea-3ffc-4f3c-856d-44e70115e202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:href="mrsn-20211231.xsd#mrsn_RevenueTransactionPriceAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueTransactionPriceAmount_d0d11e3d-9a4c-447c-ad56-0922e1bfa70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f389f6a2-9c5a-4f66-a276-71326b29f3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber_5c82709c-f3d4-4e59-b584-859bdc088c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_AccountsReceivableNet_d52d0cc6-709e-48c5-8ffc-f8cb0e7775a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiability_ee6ddc8c-cf15-4289-82e7-78189ac5aca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsDurationToTermination"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsDurationToTermination_948a24d0-53b7-4b85-8273-985fbfec6b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod_6c2df4e8-927d-418f-93a9-834bf99e6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4d852cf8-5ea2-4df0-9ea7-eef159056873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:href="mrsn-20211231.xsd#mrsn_RevenueRemainingPerformanceObligationNumber"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_RevenueRemainingPerformanceObligationNumber_0d5f68ab-1a50-47b3-a9a9-626cfb2673e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c81ecb3e-a58c-487f-b295-db2dfa361764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5719089a-40ad-4ee0-b399-b398dbf1fdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsCostsBilled"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsCostsBilled_93917a85-5aa1-4798-ab1a-8df35ff44b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone_ce01d2c3-755e-4aa0-bb0a-0ddade15e182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:href="mrsn-20211231.xsd#mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c0a6043f-0c00-427a-bd9a-693679a9eb49" xlink:to="loc_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice_19c64370-6724-4711-969f-e1bcbae17e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail_1" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsNarrativeDetail_1"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CollaborationAgreementsContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementsAbstract_1d95279b-f77a-4d51-8a6d-f9b6797a42ca" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_63e59a17-d3a2-4960-ac51-ea53de7b1e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_1d95279b-f77a-4d51-8a6d-f9b6797a42ca" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_63e59a17-d3a2-4960-ac51-ea53de7b1e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:href="mrsn-20211231.xsd#mrsn_ChangeInContractAssetsAndLiabilitiesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_1d95279b-f77a-4d51-8a6d-f9b6797a42ca" xlink:to="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_dfbe537d-977b-4150-8897-4e7cf6b7e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_dfbe537d-977b-4150-8897-4e7cf6b7e45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityIncrease_71d1e3d8-5e04-4186-a507-b6fb312115a3" xlink:href="mrsn-20211231.xsd#mrsn_ContractWithCustomerLiabilityIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:to="loc_mrsn_ContractWithCustomerLiabilityIncrease_71d1e3d8-5e04-4186-a507-b6fb312115a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractWithCustomerLiabilityDecrease_e6b658c8-8188-453c-b87a-485f88a3d475" xlink:href="mrsn-20211231.xsd#mrsn_ContractWithCustomerLiabilityDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:to="loc_mrsn_ContractWithCustomerLiabilityDecrease_e6b658c8-8188-453c-b87a-485f88a3d475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_69c3bfe6-f7f9-4d25-a7c6-5e3d0bc75847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward_9801f320-f15a-427a-ba03-85d0e9210ce5" xlink:to="loc_us-gaap_ContractWithCustomerLiability_69c3bfe6-f7f9-4d25-a7c6-5e3d0bc75847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_1cbebfc8-e4b6-41b0-81eb-07e78d31d891" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_CollaborationAgreementsAbstract_1d95279b-f77a-4d51-8a6d-f9b6797a42ca" xlink:to="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_1cbebfc8-e4b6-41b0-81eb-07e78d31d891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_167ebc7b-92cc-4602-9922-45bd49261bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_1cbebfc8-e4b6-41b0-81eb-07e78d31d891" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_167ebc7b-92cc-4602-9922-45bd49261bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_903d99ed-0831-463d-8308-b2e76d6d2c60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract_1cbebfc8-e4b6-41b0-81eb-07e78d31d891" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_903d99ed-0831-463d-8308-b2e76d6d2c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mrsn-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_eb63007b-3845-4bc4-a8cb-8494a2fbbbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_dc7142a1-77a1-4800-a93f-b958b6f8b544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_eb63007b-3845-4bc4-a8cb-8494a2fbbbd8" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_dc7142a1-77a1-4800-a93f-b958b6f8b544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="mrsn-20211231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fee3c5a3-3236-4231-a0ec-c95582a1b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9250bf58-4742-4a40-8c7c-a0967f1fb765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fee3c5a3-3236-4231-a0ec-c95582a1b2ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9250bf58-4742-4a40-8c7c-a0967f1fb765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ea48881d-748e-40b0-bf41-c61cec807432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3cbf532-a2ac-4423-93ae-f0eeca65fc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_ea48881d-748e-40b0-bf41-c61cec807432" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c3cbf532-a2ac-4423-93ae-f0eeca65fc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2b398cbf-4e0d-4d0c-ab49-16a45f64d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2b398cbf-4e0d-4d0c-ab49-16a45f64d56e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b295af87-b621-4607-b025-19a8e8ea9b88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LaboratoryEquipmentMember_21150188-6db4-4bc7-8ccb-8fb9e6f82b35" xlink:href="mrsn-20211231.xsd#mrsn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_LaboratoryEquipmentMember_21150188-6db4-4bc7-8ccb-8fb9e6f82b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_c4336dd5-dcee-4205-bf94-1fd014429aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_c4336dd5-dcee-4205-bf94-1fd014429aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_3df8b425-4b50-470d-a2d8-6710391db97c" xlink:href="mrsn-20211231.xsd#mrsn_ComputerEquipmentAndOfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_ComputerEquipmentAndOfficeEquipmentMember_3df8b425-4b50-470d-a2d8-6710391db97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeasesMember_86093004-e1bc-4871-8834-6a15ad62fe26" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ee5ed1b1-1da8-4860-9849-060f72962447" xlink:to="loc_mrsn_FinanceLeasesMember_86093004-e1bc-4871-8834-6a15ad62fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5dbeb2c0-65a6-4163-bd7f-a19437d0b034" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2a9aff40-c605-4aea-86e6-610d89df70cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_2a9aff40-c605-4aea-86e6-610d89df70cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_62644943-fea6-4570-92d6-92d9e7a7dda5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_62644943-fea6-4570-92d6-92d9e7a7dda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b018f464-abef-4e0e-ac1e-83a3a7b31b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_b018f464-abef-4e0e-ac1e-83a3a7b31b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7ee70740-cc67-4076-a666-dafb3157e0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7ee70740-cc67-4076-a666-dafb3157e0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f984facf-75b2-477e-a073-cfecf0674ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_29f576dc-ca38-4fbf-8049-bd183978d60f" xlink:to="loc_us-gaap_Depreciation_f984facf-75b2-477e-a073-cfecf0674ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpenses" xlink:type="simple" xlink:href="mrsn-20211231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_708037a5-7c8d-4d2c-8c51-7377a22d8803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a97efea0-d764-470e-948e-4ad81a22be0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_708037a5-7c8d-4d2c-8c51-7377a22d8803" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a97efea0-d764-470e-948e-4ad81a22be0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#AccruedexpensesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedexpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5fc061c5-0a29-43f3-965a-249d2583c95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_16be03a0-e80f-41b5-9939-57dc8d5574c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_5fc061c5-0a29-43f3-965a-249d2583c95d" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_16be03a0-e80f-41b5-9939-57dc8d5574c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedManufacturingExpensesCurrent_41daaf80-9297-49a4-a3fa-c9a2a9fc749c" xlink:href="mrsn-20211231.xsd#mrsn_AccruedManufacturingExpensesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_mrsn_AccruedManufacturingExpensesCurrent_41daaf80-9297-49a4-a3fa-c9a2a9fc749c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedClinicalExpensesCurrent_8f7705e8-5e81-408a-9d19-c7484851047f" xlink:href="mrsn-20211231.xsd#mrsn_AccruedClinicalExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_mrsn_AccruedClinicalExpensesCurrent_8f7705e8-5e81-408a-9d19-c7484851047f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AccruedPreclinicalExpensesCurrent_0fe2e296-eef9-47db-bfdb-eb758b9c016f" xlink:href="mrsn-20211231.xsd#mrsn_AccruedPreclinicalExpensesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_mrsn_AccruedPreclinicalExpensesCurrent_0fe2e296-eef9-47db-bfdb-eb758b9c016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3ee222a3-702f-4c9a-b047-268d4c75f2ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3ee222a3-702f-4c9a-b047-268d4c75f2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_d8951536-fa37-49df-aa66-808b06f80da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_d8951536-fa37-49df-aa66-808b06f80da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8aa928cf-e0e7-41c8-a2fb-e2f1e2ceb3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_8aa928cf-e0e7-41c8-a2fb-e2f1e2ceb3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ce78399-980e-4d84-bca0-c065d44dde0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_a6555358-0c3c-438a-a60b-5c8f46552dac" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ce78399-980e-4d84-bca0-c065d44dde0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Debt" xlink:type="simple" xlink:href="mrsn-20211231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1c578ffd-ebc8-4eee-9a77-94c757973a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_09d7e46f-ad07-4275-83b0-ff254a6e2da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1c578ffd-ebc8-4eee-9a77-94c757973a33" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_09d7e46f-ad07-4275-83b0-ff254a6e2da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a42a4ab4-cc22-4d08-81eb-77dcd5c51e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ab319dca-11ce-4ea0-bbd2-1918b0e732c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a42a4ab4-cc22-4d08-81eb-77dcd5c51e77" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ab319dca-11ce-4ea0-bbd2-1918b0e732c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_142aaa60-8510-466b-a1e9-80d686c9dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a42a4ab4-cc22-4d08-81eb-77dcd5c51e77" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_142aaa60-8510-466b-a1e9-80d686c9dd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_657a079d-7dc3-43a9-b7dc-b598ef7d8779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_657a079d-7dc3-43a9-b7dc-b598ef7d8779" xlink:to="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0580acdd-03f9-423a-87a6-8c20d3b4269e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExistingCreditFacilityMember_0e2b6e1b-fb64-4bf6-abb4-2a1e1aad5a42" xlink:href="mrsn-20211231.xsd#mrsn_ExistingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_ExistingCreditFacilityMember_0e2b6e1b-fb64-4bf6-abb4-2a1e1aad5a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedCreditFacilityMember_1eaf428a-be50-49ac-b8a4-192f76c4f001" xlink:href="mrsn-20211231.xsd#mrsn_AmendedCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_AmendedCreditFacilityMember_1eaf428a-be50-49ac-b8a4-192f76c4f001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityMember_0fedd8df-aeb1-460f-a6ef-211f98a016c4" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityMember_0fedd8df-aeb1-460f-a6ef-211f98a016c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheOneMember_28a72138-9bd6-4fd7-8ce2-c76497a1e8ea" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheOneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheOneMember_28a72138-9bd6-4fd7-8ce2-c76497a1e8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheTwoMember_d1db897b-fe9f-418c-bbc3-7f48a65dfffa" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheTwoMember_d1db897b-fe9f-418c-bbc3-7f48a65dfffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheThreeMember_261685d8-695c-4a47-aaaa-be93e69f55d1" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheThreeMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheThreeMember_261685d8-695c-4a47-aaaa-be93e69f55d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFourMember_a9dbe1d0-53c2-462b-9eeb-f19e73d3cecd" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFourMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheFourMember_a9dbe1d0-53c2-462b-9eeb-f19e73d3cecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheFiveMember_3ba857e5-ecc7-46a4-a414-2dc2a51c7f1d" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheFiveMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheFiveMember_3ba857e5-ecc7-46a4-a414-2dc2a51c7f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NewCreditFacilityTrancheSixMember_82e1f5f7-b41e-4710-9b4d-4c8041347295" xlink:href="mrsn-20211231.xsd#mrsn_NewCreditFacilityTrancheSixMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4c27813-0b8f-4b54-b654-9f1742f2b979" xlink:to="loc_mrsn_NewCreditFacilityTrancheSixMember_82e1f5f7-b41e-4710-9b4d-4c8041347295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_592f7559-d79e-4afd-8db5-f2db95f423c6" xlink:to="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c61f75cd-6076-458c-b891-aced4ccdaed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e72c9976-a396-4ffd-b91d-07e821c291b9" xlink:to="loc_us-gaap_PrimeRateMember_c61f75cd-6076-458c-b891-aced4ccdaed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38e672c5-8f50-46b5-9a38-326fdffb52d2" xlink:to="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8667cb58-ee61-4fbb-a429-4915c8a86cda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_aec9661f-7d9f-4a49-90a7-b76dbc0bd388" xlink:to="loc_srt_MinimumMember_8667cb58-ee61-4fbb-a429-4915c8a86cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e9a1b211-c60f-4247-8874-13958e7b67e5" xlink:to="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_bfbc0a0d-1aac-44c6-a02f-5417ccf81238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c22e9f7a-c5ad-4e87-a3b3-95ae670323d2" xlink:to="loc_us-gaap_LineOfCreditMember_bfbc0a0d-1aac-44c6-a02f-5417ccf81238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:href="mrsn-20211231.xsd#mrsn_DebtCovenantPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodAxis_49617a55-b887-45f3-ad23-86636d181e71" xlink:to="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursPriorToOctober292022Member_0fe70558-1d01-4048-afb5-5ebc3f2adc18" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursPriorToOctober292022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursPriorToOctober292022Member_0fe70558-1d01-4048-afb5-5ebc3f2adc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_11f84a68-deba-4420-991d-316fbefd4579" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member_11f84a68-deba-4420-991d-316fbefd4579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_2b7b1f5f-c3c4-4588-aed8-68f3331471a8" xlink:href="mrsn-20211231.xsd#mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_DebtCovenantPeriodDomain_37177895-59ea-417a-8ae2-7e650cf4f268" xlink:to="loc_mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member_2b7b1f5f-c3c4-4588-aed8-68f3331471a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fe11fe69-73d4-42b0-a8fd-c96958443a79" xlink:to="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LendersMember_f13ca06c-bc7e-491e-9dbc-7e1c48cb8571" xlink:href="mrsn-20211231.xsd#mrsn_LendersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:to="loc_mrsn_LendersMember_f13ca06c-bc7e-491e-9dbc-7e1c48cb8571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ThirdPartiesMember_67c65fe9-6160-4e2f-baf0-6a795e85d650" xlink:href="mrsn-20211231.xsd#mrsn_ThirdPartiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_27455711-648f-4275-a2a0-6c2da263f846" xlink:to="loc_mrsn_ThirdPartiesMember_67c65fe9-6160-4e2f-baf0-6a795e85d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_26a89a47-ed5c-470b-a836-18bd163a6a7a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmortizedInterestExpenseMember_1395c2b5-a3d8-43cd-a806-87c6b988206f" xlink:href="mrsn-20211231.xsd#mrsn_AmortizedInterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e419aa07-eec1-49fb-92d4-e402427771ef" xlink:to="loc_mrsn_AmortizedInterestExpenseMember_1395c2b5-a3d8-43cd-a806-87c6b988206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_dfd15ef0-cd4e-41a4-91a7-ed7ae6929f86" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CapitalizedOtherAssetsMember_b320c387-b7a7-4ad0-8b17-fa681f8b6c25" xlink:href="mrsn-20211231.xsd#mrsn_CapitalizedOtherAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2440850-197f-42e5-be6b-1a4d0f184216" xlink:to="loc_mrsn_CapitalizedOtherAssetsMember_b320c387-b7a7-4ad0-8b17-fa681f8b6c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_aa98cc06-0e80-4d91-9b23-d59478a75be5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_d6a3475c-0769-406b-a89c-36a699ef72fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_d6a3475c-0769-406b-a89c-36a699ef72fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bd794004-a4eb-4075-a46c-57026085f295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bd794004-a4eb-4075-a46c-57026085f295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3b0104af-9e67-4fd7-b8cd-262cf329a908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_3b0104af-9e67-4fd7-b8cd-262cf329a908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e2c5c514-e6fb-476f-8988-b27e1f5f41a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e2c5c514-e6fb-476f-8988-b27e1f5f41a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e14caaf8-1dc5-48f8-9c58-9ddc0e28674c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e14caaf8-1dc5-48f8-9c58-9ddc0e28674c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_aad3b5fd-b30f-4c53-a7ce-d51f2bdacc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_aad3b5fd-b30f-4c53-a7ce-d51f2bdacc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f48d673a-8e67-4377-80a6-a671e3300e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f48d673a-8e67-4377-80a6-a671e3300e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_f472835f-4db6-4789-879f-05e4c4169ffd" xlink:href="mrsn-20211231.xsd#mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount_f472835f-4db6-4789-879f-05e4c4169ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentPrepaymentFeePercent_81d1ce24-0508-480a-9e21-0d6183be8aa6" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentPrepaymentFeePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_DebtInstrumentPrepaymentFeePercent_81d1ce24-0508-480a-9e21-0d6183be8aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_bfff1b2b-8d72-4651-8b4f-369e843e4149" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentAdditionalRateInEventOfDefault"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_mrsn_DebtInstrumentAdditionalRateInEventOfDefault_bfff1b2b-8d72-4651-8b4f-369e843e4149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d91e6c2-cd39-455e-8057-328313c3b6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_0d91e6c2-cd39-455e-8057-328313c3b6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_727cc523-7781-4db8-a9ae-5f3afa9e491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_208fa957-c548-4d2b-b15f-da802afe4598" xlink:to="loc_us-gaap_InterestExpenseDebt_727cc523-7781-4db8-a9ae-5f3afa9e491c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0d630789-6c05-42c8-99d8-c4aa3f16790c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0d630789-6c05-42c8-99d8-c4aa3f16790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_738f1d54-de8d-46b8-8d69-1ff6226b9085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_us-gaap_LongTermDebtCurrent_738f1d54-de8d-46b8-8d69-1ff6226b9085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_8660634e-46de-45e8-930f-9f4846b5ba78" xlink:href="mrsn-20211231.xsd#mrsn_DebtInstrumentCarryingAmountNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_mrsn_DebtInstrumentCarryingAmountNoncurrent_8660634e-46de-45e8-930f-9f4846b5ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_6eabdb26-1c76-4c87-91f9-9409dfdf0ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_6eabdb26-1c76-4c87-91f9-9409dfdf0ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_45e27219-8e4d-4816-aba2-166e6153984f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_45e27219-8e4d-4816-aba2-166e6153984f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f1f3e3be-6e23-4331-af65-5056f7f3fd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d477bc02-d5f3-460f-b1ee-2f1e180525f0" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f1f3e3be-6e23-4331-af65-5056f7f3fd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#DebtFuturepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/DebtFuturepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29d870e5-8dd6-4df2-9514-8ccd0d460dec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29d870e5-8dd6-4df2-9514-8ccd0d460dec" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a2e3e9fa-5a57-4ef4-b9f5-d5c96a011cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a2e3e9fa-5a57-4ef4-b9f5-d5c96a011cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9d025d45-5966-4d3c-a377-7897e804b91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9d025d45-5966-4d3c-a377-7897e804b91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d8f246d4-20ee-4199-abcc-ac42c72b22fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d8f246d4-20ee-4199-abcc-ac42c72b22fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b87a7ba8-9970-4952-b914-02c0309eb218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_b87a7ba8-9970-4952-b914-02c0309eb218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_d355bef5-3632-422f-a0a9-b707ad4df679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_d355bef5-3632-422f-a0a9-b707ad4df679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_42283ba5-e38a-40e3-bdb9-14b81e775f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7d5ab1b4-6b32-40f8-aff1-d6e48e6a9f93" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_42283ba5-e38a-40e3-bdb9-14b81e775f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_f01a3ff6-218d-4acd-b26d-2c630acd2cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29d870e5-8dd6-4df2-9514-8ccd0d460dec" xlink:to="loc_us-gaap_InterestExpenseDebt_f01a3ff6-218d-4acd-b26d-2c630acd2cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_d7bf433c-f5c6-4023-85ff-cd4e7444d414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fbebf3b7-4e1b-48f8-8f0c-318927a883d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_d7bf433c-f5c6-4023-85ff-cd4e7444d414" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_fbebf3b7-4e1b-48f8-8f0c-318927a883d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_90939760-97fa-4b85-914f-e5dd43a1548f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_836a9948-5f81-4da8-b044-95f669eb0324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_90939760-97fa-4b85-914f-e5dd43a1548f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_836a9948-5f81-4da8-b044-95f669eb0324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e1496980-c95c-48eb-be55-193922dded88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e1496980-c95c-48eb-be55-193922dded88" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3b5edee3-f573-4da6-a931-d876589e584c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_6ca23973-61dd-4a94-ba0b-e496358e55e5" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2018ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2018ATMMember_6ca23973-61dd-4a94-ba0b-e496358e55e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_f40723e2-5903-46e5-8880-b1b965fa9ee7" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_f40723e2-5903-46e5-8880-b1b965fa9ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_PublicStockOfferingMember_2eab4b27-4131-4f0c-acf4-fc6fe4c31aff" xlink:href="mrsn-20211231.xsd#mrsn_PublicStockOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2f4fe6f9-a941-4a2f-b57c-2cec810f5efa" xlink:to="loc_mrsn_PublicStockOfferingMember_2eab4b27-4131-4f0c-acf4-fc6fe4c31aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2c1373eb-b360-4650-a375-f8cdbe3670ab" xlink:to="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d3b92360-ff05-43c8-8d97-4bc60d782ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_us-gaap_CommonStockMember_d3b92360-ff05-43c8-8d97-4bc60d782ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6effa451-c8c2-445f-b84e-8db56e4809dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6effa451-c8c2-445f-b84e-8db56e4809dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ExchangeWarrantsMember_8f294857-8b47-429f-8796-615ccf9d2c86" xlink:href="mrsn-20211231.xsd#mrsn_ExchangeWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_mrsn_ExchangeWarrantsMember_8f294857-8b47-429f-8796-615ccf9d2c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_59a949a1-2d15-4f86-826c-578dad275c7c" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1175701a-73d3-4522-a8a6-441c6caf1b7e" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_59a949a1-2d15-4f86-826c-578dad275c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7576dc95-5b67-4ada-ac41-dc09a8555966" xlink:to="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_7fc2871a-e38e-46af-b8ea-323d006fc846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_7fc2871a-e38e-46af-b8ea-323d006fc846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1baa44f3-fc33-47f7-8f81-cee297dbbb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1baa44f3-fc33-47f7-8f81-cee297dbbb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuanceProgramAuthorizedAmount_28c112d2-1ff9-4d25-9b37-05793186a7c3" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuanceProgramAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_StockIssuanceProgramAuthorizedAmount_28c112d2-1ff9-4d25-9b37-05793186a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c4884dd-2177-48d2-8ad8-afc89fed0800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2c4884dd-2177-48d2-8ad8-afc89fed0800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb8b697e-394a-4c61-9d48-901f16571e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cb8b697e-394a-4c61-9d48-901f16571e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_48a6e93c-634d-47df-8a4a-bf204282e134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_48a6e93c-634d-47df-8a4a-bf204282e134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_e85e6e23-b008-47ec-9ca9-ccca51cb3e65" xlink:href="mrsn-20211231.xsd#mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts_e85e6e23-b008-47ec-9ca9-ccca51cb3e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_85ed80da-6576-42de-b752-17ffdde6ad5b" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued_85ed80da-6576-42de-b752-17ffdde6ad5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ce105675-92e7-403c-81c4-3148049b75ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ce105675-92e7-403c-81c4-3148049b75ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ContractualLifeOfWarrants_184da42b-544e-41a7-8462-f9941529ebea" xlink:href="mrsn-20211231.xsd#mrsn_ContractualLifeOfWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ContractualLifeOfWarrants_184da42b-544e-41a7-8462-f9941529ebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5fd38329-a6cb-46fb-8e81-6c3aa24e04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5fd38329-a6cb-46fb-8e81-6c3aa24e04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_97f7f964-b6dd-4ba2-88eb-fa80292c59ec" xlink:href="mrsn-20211231.xsd#mrsn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised_97f7f964-b6dd-4ba2-88eb-fa80292c59ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f9e37483-942a-4244-b76b-efce9dd95057" xlink:href="mrsn-20211231.xsd#mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants_f9e37483-942a-4244-b76b-efce9dd95057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_95b28837-e718-491a-961e-3d68dd1911ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_95b28837-e718-491a-961e-3d68dd1911ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsExercisedInPeriod_92ac98a8-bff9-49a7-a4d1-1af54c25edc0" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsExercisedInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_WarrantsExercisedInPeriod_92ac98a8-bff9-49a7-a4d1-1af54c25edc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_NumberOfVotesPerCommonShare_55e90f02-0fd2-4aac-b62c-3023757d2321" xlink:href="mrsn-20211231.xsd#mrsn_NumberOfVotesPerCommonShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_mrsn_NumberOfVotesPerCommonShare_55e90f02-0fd2-4aac-b62c-3023757d2321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_26b75ca9-230d-424a-b676-940c3d738c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_537a61ea-d137-4424-a818-3e312cd44864" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_26b75ca9-230d-424a-b676-940c3d738c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockholdersEquityCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockholdersEquityCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_83fbc264-9ab0-4eaa-afaf-366b90d434cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_83fbc264-9ab0-4eaa-afaf-366b90d434cf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_30f4adce-2262-42e4-a2ae-7ab075f8bafa" xlink:to="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:href="mrsn-20211231.xsd#mrsn_WarrantsAndShareBasedPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e369c199-d064-41fd-8bdf-a7c6bbdd48cb" xlink:to="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_6725138a-c9d0-47cb-a9d5-c5dfffdb0f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationShareBasedPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:to="loc_us-gaap_DeferredCompensationShareBasedPaymentsMember_6725138a-c9d0-47cb-a9d5-c5dfffdb0f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_be4853d4-cb29-4d4c-a310-22f807cb7861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WarrantsAndShareBasedPaymentsMember_216bca1a-239b-40f1-8ed3-2575e060b7e5" xlink:to="loc_us-gaap_WarrantMember_be4853d4-cb29-4d4c-a310-22f807cb7861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:to="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_795b0052-7cb6-4d68-b791-d952a4fc086e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_90d17b53-55bb-4a7a-a3db-3ddf52b5949d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_90d17b53-55bb-4a7a-a3db-3ddf52b5949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2d4a3028-1602-497e-95a0-801df91f92d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60f76cd-054d-4e1a-aef9-c0561e0dc4e3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2d4a3028-1602-497e-95a0-801df91f92d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2fcf46f2-77ae-4939-9f09-711c9871d13b" xlink:to="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_07f3755a-0975-4c53-bbb4-86a777a32071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_521d98ca-8158-4bff-9bc6-29fe6184926c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_07f3755a-0975-4c53-bbb4-86a777a32071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptions" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptions"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eeb42213-f85c-4496-a426-ba4ea154ea6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_88f8e192-fd81-47e3-bbf0-cf7256bcd5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eeb42213-f85c-4496-a426-ba4ea154ea6d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_88f8e192-fd81-47e3-bbf0-cf7256bcd5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0641cd2-dc2d-4b5a-a312-d95193cf841c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d0641cd2-dc2d-4b5a-a312-d95193cf841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_643e2002-f0d1-4b2d-a078-05d907afba9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_643e2002-f0d1-4b2d-a078-05d907afba9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2c9651a4-4fa8-41db-a182-ff4e6644ada7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_2c9651a4-4fa8-41db-a182-ff4e6644ada7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_62d1f77a-ed1d-4a8a-b47f-8f82b2f3b060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_62d1f77a-ed1d-4a8a-b47f-8f82b2f3b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05ce6185-949e-4933-950b-bd67f94723f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b97bd01-ba25-4ddb-9d0b-6b41c61d8918" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05ce6185-949e-4933-950b-bd67f94723f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d710e1e0-3f7d-4653-a580-66e644a7f0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d710e1e0-3f7d-4653-a580-66e644a7f0c4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a02a024e-9c6d-4977-8978-271cd3a89cc9" xlink:to="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2007Member_a3c5206c-d9a0-4692-b4b0-11e054e3c360" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_StockIncentivePlan2007Member_a3c5206c-d9a0-4692-b4b0-11e054e3c360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_StockIncentivePlan2017Member_001ecf92-efe9-4415-b8d1-0e3843148a73" xlink:href="mrsn-20211231.xsd#mrsn_StockIncentivePlan2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_StockIncentivePlan2017Member_001ecf92-efe9-4415-b8d1-0e3843148a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_InducementAwardProgramMember_21a2252c-dfc7-40d4-b539-0e89bd765d30" xlink:href="mrsn-20211231.xsd#mrsn_InducementAwardProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_InducementAwardProgramMember_21a2252c-dfc7-40d4-b539-0e89bd765d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_A2017ESPPMember_f2b8080f-2eb9-4173-a3ff-8afb03b698ec" xlink:href="mrsn-20211231.xsd#mrsn_A2017ESPPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4cea9e3e-5999-4c07-bbe6-b6718a425171" xlink:to="loc_mrsn_A2017ESPPMember_f2b8080f-2eb9-4173-a3ff-8afb03b698ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_13feebc3-684a-4963-9fd3-1c3335900fe8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8be91860-2d1f-4ae4-baf8-e8a63684d294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_EmployeeStockMember_8be91860-2d1f-4ae4-baf8-e8a63684d294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3dc1144-8191-4a84-9232-e834bfa32565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3dc1144-8191-4a84-9232-e834bfa32565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a3333c8c-aaa5-4f5b-be55-0f9fa600b18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d1d3a5b-35f8-4142-9be3-4cf5f74df098" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a3333c8c-aaa5-4f5b-be55-0f9fa600b18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b9177ce-ccc4-4612-8bc0-6b40bf521a44" xlink:to="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d1ff74b8-2bdc-4c19-8772-ced08fa6b4ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:to="loc_srt_MaximumMember_d1ff74b8-2bdc-4c19-8772-ced08fa6b4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ae4555d1-1e38-483c-afec-1e8ed1350506" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fce92853-a0cd-4854-947e-0d894b757fda" xlink:to="loc_srt_MinimumMember_ae4555d1-1e38-483c-afec-1e8ed1350506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e1982904-cc03-4dc6-8306-bc0fbbb1d348" xlink:to="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d00e8eb9-e320-460e-9db6-4cef8d80030a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c15221ab-bd2f-4c13-a178-95a734fd0ef7" xlink:to="loc_us-gaap_CommonStockMember_d00e8eb9-e320-460e-9db6-4cef8d80030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ea653bc6-7b58-4113-93e0-3c322a878749" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99fdb82d-a49b-4d0d-b979-c4639076a584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_99fdb82d-a49b-4d0d-b979-c4639076a584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d0f59939-feea-48ad-80bf-be77129e28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d0f59939-feea-48ad-80bf-be77129e28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_2cf25233-aa8d-43a4-be87-f6729c318ffe" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease_2cf25233-aa8d-43a4-be87-f6729c318ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a234444-ca5c-4dd8-ac2d-d5d3e905695e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a234444-ca5c-4dd8-ac2d-d5d3e905695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0a42814a-20ba-41fe-b8ed-d97e0b1343a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0a42814a-20ba-41fe-b8ed-d97e0b1343a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60607d30-9485-4509-84c0-46d8b84d9020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60607d30-9485-4509-84c0-46d8b84d9020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4f5c4b88-139a-4c5e-8c97-6f597f11d36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4f5c4b88-139a-4c5e-8c97-6f597f11d36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aba6d5c5-81e0-48c3-973c-1f47bcf76f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aba6d5c5-81e0-48c3-973c-1f47bcf76f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23d75fef-0713-4eba-928e-7ba4522d4644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23d75fef-0713-4eba-928e-7ba4522d4644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff66cd5c-df02-42fb-af6c-b631121fd30f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ff66cd5c-df02-42fb-af6c-b631121fd30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32cbb640-4abb-463b-bdac-a8dc1129c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_32cbb640-4abb-463b-bdac-a8dc1129c72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b29f5291-9024-4d66-836b-3532beae9317" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b29f5291-9024-4d66-836b-3532beae9317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_effbfde0-0ef3-4ae7-9fef-c801204ba5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_effbfde0-0ef3-4ae7-9fef-c801204ba5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ffb63d5f-c408-4134-b131-6d64eb6ca353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ffb63d5f-c408-4134-b131-6d64eb6ca353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_55339941-e59d-4f70-8f71-92af5eee546e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_55339941-e59d-4f70-8f71-92af5eee546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1a15381-3f71-4ce5-a2c6-8756583530f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1a15381-3f71-4ce5-a2c6-8756583530f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_628969d4-62ef-4bf9-bae0-78741a41f07b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_628969d4-62ef-4bf9-bae0-78741a41f07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_31793da9-d8e1-44b0-b7f5-72ddb96621e0" xlink:href="mrsn-20211231.xsd#mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares_31793da9-d8e1-44b0-b7f5-72ddb96621e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2b761af5-1fcc-4012-9248-cf2e7d914561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11ce44ee-ac1f-4bf1-93f0-aadf3b178364" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2b761af5-1fcc-4012-9248-cf2e7d914561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsActivityUnderStockOptionPlanDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_948bedfd-fb46-42a2-8753-f1f8e26bf7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_948bedfd-fb46-42a2-8753-f1f8e26bf7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9b23f656-cd3c-492b-b8fb-b41e7a768cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9b23f656-cd3c-492b-b8fb-b41e7a768cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a7b41fec-cd6a-493a-8a93-71f1d199fa10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a7b41fec-cd6a-493a-8a93-71f1d199fa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7122f493-95e1-4b49-906f-c242276e0945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7122f493-95e1-4b49-906f-c242276e0945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3d8914c-4220-45e8-b2e5-fed96d97a64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_89a720ea-3726-4300-84ad-7e6152c6ca65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3d8914c-4220-45e8-b2e5-fed96d97a64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b96ddcb4-cb47-4e8a-87a5-27148a367061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b96ddcb4-cb47-4e8a-87a5-27148a367061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1c1cf6fe-c0e9-4160-b250-e8bd20f12212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1c1cf6fe-c0e9-4160-b250-e8bd20f12212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3eed9e1c-39ea-4994-88d9-3195e58d9bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3eed9e1c-39ea-4994-88d9-3195e58d9bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13d17a2d-1e4e-4d4c-973f-0afcff76a14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_13d17a2d-1e4e-4d4c-973f-0afcff76a14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0f737a96-9818-4c18-b076-ae664f97c96e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0f737a96-9818-4c18-b076-ae664f97c96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_fa578766-a9c5-427d-b202-5feb5a19eb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_fa578766-a9c5-427d-b202-5feb5a19eb50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96d63b7c-acc0-4b58-89ca-dded795ad0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69a6c198-6b5d-4f11-9375-dfa7f8a235b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_96d63b7c-acc0-4b58-89ca-dded795ad0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_85771b72-3bda-4166-a83a-570269b74238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_85771b72-3bda-4166-a83a-570269b74238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ddd7ced-ee0e-496c-9f84-3e7bfc13a46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4ddd7ced-ee0e-496c-9f84-3e7bfc13a46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_686110f9-40b1-4938-baca-cd1d16ea992c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72223ada-746b-469a-985b-fc7a4a0ebff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_72223ada-746b-469a-985b-fc7a4a0ebff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0ea2cba1-00f6-4de0-8fe0-42e68c3cd333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_0ea2cba1-00f6-4de0-8fe0-42e68c3cd333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2307a454-5b46-43eb-8670-2df55cb22bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2307a454-5b46-43eb-8670-2df55cb22bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db4cc00c-b43c-4cd1-aa5f-35de2e48f04e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_db4cc00c-b43c-4cd1-aa5f-35de2e48f04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6bee1ffa-e73a-4165-80f3-68570cb85bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_6bee1ffa-e73a-4165-80f3-68570cb85bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c9e562d2-cad9-4260-876f-00a6aba78114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cf1d7ce2-a946-4d22-ad5f-001c2466e244" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c9e562d2-cad9-4260-876f-00a6aba78114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_953d9428-7834-48d0-a3fa-cbef367a6e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_953d9428-7834-48d0-a3fa-cbef367a6e00" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:to="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b0818495-89a9-4246-afb8-b61c521c28f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_28db4ad6-de32-455e-9a30-4e0d0f478445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18543def-93de-43ef-a9a7-a76e5f64de44" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_28db4ad6-de32-455e-9a30-4e0d0f478445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f419b4a3-7a34-478c-a3d6-f8bfed141bdc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f526c0f7-c06b-4a18-8fd2-908659acace5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1169083-fc28-46b5-a99e-1e87fb39f6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b1169083-fc28-46b5-a99e-1e87fb39f6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bd8005ea-cbd6-4661-b167-423181672955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bd8005ea-cbd6-4661-b167-423181672955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20c9c9d6-0f15-4d6f-8e8d-f344580bbb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_20c9c9d6-0f15-4d6f-8e8d-f344580bbb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e72a1ba7-f6da-40bc-b93c-45653a9cb50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e72a1ba7-f6da-40bc-b93c-45653a9cb50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14a64659-9a17-479f-8eb2-30838abd4614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14a64659-9a17-479f-8eb2-30838abd4614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97178692-23ef-4ea0-ab8f-4917ca7091f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_97178692-23ef-4ea0-ab8f-4917ca7091f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b838ee0e-401a-4662-a391-ab0275419fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f6982e11-3bef-4a82-b34b-6f9a153197d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b838ee0e-401a-4662-a391-ab0275419fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ef333619-66d4-4c03-9624-90ceb08064c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_021553ce-bbfc-40c6-be6e-4028af3c0b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_021553ce-bbfc-40c6-be6e-4028af3c0b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7f9c93d1-7f6b-4e23-8429-25ab15165cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7f9c93d1-7f6b-4e23-8429-25ab15165cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5550b12f-8bac-4cbe-ac4a-11a14f1d7722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5550b12f-8bac-4cbe-ac4a-11a14f1d7722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_36150caf-cfd2-4b6b-8cae-6d4bc7ebda50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_36150caf-cfd2-4b6b-8cae-6d4bc7ebda50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9101d9db-c461-4d16-853b-bbaa64f41f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_16b07a62-592d-4a4f-8583-c845c1dc623e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9101d9db-c461-4d16-853b-bbaa64f41f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_789f4f38-d171-4c37-a0e8-26ea57f204e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_789f4f38-d171-4c37-a0e8-26ea57f204e3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_881a3fb7-689c-459a-930a-2bc6473f5100" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4563993d-5785-42d5-b02d-3e59bf488e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4563993d-5785-42d5-b02d-3e59bf488e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8d32852-e2f5-4703-a82c-a0722908e71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5d48bf45-b5cb-4dfe-a989-893becb986c6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_f8d32852-e2f5-4703-a82c-a0722908e71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:to="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c22c52ab-3f2a-4ae6-ae96-c08d1471083a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6ccf0440-e5a6-4752-a2be-e86992301aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6ccf0440-e5a6-4752-a2be-e86992301aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e19b3ef-08c1-4c73-b5f2-ab1cbbf17249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e19b3ef-08c1-4c73-b5f2-ab1cbbf17249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_48905b33-da9f-48f6-a12e-2de59596a171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32566c81-4490-41ba-9df0-2f6c08562a2a" xlink:to="loc_us-gaap_EmployeeStockMember_48905b33-da9f-48f6-a12e-2de59596a171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e10529e5-2f1e-4f82-80a9-a5b7875c0f9e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f8672f70-ade1-4c2a-bbe5-aa16f7a5ff9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_237375c7-1d59-46ee-92fb-92b9f1ee2e53" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f8672f70-ade1-4c2a-bbe5-aa16f7a5ff9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#StockOptionsFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d33774be-575f-40b0-a873-e374d1e044b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b52398d5-868d-48ff-8dc3-bf6c750cab08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d33774be-575f-40b0-a873-e374d1e044b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b52398d5-868d-48ff-8dc3-bf6c750cab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1486157-376b-45ad-82f7-ba373ba5f9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d33774be-575f-40b0-a873-e374d1e044b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1486157-376b-45ad-82f7-ba373ba5f9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bab588c0-8f9f-4993-96f7-60f55a67a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d33774be-575f-40b0-a873-e374d1e044b4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bab588c0-8f9f-4993-96f7-60f55a67a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12fa9420-00da-470a-be9c-73c2dca44f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d33774be-575f-40b0-a873-e374d1e044b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12fa9420-00da-470a-be9c-73c2dca44f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Leases" xlink:type="simple" xlink:href="mrsn-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_67b51f1f-7f4a-4284-9740-15674b1a8282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_88d06ab7-3be2-4d37-9b0c-7f40a1a4f822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67b51f1f-7f4a-4284-9740-15674b1a8282" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_88d06ab7-3be2-4d37-9b0c-7f40a1a4f822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_3851b697-bbd2-4cff-84ca-9118a3347ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_67b51f1f-7f4a-4284-9740-15674b1a8282" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_3851b697-bbd2-4cff-84ca-9118a3347ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cf1117c1-5723-4910-b504-aebb95c12aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cf1117c1-5723-4910-b504-aebb95c12aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_0c0f0c7b-d8ac-40bd-b870-a5ba8b2f372f" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:to="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock_0c0f0c7b-d8ac-40bd-b870-a5ba8b2f372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_6ea4bf47-f7e9-4e10-8ba0-7862d613ed8d" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:to="loc_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock_6ea4bf47-f7e9-4e10-8ba0-7862d613ed8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_550f9c1e-6d90-41f7-a48e-84e6017d3a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_550f9c1e-6d90-41f7-a48e-84e6017d3a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_83346b86-a098-4278-904e-fd2e28a51b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bfc77ff1-93e6-43d0-82f5-4fc1ae82aa9a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_83346b86-a098-4278-904e-fd2e28a51b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aeb48042-750f-4fba-8771-bfa961d87ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:href="mrsn-20211231.xsd#mrsn_LeasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aeb48042-750f-4fba-8771-bfa961d87ff5" xlink:to="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c438c897-4157-42c0-a83c-c6ac9dc6528d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceCambridgeMaMember_64226532-3a5c-4cef-99da-b92f5953c99c" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceCambridgeMaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:to="loc_mrsn_OfficeSpaceCambridgeMaMember_64226532-3a5c-4cef-99da-b92f5953c99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember_02a1c142-c5f3-46f5-9087-394948e153fa" xlink:href="mrsn-20211231.xsd#mrsn_OfficeSpaceExpansionCambridgeMaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2bf9ddf0-23ff-47c1-b9a0-0156e605ffcf" xlink:to="loc_mrsn_OfficeSpaceExpansionCambridgeMaMember_02a1c142-c5f3-46f5-9087-394948e153fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:to="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a937ed73-0605-40a1-803a-a83000332906" xlink:to="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_10f7e49f-57f0-47ea-a4a0-c39c6c2afdf3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:to="loc_srt_MinimumMember_10f7e49f-57f0-47ea-a4a0-c39c6c2afdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6ddebc12-68aa-4869-9dcf-b997ea9d94dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_072cc6c6-be6a-4c32-ad90-50f34ed398e4" xlink:to="loc_srt_MaximumMember_6ddebc12-68aa-4869-9dcf-b997ea9d94dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:href="mrsn-20211231.xsd#mrsn_LeasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesTable_3b0f6be2-1861-4d0d-92e2-bcbfebd289ae" xlink:to="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d7fd5846-31b1-4460-af21-f6dec5953e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_d7fd5846-31b1-4460-af21-f6dec5953e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78c2e353-dcf6-40ee-ac18-07ebc2186294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_78c2e353-dcf6-40ee-ac18-07ebc2186294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e685e845-710e-440d-ae85-f2d5aad5be80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_OperatingLeaseLiability_e685e845-710e-440d-ae85-f2d5aad5be80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_f386ba1f-8102-470d-a9a0-3d9cb4751c06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_SecurityDeposit_f386ba1f-8102-470d-a9a0-3d9cb4751c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLeaseTenantImprovementAllowance_873eb0c8-b318-48c1-9be3-75f9b0e88f64" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLeaseTenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_OperatingLeaseTenantImprovementAllowance_873eb0c8-b318-48c1-9be3-75f9b0e88f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9219a134-4d40-4a7d-b841-3a5a777e343a" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_9219a134-4d40-4a7d-b841-3a5a777e343a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_30b884d6-3292-47b6-ab2f-c26afd6775ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_30b884d6-3292-47b6-ab2f-c26afd6775ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5038a1ee-5ffc-4a58-b308-df61475ea337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_5038a1ee-5ffc-4a58-b308-df61475ea337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f9cc1d4b-4806-4eaf-8404-9ac0dd2f7962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_us-gaap_LeaseCost_f9cc1d4b-4806-4eaf-8404-9ac0dd2f7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_83cb3456-ea23-4593-b62a-c802a2bfc650" xlink:href="mrsn-20211231.xsd#mrsn_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesLineItems_01970914-8b81-4e66-b2a8-3d46ed0d20db" xlink:to="loc_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities_83cb3456-ea23-4593-b62a-c802a2bfc650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_404273a0-eff8-4928-a543-723c0d0ed2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_61252951-8d30-4c7f-8257-59c4b157f1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_404273a0-eff8-4928-a543-723c0d0ed2ed" xlink:to="loc_us-gaap_OperatingLeaseCost_61252951-8d30-4c7f-8257-59c4b157f1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseTotalCostAbstract_dbc52a20-c95c-4422-83f0-6246c687cced" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeaseTotalCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_404273a0-eff8-4928-a543-723c0d0ed2ed" xlink:to="loc_mrsn_FinanceLeaseTotalCostAbstract_dbc52a20-c95c-4422-83f0-6246c687cced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_52d81664-3e01-4df0-999a-fb0d920be676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_dbc52a20-c95c-4422-83f0-6246c687cced" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_52d81664-3e01-4df0-999a-fb0d920be676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_2a3e7ff1-c4f5-4442-b4fd-d8da9b409594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_dbc52a20-c95c-4422-83f0-6246c687cced" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_2a3e7ff1-c4f5-4442-b4fd-d8da9b409594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_FinanceLeaseCost_60f8e845-7666-452d-8ff6-6648499c2404" xlink:href="mrsn-20211231.xsd#mrsn_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_FinanceLeaseTotalCostAbstract_dbc52a20-c95c-4422-83f0-6246c687cced" xlink:to="loc_mrsn_FinanceLeaseCost_60f8e845-7666-452d-8ff6-6648499c2404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesSupplementalbalancesheetinformationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeOperatingLeasesAbstract_feb21931-4a65-4c8f-bca9-1ea13a0885a4" xlink:href="mrsn-20211231.xsd#mrsn_LesseeOperatingLeasesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_mrsn_LesseeOperatingLeasesAbstract_feb21931-4a65-4c8f-bca9-1ea13a0885a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b7152c5-e0bf-4fce-b9c0-f23151f839ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_feb21931-4a65-4c8f-bca9-1ea13a0885a4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b7152c5-e0bf-4fce-b9c0-f23151f839ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d477d5ab-b664-4393-bf94-c86f785271cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_feb21931-4a65-4c8f-bca9-1ea13a0885a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d477d5ab-b664-4393-bf94-c86f785271cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8986d7b9-dd06-47d0-906e-0308f4e06947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeOperatingLeasesAbstract_feb21931-4a65-4c8f-bca9-1ea13a0885a4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8986d7b9-dd06-47d0-906e-0308f4e06947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:href="mrsn-20211231.xsd#mrsn_LesseeFinanceLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_398b6776-43af-4f04-98f1-97189b68f627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_398b6776-43af-4f04-98f1-97189b68f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_6a731832-fd1f-48dd-b843-426dcf7a858a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_6a731832-fd1f-48dd-b843-426dcf7a858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1ec01dba-1b05-43b8-923b-bd5da08a0571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1ec01dba-1b05-43b8-923b-bd5da08a0571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_17ad44ff-1556-4b41-9d02-154400b4b1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LesseeFinanceLeasesAbstract_22a72671-c14c-460a-aa5e-5b1a1f3c7990" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_17ad44ff-1556-4b41-9d02-154400b4b1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_a50a9a42-fb8b-4a30-8bb4-dd2cea2daf63" xlink:href="mrsn-20211231.xsd#mrsn_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_a50a9a42-fb8b-4a30-8bb4-dd2cea2daf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cba7355d-cbdb-4a2b-b530-99bfefa10bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_a50a9a42-fb8b-4a30-8bb4-dd2cea2daf63" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cba7355d-cbdb-4a2b-b530-99bfefa10bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f4f288ae-823e-4b56-a161-57e153fb824b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageRemainingLeaseTermAbstract_a50a9a42-fb8b-4a30-8bb4-dd2cea2daf63" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f4f288ae-823e-4b56-a161-57e153fb824b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_WeightedAverageDiscountRateAbstract_4a9b338e-2f6f-4f74-94aa-0da005c8a2b8" xlink:href="mrsn-20211231.xsd#mrsn_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_mrsn_WeightedAverageDiscountRateAbstract_4a9b338e-2f6f-4f74-94aa-0da005c8a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa1eaaa5-a4b5-4df1-8eff-3bdd47d8b369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract_4a9b338e-2f6f-4f74-94aa-0da005c8a2b8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fa1eaaa5-a4b5-4df1-8eff-3bdd47d8b369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_b503988b-a1da-4abd-8b5f-3f938eaf1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_WeightedAverageDiscountRateAbstract_4a9b338e-2f6f-4f74-94aa-0da005c8a2b8" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_b503988b-a1da-4abd-8b5f-3f938eaf1ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1afa55ab-ca12-41c6-9784-92a2a4aa6215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1afa55ab-ca12-41c6-9784-92a2a4aa6215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9859787e-86f6-4951-a560-cf7caedec76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a3b4bb4-eb95-4c18-9755-9f3bf4616b87" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_9859787e-86f6-4951-a560-cf7caedec76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesSupplementalcashflowinformationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1b8ae0b4-5433-4714-a19c-0e3801b09383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_78e98ccc-5144-49bb-8494-5dba44f20d4c" xlink:href="mrsn-20211231.xsd#mrsn_LeasesSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b8ae0b4-5433-4714-a19c-0e3801b09383" xlink:to="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_78e98ccc-5144-49bb-8494-5dba44f20d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_077f5e0a-3898-4f4f-a019-c239c2eb8e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_78e98ccc-5144-49bb-8494-5dba44f20d4c" xlink:to="loc_us-gaap_OperatingLeasePayments_077f5e0a-3898-4f4f-a019-c239c2eb8e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_593cd84c-b09c-4cd3-83dd-10189798dfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_78e98ccc-5144-49bb-8494-5dba44f20d4c" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_593cd84c-b09c-4cd3-83dd-10189798dfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_666f5e4a-56ef-4edc-aba5-a7c836d4e9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrsn_LeasesSupplementalCashFlowInformationAbstract_78e98ccc-5144-49bb-8494-5dba44f20d4c" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_666f5e4a-56ef-4edc-aba5-a7c836d4e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesFutureminimumleasepaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_915a5db4-c176-4776-9dbd-aeb677a34d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d896996b-fff8-4b76-895a-02039b7d4ada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_915a5db4-c176-4776-9dbd-aeb677a34d13" xlink:to="loc_us-gaap_LeaseCost_d896996b-fff8-4b76-895a-02039b7d4ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_915a5db4-c176-4776-9dbd-aeb677a34d13" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_04c64065-d44e-467b-9d29-2bcf0e0bc1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_04c64065-d44e-467b-9d29-2bcf0e0bc1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a9a1c0da-617f-4d4a-af76-cd9b7adaa84c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a9a1c0da-617f-4d4a-af76-cd9b7adaa84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2adbb741-0698-4902-99ee-06785f8bce44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2adbb741-0698-4902-99ee-06785f8bce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0e34a25b-9402-4dd7-b50c-0d49074855d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0e34a25b-9402-4dd7-b50c-0d49074855d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_afca62f7-bb85-4566-99af-b65c0835af4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_afca62f7-bb85-4566-99af-b65c0835af4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ad254fb-80dc-4cf6-ab01-046d3d31a6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0ad254fb-80dc-4cf6-ab01-046d3d31a6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d12cbc06-50b5-467a-a1c3-558b90a78233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d12cbc06-50b5-467a-a1c3-558b90a78233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c23c22f0-29a5-4dee-aab3-9b77d2f291ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_258436f9-1b74-4136-aad4-3076eec05d1b" xlink:to="loc_us-gaap_OperatingLeaseLiability_c23c22f0-29a5-4dee-aab3-9b77d2f291ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_915a5db4-c176-4776-9dbd-aeb677a34d13" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d3d51100-5b90-47b5-a13e-a329c9871ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d3d51100-5b90-47b5-a13e-a329c9871ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_6edf0241-4f26-4b9b-b609-84006eb1fa02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_6edf0241-4f26-4b9b-b609-84006eb1fa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_87547c72-86ed-4817-af74-89feaf3e7904" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_87547c72-86ed-4817-af74-89feaf3e7904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8db77ebb-5bc1-4b9d-9eb7-cffeeee458f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8db77ebb-5bc1-4b9d-9eb7-cffeeee458f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0034b882-ce87-44be-a0c7-5e9e59dc278a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0034b882-ce87-44be-a0c7-5e9e59dc278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_acad6f7e-fd6c-4496-b9ce-8d53055588c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_acad6f7e-fd6c-4496-b9ce-8d53055588c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_46c18506-cc32-4bd3-9e00-935555526419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_46c18506-cc32-4bd3-9e00-935555526419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_c72744e1-ab7f-4923-b315-3c640e2c0ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a649e2d-2e13-4363-aac1-e1f9000da1fa" xlink:to="loc_us-gaap_FinanceLeaseLiability_c72744e1-ab7f-4923-b315-3c640e2c0ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="simple" xlink:href="mrsn-20211231.xsd#LeasesFutureminimumleasepaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ac34e6c-1dc3-48ce-bf61-ec29fabcf011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6244b195-3757-40c9-8742-126e137f8a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ac34e6c-1dc3-48ce-bf61-ec29fabcf011" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6244b195-3757-40c9-8742-126e137f8a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1db0f0e1-d2d6-427e-905c-44564dd6871f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_26630f9b-c944-4f45-90a6-3edfe1706ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1db0f0e1-d2d6-427e-905c-44564dd6871f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_26630f9b-c944-4f45-90a6-3edfe1706ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_776d7371-977b-4181-8077-31c76c12491b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1db0f0e1-d2d6-427e-905c-44564dd6871f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_776d7371-977b-4181-8077-31c76c12491b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec1f3af9-6342-4bbc-b53f-643a3faf87af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9d25fb10-7dbb-45bb-b329-c120c4c7fb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec1f3af9-6342-4bbc-b53f-643a3faf87af" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9d25fb10-7dbb-45bb-b329-c120c4c7fb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed780a76-1109-4b29-89b1-c778faaecc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed780a76-1109-4b29-89b1-c778faaecc14" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1452b12a-1ca3-42d2-b548-bdf3096c3e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1452b12a-1ca3-42d2-b548-bdf3096c3e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_88b2d4bc-8525-46b5-983f-55d4e3000f12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_88b2d4bc-8525-46b5-983f-55d4e3000f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_eddcb3c2-c48c-4c8d-a653-60818d4fe596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_eddcb3c2-c48c-4c8d-a653-60818d4fe596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b2b24a9b-561a-491c-8593-135d87fbd2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b2b24a9b-561a-491c-8593-135d87fbd2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a7b8f3ba-c08b-4a8e-8d98-0eca981a373e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a7b8f3ba-c08b-4a8e-8d98-0eca981a373e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_26619409-90e5-41bd-9f7a-4553b67a3a32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_26619409-90e5-41bd-9f7a-4553b67a3a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9bdf39f6-1681-4a1b-86c0-597338d5f0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_9bdf39f6-1681-4a1b-86c0-597338d5f0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_355ab93c-a1c4-4c97-81fc-d69b2e23bba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_65d2cbd2-1264-425d-86b1-7057a191a3d8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_355ab93c-a1c4-4c97-81fc-d69b2e23bba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesComponentsofdeferredtaxassetsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e1e67789-2862-4808-a627-f705a94f2b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c8d5600f-a6c2-41f2-8be3-4c54d3cfb315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e1e67789-2862-4808-a627-f705a94f2b3b" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c8d5600f-a6c2-41f2-8be3-4c54d3cfb315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c8d5600f-a6c2-41f2-8be3-4c54d3cfb315" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2fc83e9e-0a77-4f48-85f0-595618863606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2fc83e9e-0a77-4f48-85f0-595618863606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4fd7e008-236b-4512-9287-99a84b0ec10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4fd7e008-236b-4512-9287-99a84b0ec10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ae956056-8549-4d0e-b392-4a31d1fe8684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_ae956056-8549-4d0e-b392-4a31d1fe8684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_e6a3a730-0354-4cc4-a705-4d2dfacdbf70" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_mrsn_DeferredTaxAssetsLeaseLiabilities_e6a3a730-0354-4cc4-a705-4d2dfacdbf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsLicensedTechnology_3ad3610c-3917-4029-9e7a-5977c8644509" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsLicensedTechnology"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_mrsn_DeferredTaxAssetsLicensedTechnology_3ad3610c-3917-4029-9e7a-5977c8644509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_c04f8280-21c4-4718-b80c-9c4e46ffd4af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_c04f8280-21c4-4718-b80c-9c4e46ffd4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DeferredTaxAssetsDepreciation_effd63e5-d3fe-48ae-adb9-543cd4f101d5" xlink:href="mrsn-20211231.xsd#mrsn_DeferredTaxAssetsDepreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_mrsn_DeferredTaxAssetsDepreciation_effd63e5-d3fe-48ae-adb9-543cd4f101d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a163641e-5513-4dd8-bca3-739bb9ec6907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a163641e-5513-4dd8-bca3-739bb9ec6907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_23b138d0-5404-4b42-8f5d-b602d8451c11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_23b138d0-5404-4b42-8f5d-b602d8451c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b905f49d-c686-4357-aca1-a2d6ea2adc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b905f49d-c686-4357-aca1-a2d6ea2adc2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d30ecff1-30b6-495f-965c-b97dff1cf9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_122d7d41-caa5-4586-9f21-fe0f01809944" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d30ecff1-30b6-495f-965c-b97dff1cf9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9a4c7505-7b69-4bf3-9659-33aab93408ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c8d5600f-a6c2-41f2-8be3-4c54d3cfb315" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9a4c7505-7b69-4bf3-9659-33aab93408ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e87d710e-8e85-4afd-87ba-ef1824dd7132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9a4c7505-7b69-4bf3-9659-33aab93408ed" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e87d710e-8e85-4afd-87ba-ef1824dd7132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7a923907-db80-4c9c-b5f6-9d81164aa877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_9a4c7505-7b69-4bf3-9659-33aab93408ed" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7a923907-db80-4c9c-b5f6-9d81164aa877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_282396b5-e228-40e9-89ec-d9d417cd3620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_c8d5600f-a6c2-41f2-8be3-4c54d3cfb315" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_282396b5-e228-40e9-89ec-d9d417cd3620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesNetoperatinglosscarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f82dfe48-b278-4869-82a5-20c612d46395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f82dfe48-b278-4869-82a5-20c612d46395" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_366926cc-8643-45a9-9dbb-cf3b9cb0edff" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_5bb7a80c-1ff0-4fc5-aa6c-5e9b91c5c064" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:to="loc_us-gaap_DomesticCountryMember_5bb7a80c-1ff0-4fc5-aa6c-5e9b91c5c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a3b6099e-5302-44b2-b833-8bc78ae75344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_ecf7ff1a-d9e5-429d-8b9a-61ef73af4193" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a3b6099e-5302-44b2-b833-8bc78ae75344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6dbf3d35-cf5c-4e83-b4d7-5c2b8fc04b04" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_88fa10e9-df63-4a78-853a-a8b084bc231c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_88fa10e9-df63-4a78-853a-a8b084bc231c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_8846d1e4-90df-4bae-87a9-4880232d9349" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_mrsn_OperatingLossCarryforwardsSubjectToExpiration_8846d1e4-90df-4bae-87a9-4880232d9349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_ca636e44-7db6-4289-9657-47b7ce79e9e3" xlink:href="mrsn-20211231.xsd#mrsn_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_aa04a5de-78c5-4489-b8fa-9ab4f1aafbc0" xlink:to="loc_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration_ca636e44-7db6-4289-9657-47b7ce79e9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesTaxcreditcarryforwardDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_24e32d2e-17f3-4bc3-a1a1-05de0508d738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24e32d2e-17f3-4bc3-a1a1-05de0508d738" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0280a038-8d24-4793-884c-10a153fb65c5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e7a68f86-52eb-419e-9e19-83b1ae02d2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:to="loc_us-gaap_DomesticCountryMember_e7a68f86-52eb-419e-9e19-83b1ae02d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_bc728cdd-4042-4a6d-9e81-41e2d4c774ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f8dd2a22-df6a-4e21-ad00-b8348ad337e1" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_bc728cdd-4042-4a6d-9e81-41e2d4c774ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_0962125f-766b-4e0b-8d59-57e3f2be88f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_1b9bed91-2de0-498b-9f93-1fbe6faec742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3ad2a163-2125-4cdd-8462-6254dfa19cde" xlink:to="loc_us-gaap_ResearchMember_1b9bed91-2de0-498b-9f93-1fbe6faec742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d0242cf8-5ed4-42f5-ace0-5933b9349e44" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_b1cdce8d-cced-4691-b17f-86203c462cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_f0bca987-839f-4c1a-90b2-c8f69dbff478" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_b1cdce8d-cced-4691-b17f-86203c462cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#IncomeTaxesValuationallowanceDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4ba078d8-ec48-4f94-a51b-de0a81417160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6c7743e8-c42b-427a-8a80-5f8a3840bfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4ba078d8-ec48-4f94-a51b-de0a81417160" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6c7743e8-c42b-427a-8a80-5f8a3840bfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6c7743e8-c42b-427a-8a80-5f8a3840bfb7" xlink:to="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57dd841e-bf15-49b2-8a8c-b980c5c404b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_57dd841e-bf15-49b2-8a8c-b980c5c404b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8c08700a-cab8-4aa0-b752-26195d585a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_8c08700a-cab8-4aa0-b752-26195d585a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_aefb9e32-a39b-4298-aa0b-282a4f0d0c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_aefb9e32-a39b-4298-aa0b-282a4f0d0c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_36e174a7-4b16-425f-8685-be894839cbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceAbstract_6217b073-e5f4-4434-9f65-06efb8bdcb2b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_36e174a7-4b16-425f-8685-be894839cbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions_e9acb995-ad94-4705-b894-d7f02f8bc04e" xlink:href="mrsn-20211231.xsd#mrsn_IncomeTaxesNumberOfStateJurisdictions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6c7743e8-c42b-427a-8a80-5f8a3840bfb7" xlink:to="loc_mrsn_IncomeTaxesNumberOfStateJurisdictions_e9acb995-ad94-4705-b894-d7f02f8bc04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress_cd36e530-3455-4051-82cd-e29c39e3a1ca" xlink:href="mrsn-20211231.xsd#mrsn_IncomeTaxesNumberOfAuditsInProgress"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_6c7743e8-c42b-427a-8a80-5f8a3840bfb7" xlink:to="loc_mrsn_IncomeTaxesNumberOfAuditsInProgress_cd36e530-3455-4051-82cd-e29c39e3a1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="mrsn-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0fa3832e-16bf-42a6-8a13-ca0f98fe3c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b78a5170-8d91-4959-bed5-4dfbb4fd01fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0fa3832e-16bf-42a6-8a13-ca0f98fe3c8e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_b78a5170-8d91-4959-bed5-4dfbb4fd01fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate_f268370d-e5ce-4a50-b2ac-51d2ea3d86d3" xlink:href="mrsn-20211231.xsd#mrsn_DefinedContributionPlanEligibleAgeToParticipate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_mrsn_DefinedContributionPlanEligibleAgeToParticipate_f268370d-e5ce-4a50-b2ac-51d2ea3d86d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4b81904c-5a3b-4dcc-93e2-d88b6807729b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4b81904c-5a3b-4dcc-93e2-d88b6807729b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_07e785af-023c-42d8-8695-71df951ac7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_07e785af-023c-42d8-8695-71df951ac7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_686b30ab-b3af-4471-a3fd-7fbbf4ad8112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_686b30ab-b3af-4471-a3fd-7fbbf4ad8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_0f1e6a28-da9b-4f2d-a5e2-5f18e54240c9" xlink:href="mrsn-20211231.xsd#mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount_0f1e6a28-da9b-4f2d-a5e2-5f18e54240c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6fc26def-6e0f-43ba-8cee-34030a0113ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e0e743ae-5531-45ed-a8a2-5a8d38bdace7" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6fc26def-6e0f-43ba-8cee-34030a0113ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/Commitments" xlink:type="simple" xlink:href="mrsn-20211231.xsd#Commitments"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/Commitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b2d3a9d5-7000-4aa4-aa7e-d379335d42ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_ebf175cb-29b1-43a3-b660-08e6c7913979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b2d3a9d5-7000-4aa4-aa7e-d379335d42ed" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_ebf175cb-29b1-43a3-b660-08e6c7913979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#CommitmentsLicenseagreementsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/CommitmentsLicenseagreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf79341-6479-4c34-9482-0c605c7f5b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_daf79341-6479-4c34-9482-0c605c7f5b8e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_b5cc7352-e9e0-4c43-82cf-f48f5efb8341" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_4849e299-def9-4a72-8f37-c8275bd2f632" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementUpfrontPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:to="loc_mrsn_LicenseAgreementUpfrontPaymentsMember_4849e299-def9-4a72-8f37-c8275bd2f632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LicenseAgreementMilestonePaymentsMember_ffc2b6ce-fcc2-42cd-8536-5fd0a16843fb" xlink:href="mrsn-20211231.xsd#mrsn_LicenseAgreementMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_d133efa5-40f1-452c-976e-fe76dd1036bc" xlink:to="loc_mrsn_LicenseAgreementMilestonePaymentsMember_ffc2b6ce-fcc2-42cd-8536-5fd0a16843fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01e573c1-11b8-430c-a87c-2995eb239636" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_07224d9e-8e84-4a58-9e3d-1e083d245924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d68cee1e-ec43-444d-b12b-b6035108c60d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross_07224d9e-8e84-4a58-9e3d-1e083d245924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SubsequentEvents" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d1b2d9ad-62b9-4721-97fa-45eb517a70b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4796bf58-62c4-479b-a295-274bb2c433ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d1b2d9ad-62b9-4721-97fa-45eb517a70b2" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4796bf58-62c4-479b-a295-274bb2c433ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.mersana.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="mrsn-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.mersana.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_36b82529-20cc-4783-99a7-f124c3e955ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_36b82529-20cc-4783-99a7-f124c3e955ce" xlink:to="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b5275b39-20e2-4121-9cfb-590a18f7a8c3" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ac57dc00-f44f-4cf6-b06e-25a87c604c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_97fe735b-225d-4777-8c72-7d269f4cd13c" xlink:to="loc_us-gaap_SubsequentEventMember_ac57dc00-f44f-4cf6-b06e-25a87c604c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_20b6664e-cdef-43c1-82da-46103d13dbf8" xlink:to="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_f75de44c-f627-4ca5-9aee-20a58304cb20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_211c122d-b329-49de-9017-8d25a1123db0" xlink:to="loc_us-gaap_LineOfCreditMember_f75de44c-f627-4ca5-9aee-20a58304cb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_f38963e7-5c3c-4088-9479-57b5a9bbb6dd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_db38b99b-a18e-4c30-825d-850a9aae9bc8" xlink:href="mrsn-20211231.xsd#mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_073238b7-8cb3-492b-890f-c4fb42ad1700" xlink:to="loc_mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember_db38b99b-a18e-4c30-825d-850a9aae9bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409b6caa-4d6a-40b9-a63f-5f6d0dcac8ce" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_DevelopmentAndRegulatoryMember_45d8b7e9-1d5b-4fc1-a3c4-17d1d46c9e2e" xlink:href="mrsn-20211231.xsd#mrsn_DevelopmentAndRegulatoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:to="loc_mrsn_DevelopmentAndRegulatoryMember_45d8b7e9-1d5b-4fc1-a3c4-17d1d46c9e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CommercialMember_16642536-2b68-446e-8a6c-9e3bafd6d46f" xlink:href="mrsn-20211231.xsd#mrsn_CommercialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7f51e45c-995a-4108-a4a6-b585b2e74be6" xlink:to="loc_mrsn_CommercialMember_16642536-2b68-446e-8a6c-9e3bafd6d46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f0f99f5f-59f8-49a9-a6ed-5cce7f6f1cd3" xlink:to="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_JanssenMember_e57de7ca-1750-4145-a8b4-687be388af21" xlink:href="mrsn-20211231.xsd#mrsn_JanssenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:to="loc_mrsn_JanssenMember_e57de7ca-1750-4145-a8b4-687be388af21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SynaffixMember_0656d543-7823-49c5-9fc2-cdca3e5f4b77" xlink:href="mrsn-20211231.xsd#mrsn_SynaffixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b0ef1887-bf17-449c-bc60-63157aa4eb5e" xlink:to="loc_mrsn_SynaffixMember_0656d543-7823-49c5-9fc2-cdca3e5f4b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebd96eb7-83f0-4115-8ea0-287839adea4d" xlink:to="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_00e25db3-c028-4c72-86d3-ac11b0bd7583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4da875e5-47cd-4eba-aeda-1e7b490245ea" xlink:to="loc_us-gaap_CommonStockMember_00e25db3-c028-4c72-86d3-ac11b0bd7583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_87131c27-c9b5-4090-b0e0-4dcc2ea81b5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_722ea644-2820-49fc-a356-d7cf0dd719f8" xlink:href="mrsn-20211231.xsd#mrsn_AtMarketEquityOfferingProgram2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e1f8d4b-0cd7-47d0-87bc-d43ea89fe330" xlink:to="loc_mrsn_AtMarketEquityOfferingProgram2020ATMMember_722ea644-2820-49fc-a356-d7cf0dd719f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_749efb69-ecaf-4bd4-a1d7-28ee836cb475" xlink:to="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_67341b57-ff9e-4764-8a9f-a9e18ee2760c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_ProceedsFromCollaborators_67341b57-ff9e-4764-8a9f-a9e18ee2760c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_5d0bfa63-72a9-4190-851f-2e7910bb19fc" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationArrangementsMaximumAggregateMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_CollaborationArrangementsMaximumAggregateMilestones_5d0bfa63-72a9-4190-851f-2e7910bb19fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee_0c07ddad-133f-49e8-b5e7-5fba08a11993" xlink:href="mrsn-20211231.xsd#mrsn_CollaborationAgreementNonrefundableExecutionFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_CollaborationAgreementNonrefundableExecutionFee_0c07ddad-133f-49e8-b5e7-5fba08a11993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a4a19cca-6003-4e99-a77a-a0c84e21b433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_a4a19cca-6003-4e99-a77a-a0c84e21b433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_b1c5a436-5558-4117-bae5-952b3f7700ea" xlink:href="mrsn-20211231.xsd#mrsn_LineOfCreditFacilityTrancheAvailabilityDuration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration_b1c5a436-5558-4117-bae5-952b3f7700ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78ebabfc-4f36-4df6-9d87-d752f656232d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78ebabfc-4f36-4df6-9d87-d752f656232d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a672c564-5935-42fb-865c-9dd8a263befd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a672c564-5935-42fb-865c-9dd8a263befd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_c514d118-793e-4040-a781-a456db7d96ee" xlink:href="mrsn-20211231.xsd#mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fc6a610-b352-4096-b131-89cd73425757" xlink:to="loc_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale_c514d118-793e-4040-a781-a456db7d96ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>mrsn-20211231_g1.jpg
<TEXT>
begin 644 mrsn-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X2T$17AI9@  34T *@    @ !@ +  (
M   F   (8@$2  ,    !  $   $Q  (    F   (B $R  (    4   (KH=I
M  0    !   (PNH<  <   @,    5@  $48<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M-  R,#(R.C R.C(T(#$U.C4U.C0V   &D ,  @   !0  !$<D 0  @   !0
M !$PDI$  @    ,P,   DI(  @    ,P,   H $  P    $  0  ZAP !P
M" P   D0     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,CHP,CHR-" Q-#HT-3HQ-  R,#(R.C R.C(T(#$T.C0U.C$T      8!
M P #     0 &   !&@ %     0  $90!&P %     0  $9P!*  #     0 "
M   " 0 $     0  $:0" @ $     0  &U<         8     $   !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\  $0@ >0$  P$A  (1 0,1 ?_$ !\   $% 0$! 0$!
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MYED5@HW.V%SW/-<R/%5T8E;=;;V .SY^/7G?0 B^*[AB # "1DY5P <9_O\
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MYETG2)+J..>9@0NTSR8&>YYZ5RB>(69$)%J&<9V^<_''<[^* '_V\VY@&M,
M<'SGYZ?[?U_*F_V^Q?8IM-V<?/-(!CUSO(H CD\1S1$ QV;9&?DGD./_ !ZG
M?\)!*2P"6F5./FN' /'^_0 V3Q%-%'YGEV<@R/E2XD)_+=7;V=G;75E!<-#+
M&98U<H9GRN1G'6@";^S+7^[)_P!_G_QH_LRU_NR?]_G_ ,: #^S+7^[)_P!_
MG_QH_LRU_NR?]_G_ ,: 'BQA484S >@G?_&E^QQ?WY_^_P"_^- !]CB_OS_]
M_P!_\:/L<7]^?_O^_P#C0!8HH ** "B@ HH K7VX6K,CA2O]XX'7O689V&W
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M\^,?.G?\?:B3Q9:1(7>.^"KU^=,C\,T 0?\ "<:;_=O_ /QVC_A.--_NW_\
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M_/E/_P!])_\ %4?:9?\ GRG_ .^D_P#BJ #[3+_SY3_]])_\51]IE_Y\I_\
MOI/_ (J@ ^TR_P#/E/\ ]])_\51]IE_Y\I_^^D_^*H /M,O_ #Y3_P#?2?\
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MG[T?6@"RI?:-MNN.V&%.WS?\\!_WV* &YD_Y]U_[Z%*&E'2W _X$* %WS?\
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M^$2-_C5,2S'.;"Y&/^FQY_6@":WW32%7MYXE ^\TIY_6K/V=/63_ +^-_C0
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M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *D!90# 2(  A$! Q$!_\0
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M))^E>4?M:?\ )OOBOZ6O_I7#7J]C_P >=O\ ]<U_E0!8HHHH **** "BBB@
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M.@9[>!U!*G.,YKI?#?B73/%VBVFL:->Q:AIMTN^*XA/!YP01U# @@J<$$$$
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MKJG_ *35[)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Q_QB_Y)'XY_[ =]_P"D[UV%<?\
M&+_DD?CG_L!WW_I.] $/P4_Y([X)_P"P-:?^B5KMJXGX*?\ )'?!/_8&M/\
MT2M=M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5Y!\6O^2Q?![_ *_K[_TG%>OUY!\6O^2Q?![_ *_K[_TG% 'K
M]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>;_ +17_)$/&/\ UXM_Z$*](KS?]HK_ )(AXQ_Z\6_]"% '5> ?^1$\
M.?\ 8-MO_12UO5@^ ?\ D1/#G_8-MO\ T4M;U !1110 4444 %%%% !1110
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MI:\_^+UOK5U\7OAC'H%_8Z9J/EZH5GU*Q>\A"^5%D&-)HB3[[^/0UZ!\,_\
MDG/A;_L%6O\ Z*6MBXTJRNKZUOIK2":\M0XM[B2-6DA#@!PC$97< ,XZX% '
M :3\([C4-4\2:GXVU:V\2WNN6$>CRPZ?9/IUK'9+O/EA/.ED+,TLA9C)R"
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MDG!UKX2+>:QJFHZ'XJ\0>#GU4A]0AT5K4Q7,H79YVVX@E\N3: "T>PMM4G)
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M/V^#6B-X1E\.FZU#[%)K?]O&3S$\SS_MOVS;G9C9Y@QC&=O&<\UZ!0 4444
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y!\6O^2Q?![_K^OO\
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M_#GPM>:MX<MX/#JM:J9;F/4HS+=F*U=X8]RO''PQ9O*RP&%SU7B[X_:[X?\
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M["X(P-KKQW/7UE^&M!M/"OAW3-%L$\NRT^VCM(%]$10J_H*U* "BBB@#R?\
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MY<GP+TO5+?5SKVMZSXDU/488+<ZM>O!#<P)#(981%]GABC4I*3(&*$DGDD
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M*KV+9;U8T =31110 4444 %>-6?_ "=M??\ 8IK_ .E(KV6O&K/_ ).VOO\
ML4U_]*10![(WW3]*^+_!/P\L?%/P3A@TCX)K-XJO(9H[3QDR:5;B&X,K!+O[
M0)_M2^6</D1[_DP!7VAUXK \#^#[/P#X6L=!T^6XFL[-66-[IE:0Y8L<E0!U
M)[4 >%_&3X=^'E:YMI8I/%_Q9\10P1:--<!'GT@Q*JBZMV"[K2"-\RLP/S.Q
M&26 IO[0%K)K7A_QU/>0_P!J0Z+I^FZ2(MBGSYI;F&:X7#D+\R&V&"0/4^GI
M-U\&;C_A,-<\1Z;X\\3:'>ZPT9N([2'39458UVI&AGLY'5!R0N[&68]6-:=_
M\)]+U3PKK&@W5[?3QZM>B_N[PO&)WE$B..0FW \M% V\* />@#RS3_A['_PF
M7AG4_"GPB7X8#399;G4M5>/3+?[7;>0Z?9-EE/(TN]V1L2;57RL@[L"D\$?'
MB\T/X>M=:AHVEZ;;KX4M];T:STJV:"&5SF-[94W$<2F$ +C F4>]?1$L*RV[
MPDX5E*'UP1BO-7_9]\,S:3X#T^6;49(?!LD;V+><H:<)M(2?" .NZ.)\ +\T
M:'MB@#E-2^*_CZRT+Q/KBV^@+:^#8HEU:SDM9C+J4RV\<]S]G<38MU"R;4WK
M*25.<"J/AWQMXDTC5/C!K=WXFT&/3;74+5;*37$EMK6Q5[:W96=S,WR!9/\
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M\_ZIS_Y/T?\ %_/^J<_^3]>P44 >/_\ %_/^J<_^3]'_ !?S_JG/_D_7L%%
M'C__ !?S_JG/_D_1_P 7\_ZIS_Y/U[!10!X__P 7\_ZIS_Y/T?\ %_/^J<_^
M3]>P44 >/_\ %_/^J<_^3]'_ !?S_JG/_D_7L%% 'C__ !?S_JG/_D_1_P 7
M\_ZIS_Y/U[!10!X__P 7\_ZIS_Y/T?\ %_/^J<_^3]>P44 >/_\ %_/^J<_^
M3]'_ !?S_JG/_D_7L%% 'C__ !?S_JG/_D_1_P 7\_ZIS_Y/U[!10!X__P 7
M\_ZIS_Y/T?\ %_/^J<_^3]>P44 >/_\ %_/^J<_^3]'_ !?S_JG/_D_7L%%
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MJ<_^3]>I6EY-<W%Y%)8W%JD$@2.:5HRMP"H.]-KD@ DK\X4Y4\8P3>H \?\
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M/^J<_P#D_1_Q?S_JG/\ Y/UZ+X;\4:=XOL[F[TN9I[>"[GLG=D9/WL,C1R
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M/_QZ@#5_XOY_U3G_ ,GZ/^+^?]4Y_P#)^LK_ (; \'?] S7?_ >'_P"/4?\
M#8'@[_H&:[_X#P__ !Z@#5_XOY_U3G_R?H_XOY_U3G_R?K*_X; \'?\ 0,UW
M_P !X?\ X]1_PV!X._Z!FN_^ \/_ ,>H U?^+^?]4Y_\GZ/^+^?]4Y_\GZRO
M^&P/!W_0,UW_ ,!X?_CU'_#8'@[_ *!FN_\ @/#_ /'J -7_ (OY_P!4Y_\
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M .3]'_%_/^J<_P#D_65_PV!X._Z!FN_^ \/_ ,>H_P"&P/!W_0,UW_P'A_\
MCU &K_Q?S_JG/_D_1_Q?S_JG/_D_64/VP?!A8#^S=<'O]GA_^.UU'A7]HCP1
MXLNTM(=3:QNI#A(M0C,6X^@;E<^V<T 9G_%_/^J<_P#D_1_Q?S_JG/\ Y/U[
M!10!X_\ \7\_ZIS_ .3]'_%_/^J<_P#D_7L%% 'C_P#Q?S_JG/\ Y/T?\7\_
MZIS_ .3]>P44 >/_ /%_/^J<_P#D_1_Q?S_JG/\ Y/U[!10!\\Z[X#^-7B#Q
MCX;\27,W@)+[0?M!M8XFO1$_G)L;>"I)P.F".?6NF_XOY_U3G_R?KV"B@#Q_
M_B_G_5.?_)^C_B_G_5.?_)^O8** /'_^+^?]4Y_\GZ/^+^?]4Y_\GZ]@HH \
M?_XOY_U3G_R?H_XOY_U3G_R?KV"B@#Q__B_G_5.?_)^C_B_G_5.?_)^O8**
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M55G+-<3Q*!AQC!)KMZ\8^+OBK1?!OQB^&.HZ_K-AH>GK%JJ&[U*Z2WA#&*'
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M;G(V]<YP:YRO2OA/;2ZEX7^(-A:QM<7LVE(\<$8R[A)D+$#O@4 <WX-\%_\
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MZW\)_ WAO5KO3-1^)OV:^MG\N:+^P)VVMZ95R#^!JIK_ /R3_P"%7_72\_\
M2H5TWQ6\9>!['X@:_;:A\//[3OX[AEEOO[;GB\UL#YM@&!]!0!Q_AGX?^#?$
M%\]G)\0/L=U)>FUM(_[%F?[0I8".3.X!=V?NGIWJOX^\!^%_!\-W!8>-/[8U
MBUN/(DT_^RI8,$$ACYA8KP1VZU@^ 2#X]\.D# _M*WP/^VJU-\3/^2B^)_\
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M?>W.,G+<\YJ'7-;O?$FK76IZC-]HOKI_,EEV*NYO7"@ ?@*^VO\ AFOX<?\
M0N?^3US_ /'*/^&:_AQ_T+G_ )/7/_QR@#X?T^_GTN^MKVU?RKFWD6:)\ [6
M4@@X/!Y'>G:GJ5SK&HW5_>2>==W,K32R;0NYV.2<  #D]J^WO^&:_AQ_T+G_
M )/7/_QRC_AFOX<?]"Y_Y/7/_P <H ^._!_Q&\2> 9)FT'59=/$W^LC"K(C'
MU*."N??&:D\0?$[Q/XHUBQU35-7EO+RQ<26S,B!(F!!!" !<Y [<XYK[ _X9
MK^''_0N?^3US_P#'*/\ AFOX<?\ 0N?^3US_ /'* /C+4O&6L:O8W=E=WGFV
MUW>MJ,R>4B[K@@@OD#(X)X''M71^"/&JS>*=,N=?U[4-(33K/[)8:CI\2%K7
M;]P.@7]XF"P(ZG/7%?57_#-?PX_Z%S_R>N?_ (Y1_P ,U_#C_H7/_)ZY_P#C
ME '@OQ1^*EKJG@NXT1/%MSXUO;V>*1[M].%C!;1QDD*L> 2Y)&3Z#VKSJU^*
M'BBS\42>(K?5Y8-8D18Y+B-$4.H  5D"[2,*.".V:^O_ /AFOX<?]"Y_Y/7/
M_P <H_X9K^''_0N?^3US_P#'* /COQA\1/$7CZ2%]>U674/)SY:%5C1,]2%0
M!<^^,UGZ9XEU+1M-U.PL[CR+74D6.Z41J6D53N"[B-RC/7!&>^:^U/\ AFOX
M<?\ 0N?^3US_ /'*/^&:_AQ_T+G_ )/7/_QR@#XGT'7K_P +ZQ;:IIEP;6_M
MFW13!0VTX(Z$$'@GJ*FU;Q5JFN6%I97MR);6UDEEAC6)$"-(VYS\H'4]N@[8
MK[2_X9K^''_0N?\ D]<__'*/^&:_AQ_T+G_D]<__ !R@#XX_X3_7O^$HB\1_
M;_\ B<Q*J)<^3'P!'Y8&W;M^[QT_6J%GXBU'3]+U/3[>X\NSU+8+J/8I\S8V
MY>2,C!]"*^UO^&:_AQ_T+G_D]<__ !RC_AFOX<?]"Y_Y/7/_ ,<H ^*-+\0Z
MAHMKJ%O97'DPZA#]GN5V*WF1[@V,D''('(P:?X<\3:EX3U1=0TJZ-I=JC1[]
MBN&5AAE96!5@1V(-?:G_  S7\./^A<_\GKG_ ..4?\,U_#C_ *%S_P GKG_X
MY0!\A^$_BOXJ\#17$6AZQ)8P3N9'A\J-X]QZD(RD*>G0#I6EX-\:?;_B#_;G
MB?Q'JFGWC(WEZO: .\,F %+I@[H\9!11W Z5]5?\,U_#C_H7/_)ZY_\ CE'_
M  S7\./^A<_\GKG_ ..4 >#?%'XK6VI^"[C1$\777C6]O9XG>[?3A8P6T<9)
MVK'@$N21D^@]J\_L?BUXMTOQ%<Z[;:S)!JERBQS2K%'MD55"J"FW:< #M7US
M_P ,U_#C_H7/_)ZY_P#CE'_#-?PX_P"A<_\ )ZY_^.4 ?(.L?%#Q5KWB"RUN
M^UF>?4K%@UM+A56(@Y^5  HS@9XY[YJ'Q%\1/$'BJWNH=4OQ<QW5RMY,H@C3
M=,J",-\JC'R@# X_&OL3_AFOX<?]"Y_Y/7/_ ,<H_P"&:_AQ_P!"Y_Y/7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_B*/^%"ZM_T57QM_X&I_\17K]% 'D'_"A=6_Z*KXV_\  U/_ (BC_A0NK?\
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MBJ^-O_ U/_B*/^%"ZM_T57QM_P"!J?\ Q%>.?\-A>,_^@9H7_@/-_P#'J/\
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M*%U;_HJOC;_P-3_XBC_A0NK?]%5\;?\ @:G_ ,17CG_#87C/_H&:%_X#S?\
MQZC_ (;"\9_] S0O_ >;_P"/4 >Q_P#"A=6_Z*KXV_\  U/_ (BC_A0NK?\
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M_A0NK?\ 15?&W_@:G_Q%>.?\-A>,_P#H&:%_X#S?_'J/^&PO&?\ T#-"_P#
M>;_X]0!['_PH75O^BJ^-O_ U/_B*/^%"ZM_T57QM_P"!J?\ Q%>.?\-A>,_^
M@9H7_@/-_P#'JNZ;^V-X@CF0ZAH.FW,>?F6V:2$GZ%B^/RH ]6_X4+JW_15?
M&W_@:G_Q%'_"A=6_Z*KXV_\  U/_ (BNB^&?QAT'XH6;'3Y&MM0B7=-87&!(
M@_O#'WESW'X@5WM 'D'_  H75O\ HJOC;_P-3_XBC_A0NK?]%5\;?^!J?_$5
MZ_10!Y!_PH75O^BJ^-O_  -3_P"(H_X4+JW_ $57QM_X&I_\17K]% 'D'_"A
M=6_Z*KXV_P# U/\ XBC_ (4+JW_15?&W_@:G_P 17K]% 'D'_"A=6_Z*KXV_
M\#4_^(H_X4+JW_15?&W_ (&I_P#$5Z_10!Y!_P *%U;_ **KXV_\#4_^(H_X
M4+JW_15?&W_@:G_Q%>OT4 >0?\*%U;_HJOC;_P #4_\ B*/^%"ZM_P!%5\;?
M^!J?_$5Z_10!Y!_PH75O^BJ^-O\ P-3_ .(H_P"%"ZM_T57QM_X&I_\ $5Z_
M10!Y!_PH75O^BJ^-O_ U/_B*/^%"ZM_T57QM_P"!J?\ Q%>OT4 >0?\ "A=6
M_P"BJ^-O_ U/_B*/^%"ZM_T57QM_X&I_\17K]% 'D'_"A=6_Z*KXV_\  U/_
M (BC_A0NK?\ 15?&W_@:G_Q%>OT4 >0?\*%U;_HJOC;_ ,#4_P#B*/\ A0NK
M?]%5\;?^!J?_ !%>OT4 >0?\*%U;_HJOC;_P-3_XBC_A0NK?]%5\;?\ @:G_
M ,17K]% 'D'_  H75O\ HJOC;_P-3_XBC_A0NK?]%5\;?^!J?_$5Z_10!Y!_
MPH75O^BJ^-O_  -3_P"(H_X4+JW_ $57QM_X&I_\17K]% 'D'_"A=6_Z*KXV
M_P# U/\ XBC_ (4+JW_15?&W_@:G_P 17K]% 'D'_"A=6_Z*KXV_\#4_^(H_
MX4+JW_15?&W_ (&I_P#$5Z_10!Y!_P *%U;_ **KXV_\#4_^(H_X4+JW_15?
M&W_@:G_Q%>OT4 >0?\*%U;_HJOC;_P #4_\ B*/^%"ZM_P!%5\;?^!J?_$5Z
M_10!Y!_PH75O^BJ^-O\ P-3_ .(H_P"%"ZM_T57QM_X&I_\ $5Z_10!Y!_PH
M75O^BJ^-O_ U/_B*/^%"ZM_T57QM_P"!J?\ Q%>OT4 >0?\ "A=6_P"BJ^-O
M_ U/_B*/^%"ZM_T57QM_X&I_\17K]% 'D'_"A=6_Z*KXV_\  U/_ (BC_A0N
MK?\ 15?&W_@:G_Q%>OT4 >0?\*%U;_HJOC;_ ,#4_P#B*/\ A0NK?]%5\;?^
M!J?_ !%>OT4 >0?\*%U;_HJOC;_P-3_XBC_A0NK?]%5\;?\ @:G_ ,17K]%
M'D'_  H75O\ HJOC;_P-3_XBBO7Z* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O%/!'[/OA>ZO/%FH>,O 7
MA[4]3O\ Q!?7D%YJ6G6MW-);O)F([RK$#'12<CT%>UUP6K?%41:U?:7H/A?7
M/&%SI["._DT<6J0VLA 81M)<SPJ[[2"5C+E01NV[ER <1\1O!_CE?&WBO6_"
MEM/$;K2-(LX+BSFM5N66*[G:Z2 3Y191#+\K2*$RW7(R//Y_A#XQN-0\5ZE9
M>%=<M[6:+0IK"SUWQ&NI:A<M9Z@TTZ/)+<R+$Q7E5$ACY!W*S,J_2O@_QEIO
MCC14U/2I)FA\QX)8;B!X)X)4;:\4L;@,CJ1@@CWZ$&M^@#Y[C^&OB?4/B=%K
MTVAO;6$GC&'6BL]Q 7BMQHOV<LP61OF6;Y,*2<C(ROS4FN_#OQ78^/-4\4VF
MA2:K%:^,H-:AL;>Y@2>\M?[*6T=HC)(J!E=B=LC)D(<'IGZ%JAI]Y/?0.\UC
M<:>RRO&([EHRS*K$!QL=AM8#<,D-@C(4Y  / =)^'OB_6/B)#XCO_#3:7:R^
M-8]:-O/>6\LD-H-(-L'?8Y&\2X4JI;!S@LHW':\1?#;Q#?>&OCS:V^F[[KQ0
M7_LI?.B!N@=-AA');Y/WBLOSXZ9Z'->YT4 <)#X1\2Z?'/>V'BV^>[^Q%+31
M=2@M&TV&?RP$W&*!;AE##)_?'J>O%>::AX'U/QGXAT;4X?A8O@3QK#J=M>:A
MXPBGL0C)&P\]%E@E-Q<++&&C"31JI# MM*@5V]]\=+18;W4-+\+^(_$?ARRD
M>*YU_28+=[5"C;92B/,LTZH0<M#%(#@A2Q! ]"TO5+36]-M-1L9TNK*[B6>"
M>,Y62-@&5A[$$&@#YNT/X(7FDWESX>U;P=K_ (AMGU^74(M6C\8W%KH[0/=&
MY626U%UN$R$_<6W96=%.X!BR] WPO\2#X2WNC+I8&IR^-3K A$\7S6O]LBY\
MS=NQ_J1NQG=VQGBO?J* /GV\\(^+M/\ &2MX1T3Q'X2NI-5,UW<IK=K>^'+N
MW>Y669VMII&FB=T#_P"H@B(EE8%V7YS5\*?#?Q9X7\8:'J<N@S7,'VSQ+!<"
MWN;?=;QWMZDUO.VZ090JAR%RXR/EZX^C** /ES_A1GB]?!'P\TBVTY+=K_0[
M?PSXP7[5&&@LT=)2ZD,0[ "XA&W/_'SGHM7/$GP9O+3Q9XXBE\(:]XMTKQ-<
M+<VS:3XNFTJQ17@C@D@O85NH_D'ECYXXIB4;&TE0I^EZ* *6FV<>FZ=:VD2>
M7%!$L21[V?:%  &YN6QCJ>35VBB@ HHHH **** "BBB@ HHHH *\_P#B#X]U
MOPWXH\,:!X?T.PUG4-;%TX;4M3>QAB6!48_,EO,23OZ;1TZUZ!7D7Q6OFT#X
MH_#K79]/U>\TRSCU*.XFTG2;K4#"TD<03<EO&[ $@X)&.* .C\(>/-3U+Q)?
M^&O$NAPZ%KUM;I?1+9WIO+2[MF;;OBE:*)BR.-KJT:[=R$$A@:@U[XS>'+?P
M)XL\2>'M6TOQ9_PCMG-<W-KIFHQ289$9A&[)O\LG:1R.QX.*\\\=:)KOQFG\
M6ZKH&E:E86<?A*\T33&U2&;3)K^ZN'5Y (Y0LD:*(8U#NBY,C8R!FN<^(5A=
M_$33];O?#'A+6M*MK#P!J6CSVUSI$]G))/+Y1M[.&)T4S>7Y4OS1AD&X!6.Z
M@#W?4/BQX/T&ZTZRUOQ3HFB:I>PQS0Z?J&IPPSN'X7:CL&8$Y (')%>=:M^T
MY90^+O$>DZ3;:1K%KH>H6.F7+1ZXJWAFN)X(F9;=8F_=1F?:SEP=Z,F!U'FW
MQBM_%.K>'_B)H4&E^([">YL%AL=+\.^%EF76_P#0X\S7E_+#*AVD,@C5H95$
M>U=[%!70ZIX6UVZT?QWC1]2DDN_%_AZ[A!M)-TL4:Z=YLBC&2J^7)N;H-C9Q
M@T >]R?$#PO#XJ3PP_B/24\22#<FC-?1"\8;2^1#NWGY06Z=!FGKXTT"6S@N
MX==TN:"YN6L;>47L>R:Y7<&A5@<%P4?*C)&UN.#7S7H7@*_@N;WPQXAOOB&-
M1D\5R:HMKHVD6CZ?<9N_M$-X-0>SPBA-FY7N!(-C1J#\JGH=%T+5;7XOWGC5
M_#5ZOAG6;R[T^RL6M9C<6%R8TC;4GA(_=I<^08R=H*KY;$CSI< 'K/\ PN#P
MEI6BV-[X@\6>&-'DN((9S_Q.X6M\2!BACE?9O1MC[6VC=L; X-=E!-'<PI+"
MZRQR ,DBD%6!Y!!'45\V_L^^ [_3=0M;G6/#]W:S1_#W2M-$E[9NA63?<F:#
MYA][_5[DZ_=R.E>K? '3;W1_@CX'L=1M9[*^MM'MH9K:ZC:.2)EC V,K %2,
M8P>E 'H=%%% !1110 4444 %%%% !7P'\:?'-QX[^(&IW3REK*WE:VM(\G:L
M2D@$#U;[Q]S7WY7YO>*=)FT+Q-JNGS@^=:W4D+;O56(S0!E5VG@?P[I^L>%?
M&MY>6_G7.G6,<UJ^]E\MS*JDX! /!/7-<77I7P9CBUJ'Q5X:^U06E[K.G"*S
M>Y?9&\J2*X3/JP!Q]* ,WX9^&].\06/C"34+?[0^GZ+-=VQWLOERJ5PW!&>I
MX.1732MX(\&^"_"=SJ?@G^WK_5+1[B6X_M:>VY$K+C:N1T Z8JWI?@;5O@_X
M1\7W_BA+?3I=2TYM,LK/[0DDL[R,N6 1C\J@$\U-J_Q _P"$-^'G@&'_ (1O
MP_KGG:?*_F:S8?:'3$SC"G<,"@#'UKX>Z1XNNO!=WX4M9M&M_$<DL$EE<RF<
M6K1, [*QY9,$GG^[VZ!+S7/A;H-XVE1>$K[7[>%C$^LR:H\,CD'!=(E&TCN,
MX]ZK:/\ &2[O/B5H&N:W'!;Z;89MEL]/A\J&V@=61_+09/1B>Y.,>E=+X;^#
MOB;P[K<VJ^'=)\-^.M#G1DANKZ2*:V5"P(9D9U*N .<9QDCF@#%\)^#?"5U\
M5'LH9#XC\-?8);Z*.25HI.(3((W9""&4C!QZ=.U:'@R?X??$3Q#;>'X?AY>:
M5+>9C6^LM7FN7@./OE& &T=R>@[5U%C?:=:_&C3I=%71;:\M/#\YN_[ B46J
MW0BD9MN!AL?+USTP:S? OQO\0_$""^\(ZWKK65[J2%-/U:!$A9)OX8GVJ!M?
MID88'OSP >:> ?!L&O?$ :9>OOTJQ:6>_F7('V>$%G.0> <8SG^(4?%7PO9>
M'?$4,^D1F/0M4M8[^P5F+%8W7E"22<JVX<\\5VWA>&U^#_@/5[WQ/H3ZC=ZW
M=MI0TY[EK5O)BR96$B@G!?:IQUP.:37]2T7XH?"JY&A:$VA3^$Y!,EH;Q[K=
M;2D^80S@'A@#CG Z=: #Q5<?#[P+-IFG77@ ZK/+IUM<RW@UJXA+-)&&/R#(
M')]:K?\ "OO#=[XX\#7>EI//X5\23 ?8KEV$D+*^V6(L""0"1@@Y_F=OXC?!
MKQ?XVU#1]4T;21=V#:19H)C=0QC(A4'AG!X^E)IWV70/&WPN\(07D%_=:3>&
M:^FM7#Q+/-("8PPZ[0H!]Z .<U/QA\.=-U*ZM/\ A5_F>1*T6_\ X2&Y&[:2
M,XQQTKEO NFZ9XH^)VDV4MCY>DWNH*ALO.8[8F;A-X(8X'&>#Q7NVJ?\-"_V
ME=_8_P#CT\UO)_Y!WW,G;UYZ8ZUXY\.+&]TOXW:)::DGE:A!JRQW"94XD#X8
M97CKGIQ0!TEOJWPUU/Q4GAZ3X>SV FN_L0OK;6IY9(R7V!Q&PP><<']:@7X-
MS:EX;U:RT73I-5\06GB.33DG23;F!(R3NRP11D Y/<XS2ZQ\=+[2-<U$:;X6
M\*:;>Q32I'J-MI8%RAW$;PQ8C=]1^%48=6O?^% ZFPNI=UYXB N&W',H,&XA
MCWY /X4 <M)\,_%$7BP>&FT:X_MLC(M1@Y7&=VX';M_VLX]ZD\5_"WQ5X)>S
M76-'FM3>/Y<&QTF$C_W049OF]NM>U:39#7?$GAUII)KS46\%PF'3UOVL_P"T
MGW$>4\H()&.=I/..> :G\;6>I:'\.]"#:7H?A"^M/$D$JVUO-YD5K\AV/<,N
M[DD9)&?EQ0!XQXB^#/C/PIHYU35-"FMK%<;Y5ECDV9Z%E5B5'N0*;X9^#GC+
MQAI']J:3H4UU8<[9C)''OQUVAV!;H1P#SQ7N?B?PVEQX?\2:CXA\/P^#YIK2
M1VU[2-9'V?49/O*GD Y97..&!)^M)9Z?9>-?#7A._P!+\&0^*XK"PAA:YC\1
MO8&QE0?.&B! 4Y!;<,D]?2@#Y?NK>6SN);>>-H9XF*21R*0RL#@@CL0:].\.
M_#OPXW@77]2NM6AU;78M+%[#9V;,8[,%T ,CC&9/FQLZ+SG)QCG_ (Q:I'K'
MQ(UJZB2U3=(JM]BN3<1%E10Q60HI;)!YQUSUZUI?"W_D6?B%_P!@7_VLE 'G
M5>GZ+J7PVT33](L[S0+SQ9?W42O>WD=Y+;&VD8_ZJ., !ROJ3@GOCIS_ (9\
M2^$]+T.6UU?P9_;>HLS%+_\ M6:WV CY1Y:C!P>?>O5O!GP<U_PGX:T[Q!H_
MAX:_XHO8Q<6LD]Q"EMIJD95MCN#)+CGD;5)'4CD \@^)/A>#P7XXU71;:9Y[
M>UE C>3&_:5# -CN,X/TKJ[/1?"/P_\ "^D:CXGTJ?Q-K&KQ?:H=-CNVM8;>
MW)PKNZC<6;!('3'IWXGQIHNM>'_$E[:>(8VBUC?YMP'E61BSC=DLI().<]>]
M>CW7A"[^-'A?P[>^&I+>ZUK2[!-,O=)DG2*;;&3LE3<0"I5N>>",<G- '*>-
MH?"&J:/I^K^%XY=)NYIF@NM!FF:<Q$ %9(W(R5/3GG/2G7WP1\<:;H;ZO<^'
M;B*QCC\UV+QET7&23&&WC ZY'%= O@G2OA/?>&KCQ->*_B/^U(9I]-MIDDCM
M;52"3+@'YR>@!Q@=Z[C2_ WB/P_\6KKQQJFIVP\+>;-<R:Q]MC:.YMV!VQ!=
MV3D84+C'''04 >.>&?A/XL\86UM<:/H\E[!<"0QR++&J_(0&R68;>2.N,]LX
MJ>W^#/C6[LM0NX_#MUY%B[I.7*JP*?>VJ2"^/]D&MWQ7J<T?P;\&I:RR6UM+
MJ-_+Y*.0,K(FPGW&XX^M=Y<:I>S?M3V4<EW,Z1PK&JM(<*IM-Q4#T)YQZ\T
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M901^AK\UE4LP5022< #O7Z,^"=+DT/P;H.G3#$UI800/_O+&JG]10!N4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ;-%8W_"9:#_ -!S3?\ P+C_ ,:/^$RT'_H.:;_X%Q_XT ;-%8W_  F6@_\
M0<TW_P "X_\ &C_A,M!_Z#FF_P#@7'_C0!LT5C?\)EH/_0<TW_P+C_QH_P"$
MRT'_ *#FF_\ @7'_ (T ;-%8W_"9:#_T'--_\"X_\:/^$RT'_H.:;_X%Q_XT
M ;-%8W_"9:#_ -!S3?\ P+C_ ,:/^$RT'_H.:;_X%Q_XT ;-%8W_  F6@_\
M0<TW_P "X_\ &C_A,M!_Z#FF_P#@7'_C0!LT5C?\)EH/_0<TW_P+C_QH_P"$
MRT'_ *#FF_\ @7'_ (T ;-%8W_"9:#_T'--_\"X_\:/^$RT'_H.:;_X%Q_XT
M ;-%8W_"9:#_ -!S3?\ P+C_ ,:/^$RT'_H.:;_X%Q_XT ;-%8W_  F6@_\
M0<TW_P "X_\ &C_A,M!_Z#FF_P#@7'_C0!LT5C?\)EH/_0<TW_P+C_QH_P"$
MRT'_ *#FF_\ @7'_ (T ;-%8W_"9:#_T'--_\"X_\:/^$RT'_H.:;_X%Q_XT
M ;-%8W_"9:#_ -!S3?\ P+C_ ,:/^$RT'_H.:;_X%Q_XT ;-%8W_  F6@_\
M0<TW_P "X_\ &C_A,M!_Z#FF_P#@7'_C0!LUX'^T!\ 9_&LY\1>'E4ZP%"W-
MF2%%R ,!E)X#@<<]0!W'/L?_  F6@_\ 0<TW_P "X_\ &C_A,M!_Z#FF_P#@
M7'_C0!^>.L:#J7A^Z:VU.PN=/G4X,=Q$T9_450K]'?\ A,M!_P"@YIO_ (%Q
M_P"-'_"9:#_T'--_\"X_\: /SBHK]'?^$RT'_H.:;_X%Q_XT?\)EH/\ T'--
M_P# N/\ QH _.*BOT=_X3+0?^@YIO_@7'_C1_P )EH/_ $'--_\  N/_ !H
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MFF_^!<?^-'_"9:#_ -!S3?\ P+C_ ,: /SBHK]'?^$RT'_H.:;_X%Q_XT?\
M"9:#_P!!S3?_  +C_P : /SBHK]'?^$RT'_H.:;_ .!<?^-'_"9:#_T'--_\
M"X_\: /SBHK]'?\ A,M!_P"@YIO_ (%Q_P"-'_"9:#_T'--_\"X_\: /SBHK
M]'?^$RT'_H.:;_X%Q_XT?\)EH/\ T'--_P# N/\ QH _.*BOT=_X3+0?^@YI
MO_@7'_C1_P )EH/_ $'--_\  N/_ !H _.*BOT=_X3+0?^@YIO\ X%Q_XT?\
M)EH/_0<TW_P+C_QH _.*K%E876I7"P6=M-=3M]V*%"['Z <U^BO_  F6@_\
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M;_WPW^->D44 >;_\,Y_#3_H3M-_[X;_&C_AG/X:?]"=IO_?#?XUZ110!YO\
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M=IO_ 'PW^->D44 >;_\ #.?PT_Z$[3?^^&_QH_X9S^&G_0G:;_WPW^->D44
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MYO\ \,Y_#3_H3M-_[X;_ !H_X9S^&G_0G:;_ -\-_C7I%% 'F_\ PSG\-/\
MH3M-_P"^&_QH_P"&<_AI_P!"=IO_ 'PW^->D44 >;_\ #.?PT_Z$[3?^^&_Q
MH_X9S^&G_0G:;_WPW^->D44 >;_\,Y_#3_H3M-_[X;_&C_AG/X:?]"=IO_?#
M?XUZ110!YO\ \,Y_#3_H3M-_[X;_ !H_X9S^&G_0G:;_ -\-_C7I%% 'F_\
MPSG\-/\ H3M-_P"^&_QH_P"&<_AI_P!"=IO_ 'PW^->D44 >;_\ #.?PT_Z$
M[3?^^&_QH_X9S^&G_0G:;_WPW^->D44 >;_\,Y_#3_H3M-_[X;_&C_AG/X:?
M]"=IO_?#?XUZ110!YO\ \,Y_#3_H3M-_[X;_ !H_X9S^&G_0G:;_ -\-_C7I
M%% 'F_\ PSG\-/\ H3M-_P"^&_QH_P"&<_AI_P!"=IO_ 'PW^->D44 >;_\
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MN-):2'3CJ]KK>GQ/9VTULC!)UDBDED,31,4);S&5ED!^7!%9OB+X^Z+)\/\
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MR_)UFT^T1IR#N49&#QUH G_X6AXS_P"ALUW_ ,&4W_Q5'_"T/&?_ $-FN_\
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M&96.W'S-QT ZCL ><?\ "T/&?_0V:[_X,IO_ (JC_A:'C/\ Z&S7?_!E-_\
M%5OZ7XF\,_#]]<2VT.T\2ZJ+]X;6;5XA/9I:J2 P4,-SL>^,8Z'J*?\ %ZST
MZ33_  OK=OH]OX>U'5K1YKO3+7Y8E ?;'*J?P!QR!TX[\D@'._\ "T/&?_0V
M:[_X,IO_ (JC_A:'C/\ Z&S7?_!E-_\ %5S%% '3_P#"T/&?_0V:[_X,IO\
MXJC_ (6AXS_Z&S7?_!E-_P#%5S%% '3_ /"T/&?_ $-FN_\ @RF_^*H_X6AX
MS_Z&S7?_  93?_%5S%% '3_\+0\9_P#0V:[_ .#*;_XJC_A:'C/_ *&S7?\
MP93?_%5S%% '3_\ "T/&?_0V:[_X,IO_ (JC_A:'C/\ Z&S7?_!E-_\ %5S%
M% '3_P#"T/&?_0V:[_X,IO\ XJC_ (6AXS_Z&S7?_!E-_P#%5S%% '3_ /"T
M/&?_ $-FN_\ @RF_^*H_X6AXS_Z&S7?_  93?_%5S%% '3_\+0\9_P#0V:[_
M .#*;_XJC_A:'C/_ *&S7?\ P93?_%5S%% '3_\ "T/&?_0V:[_X,IO_ (JC
M_A:'C/\ Z&S7?_!E-_\ %5S%% '3_P#"T/&?_0V:[_X,IO\ XJC_ (6AXS_Z
M&S7?_!E-_P#%5S%% '4+\4O&:L&'BW7,@YYU&8C\MU=;X1_:4\;>&;J,W6H?
MVY9@_/;7P#$CVD W _B1[5Y510!^A?P[^(&E_$GP_'JNF.0,[9K>3'F0OW5O
MZ'N*ZNOC+]E'Q+-I/Q*&EAS]FU2!XVCSQO12ZM]0 X_X%7V;0 4444 %%%%
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MGWEOK=GX?UQ]+OC=W<J7,MQ'*MQ LB><K*R-(."A&2M>X^)/B5X0\&R%=?\
M%6BZ&X",5U+48;<X?=L/SL.&\M\>NQL=#1XE^)?A'P7'9R>(?%6BZ"EXI>V?
M4]0AMQ.HQDH78;@-R]/4>M &9\*/"<7AGP3]C_L*;P\;RXGNYM/NM6EU*<-*
MY8M+.[,3(V=S!690Q(#-]X\MX.;QE\)_#-MX.@\$77BB+3$-MI6K:=?6D%J]
MN"1"+D33++$ZC <QQR@@;ER3Y:]OKGQ0\&>%XTDUGQ;H6DJZ1R*U]J<,(9)
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M*12JZNN[T4X.35#4O@[XWTFY:";PKJLCK_%;6K3I_P!]1@C]:J?\*O\ &?\
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M/EW+'U8DE^>AZ\'/G/\ PJ_QG_T*.N_^"V;_ .)H_P"%7^,_^A1UW_P6S?\
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MO>*[K1O&.@VT5]!;,D6K*)-.OU$8!5Y WR,ISQC/)%0WWC#P=X3^('A35/\
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M=%_\&,/_ ,50!TE%<W_PLKPC_P!#3HO_ (,8?_BJ/^%E>$?^AIT7_P &,/\
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M^'-(C75(XK.RCA2/6GB>\C4+PDIB_=[E&!\O''%6?^%E>$?^AIT7_P &,/\
M\51_PLKPC_T-.B_^#&'_ .*H Z2BN;_X65X1_P"AIT7_ ,&,/_Q5'_"RO"/_
M $-.B_\ @QA_^*H Z2BN;_X65X1_Z&G1?_!C#_\ %4?\+*\(_P#0TZ+_ .#&
M'_XJ@#I**YO_ (65X1_Z&G1?_!C#_P#%4?\ "RO"/_0TZ+_X,8?_ (J@#I**
MYO\ X65X1_Z&G1?_  8P_P#Q5'_"RO"/_0TZ+_X,8?\ XJ@#I**YO_A97A'_
M *&G1?\ P8P__%4?\+*\(_\ 0TZ+_P"#&'_XJ@#I**YO_A97A'_H:=%_\&,/
M_P 51_PLKPC_ -#3HO\ X,8?_BJ .DHKF_\ A97A'_H:=%_\&,/_ ,51_P +
M*\(_]#3HO_@QA_\ BJ .DHKF_P#A97A'_H:=%_\ !C#_ /%4?\+*\(_]#3HO
M_@QA_P#BJ .DHKF_^%E>$?\ H:=%_P#!C#_\51_PLKPC_P!#3HO_ (,8?_BJ
M .DHKF_^%E>$?^AIT7_P8P__ !5'_"RO"/\ T-.B_P#@QA_^*H Z2BN;_P"%
ME>$?^AIT7_P8P_\ Q5'_  LKPC_T-.B_^#&'_P"*H Z2BN;_ .%E>$?^AIT7
M_P &,/\ \51_PLKPC_T-.B_^#&'_ .*H Z2BN;_X65X1_P"AIT7_ ,&,/_Q5
M'_"RO"/_ $-.B_\ @QA_^*H Z2BN;_X65X1_Z&G1?_!C#_\ %4?\+*\(_P#0
MTZ+_ .#&'_XJ@#I**YO_ (65X1_Z&G1?_!C#_P#%4?\ "RO"/_0TZ+_X,8?_
M (J@#I**YO\ X65X1_Z&G1?_  8P_P#Q5'_"RO"/_0TZ+_X,8?\ XJ@#I**Y
MO_A97A'_ *&G1?\ P8P__%4?\+*\(_\ 0TZ+_P"#&'_XJ@#I**YO_A97A'_H
M:=%_\&,/_P 51_PLKPC_ -#3HO\ X,8?_BJ .DHKF_\ A97A'_H:=%_\&,/_
M ,51_P +*\(_]#3HO_@QA_\ BJ .DHKF_P#A97A'_H:=%_\ !C#_ /%4?\+*
M\(_]#3HO_@QA_P#BJ .DHKF_^%E>$?\ H:=%_P#!C#_\51_PLKPC_P!#3HO_
M (,8?_BJ .DHKF_^%E>$?^AIT7_P8P__ !5'_"RO"/\ T-.B_P#@QA_^*H Z
M2BN;_P"%E>$?^AIT7_P8P_\ Q5'_  LKPC_T-.B_^#&'_P"*H Z2BN;_ .%E
M>$?^AIT7_P &,/\ \51_PLKPC_T-.B_^#&'_ .*H Z2BN;_X65X1_P"AIT7_
M ,&,/_Q5'_"RO"/_ $-.B_\ @QA_^*H Z2BN;_X65X1_Z&G1?_!C#_\ %4?\
M+*\(_P#0TZ+_ .#&'_XJ@#I**YO_ (65X1_Z&G1?_!C#_P#%4?\ "RO"/_0T
MZ+_X,8?_ (J@#I**YO\ X65X1_Z&G1?_  8P_P#Q5'_"RO"/_0TZ+_X,8?\
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M#_\ %4?\+*\(_P#0TZ+_ .#&'_XJ@#I**YO_ (65X1_Z&G1?_!C#_P#%4?\
M"RO"/_0TZ+_X,8?_ (J@#I**YO\ X65X1_Z&G1?_  8P_P#Q5'_"RO"/_0TZ
M+_X,8?\ XJ@#I**YO_A97A'_ *&G1?\ P8P__%4?\+*\(_\ 0TZ+_P"#&'_X
MJ@#I**YO_A97A'_H:=%_\&,/_P 51_PLKPC_ -#3HO\ X,8?_BJ .DHKF_\
MA97A'_H:=%_\&,/_ ,51_P +*\(_]#3HO_@QA_\ BJ .DHKF_P#A97A'_H:=
M%_\ !C#_ /%4?\+*\(_]#3HO_@QA_P#BJ .DHKF_^%E>$?\ H:=%_P#!C#_\
M51_PLKPC_P!#3HO_ (,8?_BJ .DHKF_^%E>$?^AIT7_P8P__ !5'_"RO"/\
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M_P"#&'_XJ@#I**YO_A97A'_H:=%_\&,/_P 51_PLKPC_ -#3HO\ X,8?_BJ
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MG_@$G^%=W10!PG_"B?AW_P!"7HG_ (!)_A1_PHGX=_\ 0EZ)_P" 2?X5W=%
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M)_A1_P *)^'?_0EZ)_X!)_A7RE_PTI\1_P#H8_\ R1MO_C='_#2GQ'_Z&/\
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M\*)^'?\ T)>B?^ 2?X4?\*)^'?\ T)>B?^ 2?X5\I?\ #2GQ'_Z&/_R1MO\
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M)$"'H!G3D^#>MM\,[KPZ+JQ^VR^+#KJR>8_E^1_:HO-I.S._RQC&,;N,XYH
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M FOM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#O$G_@GE_P * /8**\?_ .&H/"G_ $#O$G_@GE_PH_X:@\*?] [Q)_X)Y?\
M"@#V"BO'_P#AJ#PI_P! [Q)_X)Y?\*/^&H/"G_0.\2?^">7_  H ]@HKQ_\
MX:@\*?\ 0.\2?^">7_"C_AJ#PI_T#O$G_@GE_P * /8**\?_ .&H/"G_ $#O
M$G_@GE_PH_X:@\*?] [Q)_X)Y?\ "@#V"BO'_P#AJ#PI_P! [Q)_X)Y?\*/^
M&H/"G_0.\2?^">7_  H ]@HKQ_\ X:@\*?\ 0.\2?^">7_"C_AJ#PI_T#O$G
M_@GE_P * /8**\?_ .&H/"G_ $#O$G_@GE_PH_X:@\*?] [Q)_X)Y?\ "@#V
M"BO'_P#AJ#PI_P! [Q)_X)Y?\*/^&H/"G_0.\2?^">7_  H ]@HKQ_\ X:@\
M*?\ 0.\2?^">7_"C_AJ#PI_T#O$G_@GE_P * /8**\?_ .&H/"G_ $#O$G_@
MGE_PH_X:@\*?] [Q)_X)Y?\ "@#V"BO'_P#AJ#PI_P! [Q)_X)Y?\*/^&H/"
MG_0.\2?^">7_  H ]@HKQ_\ X:@\*?\ 0.\2?^">7_"C_AJ#PI_T#O$G_@GE
M_P * /8**\?_ .&H/"G_ $#O$G_@GE_PH_X:@\*?] [Q)_X)Y?\ "@#V"BO'
M_P#AJ#PI_P! [Q)_X)Y?\*/^&H/"G_0.\2?^">7_  H ]@HKQ_\ X:@\*?\
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MT5KO4+ZVF;[9-):LJ8MY'8P?NFPW#'Y\HGR[NT_X:@\*?] [Q)_X)Y?\*/\
MAJ#PI_T#O$G_ ()Y?\* //=3^$>J^)_"7B&./X?^(M-\0?\ ",WVGV]SXB\:
M2ZDIN)X@AAM8WNYD\MBHS)+Y)&V/Y3SMZOXL?"'7/'UUIEE8PP6UM_PB.J:/
M)=7#*8H+B86OE*R [BI\I\E00 /<9U_^&H/"G_0.\2?^">7_  H_X:@\*?\
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MPH ]@HKQ_P#X:@\*?] [Q)_X)Y?\*/\ AJ#PI_T#O$G_ ()Y?\* /8**\?\
M^&H/"G_0.\2?^">7_"C_ (:@\*?] [Q)_P"">7_"@#V"BO'_ /AJ#PI_T#O$
MG_@GE_PH_P"&H/"G_0.\2?\ @GE_PH ]@HKQ_P#X:@\*?] [Q)_X)Y?\*/\
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M==_\%LW_ ,37U?\ \-0>%/\ H'>)/_!/+_A1_P -0>%/^@=XD_\ !/+_ (4
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M[_X+9O\ XFC_ (5?XS_Z%'7?_!;-_P#$U]7_ /#4'A3_ *!WB3_P3R_X4?\
M#4'A3_H'>)/_  3R_P"% 'RA_P *O\9_]"CKO_@MF_\ B:/^%7^,_P#H4==_
M\%LW_P 37U?_ ,-0>%/^@=XD_P#!/+_A1_PU!X4_Z!WB3_P3R_X4 ?*'_"K_
M !G_ -"CKO\ X+9O_B:/^%7^,_\ H4==_P#!;-_\37U?_P -0>%/^@=XD_\
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MH5Q?:I$)K"UBU.!I;N,[L/$H;,B_*W*Y'RGTH ZRBL#_ (3GPW_PE'_",_\
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M+5_J\VB0>'-"L9KC4_$,AT_[9]E,MMI\#*?/N)B1L^5-VQ&/SN57!&['?44
M?+'BKPEK7A3X?ZE\,++0M4U'3]+UC2M1T.^MK.6=);!M2BDDBDD52/.A82;M
MQW-&5<Y^<BU=>#O$5UJS6T^BWYL?#.OZ7INDR?9B?-M#J274DJ%1S$D(M8RW
M0&!\]./IVB@#S3Q!I=[-\?/!>H1VEQ)I]OH>JPS7:Q,8HW>6S**SXP"P1L G
M)VG'0UTUK9^*E\33SW.L:1+X=;/E6$6DRI=KP,;K@W+(W.>D(S[=:Z6B@#Y\
M\1?#W7/%?A_X^:1:V=U;W6LW\;Z:[EK87>VPM0!'*1C!>-DW#@'/H:Y/Q5\-
MT\?6>L6?PX\+ZEX6CN?#UY#K/VS39M(?4KXO ]JDDLR*UQ*"EQFX&\#S&)?Y
M^?J^B@#Y7U[X=6_CVW\0:?\ #WPM?^%K:_\ "VI66L_VAI$VF'4+Z41_9%E>
M=%-S*K"<F<;P-[9<[^>]\.WU]\2/BQX0UU-#UC1[+P[HMY%?/JMA-9_Z9<FW
M @C$BKYH40R$R)NC^[ACD5[710 4444 %%%% !1110 4444 %%%% !7AWQXT
MNVNOB!\/+W5+/Q-+HEJFI"YN?"\6I-/"SQQ",,U@/-4,0?8XYKW&B@#PGX4V
M-UX1N/B3K&@VGB*?PG<1PW^G6GB"&[;4)[](&6X*K=#[4R,([95$F26#[/EQ
M73?#7P?X@\,_!7P]I6F7=II'B5[6.[OKC5M/>Z0W4Q\VY+Q)-"VXR._\8Q[X
MKU"B@#PJ3X8WOB?XY7-WXGFU5TB\*V4!U3P_=W^C6L\XN[HN@\FXR2%9#L:1
MR-P/>L3PY\&=?GN?&NEZ5J4NBZ=#XS34X_\ A)K2ZU5-4B2PM-FZ22YCED19
MEW9\Q@6A"G@%:^D** /(_P!G#0O$F@^#M8@\2^5]HD\0:I-$L>G269*-=RMY
MFV25R5<G>A'1649;[Q]<HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OD_0/!7B>SBFLXM"U!+?Q-XGU;2]4WVI"QV3:B;A;A
M]P'[LP"Z16Z$W"8SFOK"B@#YG\+V.H^ M>\%^(=4T+6O[+MG\2V5Q]ATJXNY
MH'N-1$L#-!"C2['2)B'"E>5R1N&>*N/ GBG7O#NI"/PQJ]K/>:/XV"6]U:,C
MJ]S>1O;QL1E0TBY*C/S8.,CFOLVB@#XY^,T,NL6.MZS-X:U2\T:\TOPK;BSO
MM.DMFNG35I/-MMDZI\^& *MCAU)X8&NG\::/J/CG6?$7B30M!UFVTBZNO#5J
M(+K2I[2>\FM]1$DUQY$BK(%CB=%+L@!"-@[4S7T/XD\+Z9XLL5L=6MOM=JMQ
M#=+'YC)B6*198VRI!X=%..AQ@Y'%;% 'R9H/@&_AN;SPOXAOOB&-2D\5R:HM
MKHVCVC:?<$W?VB&\&H/9X10FS<KW D&QHU!^53]/Z\UW!H>H26%A'JEZMO(8
M;&:80I<.%.V,N58*&/&2"!GI6I10!\RZ7I.FVM[HC?#+PWXQ\$>(7U6">_T6
M:RO[/1(8"X%XLD<H^PD>7NPUOEF<(R$C)IG]@ZHVD0>"1X:U2/Q8GCD:V=5%
MC,UF;?\ M#[2;S[:5\HG[-^Z\LOYF?DVXKZ=HH ^.=5^&/B[7;'4]/L-%U"*
MZNK+QG#&9H7@1S<:A$T*&1@%7SD#;22 021P,UZ9X/OK;Q9\>O#.MZ7X.UW1
M;.T\(W>GW%]JFBSV"QO]HM&CM/WB+DH!(01E#EMC-AL>]44 >:?'S2;W6/ M
MK;Z?:7%]<+K>DRM%;Q-(P1+^!W; !.%52Q/0 $FL_P"(\TWAGXM^"_%5QIVJ
M7NBVVFZCI]Q-I.G3W\D,LK6SQ[H8$>3:PAD&X*0" "1D9];HH ^7_A'X1U2;
MXC>$=7U/PUJ6GQV\WBJZ5M0LV0VK7%_$T6X\JK/&7V\_,-V,BI+?P!?:?\&M
M0M;7PY<P:C)\0O[3$$5DRRF,:TK"X"A<[1"H.\<;!G.*^G** /F+^P=4;2(/
M!7_"-:I'XK3QR-;.JBQF:T-O_:'VDWGVTKY1/V;]UY9?S,_)MQ6UX?\ !,=O
M\'/$]MJVBZ];&;Q;?:HW]D6:M?(5U,RPW:12*?-"JD;[0DA=5PJ/D*?H.B@#
MQSX,WFO:IXJUZYU*)]8TZ.VA@M/$^J>&I=$U6?\ >S,;:=)%0S+&K1D2)%%&
M2[87.['L=%% !1110 4444 %%%% !7D7Q6OFT#XH_#K79]/U>\TRSCU*.XFT
MG2;K4#"TD<03<EO&[ $@X)&.*]=HH ^>_'6B:[\9I_%NJZ!I6I6%G'X2O-$T
MQM4AFTR:_NKAU>0".4+)&BB&-0[HN3(V,@9KG/B%87?Q$T_6[WPQX2UK2K:P
M\ :EH\]M<Z1/9R23R^4;>SAB=%,WE^5+\T89!N 5CNKZGHH ^0?C%;^*=6\/
M_$30H-+\1V$]S8+#8Z7X=\++,NM_Z''F:\OY894.TAD$:M#*HCVKO8H*Z+QM
M;ZIH=QK_ /PCUOXB_MG6(HY+GP[K'A)]6T/7'-FD*AYHD!M]Q1$;SKA%38Q:
M+:VX_3E% 'SIXB\-7T/QDTKPK;:<MOH7BQK3Q#J<4##R[>33PHE7']V1AIZ<
M#!"/ZU27P'J%O\']2AAT"[35)OB'_:AC6S?SG0:TK"XQC.WR5#;^FP9SBO?;
M+PKIMCX@O]<BCF;4[U%BDFGN990B+T2-'8K$I/)$84,>3D\UMT ?+^C^%KZ\
MU+PKI%YX>U)VT?XCZEJ5RT^G3"W6&07TMO<+*4V.F7B^920K%0<$@53\=>!?
M$+>.-=UB"WUZQT.R\;P:I-)HM@D]PT;:5%"+J""6&5;CRYC\VV-V&&*_,G'U
M910!\OV/@,:EXB\*:K;P>,-=M;GQLNIW=UXHTN*U.Z/3IHUN5MXX(3"F]8EW
M2QH6=01G*LWJGPPT>\TKQU\4I9K&:SM;W78;BV>2$HDX^P6RM(A(PPW*P+#N
MI'45Z910 4444 %%%% !1110!B^,K*;4/".N6EN";B>QGBCQUW-&P'ZFOSD;
MK7Z:U\??'[X#W_AW6+O7]!M7N]%N&,LL,"EFM'/+94?P=P>W0]B0#PJBBB@
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M$^\??^"5?_CM'_#4EA_T3[Q]_P""5?\ X[7M=% 'BG_#4EA_T3[Q]_X)5_\
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M_P#CM>UT4 >*?\-26'_1/O'W_@E7_P".T?\ #4EA_P!$^\??^"5?_CM>UT4
M>*?\-26'_1/O'W_@E7_X[1_PU)8?]$^\??\ @E7_ ..U[710!XI_PU)8?]$^
M\??^"5?_ ([1_P -26'_ $3[Q]_X)5_^.U[710!XI_PU)8?]$^\??^"5?_CM
M'_#4EA_T3[Q]_P""5?\ X[7M=% 'BG_#4EA_T3[Q]_X)5_\ CM'_  U)8?\
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M .@9H7_@/-_\>H_X;"\9_P#0,T+_ ,!YO_CU '8_\+2^'O\ T1'Q!_X2=O\
M_%4?\+2^'O\ T1'Q!_X2=O\ _%5QW_#87C/_ *!FA?\ @/-_\>H_X;"\9_\
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MDL/^B?>/O_!*O_QVO:Z* /%/^&I+#_HGWC[_ ,$J_P#QVC_AJ2P_Z)]X^_\
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M+;67<Z#<#C+J.XK@F\#I#\8/A=>0Z$4LM'\-W]LMREJ1'9N?LBQQ[L80E?-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HKR2\\:?%F.\F2W^&^GSVZR,(Y6UV-2Z@\'&WC([5'_PG
M'Q@_Z)EIO_@_C_\ B: /7Z*\@_X3CXP?]$RTW_P?Q_\ Q-'_  G'Q@_Z)EIO
M_@_C_P#B: /7Z*\@_P"$X^,'_1,M-_\ !_'_ /$T?\)Q\8/^B9:;_P"#^/\
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M:;_X/X__ (F@#U^BO(/^$X^,'_1,M-_\'\?_ ,31_P )Q\8/^B9:;_X/X_\
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M_@_C_P#B: /7Z*\@_P"$X^,'_1,M-_\ !_'_ /$T?\)Q\8/^B9:;_P"#^/\
M^)H ]?HKR#_A./C!_P!$RTW_ ,'\?_Q-'_"<?&#_ *)EIO\ X/X__B: /7Z*
M\@_X3CXP?]$RTW_P?Q__ !-'_"<?&#_HF6F_^#^/_P")H ]?K$T/PIIOAZ?4
MKBS2;[1J$YN+F:YN9;B1V[ -(S%4'\*+A5R=H&:\[_X3CXP?]$RTW_P?Q_\
MQ-'_  G'Q@_Z)EIO_@_C_P#B: /7Z*\@_P"$X^,'_1,M-_\ !_'_ /$T?\)Q
M\8/^B9:;_P"#^/\ ^)H ]?HKR#_A./C!_P!$RTW_ ,'\?_Q-'_"<?&#_ *)E
MIO\ X/X__B: /7Z*\@_X3CXP?]$RTW_P?Q__ !-'_"<?&#_HF6F_^#^/_P")
MH ]?HKR#_A./C!_T3+3?_!_'_P#$T?\ "<?&#_HF6F_^#^/_ .)H ]?KY)_:
M ^ >H:9K%WXD\.VDE[IMTYFN;6!2TENY.6(4=4)YXZ<]J]7_ .$X^,'_ $3+
M3?\ P?Q__$T?\)Q\8/\ HF6F_P#@_C_^)H ^***^NM27QUK-T;C4/@CX9OKA
MNLMSJ5M(Y_$H357^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;
M:?\ QNC^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNC^
MQ_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNC^Q_%W_1!?
M"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNC^Q_%W_1!?"/\ X&VG
M_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNC^Q_%W_1!?"/\ X&VG_P ;H ^3
MZ*^L/['\7?\ 1!?"/_@;:?\ QNC^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\
M7?\ 1!?"/_@;:?\ QNC^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"
M/_@;:?\ QNC^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\
MQNC^Q_%W_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNC^Q_%W
M_1!?"/\ X&VG_P ;H ^3Z*^L/['\7?\ 1!?"/_@;:?\ QNG1Z7XPAD5X_@1X
M2C=3D,M]:@C\?+H \)^%_P ']<^)NI1+;026VDJ_^D:C(I$:J#R%/\3>P_'
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M9:;_ .#^/_XF@#U^BO(/^$X^,'_1,M-_\'\?_P 31_PG'Q@_Z)EIO_@_C_\
MB: /7Z*\@_X3CXP?]$RTW_P?Q_\ Q-'_  G'Q@_Z)EIO_@_C_P#B: /7Z*\@
M_P"$X^,'_1,M-_\ !_'_ /$T?\)Q\8/^B9:;_P"#^/\ ^)H ]?HKR#_A./C!
M_P!$RTW_ ,'\?_Q-'_"<?&#_ *)EIO\ X/X__B: /7Z*\@_X3CXP?]$RTW_P
M?Q__ !-'_"<?&#_HF6F_^#^/_P")H ]?HKR#_A./C!_T3+3?_!_'_P#$T?\
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M#\]O#]KNYRAD A=93;NHC#.7$VQ0K!BI!%,_X7IHYT/[4-*U8ZU_:O\ 8?\
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M^(--T34+3PGXEBL=?@D?1[NYBM4CO9DA:7[.!]HW(Y$<@#2!(VV'#D%2>/\
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ME/B/_P!#'_Y(VW_QNC_AI3XC_P#0Q_\ DC;?_&Z\QHH ]._X:4^(_P#T,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2[,D\YB+WL@ECCV$>1'B'YQRV7/%>\44 >(>*/A'XJ^+27?_  ELND^'9(]
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M7B+3$\#?#/PEJ5YH%SI<6I:!:MY]S<2Q[/,:06\1MXNI,8$Q.X?,-OS?1U%
M'G\G@6_D^(_@_P 0":V^Q:1HUYIT\>YO,:25K8J4&W!4>2^<D'D<'G'H%%%
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M-DQ@,Q5N"/,=I #[X>N_IJJ%4 # ' IU !1110 4444 %%%% !1110 4444
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M;_&C_A&?C3_T.?AO_P %3?XUZ_10!Y!_PC/QI_Z'/PW_ ."IO\:/^$9^-/\
MT.?AO_P5-_C7K]% 'D'_  C/QI_Z'/PW_P""IO\ &C_A&?C3_P!#GX;_ /!4
MW^->OT4 >0?\(S\:?^AS\-_^"IO\:/\ A&?C3_T.?AO_ ,%3?XUZ_10!Y!_P
MC/QI_P"AS\-_^"IO\:/^$9^-/_0Y^&__  5-_C7K]% 'D'_",_&G_H<_#?\
MX*F_QH_X1GXT_P#0Y^&__!4W^->OT4 >0?\ ",_&G_H<_#?_ (*F_P :/^$9
M^-/_ $.?AO\ \%3?XUZ_10!Y!_PC/QI_Z'/PW_X*F_QH_P"$9^-/_0Y^&_\
MP5-_C7K]% 'D'_",_&G_ *'/PW_X*F_QH_X1GXT_]#GX;_\ !4W^->OT4 >0
M?\(S\:?^AS\-_P#@J;_&C_A&?C3_ -#GX;_\%3?XUZ_10!Y!_P (S\:?^AS\
M-_\ @J;_ !H_X1GXT_\ 0Y^&_P#P5-_C7K]% 'D'_",_&G_H<_#?_@J;_&C_
M (1GXT_]#GX;_P#!4W^->OT4 >0?\(S\:?\ H<_#?_@J;_&C_A&?C3_T.?AO
M_P %3?XUZ_10!Y!_PC/QI_Z'/PW_ ."IO\:/^$9^-/\ T.?AO_P5-_C7K]%
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MD^B@#ZP_X2KQO_T6'X?_ /?,?_Q='_"5>-_^BP_#_P#[YC_^+KY/HH ^L/\
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MC/QI_P"AS\-_^"IO\:]?HH \@_X1GXT_]#GX;_\ !4W^-'_",_&G_H<_#?\
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MQCT50 /T%6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BO)+S]F'P%J%Y/<S6>H&6:1I'*ZI< ;B<G@
M/QR:C_X95^'W_/GJ7_@UN/\ XN@#U^BO(/\ AE7X??\ /GJ7_@UN/_BZ/^&5
M?A]_SYZE_P"#6X_^+H ]?HKR#_AE7X??\^>I?^#6X_\ BZ/^&5?A]_SYZE_X
M-;C_ .+H ]?HKR#_ (95^'W_ #YZE_X-;C_XNC_AE7X??\^>I?\ @UN/_BZ
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M]_SYZE_X-;C_ .+H ]?HKR#_ (95^'W_ #YZE_X-;C_XNC_AE7X??\^>I?\
M@UN/_BZ /7Z*\@_X95^'W_/GJ7_@UN/_ (NC_AE7X??\^>I?^#6X_P#BZ /7
MZ*\@_P"&5?A]_P ^>I?^#6X_^+H_X95^'W_/GJ7_ (-;C_XN@#U^BO(/^&5?
MA]_SYZE_X-;C_P"+H_X95^'W_/GJ7_@UN/\ XN@#U^BO(/\ AE7X??\ /GJ7
M_@UN/_BZ/^&5?A]_SYZE_P"#6X_^+H ]?HKR#_AE7X??\^>I?^#6X_\ BZ/^
M&5?A]_SYZE_X-;C_ .+H ]?HKR#_ (95^'W_ #YZE_X-;C_XNC_AE7X??\^>
MI?\ @UN/_BZ /7Z*\@_X95^'W_/GJ7_@UN/_ (NC_AE7X??\^>I?^#6X_P#B
MZ /7Z*\@_P"&5?A]_P ^>I?^#6X_^+H_X95^'W_/GJ7_ (-;C_XN@#U^BO(/
M^&5?A]_SYZE_X-;C_P"+H_X95^'W_/GJ7_@UN/\ XN@#U^BO(/\ AE7X??\
M/GJ7_@UN/_BZ/^&5?A]_SYZE_P"#6X_^+H ]?HKR#_AE7X??\^>I?^#6X_\
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M@#U^BO(/^&5?A]_SYZE_X-;C_P"+H_X95^'W_/GJ7_@UN/\ XN@#U^BO(/\
MAE7X??\ /GJ7_@UN/_BZ/^&5?A]_SYZE_P"#6X_^+H ]?HKR#_AE7X??\^>I
M?^#6X_\ BZ/^&5?A]_SYZE_X-;C_ .+H ]?HKR#_ (95^'W_ #YZE_X-;C_X
MNC_AE7X??\^>I?\ @UN/_BZ /7Z*\@_X95^'W_/GJ7_@UN/_ (NC_AE7X??\
M^>I?^#6X_P#BZ /7Z*\@_P"&5?A]_P ^>I?^#6X_^+H_X95^'W_/GJ7_ (-;
MC_XN@#U^BO(/^&5?A]_SYZE_X-;C_P"+H_X95^'W_/GJ7_@UN/\ XN@#U^BO
M(/\ AE7X??\ /GJ7_@UN/_BZ/^&5?A]_SYZE_P"#6X_^+H ]?HKR#_AE7X??
M\^>I?^#6X_\ BZ/^&5?A]_SYZE_X-;C_ .+H ]?HKR#_ (95^'W_ #YZE_X-
M;C_XNC_AE7X??\^>I?\ @UN/_BZ /7Z\S^*GP*T+XH?Z5*S:;K"KM6_MU!W@
M=!(O\8'U!]\<5F?\,J_#[_GSU+_P:W'_ ,71_P ,J_#[_GSU+_P:W'_Q= 'D
M-U^Q[XK6=A;:OH\T/\+S/+&Q^JB-L?G47_#'OC/_ *">A?\ @1-_\9KV/_AE
M7X??\^>I?^#6X_\ BZ/^&5?A]_SYZE_X-;C_ .+H \<_X8]\9_\ 03T+_P "
M)O\ XS1_PQ[XS_Z">A?^!$W_ ,9KV/\ X95^'W_/GJ7_ (-;C_XNC_AE7X??
M\^>I?^#6X_\ BZ /'/\ ACWQG_T$]"_\")O_ (S1_P ,>^,_^@GH7_@1-_\
M&:]C_P"&5?A]_P ^>I?^#6X_^+H_X95^'W_/GJ7_ (-;C_XN@#QS_ACWQG_T
M$]"_\")O_C-'_#'OC/\ Z">A?^!$W_QFO8_^&5?A]_SYZE_X-;C_ .+H_P"&
M5?A]_P ^>I?^#6X_^+H \<_X8]\9_P#03T+_ ,")O_C-'_#'OC/_ *">A?\
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M^&5?A]_SYZE_X-;C_P"+H ]?HKR#_AE7X??\^>I?^#6X_P#BZ/\ AE7X??\
M/GJ7_@UN/_BZ /7Z*\@_X95^'W_/GJ7_ (-;C_XNC_AE7X??\^>I?^#6X_\
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M]_SYZE_X-;C_ .+H_P"&5?A]_P ^>I?^#6X_^+H ]?HKR#_AE7X??\^>I?\
M@UN/_BZ/^&5?A]_SYZE_X-;C_P"+H ]?HKR#_AE7X??\^>I?^#6X_P#BZ/\
MAE7X??\ /GJ7_@UN/_BZ /7Z*\@_X95^'W_/GJ7_ (-;C_XNB@#U^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7@WX??'+2+/2H/$]EJSM,=6CU&U\NQDDLX(3!=HT@E$X\M6C5(V#"6(93)(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %4+'2[*PN+RXM+2"WGO)!-<RPQ*C3N%"!
MG(&6(557)YPH':K]% !1110 4444 %<U?_#KPKJWB2W\17WAC1KSQ!;%3!JU
MQ812746WE=LI7<N,G&#Q72T4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT*G_ )4;O_X[0!Z_17D'_#)/PH_Z%3_RHW?_ ,=H_P"&2?A1_P!"I_Y4;O\
M^.T >OT5Y!_PR3\*/^A4_P#*C=__ !VC_ADGX4?]"I_Y4;O_ ..T >OT5Y!_
MPR3\*/\ H5/_ "HW?_QVC_ADGX4?]"I_Y4;O_P".T >OT5Y!_P ,D_"C_H5/
M_*C=_P#QVC_ADGX4?]"I_P"5&[_^.T >OT5Y!_PR3\*/^A4_\J-W_P#':/\
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MY!_PR3\*/^A4_P#*C=__ !VC_ADGX4?]"I_Y4;O_ ..T >OT5Y!_PR3\*/\
MH5/_ "HW?_QVC_ADGX4?]"I_Y4;O_P".T >OT5Y!_P ,D_"C_H5/_*C=_P#Q
MVC_ADGX4?]"I_P"5&[_^.T >OT5Y!_PR3\*/^A4_\J-W_P#':/\ ADGX4?\
M0J?^5&[_ /CM 'K]%>0?\,D_"C_H5/\ RHW?_P =H_X9)^%'_0J?^5&[_P#C
MM 'K]%>0?\,D_"C_ *%3_P J-W_\=H_X9)^%'_0J?^5&[_\ CM 'K]%>0?\
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M *%3_P J-W_\=H_X9)^%'_0J?^5&[_\ CM 'K]%>0?\ #)/PH_Z%3_RHW?\
M\=H_X9)^%'_0J?\ E1N__CM 'K]%>0?\,D_"C_H5/_*C=_\ QVC_ (9)^%'_
M $*G_E1N_P#X[0!Z_17D'_#)/PH_Z%3_ ,J-W_\ ':/^&2?A1_T*G_E1N_\
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M3\*/^A4_\J-W_P#':/\ ADGX4?\ 0J?^5&[_ /CM 'K]%>0?\,D_"C_H5/\
MRHW?_P =H_X9)^%'_0J?^5&[_P#CM 'K]%>0?\,D_"C_ *%3_P J-W_\=H_X
M9)^%'_0J?^5&[_\ CM 'K]%>0?\ #)/PH_Z%3_RHW?\ \=H_X9)^%'_0J?\
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M?^5&[_\ CM 'K]%>0?\ #)/PH_Z%3_RHW?\ \=H_X9)^%'_0J?\ E1N__CM
M'K]%>0?\,D_"C_H5/_*C=_\ QVB@#U^N$^*7BS5?#]OH&EZ$L$>M^(M373+:
MZNHS)%:#RI)I9F0$;RL<+X7(!8KDXS7=UQGQ,\$W/C'3-.ETR[BL-?T:]34]
M+N+A"\(G560I*H()C=))$;!R ^1R!0!2T;PSXP\+^(;:>?QK/XG\.R1N+^+7
M[>UAN+=@"4D@>U@B4@GADD!XP0PP5:AH?QTTSQ%=:=#%I6L:;9:U'.VA:S?0
MQ+:ZIY:-)F(+(TBYC5I%\Y(]RJ2,T1:%X^\9>(K"3Q+)I?A?0M/$CMI_A_5)
M[R3497C>,":22W@"Q('+! K[G"DD;,'G/#?PC\7*O@?1]<N-(;0O!0D-E?6<
M\K76IL+:2V@,L)B5;?;'*6;:\FYE&,"@#%^$?QH\0ZE:PWFN27VOK_PAVC:H
M+'3;&-KBXO+B6X1RBHJ\MLCZE8T +$JH8UH_$C]H"\TWPUJZP:/K7A/Q!H]]
MH[W-EJ,%K<2RV=U>K$3%Y,DR/N594P#N![ X-8FF_L[^,]'\*"QM-6L(;U?#
MFAZ.XMK^YMA<-9W$LEQ$9XD$D4<J2;!(F6&6RN.M*/\ 9K\4VEUXAOM#TKP1
MX.>__L62STW1UE-M;26-\9V:5E@C,[.N#NVH<X0C"^8P!ZLOQTTBQT_7'UG2
M-8\/:KI)MQ)HE]'#)>3_ &AMEMY @EDCE\V3,:[7X92&VXJKJ'[06D:%HNLW
M6LZ'KFD:CI%Q90W>BSPP2W86[E$5O*OE3/&Z,VX?+(2-C C(P</7/@_XK\<7
MFM^)-5N=*T3Q5(NFKI=G8S27EG"+*Y:Y032O%&S^9([!ML8V+C&XTS7O@]XL
M\;7>LZYJ[:-INM7]UHJ1:?9W<MQ;P6MC>?:7)G:&-GD<O)@>6H&$&>2: .QU
M'XK:CI]M"5^'7BZ[O?L[W5U9VZV!:T0,RJ'E:Z$+NP4L$BDD8#!8+N&>4\/_
M +1<6L^,]6EFL+BS\!6OA>S\1)K4ZPJ$CE$KL\BB4R8VQA0HCW!DDR,%"7?%
MCX0ZWXZ\;2WQTSPYXIT273H[2VL_%%Q.UOI-P&DWW268C>&X<K(O+&)QLVB0
M!CCG_#?[.?B/3_#8\/7M[IJV.H>"+;POJ%[:SR&6UG@\_9-#&T6V5&\X9#,A
M&WOF@#N9/V@-,TW3M8N=;\.^(/#LVGZ-+K\=GJ4,'G7EG'CS'B$<SJ&4L@,<
MA1P77*C-=5X5\:77BF"TN/\ A%M9TNSNBS1SW[6H'EA59)2J3LX#[B I7>"I
MWJG&?+_%GPC\<_$RQU>;Q"^@Z?J:^%[[P_I\>GW<T\,\UT(_,N9F:%#$O[E
M(U63&YCN.!7LEK'?V2Z9:I#;RVR0[+F9IV5T95 78FPAP3G.67&!US@ &O11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'DEW\<M4M;R>!?ACXRG6.1D$L=DA5\'&X?-
MT/6H_P#A?6K?]$J\;?\ @$G_ ,77K]% 'D'_  OK5O\ HE7C;_P"3_XNC_A?
M6K?]$J\;?^ 2?_%UZ_10!Y!_POK5O^B5>-O_  "3_P"+H_X7UJW_ $2KQM_X
M!)_\77K]% 'D'_"^M6_Z)5XV_P# )/\ XNC_ (7UJW_1*O&W_@$G_P 77K]%
M 'D'_"^M6_Z)5XV_\ D_^+H_X7UJW_1*O&W_ (!)_P#%UZ_10!Y!_P +ZU;_
M *)5XV_\ D_^+H_X7UJW_1*O&W_@$G_Q=>OT4 >0?\+ZU;_HE7C;_P  D_\
MBZ/^%]:M_P!$J\;?^ 2?_%UZ_10!Y!_POK5O^B5>-O\ P"3_ .+H_P"%]:M_
MT2KQM_X!)_\ %UZ_10!Y!_POK5O^B5>-O_ )/_BZ/^%]:M_T2KQM_P" 2?\
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M_ )/_BZ]?HH \@_X7UJW_1*O&W_@$G_Q='_"^M6_Z)5XV_\  )/_ (NO7Z*
M/(/^%]:M_P!$J\;?^ 2?_%T?\+ZU;_HE7C;_ , D_P#BZ]?HH \@_P"%]:M_
MT2KQM_X!)_\ %T?\+ZU;_HE7C;_P"3_XNO7Z* /(/^%]:M_T2KQM_P" 2?\
MQ='_  OK5O\ HE7C;_P"3_XNO7Z* /(/^%]:M_T2KQM_X!)_\71_POK5O^B5
M>-O_  "3_P"+KU^B@#R#_A?6K?\ 1*O&W_@$G_Q='_"^M6_Z)5XV_P# )/\
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MO^B5>-O_  "3_P"+H_X7UJW_ $2KQM_X!)_\77K]% 'D'_"^M6_Z)5XV_P#
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M_BZ/^%]:M_T2KQM_X!)_\77K]% 'D'_"^M6_Z)5XV_\  )/_ (NC_A?6K?\
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MG_Q=>OT4 >0?\+ZU;_HE7C;_ , D_P#BZ/\ A?6K?]$J\;?^ 2?_ !=>OT4
M>0?\+ZU;_HE7C;_P"3_XNC_A?6K?]$J\;?\ @$G_ ,77K]% 'D'_  OK5O\
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MI&2-2S!02 3@<9(^M?*NN";X@6/B?Q'IUE//=>+O!7B*^L[=8F,TD/F6D-J
MAYW-%%&VT#JY IWQF^('ASQY;L_AS6;/6XK7X=:^L\UA*)HXW*6G[MG7*B0
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MJP.".GK3/^&C/AI_T..F_P#?;?X4 >D45YO_ ,-&?#3_ *''3?\ OMO\*/\
MAHSX:?\ 0XZ;_P!]M_A0!Z17.>'?!=EX;UKQ)J5M+<//KMXE]<K,RE5=8(X0
M$ 4$#;$IY).2>>PYK_AHSX:?]#CIO_?;?X4?\-&?#3_H<=-_[[;_  H ](HK
MS?\ X:,^&G_0XZ;_ -]M_A1_PT9\-/\ H<=-_P"^V_PH ](HKS?_ (:,^&G_
M $..F_\ ?;?X4?\ #1GPT_Z''3?^^V_PH U=:^'R^(/B-X>\3WVH2/;Z##,;
M#34C"HMS*IC>=WSECY3%%7  W,>21C>M_#.D6>J2ZG!I-E!J4V?,O([=%F?/
M7+@9/XFN,_X:,^&G_0XZ;_WVW^%'_#1GPT_Z''3?^^V_PH [M-+LHXX(5L[=
M8K=_,AC6)0L;<_,HQP>3R/4U7M_#.D6:7D<&E6,,=X<W2QVZ*)SZN /FZGKZ
MUQG_  T9\-/^AQTW_OMO\*/^&C/AI_T..F_]]M_A0!W%KHNGZ?IO]GVMA;6U
MAM*?98856+:>HV 8P<GMWJ#3_"^CZ59K:6.DV-G:"02B&WMTC0.#D-M QD$#
MGK7'?\-&?#3_ *''3?\ OMO\*/\ AHSX:?\ 0XZ;_P!]M_A0!Z!':Q1W$MPD
M4:3RA0\BJ S@9P">^,G'UKYN_:5_MGXW:E:?"OP@/,@^T)/K^J8)M[-5.5B<
M]"V?FVCG*H!_%CU'_AHSX:?]#CIO_?;?X55L_CU\+--A,-IXHTBVBW%S'""@
MW$Y)P%ZD]Z .O\ >"M-^'7@W2?#>D1^78:="(4R!N<]6=L?Q,Q+'W)KHZ\W_
M .&C/AI_T..F_P#?;?X4?\-&?#3_ *''3?\ OMO\* /2**\W_P"&C/AI_P!#
MCIO_ 'VW^%'_  T9\-/^AQTW_OMO\* /2**\W_X:,^&G_0XZ;_WVW^%'_#1G
MPT_Z''3?^^V_PH ](KG/!G@NS\#:;<V.GRW$T-Q?W6H.URRLPDN)GF<#"CY0
MSD#OC&2>M<U_PT9\-/\ H<=-_P"^V_PH_P"&C/AI_P!#CIO_ 'VW^% 'I%%>
M;_\ #1GPT_Z''3?^^V_PH_X:,^&G_0XZ;_WVW^% 'I%%>;_\-&?#3_H<=-_[
M[;_"C_AHSX:?]#CIO_?;?X4 >D45YO\ \-&?#3_H<=-_[[;_  H_X:,^&G_0
MXZ;_ -]M_A0!Z117F_\ PT9\-/\ H<=-_P"^V_PH_P"&C/AI_P!#CIO_ 'VW
M^% 'I%%>;_\ #1GPT_Z''3?^^V_PH_X:,^&G_0XZ;_WVW^% 'I%%>;_\-&?#
M3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO\ \-&?#3_H<=-_[[;_  H_
MX:,^&G_0XZ;_ -]M_A0!Z117F_\ PT9\-/\ H<=-_P"^V_PH_P"&C/AI_P!#
MCIO_ 'VW^% 'I%%>;_\ #1GPT_Z''3?^^V_PH_X:,^&G_0XZ;_WVW^% 'I%%
M>;_\-&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO\ \-&?#3_H<=-_
M[[;_  H_X:,^&G_0XZ;_ -]M_A0!Z117F_\ PT9\-/\ H<=-_P"^V_PH_P"&
MC/AI_P!#CIO_ 'VW^% 'I%%>;_\ #1GPT_Z''3?^^V_PH_X:,^&G_0XZ;_WV
MW^% 'I%%>;_\-&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO\ \-&?
M#3_H<=-_[[;_  H_X:,^&G_0XZ;_ -]M_A0!Z117F_\ PT9\-/\ H<=-_P"^
MV_PH_P"&C/AI_P!#CIO_ 'VW^% 'I%%>;_\ #1GPT_Z''3?^^V_PH_X:,^&G
M_0XZ;_WVW^% 'I%%>;_\-&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45
MYO\ \-&?#3_H<=-_[[;_  H_X:,^&G_0XZ;_ -]M_A0!Z117F_\ PT9\-/\
MH<=-_P"^V_PH_P"&C/AI_P!#CIO_ 'VW^% 'I%%>;_\ #1GPT_Z''3?^^V_P
MH_X:,^&G_0XZ;_WVW^% 'I%%>;_\-&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;
M?X4 >D45YO\ \-&?#3_H<=-_[[;_  H_X:,^&G_0XZ;_ -]M_A0!Z117F_\
MPT9\-/\ H<=-_P"^V_PH_P"&C/AI_P!#CIO_ 'VW^% 'I%%>;_\ #1GPT_Z'
M'3?^^V_PH_X:,^&G_0XZ;_WVW^% 'I%%>;_\-&?#3_H<=-_[[;_"C_AHSX:?
M]#CIO_?;?X4 >D45YO\ \-&?#3_H<=-_[[;_  H_X:,^&G_0XZ;_ -]M_A0!
MTEKX/AC\97/B2XO+J_O6@^RVL-P(O*L8B5,B0[45OG9$9B[.<J " ,5TE>;_
M /#1GPT_Z''3?^^V_P */^&C/AI_T..F_P#?;?X4 >D45YO_ ,-&?#3_ *''
M3?\ OMO\*/\ AHSX:?\ 0XZ;_P!]M_A0!Z117F__  T9\-/^AQTW_OMO\*/^
M&C/AI_T..F_]]M_A0!Z117F__#1GPT_Z''3?^^V_PH_X:,^&G_0XZ;_WVW^%
M 'I%%>;_ /#1GPT_Z''3?^^V_P */^&C/AI_T..F_P#?;?X4 >D45YO_ ,-&
M?#3_ *''3?\ OMO\*/\ AHSX:?\ 0XZ;_P!]M_A0!Z17R;^TM\&;RPUJZ\7:
M1;M<:?='S+V.)<FWD[N1_=;J3V.<]17M7_#1GPT_Z''3?^^V_P *3_AHSX:=
M#XQTW_OMO\* /A*BOK'7-7_9Z\0W#7-[>Z+YS'+-;RRV^X^I$94$UG?9_P!F
MW_G^TW_P8W?_ ,70!\OT5]0?9_V;?^?[3?\ P8W?_P 71]G_ &;?^?[3?_!C
M=_\ Q= 'R_6GX<\-ZGXLU>#3-)M)+V]F.%CC'0=R3T '<GBOH_[/^S:N#]NT
MW_P877_Q==GX<^+7P;\(6K6^BZ[HFFQMC?Y *E\="QQEOQ- '7?"?X?P_#3P
M7::.CK-<Y,UU,HP))6ZGZ  */9179UYO_P -&?#3_H<=-_[[;_"C_AHSX:?]
M#CIO_?;?X4 >D45YO_PT9\-/^AQTW_OMO\*/^&C/AI_T..F_]]M_A0!Z117F
M_P#PT9\-/^AQTW_OMO\ "C_AHSX:?]#CIO\ WVW^% 'I%%>;_P##1GPT_P"A
MQTW_ +[;_"C_ (:,^&G_ $..F_\ ?;?X4 >D45YO_P -&?#3_H<=-_[[;_"C
M_AHSX:?]#CIO_?;?X4 >D45YO_PT9\-/^AQTW_OMO\*/^&C/AI_T..F_]]M_
MA0!Z117F_P#PT9\-/^AQTW_OMO\ "C_AHSX:?]#CIO\ WVW^% 'I%%>;_P##
M1GPT_P"AQTW_ +[;_"C_ (:,^&G_ $..F_\ ?;?X4 >D45YO_P -&?#3_H<=
M-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO_PT9\-/^AQTW_OMO\*/^&C/AI_T
M..F_]]M_A0!Z117F_P#PT9\-/^AQTW_OMO\ "C_AHSX:?]#CIO\ WVW^% 'I
M%%>;_P##1GPT_P"AQTW_ +[;_"C_ (:,^&G_ $..F_\ ?;?X4 >D45YO_P -
M&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO_PT9\-/^AQTW_OMO\*/
M^&C/AI_T..F_]]M_A0!Z117F_P#PT9\-/^AQTW_OMO\ "C_AHSX:?]#CIO\
MWVW^% 'I%%>;_P##1GPT_P"AQTW_ +[;_"C_ (:,^&G_ $..F_\ ?;?X4 >D
M45YO_P -&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO_PT9\-/^AQT
MW_OMO\*/^&C/AI_T..F_]]M_A0!Z117F_P#PT9\-/^AQTW_OMO\ "C_AHSX:
M?]#CIO\ WVW^% 'I%%>;_P##1GPT_P"AQTW_ +[;_"C_ (:,^&G_ $..F_\
M?;?X4 >D45YO_P -&?#3_H<=-_[[;_"C_AHSX:?]#CIO_?;?X4 >D45YO_PT
M9\-/^AQTW_OMO\*/^&C/AI_T..F_]]M_A0!Z117F_P#PT9\-/^AQTW_OMO\
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MR^9G;LQSNSCWK3CD6:-71@R,,JRG((/<4 97_"'Z!_T ]-_\!(_\*/\ A#]
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M% &-_P (?H'_ $ ]-_\  2/_  H_X0_0/^@'IO\ X"1_X5LT4 8W_"'Z!_T
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ML8I)8X$DN)5C5I'8(B DC+,Q"@=22 *OT 8W_"'Z!_T ]-_\!(_\*/\ A#]
M_P"@'IO_ ("1_P"%;-% &-_PA^@?] /3?_ 2/_"C_A#] _Z >F_^ D?^%;-%
M &-_PA^@?] /3?\ P$C_ ,*/^$/T#_H!Z;_X"1_X5LT4 8W_  A^@?\ 0#TW
M_P !(_\ "C_A#] _Z >F_P#@)'_A6S10!C?\(?H'_0#TW_P$C_PH_P"$/T#_
M * >F_\ @)'_ (5LT4 8W_"'Z!_T ]-_\!(_\*/^$/T#_H!Z;_X"1_X5LT4
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M9HH QO\ A#] _P"@'IO_ ("1_P"%'_"'Z!_T ]-_\!(_\*V:* ,;_A#] _Z
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M-_\  2/_  H_X0_0/^@'IO\ X"1_X5LT4 8W_"'Z!_T ]-_\!(_\*/\ A#]
M_P"@'IO_ ("1_P"%;-% &-_PA^@?] /3?_ 2/_"C_A#] _Z >F_^ D?^%;-%
M &-_PA^@?] /3?\ P$C_ ,*/^$/T#_H!Z;_X"1_X5LT4 8W_  A^@?\ 0#TW
M_P !(_\ "C_A#] _Z >F_P#@)'_A6S10!C?\(?H'_0#TW_P$C_PH_P"$/T#_
M * >F_\ @)'_ (5LT4 8W_"'Z!_T ]-_\!(_\*/^$/T#_H!Z;_X"1_X5LT4
M8W_"'Z!_T ]-_P# 2/\ PH_X0_0/^@'IO_@)'_A6S10!C?\ "'Z!_P! /3?_
M  $C_P */^$/T#_H!Z;_ . D?^%;-% &-_PA^@?] /3?_ 2/_"C_ (0_0/\
MH!Z;_P" D?\ A6S10!C?\(?H'_0#TW_P$C_PH_X0_0/^@'IO_@)'_A6S10!C
M?\(?H'_0#TW_ ,!(_P#"C_A#] _Z >F_^ D?^%;-% &-_P (?H'_ $ ]-_\
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M?] /3?\ P$C_ ,*/^$/T#_H!Z;_X"1_X5LT4 8W_  A^@?\ 0#TW_P !(_\
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M1E9;E;99!"LI*#+A-S98,2&;/HU !1110 4444 %%%% !1110 4444 %%%%
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M#.2@#VNBO%/^&1_ ?_/36_\ P9R4?\,C^ _^>FM_^#.2@#VNBO%/^&1_ ?\
MSTUO_P &<E'_  R/X#_YZ:W_ .#.2@#VNBO%/^&1_ ?_ #TUO_P9R4?\,C^
M_P#GIK?_ (,Y* /:Z*\4_P"&1_ ?_/36_P#P9R4?\,C^ _\ GIK?_@SDH ]K
MHKQ3_AD?P'_STUO_ ,&<E'_#(_@/_GIK?_@SDH ]KHKQ3_AD?P'_ ,]-;_\
M!G)1_P ,C^ _^>FM_P#@SDH ]KHKQ3_AD?P'_P ]-;_\&<E'_#(_@/\ YZ:W
M_P"#.2@#VNBO%/\ AD?P'_STUO\ \&<E'_#(_@/_ )Z:W_X,Y* /:Z*\4_X9
M'\!_\]-;_P#!G)1_PR/X#_YZ:W_X,Y* /:Z*\4_X9'\!_P#/36__  9R4?\
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M8_\ !W_03UW_ ,"(?_C-'_#'_@[_ *">N_\ @1#_ /&:P_\ A2_P2_Z')?\
MPI4_^*H_X4O\$O\ H<E_\*5/_BJ -S_AC_P=_P!!/7?_  (A_P#C-'_#'_@[
M_H)Z[_X$0_\ QFL/_A2_P2_Z')?_  I4_P#BJ/\ A2_P2_Z')?\ PI4_^*H
MW/\ AC_P=_T$]=_\"(?_ (S1_P ,?^#O^@GKO_@1#_\ &:P_^%+_  2_Z')?
M_"E3_P"*H_X4O\$O^AR7_P *5/\ XJ@#<_X8_P#!W_03UW_P(A_^,T?\,?\
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M.2C_ (9'\!_\]-;_ /!G)0![717BG_#(_@/_ )Z:W_X,Y*/^&1_ ?_/36_\
MP9R4 >UT5XI_PR/X#_YZ:W_X,Y*/^&1_ ?\ STUO_P &<E 'M=%>*?\ #(_@
M/_GIK?\ X,Y*/^&1_ ?_ #TUO_P9R4 >UT5XI_PR/X#_ .>FM_\ @SDH_P"&
M1_ ?_/36_P#P9R4 >UT5XI_PR/X#_P">FM_^#.2C_AD?P'_STUO_ ,&<E 'M
M=%>*?\,C^ _^>FM_^#.2C_AD?P'_ ,]-;_\ !G)0![717BG_  R/X#_YZ:W_
M .#.2C_AD?P'_P ]-;_\&<E 'M=%>*?\,C^ _P#GIK?_ (,Y*/\ AD?P'_ST
MUO\ \&<E 'M=%>*?\,C^ _\ GIK?_@SDH_X9'\!_\]-;_P#!G)0![717BG_#
M(_@/_GIK?_@SDH_X9'\!_P#/36__  9R4 >UT5XI_P ,C^ _^>FM_P#@SDH_
MX9'\!_\ /36__!G)0![717BG_#(_@/\ YZ:W_P"#.2C_ (9'\!_\]-;_ /!G
M)0![717BG_#(_@/_ )Z:W_X,Y** /:Z**\]^.'BG4/"OPXU!M%;_ (J'4I(M
M)TH9P?M5Q((HV_X!O+GV0F@#T*BOGWPQ?>,E^&GQ \$Z=J5]J7C3PSJ#V=K>
M3W*->W%E*5G@=99LJ9?(D>-7D.-\66/4U-\.M6T6'QQI%MI>N>,_#%[<V]R+
MOPKXY&H7#WYC YMY[N1T\R(G<3;2.K(W(("LH![Y17Q]X<^(GB;2_P!E#7H-
M7U[4)]<N/"<^N:-KDMVWVN52A\Y!(#OWP2,OS9SLEBY)!-=;XUO]7\1:9\7_
M !1#K^K:7>^!P(]%BL;^:&W5X+&&\=IH%<1W'F/+M(E##:   <D@'TI17S'X
MB\0:OXW\-_%7QK!K>K:->>$84;1;:QOIH;>)XM/AO7,T"L$N/,>;81*K?*H
M"G).I\8?B9KFN:;HJ^&+R72K&QU/19=;O+=F5V>YNK<)8JW!!,<OF2=PIC4C
M$AP ?1%%%% '/>-O$FF>%?#\]WJD1N+:3$ M502-<,W C"G[Q(SQZ UQ]]XD
MU#X9^(K-=1+R^#]281QSS-NEL)VYVNQ/*$D^P X^[\T_BN)]>^+7A[3RGFPZ
M58S:N(6X627<(X\^ZM@@_6O,O OB;QY\5+CQ=X>\6Z<4TTV<K*TEJ(A:W"D&
M-0<<\\X;)^7KP<@'TJS!5+$X &2:Y[P=XXTKQY8W%WI$S30P3&!RZ[3D '('
MH0>#7FMOXPU'7O@9H=KIX:;6]8']DQ'G@*S1O(Q[#8O+=BP-6/#-GJ_@/QYI
MQO=+M--TG5K>/32MC,TJB:)?W+N2 <E?D]^IH ZR'XLZ)<ZFEK%#J<MO)/\
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M 0HVLR;:[5?LOPI\&0R:.VJ:SKVM-#;V%EK&M7E^;B[9"5 :XED,<:C?(Y3
M"(S8.!0!ZE17E'[-]YK-Y\.KH:]J\^N:G;ZWJEM-?3Y!D\N]E0;5R=B@+A4'
M"C '2O5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ***\G^$^M:CJ7@KQM/=7US=3V_B'6X(9)IF=HHX[F58T4D\*H
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M34X?$6D6R3:1JINH;F"2]M@Y239%( 0[QLKQKG!^\IS5S_A>=ZMQ'JA\-J/
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MIJ5SIFAW4MAX?C)CS"Q1[OL68CG:>R^G7V^E/CEJ<ND?";Q-<0$K(;7R<KU
MD98S^C&O@6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J2WN);69)H9'AFC.Y)(V*LI'<$=#4=% 'U+^SM\>KS7M
M1A\+^))S<WD@/V*_D^_(0"3'(>YP.&[XP<G%?2-?FMHNI3:+K%CJ%N2L]K.D
M\97KN5@1_*OTG4Y4'VH =1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<#\0
M_A/I_P 3-?\ #4^O_9M2T#1Y)[F30;RS6>"\G>/RXY)-QVD1JTA"E3RP.1MY
M[ZB@#QR3]G72=)\1:G?^#;P?#ZTU+38[2XM?#=E':G[1#-YL%R"F$RNYT9&1
MA(KX/'78L_AQXDUGQ!H6H^,O$NFZQ'H<KW5C;Z/HSZ>&N&B>+S)F>YG+X21\
M*NP9;)W8 'I=% 'B/B+]FJW\0? /2_AP=>>UOM.LOLEOKT5H-ZY1HY/W1?[K
MQNZE=W?(((!&CXL^"%[KUYXG@T_Q*-*T#Q8L4>NV)L?-GDVQ+"YMIO-40F2)
M%1MR2],C:<UZ[10!Y#XJ^!5UK%UXFM=)\1+HOAOQ5'%%K>FK8>9,RI$L#?99
MA(H@+PHJ-N23IE=IJ3XC?LV>!/B':'/ACP]9:H;RTN)=2;18)9Y4AEC=HF;
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MZ1]INK>288G-K.)D6/=]X>9'+M<D\C"CU6B@#S_PS\)[7PIXDN]0L+MELI-
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M^&/?&?\ T$]"_P# B;_XS1_PQ[XS_P"@GH7_ ($3?_&: /"Z*]T_X8]\9_\
M03T+_P ")O\ XS1_PQ[XS_Z">A?^!$W_ ,9H \+HKW3_ (8]\9_]!/0O_ B;
M_P",T?\ #'OC/_H)Z%_X$3?_ !F@#PNBO=/^&/?&?_03T+_P(F_^,T?\,>^,
M_P#H)Z%_X$3?_&: /"Z*]T_X8]\9_P#03T+_ ,")O_C-'_#'OC/_ *">A?\
M@1-_\9H \+HKW3_ACWQG_P!!/0O_  (F_P#C-'_#'OC/_H)Z%_X$3?\ QF@#
MPNBO=/\ ACWQG_T$]"_\")O_ (S1_P ,>^,_^@GH7_@1-_\ &: /"Z*]T_X8
M]\9_]!/0O_ B;_XS1_PQ[XS_ .@GH7_@1-_\9H \+HKW3_ACWQG_ -!/0O\
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M /%/^$S^.'_1.]$_\&Z__%4?\)G\</\ HG>B?^#=?_BJ]KHH \4_X3/XX?\
M1.]$_P#!NO\ \51_PF?QP_Z)WHG_ (-U_P#BJ]KHH \4_P"$S^.'_1.]$_\
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M$_\ !NO_ ,51_P )G\</^B=Z)_X-U_\ BJ]KHH \4_X3/XX?]$[T3_P;K_\
M%4?\)G\</^B=Z)_X-U_^*KVNB@#Q3_A,_CA_T3O1/_!NO_Q5'_"9_'#_ *)W
MHG_@W7_XJO:Z* /%/^$S^.'_ $3O1/\ P;K_ /%4?\)G\</^B=Z)_P"#=?\
MXJO:Z* /%/\ A,_CA_T3O1/_  ;K_P#%4?\ "9_'#_HG>B?^#=?_ (JO:Z*
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M ,&Z_P#Q5'_"9_'#_HG>B?\ @W7_ .*KVNB@#Q3_ (3/XX?]$[T3_P &Z_\
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M#=?_ (JO:Z* /%/^$S^.'_1.]$_\&Z__ !5'_"9_'#_HG>B?^#=?_BJ]KHH
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MJ1F,F@#VWX??M5:!KEOJ5EKT[0^(;74]:LXK;3])O7@G6RN+@+"DH1T>Z-O
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MAC3=.\(R2WD<N@W]Q=S:G=-;26RNT<EO$ML@2:5B@>8DLHW *2P!G>+OVO\
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M^C?'7X.W'QB\/:+ID&JZ?;Q:??K>3Z?X@THZKI>IH(I$$5W:B:'S5#.LJY<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>mrsn-20211231_g2.jpg
<TEXT>
begin 644 mrsn-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UE;&ES<V$@
M2&%A<V4   60 P "    %   $*:0!  "    %   $+J2D0 "     S@U  "2
MD@ "     S@U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M** "BBB@ HHHH **** "BBB@ HHKD?%'Q4\%>#=06P\1Z]#:W9&3 D<DSH,
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MA>U\%IXLEU>)M#<*1=Q(\@^8@ %5!8')P01D'@XQ0!T=%>;?\-!_#'_H9O\
MR0N?_C=;/B/XK^"_"5Q:P>(-9^R27ENMU OV6:3?$Q(#?*AQT/!YH ["BO/[
M#XY_#K5+U+2Q\1>;.X8JGV&X7. 6/)C Z UUGASQ+I/BW0XM7\/W?VNQF9E2
M7RWCR5)!X8 ]0>U &I17)0?%+P=<^#;GQ7!K&[1+680377V68;7)48V%-Q^^
MO(&.:QH?C]\,IYXXD\3H&D8*"]G<(H)..6,8 'N3@4 >C45SWB3Q[X9\(VMC
M=>(=5CM+?4&VVTHC>1). <Y0$ 8(.3@5/XE\8:%X0L;:\\17WV2"ZG6WA<1/
M)OD() ^0'' /)XH VJ*HW6M6%EK%AI5S/LO=1$IM8MC'S/+ 9^0,# (ZD9[5
M>H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ([F1H;665%W,B%@/4@5X3\ O"&@>*_".
MH^*?%&EV>M:MJ6HRF>:_@28+C!^56!"Y+$DCDY'8"O>J\3N_A'XZ\*:[?W'P
MA\5VNEZ;J4IGFL+^,,L#_P"QF.0$<GG"D *"6QF@#3\3>$=-^$WPB\97?@H7
M-M->(9"6G9O)W-L C'10H<X/WNF2<#!\*_A=X*D^$^CRWGA_3]1GU*S6YN+F
MZ@660O(HR%<\H!T 4C&,]22=+P%\*Y=!\(:QIOB[6)]<NM?+/J.Z5C$K,N&V
M!OXCGE\ G"\# KC8?A-\6?"EI/HG@/QY9IH+%C"EZ"LT0;JJGRGV?5&7G+8!
M- '&*O\ 9/PO^,7A>SE>32M'U*!;,.Q.S=<E67)]/+7/OD]ZB\-^()/ 'PW\
M5:.CXDUG0K&_TZ)?O%[A%@E('KE@?^ UZO)\$_[,^"^M>$="OTNM6U9TFN-0
MOMR++()$;) W%1A3@<\D\\UGZQ\#[_5=4^'=T;BP4>'+.VMM3R[DS"$JV(_E
M^8$[_O;>M 'GO@;1!X;F^+^C+R+'0+B'/KB-QFLKPWJ%Q=?"N+1K+X+-K-Q<
M6\L,7B%;(L79F;$@<0Y^4G'^L_AZBO:$^%6M)XD^(]^MUI_D^*M/EMK)=[AH
MW="N9!LP!D]06^E=?\,O"][X,^'&E:!JDL$MW9K()'MF9HSND9Q@L >C#M0!
MX=XKL[CP[\,_A]\,/$FH06,]]=FXU5Y;A52VMQ*S;6?.,#?U!QF/@XQ74?!7
M5]-T/XE^+O!.E:A:WNE2S?VEI4EI,LD>TXWH&4D9 *#'^PU;>K_!S_A-/BSJ
M'B'QXMI?Z&+1;;3K*&YF21,$'+E0N.3(<!C][VJM=? V#P]X\\-^(OAG%::6
MMA.W]H6]U=3MY\38!"$[^=I<=AR* /,+_7K?P]\8/B!=WOP^C\96Z7.^5I80
MZ6*KN)<DQ.%!'<X^[79?!S1KG5/$?B3X@6FD66@:%J>G&WM--LKA)$W?+N.$
MP%(,9R"JG+GBN]\%^ =2\/?$?QEKVHS6<MEKTJ-;QQ,S.H!;(<%0!][L369X
M0^&&M>!?&VO?V#=6)\(ZPC,+*25Q+:R[3@H-I7 )*_>!*XSDJ,@'FGA#P7JG
MCO\ 95?2]"8&]BU9[F.%I @GVC!0D\<YR,X&0,D=:9>7WAE-5T6#X@_#?4/A
M_/IUY&L.L:/"D<,TZD;MS&/#1Y7<"K2''0D$D]MI?P(O'^#4?A/6=3M[;5K3
M4&O[.^L6=UB?@#J%/3(]C@\XQ5&[^$?Q3\9_9-+^(WC6PN-!AE662.R3,KE>
M /\ 5)DD$\L3@\X- $FH:79>//VK;C2_$\:WFFZ)I*7%G:2',4C'RVY7HPS*
M21SG8 <@8J#XZ>%M"\%6OASQ9X3TVUT?5K75HH4%A$(5F4AWP53 )RN,XY!(
M/:NO^(OPHO?$&N6'BGP1K/\ 87B33HUBBD(/E3HIX5\ ]B0<A@P^4@CIBZ1\
M(O&7B#Q98:U\7?%%OJ\6DNLEG96*XC9P<Y<;$ Y SA26'!( P0#S[XI:5K-_
M^T-KFH>&92FI:'IL&JPJJDF3REBRH'KAB<<YQCO71^%?%MIXX_:0\.Z_885;
MKPZ?-BSDPRCS Z'Z,#SW&#WKT6P\!:I:_'K4_&\D]H=-N]-6T2)7;S@X\ODC
M;MQ\A_B].*YOPG\$;GP?\;KCQ1I<]DF@.LIBM0S":(R+]T+MV[0Q./FZ8H W
M?C]JMYI/P8UB33Y&BDG\NW=UZB-W"N/Q7*_0T>%?A%X$_P"%>:?93>'M/O?M
M-DC2WDL*M/(SH"S"7[R\G(VD8[5VGB7P[8>+/#-]H6KHSV=]$8Y-A 9>X9<@
MC<I 89!Y XKQF#X4_&#2--/AO1/B#9#P\ (D>1&6X2(@9"_NV9<<@ 28]QG@
M XJ">:+]F#QOHWVA[BSTG7%M[1W[1^?&<?GEOJQKI/ .LPWUSX>TVZ^ T<,4
M@@B?6Y-/!4# 'GDFW[_>SN[]>]=GJ?P8%I\";GP'X7N83=W$D<\MY>$HLTHD
M1G<A0Q7A  ,' "@D\D^D>'["72O#.F:=<,C36EG%!(T9)4LB!21G'&10!9OG
MGBT^XDLXC-<+$S11 @;W .%R>!D\<\5\\>';WXB? WP+#?\ B/1-(ET6;46D
MU&))V:_5I/EWE@QB/W5QC/8'')'T-J%I_:&F75GY\UM]HA>+SK=RDD>Y2-RL
M.0PSD'L:\;N?A5\1->T6V\(>*O%6G7WAF&[\Z6_Q*^HW,8)94;?E1R>NXE>.
M6 P0";XK:J_CO[7X0T&<_P!F6&G-JVMW41Z*(R]O;\]W8*Q'!V@>XK8_9W_Y
M(=HO^_<?^CWJ?Q1\#O!/B!-1O!HD8U>X@98KAKN=560)M0E5?&!A>W;H:F^#
MWPS3X;>%6@NTMVUJ[/\ I]S;32/',%=S'@/C&%?'"C\>M 'E?Q[T,^)?C?HF
MDH,R7&A3>6,?QJ+AE_\ 'E%87C_Q$WQ(\(Z-ME,HT/PN=2NV4Y!N6E2!@?<;
M2V/>O<-<\ :GJGQV\.^-(I[0:;I=D\$T3NXF9RLP!4!=I&9%ZL.A_'CM ^ V
MI:)X<\>:>MUIQDU]?)TW:S[88@[,H?Y,@\KTW8V]Z ./GME\2Z;\'/".JRN-
M%O(3/<1*VT3,I( )]<97(Y&\XKT'XS_#7P=;?"G5-0T_0M/TJ\TV-9K>YLK=
M87W!@-K%0-P.<<YZYZU8U+X*OK?PL\-Z'=:FNG>(/#Z*;74K/+*C@Y(!.UL'
M .1@@@'M@X4WPC^)_C%K;3/B5XXM)]!A=9)(-.7]Y,01\I_=(#QGYF+8.#@T
M <=\2[#4/B&OPMM);@+J.K:.29I1D/*44Y/^\1R>V<\TE[XWG\8:M\*H-8W)
MKVC^(19:E%)P_F+-  Y'JV#G_:#5['XD^'%YJ/Q$\%:QHS65MI?AQ6C>W=W#
M[, *$ 4@X [D5@>+_@C=:K\:-'\:^'Y[*W@BO+>ZU&"=F5G:*126C"J02RKR
M"1\PSGDT :?QT\,Z"_PO\1ZT^B:<VJ^3&?MYM(S/D.BC]YC=]WCKTXKEM9\-
M:%8_LI#5;+1=.M]1FT*U,MY%:(DTA8Q%MS@;CD\G)YKU3XC^&KSQA\.]6T'3
M)((KJ]C5(WN&*H"'5N2 3T'H:Q=6\!:I?_ 6/P1#/:+J2Z;;VAE9V\G?'LR<
M[=V/E./E_"@#QV3XH>)V^!X\/'X;:L-._L46G]L9E\GR_*V^=_J<;<<_>Q[U
M[3\%?^2+^&O^O3_V=JDD\&:@_P #QX-$UM_:/]BC3_-W-Y/F"+9G.W.W/?&?
M:M+X>^';OPG\/M(T+49(9;JQ@\N1X&)0G<3P2 >_H* /+M+T33_'7[3GBIO%
M=K'J,6B6D45E:7*AXE4@<E#PW+.<'(R^>PQZ+I?PL\*:'XY;Q5HVG_V?>FW\
M@06K>5;CL6\M<#)& 1]W@'&[FN<\>_"O6M0\9)XU^'6O)H?B+R1!<"=<PW2X
M"@M\K<A0!@JP.U/NE<EO@'X;>+[#QO+XO^(?BK^T]4\DVT5O8NRP&/'&X;4!
M&2QV!<;OFR3T ,_]GY2EYX\5N"-?E!_-JY/3O^0A\?/^N$O\IZZ75/A-X^T#
MQMJ^L_"OQ59:;:ZS*;BYM;Y,A)"=Q 'ENI&2Q!PI ..>ITO#/P@U+0_ASXML
M+_58=0\2^*()!=7;EA$'9&"C.-Q 9V); /S=.* /)OA9XA;X;Z#/J+N(X];\
M-7-Y;ACC?=P7$J(N/=2#GTJS\'="?0/C5>Z>P;S&\,I,P;KOE@@D8?\ ?3$5
MV.N_ +5=:^'?@O06O-.CO-#DE6\E$DFUXI9-S;#LR3P, @#KS7:67P[U"T^/
M-_XU\VR_LJZTT6BP*6\T,%C'*[=NW">OIQ0!C?LR_P#)'4_Z_P"?_P!EKSC0
M/^3=?B=_V%V_]#BKJXO@_P#$SP==:C9?#/QE8V>A7DIE6"\!$D9/&!^Z< @8
M&Y2I.!P,"NAM?@W<Z3\"M5\%Z=J$-SJVJ-Y\]Y<;DC:4LA/0,P 5 .^2,X&<
M  [#X8?\DG\+?]@FV_\ 1:UYU\==7L-3\8>#_!.HZA;65A<78U#5)+F41QK"
MF0H9B0/FQ(,'N%JMI?@3X]Z-I-KIFF^-?#\-G9PK#!'Y0;8BC &3;$G@=2:U
M_P#A2C^*OB+J_B#XFBSU2TF@C@L+:UNID,84 %FVA,$XS@$C+M[4 9OP*U/3
MK+Q!XO\ A_#>VFI:=;W+7>G/%*LT<UN_#+D9! !CR.>6:J?Q#\(^&[+XY?#Z
MPLO#^E6]G=O+]IMHK*-(YL8QO4+AOQKH(O@FGA7XG:!XC^'*6FFV%L&BU.TN
M;J9C*C<$ID/D[6/!(&57W-;WC#P'J?B#XI>$?$EE/:)9Z(TAN8Y782/NQC8
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M_.D @#/*=TGR<,!*",;AD4 >-^(YM%\?3?$#Q7<:]I]K?6DT<>@PRW:1RO%
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MH.Y3@].HKFE^$OC:7X)ZEX"O]3TFY*W,;:9=&:4;8A)O9)!Y>5QCC&[[Q'
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MN3'*]U<;@85.[;Y;*R@%5#8P  ?0M9OB#7+;PWH<^JWR2R00% RP@%CN<(,
MD#JP[UY##I&GVG@^7Q%#:1#68O&;+%?%?WT:'5/+:-7ZA"K,"@.T[FXY-5/%
M)\/GPWKW_"0?9_\ A-1KC;-X_P!+\G[4OE;,_-]G\C;T^3KGYLT >VZQK%GH
M6EO?ZE(8X$>./*J6)=W5$4 >K,H]!GD@<U'IVNVVIZQJ^FP)*LVDS1PSLX 5
MF>))1MP<D;7 Y YS]:YCXQ6=E=_#B9M2MK>>&WOK*8FXC5EB4748=^>@\MG!
M/]TMG@FN,UC0="OX/BIK"6=K<2V%K'+IER@#"UV:;$Z/ 1PAR%.Y<9"KV H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4S
MR8C.)S&GFA2@DVC<%SG&?3('%/HH **** "BBB@ HHHH **** "BBB@#F!X(
MBDOH)+_7-7U"SMKS[;!I]W-&\4<H8NAW[!*P5CE59V PO'RC&EI>@0Z;JVHZ
MF]U<WMYJ#*'EN=F8XTW;(D"*H"*68C.6.XY)K5HH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***CBN()VE6":.5H7\N0(P.QL [3CH<$''N* )*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;'(M[6&1%CWQ,,'>P4L_P JX;IN^]5?7HH=%\8:MX4T>&.V\.W6L:#%<6D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M=XA_Y%G5/^O.7_T UHUG>(?^19U3_KSE_P#0#0!HT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9WB'_D6=4_Z\Y?_0#6C6=XA_Y%G5/^O.7_ - - &C1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 445QNJ^.O[+\8):21P)H=NZ6FH7\C[?(NI5+Q+DG
M4-D=9X^@#4 =E16)>>-?"VG);OJ'B32+5+I/,@::^C02KG&Y26Y&>,BKRZSI
MCWPLDU&T:[8!A;B=3(01D';G/(Y^E %VBBB@ HKG_%_BR/PGI\$YLY;Z::0@
M6\/WA$BEY9.AX2-6..YVKP6%5M;^(_AC0M2T_3KF_-Q?:B$:VM;.)IY'1NCX
M0'"^YZ]LT =37*^*O&IT:P7_ (1[3)_$>HRW!M([:Q(98I0,D3/TC '7//\
M.J:6WC7Q'K>JVFN16NB>&F2:VA6TN"U[/GA9A(IQ'QR!C(Z$=ZW?"WA+1?!F
MCC3?#UDMK!NWN<Y>5\8+.QY8\=30!BQ^"KG6?%ECXG\3:G>&2UCBDMM%AFQ:
MV<^S#G(P93DG!('!QTP!V,<:11JD2*B*,!5& /PIU% !1110 4444 %%%% !
M4<5O! TK00QQ-,_F2%% WM@#<<=3@ 9]A4E% !1110 5G>(?^19U3_KSE_\
M0#6C6=XA_P"19U3_ *\Y?_0#0!HT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%4M2UG3-&2%]6O[:R6>588C<2A/,<]%&>IKG-8\;/>0ZEI_P]6SU[7[%XXYK
M=IPD5MO)&]VZ,%P<JIW?2ETWP);76H:9XA\91V^J^)K2W$9N55A#&P8MF.,D
M@$9 W8R<9XH SY=<\:>)(]?M]-\/W6A6D%M*EA>321BZN+A2-NR-_D"M@@,Q
MQR#FN5TWP(K^!FT/Q7X+\4Z]<W$K7=Q=W=[8LRW+QA'>,_:@0/0'/OFO::*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLJ\BFM3;11+=,TMLT?ER( )<".7MQ@T >RT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G>(?^
M19U3_KSE_P#0#6C6=XA_Y%G5/^O.7_T T :-%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !144UW;V\L$5Q/%%)</Y<*.X4RMM+;5!ZG:K' [
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M&TGL !WKU&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX#'_  FOQ*U_QW+\]A9DZ/HV>AC0YEE'^\W0^F17J% !1110!C>+_#=MXO\
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M54MA5&25&23Q6AXGL;2YT"_GN+6&66*TE,<CQAF0[2>">G- &Q1110 4444
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M;V\*%Y996"JB@9))/  '>N-D^)^GZGH=U?>!;&Z\62VUTMJT-DIC4,P)W%W
M&P8P6&<9';F@#MZ9--';P233NL<4:EW=C@* ,DDUQ5\WQ)UC2M-ETE-$\.W$
ML;-?0WC/=R0MN^4(R@*WR\GT/ S61XMTCQ9K/C;3]"C\4Q/I&H1"74M+_LU
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M'G("AY&>O0C-8&G_ !>M+GXHRZ.-0@N+.ZD>RL[2)"9$FCQB1FV\+*QD49.
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MO#M^]E:KHFNZAK5MXRT75]/AG$NMWCQWUN][#'YRQM*49'1R",8&>@R />:
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MY9B  !V      '2@#B?C1\.9_'7AV*\TJ=XM6TF.62UC08^T[@-T1888;@I
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MNV7PYKXX624XM+T XWQ2'CG^Z3QTZ\#T>L_6M!TKQ%I[6.NZ?;W]JW6*XC#
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M7IM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(7/ &TA< '!QC)Z_X6^$&\/7&MZD$U2*#4VA6%-7G\VZ=8PV9).?E+&0@+U
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MQ.B_%SPGXAM6GT>35KP1D+,MOHEY,86(SL8I$P##ZUTFBZ_8>((;F336N/\
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ME0WLS''U%>F5YGX,/_"3?&;Q=XG/S6NE*F@V3=1E#OG_ /'R/SKTR@ HHHH
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M!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %8GB_PK8>-/#%UHNJ B.<9CE3[\$@Y613V(/]1WK;HH \^^'/
MBS4&O+KP5XSD \3:0O\ K3P-0M_X)TSU..&]_P 0/0:XSXA^"9O$MK:ZKH$Z
MV/B?2&,VFWF.">\3^J-T/I^8,W@#QU%XSTN9+JW.G:WI[^1J>FR</;RCN/5#
MU!_PH ZVBBB@ HHHH ***K:EJ%KI&E7>I:A+Y-I9PO//)M+;$12S' !)P >
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MI=I>Y-_.AO+UF^\9I3O;/N,A?^ UV-%% !1110 4444 %%%% !1110 4444
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M9ZE;HXD6*\MUF16 (# ,",X)&?<UFVW@'P?9W45U9^$]#@N(7$D4L6FPJ\;
MY#*0N001D$5T%% !1110 4444 %%%% !1110 5S]SX!\'WEU+=7GA/0Y[B9S
M)+++IL+/(Q.2S$KDDDY)-=!10!RVI_#/P9JNAMI,WAS3X+0N956TMU@:.0@#
M>I0 AL <]\#.:Y'S_&?PH.+O[5XQ\(H?]<!NU#3T_P!H?\M5'KU^@&*]7HH
MRO#OB;1_%FCQ:IX?OXKVTD'WHSRI_NLIY4^QP:U:\^\0?"R(ZO)XA\!ZB_A?
M7WYD>W7-M=XYVS1=#D]QSWP35"/XHZSX4(MOBEX:N-/51@:QI:-<V<GN<9:/
MOP<GB@#U"BO*K;XL6>MZCJDNE^._"6EZ;;7"16BZC:NTLZ>3$[2<W,7&]W7&
MW^"J-K\8]4NM<OM%\-P6OCB\\F$VL^D64EI;PNQD#B=Y)9 % 6,A@0#N([4
M>B>,?&>D>!]#.HZS*<L=EO;1#=+<R'HB+W)_(=ZY7PAX0U77]?C\<_$6,#4@
M,Z5I&<QZ7&>A([RGN>WUP%L^%/AY=C7$\6?$"]36/$FS$*(N+;3E_N0J>_\
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M-4>?K7_/A8?^!S__ !J@#1HK.\_6O^?"P_\  Y__ (U1Y^M?\^%A_P"!S_\
MQJ@#1HK.\_6O^?"P_P# Y_\ XU4%FNMVL#1M:6,I:623<;UQ@,[,!_JNV<?A
M0!L45G>?K7_/A8?^!S__ !JCS]:_Y\+#_P #G_\ C5 &C16=Y^M?\^%A_P"!
MS_\ QJCS]:_Y\+#_ ,#G_P#C5 &C16.BZVNHS7)M+$K)%'&(_MKX4J7.?]5W
MWC\JG\_6O^?"P_\  Y__ (U0!HT5G>?K7_/A8?\ @<__ ,:H\_6O^?"P_P#
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M,166.3<+USD*ZL1_JN^,?C0!L45G>?K7_/A8?^!S_P#QJCS]:_Y\+#_P.?\
M^-4 :-%9WGZU_P ^%A_X'/\ _&J//UK_ )\+#_P.?_XU0!Q5UX#D3Q-K-ZG@
MOPEK,%]=I<P3:C,8Y8@+>*,IM^RR #=&S<-_'TSFMOPMH6I6'B'4M1U#3-)T
MJ&XLK6T@M=,N6F4>4]PS,<PQ@9\\   _=-:=\NMWFG7-LEI8Q--$T8D%ZY*$
M@C/^J[9J?S]:_P"?"P_\#G_^-4 :-%9WGZU_SX6'_@<__P :H\_6O^?"P_\
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M\+#_ ,#G_P#C5'GZU_SX6'_@<_\ \:H T:*SO/UK_GPL/_ Y_P#XU1Y^M?\
M/A8?^!S_ /QJ@#1HK'MUUN">ZD:TL7%Q*) IO7^0;%7'^J_V<_C4_GZU_P ^
M%A_X'/\ _&J -&BL[S]:_P"?"P_\#G_^-4>?K7_/A8?^!S__ !J@#1HK.\_6
MO^?"P_\  Y__ (U4#KK;:C#<BTL0L<4D9C^VOABQ0Y_U7;8?SH V**SO/UK_
M )\+#_P.?_XU1Y^M?\^%A_X'/_\ &J -&BL[S]:_Y\+#_P #G_\ C5'GZU_S
MX6'_ ('/_P#&J -&BL>\76[J!8UM+&(K+')N%ZYR%=6(_P!5WQC\:G\_6O\
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MSIK,4GWH?EDW,?WOR[C@\A@<#I0!Z'1110 4$X&3P**\L\9:]#X]AU?PGX=
MGU?1;^*2\T>ZF\@:G;H0717!QL;..>X&X &@#U,$,H*G(/(([T5XK\+9[_0?
MB+>>'+39!I-RD\[Z$+H7+Z&Z%-H:125 DWM\@)P1ZYKVJ@ HHHH *0,&SM(.
M#@X/>N-\7^+["'5I/!'V]]*UG6=-E.G7K\1K*P9$&X'(<$9 QSC@YXKR?2+7
M5_ ?CC0VL].A\/7MP;:SO=$34!=?VR&D*27*(I8IM W[FP>&ST.0#Z+HHHH
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M+:AL/;2H3\PX(R2=K#()KOK*QM=-LHK2PMX[:VB&(XHE"JH]@* )E&U I);
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MMM"1D/(%)48[\]N]:E% 'SZGC+4-8\,Z9>(]]JS1ZG&--\2W'D1"&^9%Q;O
M@#+"Q8QL3_>SV4UZ+;_#[2?$GC.R\?:Q:74=V]E 5TJ[ VV\R[B'8=W4-@=@
M<GN,:2_#/PFGBC^WX]+"7OGBY*K,XA:<=)3%G87&<[L9SSUYKJZ "BBB@ KY
MVUCXBZQ?P7<.NSP:M93/<PZWX8CL_)N=*MXR?WZ2=6VJ%;<>,],=OHFL+Q-X
M/TWQ9;QV^IR7<< ?,T=K<-"+E<8,<NWED(/W: .,/@?_ (63H>B)XUDNO-T&
MZ=&FC^1-6A:,;9 >H612A;'((=?>O3+>WAM+6*WM8DA@A0)''&H544#   Z
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M%R/ELV\M58JO]\A1D]N@KM:** "H;N66&QGEMXO.E2-F2,'&]@,@?B>*FHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@8]*S-!^),NL>(/#TVHSZAH\%WHDU[<Z=<Z:B1L8S\TWF%S(J\$J "&4@DT
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M(AXVR.PR0>HQ@]_10!XM!\+?'VF>$]'L;#7=*O&M;JX>YT?49+A].:"1 L<
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M$X5>FT>PQD^T44 >3Z9\,O$S^&?'MKK^HZ9)J/BG,D<MJ'$43F,C:01D*"0
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M26;>Z+)"A4+,,# .X]-WK[5T>F6?Q/BM+BZU75/#L^H3W,(2RCAE6TMK=?\
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M=CR6=G'"S+G."5 R,]JAU#P3X5U:^DO=5\,Z/>W<N/,N+FPBDD?  &6923@
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M2L?LT=Q]MM_(DD$22^:NUW+;0H.<$EOEQUSQ6;?>-?"NEZA)8ZEXET>SO(R
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M5XFCO;&]URY73H/LT;'R(K.8 HQ7<"\D;-N!SM8#H3G$CUS5!>>$_%%QJ_\
M;5Y<>'=0U-++RHU2&3R8G\N/RU#;,_)\VYOEZYR* /;**\5?QOXOL?".IW\E
MU<$MX;.J07%\;#<LP*8:&*!V)@8.>9 2-H&XDUKZSXF\0>&KKQ%I;ZS)?&"'
M36AO[F"%6L_M4[PR/A$52J!0PW X(^8L* /38[RVFNIK:&XBDN+?:9HE<%H]
MPRNX=1D XSUJ:O'O-UK2_%/BRUTO76OK]KS3(&G=K6*\E0H[-''N40&;;G 9
M "H/0_-7H'@G59M6\.EKRXN9[NUN9K6X-W;QPRJZ2$;7$9,98#&60[6Z@#H
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MDC(X)S5JUT72[&*UCLM-L[:.S#"V2&!4$ ;[VP ?+GOCK5VB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
5HH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543952760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Mersana Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3562403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">840 Memorial Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-0020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRSN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 799,836,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,389,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant&#8217;s fiscal year ended December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001442836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543951096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLineItems', window );"><strong>Auditor [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540952744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177,947<span></span>
</td>
<td class="nump">$ 255,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,951<span></span>
</td>
<td class="nump">3,486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">188,898<span></span>
</td>
<td class="nump">258,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">12,889<span></span>
</td>
<td class="nump">10,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">2,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">206,111<span></span>
</td>
<td class="nump">273,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,321<span></span>
</td>
<td class="nump">8,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">28,716<span></span>
</td>
<td class="nump">16,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">47,523<span></span>
</td>
<td class="nump">30,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">11,247<span></span>
</td>
<td class="nump">10,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">24,626<span></span>
</td>
<td class="nump">4,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">84,370<span></span>
</td>
<td class="nump">45,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note&#160;13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 175,000,000 shares authorized; 73,709,056 and 68,841,288&#160;shares issued and outstanding at December&#160;31, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">572,213<span></span>
</td>
<td class="nump">508,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(450,479)<span></span>
</td>
<td class="num">(280,419)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">121,741<span></span>
</td>
<td class="nump">228,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 206,111<span></span>
</td>
<td class="nump">$ 273,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543872088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">175,000,000<span></span>
</td>
<td class="nump">175,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,709,056<span></span>
</td>
<td class="nump">68,841,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">73,709,056<span></span>
</td>
<td class="nump">68,841,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543778696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 42,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">132,013<span></span>
</td>
<td class="nump">67,036<span></span>
</td>
<td class="nump">55,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,888<span></span>
</td>
<td class="nump">21,902<span></span>
</td>
<td class="nump">17,283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">168,901<span></span>
</td>
<td class="nump">88,938<span></span>
</td>
<td class="nump">72,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
<td class="num">(234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(1,202)<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(170,060)<span></span>
</td>
<td class="num">(88,045)<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(170,060)<span></span>
</td>
<td class="num">(88,070)<span></span>
</td>
<td class="num">(28,175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(170,060)<span></span>
</td>
<td class="num">(88,045)<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (170,060)<span></span>
</td>
<td class="num">$ (88,045)<span></span>
</td>
<td class="num">$ (28,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders &#8212; basic (in dollars per share)</a></td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders &#8212; diluted (in dollars per share)</a></td>
<td class="num">$ (2.41)<span></span>
</td>
<td class="num">$ (1.43)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; basic (in shares)</a></td>
<td class="nump">70,580,949<span></span>
</td>
<td class="nump">61,485,205<span></span>
</td>
<td class="nump">43,492,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders &#8212; diluted (in shares)</a></td>
<td class="nump">70,580,949<span></span>
</td>
<td class="nump">61,485,205<span></span>
</td>
<td class="nump">43,492,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537421336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At market equity offering program (2018 ATM)</div></th>
<th class="th"><div>Public Stock Offering</div></th>
<th class="th"><div>At Market Equity Offering Program (2020 ATM)</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>At market equity offering program (2018 ATM)</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Public Stock Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Public Stock Offering</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>At Market Equity Offering Program (2020 ATM)</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,234,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2018</a></td>
<td class="nump">$ 8,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (164,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised', window );">Exercise of stock options and warrants</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares', window );">Retirement of common stock in exchange for common stock warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,575,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue', window );">Retirement of common stock in exchange for common stock warrant</a></td>
<td class="num">(8,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,986)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrant in exchange for retirement of common stock</a></td>
<td class="nump">8,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,208)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,388,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2019</a></td>
<td class="nump">78,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(192,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,599<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,977<span></span>
</td>
<td class="nump">$ 163,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised', window );">Exercise of common stock warrant in exchange for common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,045)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,841,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">228,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">508,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(280,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">421,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">18,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock units, net of employee tax obligation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Vesting of restricted stock units, net of employee tax obligation</a></td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(170,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(170,060)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,709,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 121,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (450,479)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period and exercise of common stock warrant in exchange for common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock that have been retired in exchange for common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been retired in exchange for common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543929352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">421,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,837<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">421,381<span></span>
</td>
<td class="nump">697,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,837<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember', window );">At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction', window );">Issuance costs</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discounts and commissions deducted from cash proceeds received on stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537098856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (170,060)<span></span>
</td>
<td class="num">$ (88,045)<span></span>
</td>
<td class="num">$ (28,208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and discounts on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">18,409<span></span>
</td>
<td class="nump">7,172<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,734)<span></span>
</td>
<td class="num">(1,950)<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">483<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="num">(3,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">12,570<span></span>
</td>
<td class="nump">7,280<span></span>
</td>
<td class="num">(3,569)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncreaseDecreaseInOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(1,281)<span></span>
</td>
<td class="num">(1,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(828)<span></span>
</td>
<td class="num">(41,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(139,988)<span></span>
</td>
<td class="num">(74,696)<span></span>
</td>
<td class="num">(67,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(53,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(648)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(605)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(648)<span></span>
</td>
<td class="nump">37,027<span></span>
</td>
<td class="num">(27,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">1,837<span></span>
</td>
<td class="nump">3,138<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from purchases of common stock under ESPP</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee tax obligations related to vesting of restricted stock units</a></td>
<td class="num">(259)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromDebtNetIssuanceCosts', window );">Proceeds from issuance of debt, net of issuance costs</a></td>
<td class="nump">24,042<span></span>
</td>
<td class="num">(197)<span></span>
</td>
<td class="nump">4,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="num">(5,486)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance lease obligations</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">63,646<span></span>
</td>
<td class="nump">230,412<span></span>
</td>
<td class="nump">97,704<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(76,990)<span></span>
</td>
<td class="nump">192,743<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">255,415<span></span>
</td>
<td class="nump">62,672<span></span>
</td>
<td class="nump">60,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">178,425<span></span>
</td>
<td class="nump">255,415<span></span>
</td>
<td class="nump">62,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant', window );">Fair value of common stock retired in exchange for issuance of common stock warrant</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Debt financing costs in accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">9,980<span></span>
</td>
<td class="nump">4,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="nump">609<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">163,990<span></span>
</td>
<td class="nump">92,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgramMember', window );">At Market Equity Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">$ 43,087<span></span>
</td>
<td class="nump">$ 63,036<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of common stock retired in exchange for issuance of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromDebtNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) during the period from borrowings in aggregate debt. Includes proceeds from short-term and long-term debt and delayed cash payments of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromDebtNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540689000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged over 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#8217;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering the novel stimulator of interferon genes (STING) agonist ImmunoLock payload, together provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#8217;s clinical candidates include upifitamab rilsodotin (UpRi) and XMT-1592. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lead product candidate, UpRi, is a first-in-class Dolaflexin ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and other cancers. The Company is currently evaluating UpRi in platinum-resistant ovarian cancer in a single-arm registrational trial, referred to as UPLIFT, for which the Company expects to complete enrollment in the third quarter of 2022. The Company is also conducting a Phase 1/2 umbrella combination trial, referred to as UPGRADE. The first combination the Company is exploring is the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer. The Company may explore other combinations in the future. The Company expects to report interim data from UPGRADE in the second half of 2022. In the second quarter of 2022, the Company expects to initiate enrollment in a randomized placebo-controlled Phase 3 trial, referred to as UP-NEXT, to evaluate UpRi as single agent maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer that have high NaPi2b expression.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's second clinical candidate, XMT-1592, is a NaPi2b-targeted ADC leveraging the Dolasynthen platform. The Company is conducting a Phase 1 dose exploration trial in patients with ovarian cancer and non-small cell lung cancer, or NSCLC, which it expects to complete in the second half of 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since inception. The Company&#8217;s net loss was $170,060, $88,045 and $28,208 for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2021, the Company had an accumulated deficit of $450,479. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#8217;s stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its currently available funds will be sufficient to fund the Company&#8217;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#8217;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#8217;s estimates, the Company may need to seek additional funding.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). </span></div>Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396625942344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical studies, clinical trials and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method better predicts the amount of consideration to which the Company will be entitled.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also considers the guidance in ASC Topic 606 by analogy in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820), establishes a three-level valuation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $2,356 and $2,153 as of December&#160;31, 2021 and 2020, respectively, comprised of $1,418 and $1,832, respectively, held by a service provider, restricted cash of $478 and $321, respectively, held as a security deposit for a standby letter of credit related to a facility lease, and $460 as of December&#160;31, 2021 of deferred financing costs related to the New Credit Facility (as defined below) with Silicon Valley Bank (SVB) and Oxford Financial LLC (Oxford). For additional information regarding the New Credit Facility, please refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit (RSU), at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares outstanding and, for the year ended December 31, 2019, 2,575,000 Exchange Warrants (as defined in Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with ASC Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method. For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,199,512&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the year ended December&#160;31, 2021, comprehensive loss equaled net loss. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540514296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">Collaboration Agreements<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merck KGaA</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a non-refundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $780,000 in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid-single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $84,000; regulatory milestones $264,000; and sales milestones $432,000. There are six individual development milestones per target, payable upon the completion of various activities, from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, the Company had received $3,000 related to development milestones under the Merck KGaA Agreement. There have been no additional milestone payments in the years ended December&#160;31, 2021 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC drug substance and clinical GMP drug substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for six designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plan for other designated targets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021 and 2020, the total estimated transaction price for the Merck KGaA Agreement was $21,325. The transaction price of $21,325 was allocated to the performance obligations as follows: approximately $3,941 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third and sixth designated target; $3,152 for the license and corresponding research and development services unit of account for the fourth designated target; $2,746 for the license and corresponding research and development services unit of account for the fifth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has completed its research service obligations associated with four of the six designated targets. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded collaboration revenue of $43, $828 and $853, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $1,280 related to the Merck KGaA Supply Agreement. There were no amounts recognized during the years ended December&#160;31, 2021 and 2020 related to the Merck KGaA Supply Agreement.&#160;There was no balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2021 or December&#160;31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had recorded $3,944 and $3,987, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda XMT-1522 Strategic Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda Pharmaceutical, Inc.'s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days&#8217; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of 30 days after the effective termination date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Strategic Research and Development Partnership</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#8217;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon 45 days&#8217; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Analysis</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligations, the Company recognized the remaining deferred revenue of $39,965 related to the termination of the Takeda agreements in the first quarter of 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the termination of the agreements, the Company had identified 14 performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were one performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the year ended December&#160;31, 2019, the Company recorded total revenue of $39,965 related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. The Company did not record any revenue under the 2016 Restated Agreement and the XMT-1522 Agreement in the years ended December 31, 2021 and 2020. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the year ended December&#160;31, 2019, the Company was billed approximately $200 from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. During the year ended December&#160;31, 2019, the Company billed Takeda $195 related to ASC 808 costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contract Assets and Liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,944&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded revenue of $0, $0 and $25, respectively, related to these services. The next </span></div>potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical trial by Asana BioSciences. As of December&#160;31, 2021, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540692376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the carrying value of the Company&#8217;s outstanding borrowing under the Prior Credit Facility and New Credit Facility (as defined below, respectively) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Prior Credit Facility and New Credit Facility are discussed in more detail in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540572488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded assets under finance leases of $609, $0, and $429 as property and equipment during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Financing leases are discussed in more detail in Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Depreciation expense for the&#160;years ended December&#160;31, 2021, 2020 and 2019 was $855, $1,010 and $1,245, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540714632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540613416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with SVB pursuant to which the Company borrowed $5,000. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 28, 2020, the Company entered into a second amendment (the Second Amendment) to the Original Agreement with SVB (the Prior Credit Facility). Pursuant to the Second Amendment, the Company drew $5,200 upon execution of the Second Amendment, the proceeds of which were used to repay the Company&#8217;s existing balance under the Original Agreement and satisfy its obligations to SVB. The Amended Credit Facility accrued interest at a floating per annum rate equal to the greater of (i) 4.25% and (ii) 1.00% above the Prime Rate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, the Company entered into a loan and security agreement (the New Credit Facility) with SVB and Oxford (Oxford and SVB, together the Lenders). Pursuant to the New Credit Facility, the Company can borrow term loans in an aggregate amount of $100,000, which includes (i) $60,000 in up to three principal advances through December 31, 2022, (ii) an additional $10,000 in one principal advance, if the Company reaches certain development milestone events through December 31, 2022, (iii) an additional $10,000 in one principal advance, if the Company reaches additional development milestone events through June 30, 2023 and (iv) an additional tranche of $20,000, subject to conditional approval from the Lenders. The Company drew $25,000 upon execution of the New Credit Facility, of which $5,500 of the proceeds was used to repay the existing balance under the Prior Credit Facility and satisfy its obligations to SVB, resulting in the recording of a $398 loss on extinguishment, which is presented within interest expense for the year ended December 31, 2021 on the Consolidated Statements of Operations and Comprehensive Loss. Upon entering into the New Credit Facility, the Company terminated all commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by the Company to SVB under the Prior Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The New Credit Facility bears interest at a floating per annum rate equal to the greater of (i) 8.50% and (ii) 5.25% above the Prime Rate. Interest is payable monthly in arrears on the first day of each month. The Company is obligated to make interest-only payments through November 1, 2024, followed by equal monthly principal payments and applicable interest through the maturity date of October 1, 2026 (the Maturity Date). If certain development milestones are met, then the interest-only period will be extended to November 1, 2025.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also required to make a final payment to the Lenders equal to 4.25% of the principal amount of the term loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#8217;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Company&#8217;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) 3.0% of the term loans then extended to the Company if the prepayment occurs on or prior to the first anniversary of the funding date of such term loan, (b) 2.0% of the term loans then extended to the Company if the prepayment occurs after the first anniversary of the funding date of such term loan but on or prior to the second anniversary of the funding date of such term loan, or (c) 1.0% of the term loans then extended to the Company if the prepayment occurs after the second anniversary of the funding date of such term loan but before the Maturity Date. The New Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The restrictive covenants include, among others, requirements relating to the Company&#8217;s ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s payment obligations under the New Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#8217;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon the Lenders' demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of December&#160;31, 2021, the Company was in compliance with all covenants under the New Credit Facility. As such, as of </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entering into the New Credit Facility, the Company paid $958 in costs, of which $210 was paid to Lenders and $748 was paid to third parties. Certain costs were recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method, which was comprised of $151 of the costs paid to the Lenders and $273 of the costs paid to third parties. The remaining costs of $533 were capitalized in other assets related to the Company's right to borrow additional amounts from the Lenders in the future and amortized to interest expense over the relevant draw period on a straight-line basis.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $25,000 outstanding under the New Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021 and 2020, the Company recognized $797 and $340, respectively, of interest expense related to the Prior Credit Facility and New Credit Facility, as applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540546888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At-the-market equity offering program</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. During the year ended December 31, 2020, the Company sold 10,900,599 shares of common stock and received net proceeds of $62,976 through the 2018 ATM. In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $100,000 of its common stock from time to time at prevailing market prices. As of December&#160;31, 2021, the Company had sold 3,961,074 shares of common stock and received net proceeds of $43,087 under the 2020 ATM.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-on offering</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company sold 9,200,000 shares of common stock, in an underwritten public offering price to the public of $19.00 per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $163,990.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2021 and 2020 there were warrants to purchase 39,474 shares of common stock. During the year ended December&#160;31, 2021, there were no exercises of warrants in exchange for shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of 2,575,000 shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of 2,575,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with ASC Topic 480, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors of the Company (the Board).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020 there were 9,199,512 and 6,869,189 shares of common stock, respectively, reserved for the exercise of outstanding stock options and warrants.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,199,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540613416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td>
<td class="text">Stock Options<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2017, there were 3,141,625 options outstanding under the Company&#8217;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations or forfeitures of options granted under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017 the Company&#8217;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, RSUs or other stock-based awards. The number of shares of common stock issuable under the Plan cumulatively increases annually by 4% of the outstanding shares or such lesser amount determined by the Board. The terms of the awards made under the Plan are determined by the Board, subject to the provisions of the Plan. In January 2021, the number of shares of common stock issuable under the 2017 Plan was increased by 2,753,651 shares. As of December&#160;31, 2021 there were 1,308,183 shares available for future issuance under the Plan. During the year ended December&#160;31, 2021, the Company granted to employees 715,716 RSUs and options to purchase 2,870,720 shares of common stock under the 2017 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the 2017 Plan, both with respect to incentive stock options and nonqualified stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Options granted under the Plan expire no later than 10 years from the date of grant. Options under the 2007 Plan were granted at an exercise price established by the Board (or a committee thereof) that was not less than the fair market value of the underlying common stock on the date of grant and subject to such vesting provisions determined by the Board (or a committee thereof). The Board may accelerate vesting or otherwise adjust the terms of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants to its employees, upon approval by the Board, options to purchase shares of common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The securities are issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the options granted under the 2017 Plan. As of December&#160;31, 2021 there were options to purchase 757,500 shares of common stock granted as inducement awards outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option activity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2021, 2020 and 2019, was $11.71, $7.99 and $2.47 per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019, was $4,299, $11,147, and $202, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from the exercise of stock options was $1,837, $3,138 and $175 for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company periodically issues RSUs with a service condition to certain officers and other employees that typically vest between one year and four years from the grant date.</span></div><div><span><br/></span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019, was $5,790, $0, and, $0, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the provisions of ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to account for all stock-based awards to employees and non-employees.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measurement date for awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $38,958 and $9,929 of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of 2.6 years and 2.8 years, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility for the Company&#8217;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. No dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs is determined based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under the 2017 ESPP, plus an annual increase, to be added as of January 1st of each year, equal to the least of (i) 450,000 shares of common stock; (ii) one percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December 31st; and (iii) the number of shares of common stock determined by the Board on or prior to such date for such year, up to maximum of 4,725,000 shares of common stock in the aggregate. During the years ended December&#160;31, 2021 and 2020 the Company issued 78,253 and 80,267 shares, respectively, under the 2017 ESPP. As of December&#160;31, 2021, there were 566,565 shares available for issuance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540624936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office and lab space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease (the Office Lease) to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the Office Lease for an additional five years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional office space in its existing building for five years, beginning July 1, 2021, and committed the Company to lease payments of $4,983 over that period (the Expansion Lease). In connection with the Expansion Lease, the Company increased the balance of the security deposit by increasing the standby letter of credit for the benefit of its landlord by $157. The Expansion Lease also provided the Company with a tenant improvement allowance of $51. Independent from the option under the Office Lease, the Company has an option to extend the lease term of the Expansion Lease for an additional five years. The Company&#8217;s exercise of the options to extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use (ROU) asset and liability and are reflected as an expense in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the signing of the Expansion Lease in April 2021, the Company recorded an increase of $3,783 to its ROU asset and lease liabilities in the second quarter of 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $478 in connection with the Office Lease and Expansion Lease as of December&#160;31, 2021 and $321 in connection with the Office Lease as of December&#160;31, 2020, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has remaining finance lease terms of one year to five years for certain equipment, some of which include options to purchase at fair value. For the year ended December&#160;31, 2021, the Company recorded assets under finance leases of $609 as property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,889&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">Other liabilities, current</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">Other liabilities</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $3,390, $2,644 and $2,160 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,550&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an operating lease for its office and lab space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease (the Office Lease) to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the Office Lease for an additional five years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional office space in its existing building for five years, beginning July 1, 2021, and committed the Company to lease payments of $4,983 over that period (the Expansion Lease). In connection with the Expansion Lease, the Company increased the balance of the security deposit by increasing the standby letter of credit for the benefit of its landlord by $157. The Expansion Lease also provided the Company with a tenant improvement allowance of $51. Independent from the option under the Office Lease, the Company has an option to extend the lease term of the Expansion Lease for an additional five years. The Company&#8217;s exercise of the options to extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use (ROU) asset and liability and are reflected as an expense in the period incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the signing of the Expansion Lease in April 2021, the Company recorded an increase of $3,783 to its ROU asset and lease liabilities in the second quarter of 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $478 in connection with the Office Lease and Expansion Lease as of December&#160;31, 2021 and $321 in connection with the Office Lease as of December&#160;31, 2020, collateralized by a money market account.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has remaining finance lease terms of one year to five years for certain equipment, some of which include options to purchase at fair value. For the year ended December&#160;31, 2021, the Company recorded assets under finance leases of $609 as property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,889&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">Other liabilities, current</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">Other liabilities</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense was $3,390, $2,644 and $2,160 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,550&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540578920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2021, 2020 and 2019 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,051)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2021, the Company had Federal and State net operating loss carryforwards of approximately $403,579 and $337,057, respectively. Of the $403,579 of Federal net operating loss carryforwards, $34,149 expire at various dates through 2037. The remaining $369,430 of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2041. At December&#160;31, 2021, the Company had Federal and State research and development tax credit carryforwards of approximately $10,077 and $3,061, respectively, which expire at various dates through 2041.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $130,051 and $77,375 at December&#160;31, 2021 and December&#160;31, 2020, respectively. The valuation allowance increased by $52,676 and $28,468 during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the Company&#8217;s net operating losses generated during the periods, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#8217;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#8217;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2021 and 2020, the Company had no unrecognized tax benefits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#8217;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States federal tax jurisdiction and four state jurisdictions. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2021, 2020 and 2019. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2017, although carryforward attributes that were generated prior to tax&#160;year 2017 may still be adjusted upon examination to the extent utilized in a future period. There are no federal or state audits currently in progress.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540590680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanThe Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of 21 are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to 95% of eligible pay on a pre&#8211;tax basis up to the federal annual limits. For the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#8217; contributions at 50% on the first 6% up to $6. For the period from August 1, 2019 to December&#160;31, 2020 and for the year ended December&#160;31, 2021, the Company matched the employees&#8217; contributions at 100% on the first 4% up to $7. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, the Company recorded expense of $764, $486 and $404, respectively, related to its contribution to its 401(k)&#160;Plan.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540605688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">Commitments<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded research and development expense related to non-refundable license payments of $3,075, $250, and $750, respectively. Further development milestones of $2,125, $750 and $600, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these consolidated financial statements for the Company&#8217;s future obligations related to leases as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540609688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Research Collaboration and License Agreement</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into the Janssen Collaboration pursuant to which the Company granted Janssen an exclusive license to use the Company's proprietary Dolasynthen platform and other technology to develop, manufacture and commercialize ADCs directed to up to three targets selected by Janssen. The Company is responsible for performing bioconjugation activities to create ADCs for Janssen based on antibodies provided by Janssen. The Company will also perform certain chemistry, manufacturing and controls development and early stage manufacturing activities for ADCs that Janssen progresses through development, up to and including the manufacturing of clinical drug substance, at Janssen&#8217;s cost. Except with respect to this limited manufacturing, Janssen will be responsible for the further development, manufacturing and </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of the ADCs developed under the Janssen Collaboration, including obtaining any necessary regulatory approvals, at Janssen&#8217;s cost.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received an upfront payment of $40,000 in February 2022. The Company is eligible to receive development and regulatory milestones with an aggregate total of $501,000, if licensed products directed to all three Targets are advanced by Janssen. The Company is also eligible to receive commercial milestones with an aggregate total of $530,000 in the event of commercialization of three Targets by Janssen and tiered royalties based on mid-single digits to low-double digits on future net sales of licensed ADCs </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Janssen Collaboration will continue in effect until the date on which the royalty term and all payment obligations with respect to all licensed ADCs in all countries have expired.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Other Events</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company amended the Commercial License and Option Agreement with Synaffix B.V. (Synaffix) in connection with the Janssen Collaboration, and agreed to pay Synaffix a non-refundable execution fee of $1,500 which will be applied against future target license fees or development milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further in connection with the Janssen Collaboration, on February 17, 2022, the Company amended the New Credit Facility described in Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements. Pursuant to this amendment the Company has agreed to replace the tranche B term loan and the tranche C term loan with a single combined term loan tranche in an aggregate principal amount of $20,000. Also, the combined term loan tranche will now be available any time on or prior to June 30, 2023, within 90 days of the Company achieving both of the prior tranche B and tranche C term loan milestones. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2021 and through February 25, 2022, the Company sold 9,493,776 shares of common stock resulting in net proceeds of $45,579 from ATM offerings, with substantial participation from existing long-term investors. Approximately $9,414 remains unsold and available for sale under the 2020 ATM.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542975400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical studies, clinical trials and related services;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other research and development materials;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fees and costs related to regulatory filings and activities;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with collaboration agreements and license fees and milestone payments related to license agreements;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with clinical, preclinical, discovery and other research activities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort </span></div>expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#8217;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The promised good or services in the Company&#8217;s arrangement typically consist of license rights to the Company&#8217;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method better predicts the amount of consideration to which the Company will be entitled.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also considers the guidance in ASC Topic 606 by analogy in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC&#160;820), establishes a three-level valuation </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Other Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded other assets of $2,356 and $2,153 as of December&#160;31, 2021 and 2020, respectively, comprised of $1,418 and $1,832, respectively, held by a service provider, restricted cash of $478 and $321, respectively, held as a security deposit for a standby letter of credit related to a facility lease, and $460 as of December&#160;31, 2021 of deferred financing costs related to the New Credit Facility (as defined below) with Silicon Valley Bank (SVB) and Oxford Financial LLC (Oxford). For additional information regarding the New Credit Facility, please refer to Note 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Accounting for Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Stock-based Compensation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of each restricted stock unit (RSU), at its grant date based on the closing market price of the Company&#8217;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records forfeitures as a cumulative adjustment in the period in which they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares outstanding and, for the year ended December 31, 2019, 2,575,000 Exchange Warrants (as defined in Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders' Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with ASC Topic 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method. For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2021, 2020 and 2019.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with ASC Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#8217;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#8217;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#8217;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes in accordance with ASC Topic 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) comprises net loss and other comprehensive loss. For the year ended December&#160;31, 2021, comprehensive loss equaled net loss. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Off-balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk </span></div>primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to any significant concentrations of credit risk from these financial instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. The adoption of this standard did not have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542402728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash included in other assets, noncurrent</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,672&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,415&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,720,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,199,512&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,207,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of estimated useful life of property and equipment</a></td>
<td class="text">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.380%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment, office equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or life of lease</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540662648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of changes in the balances of our contract assets and liabilities and recognized revenue</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2021 and December&#160;31, 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,944&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Beginning</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Deductions</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">End of Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,987&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue recognized in the period from:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts included in the contract liability at the beginning of the period</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance obligations satisfied in previous periods</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540594104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,650&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,365&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396541598680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following as of December&#160;31, 2021 and 2020:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued manufacturing expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,319&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued preclinical expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540491208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $25,000 outstanding under the New Credit Facility and the debt consisted of the following:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term-debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt financing costs, net of accretion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion related to final payment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of estimated future payments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the estimated future principal payments due are as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,417</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540696664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule for number of common stock reserved for exercise of outstanding stock options and warrants</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,474&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,199,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542494792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">of Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Contractual Term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Intrinsic Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(421,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(657,358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342,429&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,997,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit activity</a></td>
<td class="text"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of the RSU activity under the 2017 Plan is as follow:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715,716&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(419,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(195,538)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">817,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of stock-based compensation expense by award type</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense by award type included within the Company&#8217;s consolidated statement of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,230&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,187&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense included in Total operating expenses</span></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense as reflected in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents stock-based compensation expense as reflected in the Company&#8217;s consolidated statements of operations and comprehensive loss:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense included in Total operating expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,409&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for estimating fair value of option awards</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black&#8211;Scholes option pricing model with the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396536947096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of lease expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,755&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock', window );">Schedule of supplemental balance sheet information related to leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,889&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,936&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,247&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, gross</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, accumulated depreciation</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">Other liabilities, current</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">Other liabilities</span></span></span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock', window );">Schedule of supplemental cash flow information related to leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,550&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum payments on finance leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,147&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,188&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,550&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540537080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax rates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2021, 2020 and 2019 are as follows:</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.296%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership shift</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of net deferred tax assets</a></td>
<td class="text">Significant components of the Company&#8217;s net deferred tax assets as of December&#160;31, 2021 and 2020 are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,361&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,051)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,375)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,433)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543884104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 170,060<span></span>
</td>
<td class="nump">$ 88,045<span></span>
</td>
<td class="nump">$ 28,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 450,479<span></span>
</td>
<td class="nump">$ 280,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540495752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueCollectionPeriod', window );">Billing term</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueCollectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which entity receives payment upon billing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueCollectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543790120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 177,947<span></span>
</td>
<td class="nump">$ 255,094<span></span>
</td>
<td class="nump">$ 62,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other assets, noncurrent</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash per statement of cash flows</a></td>
<td class="nump">$ 178,425<span></span>
</td>
<td class="nump">$ 255,415<span></span>
</td>
<td class="nump">$ 62,672<span></span>
</td>
<td class="nump">$ 60,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537253240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="nump">$ 2,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainageDeposit', window );">Held by service provider</a></td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit for security deposit</a></td>
<td class="nump">478<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | New Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainageDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainageDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396545351448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Stock Based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396544031656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net loss per share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
<td class="nump">5,207,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">8,342,429<span></span>
</td>
<td class="nump">6,112,948<span></span>
</td>
<td class="nump">4,720,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">817,609<span></span>
</td>
<td class="nump">716,767<span></span>
</td>
<td class="nump">447,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542732808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember', window );">Computer equipment and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements, estimated useful lives</a></td>
<td class="text">Shorter of useful life or life of lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540540840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Risks (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Concentration of Credit Risk and Off-balance Sheet Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Financial instruments with off-balance sheet risk</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396533344088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Narrative (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>USD ($) </div>
<div>target </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>target</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,944,000<span></span>
</td>
<td class="nump">$ 3,987,000<span></span>
</td>
<td class="nump">$ 4,815,000<span></span>
</td>
<td class="nump">$ 4,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="nump">42,123,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,013,000<span></span>
</td>
<td class="nump">67,036,000<span></span>
</td>
<td class="nump">55,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsUpfrontPayment', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber', window );">Number of targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense', window );">Amount of additional fees receivable when target is designated and commercial license to target is granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones', window );">Aggregate milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestones', window );">Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsRegulatoryMilestones', window );">Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsSalesMilestones', window );">Sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber', window );">Number of individual development milestones per target | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber', window );">Number of individual regulatory milestones per target | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber', window );">Number of individual commercial milestones | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived', window );">Amount of development milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone', window );">Next potential development milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration', window );">Prior written notice for termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber', window );">Number of targets designated | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,325,000<span></span>
</td>
<td class="nump">21,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber', window );">Number of service obligations completed of designated targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">828,000<span></span>
</td>
<td class="nump">853,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice', window );">Milestone Payment Not Received, Included in Estimated Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, first and second targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,941,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, third and sixth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, fourth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | License and corresponding research and development services, fifth target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Rights to future technological improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Rights to future technological improvements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Joint research committee services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueTransactionPriceAmount', window );">Revenue, transaction price, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember', window );">Merck KGaA | Joint research committee services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember', window );">Merck KGaA Agreement and Merck KGaA supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944,000<span></span>
</td>
<td class="nump">3,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">XMT-1522 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDurationToTermination', window );">Period of time until agreement terminated</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod', window );">Period of shared development costs following effective termination date</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsCostsBilled', window );">ASC 808 costs billed to Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember', window );">2016 Restated Tokeda agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber', window );">Number of targets | target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsDurationToTermination', window );">Period of time until agreement terminated</a></td>
<td class="text">45 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">2016 Restated Tokeda agreement and XMT-1522 agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueRemainingPerformanceObligationNumber', window );">Number of performance obligations | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 39,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember', window );">2016 Restated Tokeda agreement and XMT-1522 agreement | License and related research and development services, including phase 1 development and transfer certain materials and know how</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_RevenueRemainingPerformanceObligationNumber', window );">Number of performance obligations | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember', window );">Asana BioSciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone', window );">Next potential milestone payment eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember', window );">Asana BioSciences | Limited services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember', window );">Merck KGaA supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual commercial milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual development milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of individual regulatory milestones per target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsCostsBilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs billed during the period under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsCostsBilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum development milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the next potential development milestone the company will be eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the development milestone payment received by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsDurationToTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsDurationToTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsMaximumAggregateMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the next potential milestone the company will be eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum sales milestone amount the company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsTargetsDesignatedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets designated as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsTargetsDesignatedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborativeArrangementsExclusiveTargetsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborativeArrangementsExclusiveTargetsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborativeArrangementsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payment received during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborativeArrangementsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments, which had not been received, included in the estimated transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueRemainingPerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueRemainingPerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_RevenueTransactionPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_RevenueTransactionPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_RightsToFutureTechnologicalImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_RightsToFutureTechnologicalImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_JointResearchCommitteeServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_JointResearchCommitteeServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrsn_LimitedServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrsn_LimitedServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542977768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementsAbstract', window );"><strong>Collaboration agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at beginning of period</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">4,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractWithCustomerLiabilityIncrease', window );">Deferred revenue, additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractWithCustomerLiabilityDecrease', window );">Deferred revenue, deductions</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance at end of period</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract', window );"><strong>Revenue recognized in the period from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amounts included in the contract liability at the beginning of the period</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ChangeInContractAssetsAndLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Contract Assets And Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ChangeInContractAssetsAndLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractWithCustomerLiabilityDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractWithCustomerLiabilityDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractWithCustomerLiabilityIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractWithCustomerLiabilityIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396533251512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 9,650<span></span>
</td>
<td class="nump">$ 9,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(7,682)<span></span>
</td>
<td class="num">(7,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">$ 1,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Total property and equipment at cost</a></td>
<td class="nump">6,725<span></span>
</td>
<td class="nump">6,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">1,906<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember', window );">Computer equipment and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_FinanceLeasesMember', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, equipment and software, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment at cost</a></td>
<td class="nump">$ 609<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_ComputerEquipmentAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_FinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_FinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543748648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_AccruedManufacturingExpensesCurrent', window );">Accrued manufacturing expenses</a></td>
<td class="nump">$ 8,476<span></span>
</td>
<td class="nump">$ 4,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">7,879<span></span>
</td>
<td class="nump">5,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_AccruedPreclinicalExpensesCurrent', window );">Accrued preclinical expenses</a></td>
<td class="nump">3,848<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">7,319<span></span>
</td>
<td class="nump">5,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 28,716<span></span>
</td>
<td class="nump">$ 16,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_AccruedManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_AccruedManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_AccruedPreclinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_AccruedPreclinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396534562440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 29, 2021</div></th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>May 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">797,000<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember', window );">Existing Credit Facility | Prime rate | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember', window );">Amended Credit Facility | Prime rate | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount', window );">Final payment as percentage of original principal amount</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentAdditionalRateInEventOfDefault', window );">Additional rate in event of default</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Capitalized Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Lenders | Amortized Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">151,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Third Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Third Parties | Amortized Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Prepayment Occurs Prior To October 29, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Prepayment Occurs Between October 29, 2022 and October 29, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Line of Credit | Prepayment Occurs After October 29, 2023 but Before October 1, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentPrepaymentFeePercent', window );">Prepayment fee percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest rate percentage</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember', window );">New Credit Facility | Prime rate | Minimum | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheOneMember', window );">New Credit Facility, Tranche One | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheTwoMember', window );">New Credit Facility, Tranche Two | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheThreeMember', window );">New Credit Facility, Tranche Three | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFourMember', window );">New Credit Facility, Tranche Four | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFiveMember', window );">New Credit Facility, Tranche Five | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheSixMember', window );">New Credit Facility, Tranche Six | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentAdditionalRateInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the additional percentage of rate in event of default under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentAdditionalRateInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentPrepaymentFeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of prepayment fee under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentPrepaymentFeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the final payment as percentage of original principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_ExistingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrsn_CapitalizedOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrsn_CapitalizedOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_LendersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_LendersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=mrsn_AmortizedInterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=mrsn_AmortizedInterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_ThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_ThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursPriorToOctober292022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursPriorToOctober292022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtCovenantPeriodAxis=mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_NewCreditFacilityTrancheSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396542731224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term-debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DebtInstrumentCarryingAmountNoncurrent', window );">Total debt, net of current portion</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt financing costs, net of accretion</a></td>
<td class="num">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Accretion related to final payment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">$ 24,626<span></span>
</td>
<td class="nump">$ 4,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DebtInstrumentCarryingAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DebtInstrumentCarryingAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396541862392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Future payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Estimated future principal payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">2,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">10,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537893080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 02, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 26, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued', window );">Number of shares into which warrant issued during period may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ContractualLifeOfWarrants', window );">Contractual life of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,199,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WarrantsExercisedInPeriod', window );">Issuance of common upon exercise of warrant (in shares)</a></td>
<td class="nump">2,574,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_NumberOfVotesPerCommonShare', window );">Number of votes per common share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants', window );">Number of common shares exchanged for warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of common stock into which warrants may be converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember', window );">Warrants and share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,199,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceProgramAuthorizedAmount', window );">Amount of shares authorized to be offered and sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM) | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember', window );">At market equity offering program (2018 ATM) | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,976,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember', window );">At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_StockIssuanceProgramAuthorizedAmount', window );">Amount of shares authorized to be offered and sold | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,087,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember', window );">At Market Equity Offering Program (2020 ATM) | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,961,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 163,990,000<span></span>
</td>
<td class="nump">$ 92,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares sold, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts', window );">Proceeds from stock issuance, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember', window );">Public Stock Offering | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">24,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares exchanged for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ContractualLifeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The contractual life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ContractualLifeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_NumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes for each shares held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_NumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuanceProgramAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock shares authorized to be issued under the program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuanceProgramAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2018ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543969928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember', window );">Warrants and share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember', window );">Share-based payments | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">8,342,429<span></span>
</td>
<td class="nump">6,112,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember', window );">Share-based payments | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">817,609<span></span>
</td>
<td class="nump">716,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">39,474<span></span>
</td>
<td class="nump">39,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mrsn_WarrantsAndShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_DeferredCompensationShareBasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537997560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,342,429<span></span>
</td>
<td class="nump">6,112,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,308,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.71<span></span>
</td>
<td class="nump">$ 7.99<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,299<span></span>
</td>
<td class="nump">$ 11,147<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,837<span></span>
</td>
<td class="nump">$ 3,138<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,199,512<span></span>
</td>
<td class="nump">6,869,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,253<span></span>
</td>
<td class="nump">80,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period of unrecognized stock compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,790<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period of unrecognized stock compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member', window );">2007 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,141,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease', window );">Cumulative annual increase in number of shares issuable, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="nump">2,753,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,870,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member', window );">2017 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member', window );">2017 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member', window );">2017 Plan | Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember', window );">Inducement Award Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_A2017ESPPMember', window );">2017 ESPP | Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease', window );">Cumulative annual increase in number of shares issuable, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_A2017ESPPMember', window );">2017 ESPP | Employee stock purchase plan | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares', window );">Maximum annual increase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mrsn_A2017ESPPMember', window );">2017 ESPP | Employee stock purchase plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,725,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be added annually to the plan on the first day of the fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_StockIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_InducementAwardProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mrsn_A2017ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mrsn_A2017ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396533263112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Activity Under Stock Option Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">6,112,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">3,308,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(421,381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(657,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">8,342,429<span></span>
</td>
<td class="nump">6,112,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,342,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period (in shares)</a></td>
<td class="nump">3,997,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 7.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">16.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">4.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
<td class="nump">11.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">11.25<span></span>
</td>
<td class="nump">$ 7.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">11.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period (in dollars per share)</a></td>
<td class="nump">$ 7.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Options outstanding</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options, Vested and expected to vest</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Options exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="nump">$ 8,458<span></span>
</td>
<td class="nump">$ 114,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options, Vested and expected to vest</a></td>
<td class="nump">8,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
<td class="nump">$ 7,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543938072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Restricted Stock Units (Details) - Unvested restricted stock units - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at beginning of period (in shares)</a></td>
<td class="nump">716,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(419,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(195,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at end of period (in shares)</a></td>
<td class="nump">817,609<span></span>
</td>
<td class="nump">716,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value (in dollars)</a></td>
<td class="nump">$ 5,086<span></span>
</td>
<td class="nump">$ 19,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">5.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 15.68<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537204760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 18,409<span></span>
</td>
<td class="nump">$ 7,172<span></span>
</td>
<td class="nump">$ 4,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">14,528<span></span>
</td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">4,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">9,984<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense included in Total operating expenses</a></td>
<td class="nump">$ 8,425<span></span>
</td>
<td class="nump">$ 3,331<span></span>
</td>
<td class="nump">$ 2,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537216936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396539051032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit for security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for financing lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,390<span></span>
</td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Finance lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Finance lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember', window );">Office space, Cambridge, MA, Leased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceExpansionCambridgeMaMember', window );">Office Space Expansion Cambridge Ma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 4,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Letter of credit for security deposit</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_OperatingLeaseTenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LeasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LeasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_OperatingLeaseTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_OperatingLeaseTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceCambridgeMaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceExpansionCambridgeMaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mrsn_OfficeSpaceExpansionCambridgeMaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543794552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,502<span></span>
</td>
<td class="nump">$ 2,755<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinanceLeaseTotalCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_FinanceLeaseCost', window );">Finance lease cost</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of finance lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_FinanceLeaseTotalCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Total Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_FinanceLeaseTotalCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537763176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental balance sheet information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeOperatingLeasesAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 12,889<span></span>
</td>
<td class="nump">$ 10,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">1,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">11,247<span></span>
</td>
<td class="nump">10,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LesseeFinanceLeasesAbstract', window );"><strong>Finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Property and equipment, gross</a></td>
<td class="nump">1,038<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Less: Accumulated depreciation</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Other liabilities, current</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Other liabilities</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, current, statement of financial position</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance lease, liability, noncurrent, statement of financial position</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeFinanceLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeFinanceLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LesseeOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LesseeOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540910216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental cash flow information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LeasesSupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 3,241<span></span>
</td>
<td class="nump">$ 2,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LeasesSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases, Supplemental Cash Flow Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LeasesSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396533229800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Future minimum lease payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Rent expense</a></td>
<td class="nump">$ 3,390<span></span>
</td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="nump">$ 2,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">4,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026 and thereafter</a></td>
<td class="nump">1,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">17,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(3,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">13,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026 and thereafter</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540611176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396534550168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">General business credits</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Impact of ownership shift</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(53.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.00%)<span></span>
</td>
<td class="num">(32.30%)<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396534480728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of deferred tax assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 106,055<span></span>
</td>
<td class="nump">$ 64,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">12,424<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">6,892<span></span>
</td>
<td class="nump">4,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">3,698<span></span>
</td>
<td class="nump">3,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsLicensedTechnology', window );">Licensed technology</a></td>
<td class="nump">2,775<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">133,484<span></span>
</td>
<td class="nump">80,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(130,051)<span></span>
</td>
<td class="num">(77,375)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets less valuation allowance</a></td>
<td class="nump">3,433<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(3,433)<span></span>
</td>
<td class="num">(2,986)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(3,433)<span></span>
</td>
<td class="num">(2,986)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DeferredTaxAssetsLicensedTechnology">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DeferredTaxAssetsLicensedTechnology</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396540919528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Net operating loss carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carry-forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 403,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_OperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">34,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not subject to expiration</a></td>
<td class="nump">369,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carry-forwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 337,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543764216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax credit carryforward (Details) - Research and Development<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 10,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396537393800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Valuation allowance (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>jurisdiction </div>
<div>audit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 130,051,000<span></span>
</td>
<td class="nump">$ 77,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in valuation allowance</a></td>
<td class="nump">52,676,000<span></span>
</td>
<td class="nump">28,468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncomeTaxesNumberOfStateJurisdictions', window );">Number of state jurisdictions in which entity files income tax returns | jurisdiction</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_IncomeTaxesNumberOfAuditsInProgress', window );">Number of federal or state audits in progress | audit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncomeTaxesNumberOfAuditsInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of federal and (or) state audits in progress.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncomeTaxesNumberOfAuditsInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_IncomeTaxesNumberOfStateJurisdictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of state jurisdictions in which entity files income tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_IncomeTaxesNumberOfStateJurisdictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396539111128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DefinedContributionPlanEligibleAgeToParticipate', window );">Eligible age to participate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution by employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage employer matches of the employee's percentage contribution matched</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount', window );">Maximum annual amount employer contributes per employee</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefit expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DefinedContributionPlanEligibleAgeToParticipate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum age for employees to be eligible to participate in defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DefinedContributionPlanEligibleAgeToParticipate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum annual amount the employer contributes per employee to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396534478328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - License agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember', window );">License Agreement, Upfront Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expense</a></td>
<td class="nump">$ 3,075<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember', window );">License Agreement, Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross', window );">Research and development expense</a></td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementUpfrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrsn_LicenseAgreementMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140396543026488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 17, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember', window );">At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock | At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,961,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale', window );">Value of shares available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common&#160;Stock | At Market Equity Offering Program (2020 ATM)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,493,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Synaffix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationAgreementNonrefundableExecutionFee', window );">Collaboration Agreement Nonrefundable Execution Fee</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Development and Regulatory | Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones', window );">Aggregate milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Commercial | Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones', window );">Aggregate milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Line of Credit | Amended New Credit Facility, Combined Tranche Four and Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration', window );">Tranche availability duration (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationAgreementNonrefundableExecutionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable execution fee to be paid as part of a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationAgreementNonrefundableExecutionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_CollaborationArrangementsMaximumAggregateMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_CollaborationArrangementsMaximumAggregateMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_LineOfCreditFacilityTrancheAvailabilityDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period within which the term loan tranche will be available after achieving the tranche loan milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_LineOfCreditFacilityTrancheAvailabilityDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of remaining shares of common stock available for sale under the program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrsn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mrsn_AtMarketEquityOfferingProgram2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_JanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_JanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_SynaffixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mrsn_SynaffixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentAndRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_DevelopmentAndRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrsn_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrsn_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>mrsn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrsn="http://www.mersana.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mrsn-20211231.xsd" xlink:type="simple"/>
    <context id="i20946113a6b640bf91ee43d05d504400_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia3e7551cb27b48f7ae6ca63cb9d0f3a0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7fc42ca8bd44444faceba42910feb1ec_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="i1b5567939ee84f85a796f7340017d974_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i81852bd3e7134038a2f1b0bf58ab6969_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i514791eca1f44909a5e5f94b71ea3a98_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i99fce85f8b8644a3b03a21943edd68ed_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5086b7eefe4a4fd9a4cd20e7feb840a8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9be11c24e8ce4dcf855d9e19a0e8605d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1625de5080394e76934616170e525c3e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2263e5f0b5374b6eb63797459412baea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5079a121336542a2ad5e6a69a5d2da56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73784c7eb6bd4fecafcc0ade4d41a8ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i90e630e58b154d58ada0eb8b3903547b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie614b7c768c042aba10411ce72a641cd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9c64af17ca343848603ecfba6316570_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0901ec303026453cb60c34b79bfee33d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i01fe62fe6f7e48d490b1f867f9484c23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1be31f3383e848e98115c2ab8721f353_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic668054d04aa44eeb592807dc2bc4b8a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i08fa6f9dba864472a6d18ffa609a28c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i67df1b00583c408f8c9ae48510a0ca54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8074fd8df0f64ee79d269ef09013964b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2978fef777442ca8ce412714c126f1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i316531b1bea0420aa2f2b09a689cd4aa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03e3cf73141c45a28882cef716068d1d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47e4c776ea1e49f19f94fa71ab035bad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4e856d009884f45bf3990d70080916f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i416501272258413a9fbcffc3613015f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie72f092e073f4caea321165cbb01d83d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e7ad9dfbc0149afaf920277bb3301a3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i06c71214218f46bb9d5a65ebdabaa5e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63559c339ac14a4f808281cc61d2e001_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8e350e8b8c7c4fad8a6f1dbcaef3d9c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57c7504cae894df18aaaa3b793ed4bcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5cd2bc576a64407b348ad9bfc065f8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c4fdc5ae4df447da4c58088b9961c67_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe1588dcb89e4bfa84977ab490cf0417_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48c7830bb0b0416eb5d577f21baf0aac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id97077e4c81a481a8647699765887a0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i667df8466ca44fb6a82fd19ed57ff48f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida5a046a9dbb4cc0988324aea0d475c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i62083aff246944c9b4984de9c9c1ef1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i809dbadb11db4e24afbe3cdcfe4f79d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9f98a71f7de2423c9004b46d1a094d47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i57bf8dc50aad4550b09f65fd101d5b8e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2289a4965c8d4c269148c6c1a7f94f33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i311ddb6991d8496f92c657e71d74c7e1_D20140601-20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-06-01</startDate>
            <endDate>2014-06-30</endDate>
        </period>
    </context>
    <context id="i9eb13aee4e814a53a64da4507bad3321_I20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="i4af5ca3b68bb4ed7b6a33a6008c3ab69_D20150101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i691905a855ea444a81cdb006aa684830_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd780cc96bb64b56a539baf9ff6aa050_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9790c299a9564e76a73c4df8750539ba_I20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="ic09d46e0ab9d49a69193af570876fd88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22751430a1af485c87dd79584475d813_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i724be6926e0f43708c3842a241f2b234_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic393ee0337764f848b485d8f53c57f94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8719cb8746fc444a8b30ec920ba9e272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24a96471c63a400b9ce4997aa4039334_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i266b15fef82f4d77ab6acfccdce49876_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1c1155ad2bf48ed93491e3ec3ff0c2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:RightsToFutureTechnologicalImprovementsMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i578ab44d714748d09da2b37adc7d98a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:JointResearchCommitteeServicesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5c642871deec4bf2ae3f141820fc4f9c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie5e3153e090a41668aa9d9e117b855f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic7616293f91948f28dd309eb148c545e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib939e9ec9abd4ac39881b2e5f6f0a6f4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:SupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ce0872b58f0463c95884113a6545230_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="icf84ce2b240441789956b1e89bcf4595_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i4f0a4b79107a46de82588501551a7baa_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ifd81097c435142008a0e8197ddc84278_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i26419f71b3384c04a3f6605f62bc5c57_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iccb4e2fad20448bcb47f9ece79c43d47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8f3b11dfbc64275ac3f70f6dc51c46b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie83b8c61371748b8a4dad5a60b07f3eb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49b1abd1d2b641b89c50bc6d8090ae6a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8221344b85a746f1bbc5dd99c40db4af_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia01be325b8014d11a057d07ade151aab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc721e5fefa54193b4555f316c8c4e98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrsn:LimitedServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic3cf57eb0c394db486c86ab2341698c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie27da38d053440e3a567adb14304e888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52ca22aff95e471781a54f27faf5c489_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibd0a4f6ba5534268909637379ffb82d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66a2e3ad74d845418bc9e56f04eed7ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i376e781b4402454fa5e969dd3afdcc1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i781aa82fa62448f7922e5f7b324d73f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:ComputerEquipmentAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i05eab9496cd948acb8f286ed906bc0da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia64cb818b4e64c72b7ce08b160086366_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife05150f2ac84983998d474cda265a0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:FinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i46ac06dbc12246b49e2a5075fae37c0f_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="if0db434ef0b14ed0861021376bc27afa_I20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-08</instant>
        </period>
    </context>
    <context id="iab899b1838874099a8e5ac2ff7777f3b_D20190508-20190508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:ExistingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-08</startDate>
            <endDate>2019-05-08</endDate>
        </period>
    </context>
    <context id="i4009d30c89524098b6f75ea92a8511f0_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ia0f44c7208fa4c7f961ffd639310b35d_I20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-28</instant>
        </period>
    </context>
    <context id="idf785a49089f45d398bf851be2b7932a_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ic2eadf722ff64d92ae9288bc5dfe2b84_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i712f21030d394390afd89dbcc6e8b06c_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i096da856c8104fe6ab086e5efc3eec34_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="ifc33cdd85a414f2cb35b3a6e5e998ca2_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i786194604a4b4117b25a3e6b81f087f9_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="ic9ad9876d541413f801749cf53712cf7_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="idcf2d9fb74094c5991ba27cf6c512eda_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityTrancheSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i422c756559014c5d9009424c3496c2ef_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i27e84780e10842d2bd65ee2008d484a1_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="idd180a13515a4868acdde8a30e3a9cd9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic8b569721ff344e2aa89e9d46ede08d2_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="i42af7c89af7b48a79ad2c8608164b77c_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="ic6c994875ee643a9bdf93806ee028002_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursPriorToOctober292022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i9ecaffff610841b798a218f5d8f6512a_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursBetweenOctober292022AndOctober292023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i3c85f701a6a3492b83ae133b0f08ef74_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="mrsn:DebtCovenantPeriodAxis">mrsn:PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="ia0ea172aa94b48648314fda755ca7392_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:LendersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="ib909e4352d504cd6b40dc90f0dbdd2b3_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i54e050cde4d9454b8bfc4b3d17c5dc2a_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mrsn:AmortizedInterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:LendersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i649899397fe049798792f393cde3e4cc_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">mrsn:AmortizedInterestExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:ThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="ib1b33420048243f9a32ec5f4a1baff18_D20211029-20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrsn:CapitalizedOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-29</startDate>
            <endDate>2021-10-29</endDate>
        </period>
    </context>
    <context id="i89f02922d04244f98f6fa502e3378212_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:NewCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="iffee20b1411845d4b0b9f086f3c189b9_I20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2018ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="i2c0c094572df4f53b6e958fe1bcfe81b_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i828ebe879492478780a584c32808e4db_D20200501-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37036005f77a435e8823d902b65b4b26_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2f9e97774b6a4b27bd93e83aa57935c4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="i338c16ccd7cd41ef810857176b3cb944_I20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="i5c6d26ecc5ca4927bf170e6f70476126_D20191126-20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-26</startDate>
            <endDate>2019-11-26</endDate>
        </period>
    </context>
    <context id="i7d00f365edee446b858df5048d05be98_I20191126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-26</instant>
        </period>
    </context>
    <context id="ic1c0f959152f49bbb6f2f1b5870fdd72_D20200302-20200302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="i6e2b696bd2b946689884d6db1dbaebcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e33d28def5e47e48376a78023729e2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mrsn:WarrantsAndShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff2b446a5705439d8204e2db3af84557_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2836cc08d6b440048b685415e74ef94a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcfae73b76f849c2beedf48b3fd3ddb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ed739e482d84b91bdcedea1d7aa35da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:DeferredCompensationShareBasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id9a2b387a4dd4de5a44607493ebe2f7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica825e7423074dfd9b2d51c5b1e0acfa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i737243bf173d4209a6e2039ac6c813f9_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i3eec540f391a482b8cf41ac59c16c58d_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i5ec75714d1fa4db7ab67c66b6d110b6e_D20170601-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="ia71270946b0347db9fb2c7e2adb5eb55_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i34baed2717f54091a1033f9099b12641_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fac48995f2c4c16a220008833e49a01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c201fa2273b4d5692775bfe687ff519_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaaff1344197a4f7f88291b1ff2549f0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:StockIncentivePlan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if90621fb17914192b3cc20226646f468_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:InducementAwardProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c64324e16174923bd142062def84677_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e1147f1b66d4b6bae33bea0cccbebbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67789eba647e4e8f9ca09e243889e50e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6d675eb3e6d43b4bf7380c997407796_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic58196efabc4455dbc9f56d50edcfad0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2375a12808cf4680aa725acb17071871_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iace44621dbb84817a2c5f4a3278c74ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i23b915dd88e74298a6e79a691ceb3e41_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ac3651a9b134a21b2606a2b6c456826_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i995f53d89db1431783ca696f65ff827c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4ac073dc733f464e923ffe588304cf3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b69daa12d7d496a8e30d2f4f904d645_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87d0d7495bf34973b75e45d3a456802f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i76db584e2a3847a19b4d09782ea823f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b750e97432649f8902f0c0b2b12632e_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i18e0acc3be3c4a918d77e823eeaf9a9b_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="id1dc96fa4ed842f4aedd626c47454440_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i8c8f204b2f8f47c883a50a6b32629116_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrsn:A2017ESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i0c8751ae82ab48e580bd5035e380db22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id16df4d7be5d45f09336d071d6b927ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9166def068646cba741aa6d728d2b9c_I20210405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceExpansionCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-05</instant>
        </period>
    </context>
    <context id="id7a8cc110a0642b68c553e48f18a1285_D20210405-20210405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mrsn:OfficeSpaceExpansionCambridgeMaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-04-05</endDate>
        </period>
    </context>
    <context id="i2a56f442c69248c78859ce174629ab21_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i038ae3a73230483884690b9a78423777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if17d87454f6c4db7839bfac2ed9aa926_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i72c467d1b1b6423e92438fcea0715adb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i673a5d42881e4cb3b1331529587e448a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a07a4efd2d24b99831852b517363a51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6461b8d4e239490992a75468dcd510eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6f43b37474ae4a6eae2f68ccd01a3200_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf265381e7674d2ea77457e88a5120d9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementUpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib13441f134534f4b8413f2279bfe29f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c1b55d99d3a4d06949a1920a27b38ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i705217f95c8147c9a0aef1b16e6593b9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mrsn:LicenseAgreementMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia138aba2a3b3406494fad2a37a13b0ee_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="ib699aaf9d802436e8631493e14953d6c_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:DevelopmentAndRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="ic7ee2b32513f4e59b994d6020d4f8ef4_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:JanssenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrsn:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i89e4886837f24a38b80b1747ed92ef46_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">mrsn:SynaffixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrsn:AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-17</instant>
        </period>
    </context>
    <context id="ib6fa9d8c34a04518a93d648eb4c54a81_D20220101-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="i5fa034c85dbc456988299ee454032879_D20220101-20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-02-25</endDate>
        </period>
    </context>
    <context id="ie7884cd54894446b89c3403a61b91a97_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001442836</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mrsn:AtMarketEquityOfferingProgram2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="target">
        <measure>mrsn:target</measure>
    </unit>
    <unit id="milestone">
        <measure>mrsn:milestone</measure>
    </unit>
    <unit id="agreement">
        <measure>mrsn:agreement</measure>
    </unit>
    <unit id="vote">
        <measure>mrsn:vote</measure>
    </unit>
    <unit id="jurisdiction">
        <measure>mrsn:jurisdiction</measure>
    </unit>
    <unit id="audit">
        <measure>mrsn:audit</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xNi0xLTEtMS0xNDM0Mg_b30060a3-52bb-40d6-ab8a-5d87efb69256">0001442836</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xOC0xLTEtMS0xNDM0Mg_14d1b3ea-ce46-464d-a6a3-37f4d069ee20">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18xOS0xLTEtMS0xNDM0Mg_f83e2399-28c8-4040-b4eb-bc51b3fa154e">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N180L2ZyYWc6YTM0NTVjMWU5MWM4NGRiNGIyNTNhZWY3NDdkNzU1YzcvdGFibGU6NmY1NTI2YjI4Y2RhNDY0MTg5MGIxYTFjMzhhYmI3YWMvdGFibGVyYW5nZTo2ZjU1MjZiMjhjZGE0NjQxODkwYjFhMWMzOGFiYjdhY18yMC0xLTEtMS0xNDM0Mg_3136b473-2503-4c8c-98e2-1bd56c8b486b">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEy_458933e5-d883-4908-a432-7ecc34167990">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAw_4b6b80c2-1137-40b5-a617-d065ade6f4d7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yMTQ_9a611f80-7233-4fda-b5a0-2455f3c82a0e">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yMTQ_71eddbf8-e55e-407e-b707-9cccf173cf2f">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA2_94e65d35-f728-4187-adcd-96f0dd9f8ca2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDE1_a877bc77-280c-4f7d-ad0f-5f0fd9885491">001-38129</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA4_53e2ace6-eba3-4915-9df9-d7d9353045d8">Mersana Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8wLTAtMS0xLTE0MzQy_82bcd39f-5f3f-47cb-a1f6-6edbf07324e2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8wLTItMS0xLTE0MzQy_da4f2f3a-548e-4b4b-bb94-bcaecc6b7977">04-3562403</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfNA_76ba928a-16ef-4160-bf57-bdda1d88ec99">840 Memorial Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfNw_ec3263ab-6063-4cd6-810a-649af78d6a16">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTAtMS0xLTE0MzQyL3RleHRyZWdpb246ODI4OWNkMjAyZWNiNGNlZGIzNTdmYzgwMzI4ZGVmZGFfMTE_9b788638-f8b7-4f07-8725-4fd482055dd7">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OWQzMjQ1MzQ2YWVjNGVmNDlhMDRiZjA1ZmQwNDlhZjkvdGFibGVyYW5nZTo5ZDMyNDUzNDZhZWM0ZWY0OWEwNGJmMDVmZDA0OWFmOV8zLTItMS0xLTE0MzQy_3b9e688e-a6e9-4eb5-a8ea-d8f27949b0e3">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDA5_31e476ee-9b37-4dc3-a318-fb2e2edcb5e7">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEw_94e5322a-5778-4710-b364-0054555c6f3c">498-0020</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTAtMS0xLTE0MzQy_7d880790-878f-419a-b1cb-74efd02fbc44">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTEtMS0xLTE0MzQy_bd4c5439-1114-4bfa-851b-b454ccdaad4c">MRSN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6YjEwOGIxYmVmYTAzNGY5ZThmMjMxMmQ5MTI3MWY1ZjEvdGFibGVyYW5nZTpiMTA4YjFiZWZhMDM0ZjllOGYyMzEyZDkxMjcxZjVmMV8xLTItMS0xLTE0MzQy_a1bac47b-e859-4de7-8339-19aba1a29998">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF80Mzk4MDQ2NTE2NjQz_0f2f0267-8d5e-4f80-8f54-82eb0077a564">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAx_acdb2f88-8857-45e6-92eb-ef31f3057094">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMzk4_e14cb182-248a-4289-8829-fff6fcd747f8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMzk5_ae0b8031-82a4-4b25-ac07-b5459b85c0ae">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8wLTAtMS0xLTE0MzQy_7f54c532-affc-4c26-9f84-17f702f714b7">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8xLTMtMS0xLTE0MzQy_2092d6be-30e6-42bd-830b-31ffe720ff82">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGFibGU6OGVjM2E4MmNkY2ZkNDY3YTg2MTcyOGI5NDU2MWFjN2IvdGFibGVyYW5nZTo4ZWMzYTgyY2RjZmQ0NjdhODYxNzI4Yjk0NTYxYWM3Yl8yLTMtMS0xLTE0MzQy_a0bc76a1-b483-453a-b231-013c6ef7588c">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDEx_f037ca0a-ffd1-45e9-a4e5-0c06ca1876ec">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDE2_169f730d-6617-4616-abd2-73652ea43f08">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ia3e7551cb27b48f7ae6ca63cb9d0f3a0_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8yOTky_62a09884-18fe-474e-b16b-1c40d738df7a"
      unitRef="usd">799836646</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i7fc42ca8bd44444faceba42910feb1ec_I20220225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zMTI5_99082ccc-303d-4a55-90e9-615ccc2ff77b"
      unitRef="shares">83389806</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xL2ZyYWc6NzY5YmFmOTk0MmJiNGY5NTgzMDM3NTRhMmY0YTQwOGQvdGV4dHJlZ2lvbjo3NjliYWY5OTQyYmI0Zjk1ODMwMzc1NGEyZjRhNDA4ZF8zNDAz_c22ff07e-06f0-458e-bd7e-6493307dbabb">Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant&#x2019;s fiscal year ended December 31, 2021 are incorporated by reference in Part III of this Annual Report on Form 10-K to the extent stated herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N182Ny9mcmFnOmVkYWMxODkyMzI3MDQ1ZTE4MjhhZWU2MDQwYzJmMWMyL3RleHRyZWdpb246ZWRhYzE4OTIzMjcwNDVlMTgyOGFlZTYwNDBjMmYxYzJfNzE0NjgyNTU4MzY3Ng_8057e5ee-8653-442c-bdfa-a8f3410ee462"
      unitRef="usd">25000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <dei:AuditorFirmId
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183MC9mcmFnOjdlNDYwMDMxNTEzNzQ4MzNiNGMxYTVkODI3Zjc0NTRjL3RhYmxlOjY3MGVhZTA2ODIwZjQ3YTM5MmQyNTY5Nzc3OTZlNGU0L3RhYmxlcmFuZ2U6NjcwZWFlMDY4MjBmNDdhMzkyZDI1Njk3Nzc5NmU0ZTRfMS0wLTEtMS0xODE0Ni90ZXh0cmVnaW9uOjdhMTQ1ZWNjYzY5YTQzNmFhYmU2NDVmMWY5YmJiMTFkXzQzOTgwNDY1MTExODY_fda4a4db-8dae-4376-920f-6df26d4e4d78">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183My9mcmFnOjU5YTExNmQ0YmM2NDQxZGJiNWQyMTQ3ZjAzNzEzZWZlL3RleHRyZWdpb246NTlhMTE2ZDRiYzY0NDFkYmI1ZDIxNDdmMDM3MTNlZmVfMjg1ODczMDIzMjk4MjM_c2c94ceb-3e83-49b6-8275-faa532f51631">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183My9mcmFnOjU5YTExNmQ0YmM2NDQxZGJiNWQyMTQ3ZjAzNzEzZWZlL3RleHRyZWdpb246NTlhMTE2ZDRiYzY0NDFkYmI1ZDIxNDdmMDM3MTNlZmVfMjg1ODczMDIzMjk4MjQ_af2d87ca-d3a7-4198-9a2e-3cf9be5dcc24">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMy0xLTEtMS0xNDM0Mg_b5ec9727-375e-493a-a247-24bf81aa37e5"
      unitRef="usd">177947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMy0zLTEtMS0xNDM0Mg_bbb55718-89e9-4ea9-ace3-373715a4be2a"
      unitRef="usd">255094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNi0xLTEtMS0xNDM0Mg_b8d39333-fb90-468f-b1b5-3b36aa3949dd"
      unitRef="usd">10951000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNi0zLTEtMS0xNDM0Mg_187c18a9-dc8c-4735-a656-8f4ea0da99c7"
      unitRef="usd">3486000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNy0xLTEtMS0xNDM0Mg_b1b49c7e-516e-4b24-8172-4a24062022be"
      unitRef="usd">188898000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfNy0zLTEtMS0xNDM0Mg_eaad561b-6400-48f3-8b10-7bc911f978f4"
      unitRef="usd">258580000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOC0xLTEtMS0xNDM0Mg_a1949567-502b-4509-b900-19bbca77608d"
      unitRef="usd">1968000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOC0zLTEtMS0xNDM0Mg_a5f8e612-ba1b-4f30-b1fb-097a88fc3159"
      unitRef="usd">1730000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOS0xLTEtMS0xNDM0Mg_eaf7f3f0-15c2-4923-a22a-dc7a1dd15b36"
      unitRef="usd">12889000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfOS0zLTEtMS0xNDM0Mg_e5ac401b-57f7-48ff-a69d-a7d4a6eeca7d"
      unitRef="usd">10936000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTAtMS0xLTEtMTQzNDI_bf597c7c-b3a7-4b0c-bdcb-226a0da9095a"
      unitRef="usd">2356000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTAtMy0xLTEtMTQzNDI_5d8b2d69-1ba5-49f3-8580-b2b5a881ec44"
      unitRef="usd">2153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTEtMS0xLTEtMTQzNDI_6f3f9d29-0fe6-425d-8d64-0ce451de42a4"
      unitRef="usd">206111000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTEtMy0xLTEtMTQzNDI_00b2afa5-ed2f-4a8a-b920-14b9de6c217d"
      unitRef="usd">273399000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTQtMS0xLTEtMTQzNDI_feb52814-ce50-4755-bdfc-051b6c5b6a48"
      unitRef="usd">12321000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTQtMy0xLTEtMTQzNDI_afaae9ba-2e53-47e1-af82-549a9476bcc4"
      unitRef="usd">8340000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTUtMS0xLTEtMTQzNDI_cab43154-4090-47e0-9ccf-a5fd65246146"
      unitRef="usd">28716000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTUtMy0xLTEtMTQzNDI_0015543b-b0d4-49b1-9a5b-93ce12901f13"
      unitRef="usd">16146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTYtMS0xLTEtMTQzNDI_b6933404-8536-4a2f-a6d8-6d823fab4e6c"
      unitRef="usd">3944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTYtMy0xLTEtMTQzNDI_31f3b4b6-567c-470f-abc6-f4ae950c72f8"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTctMS0xLTEtMTQzNDI_2a2a4450-daad-486f-83ad-f608df9c15f4"
      unitRef="usd">2303000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTctMy0xLTEtMTQzNDI_00cbfb6a-4d05-4a97-99fe-31531472d4d8"
      unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTktMS0xLTEtMTQzNDI_f80e25a9-82f7-4521-aca2-7f38872f59c6"
      unitRef="usd">239000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMTktMy0xLTEtMTQzNDI_2b0b82e2-176c-4aa4-8199-448de8a5bfeb"
      unitRef="usd">93000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjAtMS0xLTEtMTQzNDI_783a73b1-bc61-426b-8084-d84b53812b89"
      unitRef="usd">47523000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjAtMy0xLTEtMTQzNDI_4829c51f-10b3-45ae-89d4-c114165803ab"
      unitRef="usd">30003000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjEtMS0xLTEtMTQzNDI_3b2340ee-2b45-48fd-b3d2-083a33697d9e"
      unitRef="usd">11247000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjEtMy0xLTEtMTQzNDI_a4e42467-67fc-411f-aea6-cb87011c21b6"
      unitRef="usd">10158000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjItMS0xLTEtMTQzNDI_7a480859-df9f-4f11-938c-53120ac935db"
      unitRef="usd">24626000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjItMy0xLTEtMTQzNDI_fcfe2112-b221-4f42-99c7-f7412667e7f4"
      unitRef="usd">4977000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjMtMS0xLTEtMTQzNDI_5b396c75-d40c-4252-9cc3-8b8cf9adddbe"
      unitRef="usd">974000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjMtMy0xLTEtMTQzNDI_207a66f6-b0f2-458a-b05c-323449a07972"
      unitRef="usd">174000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjQtMS0xLTEtMTQzNDI_c19121f9-450e-49b0-894d-28bf4426ce2e"
      unitRef="usd">84370000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjQtMy0xLTEtMTQzNDI_b28df35c-fb3f-473b-8f3c-6121c5387579"
      unitRef="usd">45312000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjUtMS0xLTEtMTQzNDI_1321e33f-57e6-4f42-ba24-3f54842edc09"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjUtMy0xLTEtMTQzNDI_9d8e0058-8d6f-4b18-8ff6-720d0bf50fb7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8yMQ_32213049-c535-4a6a-86b2-e56bb358a27f"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8yMQ_598f148e-0237-44e9-99f1-48af4ecb99c4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8zNQ_80fc022f-b6fa-4186-9704-57f5efbf3b79"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV8zNQ_cec385f8-527e-44f0-a804-ad54157bbdda"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_2438662d-f377-47f5-b8d6-d66c165bfc16"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_de8b37cc-da18-415e-a54c-3f592a62628c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_e0075950-1ab5-4f9b-b657-38a13ac3d22b"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjYTZlYWIwYzJhYzA0MDc4ODI3OTdjNGVhNjUyYzI1ZV81Nw_fdf6f98c-cbbc-4ab6-a888-970818499daf"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMS0xLTEtMTQzNDI_a0b1c433-4cda-4661-84ac-b6e08a87cd1d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjctMy0xLTEtMTQzNDI_4e7fe15c-b091-44d5-9230-d9a829437150"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8xOA_4bfcfeb0-8afd-435f-bcd9-7b39da1b3dd0"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8xOA_957bc2c5-74e6-4917-b7b0-46e2a67c99d3"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8zMg_372042d6-827d-462a-9f1d-f8d6eae0a070"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV8zMg_a34993da-9458-4fa9-8adb-020cf07fdef8"
      unitRef="shares">175000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV81NA_936d4462-849f-463a-a2ae-36a484db2393"
      unitRef="shares">73709056</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV81NA_b2be85d6-c8d4-40e3-92d1-6d809aad5095"
      unitRef="shares">73709056</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV82MQ_ddbadf7d-1f83-4662-808d-aae7c5642da2"
      unitRef="shares">68841288</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpjMWMxZDQ0NzU3YzU0OGYyYmVlYjYwNmE4NTczMWJhOV82MQ_f8d26cac-6190-4eff-8abc-2281813b0ffd"
      unitRef="shares">68841288</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMS0xLTEtMTQzNDI_9d17ffba-d50c-497c-bef8-bf137613324a"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjgtMy0xLTEtMTQzNDI_d6a7fd9d-c579-48e8-9b08-09e1e813159c"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjktMS0xLTEtMTQzNDI_0773ec8f-9487-4b66-a19c-fabc62b8f1a9"
      unitRef="usd">572213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMjktMy0xLTEtMTQzNDI_76b7975f-ae8c-4a12-bf33-0bbd9db3f2a6"
      unitRef="usd">508499000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzEtMS0xLTEtMTQzNDI_172e66bd-9788-4d88-ba09-e07790af8abf"
      unitRef="usd">-450479000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzEtMy0xLTEtMTQzNDI_f921c547-9b20-4aaf-b8d5-52cd9447ea45"
      unitRef="usd">-280419000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzItMS0xLTEtMTQzNDI_daae871a-df5d-4267-bec2-94ffe49643e8"
      unitRef="usd">121741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzItMy0xLTEtMTQzNDI_aa257e92-4298-4d9c-a119-3e837f605764"
      unitRef="usd">228087000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzMtMS0xLTEtMTQzNDI_f5e11735-c3e1-4d12-9c88-f6cf954ff711"
      unitRef="usd">206111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183Ni9mcmFnOjVhNjNiZDljNTRlYTQ3MzE4MjYyNzc2MjlmMTMxZWM0L3RhYmxlOjA1MzA1YzQ0ZjcxNTQxNzI4ZDEzYjhlM2FiOGY3YmExL3RhYmxlcmFuZ2U6MDUzMDVjNDRmNzE1NDE3MjhkMTNiOGUzYWI4ZjdiYTFfMzMtMy0xLTEtMTQzNDI_8796ff47-cddd-4727-a74c-c38fa88729f8"
      unitRef="usd">273399000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi0xLTEtMS0xNDM0Mg_aba8dc7a-f8d1-40d1-8867-abc3c14d5363"
      unitRef="usd">43000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi0zLTEtMS0xNDM0Mg_cb78efea-45b1-444b-872e-16918e515faa"
      unitRef="usd">828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMi01LTEtMS0xNDM0Mg_265fcbe6-61e6-4f89-92aa-3ad1c8f5f15e"
      unitRef="usd">42123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC0xLTEtMS0xNDM0Mg_eff8bd66-6fab-4ee8-83c0-5eb11eed084f"
      unitRef="usd">132013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC0zLTEtMS0xNDM0Mg_1d6c733b-1f0f-4e08-8b49-d7840842afe6"
      unitRef="usd">67036000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNC01LTEtMS0xNDM0Mg_8265709d-2f51-4dd1-a8b3-4db50e619b30"
      unitRef="usd">55040000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS0xLTEtMS0xNDM0Mg_b2eb826d-402c-4421-a088-174ca9676c6a"
      unitRef="usd">36888000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS0zLTEtMS0xNDM0Mg_25a5e6ef-12f9-47bd-9d44-ed771b3c04ea"
      unitRef="usd">21902000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNS01LTEtMS0xNDM0Mg_42cbeae9-2a38-483e-a327-0069374cbd6e"
      unitRef="usd">17283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi0xLTEtMS0xNDM0Mg_ffcc5614-f9b5-4048-9d7c-51738f564e59"
      unitRef="usd">168901000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi0zLTEtMS0xNDM0Mg_e21f6e9b-7bc0-4f19-9bb4-3c39d17b147d"
      unitRef="usd">88938000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfNi01LTEtMS0xNDM0Mg_940d99e1-1d26-40f8-a127-0167722c15dd"
      unitRef="usd">72323000</us-gaap:OperatingExpenses>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC0xLTEtMS0xNDM0Mg_1cb95c7b-261c-4e11-b44d-f34913ca110b"
      unitRef="usd">65000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC0zLTEtMS0xNDM0Mg_4d0071dd-64b7-49d0-a30d-f4346cd46184"
      unitRef="usd">424000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOC01LTEtMS0xNDM0Mg_cbd6df39-ff9c-452e-8733-77aea3698deb"
      unitRef="usd">2226000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS0xLTEtMS0xNDM0Mg_91aac8b0-f711-4079-ba4e-1065e9f5dcd9"
      unitRef="usd">1267000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS0zLTEtMS0xNDM0Mg_0a954f32-a57d-4d86-8596-f4961bbeae68"
      unitRef="usd">359000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfOS01LTEtMS0xNDM0Mg_15555a8a-25c2-4938-a5dc-4008094dd88a"
      unitRef="usd">234000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtMS0xLTEtMTQzNDI_5004be2d-29dc-4c3d-8965-3e629e0dfeb4"
      unitRef="usd">-1202000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtMy0xLTEtMTQzNDI_c33bcfd7-8e55-425b-abdd-c52d6abe3007"
      unitRef="usd">65000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTAtNS0xLTEtMTQzNDI_7d7129a3-7ffe-4c24-aaca-a4580dc6a017"
      unitRef="usd">1992000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtMS0xLTEtMTQzNDI_a6c06875-122a-448f-8426-627aacdf0b8d"
      unitRef="usd">-170060000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtMy0xLTEtMTQzNDI_b0fa8af4-dfbe-4a34-8b68-c31d3c73606c"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTEtNS0xLTEtMTQzNDI_da8315e9-2fb5-4e76-b867-80df1a807688"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtMS0xLTEtMTQzNDI_e496a9d0-991a-4c82-ad34-f388a9b62274"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtMy0xLTEtMTQzNDI_bf952b70-f649-4c2b-9d00-be37a33429bc"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTMtNS0xLTEtMTQzNDI_eeb9cb15-d4ab-453a-b964-4b8f1a826493"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtMS0xLTEtMTQzNDI_4a393f62-85c7-428c-bd1d-957e26423814"
      unitRef="usd">-170060000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtMy0xLTEtMTQzNDI_305de681-2105-4c2f-a7f3-1e92488d8105"
      unitRef="usd">-88070000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTQtNS0xLTEtMTQzNDI_2784e70b-8f65-434b-9f13-23f392ead49e"
      unitRef="usd">-28175000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMS0xLTEtMTQzNDI_240f0fe4-2d94-4d2b-820b-b1486d220bed"
      unitRef="usd">-170060000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMS0xLTEtMTQzNDI_2551dc28-2bcd-4ef0-bfbc-fd540ef37a1a"
      unitRef="usd">-170060000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMy0xLTEtMTQzNDI_1537a390-22c5-4cbf-ab67-89d8ffc6e685"
      unitRef="usd">-88045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtMy0xLTEtMTQzNDI_cfff28a4-2e8d-4aba-a716-454b5e86e0b3"
      unitRef="usd">-88045000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtNS0xLTEtMTQzNDI_7236e12e-0509-4a0b-9f8c-c11c48646d23"
      unitRef="usd">-28208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTUtNS0xLTEtMTQzNDI_96f71f33-6011-41f4-8dfd-0106fe71d60a"
      unitRef="usd">-28208000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMS0xLTEtMTQzNDI_5ef14567-e30c-47fe-b128-16a73d427473"
      unitRef="usdPerShare">-2.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMS0xLTEtMTQzNDI_bd1b7f3d-1818-4730-8f22-4f9b5d6cdee4"
      unitRef="usdPerShare">-2.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMy0xLTEtMTQzNDI_372a600f-f6fb-4708-8d9c-55f393a1b889"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtMy0xLTEtMTQzNDI_cb411d58-0cce-476b-b147-fbaeb202d040"
      unitRef="usdPerShare">-1.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtNS0xLTEtMTQzNDI_a9595224-9e04-433f-a54c-a11f38a7245f"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTYtNS0xLTEtMTQzNDI_c98ba7f8-267f-44e8-934c-60faaf512fe5"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMS0xLTEtMTQzNDI_3caaf802-2a96-4ea4-b030-32e280851e7d"
      unitRef="shares">70580949</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMS0xLTEtMTQzNDI_73b54f8f-0da9-4b16-951e-3279e65a6073"
      unitRef="shares">70580949</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMy0xLTEtMTQzNDI_27081e00-9a44-4b00-87d3-cafe021860a6"
      unitRef="shares">61485205</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctMy0xLTEtMTQzNDI_7e89d2fa-a552-43aa-bd4f-71a363189b00"
      unitRef="shares">61485205</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctNS0xLTEtMTQzNDI_45e6b09a-3ad2-4075-9601-9a9a7ecdfca5"
      unitRef="shares">43492113</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N183OS9mcmFnOjBkOTNjZWQ1ZjlkNzQ5Yzg5ZjVlYTM2NDg5MzMxMDczL3RhYmxlOmU3NTQxZTlhYTI5MjQwNjQ4ODZkZGUzZTdiNDUwM2FjL3RhYmxlcmFuZ2U6ZTc1NDFlOWFhMjkyNDA2NDg4NmRkZTNlN2I0NTAzYWNfMTctNS0xLTEtMTQzNDI_7eee68d8-e90d-4897-8976-41696fd05011"
      unitRef="shares">43492113</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0xLTEtMS0xNDM0Mg_af7f379d-7685-4472-9682-b8aeed624513"
      unitRef="shares">23234472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0zLTEtMS0xNDM0Mg_73f5784d-f02c-44ff-99bc-15bfd9139d2b"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i81852bd3e7134038a2f1b0bf58ab6969_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi01LTEtMS0xNDM0Mg_21b5ae1e-6bb7-4d12-990a-ffa365a024ad"
      unitRef="usd">172966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i514791eca1f44909a5e5f94b71ea3a98_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi03LTEtMS0xNDM0Mg_9f0bd979-e1b6-45af-bd67-bd9d9615ef1e"
      unitRef="usd">-8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99fce85f8b8644a3b03a21943edd68ed_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi05LTEtMS0xNDM0Mg_b08e1090-f3a4-4b08-a5bd-762fac453ad4"
      unitRef="usd">-164166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMi0xMS0xLTEtMTQzNDI_776472ac-4cb4-41f9-9695-c8224d10ce2a"
      unitRef="usd">8795000</us-gaap:StockholdersEquity>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0wLTEtMS0xNDUzMC90ZXh0cmVnaW9uOjNjNjM5YjQyY2YwYzQyZWY4YjY1ODg1NTFmYTJkMzk3Xzc3_f4c1037a-7665-4f9a-8849-dc633756808e"
      unitRef="usd">5587000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0xLTEtMS0xNDUyNA_9255c3ea-18d5-4858-b8d7-66840e936142"
      unitRef="shares">24437500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2fb893b7e6cb41379815f434acd8561f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0zLTEtMS0xNDUyNA_5db5533b-6479-4196-801f-48b9d0dc7410"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5086b7eefe4a4fd9a4cd20e7feb840a8_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy01LTEtMS0xNDUyNA_92dc9983-bea4-4dfa-931b-71977859265d"
      unitRef="usd">92160000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMy0xMS0xLTEtMTQ1MjQ_8c1652a0-8707-498a-8350-583307176fa5"
      unitRef="usd">92162000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised
      contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC0xLTEtMS0xNDM0Mg_6dd2e3bc-8ec8-43fb-8adb-dbb5d53d4b7c"
      unitRef="shares">150978</mrsn:StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised>
    <mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC01LTEtMS0xNDM0Mg_78597789-14a5-46c8-87f1-c25c1197d7f2"
      unitRef="usd">175000</mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNC0xMS0xLTEtMTQzNDI_95054e5c-91ef-483e-b73f-3b0fec85fb77"
      unitRef="usd">175000</mrsn:StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS0xLTEtMS0xNDM0Mg_4aeb6364-617c-4154-bd0d-890b145a7e9c"
      unitRef="shares">140073</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS01LTEtMS0xNDM0Mg_a42817ab-7266-4cb9-8a68-7edc8f27716d"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNS0xMS0xLTEtMTQzNDI_c6555bbc-925b-4afc-9acd-6bb4a3e75d63"
      unitRef="usd">489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares
      contextRef="i2c7c61b4dfb84f9bb9e18165e54aec63_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xLTEtMS0xNDU0Mw_7ecf6966-2cca-46f2-b19e-d69066d29c6b"
      unitRef="shares">2575000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantShares>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue
      contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi01LTEtMS0xNDU0Mw_c325b573-ecc9-4661-83b3-991daa0b3cc8"
      unitRef="usd">8986000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue>
    <mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xMS0xLTEtMTQ1NDM_608fa07a-ec2a-4ec9-a688-e21e726bc90e"
      unitRef="usd">8986000</mrsn:StockRetiredDuringPeriodExchangedForCommonStockWarrantValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy01LTEtMS0xNDU0Mw_8fd547aa-2b8e-4bb6-80c9-dd4f69fa2906"
      unitRef="usd">8986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy0xMS0xLTEtMTQ1NDM_7bbe1bd9-27a5-4fd4-b4bc-a610a8e9eae2"
      unitRef="usd">8986000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i11157f9340e348809b520ac7d632cb8e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi01LTEtMS0xNDM0Mg_1f2c5733-c8e1-4db2-8f5b-2c9307d91dc6"
      unitRef="usd">4872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNi0xMS0xLTEtMTQzNDI_397f9e93-69f8-4d37-bd1a-975acbfee977"
      unitRef="usd">4872000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9be11c24e8ce4dcf855d9e19a0e8605d_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy03LTEtMS0xNDM0Mg_7f4c63d2-7722-40b7-b86d-e74fd6bdfc89"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfNy0xMS0xLTEtMTQzNDI_e1fb6ff7-0c70-4a1d-8e20-6a884bba3bd9"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1625de5080394e76934616170e525c3e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOC05LTEtMS0xNDM0Mg_8e36774c-f51f-4017-9ffc-a26da75faf81"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOC0xMS0xLTEtMTQzNDI_bfe81a6e-77c7-4b8b-9ec0-80e615d06bdd"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i2263e5f0b5374b6eb63797459412baea_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0xLTEtMS0xNDM0Mg_9fcdc777-1456-467b-ac56-059a954e8798"
      unitRef="shares">45388023</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2263e5f0b5374b6eb63797459412baea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0zLTEtMS0xNDM0Mg_fb5ea550-fc9c-4ad1-a2df-368d2c117e3d"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5079a121336542a2ad5e6a69a5d2da56_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS01LTEtMS0xNDM0Mg_b7bcbeef-5957-420f-be7c-1d8458a9c24c"
      unitRef="usd">270662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i73784c7eb6bd4fecafcc0ade4d41a8ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS03LTEtMS0xNDM0Mg_2fe1fcf5-37b4-4126-93c8-7fd5b44eb7ab"
      unitRef="usd">25000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i90e630e58b154d58ada0eb8b3903547b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS05LTEtMS0xNDM0Mg_013ef5d6-f724-4a87-a6b8-177ec7bdfe29"
      unitRef="usd">-192374000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfOS0xMS0xLTEtMTQzNDI_c6c659b2-27c5-404e-baa5-8cfc71b1004f"
      unitRef="usd">78318000</us-gaap:StockholdersEquity>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMC0xLTEtMTQ1NzYvdGV4dHJlZ2lvbjo2MDJlMDY4MjU1NWE0NDQwYTA2YzhjOGNlYzFlZjExMV8zODQ4MjkwNjk3MzQz_fd9cedaf-dfd6-4327-81e0-daaa76c67888"
      unitRef="usd">2176000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMS0xLTEtMTQ1Nzk_799d16ef-1a1c-4636-979a-6dacd0421afe"
      unitRef="shares">10900599</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMy0xLTEtMTQ1Nzk_41d751f6-4a51-4f20-a8ca-e1b373b5ed55"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0901ec303026453cb60c34b79bfee33d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItNS0xLTEtMTQ1Nzk_02ba4eff-70d8-4960-8e07-08b2a147f133"
      unitRef="usd">62976000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMTEtMS0xLTE0NTc5_82afc4dc-a0ca-41a8-9d73-27aa0b9f0605"
      unitRef="usd">62977000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMC0xLTEtMTQ1NzYvdGV4dHJlZ2lvbjpmNTQ1OWYyM2EzNDM0MTIzOTQxNDBjMmFmYzJiNTgxYl83Nw_c04300aa-ff6e-4e06-9561-df50f635d213"
      unitRef="usd">10809000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMS0xLTEtMTQ1Nzk_587b3031-46c7-4d44-92a1-251d07cfb004"
      unitRef="shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia9d59a9014ec4ea8919146c53f4e033a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMy0xLTEtMTQ1Nzk_546ab9b7-a0d6-48ac-99e5-a8f4f27a73d7"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i01fe62fe6f7e48d490b1f867f9484c23_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtNS0xLTEtMTQ1Nzk_a85d36f5-2e83-432d-a560-36465291004f"
      unitRef="usd">163990000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTMtMTEtMS0xLTE0NTc5_b12f3c08-389d-4f0c-893f-035782ee6b31"
      unitRef="usd">163991000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised
      contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTQtMS0xLTEtMjE0NTI_06c5f9ab-d426-4539-9c65-f060d92fb77e"
      unitRef="shares">2574971</mrsn:StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtMS0xLTEtMTQzNDI_5c2409e4-9c52-446f-98d4-d88def90fb4e"
      unitRef="shares">697428</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtNS0xLTEtMTQzNDI_5f23fabd-3059-4574-83d2-af87e205b7aa"
      unitRef="usd">3138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTEtMTEtMS0xLTE0MzQy_6ad38378-502b-4c9c-a5be-55132eeac641"
      unitRef="usd">3138000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i79c4933647dd4d99ac82643991a7b5dd_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMS0xLTEtMTQzNDI_5ec6232a-09b8-4556-adf8-dda4b02d36d3"
      unitRef="shares">80267</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItNS0xLTEtMTQzNDI_6bb0da93-6ffa-4933-b38a-ca8a49bc80ea"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTItMTEtMS0xLTE0MzQy_a4777c38-2cf6-48ac-bb57-cc26ccecae54"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i50e76704aa1d48c09ef487e56f041a5b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTUtNS0xLTEtMTQzNDI_47201990-d56c-48d7-a598-3f2e9fcdfde2"
      unitRef="usd">7172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTUtMTEtMS0xLTE0MzQy_a354aedd-2815-4847-88b2-2d915d354b73"
      unitRef="usd">7172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1be31f3383e848e98115c2ab8721f353_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTYtNy0xLTEtMTQzNDI_f00f9b3f-7716-4229-a1df-30ad665d6532"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTYtMTEtMS0xLTE0MzQy_f0fd4269-53a6-4e77-9265-16b1655aae15"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic668054d04aa44eeb592807dc2bc4b8a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTctOS0xLTEtMTQzNDI_d5565661-4ff9-4a07-867e-f06d3fd76129"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTctMTEtMS0xLTE0MzQy_37c729ad-3eac-4d61-977b-179df1953b3a"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i08fa6f9dba864472a6d18ffa609a28c1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMS0xLTEtMTQzNDI_7e6b1b3d-c411-4087-8b5a-1eac394a408b"
      unitRef="shares">68841288</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i08fa6f9dba864472a6d18ffa609a28c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMy0xLTEtMTQzNDI_5b2b12fc-8964-445e-9590-dd3874398bc9"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67df1b00583c408f8c9ae48510a0ca54_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtNS0xLTEtMTQzNDI_b8289b3f-2882-4b0c-8b07-e92f2d1561f8"
      unitRef="usd">508499000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8074fd8df0f64ee79d269ef09013964b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtNy0xLTEtMTQzNDI_25c4cfca-98a4-463b-9810-79c08f2ba014"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id2978fef777442ca8ce412714c126f1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtOS0xLTEtMTQzNDI_e5d0258f-1b42-43c4-aeda-013bb1e16de5"
      unitRef="usd">-280419000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTgtMTEtMS0xLTE0MzQy_f7424100-010f-4d09-8ffd-1e1316a7fc61"
      unitRef="usd">228087000</us-gaap:StockholdersEquity>
    <mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction
      contextRef="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMC0xLTEtMTQzNDIvdGV4dHJlZ2lvbjpiNTc1N2Y2MDE0YWM0MTg1YWExODk5ZTNkZjdiZGZkNl8zODQ4MjkwNjk3MzIz_535a5ec4-4659-4ad1-b563-23ddfc3e0b05"
      unitRef="usd">988000</mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMS0xLTEtMTQzNDI_3a51a725-9d1e-4b58-817b-b1ae821d3ccd"
      unitRef="shares">3961074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i316531b1bea0420aa2f2b09a689cd4aa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktNS0xLTEtMTQzNDI_03e87319-8731-4aad-a0e3-a55ce5d3b3b6"
      unitRef="usd">43087000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i19fe06fc68864c999c081bda0c02713e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMTktMTEtMS0xLTE0MzQy_a14a384f-c9e2-406d-9158-175415b4002f"
      unitRef="usd">43087000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItMS0xLTEtMTQzNDI_4276c490-c68b-4d26-91ab-2500b5e872ff"
      unitRef="shares">421381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItNS0xLTEtMTQzNDI_dcc06555-5f61-4e9d-a302-f1e3badd0990"
      unitRef="usd">1837000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjItMTEtMS0xLTE0MzQy_2f28a8cb-8d59-4ccf-a3cc-2d20e2324e35"
      unitRef="usd">1837000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMS0xLTEtMTY0MTc_2409980b-99d9-4273-bdf2-a68aa1af5972"
      unitRef="shares">407060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtNS0xLTEtMjE0NTc_5d22737a-7cba-4cfe-a3cc-cad4311131b8"
      unitRef="usd">259000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMTEtMS0xLTIxNDU3_a07d6fd9-4cab-433d-bdf6-3236e28e4ad6"
      unitRef="usd">259000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMS0xLTEtMTQzNDI_fc659516-d9e8-47cc-8ec6-ef845cafe73c"
      unitRef="shares">78253</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtNS0xLTEtMTQzNDI_2c594a4c-9a96-460d-913c-dcaa1d656fcf"
      unitRef="usd">640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjMtMTEtMS0xLTE0MzQy_72ab0983-e4b1-4021-9fdd-957070a2faa7"
      unitRef="usd">640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4729807ce3ad471c9246ba62406682e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjQtNS0xLTEtMTQzNDI_72767882-f515-45b5-bb4b-6bf0c2af2c36"
      unitRef="usd">18409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjQtMTEtMS0xLTE0MzQy_233f54bd-8b61-4eec-95f4-bf19e1339ea3"
      unitRef="usd">18409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i03e3cf73141c45a28882cef716068d1d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjYtOS0xLTEtMTQzNDI_f81abba4-336e-4f5f-98c6-f83e209ac307"
      unitRef="usd">-170060000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjYtMTEtMS0xLTE0MzQy_4d86d4e8-559c-4485-ad37-43c2c96dec3c"
      unitRef="usd">-170060000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMS0xLTEtMTQzNDI_373d85dc-5b5e-4b21-9d8f-4344649df53c"
      unitRef="shares">73709056</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifff4dfd91f3844dfb5ec0e18fe4672f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMy0xLTEtMTQzNDI_177311ce-e46b-4e6b-921a-777f79847187"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47e4c776ea1e49f19f94fa71ab035bad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctNS0xLTEtMTQzNDI_f1de44df-7f3f-4bb1-b5d3-7ce87e3a04ed"
      unitRef="usd">572213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4e856d009884f45bf3990d70080916f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctNy0xLTEtMTQzNDI_05c67784-1541-4eff-96df-7235151d8ab7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i416501272258413a9fbcffc3613015f6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctOS0xLTEtMTQzNDI_b0fb1004-7a50-49a5-8a4f-54902677e1c6"
      unitRef="usd">-450479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184NS9mcmFnOmMwZmE4NjljNWNjMzQxNTA5YjlhZDA5MDYxZjlmOTk4L3RhYmxlOmY2MTdmOTMwY2Q0NDQyMTY4YTBkZjU2ZTdlMjMwM2FlL3RhYmxlcmFuZ2U6ZjYxN2Y5MzBjZDQ0NDIxNjhhMGRmNTZlN2UyMzAzYWVfMjctMTEtMS0xLTE0MzQy_88650035-9852-493b-8849-02269d63a88f"
      unitRef="usd">121741000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy0xLTEtMS0xNDM0Mg_4cf7ad8c-7ad4-4492-9742-66dbb26b373a"
      unitRef="usd">-170060000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy0zLTEtMS0xNDM0Mg_fa496f9b-52ff-4807-b72e-d00153198263"
      unitRef="usd">-88045000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMy01LTEtMS0xNDM0Mg_17b705ea-6b37-48f8-80fd-feef84e7ee4a"
      unitRef="usd">-28208000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS0xLTEtMS0xNDM0Mg_9c0f8a9c-1809-4b1d-b7e1-5520f0ab766e"
      unitRef="usd">855000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS0zLTEtMS0xNDM0Mg_c8e1d9a3-d574-45c8-a810-5bc61670f313"
      unitRef="usd">1010000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNS01LTEtMS0xNDM0Mg_3916eb51-9bdf-41a6-b004-84f533be77b0"
      unitRef="usd">1245000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy0xLTEtMS0xNDM0Mg_67c06654-1499-4644-a795-9a436693900d"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy0zLTEtMS0xNDM0Mg_4a6686e4-c021-4ce0-9ad2-e35a6ce55bcc"
      unitRef="usd">86000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNy01LTEtMS0xNDM0Mg_e0510809-0052-45aa-8a35-9659a8a5641a"
      unitRef="usd">222000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC0xLTEtMS0xNDM0Mg_a4731134-2905-4595-bdcb-095f8cd474b3"
      unitRef="usd">18409000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC0zLTEtMS0xNDM0Mg_a8816ba4-362a-4ef1-80c4-4da358e4af37"
      unitRef="usd">7172000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfOC01LTEtMS0xNDM0Mg_a23659cf-66e7-415c-9d9c-3761aa966c2a"
      unitRef="usd">4872000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtMS0xLTEtMTQzNDI_9ff1de75-704b-4804-b3ef-6a78d9c12b43"
      unitRef="usd">-723000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtMy0xLTEtMTQzNDI_aab1c876-1212-44ac-8a2b-ad53b61f2946"
      unitRef="usd">-148000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTAtNS0xLTEtMTQzNDI_d08fa469-c9ca-4438-8539-8f614c4526c1"
      unitRef="usd">-103000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItMS0xLTEtMTQzNDI_b1082b6e-be32-4d60-9b70-31b3d39d09ff"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItMy0xLTEtMTQzNDI_56455993-3ed3-46eb-a5fb-367669362b3e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTItNS0xLTEtMTQzNDI_8f13ee99-12f5-4aaf-8b3f-b14ba4a23f21"
      unitRef="usd">-459000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtMS0xLTEtMTQzNDI_125d9dd0-3800-4031-a62b-44035e40e37a"
      unitRef="usd">2734000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtMy0xLTEtMTQzNDI_3de746de-a5ff-42cf-a323-63a430a7de70"
      unitRef="usd">1950000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTMtNS0xLTEtMTQzNDI_9d59fa72-3010-4d75-8a60-7a4c4dec4a3c"
      unitRef="usd">-2179000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtMS0xLTEtMTQzNDI_4b8c167e-22a9-4fa8-861e-9d2ae6adc323"
      unitRef="usd">718000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtMy0xLTEtMTQzNDI_b8c85bc9-4f66-4fa7-9727-3b20837b7c3e"
      unitRef="usd">700000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTQtNS0xLTEtMTQzNDI_ed7f2336-4ad3-4377-ad60-c22586ca1b43"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtMS0xLTEtMTQzNDI_8e226c4c-8f12-4dfb-9e75-6c83a2b92dc1"
      unitRef="usd">483000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtMy0xLTEtMTQzNDI_e6501de7-8793-4c28-9be0-392f4046ff32"
      unitRef="usd">942000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTUtNS0xLTEtMTQzNDI_8710c371-3079-45e0-b9f6-109cb28c4bdc"
      unitRef="usd">-3110000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtMS0xLTEtMTQzNDI_2f75d3df-9385-4d37-b136-69ee25b96731"
      unitRef="usd">12570000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtMy0xLTEtMTQzNDI_964e6b36-ead4-4fc0-8547-b1707adc86cb"
      unitRef="usd">7280000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTYtNS0xLTEtMTQzNDI_9982cec5-2916-4be2-bfe6-f32ebe06b507"
      unitRef="usd">-3569000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctMS0xLTEtMTQzNDI_f3d858c4-a519-42af-9414-fa550047c3dd"
      unitRef="usd">-1829000</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctMy0xLTEtMTQzNDI_b7dfa449-ff8f-4b05-bb33-88dedb66ee05"
      unitRef="usd">-1642000</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <mrsn:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTctNS0xLTEtMTQzNDI_4bf8da17-c65e-4426-b0a2-2dee0c567707"
      unitRef="usd">-1771000</mrsn:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtMS0xLTEtMTQzNDI_9602e164-538f-4617-8276-352f56bf4b26"
      unitRef="usd">-1827000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtMy0xLTEtMTQzNDI_c55b160d-8940-4347-a6d5-e1a3919485ba"
      unitRef="usd">-1281000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTgtNS0xLTEtMTQzNDI_f3d213e4-e91e-4866-b356-5b2194336eba"
      unitRef="usd">-1883000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktMS0xLTEtMTQzNDI_8036d6ef-f063-48fd-bd9e-3cb64348b5b2"
      unitRef="usd">-43000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktMy0xLTEtMTQzNDI_1b680e38-d7e1-41ad-b105-8c1ae76ce74a"
      unitRef="usd">-828000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMTktNS0xLTEtMTQzNDI_6a44e1f4-0af2-49b1-993a-a1e71ec496f3"
      unitRef="usd">-41381000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMS0xLTEtMTY1Mjc_cac8f5c6-d398-4932-ad70-27b00d492f62"
      unitRef="usd">525000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMy0xLTEtMTY1MzQ_6c3f339e-9dcb-4a6d-98cd-304e5917bf66"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtNS0xLTEtMTY1NDE_23530f5d-377d-4342-9d1d-f3a062eaefc3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMS0xLTEtMTQzNDI_ef4974b5-591b-43f0-9d8a-25b5387d420e"
      unitRef="usd">-139988000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtMy0xLTEtMTQzNDI_119f2993-26bd-4ba1-af7f-1c107a4376cb"
      unitRef="usd">-74696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjAtNS0xLTEtMTQzNDI_18150b94-c055-42e1-8a29-21e5e3f306b6"
      unitRef="usd">-67744000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtMS0xLTEtMTQzNDI_0f0b4fb2-e168-4b2c-be7f-25110364e588"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtMy0xLTEtMTQzNDI_558fc3be-95a4-4f54-9269-3e3791ad64bd"
      unitRef="usd">37500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjMtNS0xLTEtMTQzNDI_e4c369e4-5b1a-4ecf-90ea-3084ea3b84a7"
      unitRef="usd">27000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtMS0xLTEtMTQzNDI_25c05b06-dbb0-4687-bac0-622d9ba33a3b"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtMy0xLTEtMTQzNDI_23c36f54-1b8a-4def-9047-4f3c54ae7e52"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjQtNS0xLTEtMTQzNDI_e51e89f6-b1db-4ca1-b89e-56f7b3a445d4"
      unitRef="usd">53688000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtMS0xLTEtMTQzNDI_cf371ace-98c5-49e9-99bc-ebc4ea518214"
      unitRef="usd">648000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtMy0xLTEtMTQzNDI_d21fec26-ac46-4178-a861-a243c93ee44c"
      unitRef="usd">473000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjUtNS0xLTEtMTQzNDI_baccc98d-42db-4a97-b53c-e5da2e89358b"
      unitRef="usd">605000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtMS0xLTEtMTQzNDI_094c2415-6666-4736-b7be-b8bd7dea964d"
      unitRef="usd">-648000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtMy0xLTEtMTQzNDI_e39b8d90-a621-47b4-bc85-332602d962ad"
      unitRef="usd">37027000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjYtNS0xLTEtMTQzNDI_d4c1172d-ac42-4982-a6ec-6fa2331d14cb"
      unitRef="usd">-27293000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie72f092e073f4caea321165cbb01d83d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktMS0xLTEtMTQzNDI_766e0ada-476f-45e9-9245-f55431e6a558"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3550b8a99c8044fb8e7bd98b487eaa1c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktMy0xLTEtMTQzNDI_fb072e77-31c4-49f9-a672-1e0cb9d22217"
      unitRef="usd">163990000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic9047a21e4f4412ea9a814dffd99e886_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMjktNS0xLTEtMTQzNDI_4f0b06be-2a4c-4888-bb94-d5dd427d2f78"
      unitRef="usd">92162000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7e7ad9dfbc0149afaf920277bb3301a3_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtMS0xLTEtMTQzNDI_c2e156fe-8b44-431f-9f5c-658d39b56cf7"
      unitRef="usd">43087000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i06c71214218f46bb9d5a65ebdabaa5e0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtMy0xLTEtMTQzNDI_834b8ff1-0bd4-40ee-8695-c16bfcaf9357"
      unitRef="usd">63036000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i63559c339ac14a4f808281cc61d2e001_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzAtNS0xLTEtMTQzNDI_db6e28a2-5f80-48ee-b93d-05b9812cb145"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItMS0xLTEtMTQzNDI_245a3acd-2c69-4659-89bf-f1036e4c7bfe"
      unitRef="usd">1837000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItMy0xLTEtMTQzNDI_6f5586ce-4ee0-4e58-8c3b-a32c37634048"
      unitRef="usd">3138000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzItNS0xLTEtMTQzNDI_54b571fc-ad74-4689-b622-a1069654a4f0"
      unitRef="usd">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtMS0xLTEtMTQzNDI_012710e2-26f6-4e58-bbfb-c51858d71190"
      unitRef="usd">640000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtMy0xLTEtMTQzNDI_27a74fcd-1798-49c6-9b0a-b167d0647726"
      unitRef="usd">561000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzMtNS0xLTEtMTQzNDI_e250fc1a-aa30-4fe3-ba9b-129183192649"
      unitRef="usd">489000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMS0xLTEtMTU1Njg_674b3b0e-26a5-4f2b-b70f-e8eb57dcfd96"
      unitRef="usd">259000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMy0xLTEtMTU1Njg_8521d929-99a3-437f-80b1-2faf3b891bac"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtNS0xLTEtMTU1Njg_2bcb9f0d-07b3-49d0-91ef-f20d29e98b8b"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMS0xLTEtMTQzNDI_161c8116-db41-4205-95cb-ca99c69c3d71"
      unitRef="usd">24042000</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtMy0xLTEtMTQzNDI_514baf6e-d0ae-414f-8f59-774c82945551"
      unitRef="usd">-197000</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <mrsn:ProceedsFromDebtNetIssuanceCosts
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzQtNS0xLTEtMTQzNDI_9e820ba8-eabe-4522-a0ef-9d75c0c804b9"
      unitRef="usd">4965000</mrsn:ProceedsFromDebtNetIssuanceCosts>
    <us-gaap:RepaymentsOfDebt
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctMS0xLTEtMTY1NjY_c93b26dd-4af1-4346-b0e0-83a2731aefee"
      unitRef="usd">5486000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctMy0xLTEtMTY1NzQ_5b5a5c27-9da2-4997-b0bd-08e27fc43047"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzctNS0xLTEtMTY1ODY_35cebb4d-3f5c-4698-9c68-6b5a59f2d4e4"
      unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtMS0xLTEtMTQzNDI_845bc1f6-ffab-4251-9223-01d21a859271"
      unitRef="usd">215000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtMy0xLTEtMTQzNDI_62e5b2b9-d86e-46dc-a5bf-d81aba5d5f82"
      unitRef="usd">116000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzUtNS0xLTEtMTQzNDI_4e2a264b-4094-4cc0-a28f-f3a62710ff9b"
      unitRef="usd">87000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtMS0xLTEtMTQzNDI_421bec31-913c-4eef-955b-bb18d18b3d1b"
      unitRef="usd">63646000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtMy0xLTEtMTQzNDI_18899bff-defb-4cb2-a869-b8e6df1eb3f9"
      unitRef="usd">230412000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzYtNS0xLTEtMTQzNDI_a874dbec-9ed5-4644-9f52-7cb521459f68"
      unitRef="usd">97704000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtMS0xLTEtMTQzNDI_5f9663f5-ba4b-4582-9c21-efa53bb5f6c7"
      unitRef="usd">-76990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtMy0xLTEtMTQzNDI_6b10a763-d4c6-41af-be6b-80efdc7ed6ba"
      unitRef="usd">192743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzgtNS0xLTEtMTQzNDI_4be1c4cb-9963-484f-a1fb-d8d734fb89a7"
      unitRef="usd">2667000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktMS0xLTEtMTQzNDI_93222b07-d294-47a4-ac65-639995016810"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktMy0xLTEtMTQzNDI_d566fcf2-acd2-4f50-bbad-fc2fb3b4cd17"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibe0e3215d854451a8cd20a3e2fd63ff1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfMzktNS0xLTEtMTQzNDI_4425abe1-0ba6-420c-b7a1-779a02a35a15"
      unitRef="usd">60005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtMS0xLTEtMTQzNDI_462d841a-371b-4acb-a540-0d214c757a91"
      unitRef="usd">178425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtMy0xLTEtMTQzNDI_ed71ab74-8f6a-49ff-9c47-85f50a69ee31"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDAtNS0xLTEtMTQzNDI_a5856cb5-cce1-4529-9b15-fb1dc265e7a3"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtMS0xLTEtMTQzNDI_dd3dee51-41da-4d87-b948-8fb6e09ca55d"
      unitRef="usd">0</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtMy0xLTEtMTQzNDI_2a4175fc-b936-4409-a6b4-88246f3bea50"
      unitRef="usd">0</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDMtNS0xLTEtMTQzNDI_58e0ef8c-995d-4e9b-acba-7e6c36decea7"
      unitRef="usd">8986000</mrsn:FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtMS0xLTEtMTQzNDI_505666fc-b116-495f-b06a-33f91351be6e"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtMy0xLTEtMTQzNDI_e02494b0-169c-4259-8367-9097183cc649"
      unitRef="usd">102000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDUtNS0xLTEtMTQzNDI_25dfc680-6d0d-4b29-9b92-6af2a62f8b22"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtMS0xLTEtMTQzNDI_8cc755c8-3bce-4f09-b4f7-08918d3f594d"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtMy0xLTEtMTQzNDI_908f1c30-edfc-40e9-8d1d-73c677f8984b"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDYtNS0xLTEtMTQzNDI_e2c33bcc-ba6a-491a-a51a-eb15e3811dc2"
      unitRef="usd">180000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:InterestPaidNet
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctMS0xLTEtMTQzNDI_7a2e5380-a538-4e05-981f-a922dd5bffe4"
      unitRef="usd">429000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctMy0xLTEtMTQzNDI_4b2a2d79-cdf7-4537-bacb-38d76095ee6c"
      unitRef="usd">234000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDctNS0xLTEtMTQzNDI_10c08c3a-84b3-4847-a2f3-4b7c84d6c299"
      unitRef="usd">132000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtMS0xLTEtMTQzNDI_1e2279d0-bebb-4cd8-bb6c-a5169a13d42b"
      unitRef="usd">3783000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtMy0xLTEtMTQzNDI_a4b7af4f-9305-4cd8-a8cf-25ba331f6ac2"
      unitRef="usd">9980000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDgtNS0xLTEtMTQzNDI_81612b99-2652-4946-a14e-1071e6fbe7b5"
      unitRef="usd">4369000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktMS0xLTEtMTQzNDI_362e8685-accf-4f9a-85aa-cda31fad23eb"
      unitRef="usd">609000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktMy0xLTEtMTQzNDI_225a8f48-5766-4e4a-95d2-b8aed8309f29"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N184OC9mcmFnOjBiZDc5ZWFiZGJkZTQ1Nzc4MzlkZTg1NjcwNzcxMzJiL3RhYmxlOjliNDk1NTQ3MmY1MzQ5ZGRiNGM3MmI3MTZkZGY2ZWQ0L3RhYmxlcmFuZ2U6OWI0OTU1NDcyZjUzNDlkZGI0YzcyYjcxNmRkZjZlZDRfNDktNS0xLTEtMTQzNDI_979cc30c-1b51-4c50-9d96-7b9cefa718ae"
      unitRef="usd">429000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfNDQ0NQ_047a944d-90ba-4bd9-83b0-1b38918dceec">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with significant unmet need. The Company has leveraged over 20 years of industry learning in the ADC field to develop proprietary and differentiated technology platforms that enable it to design ADCs to have improved efficacy, safety and tolerability relative to existing ADC therapies. The Company&#x2019;s innovative platforms, which include Dolaflexin and Dolasynthen, each delivering its DolaLock payload, as well as Immunosynthen, delivering the novel stimulator of interferon genes (STING) agonist ImmunoLock payload, together provide an efficient product engine that has enabled a robust discovery pipeline for the Company and its partners. The Company&#x2019;s clinical candidates include upifitamab rilsodotin (UpRi) and XMT-1592. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lead product candidate, UpRi, is a first-in-class Dolaflexin ADC targeting NaPi2b, an antigen broadly expressed in ovarian cancer and other cancers. The Company is currently evaluating UpRi in platinum-resistant ovarian cancer in a single-arm registrational trial, referred to as UPLIFT, for which the Company expects to complete enrollment in the third quarter of 2022. The Company is also conducting a Phase 1/2 umbrella combination trial, referred to as UPGRADE. The first combination the Company is exploring is the combination of UpRi with carboplatin, a standard platinum chemotherapy broadly used in the treatment of platinum-sensitive ovarian cancer. The Company may explore other combinations in the future. The Company expects to report interim data from UPGRADE in the second half of 2022. In the second quarter of 2022, the Company expects to initiate enrollment in a randomized placebo-controlled Phase 3 trial, referred to as UP-NEXT, to evaluate UpRi as single agent maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer that have high NaPi2b expression.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's second clinical candidate, XMT-1592, is a NaPi2b-targeted ADC leveraging the Dolasynthen platform. The Company is conducting a Phase 1 dose exploration trial in patients with ovarian cancer and non-small cell lung cancer, or NSCLC, which it expects to complete in the second half of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, the need for additional capital, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval and reimbursement for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development of technological innovations by competitors, reliance on third party manufacturers and the ability to transition from pilot-scale production to large-scale manufacturing of products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since inception. The Company&#x2019;s net loss was $170,060, $88,045 and $28,208 for the years ended December&#160;31, 2021, 2020 and 2019, respectively. The Company expects to continue to incur operating losses for at least the next several years.&#160;As of December&#160;31, 2021, the Company had an accumulated deficit of $450,479. The future success of the Company is dependent on, among other factors, its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. The Company has devoted substantially all of its financial resources and efforts to research and development and general and administrative expense to support such research and development. Net losses and negative operating cash flows have had, and will continue to have, an adverse effect on the Company&#x2019;s stockholders&#x2019; equity and working capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its currently available funds will be sufficient to fund the Company&#x2019;s operations through at least the next twelve months from the issuance of this Annual Report on Form 10-K. Management&#x2019;s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management&#x2019;s estimates, the Company may need to seek additional funding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). &lt;/span&gt;&lt;/div&gt;Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). All dollar amounts, except per share data in the text and tables herein, are stated in thousands unless otherwise indicated.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQzMw_58682e89-fcb7-4fef-aa1e-2718e909b75a"
      unitRef="usd">-170060000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQzNw_e5e6eeb9-ec7c-49b1-88f9-e2d43c88d76e"
      unitRef="usd">-88045000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjQ0NA_8832e105-3eb1-45b9-955c-66c696057a6d"
      unitRef="usd">-28208000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185NC9mcmFnOmEyNDBhNjA1MzNkZDQ2NWJiNjhlMzg2YTE3MWY2NTlmL3RleHRyZWdpb246YTI0MGE2MDUzM2RkNDY1YmI2OGUzODZhMTcxZjY1OWZfMjY0Mw_6ca52c35-3595-4fea-b425-1b7543d9603b"
      unitRef="usd">-450479000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDM_cd92e6be-065d-4067-ba7e-ab3c11fba0af">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical studies, clinical trials and related services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other research and development materials;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and costs related to regulatory filings and activities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with collaboration agreements and license fees and milestone payments related to license agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other costs associated with clinical, preclinical, discovery and other research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#x2019;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement typically consist of license rights to the Company&#x2019;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method better predicts the amount of consideration to which the Company will be entitled.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also considers the guidance in ASC Topic 606 by analogy in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;820), establishes a three-level valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded other assets of $2,356 and $2,153 as of December&#160;31, 2021 and 2020, respectively, comprised of $1,418 and $1,832, respectively, held by a service provider, restricted cash of $478 and $321, respectively, held as a security deposit for a standby letter of credit related to a facility lease, and $460 as of December&#160;31, 2021 of deferred financing costs related to the New Credit Facility (as defined below) with Silicon Valley Bank (SVB) and Oxford Financial LLC (Oxford). For additional information regarding the New Credit Facility, please refer to Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of each restricted stock unit (RSU), at its grant date based on the closing market price of the Company&#x2019;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records forfeitures as a cumulative adjustment in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares outstanding and, for the year ended December 31, 2019, 2,575,000 Exchange Warrants (as defined in Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method. For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,199,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net loss and other comprehensive loss. For the year ended December&#160;31, 2021, comprehensive loss equaled net loss. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to any significant concentrations of credit risk from these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjI_6c522937-442e-480e-af68-b62e7249538c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements include those of the Company and its wholly owned subsidiary, Mersana Securities Corp. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTk_12386ac4-48ce-401e-bc9b-6f13086a8a58">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company's consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company's management evaluates its estimates which include, but are not limited to, management's judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTA_9b6b18cf-9cc9-417b-8d98-68e2a8788e08">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision-maker, or decision making group, in deciding how to allocate resources and assess performance. The Company views its operations and manages its business as a single operating segment, which is the business of discovering and developing ADCs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTE_e61a8e46-b0e6-478c-aa8f-3905d6dc2a57">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred and include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;employee-related expenses, including salaries, bonuses, benefits, travel and stock-based compensation expense;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and expenses incurred under agreements with contract research organizations, investigative sites and other entities in connection with the conduct of preclinical studies, clinical trials and related services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the cost of acquiring, developing and manufacturing ADC product candidates, clinical trial materials and other research and development materials;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;fees and costs related to regulatory filings and activities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with collaboration agreements and license fees and milestone payments related to license agreements;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;costs associated with creating and obtaining approval for the NaPi2b companion or complementary diagnostic biomarker;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;facilities, depreciation and other expenses, which include direct and allocated expenses for rent, utilities, maintenance of facilities, insurance and other supplies; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;other costs associated with clinical, preclinical, discovery and other research activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs for certain development activities, such as preclinical studies, clinical trials and manufacturing development activities, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided to the Company by its vendors on their actual costs incurred or level of effort &lt;/span&gt;&lt;/div&gt;expended.&#160;Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the consolidated balance sheets as prepaid or accrued preclinical, manufacturing and clinical expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTc_10472d82-0a99-46c9-8744-fa98b2e75050">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaboration agreements which are within the scope of Accounting Standards Update (ASU) No. 2014-9, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606), under which the Company licenses rights to its technology and certain of the Company&#x2019;s product candidates and performs research and development services for third parties.&#160;The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front fees; reimbursement of research and development costs; development, regulatory and commercial milestone payments;&#160;and royalties on net sales of licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.&#160;To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of Topic 606, the Company performs the following five steps: (i) identification of contract(s) with a customer; (ii) determination of whether the promised goods or services are performance obligations; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The promised good or services in the Company&#x2019;s arrangement typically consist of license rights to the Company&#x2019;s intellectual property and research and development services.&#160;The Company also has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts with the customer if such option is elected by the customer, unless the option provides a material right which would not be provided without entering into the contract.&#160;Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer.&#160;Promised goods or services are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources or (ii) the promised good or service is separately identifiable from other promises in the contract.&#160;In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on their own or whether the required expertise is readily available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract.&#160;The consideration may include both fixed consideration and variable consideration.&#160;At the inception of each arrangement that includes variable consideration and at each reporting period, the Company evaluates the amount of potential payment and the likelihood that the payments will be received.&#160;The Company utilizes either the most likely amount method or expected value method to estimate the amount expected to be received based on which method better predicts the amount of consideration to which the Company will be entitled.&#160;If it is probable that a significant revenue reversal would not occur, the variable consideration is included in the transaction price. We assessed each of our revenue generating arrangements in order to determine whether a significant financing component exists and concluded that a significant financing component does not exist in any of our arrangements because: (a) the promised consideration approximates the cash selling price of the promised goods and services; and (b) timing of payment approximates the transfer of goods and services and performance is over a relatively short period of time within the context of the entire term of the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments. At contract inception and at each reporting period, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not included in the transaction price.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price.&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&#160;To date, the Company has not recognized any royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates the transaction price based on the estimated standalone selling price of the underlying performance obligations or in the case of certain variable consideration to one or more performance obligations.&#160;The Company must develop assumptions that require judgment to determine the standalone selling price for each performance obligation identified in the contract.&#160;The Company utilizes key assumptions to determine the standalone selling price, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs to complete the respective performance obligation.&#160;Certain variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance obligations consisting of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees.&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance&#160;and related revenue recognition.&#160;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Such billings generally have 30-day terms. Up-front payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right to consideration is unconditional.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <mrsn:RevenueCollectionPeriod
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTExNjc_e0c7139d-80e4-4abf-b033-6a665f2fec5a">P30D</mrsn:RevenueCollectionPeriod>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDg_a8bf7709-b551-414f-91e3-a05bc5679f83">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the elements of its collaboration agreements that represent joint operating activities in accordance with ASC Topic 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;808). Accordingly, the elements of the collaboration agreements that represent activities in which both parties are active participants and to which both parties are exposed to the significant risks and rewards that are dependent on the commercial success of the activities, are recorded as collaborative arrangements. The Company also considers the guidance in ASC Topic 606 by analogy in determining the appropriate treatment for the transactions between the Company and its collaborative partners and the transactions between the Company and third parties. Generally, the classification of transactions under the collaborative arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. To the extent revenue is generated from a collaboration, the Company will recognize its share of the net sales on a gross basis if it is deemed to be the principal in the transactions with customers, or on a net basis if it is instead deemed to be the agent in the transactions with customers, consistent with the guidance in Topic 606.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTg_716db5a9-8839-4a3d-8193-358f3c441abe">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic&#160;820,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC&#160;820), establishes a three-level valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDQ_ddf06593-6fbf-42f7-ad4b-f13fa2d1a996">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity, or a remaining maturity at the time of purchase, of three months or less to be cash equivalents. The Company invests excess cash primarily in money market funds, commercial paper and government agency securities, which are highly liquid and have strong credit ratings. These investments are subject to minimal credit and market risks. Cash and cash equivalents are stated at cost, which approximates market value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDE_aa453887-e181-4c10-a874-ea6808117d2a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDU_c23930a8-619d-4029-bc6d-74bfe08e753d">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash included in other assets, noncurrent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total cash, cash equivalents and restricted cash per statement of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi0xLTEtMS0xNDM0Mg_3feeaed5-efad-4af7-af38-29cfe4f08774"
      unitRef="usd">255094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi0zLTEtMS0xNDM0Mg_cac51bd5-31c6-4aac-b38d-cdbd9176b4b9"
      unitRef="usd">177947000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi01LTEtMS0xNDM0Mg_cc0056a0-d272-4073-bf28-a60526b0c74f"
      unitRef="usd">62351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMi03LTEtMS0xNDM0Mg_4e929421-2b4b-4951-ba35-0bb0feb16aa7"
      unitRef="usd">255094000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy0xLTEtMS0xNDM0Mg_255c0f49-366f-4a77-8b40-17f2ca44fa70"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy0zLTEtMS0xNDM0Mg_576c473b-c130-43f0-adc0-dd165cda6eef"
      unitRef="usd">478000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy01LTEtMS0xNDM0Mg_6d6684f0-8604-44d4-87e2-8191c7273604"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfMy03LTEtMS0xNDM0Mg_03438108-9249-41ad-b258-ed599cd720f7"
      unitRef="usd">321000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC0xLTEtMS0xNDM0Mg_23aa74e6-1721-4452-8989-dc431b8d3d04"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC0zLTEtMS0xNDM0Mg_1696b3f1-8fab-435c-bee5-f25b83dbff9a"
      unitRef="usd">178425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC01LTEtMS0xNDM0Mg_96374731-0ec6-41c4-b501-c0336f282f5f"
      unitRef="usd">62672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjUwZjIzOGZjODk2ZDQ5MjY4YzE3ZGI4YTAxY2RhMTgxL3RhYmxlcmFuZ2U6NTBmMjM4ZmM4OTZkNDkyNjhjMTdkYjhhMDFjZGExODFfNC03LTEtMS0xNDM0Mg_9037c322-5e49-4f44-8353-5d8cb37eb318"
      unitRef="usd">255415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTI_44103272-6821-4494-a0e5-0406cc59c07c">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded other assets of $2,356 and $2,153 as of December&#160;31, 2021 and 2020, respectively, comprised of $1,418 and $1,832, respectively, held by a service provider, restricted cash of $478 and $321, respectively, held as a security deposit for a standby letter of credit related to a facility lease, and $460 as of December&#160;31, 2021 of deferred financing costs related to the New Credit Facility (as defined below) with Silicon Valley Bank (SVB) and Oxford Financial LLC (Oxford). For additional information regarding the New Credit Facility, please refer to Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5NDI_0f0a99f5-7c8b-4a51-8f65-801fd4025dd8"
      unitRef="usd">2356000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5NDk_7fd00672-c8d5-436a-8db3-e5064030554e"
      unitRef="usd">2153000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RetainageDeposit
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTY5OTY_9528abcc-4fdd-4128-b75f-234c472332c8"
      unitRef="usd">1418000</us-gaap:RetainageDeposit>
    <us-gaap:RetainageDeposit
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwMDM_414f6ecb-fea2-44be-a4cc-49f22176b2e6"
      unitRef="usd">1832000</us-gaap:RetainageDeposit>
    <us-gaap:SecurityDeposit
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwNzI_2938eef7-f583-49e9-b531-722f9dd4d8e2"
      unitRef="usd">478000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTcwNzk_175bbea6-575b-4016-ba6e-552bd2b88289"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8e350e8b8c7c4fad8a6f1dbcaef3d9c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTA5OTUxMTYzMTYyNTQ_271f3e4c-44bc-4c97-b6af-8763e133988b"
      unitRef="usd">460000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTY_5851cbe2-b741-4895-ba2f-364fd2ea3ce0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718 Compensation&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(ASC 718). ASC 718 requires all stock-based payments to employees, directors and non-employees to be recognized as expense in the statements of operations based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to the lack of a public market for the Company's common stock prior to completion of the initial public offering and a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the historical volatility of a representative group of companies with similar characteristics to the Company, including stage of product development and life science industry focus. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No. 107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. For options granted to non-employees, the Company utilizes the contractual term of the arrangement as the basis for the expected term assumption. The risk-free interest rate is based on a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of each restricted stock unit (RSU), at its grant date based on the closing market price of the Company&#x2019;s common stock on that date. For stock-based compensation subject to service-based vesting conditions, the Company recognizes stock-based compensation expense equal to the grant date fair value of stock-based compensation on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records forfeitures as a cumulative adjustment in the period in which they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMTkzMzc_91bb8522-ab16-4ff4-a793-5b537642911b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDk_e18a48b9-42b4-4081-a26e-4218ea688485">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares outstanding and, for the year ended December 31, 2019, 2,575,000 Exchange Warrants (as defined in Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) outstanding during the period, without further consideration for potentially dilutive securities. In accordance with ASC Topic 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Exchange Warrants are included in the computation of basic net loss per share because the exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock method. For purposes of the diluted net loss per share calculation, stock options, unvested RSUs and warrants to purchase common stock are considered to be potentially dilutive securities, but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i57c7504cae894df18aaaa3b793ed4bcf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMjAxMjU_d84ce66a-c9d9-4b52-bf18-b517a0c96c83"
      unitRef="shares">2575000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjM_523cf3be-8af7-475c-aeac-09010990b2a4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,720,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,199,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,207,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5cd2bc576a64407b348ad9bfc065f8d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi0xLTEtMS0xNDM0Mg_f404ee94-1ad8-49a5-92ad-f95b2d03ad01"
      unitRef="shares">8342429</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6c4fdc5ae4df447da4c58088b9961c67_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi0zLTEtMS0xNDM0Mg_2cc83417-aaf5-436e-82e4-2df93a5f6c63"
      unitRef="shares">6112948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe1588dcb89e4bfa84977ab490cf0417_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMi01LTEtMS0xNDM0Mg_7f62863c-994b-4876-9110-387caff86bb8"
      unitRef="shares">4720772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i48c7830bb0b0416eb5d577f21baf0aac_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy0xLTEtMS0xNDM0Mg_8693e771-a578-4060-a3d0-6d7bef72bc9e"
      unitRef="shares">817609</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id97077e4c81a481a8647699765887a0a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy0zLTEtMS0xNDM0Mg_7f9a84d0-7282-43f6-b966-ddf7aad10066"
      unitRef="shares">716767</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i667df8466ca44fb6a82fd19ed57ff48f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfMy01LTEtMS0xNDM0Mg_d969da79-4c45-467e-aaae-3f6942ba547d"
      unitRef="shares">447336</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ida5a046a9dbb4cc0988324aea0d475c4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC0xLTEtMS0xNDM0Mg_fe00e153-1019-4328-b12f-fd1e4cd6245b"
      unitRef="shares">39474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i62083aff246944c9b4984de9c9c1ef1a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC0zLTEtMS0xNDM0Mg_dee25e4f-5b13-4f4a-93c8-52551a255e1d"
      unitRef="shares">39474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i809dbadb11db4e24afbe3cdcfe4f79d9_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNC01LTEtMS0xNDM0Mg_ce4ab38d-d270-46c1-9769-c6522697786b"
      unitRef="shares">39474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS0xLTEtMS0xNDM0Mg_9caff05f-b2e6-4ccf-bcd5-f32458d5e5ad"
      unitRef="shares">9199512</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS0zLTEtMS0xNDM0Mg_546b70c2-d18d-42f4-9a9d-298623a987ae"
      unitRef="shares">6869189</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOmJlMDRlY2I4MWU4MjQzNjJiMDg4MzM5MzlkNzRkNDEyL3RhYmxlcmFuZ2U6YmUwNGVjYjgxZTgyNDM2MmIwODgzMzkzOWQ3NGQ0MTJfNS01LTEtMS0xNDM0Mg_e960a2f1-302b-42b0-86ce-723ff0da4c9d"
      unitRef="shares">5207582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTM_fb08cb9f-8eeb-4bd8-a432-9e2dc4ef8f87">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or sale, the cost of the assets disposed of and the related accumulated depreciation are eliminated from the balance sheet and related gains or losses are reflected in the statement of operations. There were no material sales of assets during the&#160;years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. If an impairment review is performed to evaluate an asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the asset to its carrying value. If the carrying amount of the asset exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company did not recognize impairment charges during the&#160;years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjQ_f7402ce2-0619-490c-bacc-8a157ca44755">Depreciation is computed using the straight-line method over the estimated useful life of each asset as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.380%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment, office equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrsn:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9f98a71f7de2423c9004b46d1a094d47_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMC0xLTEtMS0xNDM0Mg_0ac2680d-a311-4934-bb76-c1d6fb18449a">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i57bf8dc50aad4550b09f65fd101d5b8e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMS0xLTEtMS0xNDM0Mg_e1d7ba5d-26ba-4bd1-8100-ce309ac83b01">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="i2289a4965c8d4c269148c6c1a7f94f33_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RhYmxlOjQ5ZDAwN2U4NWY2OTQ1MGVhY2U0MmNiY2ExZjcwOGVjL3RhYmxlcmFuZ2U6NDlkMDA3ZTg1ZjY5NDUwZWFjZTQyY2JjYTFmNzA4ZWNfMi0xLTEtMS0xNDM0Mg_5d323dae-795e-437c-a894-cc4dbbeddffc">Shorter of useful life or life of lease</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_772aec4e-f33c-4a4e-9b2d-5494c64c1f59"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_9fed0a46-4e1a-4409-aff1-ef2d53210028"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzg0ODI5MDczODE3Nw_b1fc8652-0522-40ea-9bc8-158d03bbe2e0"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDc_b9f25c86-8995-4a62-95b1-169f47029661">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use lease assets (ROU assets), current portion of lease obligations and long-term lease obligations on the Company&#x2019;s consolidated balance sheets. Assets subject to finance leases are included in property and equipment, and the related lease obligation is included in other current liabilities and other long-term liabilities on the Company&#x2019;s consolidated balance sheets. Lease assets are tested for impairment in the same manner as long-lived assets used in operations. Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method. The Company has elected the short-term lease recognition exemption for short-term leases, which allows the Company not to recognize lease liabilities and ROU assets on the consolidated balance sheets for leases with an original term of twelve months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease obligations represent the Company&#x2019;s obligation to make lease payments arising from the lease. Operating lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate to discount lease payments. The incremental borrowing rate reflects the fixed rate at which the Company could borrow, on a collateralized basis, the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.&#160;Prospectively, the Company will adjust the ROU assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lease agreements with lease and non-lease components, which are generally accounted for separately.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjA_25321502-1ad0-43d5-bc2a-09c4ad8e2336">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses patent application and related legal costs as incurred and classifies such costs as general and administrative expenses in the accompanying consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MjE_942cf43b-fc15-4f8f-9458-bdf7120dc17e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes in accordance with ASC Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides for deferred taxes using an asset and liability approach.&#160;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.&#160;The Company determines its deferred tax assets and liabilities based on differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&#160;Valuation allowances are provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is more likely than not to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MTQ_7e512349-d9f5-4cc0-886b-ce8f0b47083f">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) comprises net loss and other comprehensive loss. For the year ended December&#160;31, 2021, comprehensive loss equaled net loss. For the years ended December&#160;31, 2020 and 2019, other comprehensive income (loss) consisted of changes in unrealized income and loss on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDI_247cc05f-818c-444d-a465-86a39f2e01c0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Off-balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that potentially subject the Company to concentrations of credit risk &lt;/span&gt;&lt;/div&gt;primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company has not experienced any credit losses and does not believe that it is subject to any significant concentrations of credit risk from these financial instruments.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMjY5MzM_ff6eb565-faea-4626-8eea-3a2b80167bc3"
      unitRef="usd">0</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N185Ny9mcmFnOjY3MzU3YzE0Y2M5ZjQ3ODI4YTAyZThjNmU3MTdhNjRjL3RleHRyZWdpb246NjczNTdjMTRjYzlmNDc4MjhhMDJlOGM2ZTcxN2E2NGNfMzA5MDY_979c7f12-bd39-49da-aae8-235793f64f9e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as part of its initiative to reduce complexity in the accounting standards. The amendments in ASU 2019-12 eliminate certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also clarifies and simplifies other aspects of the accounting for income taxes. The amendments in ASU 2019-12 are effective for the fiscal years beginning after December 15, 2020. The adoption of this standard did not have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE3MjY2_d7912644-7b30-46c2-a232-1bb899c1482f">Collaboration Agreements&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merck KGaA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Company entered into a Collaboration and Commercial License Agreement with Merck KGaA (the Merck KGaA Agreement). Upon the execution of the Merck KGaA Agreement, Merck KGaA paid the Company a non-refundable technology access fee of $12,000 for the right to develop ADCs directed to six exclusive targets over a specified period of time. No additional fees are due when a target is designated and the commercial license to the target is granted. Merck KGaA will be responsible for the product development and marketing of any products resulting from this collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Merck KGaA Agreement, the Company and Merck KGaA develop research plans to evaluate Merck KGaA's antibodies as ADCs incorporating the Company's technology. The Company receives reimbursement for its efforts under the research plans. The goal of the research plans is to provide Merck KGaA with sufficient information to formally nominate a development candidate and begin IND-enabling studies or cease development on the designated target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the payments received for research and development activities performed on behalf of Merck KGaA, the Company could be eligible to receive up to a total of $780,000 in future milestones related to all targets under the Merck KGaA Agreement, plus low to mid-single digit royalties on the commercial sales of any resulting products during the applicable royalty term. The total milestones are categorized as follows: development milestones $84,000; regulatory milestones $264,000; and sales milestones $432,000. There are six individual development milestones per target, payable upon the completion of various activities, from the delivery of ADCs meeting defined specifications, through the dosing in a Phase&#160;3 clinical trial. There are five regulatory milestones, which are payable upon regulatory approvals for a first indication in each of the U.S., European Union and Japanese markets and regulatory approvals for both a second and a third indication in the United States. There are three individual commercial milestones, which are payable upon the attainment of certain defined thresholds for annual net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to 2020, the Company had received $3,000 related to development milestones under the Merck KGaA Agreement. There have been no additional milestone payments in the years ended December&#160;31, 2021 or 2020. The next potential milestone payment the Company will be eligible to receive will be a development milestone of $500 on Merck KGaA's designation of a preclinical development candidate for any target. Revenue will be recognized when achievement of the milestone is considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Merck KGaA Agreement will expire upon the expiration of the last royalty term for a product under the Merck KGaA Agreement, after which time, Merck KGaA will have a perpetual, royalty-free license, or if Merck KGaA does not designate any ADC product candidates produced by the Company under the Merck KGaA Agreement as preclinical development candidates, upon the expiration of the last to expire research program. Merck KGaA may terminate the Merck KGaA Agreement in its entirety or with respect to any target for convenience upon 60 days' prior written notice. Each party may terminate the Merck KGaA Agreement in its entirety upon bankruptcy or similar proceedings of the other party or upon an uncured material breach of the Merck KGaA Agreement by the other party. However, if such breach only relates to one target, the agreement may only be terminated with respect to such target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a Supply Agreement with Merck KGaA (the Merck KGaA Supply Agreement). Under the terms of the Merck KGaA Supply Agreement, the Company will provide Merck KGaA preclinical non-GMP ADC drug substance and clinical GMP drug substance for use in clinical trials associated with one of the antibodies designated under the Merck KGaA Agreement. The Company receives fees for its efforts under the Merck KGaA Supply Agreement and reimbursement equal to the supply cost. The Company may also enter into future supply agreements to provide clinical supply material should Merck KGaA pursue clinical development of any other candidates nominated under the Merck KGaA Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the following performance obligations under the Merck KGaA Agreement: (i)&#160;exclusive license and research services for six designated targets, (ii)&#160;rights to future technological improvements and (iii)&#160;participation of project team leaders and providing joint research committee services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has concluded that each license for a designated target is not distinct from the research services performed related to the designated target as Merck KGaA cannot obtain the benefit of the license without the related research services.&#160;Each license for a designated target and the related services performance obligation is considered distinct from every other license for a designated target and related services performance obligation as each research plan is pursued independent of every other research plan for other designated targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the expected value approach to estimate the amount of consideration related to the payment of fees associated with development and research services.&#160;The Company utilizes the most likely amount approach to estimate any development and regulatory milestone payments to be received.&#160;As of the date of initial application of Topic 606, there were no milestones payments that had not already been received, included in the estimated transaction price.&#160;The Company considered the stage of development and the remaining risks associated with the remaining development required to achieve the milestone, as well as whether the achievement of the milestone is outside the control of the Company or Merck KGaA.&#160;The milestone payment amounts were fully constrained, as a result of the uncertainty whether any of the associated milestones would be achieved.&#160;The Company has determined that any commercial milestones and sales based royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted and therefore have also been excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The transaction price was allocated to the performance obligations based on the relative estimated standalone selling prices of each performance obligation or in the case of certain variable consideration to one or more performance obligations.&#160;The estimated standalone selling prices for performance obligations, that include a license and research services, were developed using the estimated selling price of the license and an estimate of the overall effort to perform the research service and an estimated market rate for research services. The estimated standalone selling price of the licenses was established based on comparable transactions.&#160;The estimated standalone selling price for the rights to future technological improvements was developed based on the estimated selling prices of a license or rights received, as well as considering the probability that additional technology would be made available or the probability the counterpart would utilize the technology. The estimated standalone selling price for the joint research committee services was developed using an estimate of the time and costs incurred to participate in the committees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company re-evaluates the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. As of December&#160;31, 2021 and 2020, the total estimated transaction price for the Merck KGaA Agreement was $21,325. The transaction price of $21,325 was allocated to the performance obligations as follows: approximately $3,941 for each of the license and corresponding research and development services units of account for the first and second designated targets; $3,439 for each of the license and corresponding research and development services units of account for the third and sixth designated target; $3,152 for the license and corresponding research and development services unit of account for the fourth designated target; $2,746 for the license and corresponding research and development services unit of account for the fifth designated target; $425 for rights to future technological improvements; and $242 for joint research committee services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is recognizing revenue related to the exclusive license and research and development services performance obligation over the estimated period of the research and development services using a proportional performance model.&#160;The Company measures proportional performance based on the costs incurred relative to the total costs expected to be incurred.&#160;To &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the extent that the Company receives fees for the research services as they are performed, these amounts are recorded as deferred revenue. Revenue related to future technological improvements and joint research committee services will be recognized ratably over the performance period (which in the case of the joint research committee services approximate the time and cost incurred each period), which are 10 and 5 years, respectively.&#160;The Company is continuing to reassess the estimated remaining term at each subsequent reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has completed its research service obligations associated with four of the six designated targets. During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded collaboration revenue of $43, $828 and $853, respectively, related to its efforts under the Merck KGaA Agreement. During the year ended December&#160;31, 2019, the Company recognized collaboration revenue and corresponding research and development expense of $1,280 related to the Merck KGaA Supply Agreement. There were no amounts recognized during the years ended December&#160;31, 2021 and 2020 related to the Merck KGaA Supply Agreement.&#160;There was no balance in accounts receivable related to the Merck KGaA Agreement and Merck KGaA Supply Agreement as of either December&#160;31, 2021 or December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had recorded $3,944 and $3,987, respectively, in deferred revenue related to the Merck KGaA Agreement and Merck KGaA Supply Agreement that will be recognized over the remaining performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda XMT-1522 Strategic Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Company entered into a Development Collaboration and Commercial License Agreement with Takeda Pharmaceutical, Inc.'s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. for the development and commercialization of XMT-1522 (the XMT-1522 Agreement). Under the XMT-1522 Agreement, Takeda was granted the exclusive right to commercialize XMT-1522 outside of the United States and Canada. Under the XMT-1522 Agreement, the Company was responsible for conducting certain Phase 1 development activities for XMT-1522, including the ongoing Phase 1 clinical trial, at its own expense. The parties agreed to collaborate on the further development of XMT-1522 in accordance with a global development plan (Post-Phase 1 Development). On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the XMT-1522 Agreement upon 30 days&#x2019; prior written notice. The XMT-1522 Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the XMT-1522 Agreement as of March 31, 2019. Under the XMT-1522 Agreement, the Company and Takeda shared equally all agreed Post-Phase 1 Development costs through the date of termination and for a period of 30 days after the effective termination date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Strategic Research and Development Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2014, the Company entered into a Research Collaboration and Commercial License Agreement with Takeda&#x2019;s wholly owned subsidiary, Millennium Pharmaceuticals, Inc. (the 2014 Agreement). The 2014 Agreement was amended in January 2015 and amended and restated in January 2016 (the 2016 Restated Agreement). The agreements provided Takeda with the right to develop ADCs directed to a total of seven exclusive targets, designated by Takeda, over a specified period of time. On January 2, 2019, the Company received notice from Takeda stating that Takeda was exercising its right to terminate the 2016 Restated Agreement upon 45 days&#x2019; prior written notice. The 2016 Restated Agreement terminated in accordance with its provisions, and the Company and Takeda wound down activities related to the 2016 Restated Agreement as of March 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Analysis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration agreements with Takeda were terminated following receipt of written notices during the first quarter of 2019. As there are no further performance obligations, the Company recognized the remaining deferred revenue of $39,965 related to the termination of the Takeda agreements in the first quarter of 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the termination of the agreements, the Company had identified 14 performance obligations in the agreements. The Company concluded that the license related to each of the designated targets was not distinct from the research services performed related to each of the designated targets as Takeda could not have obtain the benefit of the license without the related research services. Each license to a designated target and the related service performance obligation was considered distinct from every other license to a designated target and related services performance obligation as each research plan was pursued independent of the any other research plans for other designated targets. Further, the material rights provided were determined &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to be distinct from the other performance obligations in the arrangement as they were options in the contract Takeda agreements and not required for Takeda to obtain the benefit of the other promised goods or services in the arrangement. Similarly, the Company concluded that the XMT-1522 license and the related research and development services, including the Phase 1 development and the transfer of certain materials and know-how related to the Company's manufacturing processes, were one performance obligation. The license to the Company's intellectual property was not determined to be distinct from the research and related development services that the Company was obligated to perform. For the year ended December&#160;31, 2019, the Company recorded total revenue of $39,965 related to its efforts under the 2016 Restated Agreement and the XMT-1522 Agreement. The Company did not record any revenue under the 2016 Restated Agreement and the XMT-1522 Agreement in the years ended December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the Post-Phase 1 Development activities under the XMT-1522 Agreement represented joint operating activities in which both parties were active participants and of which both parties were exposed to significant risks and rewards that are dependent on the commercial success of the activities. Accordingly, the Company accounted for the Post-Phase 1 Development activities in accordance with ASC 808. For the year ended December&#160;31, 2019, the Company was billed approximately $200 from Takeda representing Post-Phase 1 Development costs incurred by Takeda. These amounts have been reflected as research and development costs in the consolidated statement of operations. During the year ended December&#160;31, 2019, the Company billed Takeda $195 related to ASC 808 costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contract Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided limited services for a collaboration partner, Asana BioSciences. For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded revenue of $0, $0 and $25, respectively, related to these services. The next &lt;/span&gt;&lt;/div&gt;potential milestone the Company is eligible to receive is $2,500 upon dosing the fifth patient in a Phase 1 clinical trial by Asana BioSciences. As of December&#160;31, 2021, the Company considered this next milestone to be fully constrained as there is considerable judgment involved in determining whether it is probable that a significant revenue reversal would occur. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestone is outside the control of the Company and there is a high level of uncertainty in achieving this milestone, as this would require initiation of clinical trials by the collaboration partner. The Company reevaluates the probability of achievement of a milestone subject to constraint at each reporting period and as uncertain events are resolved or other changes in circumstances occur.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrsn:CollaborativeArrangementsUpfrontPayment
      contextRef="i311ddb6991d8496f92c657e71d74c7e1_D20140601-20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzI5Mw_42f3380c-74e0-4834-8766-a1975899d683"
      unitRef="usd">12000000</mrsn:CollaborativeArrangementsUpfrontPayment>
    <mrsn:CollaborativeArrangementsExclusiveTargetsNumber
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzMzOA_44153a3a-8685-4528-8d16-4ee6acf5ce40"
      unitRef="target">6</mrsn:CollaborativeArrangementsExclusiveTargetsNumber>
    <mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM5Mg_cad9093f-561a-4715-ac9d-b038508d3b5f"
      unitRef="usd">0</mrsn:CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense>
    <mrsn:CollaborationArrangementsMaximumAggregateMilestones
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEzMDM_baf3fd26-4490-40f8-9f24-784fae96da06"
      unitRef="usd">780000000</mrsn:CollaborationArrangementsMaximumAggregateMilestones>
    <mrsn:CollaborationArrangementsDevelopmentMilestones
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1Nzk_9f4e9da1-323a-4671-8ab9-478f50895d6c"
      unitRef="usd">84000000</mrsn:CollaborationArrangementsDevelopmentMilestones>
    <mrsn:CollaborationArrangementsRegulatoryMilestones
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MDU_c4c5d0f7-28bf-415a-a55f-729afa93a5b4"
      unitRef="usd">264000000</mrsn:CollaborationArrangementsRegulatoryMilestones>
    <mrsn:CollaborationArrangementsSalesMilestones
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MzA_73226bca-19be-4c32-a953-4880c7daaeec"
      unitRef="usd">432000000</mrsn:CollaborationArrangementsSalesMilestones>
    <mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2NDQ_fb8aa75f-54bf-4143-820f-37887089fe54"
      unitRef="milestone">6</mrsn:CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber>
    <mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE4NTk_02e94e4d-6c33-4d32-8042-c81d92c2e17b"
      unitRef="milestone">5</mrsn:CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber>
    <mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber
      contextRef="i9eb13aee4e814a53a64da4507bad3321_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIxMDc_2571e7b0-5149-4d5c-bed4-3e797f25b938"
      unitRef="milestone">3</mrsn:CollaborationArrangementIndividualCommercialMilestonesTargetNumber>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="i4af5ca3b68bb4ed7b6a33a6008c3ab69_D20150101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIyNzQ_ee97a38e-46d5-42e6-973c-189728cc31ca"
      unitRef="usd">3000000</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIzNTk_6add3ac2-236a-4859-9e7a-6cb175eb7612"
      unitRef="usd">0</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived
      contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzIzNTk_7551842e-22b8-40f7-9f91-10cf03c18f20"
      unitRef="usd">0</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceived>
    <mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzI1MzM_c60d7f0e-2f6d-4b3e-bf3c-7f1a10236269"
      unitRef="usd">500000</mrsn:CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone>
    <mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration
      contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzMyNjc_615d8e51-abb2-4a73-8e1b-a212aa9847e2">P60D</mrsn:CollaborationArrangementsPriorWrittenTerminationNoticeDuration>
    <mrsn:CollaborationArrangementsTargetsDesignatedNumber
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQ0ODM_1a5b2e10-e7f7-4b9e-9b99-94d23bd0b0ac"
      unitRef="target">6</mrsn:CollaborationArrangementsTargetsDesignatedNumber>
    <mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice
      contextRef="i9790c299a9564e76a73c4df8750539ba_I20180101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzU1NzE_aa2aca78-a0be-47b5-a73f-76b4bf76bf61"
      unitRef="usd">0</mrsn:MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzc3MjQ_b41a6e01-4c59-44d5-a1a4-bbb169f07227"
      unitRef="usd">21325000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="ic09d46e0ab9d49a69193af570876fd88_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzc3MjQ_e4589cb7-96d7-467b-b8b7-1b59aa0e1aac"
      unitRef="usd">21325000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQzOTgwNDY1MzM4MDc_221572c0-0e95-4e19-9c88-7eff19347ae2"
      unitRef="usd">21325000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i22751430a1af485c87dd79584475d813_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgwNjI_5500512f-f253-45b9-9d8e-7ee97a17ff6a"
      unitRef="usd">3941000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i724be6926e0f43708c3842a241f2b234_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgyMDM_3e11ba97-32aa-4699-8144-5fd1291dad64"
      unitRef="usd">3439000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="ic393ee0337764f848b485d8f53c57f94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzgzNDI_ed1c94ce-9d15-4040-8d17-68964fae2dc0"
      unitRef="usd">3152000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i8719cb8746fc444a8b30ec920ba9e272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg0NjM_62e083b8-1709-4203-9752-ac16be048911"
      unitRef="usd">2746000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i24a96471c63a400b9ce4997aa4039334_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg1ODM_e2dff16a-a6d1-406d-b4c7-f5367488cb51"
      unitRef="usd">425000</mrsn:RevenueTransactionPriceAmount>
    <mrsn:RevenueTransactionPriceAmount
      contextRef="i266b15fef82f4d77ab6acfccdce49876_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzg2Mzk_675ea284-44f9-44c6-accf-e67bf1ac3f3f"
      unitRef="usd">242000</mrsn:RevenueTransactionPriceAmount>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="if1c1155ad2bf48ed93491e3ec3ff0c2b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk0NTU_805dcb52-d825-42fe-a767-d4a713f58ea8">P10Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i578ab44d714748d09da2b37adc7d98a6_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk0NjI_e0f64f54-2a55-4140-a302-28a75588608a">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk2Njk_e8738756-aecf-46a4-a296-c938d04f8528"
      unitRef="target">4</mrsn:CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber>
    <mrsn:CollaborationArrangementsTargetsDesignatedNumber
      contextRef="ibd780cc96bb64b56a539baf9ff6aa050_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk2Nzk_361cacca-c88d-47d3-8932-a89f0fccc2f4"
      unitRef="target">6</mrsn:CollaborationArrangementsTargetsDesignatedNumber>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i691905a855ea444a81cdb006aa684830_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3ODY_f82436e4-33e4-495b-90d7-79365d13f3d4"
      unitRef="usd">43000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7dac85ff05f14ed3a29c78e7559c6248_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3OTA_f78319bb-5fea-4736-9ba5-d8c130bad3e5"
      unitRef="usd">828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c642871deec4bf2ae3f141820fc4f9c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk3OTc_4727e48d-844b-47de-8fc9-ebc0f636e2cb"
      unitRef="usd">853000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5e3153e090a41668aa9d9e117b855f2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5Xzk5OTU_afaca21a-8dff-48e4-a1ac-6129c89247a1"
      unitRef="usd">1280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7616293f91948f28dd309eb148c545e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMDUz_29c2f0b2-381d-41f5-ba2f-68bf6d7776a5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib939e9ec9abd4ac39881b2e5f6f0a6f4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMDUz_8585831b-2243-4016-b0f8-fd707a0448f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNet
      contextRef="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMTYy_0b8dadaf-2dd2-4cc1-9e29-a4a462f93d72"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i4ce0872b58f0463c95884113a6545230_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMTYy_c95c19b4-c565-483d-b7d4-04f9cb29faeb"
      unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i45c0cdd6b2ba4604b63d139fc37b6e31_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMzI5_a1652157-b17b-4eb5-bcf7-40320a38da81"
      unitRef="usd">3944000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4ce0872b58f0463c95884113a6545230_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEwMzM2_0849524e-e7e3-4e1d-a6bc-1a263834c96f"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiability>
    <mrsn:CollaborationArrangementsDurationToTermination
      contextRef="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzExNDE4_927a96f1-cf96-4b27-87ba-bb9a8a714a88">P30D</mrsn:CollaborationArrangementsDurationToTermination>
    <mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod
      contextRef="i62e81096856f45e9ae23ed1c283f5daf_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzExNzgw_78c5389e-4b94-4f77-b6eb-949c909fdf3e">P30D</mrsn:CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod>
    <mrsn:CollaborativeArrangementsExclusiveTargetsNumber
      contextRef="icf84ce2b240441789956b1e89bcf4595_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyMjcx_e4b0ca2c-4e56-4313-a61d-7d8ad6665b3c"
      unitRef="target">7</mrsn:CollaborativeArrangementsExclusiveTargetsNumber>
    <mrsn:CollaborationArrangementsDurationToTermination
      contextRef="i4f0a4b79107a46de82588501551a7baa_D20190102-20190102"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyNDk5_5e5de1e4-74bf-4b6f-b530-251c3d86dac5">P45D</mrsn:CollaborationArrangementsDurationToTermination>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ifd81097c435142008a0e8197ddc84278_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEyOTcy_5371913b-f29c-47d2-8513-efb124e55dcd"
      unitRef="usd">39965000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <mrsn:RevenueRemainingPerformanceObligationNumber
      contextRef="i26419f71b3384c04a3f6605f62bc5c57_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzEzMTI4_5d355d52-2da8-4046-be49-8300c1371faf"
      unitRef="agreement">14</mrsn:RevenueRemainingPerformanceObligationNumber>
    <mrsn:RevenueRemainingPerformanceObligationNumber
      contextRef="iccb4e2fad20448bcb47f9ece79c43d47_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE0Mjk4_9ffa3b75-d5e8-441d-8d86-d89fc6168628"
      unitRef="agreement">1</mrsn:RevenueRemainingPerformanceObligationNumber>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8f3b11dfbc64275ac3f70f6dc51c46b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzQzOTgwNDY1MzgwMjE_eaaee258-3aae-4f39-9e21-6cb04e3f2efa"
      unitRef="usd">39965000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie83b8c61371748b8a4dad5a60b07f3eb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM4NDgyOTA3MjU0OTk_032958f2-ab8e-40fb-9c9a-6e0c8c77cc01"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49b1abd1d2b641b89c50bc6d8090ae6a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzM4NDgyOTA3MjU0OTk_daed1269-753c-4cd1-bc23-8f842ff058cc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1MTg0_88b4e4e2-ea70-4878-b687-18ada7814f0f"
      unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpense>
    <mrsn:CollaborationArrangementsCostsBilled
      contextRef="i057b2bf4e81b4a5ca1bc6999a785bbbd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE1NTgy_6f4f668f-7c23-4a18-bafe-a0e62d359b7e"
      unitRef="usd">195000</mrsn:CollaborationArrangementsCostsBilled>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE3MjY3_b66bd3d3-bde8-40a1-9ee0-7737fd1dec62">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in the balances of our contract assets and liabilities during the years ended December&#160;31, 2021 and December&#160;31, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Beginning&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Additions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Deductions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;End of Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company recognized the following revenues as a result of changes in the contract asset and the contract liability balances in the respective periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue recognized in the period from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts included in the contract liability at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance obligations satisfied in previous periods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzItMS0xLTEtMTQzNDI_c7400b65-d557-4e83-b6fb-f4edc8960289"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzItNy0xLTEtMTQzNDI_8c4e4a8b-8342-4c07-9a46-d0c0fe818b59"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtMS0xLTEtMTQzNDI_bba8c213-bb0d-4310-aaf7-fdc550752049"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiability>
    <mrsn:ContractWithCustomerLiabilityIncrease
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtMy0xLTEtMTQzNDI_e35e9b51-bb5a-4bb8-b726-4597da788b1f"
      unitRef="usd">0</mrsn:ContractWithCustomerLiabilityIncrease>
    <mrsn:ContractWithCustomerLiabilityDecrease
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtNS0xLTEtMTQzNDI_fbd0f63e-3add-4d51-b239-4ba4137a6abd"
      unitRef="usd">43000</mrsn:ContractWithCustomerLiabilityDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZToxZGZlOTU2YzFkMTY0MzVkOTU4ZDI5MTFhNjBmZmE0Zi90YWJsZXJhbmdlOjFkZmU5NTZjMWQxNjQzNWQ5NThkMjkxMWE2MGZmYTRmXzQtNy0xLTEtMTQzNDI_6abc2e49-054d-4f67-a741-a82958641dc3"
      unitRef="usd">3944000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzItMS0xLTEtMTQzNDI_5c3b5440-da14-4be7-8f6c-3c17b3b3490c"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzItNy0xLTEtMTQzNDI_a55eb6b1-0244-4d67-ade3-abdad2556ce6"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie614b7c768c042aba10411ce72a641cd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtMS0xLTEtMTQzNDI_6edbb288-a1fa-4985-bd48-40694f5135bf"
      unitRef="usd">4815000</us-gaap:ContractWithCustomerLiability>
    <mrsn:ContractWithCustomerLiabilityIncrease
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtMy0xLTEtMTQzNDI_e57073ff-04c4-4741-ad55-9f5b9961b002"
      unitRef="usd">0</mrsn:ContractWithCustomerLiabilityIncrease>
    <mrsn:ContractWithCustomerLiabilityDecrease
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtNS0xLTEtMTQzNDI_dc8fd352-1212-44a7-979f-970bdb2f477b"
      unitRef="usd">828000</mrsn:ContractWithCustomerLiabilityDecrease>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpjNTVhYzE4NTM4MTA0ZDkyYWM5MmJmNDAxNGZhNjg1Yy90YWJsZXJhbmdlOmM1NWFjMTg1MzgxMDRkOTJhYzkyYmY0MDE0ZmE2ODVjXzQtNy0xLTEtMTQzNDI_a6631364-7fe5-489c-b44c-811b871c90db"
      unitRef="usd">3987000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzMtMS0xLTEtMTQzNDI_df3f51da-5d0c-480a-a06f-3c675ae5329f"
      unitRef="usd">43000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzMtMy0xLTEtMTQzNDI_bd90db1a-33fe-43f8-83b5-d50402ae775d"
      unitRef="usd">828000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzQtMS0xLTEtMTQzNDI_689e1296-de8e-4701-9d3f-ded8e0db5f7e"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90YWJsZTpmZmEzMWJiZWQ1OTI0OTlmOTBjNGE0M2VhYTE5YTVlMi90YWJsZXJhbmdlOmZmYTMxYmJlZDU5MjQ5OWY5MGM0YTQzZWFhMTlhNWUyXzQtMy0xLTEtMTQzNDI_7c8cb84e-e88c-49af-b3a6-b35e9f25704f"
      unitRef="usd">0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8221344b85a746f1bbc5dd99c40db4af_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTUz_54b3ee56-de5f-461d-9dea-6036de827f34"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia01be325b8014d11a057d07ade151aab_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTU3_afebb587-83f8-4444-99ca-dabb1765bebb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc721e5fefa54193b4555f316c8c4e98_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2MTY0_b39ecfe0-176b-4591-8310-1ee331d7ac7d"
      unitRef="usd">25000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone
      contextRef="ic3cf57eb0c394db486c86ab2341698c0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDMvZnJhZzpiMmYyMDU1MTI4ZDE0NDFkODUyNmFhOTQ1ZTY1Njk5OS90ZXh0cmVnaW9uOmIyZjIwNTUxMjhkMTQ0MWQ4NTI2YWE5NDVlNjU2OTk5XzE2NDUy_8a8fa1ad-c21c-4c74-943a-f368058f31e3"
      unitRef="usd">2500000</mrsn:CollaborationArrangementsMilestonePaymentReceivableNextMilestone>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMDYvZnJhZzphMjI1OTIzYjQzMzc0OTMwOWVjZjc4ZTRiYzI4MzBhMy90ZXh0cmVnaW9uOmEyMjU5MjNiNDMzNzQ5MzA5ZWNmNzhlNGJjMjgzMGEzXzk4MQ_1ad36932-3323-4924-a0e7-42f76122bd11">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the consolidated balance sheets for prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the carrying value of the Company&#x2019;s outstanding borrowing under the Prior Credit Facility and New Credit Facility (as defined below, respectively) approximated fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. The Prior Credit Facility and New Credit Facility are discussed in more detail in Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM1Nw_1500a9be-205d-4881-8586-448e95f6bf4c">Property and Equipment&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded assets under finance leases of $609, $0, and $429 as property and equipment during the years ended December&#160;31, 2021, 2020 and 2019, respectively. Financing leases are discussed in more detail in Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Depreciation expense for the&#160;years ended December&#160;31, 2021, 2020 and 2019 was $855, $1,010 and $1,245, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM1OA_05589634-9cde-4efb-8f4f-ce506adc82c1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie27da38d053440e3a567adb14304e888_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzEtMS0xLTEtMTQzNDI_f0a80d97-96b8-48ab-95c3-ffbbd35d442a"
      unitRef="usd">6725000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i52ca22aff95e471781a54f27faf5c489_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzEtMy0xLTEtMTQzNDI_b72fac20-291a-49a7-9ee2-174d09b0602f"
      unitRef="usd">6520000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd0a4f6ba5534268909637379ffb82d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzItMS0xLTEtMTQzNDI_6480fdb2-9796-4a4f-9c9f-7d6b2d128ba2"
      unitRef="usd">1906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i66a2e3ad74d845418bc9e56f04eed7ad_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzItMy0xLTEtMTQzNDI_b8947ecb-19e4-4eec-8f37-f85499bb0f21"
      unitRef="usd">1886000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i376e781b4402454fa5e969dd3afdcc1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzMtMS0xLTEtMTQzNDI_a496578c-909b-4305-b092-610a90c68440"
      unitRef="usd">1019000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i781aa82fa62448f7922e5f7b324d73f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzMtMy0xLTEtMTQzNDI_2e2db6e2-dff7-435e-8b33-7bd240d7723c"
      unitRef="usd">959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzQtMS0xLTEtMTQzNDI_75497c60-b7c4-4ef3-b913-e4740c6d2aac"
      unitRef="usd">9650000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzQtMy0xLTEtMTQzNDI_c15419be-8f6d-45c7-bf4b-9f8388eb4bfe"
      unitRef="usd">9365000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzUtMS0xLTEtMTQzNDI_5dba44a2-c081-4d4a-aa79-3db7f97954d7"
      unitRef="usd">7682000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzUtMy0xLTEtMTQzNDI_00a96dea-39cd-499d-b2d6-488b8acbede9"
      unitRef="usd">7635000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzYtMS0xLTEtMTQzNDI_50fd79bb-ac14-48a3-8eb3-6aa9b71b43b5"
      unitRef="usd">1968000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90YWJsZTpjODZlMDYzZTNkZWU0YzQ1YTdkODQ5NWM4YTUxZTUwMC90YWJsZXJhbmdlOmM4NmUwNjNlM2RlZTRjNDVhN2Q4NDk1YzhhNTFlNTAwXzYtMy0xLTEtMTQzNDI_b15508a6-3993-4ce4-b4b7-93927371ba00"
      unitRef="usd">1730000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i05eab9496cd948acb8f286ed906bc0da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE2NDkyNjc0NDIxMDY_0beb0926-a206-4798-8c86-bc0ff150dff2"
      unitRef="usd">609000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia64cb818b4e64c72b7ce08b160086366_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE2NDkyNjc0NDIxMDE_d17b6c66-2cbe-43d1-8418-21a6d1fffa54"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ife05150f2ac84983998d474cda265a0d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzE1MQ_5a44b517-6d01-4488-8d4c-d02fba3c4599"
      unitRef="usd">429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:Depreciation
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzMzMA_93afc0f3-4d45-4ee7-a028-97525524ae71"
      unitRef="usd">855000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzMzNA_d2c03948-44ba-4ab9-a1b2-1b81f49830be"
      unitRef="usd">1010000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTIvZnJhZzo1ZGI1NTA1OTdiY2U0NzdmYjYwZTgyYTFhMjU4MDMyZC90ZXh0cmVnaW9uOjVkYjU1MDU5N2JjZTQ3N2ZiNjBlODJhMWEyNTgwMzJkXzM0MQ_9178efc0-35d5-4483-acee-0cd75097f693"
      unitRef="usd">1245000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90ZXh0cmVnaW9uOjQyZDYzMDY3MzVkMTRkMTc5ZTVjMDkzODFkY2ViZTdlXzg2_755e32ba-4a4e-4517-898e-5258a94d24b3">Accrued Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90ZXh0cmVnaW9uOjQyZDYzMDY3MzVkMTRkMTc5ZTVjMDkzODFkY2ViZTdlXzg1_917207bb-b40f-4a05-a976-b839a4c3260d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following as of December&#160;31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued preclinical expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <mrsn:AccruedManufacturingExpensesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzEtMS0xLTEtMTQzNDI_5b395f80-70c2-4a33-a7fc-c76d3527c98a"
      unitRef="usd">8476000</mrsn:AccruedManufacturingExpensesCurrent>
    <mrsn:AccruedManufacturingExpensesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzEtMy0xLTEtMTQzNDI_03744c67-d8a6-43aa-a0ef-57d1aaff0ee3"
      unitRef="usd">4157000</mrsn:AccruedManufacturingExpensesCurrent>
    <mrsn:AccruedClinicalExpensesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzItMS0xLTEtMTg3MjE_d6c5dbee-8ede-46c5-8cb8-c01cad312257"
      unitRef="usd">7879000</mrsn:AccruedClinicalExpensesCurrent>
    <mrsn:AccruedClinicalExpensesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzItMy0xLTEtMTg3MTY_4323fc11-240f-41c6-a6c5-12172d8d9163"
      unitRef="usd">5126000</mrsn:AccruedClinicalExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMjY5OTY_f559e86e-9f1b-442b-b2e4-07282f08b2dd"
      unitRef="usd">7319000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMjY5OTY_159e9e4e-fa1b-44d2-b697-375a9c676a6e"
      unitRef="usd">5412000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <mrsn:AccruedPreclinicalExpensesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMTg3MzM_40792e5b-8727-4823-a808-37769313d3fe"
      unitRef="usd">3848000</mrsn:AccruedPreclinicalExpensesCurrent>
    <mrsn:AccruedPreclinicalExpensesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMTg3NDc_7bdeb011-4931-4e4b-9c86-628a5a5b00ed"
      unitRef="usd">619000</mrsn:AccruedPreclinicalExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMS0xLTEtMTQzNDI_9af6847d-efc7-413a-9317-2bd27ba4fff7"
      unitRef="usd">909000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzMtMy0xLTEtMTQzNDI_6ebeae15-5cb8-4ad9-8514-4ca335eaf0ee"
      unitRef="usd">757000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzQtMS0xLTEtMTQzNDI_f6b3e07b-c27a-4048-96d8-51e46b65c0ca"
      unitRef="usd">285000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzQtMy0xLTEtMTQzNDI_d8109331-9642-455c-8acb-35075974b6a7"
      unitRef="usd">75000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzUtMS0xLTEtMTQzNDI_a4c73a70-ab41-474e-abb5-68d8642a014f"
      unitRef="usd">28716000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTUvZnJhZzo0MmQ2MzA2NzM1ZDE0ZDE3OWU1YzA5MzgxZGNlYmU3ZS90YWJsZTowNjI4OTUzZmIzZmI0YzA2YmNmODRmNGMwYjhlMmJlMS90YWJsZXJhbmdlOjA2Mjg5NTNmYjNmYjRjMDZiY2Y4NGY0YzBiOGUyYmUxXzUtMy0xLTEtMTQzNDI_a9a42fc2-fe48-48d5-a012-e7b2b49d0e19"
      unitRef="usd">16146000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NDg_e893538e-65f0-4496-a8a8-5a6f0ef0c64a">Debt&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2019, the Company entered into a loan and security agreement (the Original Agreement) with SVB pursuant to which the Company borrowed $5,000. The Original Agreement accrued interest at a floating per annum rate equal to the greater of (i) 4.0% and (ii) 1.50% below the Prime Rate. The Original Agreement had an interest-only period through August 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 28, 2020, the Company entered into a second amendment (the Second Amendment) to the Original Agreement with SVB (the Prior Credit Facility). Pursuant to the Second Amendment, the Company drew $5,200 upon execution of the Second Amendment, the proceeds of which were used to repay the Company&#x2019;s existing balance under the Original Agreement and satisfy its obligations to SVB. The Amended Credit Facility accrued interest at a floating per annum rate equal to the greater of (i) 4.25% and (ii) 1.00% above the Prime Rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 29, 2021, the Company entered into a loan and security agreement (the New Credit Facility) with SVB and Oxford (Oxford and SVB, together the Lenders). Pursuant to the New Credit Facility, the Company can borrow term loans in an aggregate amount of $100,000, which includes (i) $60,000 in up to three principal advances through December 31, 2022, (ii) an additional $10,000 in one principal advance, if the Company reaches certain development milestone events through December 31, 2022, (iii) an additional $10,000 in one principal advance, if the Company reaches additional development milestone events through June 30, 2023 and (iv) an additional tranche of $20,000, subject to conditional approval from the Lenders. The Company drew $25,000 upon execution of the New Credit Facility, of which $5,500 of the proceeds was used to repay the existing balance under the Prior Credit Facility and satisfy its obligations to SVB, resulting in the recording of a $398 loss on extinguishment, which is presented within interest expense for the year ended December 31, 2021 on the Consolidated Statements of Operations and Comprehensive Loss. Upon entering into the New Credit Facility, the Company terminated all commitments by SVB to extend further credit under the Prior Credit Facility and all guarantees and security interests granted by the Company to SVB under the Prior Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The New Credit Facility bears interest at a floating per annum rate equal to the greater of (i) 8.50% and (ii) 5.25% above the Prime Rate. Interest is payable monthly in arrears on the first day of each month. The Company is obligated to make interest-only payments through November 1, 2024, followed by equal monthly principal payments and applicable interest through the maturity date of October 1, 2026 (the Maturity Date). If certain development milestones are met, then the interest-only period will be extended to November 1, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also required to make a final payment to the Lenders equal to 4.25% of the principal amount of the term loans then extended to the Company. This final payment is accreted under the effective interest method over the life of each term loan. The term loans are secured by substantially all of the Company&#x2019;s assets, except for its intellectual property which is subject to a negative pledge, and certain other customary exclusions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Company&#x2019;s option, it may prepay the outstanding principal balance of any term loans in whole but not in part, subject to a prepayment fee of: (a) 3.0% of the term loans then extended to the Company if the prepayment occurs on or prior to the first anniversary of the funding date of such term loan, (b) 2.0% of the term loans then extended to the Company if the prepayment occurs after the first anniversary of the funding date of such term loan but on or prior to the second anniversary of the funding date of such term loan, or (c) 1.0% of the term loans then extended to the Company if the prepayment occurs after the second anniversary of the funding date of such term loan but before the Maturity Date. The New Credit Facility includes customary affirmative and restrictive covenants applicable to the Company. Affirmative covenants include, among others, covenants requiring the Company to maintain its corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The restrictive covenants include, among others, requirements relating to the Company&#x2019;s ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets and agree to a change in control, in each case subject to certain customary exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s payment obligations under the New Credit Facility are subject to acceleration upon the occurrence of specified events of default, which include, but are not limited to, the occurrence of a material adverse change in the Company&#x2019;s business, operations, or financial or other condition. Amounts outstanding upon the occurrence of an event of default are payable upon the Lenders' demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. As of December&#160;31, 2021, the Company was in compliance with all covenants under the New Credit Facility. As such, as of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021, the classification of the loan balance as stated on the balance sheet was based on the timing of defined future payment obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with entering into the New Credit Facility, the Company paid $958 in costs, of which $210 was paid to Lenders and $748 was paid to third parties. Certain costs were recorded as a reduction of the carrying amount on the term loan and amortized as interest expense using the effective-interest method, which was comprised of $151 of the costs paid to the Lenders and $273 of the costs paid to third parties. The remaining costs of $533 were capitalized in other assets related to the Company's right to borrow additional amounts from the Lenders in the future and amortized to interest expense over the relevant draw period on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $25,000 outstanding under the New Credit Facility and the debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term-debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt financing costs, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion related to final payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the estimated future principal payments due are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021 and 2020, the Company recognized $797 and $340, respectively, of interest expense related to the Prior Credit Facility and New Credit Facility, as applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i46ac06dbc12246b49e2a5075fae37c0f_D20190508-20190508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzE3OQ_76fa06d7-8526-4929-abe5-7dac6a3f50f5"
      unitRef="usd">5000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0db434ef0b14ed0861021376bc27afa_I20190508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4MA_514c3e7a-9f48-4657-9ff3-c7652a57d19a"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iab899b1838874099a8e5ac2ff7777f3b_D20190508-20190508"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI5Mg_1faf12d2-f055-4f14-8ee0-6d5847eb4c36"
      unitRef="number">-0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4009d30c89524098b6f75ea92a8511f0_D20200828-20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDkwMTE_0a8c2bf6-f56f-43f9-bd85-682f8b05ab36"
      unitRef="usd">5200000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia0f44c7208fa4c7f961ffd639310b35d_I20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzEzMjQ_4ff233ba-3e7b-4289-bc68-aa0ebe0afcd1"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idf785a49089f45d398bf851be2b7932a_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzEzMzY_8bc67fb9-ffcc-40d1-b817-f1628488cd40"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic2eadf722ff64d92ae9288bc5dfe2b84_I20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODA_c6e04339-8b7f-40c2-8aad-a3ec4d6c230f"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i712f21030d394390afd89dbcc6e8b06c_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_9702f9d0-7c95-4de8-b124-3a51490ca9b6"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i096da856c8104fe6ab086e5efc3eec34_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_a86c0765-522e-4d8c-b20b-d6fc55d98107"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifc33cdd85a414f2cb35b3a6e5e998ca2_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4ODk_cffe05a6-e837-4e2e-9950-e6794b5dbe94"
      unitRef="usd">60000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i786194604a4b4117b25a3e6b81f087f9_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM4OTg_c9b56969-8c77-4184-837d-e763ba8fac1f"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic9ad9876d541413f801749cf53712cf7_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MDc_636f0066-c201-4177-b3cd-a6c1530d0475"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idcf2d9fb74094c5991ba27cf6c512eda_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MTY_6f2ab47d-0189-41bb-805f-50a5e0c8bcf9"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MjQ_97c1500a-b3b3-472b-acb5-4d530f9c046c"
      unitRef="usd">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i27e84780e10842d2bd65ee2008d484a1_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5MzI_b33876a3-c679-425e-8697-48e3f77ba975"
      unitRef="usd">5500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idd180a13515a4868acdde8a30e3a9cd9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQzOTgwNDY1MzM1Nzg_fb08b452-cf3d-452d-8135-348cc32e09a5"
      unitRef="usd">-398000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic8b569721ff344e2aa89e9d46ede08d2_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4NTg3MzAyMzQ1NjA2_e4e0fb48-2b7a-46a9-a734-b51ce6455645"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i42af7c89af7b48a79ad2c8608164b77c_D20211029-20211029"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NDA_1e8e866d-2889-4eb6-832b-7f72591f224b"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount
      contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzIwOTg_75ada437-cba3-4420-be3a-c114e3b99162"
      unitRef="number">0.0425</mrsn:FinalPaymentAsPercentageOfOriginalPrincipalAmount>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="ic6c994875ee643a9bdf93806ee028002_D20211029-20211029"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI2MTU_5d4ae6fd-5109-41dd-8357-8bb8039cdb7c"
      unitRef="number">0.030</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="i9ecaffff610841b798a218f5d8f6512a_D20211029-20211029"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI3MjY_e8f1bd1b-179e-4990-bee6-8fb0be293a61"
      unitRef="number">0.020</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentPrepaymentFeePercent
      contextRef="i3c85f701a6a3492b83ae133b0f08ef74_D20211029-20211029"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzI4NjY_fcc672c5-045e-44ea-a95a-7227c967e2d8"
      unitRef="number">0.010</mrsn:DebtInstrumentPrepaymentFeePercent>
    <mrsn:DebtInstrumentAdditionalRateInEventOfDefault
      contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQyNzA_435b8b52-2462-4732-ba4f-e52f08c13afc"
      unitRef="number">0.050</mrsn:DebtInstrumentAdditionalRateInEventOfDefault>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i422c756559014c5d9009424c3496c2ef_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQ2Mjg_d4763217-a896-459e-ae32-ebe81143b4cb"
      unitRef="usd">958000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ia0ea172aa94b48648314fda755ca7392_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NTI_c67c8acd-7446-4916-9ff6-f1c6cea6c7e4"
      unitRef="usd">210000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib909e4352d504cd6b40dc90f0dbdd2b3_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NTc_870abcf4-3bb5-45ee-aa28-a77c69d02a5c"
      unitRef="usd">748000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i54e050cde4d9454b8bfc4b3d17c5dc2a_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzQ3NzQ_2f40c09c-d473-4186-958c-0f2c93bb9a87"
      unitRef="usd">151000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i649899397fe049798792f393cde3e4cc_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NjI_61add7fc-3312-4677-bb87-a18f422b126b"
      unitRef="usd">273000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ib1b33420048243f9a32ec5f4a1baff18_D20211029-20211029"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzcxNDY4MjU2MDM5NDc_e38859b6-bb20-4bd5-aca6-9bf39d2ae7d4"
      unitRef="usd">533000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NDk_2f2015ab-f5ab-439a-a3f6-0523aaccb345">&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $25,000 outstanding under the New Credit Facility and the debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term-debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt financing costs, net of accretion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion related to final payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i89f02922d04244f98f6fa502e3378212_D20200828-20200828"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUxMDE_941c4dfc-c133-4f3d-8e0d-31af407bef5a"
      unitRef="usd">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzEtMS0xLTEtMTQzNDI_8057e5ee-8653-442c-bdfa-a8f3410ee462"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzItMS0xLTEtMTQzNDI_cb5eb2b5-eeec-4a40-b5d7-4c305fc83a73"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <mrsn:DebtInstrumentCarryingAmountNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzMtMS0xLTEtMTQzNDI_24dc66a9-0862-4501-a169-07eb4fda76b1"
      unitRef="usd">25000000</mrsn:DebtInstrumentCarryingAmountNoncurrent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzQtMS0xLTEtMTQzNDI_1e566276-33af-4a8a-b300-a6cfbe4bf8ff"
      unitRef="usd">410000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzUtMS0xLTEtMTQzNDI_8e09c9f3-686d-4df3-b277-72ebe047e1eb"
      unitRef="usd">36000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTo5NmE0MzE4ZDkxOWM0NTQzYWRhOTI1NzFmNjQxMTFkYS90YWJsZXJhbmdlOjk2YTQzMThkOTE5YzQ1NDNhZGE5MjU3MWY2NDExMWRhXzYtMS0xLTEtMTQzNDI_62ad3188-180d-438f-b0f8-bc5ebf39b46f"
      unitRef="usd">24626000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzU0NTA_d65f5f0b-8034-44c2-b0fe-3c7483255e39">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the estimated future principal payments due are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,417&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzAtMS0xLTEtMTQzNDI_5033c9b3-4cbc-40db-84fc-71d4ba4356c4"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzEtMS0xLTEtMTQzNDI_054a0d53-f163-4db8-862a-ad26bc441c9e"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzItMS0xLTEtMTQzNDI_d9e80b63-73ca-4970-ba19-eeeecab52036"
      unitRef="usd">2083000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzMtMS0xLTEtMTQzNDI_73e1b09c-b7d6-4b18-9875-737a94fe1203"
      unitRef="usd">12500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzQtMS0xLTEtMTgxMDI_50d2eb2c-695b-43e6-ba04-fdb1098943b8"
      unitRef="usd">10417000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90YWJsZTozYmZhOGFmZTY3YzA0ZDE3YjFhYjA3Mjk1NTIzNmNjYS90YWJsZXJhbmdlOjNiZmE4YWZlNjdjMDRkMTdiMWFiMDcyOTU1MjM2Y2NhXzQtMS0xLTEtMTQzNDI_0a2eac52-b1f6-463b-936e-aabe852aa43b"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:InterestExpenseDebt
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUzMjE_1ba92941-c50d-438e-82b7-2f8634cfdfb5"
      unitRef="usd">797000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMTgvZnJhZzplNzVlYzIyMTg5MjU0ZGVhYWFlZDJiMjYxMTEwNWJiMS90ZXh0cmVnaW9uOmU3NWVjMjIxODkyNTRkZWFhYWVkMmIyNjExMTA1YmIxXzUzMjg_8fcdfb13-4d3b-449b-ab46-d57605dc683b"
      unitRef="usd">340000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM3NzI_ee70766e-9ef0-4461-abc5-815f34d181ba">Stockholders&#x2019; Equity&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had 25,000,000 shares of authorized preferred stock. No shares of preferred stock have been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;At-the-market equity offering program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Company established an at-the-market (ATM) equity offering program (the 2018 ATM) pursuant to which it could offer and sell up to $75,000 of its common stock from time to time at prevailing market prices. During the year ended December 31, 2020, the Company sold 10,900,599 shares of common stock and received net proceeds of $62,976 through the 2018 ATM. In May 2020, the Company terminated the 2018 ATM and established a new ATM equity offering program (the 2020 ATM) pursuant to which it is able to sell up to $100,000 of its common stock from time to time at prevailing market prices. As of December&#160;31, 2021, the Company had sold 3,961,074 shares of common stock and received net proceeds of $43,087 under the 2020 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Follow-on offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company sold 9,200,000 shares of common stock, in an underwritten public offering price to the public of $19.00 per share. Net proceeds to the Company after deducting fees, commissions and other expenses related to the offering were $163,990.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a 2013 Series&#160;A-1 Preferred Stock issuance, the Company granted to certain investors warrants to purchase 129,491 shares of common stock. The warrants have a $0.05 per share exercise price and a contractual life of 10 years. The fair value of these warrants was recorded as a component of equity at the time of issuance. As of December&#160;31, 2021 and 2020 there were warrants to purchase 39,474 shares of common stock. During the year ended December&#160;31, 2021, there were no exercises of warrants in exchange for shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exchange warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 26, 2019, the Company entered into an exchange agreement with entities affiliated with Biotechnology Value Fund, L.P. (the Exchanging Stockholders), pursuant to which the Exchanging Stockholders exchanged an aggregate of 2,575,000 shares of common stock for warrants (the Exchange Warrants) to purchase an aggregate of 2,575,000 shares of common stock (subject to adjustment in the event of any stock dividends and splits, reverse stock split, merger or consolidation, change of control, reorganization or similar transaction, as described in the Exchange Warrants), with an exercise price of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC Topic 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded the retirement of the common stock exchanged as a reduction of common shares outstanding and a corresponding debit to additional paid-in-capital at the fair value of the Exchange Warrants on the issuance date. While outstanding, the Exchange Warrants were classified as equity in accordance with ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the fair value of the Exchange Warrants was recorded as a credit to additional paid-in capital and is not subject to remeasurement. The Company determined that the fair value of the Exchange Warrants is substantially similar to the fair value of the retired shares on the issuance date due to the negligible exercise price for the Exchange Warrants. On March 2, 2020, the Exchanging Stockholders exercised the Exchange Warrants in full on a net cashless exercise basis, resulting in the issuance of 2,574,971 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the common stock are entitled to one vote for each share held. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors of the Company (the Board).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020 there were 9,199,512 and 6,869,189 shares of common stock, respectively, reserved for the exercise of outstanding stock options and warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,199,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4Xzcx_24f6a0f1-3cd1-4758-9a28-e65712c58815"
      unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzExMg_af035335-77ca-4ae6-afa1-acc34bd4f859"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <mrsn:StockIssuanceProgramAuthorizedAmount
      contextRef="iffee20b1411845d4b0b9f086f3c189b9_I20180731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM0NQ_18407370-e571-425f-aa1e-f7d07c2898bf"
      unitRef="usd">75000000</mrsn:StockIssuanceProgramAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i90b59a6592d446c0a49cb9607722d36e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTU1Mjg_799d16ef-1a1c-4636-979a-6dacd0421afe"
      unitRef="shares">10900599</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic9c64af17ca343848603ecfba6316570_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTkzNDM_f640e079-6332-4a69-ab6f-24934cda8769"
      unitRef="usd">62976000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mrsn:StockIssuanceProgramAuthorizedAmount
      contextRef="i2c0c094572df4f53b6e958fe1bcfe81b_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4Xzg4NA_eb539018-64d0-4ef5-a122-ad89831f17d4"
      unitRef="usd">100000000</mrsn:StockIssuanceProgramAuthorizedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0b819cc168a7463ab7a8bb8619734286_D20200501-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzQzOTgwNDY1MTU0OTk_3a51a725-9d1e-4b58-817b-b1ae821d3ccd"
      unitRef="shares">3961074</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i828ebe879492478780a584c32808e4db_D20200501-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM4NDgyOTA3MDQxNDM_4906b50e-9a43-441b-8c0b-d22f3e136686"
      unitRef="usd">43087000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i37036005f77a435e8823d902b65b4b26_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzEwNzA_5d7f7a50-4f3f-428f-931a-9dab470d1590"
      unitRef="shares">9200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i2f9e97774b6a4b27bd93e83aa57935c4_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzExNTU_83a4973d-c746-435d-b4e5-a759e9035c17"
      unitRef="usdPerShare">19.00</us-gaap:SharesIssuedPricePerShare>
    <mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts
      contextRef="i37036005f77a435e8823d902b65b4b26_D20200601-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzEyNzk_af7fc92d-ca56-4eb0-b92b-78bb835af8de"
      unitRef="usd">163990000</mrsn:ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts>
    <mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued
      contextRef="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE0MTc_54549fc0-0140-4e1f-b646-a98604edb05d"
      unitRef="shares">129491</mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i338c16ccd7cd41ef810857176b3cb944_I20131231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE0NjQ_9633e068-0c54-4906-b578-3334dedf283a"
      unitRef="usdPerShare">0.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mrsn:ContractualLifeOfWarrants
      contextRef="iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE1MTg_e0b2bfde-b633-44af-8160-bc1913db4307">P10Y</mrsn:ContractualLifeOfWarrants>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE2NjY_42d490d2-bc47-4b26-aa0b-a4e8c3acabb5"
      unitRef="shares">39474</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE2NjY_700de3e4-b165-4ec2-9972-312538d19181"
      unitRef="shares">39474</us-gaap:ClassOfWarrantOrRightOutstanding>
    <mrsn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzE3MzA_9b9613af-e1be-448d-92ad-8b60840312ae"
      unitRef="shares">0</mrsn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants
      contextRef="i5c6d26ecc5ca4927bf170e6f70476126_D20191126-20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzIwNDY_b1be402e-8ff2-4afc-a5f1-caec5008d7b4"
      unitRef="shares">2575000</mrsn:ClassOfWarrantOrRightSharesExchangedForWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7d00f365edee446b858df5048d05be98_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzIxMzc_df6448e3-b5f8-4e52-8f13-9261eb3ed866"
      unitRef="shares">2575000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7d00f365edee446b858df5048d05be98_I20191126"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzI0MDQ_69dd45a4-8278-4e9d-83e5-2f975ac69d6d"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <mrsn:WarrantsExercisedInPeriod
      contextRef="ic1c0f959152f49bbb6f2f1b5870fdd72_D20200302-20200302"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzMzOTU_99745d4c-eb3e-4506-83e8-a2c842cbadfe"
      unitRef="shares">2574971</mrsn:WarrantsExercisedInPeriod>
    <mrsn:NumberOfVotesPerCommonShare
      contextRef="iab96e0e1da4049c8b62a439b2d988b00_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM0ODM_ef2aed3a-c8fd-4a78-8350-7ea04bbe46ca"
      unitRef="vote">1</mrsn:NumberOfVotesPerCommonShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6e2b696bd2b946689884d6db1dbaebcc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM2NTM_263fd154-d0ec-47f2-8428-09817751600c"
      unitRef="shares">9199512</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6e33d28def5e47e48376a78023729e2b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM2NjA_a57dafc6-68d6-416a-ba99-0a0c11df8146"
      unitRef="shares">6869189</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90ZXh0cmVnaW9uOjdjZjNhMjNmMDg3NDQ5OTA4NTE4N2I3MWRhZTM2ZDQ4XzM3NzE_1daca46c-d809-476d-94d0-0bd31e9ed537">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,199,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iff2b446a5705439d8204e2db3af84557_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzEtMS0xLTEtMTQzNDI_22923bad-4834-45f0-a364-f7903d9a15f6"
      unitRef="shares">8342429</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2836cc08d6b440048b685415e74ef94a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzEtMy0xLTEtMTQzNDI_fb56be5c-a7a0-47ca-a6a2-ef41fa6134f4"
      unitRef="shares">6112948</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibcfae73b76f849c2beedf48b3fd3ddb2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzItMS0xLTEtMTQzNDI_625703f7-6246-4bf4-a5a5-84381d4033a6"
      unitRef="shares">817609</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3ed739e482d84b91bdcedea1d7aa35da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzItMy0xLTEtMTQzNDI_b1ccc8cf-6c2b-40cc-8097-ea51dc2e5113"
      unitRef="shares">716767</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id9a2b387a4dd4de5a44607493ebe2f7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzMtMS0xLTEtMTQzNDI_38f6c525-efc3-4d51-8864-33f5ef308d9d"
      unitRef="shares">39474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ica825e7423074dfd9b2d51c5b1e0acfa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzMtMy0xLTEtMTQzNDI_4e2219a4-505a-4fbb-8e6d-3c977da2e4bc"
      unitRef="shares">39474</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzUtMS0xLTEtMTQzNDI_d1619932-ebc2-4219-9ac5-931be61f8ab2"
      unitRef="shares">9199512</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjQvZnJhZzo3Y2YzYTIzZjA4NzQ0OTkwODUxODdiNzFkYWUzNmQ0OC90YWJsZTplNmEwZmIyYmJhZTc0ZDdmODI0MjQ5NDI1ZmRhYzUyOC90YWJsZXJhbmdlOmU2YTBmYjJiYmFlNzRkN2Y4MjQyNDk0MjVmZGFjNTI4XzUtMy0xLTEtMTQzNDI_985bca9c-c1c7-4cdc-83b8-b713a31a2e80"
      unitRef="shares">6869189</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTY_db945089-435a-4dc8-bbaa-bc72164a7dd1">Stock Options&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2017, there were 3,141,625 options outstanding under the Company&#x2019;s 2007 Stock Incentive Plan.&#160;The 2007 Plan expired in June 2017. Any cancellations or forfeitures of options granted under the 2007 Stock Incentive Plan will increase the options available under the 2017 Stock Incentive Plan as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017 the Company&#x2019;s shareholders approved the 2017 Stock Incentive Plan (the 2017 Plan or the Plan).&#160;Under the 2017 Plan initially, up to 2,255,000 shares of common stock may be granted to the Company's employees, officers, directors, consultants and advisors in the form of options, RSUs or other stock-based awards. The number of shares of common stock issuable under the Plan cumulatively increases annually by 4% of the outstanding shares or such lesser amount determined by the Board. The terms of the awards made under the Plan are determined by the Board, subject to the provisions of the Plan. In January 2021, the number of shares of common stock issuable under the 2017 Plan was increased by 2,753,651 shares. As of December&#160;31, 2021 there were 1,308,183 shares available for future issuance under the Plan. During the year ended December&#160;31, 2021, the Company granted to employees 715,716 RSUs and options to purchase 2,870,720 shares of common stock under the 2017 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the 2017 Plan, both with respect to incentive stock options and nonqualified stock options, the exercise price per share will equal the fair market value of the common stock on the date of grant, as determined by the Board, and the vesting period is generally four years. Options granted under the Plan expire no later than 10 years from the date of grant. Options under the 2007 Plan were granted at an exercise price established by the Board (or a committee thereof) that was not less than the fair market value of the underlying common stock on the date of grant and subject to such vesting provisions determined by the Board (or a committee thereof). The Board may accelerate vesting or otherwise adjust the terms of granted options in the case of a merger, consolidation, dissolution, or liquidation of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants to its employees, upon approval by the Board, options to purchase shares of common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The securities are issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering. These options are subject to terms substantially the same as the options granted under the 2017 Plan. As of December&#160;31, 2021 there were options to purchase 757,500 shares of common stock granted as inducement awards outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,308,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2021, 2020 and 2019, was $11.71, $7.99 and $2.47 per share, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2021, 2020 and 2019, was $4,299, $11,147, and $202, respectively. The aggregate intrinsic value represents the difference between the exercise price and the selling price received by option holders upon the exercise of stock options during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from the exercise of stock options was $1,837, $3,138 and $175 for the&#160;years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company periodically issues RSUs with a service condition to certain officers and other employees that typically vest between one year and four years from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of the RSU activity under the 2017 Plan is as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs vested during the years ended December&#160;31, 2021, 2020 and 2019, was $5,790, $0, and, $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the provisions of ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to account for all stock-based awards to employees and non-employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The measurement date for awards is generally the date of grant. Stock-based compensation expense is recognized over the requisite service period, which is generally the vesting period, using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense by award type included within the Company&#x2019;s consolidated statement of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $38,958 and $9,929 of unrecognized compensation expense related to unvested stock options and unvested RSUs, respectively, that is expected to be recognized over a weighted average period of 2.6 years and 2.8 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black&#x2013;Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility for the Company&#x2019;s common stock is determined based on the historical volatility of comparable publicly traded companies. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the expected term of the option. No dividend yield was assumed as the Company has not historically and does not expect to pay dividends on its common stock. The expected term of the options granted is based on the use of the simplified method, in which the expected term is presumed to be the mid-point between the vesting date and the end of the contractual term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs is determined based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2017, the Board adopted and the Company's stockholders approved the 2017 employee stock purchase plan (the 2017 ESPP). The Company initially reserved 225,000 shares of common stock for issuance under the 2017 ESPP, plus an annual increase, to be added as of January 1st of each year, equal to the least of (i) 450,000 shares of common stock; (ii) one percent of the number of shares of common stock outstanding as of the close of business on the immediately preceding December 31st; and (iii) the number of shares of common stock determined by the Board on or prior to such date for such year, up to maximum of 4,725,000 shares of common stock in the aggregate. During the years ended December&#160;31, 2021 and 2020 the Company issued 78,253 and 80,267 shares, respectively, under the 2017 ESPP. As of December&#160;31, 2021, there were 566,565 shares available for issuance.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i737243bf173d4209a6e2039ac6c813f9_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzc0_68b6f19d-a788-4455-bbe9-24104beeb7a2"
      unitRef="shares">3141625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3eec540f391a482b8cf41ac59c16c58d_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQ3MQ_1d868701-4488-4173-9165-8cc1247cbea8"
      unitRef="shares">2255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease
      contextRef="i5ec75714d1fa4db7ab67c66b6d110b6e_D20170601-20170630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzc3Mw_937d8fae-a0d1-45a2-8d77-36dc8ff25cff"
      unitRef="number">0.04</mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ia71270946b0347db9fb2c7e2adb5eb55_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQzOTgwNDY1MjMzNTI_577020aa-e50f-4911-abb7-33410b345bd7"
      unitRef="shares">2753651</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i34baed2717f54091a1033f9099b12641_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk2MA_29ad4810-b0be-4c95-b0bc-df4054fc09f3"
      unitRef="shares">1308183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzcxNDY4MjU1OTU3ODk_f3e8c098-2683-4125-a5b5-88e2d65d852a"
      unitRef="shares">715716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1fac48995f2c4c16a220008833e49a01_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzMzNTM1MTA0NjY4NzUw_4f8ab782-eebf-45a4-9132-8492c6cd0906"
      unitRef="shares">2870720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2c201fa2273b4d5692775bfe687ff519_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNDE0_9b94a362-0735-459a-af7f-c903e8520ed4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="iaaff1344197a4f7f88291b1ff2549f0c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNDQx_5327764b-a627-4d45-9eb3-f860a04373c8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if90621fb17914192b3cc20226646f468_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzY1OTcwNjk3NzM4MDU_209f9303-ae48-454c-8029-64866370fedd"
      unitRef="shares">757500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTg_3be02eb6-f0cb-4625-aea8-f6f6c8d1080e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;of Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,308,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(421,381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(657,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,342,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,997,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtMS0xLTEtMTQzNDI_b020107d-70d1-4429-9ba9-18500e772f4e"
      unitRef="shares">6112948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtMy0xLTEtMTQzNDI_ce58eef8-a2d1-4eda-80c8-99e65e2e71d9"
      unitRef="usdPerShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtNS0xLTEtMTQzNDI_a25828be-6c57-4a6c-9adb-b2680eddd781">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzEtNy0xLTEtMTQzNDI_51102fd6-3050-425c-a7bd-cd7365efb5fa"
      unitRef="usd">114729000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzItMS0xLTEtMTQzNDI_91f57f6c-f39c-46cc-a22e-afc77508f76b"
      unitRef="shares">3308220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzItMy0xLTEtMTQzNDI_b664e1e4-6c55-45ce-98a5-2131acf15780"
      unitRef="usdPerShare">16.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzMtMS0xLTEtMTQzNDI_4a0112b4-b72d-4ac2-a81a-98440e0dbdd6"
      unitRef="shares">421381</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzMtMy0xLTEtMTQzNDI_0e70fe12-c550-4189-b81a-0e6607d446ce"
      unitRef="usdPerShare">4.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzQtMS0xLTEtMTQzNDI_1ad7cb62-4b4a-4668-86ed-e54d8384a371"
      unitRef="shares">657358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzQtMy0xLTEtMTQzNDI_c5419526-21a6-48d1-9d38-fe3bb5a8ca2b"
      unitRef="usdPerShare">11.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtMS0xLTEtMTQzNDI_01b12bc6-d732-49a2-85f2-2021a2a02356"
      unitRef="shares">8342429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtMy0xLTEtMTQzNDI_fd5e2833-1129-4118-af02-ee10934d7b3d"
      unitRef="usdPerShare">11.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtNS0xLTEtMTQzNDI_c1abf0ac-e4dd-4e7c-b51f-5e587508c87d">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzUtNy0xLTEtMTQzNDI_f6aafb64-9901-4d16-abfc-fa0e1c4cbd15"
      unitRef="usd">8458000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtMS0xLTEtMjI5NTI_e82c4530-fd8e-4364-ab7f-9f20084e0c6a"
      unitRef="shares">8342429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtMy0xLTEtMjI5NTI_4a132ac5-38e6-412e-9ce1-30ff4c16a46c"
      unitRef="usdPerShare">11.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtNS0xLTEtMjI5NTI_18539dd6-6b09-4407-8f07-b7b305d46be9">P7Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzYtNy0xLTEtMjI5NTI_8cf4cd1c-b9c9-43fd-bc4c-6e5740505966"
      unitRef="usd">8458000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctMS0xLTEtMTQzNDI_a1004141-a27f-458b-b2c0-3a1651f0ea24"
      unitRef="shares">3997529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctMy0xLTEtMTQzNDI_950154b9-6a57-43b8-a4fa-f562084e9cef"
      unitRef="usdPerShare">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctNS0xLTEtMTQzNDI_599af6f8-a93d-4f56-853d-6135b03d06b1">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4NTI1MjBhYzIyMmU0MmM3YTcwNmZiZDA5YjFmODIyZC90YWJsZXJhbmdlOjg1MjUyMGFjMjIyZTQyYzdhNzA2ZmJkMDliMWY4MjJkXzctNy0xLTEtMTQzNDI_13a5aa44-e567-4520-86ad-5d95d53d3d2d"
      unitRef="usd">7539000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MTI_15c698b1-2b77-45d8-873a-1c529e5d3982"
      unitRef="usdPerShare">11.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MTY_4ef398f3-6c0c-47ab-bb60-1c65325888cf"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI2MjM_c07d5c52-9c3e-4aaa-aaff-da200cd77711"
      unitRef="usdPerShare">2.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyNzg_a2c966db-d78d-47e8-9388-45399009e1a3"
      unitRef="usd">4299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyODM_1a6c2034-f0e5-4cb7-9f66-8445b3279c3d"
      unitRef="usd">11147000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUyOTI_a2aa0de3-641e-44d2-a6e8-8407cc9deb7c"
      unitRef="usd">202000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MDQ_0d9f59db-b813-4251-a6f0-c7665d58ec29"
      unitRef="usd">1837000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MDg_caad72e0-bc25-4100-bac4-4ebba8ac56e4"
      unitRef="usd">3138000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI3MTU_13530c97-7c84-4210-b09c-5c362c9c80a2"
      unitRef="usd">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1c64324e16174923bd142062def84677_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzEwNDQ1MzYwNDc1NzAw_e796f0f3-2613-43da-b656-78956a295043">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0e1147f1b66d4b6bae33bea0cccbebbb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzEwNDQ1MzYwNDc1NzA4_35b15461-f830-4789-bbbf-019e183044be">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTk_bd37ebdd-0664-4f65-98a4-107391d02d6f">&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of the RSU activity under the 2017 Plan is as follow:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&lt;br/&gt;of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(419,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(195,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;817,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtMS0xLTEtMTQzNDI_2a7fee7f-1b96-4987-ab15-f28bca3dc18a"
      unitRef="shares">716767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtMy0xLTEtMTQzNDI_1d7b2d12-ee80-4afe-9519-dc40efb807e4">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtNS0xLTEtMTQzNDI_35a9bb5b-b495-4eb4-9816-669ffa94580b"
      unitRef="usd">19073000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzEtNy0xLTEtMTQzNDI_2d2a82fa-37ec-41b0-9ab2-08172177e118"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i048fbd6e8dfa47ce8f6fccd50fa82fb0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzItMS0xLTEtMTQzNDI_f3e8c098-2683-4125-a5b5-88e2d65d852a"
      unitRef="shares">715716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzItNy0xLTEtMTQzNDI_884ac588-884a-4a46-83c6-4c72f19c2214"
      unitRef="usdPerShare">18.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzMtMS0xLTEtMTQzNDI_c6a8fabb-30fe-4560-b749-dfa9a7337b9a"
      unitRef="shares">419336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzMtNy0xLTEtMTQzNDI_913186d4-1af9-42d5-966d-774a2adc3a96"
      unitRef="usdPerShare">5.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzQtMS0xLTEtMTQzNDI_aaa49bab-8639-429d-b7d3-317d10d553e6"
      unitRef="shares">195538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzQtNy0xLTEtMTQzNDI_7cf84cb4-e9ae-4eaf-9a84-aeef29ca2941"
      unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtMS0xLTEtMTQzNDI_f637e3d8-9e2f-4f3f-a68a-4ce6076badb5"
      unitRef="shares">817609</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtMy0xLTEtMTQzNDI_45c5e87b-52f7-44a7-b999-3b8a9f52ebd0">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtNS0xLTEtMTQzNDI_1721a456-4d86-4838-bece-182a0cf3dda5"
      unitRef="usd">5086000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo3YjFkODhmMzNhMGI0MTkzODUyOTdhMjIzNTA5Y2IwNS90YWJsZXJhbmdlOjdiMWQ4OGYzM2EwYjQxOTM4NTI5N2EyMjM1MDljYjA1XzUtNy0xLTEtMTQzNDI_5ea4da04-cf84-4908-b003-b1cc2e3bc52b"
      unitRef="usdPerShare">15.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNDQ_5574f653-0420-4685-8791-aebc731c5ec9"
      unitRef="usd">5790000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNTM_736a6688-b03c-402d-8acb-01dd5902ecb3"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzk4OTU2MDQ2NjUzNjQ_80f275a2-94a0-4008-809f-1281292b78b7"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTM_4a71cf74-b463-4e29-9d91-b40eaed71bca">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense by award type included within the Company&#x2019;s consolidated statement of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItMS0xLTEtMTQzNDI_7c36b616-0a1f-41d0-ab6a-4ac93b6bfafe"
      unitRef="usd">14528000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6d675eb3e6d43b4bf7380c997407796_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItMy0xLTEtMTQzNDI_9674eba4-347f-4d43-a2bc-110553384a17"
      unitRef="usd">5725000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic58196efabc4455dbc9f56d50edcfad0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzItNS0xLTEtMTQzNDI_6d8cd394-396f-4446-9970-5f3701bae6e5"
      unitRef="usd">4230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtMS0xLTEtMTQzNDI_0de3e10a-0b3e-43fd-ac8a-139908161c11"
      unitRef="usd">3522000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c37cc4225194662bb5f4a30b715bb01_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtMy0xLTEtMTQzNDI_41291ce8-d803-4923-83a1-5dc9e7a1e648"
      unitRef="usd">1187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f3ad868a85e418fa0000ab508d97ec5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzMtNS0xLTEtMTQzNDI_69045eb4-4eb3-450f-8902-11eb2b8d7004"
      unitRef="usd">410000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtMS0xLTEtMTQzNDI_aac25174-161a-4a3e-9e56-8d8241a3f8d5"
      unitRef="usd">359000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2375a12808cf4680aa725acb17071871_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtMy0xLTEtMTQzNDI_b280e712-1f43-4283-8515-17a892ddf289"
      unitRef="usd">260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iace44621dbb84817a2c5f4a3278c74ab_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzQtNS0xLTEtMTQzNDI_ad934838-fcb9-40e3-a8e8-8eed8c75c175"
      unitRef="usd">232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtMS0xLTEtMTQzNDI_50fc8701-0749-44a4-88a5-97f746d8cbd4"
      unitRef="usd">18409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtMy0xLTEtMTQzNDI_84f9d7f8-5aa9-4735-8554-178619897789"
      unitRef="usd">7172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZToyOTAyYjNhYzk2NzM0Mjg1OTJmZjA1YTI2NDU3ZTQ3Zi90YWJsZXJhbmdlOjI5MDJiM2FjOTY3MzQyODU5MmZmMDVhMjY0NTdlNDdmXzUtNS0xLTEtMTQzNDI_22f8ab0a-fb1c-4fd4-bab4-8cc8133bafe7"
      unitRef="usd">4872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTc_3684b3d5-af63-4971-b221-f54c7e94f671">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents stock-based compensation expense as reflected in the Company&#x2019;s consolidated statements of operations and comprehensive loss:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense included in Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23b915dd88e74298a6e79a691ceb3e41_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItMS0xLTEtMTQzNDI_05a44bd2-fa39-4afa-92e7-6dc54b971f30"
      unitRef="usd">9984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0ac3651a9b134a21b2606a2b6c456826_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItMy0xLTEtMTQzNDI_c972ab3e-9341-4257-8367-b809f6c6b74e"
      unitRef="usd">3841000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i995f53d89db1431783ca696f65ff827c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzItNS0xLTEtMTQzNDI_eae440b7-edb1-46d9-8290-16a31fbea483"
      unitRef="usd">2245000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ac073dc733f464e923ffe588304cf3a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtMS0xLTEtMTQzNDI_2e44b8ba-3d2f-4546-8d9b-10309fce794d"
      unitRef="usd">8425000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9b69daa12d7d496a8e30d2f4f904d645_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtMy0xLTEtMTQzNDI_bab3e27f-dc6e-4521-a631-4efe8e6b1d27"
      unitRef="usd">3331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i87d0d7495bf34973b75e45d3a456802f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzMtNS0xLTEtMTQzNDI_2efc9d52-76dd-495c-9b75-b4f106557dd3"
      unitRef="usd">2627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtMS0xLTEtMTQzNDI_967a8ddc-8593-4d14-9b54-6a3afbefdd33"
      unitRef="usd">18409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtMy0xLTEtMTQzNDI_6c6bc5c3-e00e-4c8f-8fff-b498ee6589a5"
      unitRef="usd">7172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTpiMTMwMDhmN2Y2YjM0OTczYjJjZjJlYWUxNTJjYThhMy90YWJsZXJhbmdlOmIxMzAwOGY3ZjZiMzQ5NzNiMmNmMmVhZTE1MmNhOGEzXzQtNS0xLTEtMTQzNDI_5113296e-2039-46a9-bb0c-66bef542d8fa"
      unitRef="usd">4872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i76db584e2a3847a19b4d09782ea823f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM5NTY_40ff9469-c121-44db-9110-977425d5b33b"
      unitRef="usd">38958000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i67789eba647e4e8f9ca09e243889e50e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM5NjM_25734405-8054-4ae1-8f2a-6b587b4a3a11"
      unitRef="usd">9929000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5d31b875299c4104b0ffa3e9f2e6d43f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQxMzg_696ccbbe-656f-4a20-84c5-55be129f3f23">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i94e42285311c41d3a7b80346455ec74e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQxNDU_81b3ce00-ed63-4763-9b08-88f82d67b3eb">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU1NTI_f76d174c-f77d-41b5-bf21-1b0069491802">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black&#x2013;Scholes option pricing model with the following weighted average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItMS0xLTEtMTQzNDI_4be74895-3984-408d-a327-d7afeff34520"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItMy0xLTEtMTQzNDI_77cc33cd-696c-4b9b-9a94-150956883df3"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzItNS0xLTEtMTQzNDI_c0bc6528-ebaf-48fb-b40a-9639f2bb04f7"
      unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtMS0xLTEtMTQzNDI_3ffa9b0c-e685-4395-ac4f-ff0c51259e00"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtMy0xLTEtMTQzNDI_7f9a05bd-7762-4ec1-a786-3d1c2f13e6d3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzMtNS0xLTEtMTQzNDI_f775af91-8790-49d7-ac1c-ca79384335a8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtMS0xLTEtMTQzNDI_fbbcf68c-b8f6-4721-b500-f9d707ad1a67">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtMy0xLTEtMTQzNDI_f7bae689-12ee-4426-9f03-893befad94bc">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzQtNS0xLTEtMTQzNDI_2b9ebadd-83f5-4dc6-ae5d-8e10103a0a5e">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtMS0xLTEtMTQzNDI_f30c1653-9975-4868-9810-8a1114cf19a8"
      unitRef="number">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtMy0xLTEtMTQzNDI_689f2175-2cca-4952-9220-ffa3031ec19f"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90YWJsZTo4OGJjMTQzOWMzYWQ0NjIwOGJkNzU3YjU2NjJiZWZlZC90YWJsZXJhbmdlOjg4YmMxNDM5YzNhZDQ2MjA4YmQ3NTdiNTY2MmJlZmVkXzUtNS0xLTEtMTQzNDI_35f2c9fc-e403-4565-8598-ed301ac948a2"
      unitRef="number">0.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzQ1OTc_aba376b3-63cf-4aa0-974d-615da4fc946b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1b750e97432649f8902f0c0b2b12632e_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUyNTk_b3fce34a-7143-4782-b666-a54c78412b87"
      unitRef="shares">225000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares
      contextRef="i18e0acc3be3c4a918d77e823eeaf9a9b_D20170101-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNTQ2_097c3656-a888-44ca-85f8-09e27fe8dbe0"
      unitRef="shares">450000</mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares>
    <mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease
      contextRef="id1dc96fa4ed842f4aedd626c47454440_D20170101-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzM4NDgyOTA3MTM3NTY_8c5852f6-93ab-4678-8af7-dcffe6b86df1"
      unitRef="number">0.01</mrsn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8c8f204b2f8f47c883a50a6b32629116_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzI5MTM3MDU4MTUwNTM1_ca8ee364-936c-4363-8199-1941dd58dbab"
      unitRef="shares">4725000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i615a701f087a40fb8ab1ef871223dfd4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUzNzE_43b9662b-df86-422a-9cd3-37bde62b35c6"
      unitRef="shares">78253</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i2375a12808cf4680aa725acb17071871_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzUzNzg_ac67a3e4-979f-46a9-b4f2-6f0c4b8e7e12"
      unitRef="shares">80267</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0c8751ae82ab48e580bd5035e380db22_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMjcvZnJhZzpiN2ZiNzI4OTVmMjQ0NjU0YjA3ZGU4NTkyMGU0OWY0Zi90ZXh0cmVnaW9uOmI3ZmI3Mjg5NWYyNDQ2NTRiMDdkZTg1OTIwZTQ5ZjRmXzU0NDU_5a3eeff2-40ae-47ba-9cde-5acc64cbaaa9"
      unitRef="shares">566565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDI_54fe8d61-d52f-4b93-8121-e4cf4fc75387">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for its office and lab space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease (the Office Lease) to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the Office Lease for an additional five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional office space in its existing building for five years, beginning July 1, 2021, and committed the Company to lease payments of $4,983 over that period (the Expansion Lease). In connection with the Expansion Lease, the Company increased the balance of the security deposit by increasing the standby letter of credit for the benefit of its landlord by $157. The Expansion Lease also provided the Company with a tenant improvement allowance of $51. Independent from the option under the Office Lease, the Company has an option to extend the lease term of the Expansion Lease for an additional five years. The Company&#x2019;s exercise of the options to extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use (ROU) asset and liability and are reflected as an expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the signing of the Expansion Lease in April 2021, the Company recorded an increase of $3,783 to its ROU asset and lease liabilities in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $478 in connection with the Office Lease and Expansion Lease as of December&#160;31, 2021 and $321 in connection with the Office Lease as of December&#160;31, 2020, collateralized by a money market account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has remaining finance lease terms of one year to five years for certain equipment, some of which include options to purchase at fair value. For the year ended December&#160;31, 2021, the Company recorded assets under finance leases of $609 as property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense was $3,390, $2,644 and $2,160 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDI_6a2fcbcb-33a8-4f6b-a4e1-cff7bcbaa479">Leases&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for its office and lab space in Cambridge, MA and operating and finance leases for certain equipment. In March 2020, the Company entered into the Seventh Amendment to the office and lab space lease (the Office Lease) to extend the term of the lease through March 2026. The Company has an option to extend the lease term of the Office Lease for an additional five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2021, the Company entered into an Eighth Amendment to the Office Lease, which granted the Company additional office space in its existing building for five years, beginning July 1, 2021, and committed the Company to lease payments of $4,983 over that period (the Expansion Lease). In connection with the Expansion Lease, the Company increased the balance of the security deposit by increasing the standby letter of credit for the benefit of its landlord by $157. The Expansion Lease also provided the Company with a tenant improvement allowance of $51. Independent from the option under the Office Lease, the Company has an option to extend the lease term of the Expansion Lease for an additional five years. The Company&#x2019;s exercise of the options to extend the lease terms of both the Office Lease and Expansion Lease were not considered reasonably certain as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Expansion Agreement is a lease modification accounted for as a separate contract, because it expands the scope of the Office Lease and the additional lease payments are commensurate with market rents. The Company assessed the lease classification of the Expansion Lease as of the date of signing and determined that the Expansion Lease should be accounted for as an operating lease. The right-of-use asset and corresponding operating lease liability have been calculated based on the present value of lease payments over the lease term. The Company determined the appropriate incremental borrowing rate to utilize as a discount rate by using a synthetic credit rating which was estimated based on an analysis of outstanding debt of companies with similar credit and financial profiles. Since the operating lease is a net lease, as the non-lease components (i.e., common area maintenance) are paid separately from rent based on actual costs incurred, such non-lease components were not included in the right-of-use (ROU) asset and liability and are reflected as an expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the signing of the Expansion Lease in April 2021, the Company recorded an increase of $3,783 to its ROU asset and lease liabilities in the second quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a standby letter of credit agreement for the benefit of its landlord in the amount of $478 in connection with the Office Lease and Expansion Lease as of December&#160;31, 2021 and $321 in connection with the Office Lease as of December&#160;31, 2020, collateralized by a money market account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has remaining finance lease terms of one year to five years for certain equipment, some of which include options to purchase at fair value. For the year ended December&#160;31, 2021, the Company recorded assets under finance leases of $609 as property and equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense was $3,390, $2,644 and $2,160 for the years ended December&#160;31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="id16df4d7be5d45f09336d071d6b927ad_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODAx_38c4fbdd-d832-4334-8217-d316696e7cb9">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODEx_bd6dcd5e-b83e-498e-8e8a-a7a796103acd">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzAzMDM_5133a878-9204-4a81-a9fc-934415a24890"
      unitRef="usd">4983000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SecurityDeposit
      contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3Xzk4OTU2MDQ2NjY5NjI_d2a3b9d3-9af5-4de5-a0a7-e72a9e2ee8ed"
      unitRef="usd">157000</us-gaap:SecurityDeposit>
    <mrsn:OperatingLeaseTenantImprovementAllowance
      contextRef="id7a8cc110a0642b68c553e48f18a1285_D20210405-20210405"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzA2MTc_add1cc58-7403-442c-9c70-832d4ada924c"
      unitRef="usd">51000</mrsn:OperatingLeaseTenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia9166def068646cba741aa6d728d2b9c_I20210405"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzA3NjY_d93f733a-0899-4757-85c3-18215ae46580">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <mrsn:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i2a56f442c69248c78859ce174629ab21_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM2ODE_870d587b-515a-41dd-9833-552398328dd1"
      unitRef="usd">3783000</mrsn:IncreaseDecreaseInOperatingLeaseLiabilities>
    <mrsn:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i2a56f442c69248c78859ce174629ab21_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM2ODE_b0a82c62-7d30-435e-963a-a5a4e40a9c8e"
      unitRef="usd">3783000</mrsn:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:SecurityDeposit
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzM5NDE_39d6b765-1c07-4500-9226-828ce84452c3"
      unitRef="usd">478000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3Njk1NjM_831bface-a09e-4705-ab76-148aaba7fefd"
      unitRef="usd">321000</us-gaap:SecurityDeposit>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i038ae3a73230483884690b9a78423777_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODI5_d22e3924-0739-4b50-b878-444b77874e12">P1Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="if17d87454f6c4db7839bfac2ed9aa926_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI5MTM3MDU4MTUyODQ5_b29a2b6f-62cc-4141-ae8c-e70c747f736f">P5Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzY1OTcwNjk3NzQ1OTQ_8cf150d4-93da-42d6-9f82-8b4858902475"
      unitRef="usd">609000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDE_532e28b4-4a52-458c-ab2d-88db780ae4c3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItMS0xLTEtMTQzNDI_53a4deaf-233c-4f27-a3b8-7fdf7f9ee104"
      unitRef="usd">3502000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItMy0xLTEtMTQzNDI_a5c30611-ca59-4faf-a051-36cd208ed1f8"
      unitRef="usd">2755000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzItNS0xLTEtMjAzMjA_d2074cbc-f655-49d7-bd79-986461dad14e"
      unitRef="usd">2160000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtMS0xLTEtMTQzNDI_aa8554fb-2fae-4c9f-8917-b139559516d5"
      unitRef="usd">169000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtMy0xLTEtMTQzNDI_a19e2764-6adb-470e-a670-8bcd705457f7"
      unitRef="usd">101000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzUtNS0xLTEtMjAzMTI_cde5f335-5a80-4ec5-880d-1c5cccc0f812"
      unitRef="usd">75000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtMS0xLTEtMTQzNDI_558512b6-679e-4292-8e41-81f04bd25742"
      unitRef="usd">28000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtMy0xLTEtMTQzNDI_06fb56f6-b25b-40fd-a0ff-a9fd91f9b67a"
      unitRef="usd">21000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzYtNS0xLTEtMjAzMTI_0f16067b-078a-4b55-9682-229c3c85e241"
      unitRef="usd">20000</us-gaap:FinanceLeaseInterestExpense>
    <mrsn:FinanceLeaseCost
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctMS0xLTEtMTQzNDI_a36ed8ab-4f74-4def-9617-ef820b7ca3fb"
      unitRef="usd">197000</mrsn:FinanceLeaseCost>
    <mrsn:FinanceLeaseCost
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctMy0xLTEtMTQzNDI_32b82b35-5bfe-4b78-b765-d02076ecc1a1"
      unitRef="usd">122000</mrsn:FinanceLeaseCost>
    <mrsn:FinanceLeaseCost
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo4OGE0YjYyMzA3MjI0NzNjYTIzYzYwZjI1NzVhMTkyNS90YWJsZXJhbmdlOjg4YTRiNjIzMDcyMjQ3M2NhMjNjNjBmMjU3NWExOTI1XzctNS0xLTEtMjAzMTI_e1d84e54-8463-4d36-87ce-1c51e4c51c85"
      unitRef="usd">95000</mrsn:FinanceLeaseCost>
    <mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDU_09bba9d2-d5b8-4184-9ca1-1f8273ca7c07">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_20e5c4b8-7aaf-4e1e-9b56-69afd7a84b18"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTAtMS0xLTE0MzQy_a7421411-9d79-421e-8b13-55fae251793a"&gt;Other liabilities, current&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_1f942992-ba98-4545-8afd-9b6015cef61d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTAtMS0xLTE0MzQy_99c0361f-a596-42ff-9fd2-e72baf6d5ed5"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzMtMS0xLTEtMTQzNDI_52644c4f-2b63-459f-9db2-48a1fe952513"
      unitRef="usd">12889000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzMtMy0xLTEtMTQzNDI_1741773f-a811-4de0-907e-863ab9ea7aa5"
      unitRef="usd">10936000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzQtMS0xLTEtMTQzNDI_195d62ef-cc9e-4b32-bf3a-487bfe07536e"
      unitRef="usd">2303000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzQtMy0xLTEtMTQzNDI_556df544-566a-48ce-b180-34544dbdc013"
      unitRef="usd">1437000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzUtMS0xLTEtMTQzNDI_43d31e92-3a69-4e64-b045-6f75c7926f3a"
      unitRef="usd">11247000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzUtMy0xLTEtMTQzNDI_abb19c10-95f8-45a2-9ec3-56576a444756"
      unitRef="usd">10158000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzgtMS0xLTEtMTQzNDI_21b82d14-5515-45ef-887c-5d25c23f8194"
      unitRef="usd">1038000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzgtMy0xLTEtMTQzNDI_dd23f968-cc05-48ae-b163-ff257dd87ec4"
      unitRef="usd">429000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzktMS0xLTEtMTQzNDI_c6ed6544-f447-4402-a80a-d20cb91b7023"
      unitRef="usd">345000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzktMy0xLTEtMTQzNDI_266bf7a3-1d7f-4f9a-b830-6c7af518e6ea"
      unitRef="usd">176000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTEtMS0xLTE0MzQy_7e74fce8-dcbe-4f8d-899f-73e2ec22e2e4"
      unitRef="usd">239000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzEwLTMtMS0xLTE0MzQy_92f46d93-a2f9-4016-9691-c8ab5ca92ee8"
      unitRef="usd">93000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTEtMS0xLTE0MzQy_5aa72b0b-6b0f-459b-8670-3f5962735c83"
      unitRef="usd">449000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzExLTMtMS0xLTE0MzQy_40d12ad0-6a99-4988-a8e0-0a602b6759e8"
      unitRef="usd">174000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE0LTEtMS0xLTE0MzQy_cd50fd95-7760-4e04-9424-2b38db00285a">P4Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE0LTMtMS0xLTE0MzQy_b0d0ab82-d096-4720-a026-9be94523ed54">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE1LTEtMS0xLTE0MzQy_9336db64-0e38-4516-b7c7-f0a10eda3ccc">P4Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE1LTMtMS0xLTE0MzQy_63de183a-c911-43e2-acd7-e7628c703cea">P2Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE4LTEtMS0xLTE0MzQy_b862adc0-00fb-4026-913d-ca6ae89043d4"
      unitRef="number">0.108</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE4LTMtMS0xLTE0MzQy_c9a416a0-9226-4b48-a774-040e5db4ea2b"
      unitRef="number">0.108</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE5LTEtMS0xLTE0MzQy_ac39b9a3-4fa3-4553-8457-14b436209fab"
      unitRef="number">0.054</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo2YTA5MzEzMzlmOTU0ZDc4OTY3M2E2MmIyMjJjZjZhMS90YWJsZXJhbmdlOjZhMDkzMTMzOWY5NTRkNzg5NjczYTYyYjIyMmNmNmExXzE5LTMtMS0xLTE0MzQy_4b66fd60-9e06-4f55-95f1-4445cab043a8"
      unitRef="number">0.069</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDQ_19eb36c0-5c29-4e3a-9602-c613279b8b37">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzMtMS0xLTEtMTQzNDI_b40761d5-3b18-41fc-a3bf-d68c12a22bbc"
      unitRef="usd">3241000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzMtMy0xLTEtMTQzNDI_e19508c0-11df-4349-8f29-17ecd2e4a29f"
      unitRef="usd">2394000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzQtMS0xLTEtMTQzNDI_b02fd481-13dd-455b-941e-fcd28cd69a35"
      unitRef="usd">28000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzQtMy0xLTEtMTQzNDI_2121ee49-ca81-4508-ac64-57f8032c4177"
      unitRef="usd">21000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzUtMS0xLTEtMTQzNDI_370766ed-ecf7-4a10-b5a5-6c3a10cbbb12"
      unitRef="usd">215000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTplMDE4ZmM1NGU4ZDE0MmYwYmZiNWVkMTMzZWE2ZWQ3Ni90YWJsZXJhbmdlOmUwMThmYzU0ZThkMTQyZjBiZmI1ZWQxMzNlYTZlZDc2XzUtMy0xLTEtMTQzNDI_491522b8-8182-41cc-8da0-d89b27a8390b"
      unitRef="usd">116000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:LeaseCost
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NTI_db5ed081-c8d1-42f4-95fd-499f11049886"
      unitRef="usd">3390000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NTY_6a88a3c4-af8e-4bf0-b055-e81277a91ef5"
      unitRef="usd">2644000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI1NjM_ef70ad79-20d6-4f8d-8da9-2d533167f959"
      unitRef="usd">2160000</us-gaap:LeaseCost>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDM_84c7e229-f38a-496d-9d5f-5294411722fe">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90ZXh0cmVnaW9uOjAxODZlMzMzOGQ4NjQ5YzViZDdlNjVhZTg0YjA0YmE3XzI3MDY_ad044661-329c-439c-ac31-dec7d453381c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzEtMS0xLTEtMTQzNDI_48b7f8f7-9b39-424a-8f2b-5ba645c41ed9"
      unitRef="usd">3795000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzEtMy0xLTEtMTQzNDI_85c83164-5bb1-4790-bcc1-8c0496a09a00"
      unitRef="usd">269000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzItMS0xLTEtMTQzNDI_b829861f-ab23-4023-b8fe-3c8196475452"
      unitRef="usd">3909000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzItMy0xLTEtMTQzNDI_9a1024d3-ef1b-456d-84a5-76a8cc0a59a6"
      unitRef="usd">262000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzMtMS0xLTEtMTQzNDI_6433be4c-9710-45e7-a62f-f2810df141e0"
      unitRef="usd">4027000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzMtMy0xLTEtMTQzNDI_287ab145-38f7-4973-a916-524cf358377b"
      unitRef="usd">141000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzQtMS0xLTEtMTQzNDI_9433d7fe-9d0c-44ba-98f5-f1b30d717487"
      unitRef="usd">4147000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzQtMy0xLTEtMTQzNDI_a8d31172-c02c-455e-a69f-cec63c1b0d1d"
      unitRef="usd">48000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzUtMS0xLTEtMTQzNDI_2cf158e5-4c9c-43bf-84a3-51347339fd22"
      unitRef="usd">1310000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzUtMy0xLTEtMTQzNDI_5fd73d13-9742-458a-99d5-3a0dbc41bcc9"
      unitRef="usd">8000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzYtMS0xLTEtMTQzNDI_d171aa8f-3c52-4452-8faf-ce77257323b1"
      unitRef="usd">17188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzYtMy0xLTEtMTQzNDI_8c10c049-b689-4af8-8941-5503f4266ac3"
      unitRef="usd">728000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzctMS0xLTEtMTQzNDI_75660788-2901-4202-a8c8-e6c598b98d5c"
      unitRef="usd">3638000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzctMy0xLTEtMTQzNDI_4ecddfc8-8503-46cb-aa36-8ed9591f50d8"
      unitRef="usd">40000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzgtMS0xLTEtMTQzNDI_58ae3f3d-e79c-46f8-a67b-a81087e3b007"
      unitRef="usd">13550000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzAvZnJhZzowMTg2ZTMzMzhkODY0OWM1YmQ3ZTY1YWU4NGIwNGJhNy90YWJsZTo1YWMyMTg4ZWI0YzA0ZmI4OWVmMjgzMmNmOTQ3NWQzMC90YWJsZXJhbmdlOjVhYzIxODhlYjRjMDRmYjg5ZWYyODMyY2Y5NDc1ZDMwXzgtMy0xLTEtMTQzNDI_5b63e05f-9169-4355-9408-c5ccdcf0dfa2"
      unitRef="usd">688000</us-gaap:FinanceLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTY_fb105612-acd8-4100-935f-5026b7287de6">Income Taxes&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded no income tax benefit for the net operating losses incurred in each year, due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2021, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership shift&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net operating losses (NOL) since inception. At December&#160;31, 2021, the Company had Federal and State net operating loss carryforwards of approximately $403,579 and $337,057, respectively. Of the $403,579 of Federal net operating loss carryforwards, $34,149 expire at various dates through 2037. The remaining $369,430 of Federal net operating loss carryforwards do not expire. The State net operating loss carryforwards expire at various dates through 2041. At December&#160;31, 2021, the Company had Federal and State research and development tax credit carryforwards of approximately $10,077 and $3,061, respectively, which expire at various dates through 2041.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 740, management of the Company has evaluated the evidence bearing upon the reliability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of all of these assets. Accordingly, the Company recorded a valuation allowance of $130,051 and $77,375 at December&#160;31, 2021 and December&#160;31, 2020, respectively. The valuation allowance increased by $52,676 and $28,468 during the years ended December&#160;31, 2021 and 2020, respectively, primarily as a result of the Company&#x2019;s net operating losses generated during the periods, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the NOLs and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section&#160;382 due to ownership change limitations that have occurred previously or that could occur in the future in accordance with Section&#160;382, as well as similar state provisions. These ownership changes may limit the amount of NOLs and research and development tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. If a change in control as defined by Section&#160;382 has occurred at any time since the Company&#x2019;s formation, utilization of its NOLs or research and development tax credit carryforwards would be subject to an annual limitation under Section&#160;382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, which could then be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or research and development tax carryforwards before their utilization. The Company has determined that ownership changes have occurred through November 4, 2019 and that certain NOLs and research and development tax credit carryforwards will be subject to limitation. The amounts presented do not include NOLs or research and development tax credit carryforwards that will expire unused due to ownership changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. The Company&#x2019;s reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company in its tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit. As of December&#160;31, 2021 and 2020, the Company had no unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not conducted a study of its research and development credit carryforwards. This study may result in an adjustment to research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company&#x2019;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations if an adjustment were required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest and penalties related to uncertain tax positions would be classified as income tax expense in the accompanying statements of operations. As of December&#160;31, 2021 and 2020, the Company had no accrued interest or penalties related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States federal tax jurisdiction and four state jurisdictions. The Company did not have any foreign operations during the&#160;years ended December&#160;31, 2021, 2020 and 2019. The statute of limitations for assessment by the Internal Revenue Service and state tax authorities is closed for tax&#160;years prior to 2017, although carryforward attributes that were generated prior to tax&#160;year 2017 may still be adjusted upon examination to the extent utilized in a future period. There are no federal or state audits currently in progress.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_054b904d-95cb-40a2-8c2f-635f2c44766f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_2338ea19-ca21-41a4-aa4b-8960e19765a0"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzc4_de02c164-3dda-462e-b8c5-3726b9732f9e"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTg_78b1a79f-0efe-461f-945d-0cbd75332366">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income taxes computed using the U.S. federal statutory rate to that reflected in operations as of December&#160;31, 2021, 2020 and 2019 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership shift&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtMS0xLTEtMTQzNDI_7fbb007a-9707-4c96-9a11-ad16ddf45d12"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtMy0xLTEtMTQzNDI_2be0c066-50c0-47b9-83d6-260231385c7d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzEtNS0xLTEtMTQzNDI_77b18511-96f6-46e2-b178-410eb62d4347"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItMS0xLTEtMTQzNDI_df18c395-6e15-4476-b5a9-af02546a8809"
      unitRef="number">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItMy0xLTEtMTQzNDI_919fcf49-f29d-45ed-b403-10736a4e543d"
      unitRef="number">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzItNS0xLTEtMTQzNDI_e5806561-ed91-48e5-baa9-5857d9ef61d5"
      unitRef="number">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtMS0xLTEtMTQzNDI_4844e090-dfad-43b3-a89d-2baca91e6ec2"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtMy0xLTEtMTQzNDI_35527001-aff0-4110-a602-3807e99a88c6"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzMtNS0xLTEtMTQzNDI_08bea209-e460-4931-b2e5-705db37fc81f"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtMS0xLTEtMTQzNDI_3c7923ac-e19f-4494-9066-018ad88ecaa4"
      unitRef="number">0.038</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtMy0xLTEtMTQzNDI_dcbdb5c6-62b2-44b3-89cd-5dd3ae32f940"
      unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzUtNS0xLTEtMTQzNDI_82679329-127b-4018-81da-2d07bdbc7542"
      unitRef="number">0.103</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtMS0xLTEtMTQzNDI_b87e605f-568a-4140-a529-baf78ce65d3a"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtMy0xLTEtMTQzNDI_20884c4b-b252-4d59-9b29-87a8ff75c94e"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzYtNS0xLTEtMTQzNDI_7e71fd65-9bd6-48f5-95ba-731c6e1b47a3"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctMS0xLTEtMTQzNDI_e9f9cc9f-03a1-484d-bced-4a9e8c9fb27a"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctMy0xLTEtMTQzNDI_73158a97-31c5-497a-9243-6567f755a368"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzctNS0xLTEtMTQzNDI_5ef83722-45fa-475e-8d75-e1692e24e0a1"
      unitRef="number">-0.533</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtMS0xLTEtMTQzNDI_f5fcf5b0-1fee-4d9d-b3c4-468c87bedd73"
      unitRef="number">-0.310</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtMy0xLTEtMTQzNDI_c78a5651-b77b-4f25-9aca-90f50df848a8"
      unitRef="number">-0.323</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzgtNS0xLTEtMTQzNDI_c3ba6204-e356-4461-b11b-11f667089e43"
      unitRef="number">0.179</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktMS0xLTEtMTQzNDI_34b28509-465f-4c0e-a46e-1491d4c66cee"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktMy0xLTEtMTQzNDI_f868978a-237f-4caa-af99-e638f9c11c41"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTo4NTViZjcwMjNlZjI0MjQ0OTg3OTc1MmYwMDIyODI3Mi90YWJsZXJhbmdlOjg1NWJmNzAyM2VmMjQyNDQ5ODc5NzUyZjAwMjI4MjcyXzktNS0xLTEtMTQzNDI_4cd3c1d9-6aa7-4d97-a4c6-18c483a511cf"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyOTc_18053b82-948b-4c5b-a453-3c6bd348ac5c">Significant components of the Company&#x2019;s net deferred tax assets as of December&#160;31, 2021 and 2020 are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzItMS0xLTEtMTQzNDI_6b60fe61-c450-4fee-8f0b-a9be5321a1a4"
      unitRef="usd">106055000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzItMy0xLTEtMTQzNDI_72c3da67-2370-4c08-b219-86b833b6fdc7"
      unitRef="usd">64259000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzMtMS0xLTEtMTQzNDI_00cf6355-8f8c-420e-bfa0-6ab7b6b34b05"
      unitRef="usd">12424000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzMtMy0xLTEtMTQzNDI_8f74bf17-a34f-42b7-b01d-4cfccaedf3ca"
      unitRef="usd">5670000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzQtMS0xLTEtMTQzNDI_8b2c15af-bc9f-4fd1-be98-9d305a2487d2"
      unitRef="usd">6892000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzQtMy0xLTEtMTQzNDI_36b7b942-3c3c-4801-b524-da57df8a2f50"
      unitRef="usd">4058000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <mrsn:DeferredTaxAssetsLeaseLiabilities
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzUtMS0xLTEtMTQzNDI_e29d90c1-90ba-47fb-830e-e4e373d296c5"
      unitRef="usd">3698000</mrsn:DeferredTaxAssetsLeaseLiabilities>
    <mrsn:DeferredTaxAssetsLeaseLiabilities
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzUtMy0xLTEtMTQzNDI_ade4f6b5-7d76-4ebd-87c4-6b864b0d4a21"
      unitRef="usd">3166000</mrsn:DeferredTaxAssetsLeaseLiabilities>
    <mrsn:DeferredTaxAssetsLicensedTechnology
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzYtMS0xLTEtMTQzNDI_37a1b97e-9e28-442f-99b8-9f0e333cd959"
      unitRef="usd">2775000</mrsn:DeferredTaxAssetsLicensedTechnology>
    <mrsn:DeferredTaxAssetsLicensedTechnology
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzYtMy0xLTEtMTQzNDI_cb18c7f4-1bc6-4dda-a3fc-d5b775a0f4a6"
      unitRef="usd">1534000</mrsn:DeferredTaxAssetsLicensedTechnology>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzctMS0xLTEtMTQzNDI_b6a995d0-871f-49fa-a5bc-44c6fa5afee6"
      unitRef="usd">1076000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzctMy0xLTEtMTQzNDI_b85179e0-a715-4ffd-9a2e-7737a4bef538"
      unitRef="usd">1088000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <mrsn:DeferredTaxAssetsDepreciation
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzgtMS0xLTEtMTQzNDI_59c78c97-4ed3-432d-b4f2-0584354a2d2c"
      unitRef="usd">493000</mrsn:DeferredTaxAssetsDepreciation>
    <mrsn:DeferredTaxAssetsDepreciation
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzgtMy0xLTEtMTQzNDI_a76f4b26-268c-4b50-982a-154850db75ac"
      unitRef="usd">502000</mrsn:DeferredTaxAssetsDepreciation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEwLTEtMS0xLTE0MzQy_0a5414f9-f5a7-4f8a-9249-df9e45c0d2d8"
      unitRef="usd">71000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEwLTMtMS0xLTE0MzQy_1a84fdd3-8056-414e-8e7b-89a0aa6e533a"
      unitRef="usd">84000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzExLTEtMS0xLTE0MzQy_9106907e-0242-4214-97c4-c1a6b08e6b0d"
      unitRef="usd">133484000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzExLTMtMS0xLTE0MzQy_e105727b-2331-4131-a866-8fc9581ba3bd"
      unitRef="usd">80361000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEyLTEtMS0xLTE0MzQy_bf988841-53de-49b5-ad90-a6bddeae30fa"
      unitRef="usd">130051000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEyLTMtMS0xLTE0MzQy_2fa859d6-eeaf-4659-b07f-ef7664897692"
      unitRef="usd">77375000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEzLTEtMS0xLTE0MzQy_915a87f3-e87a-49fc-98bf-498f6c3c9546"
      unitRef="usd">3433000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzEzLTMtMS0xLTE0MzQy_074024f7-77bc-4aec-9eb1-af4e1d265e90"
      unitRef="usd">2986000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE1LTEtMS0xLTE0MzQy_636db9be-c5c8-43e5-8c6f-42633a67fed4"
      unitRef="usd">3433000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE1LTMtMS0xLTE0MzQy_0ff8a08c-33ff-405c-b3e3-310acb9e90a0"
      unitRef="usd">2986000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE2LTEtMS0xLTE0MzQy_d0156bfa-3e68-493d-ac9f-763a9b69e58d"
      unitRef="usd">3433000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE2LTMtMS0xLTE0MzQy_6e1f7458-c830-46e3-8280-1f65d4b44da7"
      unitRef="usd">2986000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE3LTEtMS0xLTE0MzQy_28c97e38-9429-4472-b27f-c71df08481f3"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90YWJsZTphODI2N2I3NDkwZWU0YWJlOGZjMWIxNWZkMmNkNTVkOC90YWJsZXJhbmdlOmE4MjY3Yjc0OTBlZTRhYmU4ZmMxYjE1ZmQyY2Q1NWQ4XzE3LTMtMS0xLTE0MzQy_20d0722b-1e25-48d9-b766-ae533a537974"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzgzMw_f961a954-34ec-42b0-b50e-ba7e421ea1a2"
      unitRef="usd">403579000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i673a5d42881e4cb3b1331529587e448a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzg0MA_089aebc1-5f48-45af-8977-f3416336bd18"
      unitRef="usd">337057000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzY1OTcwNjk3NzczMTE_f961a954-34ec-42b0-b50e-ba7e421ea1a2"
      unitRef="usd">403579000</us-gaap:OperatingLossCarryforwards>
    <mrsn:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzkxMw_bb91c7e2-c9ab-4214-8c45-548e15333269"
      unitRef="usd">34149000</mrsn:OperatingLossCarryforwardsSubjectToExpiration>
    <mrsn:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i72c467d1b1b6423e92438fcea0715adb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4Xzk2OA_1aad3432-70b4-4c49-b3f4-9cbacc116760"
      unitRef="usd">369430000</mrsn:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i3a07a4efd2d24b99831852b517363a51_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzEyMTk_1516c36e-8dc5-4145-a3ee-8050213f8f0e"
      unitRef="usd">10077000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i6461b8d4e239490992a75468dcd510eb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzEyMjY_d69175a1-2130-42eb-ba1f-b32efc089c72"
      unitRef="usd">3061000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE2ODE_4a240a48-d985-41f8-8b49-e2395a9d9343"
      unitRef="usd">130051000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE2ODg_d01d98c9-87c8-430a-8c1e-1145d5ef5cb7"
      unitRef="usd">77375000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE3NTY_e5919326-da83-4f7e-a4e3-4b3ba04ac4d2"
      unitRef="usd">52676000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzE3NzY_55e294a7-8869-4b2c-94e2-99bc2b8e8dae"
      unitRef="usd">28468000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzM4MzU_982eb52a-0fad-4a22-8c1a-ddd1c36a778a"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzM4MzU_e5f53326-8eb5-4545-be4a-00bf7a09989f"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ2NzY_0e2ff762-4e9a-4d21-9a65-391dbbce6d13"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ2NzY_391e89ae-91f5-4ddb-9a0d-c59167bd46ac"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <mrsn:IncomeTaxesNumberOfStateJurisdictions
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzQ4MzI_f71e4353-fd6c-48d5-8c6d-dc1960db332c"
      unitRef="jurisdiction">4</mrsn:IncomeTaxesNumberOfStateJurisdictions>
    <mrsn:IncomeTaxesNumberOfAuditsInProgress
      contextRef="i1b5567939ee84f85a796f7340017d974_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzYvZnJhZzoyMjhiZDgwMWIwMzg0NGI5OTlhN2QyMDA1NDBkNDRlOC90ZXh0cmVnaW9uOjIyOGJkODAxYjAzODQ0Yjk5OWE3ZDIwMDU0MGQ0NGU4XzUyNDg_bcb7524b-1808-46a9-801b-99fd5789e1c1"
      unitRef="audit">0</mrsn:IncomeTaxesNumberOfAuditsInProgress>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzg2Mg_ab49d2d2-bd29-4d92-85ec-1c6ed1032e0c">Employee Benefit PlanThe Company has a defined contribution plan established under Section&#160;401(k)&#160;of the Internal Revenue Code (401(k)&#160;Plan), which covers substantially all employees. Employees who have attained the age of 21 are eligible to participate in the 401(k)&#160;Plan with no service requirement. Employees may contribute up to 95% of eligible pay on a pre&#x2013;tax basis up to the federal annual limits. For the period from January 1, 2019 to July 31, 2019, the Company matched the employees&#x2019; contributions at 50% on the first 6% up to $6. For the period from August 1, 2019 to December&#160;31, 2020 and for the year ended December&#160;31, 2021, the Company matched the employees&#x2019; contributions at 100% on the first 4% up to $7. For the&#160;years ended December&#160;31, 2021, 2020 and 2019, the Company recorded expense of $764, $486 and $404, respectively, related to its contribution to its 401(k)&#160;Plan.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <mrsn:DefinedContributionPlanEligibleAgeToParticipate
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzIzMw_e0c0890a-6a1e-4e6f-9cac-743c3495c6ed">P21Y</mrsn:DefinedContributionPlanEligibleAgeToParticipate>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzM0Mw_4634748c-7313-4229-8ba9-c6cb3ec1292c"
      unitRef="number">0.95</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU0Mg_fe73d255-8482-4d85-bec6-216a0cf6bd0a"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU1OA_8b7f5e15-791e-48cd-97c6-2e493feaf7f2"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="ic1710c92e78b4ba78ca98636b9dcf403_D20190101-20190731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzU2Nw_c325ab87-212d-4342-b6d5-749d1db504b0"
      unitRef="usd">6000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzY5MQ_096059c8-1b21-4c7f-bb07-f2d501c6ef58"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzY5MQ_7bb95192-faa4-4fa7-a8dc-e82743952aef"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcwNw_0c5b26a4-64cb-460b-80ca-5f6d011fb91b"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcwNw_88d0c689-7f24-4eda-9859-891c4a724dda"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcxNg_33e7b732-dc40-49b4-94e5-054548e144a0"
      unitRef="usd">7000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount
      contextRef="i2ff9b8b9462e44da9cbd7c41845e7c5e_D20190801-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzcxNg_ce5f2793-3ef1-46c9-ba24-d3207eeac829"
      unitRef="usd">7000</mrsn:DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc4Nw_9b7bd53a-77d5-4795-bfcf-8ba300938c2c"
      unitRef="usd">764000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie0df9edbafc7478dbdbb990c1d15b98e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc5MQ_82d31fc6-42a2-432b-b217-bc767f740c30"
      unitRef="usd">486000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xMzkvZnJhZzphYTM0ODQ0YzM0NmQ0ODQzYWUwNjA1NGQzY2EwNzI2ZS90ZXh0cmVnaW9uOmFhMzQ4NDRjMzQ2ZDQ4NDNhZTA2MDU0ZDNjYTA3MjZlXzc5OA_8c938d57-949d-4dbf-8e7c-19af028b94d2"
      unitRef="usd">404000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:CommitmentsDisclosureTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzQzNQ_c8b206f1-173f-4187-963c-1c045cf2d975">Commitments&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020 and 2019, the Company recorded research and development expense related to non-refundable license payments of $3,075, $250, and $750, respectively. Further development milestones of $2,125, $750 and $600, respectively, were also recorded as research and development expense during the years ended December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these consolidated financial statements for the Company&#x2019;s future obligations related to leases as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE3OA_6742fb3e-0b6b-4e83-a600-d0ba655e3d99"
      unitRef="usd">3075000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i6f43b37474ae4a6eae2f68ccd01a3200_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE4Mg_2b98dfa0-f070-439a-85b1-0bc0f51202f5"
      unitRef="usd">250000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ibf265381e7674d2ea77457e88a5120d9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzE5MA_4d6ffce2-933a-412f-99c7-8232615c739c"
      unitRef="usd">750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="ib13441f134534f4b8413f2279bfe29f0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzIzOA_04282dc4-7459-403e-bc09-36975a4d7a59"
      unitRef="usd">2125000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i9c1b55d99d3a4d06949a1920a27b38ba_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzI0Mg_67db200a-02ea-42cd-a639-a49629f3925c"
      unitRef="usd">750000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
      contextRef="i705217f95c8147c9a0aef1b16e6593b9_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDIvZnJhZzo0ZDYwYzk4NDJlNDQ0YmEwYTM4NTAzMWI4Zjg2MTg4MS90ZXh0cmVnaW9uOjRkNjBjOTg0MmU0NDRiYTBhMzg1MDMxYjhmODYxODgxXzI0OQ_5a0ac685-6d88-4ef8-b89e-c5fd3ad1c8da"
      unitRef="usd">600000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i20946113a6b640bf91ee43d05d504400_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzM4NDgyOTA3MTU2MjE_79ae84c2-568d-4ae9-b12e-478f16ec22bc">Subsequent Events&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company entered into the Janssen Collaboration pursuant to which the Company granted Janssen an exclusive license to use the Company's proprietary Dolasynthen platform and other technology to develop, manufacture and commercialize ADCs directed to up to three targets selected by Janssen. The Company is responsible for performing bioconjugation activities to create ADCs for Janssen based on antibodies provided by Janssen. The Company will also perform certain chemistry, manufacturing and controls development and early stage manufacturing activities for ADCs that Janssen progresses through development, up to and including the manufacturing of clinical drug substance, at Janssen&#x2019;s cost. Except with respect to this limited manufacturing, Janssen will be responsible for the further development, manufacturing and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialization of the ADCs developed under the Janssen Collaboration, including obtaining any necessary regulatory approvals, at Janssen&#x2019;s cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received an upfront payment of $40,000 in February 2022. The Company is eligible to receive development and regulatory milestones with an aggregate total of $501,000, if licensed products directed to all three Targets are advanced by Janssen. The Company is also eligible to receive commercial milestones with an aggregate total of $530,000 in the event of commercialization of three Targets by Janssen and tiered royalties based on mid-single digits to low-double digits on future net sales of licensed ADCs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the Janssen Collaboration will continue in effect until the date on which the royalty term and all payment obligations with respect to all licensed ADCs in all countries have expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Other Events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company amended the Commercial License and Option Agreement with Synaffix B.V. (Synaffix) in connection with the Janssen Collaboration, and agreed to pay Synaffix a non-refundable execution fee of $1,500 which will be applied against future target license fees or development milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further in connection with the Janssen Collaboration, on February 17, 2022, the Company amended the New Credit Facility described in Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these consolidated financial statements. Pursuant to this amendment the Company has agreed to replace the tranche B term loan and the tranche C term loan with a single combined term loan tranche in an aggregate principal amount of $20,000. Also, the combined term loan tranche will now be available any time on or prior to June 30, 2023, within 90 days of the Company achieving both of the prior tranche B and tranche C term loan milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December&#160;31, 2021 and through February 25, 2022, the Company sold 9,493,776 shares of common stock resulting in net proceeds of $45,579 from ATM offerings, with substantial participation from existing long-term investors. Approximately $9,414 remains unsold and available for sale under the 2020 ATM.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ia138aba2a3b3406494fad2a37a13b0ee_D20220201-20220228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MDg_fa8481fa-e953-45bf-ba3f-d4ae74d6579b"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <mrsn:CollaborationArrangementsMaximumAggregateMilestones
      contextRef="ib699aaf9d802436e8631493e14953d6c_I20220228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MTY_a91d64eb-ad19-45f1-9bfb-eb38ae31bfcf"
      unitRef="usd">501000000</mrsn:CollaborationArrangementsMaximumAggregateMilestones>
    <mrsn:CollaborationArrangementsMaximumAggregateMilestones
      contextRef="ic7ee2b32513f4e59b994d6020d4f8ef4_I20220228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MjU_d390a157-1b1d-4d2b-86f0-2a2ae9673a51"
      unitRef="usd">530000000</mrsn:CollaborationArrangementsMaximumAggregateMilestones>
    <mrsn:CollaborationAgreementNonrefundableExecutionFee
      contextRef="i89e4886837f24a38b80b1747ed92ef46_D20220202-20220202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2MzQ_5eaf1600-ce10-4ee5-9f9b-e845b8960e55"
      unitRef="usd">1500000</mrsn:CollaborationAgreementNonrefundableExecutionFee>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzcxNDY4MjU1OTA2NDE_de98a891-dcee-4a68-a2a5-e62acd599806"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <mrsn:LineOfCreditFacilityTrancheAvailabilityDuration
      contextRef="i1efcb07f15604d9bb19c95fc9ff7b44a_I20220217"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzM4NDgyOTA3MTI0NzU_331d0b07-391c-483c-8f96-e6cbe9e09eb0">P90D</mrsn:LineOfCreditFacilityTrancheAvailabilityDuration>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib6fa9d8c34a04518a93d648eb4c54a81_D20220101-20220225"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2MzQ1_178a6330-ebb2-4644-a3d5-8f6d78d00c76"
      unitRef="shares">9493776</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5fa034c85dbc456988299ee454032879_D20220101-20220225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2NDAx_e3222023-91ca-46e2-9443-a20bad28b0f7"
      unitRef="usd">45579000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mrsn:SaleOfStockRemainingAmountUnsoldAndAvailableForSale
      contextRef="ie7884cd54894446b89c3403a61b91a97_I20220225"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU0YzgyOWFiYjhlMDQ2ZTBiYTQ2MzlhZjk1OTJlOTQ3L3NlYzo1NGM4MjlhYmI4ZTA0NmUwYmE0NjM5YWY5NTkyZTk0N18xNDgvZnJhZzo5M2JhMWUzOGNmOTg0NzlkODljMGMzNjU3MmE3YjQwZC90ZXh0cmVnaW9uOjkzYmExZTM4Y2Y5ODQ3OWQ4OWMwYzM2NTcyYTdiNDBkXzMzNTM1MTA0NjY2NTA1_cc9ca653-e5b8-4594-be6d-c249dce76978"
      unitRef="usd">9414000</mrsn:SaleOfStockRemainingAmountUnsoldAndAvailableForSale>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVQ?*6I7FAS%GL%K= W!_J93=G;@7E%]X+O\#4$L#!!0    ( '-)7%2M98+
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MVM#QZ+TME&[[NC505;Z7#@IM9_II89]"T,[![A^5PI/A#N@?U^0/4$L#!!0
M   ( '-)7%1L;?S7:@4  *T5   8    >&PO=V]R:W-H965T<R]S:&5E=#,N
M>&ULQ5AI;^,V$/TKA#?8[@).3%)WXAC(@:(%>@2;W?8S+=$Q$4GTDE2._OJ2
MLB/9(L5X@0+]D%C'S.C-:/0>A_-G+A[EFE(%7JJREI>3M5*;\]E,YFM:$7G&
M-[36=U9<5$3I4_$PDQM!2=$Z5>4,0QC/*L+JR6+>7KL3BSEO5,EJ>B> ;*J*
MB-=K6O+GRPF:O%WXPA[6RER8+>8;\D#OJ?JVN1/Z;-9%*5A%:\EX#01=74ZN
MT/D-3HU#:_$7H\]R[QB85):</YJ37XO+"32(:$ES94(0_?-$;VA9FD@:Q_==
MT$GW3..X?_P6_><V>9W,DDAZP\N_6:'6EY-T @JZ(DVIOO#G7^@NH<C$RWDI
MV__@>6<+)R!OI.+5SEDCJ%B]_24ONT+L.:!PQ 'O'/"Q#L'.(6@3W2)KT[HE
MBBSF@C\#8:QU-'/0UJ;UUMFPVKS&>R7T7:;]U.*&UY*7K""*%N":E*3.*;@W
MX20X!=_N;\&GD\_@!+ :?%WS1I*ZD/.9TD\V_K-\]Y3K[5/PR%-N:7X& C0%
M&&+D<+\YWAT>NL]TOEW2N$L:M_&"L:0;(6BM )%2YWGNB1AT$8,V8C@6D<@U
MT+4!N3F@WQOV1$K]"&>MMJ&B-I3YS)X6*$FR,)G/GO9K8IOA*()9V)D=( T[
MI*$7Z9V@&\(*0%\T$T@J6]1<K:G0[;9?%A?R;>AX'SG,(C0 ;EL%81J[84<=
M[,@+^RM7I#P"860C3-,T2P<0;3,<I5$*W2#C#F3\3FTUO0KUVM;4-,%&$YZ:
M@IHJ%];8QIK%0Z0.HR08P9ET.!,OSC\U2J)8_0!*JBD0",-UIWQUVNB3\=HF
M-A2L:SL [+""63#R^M,.<>I'W#;H.+34?I]!% ^0.8Q0%+B!91VP[(B^' >6
MV<^$,4+#3\9AE@1!EKG!(=BS.SR*Z4I&EJQDBE$OW:$]V4#>O*_RG#>:W\"&
MO))E29V:@!P-$^!A[@ZS- A'6ASU'(_P>PA%0WNB<R+$=MW3! T;QV&&8A2.
M]#3J10/Y5>.6KJA^/X5>#SW1NG$7,;#9- O#(4*759J, .RU OG%8D@4>VWD
MQ&HS/PY@,,3J4)$P&,/:"P3R*\26(MY#Z"#^8,A@#J-LA"90+PW(KPV' O8>
M3)OUPR3"5B5MLP!".(:UEP?T8_KP'EH'Y2-LK6=<9A!%Z0C:7AJ07QM^X_7#
MJ:*BTLOWY;C:(@?]AS&VOG7;+,R2L>[L90+Y=>*X[K1E($NL3]TV0LG(HA#W
M0H'A$>WY#KY=C .FUE\N'"!TF(51@/ (QEYSL%]S;GA5,6665!)\^H,K^O$#
MBN$%"CX[P7J#F?'X7&Y(3B\G>OZ55#S1R0*X9I/_(-!APGMCBG].N5<\?USS
MLJ!"_M0N*-6K+W O/-@O/'H(V"F/-(^8@A-XIHD#:3470$\N#;T .)KJ2^8/
MR#419E)HU)H+]@\M+D!WD4EI5+:=(AHEE3XPQ$$4T%,;K994;-_2V_376CIO
MP:G60;FA[6!?OCK?J2US5O/Y3 [+U<L@]LN@:3Q>>VJ%$F^QDF":P&P*H[C-
M/DZG:8BF>NV\S?]_J:0MPD.^]IH<5K(7:>P7Z:NB8&;[1G.-F4)/6:TGY@W3
MW.,$:0MQE&",ACKHLH-I.+9\QKUH8[]HZS5D4S5ENSE2T!7+F5-:L*W#IV$$
MPV2XLG 9XA2&: QI+]G8+]E;_I9[A/'Q0XI1<N&DC1ULUT"GM62X0'?888UZ
M;'F)>^7&?N6V1*=MZ1],(K6W25P3ELO.-6+-]O;2S$;F[T0\L%KJE=!*.\*S
M1$<0V[W![8GBFW9[;<F5XE5[N*9$@S<&^OZ*:Z7:G9@=NVZ'=O$O4$L#!!0
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MR_ID4$^T*-WF^B"TV:K=,#>G*9 VP-Q?"J%?)W:_;L]GR5]02P,$%     @
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M9Q0)NBEY*E/S-M:\X92Y)J(.N2*:@CK('MB_<-<K\7BS7&JZ&2GHK6V@&@Q
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M73^U_8@UV<Y"$@ 2Q3.M.8W!9&OH&5LSMVOP2D8%(36V*#4BO6#'CYXU*UL
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MCJ930V>G8 T>,)-Q\H;P),>ZV#AXRHT0 X5CJ(-B14JG@:/N+_9S^^42;YJ
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M,R#U&!\F8<(CCC]%"*-:3 @5O)UAN7(ML=\..ASPU6H:)9''GJ?V!@]$"4%
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ML#/\$1\[&_L=JI?13WYM%+@4^,-F].,M3<>__N6_S=QOI]WQ3X:%U_F'UWX
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M^ZYN2#C 2*8@%'56>\]+[(ZMZ@*1(9AM,+A*[AA O*QRDD[D$\_O6!3&3M@
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M'N#6ILB]=,H23RDA=)')78A[, &+C@8IV[2+!&N9MVAS?DUNGGCTB/T==N[
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MR/D4'M9M4!XC!#/3I]"'6#VRR81MQ>, V.K!=&42%$TNBKF7"QW+A([T\'[
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MY"68C@U_=9!$@=^7GL/=7L3!_CNV^ Y02P,$%     @ <TE<5 <S*C,F P
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MC3L_QQYO_ -^LG]H)]@_;U;6&63'OYY1,^G43+R:R?](Y[,H5(BO;<TS<35
MI5EAMF)P!/WG/RW29/[7@Q_WR&1AC,B9I47LQC*]9J!05"MA.AHCY@K![G15
M<[5G!<]9.HWB.*8_9@L.523'&U=H(_\ 7'T,/ 1CO85/W@)Q*]A*",6DM8W(
MA^S&74#E!<K]"_J+"-;J-:2DVD!>;PROV'O%_MZ4>]B8+(YM%-;Q52F1WCGC
M*.$CN)<WGSZ\.@OZDG (D?EE=6-LPY5C3K-=(;."2<<RW91Y$ 4\W$!S8$U-
M:U[,/37DIG06*ZL*/23XN3:Z8@ZMB1;Z7^Z(C"V7)9G0VE<;F0D[9&\:;QC9
MLQ?<,$$E\DUTXF//+0+-DCA:(CS3Y;+'^I$I9+4!$CI;SI17JC,A<K_RQ2R-
MEO,9<(UN-@7K,S(DUC_P_0G53A@T&NZ V)?PNHX" H4[_^8_Q""-GXF!M R(
MGLH^_4F;EO\'_K^[&CSGXV@Y2Z)X/OGO*)^,HW@Q9PUB;%C?_2%[ITN,P L
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MZ8"9\,4HW#A=^Z\T*^V<KOQE(3B2B!;@_5HC\=H;4M!]MKO^-U!+ P04
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M^5=$C=4_LN9^'XHPV5H4RAC0E67=P:MSU:H&<$GZWO+2-S68M;S2D.E)VD-
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M%6)10Q,POJKKMK^A#8:O@%[_%U!+ P04    " !S25Q4DR]K.OT(  #X*@
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M>79N;DJSX?\VXK=N:7*^7"N)9-("O%\:4S8WM$'[9]?'_P)02P,$%     @
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MPMG5E]-\E),\K]?2K!39Y%;6360B"6,))<1EGD:Q+_,LKD_GH^L')#A<O5%
M(;KFP'%:#^@]FDRA@%<1V 7@?EOK4&J.4%RJL%/*\*9".K=G_]W8QL1=$K&
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M8<#I:71DF1@G-!_:HAX=G([Z::Q6=[*O1FW(J#O*^(?&FG)@UTK'L8F!HL,
MQQ'76;4++JC+&8%;%A-JKE-(,BNXFQ^=^]QS-?AZME%NQ=\(*4$BZ\4/:?W3
M_C/DR_CU[; \?L/\6;H5DIBH586MX]%\>B%<_"X8;X+=\K<X3/[!;OARK20T
MH 5X7UE4O/:&&/0?9U_\'U!+ P04    " !S25Q4@;]8LG4#   #"   &0
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M7!9_:C$RJ%\H AC.]&V8>@N&5)+%&;S%\*RMO'I[X.S5-E^&E)RH!BH)>M@
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MW$Y%(I(^$83#V]8ZQWD(Q J<[1H)T^EX#-993U(^OAW5^R"*J6ELG&HPLFD
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ML?CD%LO3$8,#ZPR#:L4Y7)BLY@8%S'F+$,4C(,J?=L#'2&EHNJ?/KR8Y0;U
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MY!MM,(LL-S\D;62QMVO0]V62(W5'[G2:1;OQRJ7E_#5)O\#6_F3Y+@NV8J/
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M=XN#WE<B)$N7[%99HL69$$]0<M&Y=PX,4O3<NHL,'_<YJK1JB+HH.L'\FTA
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MLE8XLA#*06@J!5)03X-9?%=F[KU_\(W"3A_MD5.REG+CC"]D&D0N(&!0&<>
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MJ"?2>J/XTLYHKUSIB<\N"SW%$V$"]/,YYVJS,3_0_B\8_ -02P,$%     @
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MVR_,:^,P1(/,+C3@QA"W<UBV_'Z@]0Y\7AM#)\,3]"]2\1=02P,$%     @
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M\U;WZ++W&K:_$-3A7K@M.-LAJ0%.%T;.5DE%FP_?(FADXWR'H :4W?CM@C9
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MQ9\K2N94Z /J\P57"5V]T#]VJ'\U=/8?4$L#!!0    ( '-)7%1NGR\)4@,
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MI)"> OA86UM@]%C@3=2+N(;DB@S"MR0*HK"#T.KEZ4%'^OK%Z>&TIYI!:]?
MX0U>9!=M[>J!CEOHV$''%Z$;NZFSN\N[&F#H .R!LEN@)+MC,9^-6/=%G/ >
MMKR'STC2\.:';[-'CE$+.^J58PT9* 4I'FX[$!6\Q>.%4Y$ H89L(&=",)$3
MF9$M*";3+KWJ%49'M0ZFD_&99$^#XDDX[-9DW)(?_R-YFJ;,?C.=OHZ?4#CW
MM2_BA.&D93CY1X:XW:OD(L7)4Y4&9QR?ADRB23?+:<MR^O\? >!YV&O_M,/^
M.#YCW15T](V<T Z#PZD>]&Z*NYHO\DYD+M@?+ $/9E- 0Y=D2I;7/=LD/+I
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M7"X5(UZ_$>J.9*6Y-=\SJ>[@IIFJ=Q5P;:"^[QF3SQT=H'VI;?X"4$L#!!0
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M=]4<LY;?EJ+7285GPA1017%4W;+G8G@^2&5L[0(?L[716[\TAES'E.LX:"1
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MT/V<$&@7#MHV"X%%(9YE';N?,VOQ$[14RB% +>Q<_?U.[I59S%<& !GO)"A
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M@>L#:G_-F-Q--, VY/034$L#!!0    ( '-)7%3LU!BJR08  *@B   9
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M3;*9P,F$0K03[HZ!KN].H#_I#B=L-#/0'M!D&8LGSNLD7>8R6.C2 98Q2VV
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MB=/>VX?>9I(F?99A;3,!Y$IRG/S[2H !QR#(G;XD2&AWSQ[69R7-]HP_BPV
M1*]IDHFKT4;*[:5EB7 #*15CMH5,O5DQGE*IAGQMB2T'&N5&:6*1R<2S4AIG
MH_DLG[OC\QG;R23.X(XCL4M3RM]N(&'[JQ$>'2;NX_5&Z@EK/MO2-3R ?-S>
M<36R*B]1G$(F8I8A#JNKT36^7!!7&^0KGF+8B\8STJDL&7O6@V_1U6BB$4$"
MH=0NJ/KW @M($NU)X?A=.AU5,;5A\_G@_6N>O$IF204L6/(KCN3F:A2,4 0K
MNDOD/=O_"V5".<"0)2+_B_;EVLD(A3LA65H:*P1IG!7_Z6M)1,- )=IN0$H#
M,M3 +@WL/-$"69[6+95T/N-LC[A>K;SIAYR;W%IE$V?Z,SY(KM[&RD[.'R0+
MG]&/K>94H,_H6M,:RS?TF$7 4?,UNDMHALYN0=(X$>=J\>/#+3K[=(X^(0N)
M#>4@4)PIRUB*"S6IGG]NV$[0+!(S2RJT.J85ELAN"F2D QDFZ#O+Y$:@+PI*
M=.S 4FE6N9)#KC?$Z/$6PC&R\04B$X); "V&FT\,<.R*>COW9W?X^V^7+A7%
M;(4><NX,+IW*I9.[=#I<_MA)(17=<;9&5*(EK.,LTP,59 L\9A$Z4U^E^%;G
M;=^D\._E_K4$O,P]C,G4"6;62PLPMP+FFH&5!;;F-)/0B\(]06';DX!HVMM0
M>!4*SXCBRROP,!;]\;V3^)\=@NT M\?WJ_B^,?Z"9J$2K/[X_FE\S_5MM^,K
M!%7\X"/E 5DTO#""$TB![1"'3"M(Q6_H=)VQ@*85]*D1^A,(73<*/(+7K>H!
M:B 9>E'3?<BGO<B/$.%)+9V3044-15G190(7'^:UC'%4Z].I[W;":R@[-NK+
MK[R%0:1$_06XZLGH4/_HCL<A&/0&DSH(^1N*$[$DH5SHJ8*,=BZ*6$&#"W\<
M.!U$U#J+;2/&?QJB,Q!(X7#: (*]L=]1P[B69VS6YV,!&HC%.<'BC&VO THM
MR-BLR,=:-!"*>TH+'OM=6&I9QF9=[M6E@?"\-GC$?:=0Y;*!559K.S:+>Y]"
M#<S![\GA&%VM_+A'^@=KU4"<00N)GMT!LU9Y/#5JUG44Q1HH3=!M+,*$B9UY
M9T1JM29FM3[(8:6&]Z"/.;KF%FJ?R=6!8J?"_@2>7E0;8E979AL+/2%]] ::
M2H+28B>K]K01?6O;#"\&NK(K5T&+JV-JZDY!\%^GY@(9"KZ5*S.&85P=)UAW
M*6+N4O_KVS=^*JWYF$.Z93Y>F8\IC[J3$7,GNUZO.:RI!/1-H8[583I$3S39
MP?"*+0*XS=V0T]A7EL5XN@ICQ^_:DY"Z 1)S ^Q/X.-U=7ID.<KH&&G='XFY
M/PZ@NJ] W!,2?==^3Z'5.+NGP-?YE89 (=MELCC:5K/5M<EU?EGP;OX&7RZ*
MRX_:37$7\YURM2L3*(&5<CD9^PH2+ZXWBH%DV_R&8,FD9&G^N &JSO]Z@7J_
M8DP>!CI =<DT_P-02P,$%     @ <TE<5!U9DOR\ P  ?PP  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3(N>&ULI5??<]HX$/Y7-)X^)#,-MFQLH /,)'"]
MZT/O,J%)GX6]@":VQ$D"VO^^*]D8-QB'FWL!_=C]]MO5:K4>'Z1ZU1L 0WX4
MN= 3;V/,]I/OZW0#!=,]N06!.RNI"F9PJM:^WBI@F5,J<C\,@L0O&!?>=.S6
M'M5T+'<FYP(>%=&[HF#JYP/D\C#QJ'=<>.+KC;$+_G2\96M8@'G>/BJ<^35*
MQ@L0FDM!%*PFWCW]-*.)57 2+QP.NC$FUI6EE*]V\B6;>(%E!#FDQD(P_-O#
M#/+<(B&/?RM0K[9I%9OC(_IGYSPZLV0:9C+_SC.SF7A#CV2P8KO</,G#7U Y
M%%N\5.;:_9)#)1MX)-UI(XM*&1D47)3_[$<5B(8".MJN$%8*X5N%_@6%J%*(
MG*,E,^?6G!DV'2MY(,I*(YH=N-@X;?2&"WN,"Z-PEZ.>F2Z,3%_)/UL;4TWN
MR!-HHWAJ("/EUK/@1I.;.1C&<WV+(L]BCT(HH$ZRVLGNG"Q*+.;DYL,M^4!\
MHC<,Y0@7)=)'7,3QMXW<:28R/?8->F&Y^&G%^*%D'%Y@3$/R50JST>0/D4'V
M.X"/[M<Q"(\Q> @[$>>0]DA$/Y(P"&D+H=GUZD$'G:@^DLCA11?P_MX52U!$
MKLC"Q:X#LE]#]AUD_P)D?63,D"6LN1!<K*V%+2@N,W*#1U(>U&W;@93@B0.W
M=6$_'=!DD S&_KZ%5%R3BCM)O924WK$=G]F^Z]-1%"7MQI/:>-)I'&O "O@5
M]I-S^W04Q]&PW?Z@MC^X^D1 9->?Q>",SY .DF!4TRE3]ERLZ\B&->MA9VI^
M=U416=_O06&5QW)AGPJ;3#.\DPJ+\H[EY!NH@N#M)O?KM8(U,T"^X"['XI^2
M%Y;OH".G1S6746<$CUSN6,5%U5S2!A>#7-KBV U.R4]@BB2D<*6FK2A< ]#A
M)@U.%3KHA#H%D==!W-L@NE3)9)XSU9XK%7#<R((X&"9O4J5%BHZ"0=2>*K3Q
MLM"KDN7NF"Q_*B8,F5M//C.NWLT$&IY,A?^[OE6!LDOE_6H/67@6C N5AI[J
M.8TZV3F_X3^Q* %'S2,9]J+1!2:G9X!VOP.-DGLED?X9D;@774J-4^6GW:7_
M]^I[)97X/"9A+^I?X')Z"&CW2]!=B:_D5IH8-KG%O63X]J8E[R:7WVCE"E!K
MU^%JK&@[8<J.IEZMN^A[USN^67^PW;5K$4\P96O^E2F\(9KDL$+(H#= /JKL
M=LN)D5O7,"ZEP?;3#3?XA0#*"N#^2DISG%@#]3?']!=02P,$%     @ <TE<
M5-_4^P>) P  )PX  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULQ5==
M;Z,X%/TK%IJ'&6FG8 ,)&261)DGWXV&T5;O=?7;!25#!9FTGZ?S[O38$*!"V
M#Y'R4FQS[K'//<WE>GX2\E7M&=/H+<^X6CA[K8MOKJOB/<NINA,%X_!F*V1.
M-4SESE6%9#2Q07GF$L^;N#E-N;.<V[4'N9R+@\Y2SAXD4H<\I_+GBF7BM'"P
M<UYX3'=[;1;<Y;R@._;$]'/Q(&'FUBQ)FC.N4L&19-N%\QU_V^"9";"(OU-V
M4JTQ,E)>A'@UDS^2A>.9$[&,Q=I04'@<V9IEF6&"<_Q;D3KUGB:P/3ZS_VK%
M@Y@7JMA:9/^DB=XOG,A!"=O20Z8?Q>EW5@D*#5\L,F7_HE.%]1P4'Y06>14,
M)\A37C[I6Y6(5@">7 @@50#I!@07 OPJP/]H0% %!#8SI12;APW5=#F7XH2D
M00.;&=ADVFB0GW+C^Y.6\#:%.+U\TB)^17\6Q@2%OJ)ROH),)F@M<OCW4M0:
M=/]FQ@Q]WC!-TTQ] ?#STP9]_O0%?4(I1W_MQ4%1GJBYJ^%@AMZ-JT.LRD.0
M"X? !/T07.\5NN<)2]X3N*"HED7.LE9DE''#XCODXU\0\0@>.-#ZX^'>0/CF
MP^%X-J+&KTWR+9\_:I(H31KA"VJ^P/(%8WQ?7ZS)<=MD5IF<\C@[@!/65Z%I
M!ILS"1B^.V,&;2ZW#>VVIN(<ES@*/$C!L9W[/FJ*I^0]:-,'!5$+]$YW6.L.
M_U_W!_(XJ?DF5_%E6O--;^-+N>VD[4L0DJCC2Q\53DG8\:4/"HCO#?L2U;JC
M4=W/_,B4!ED2'C*-S5#9W!YXJL<R.ZMWF%W%*>PU==.[C5?5ONT,^R'I_#S6
M RB,HVG'K %4@"^8A5N?##PJ_3XO,O&3L<JCXB#C/>0!%1GE8[DES0;D.FXU
M!13[-W++'W"K6_ &0&3B=;T: /D7"AYN*CT>+_6/3#$*_B#X,D,_=(1&KX"V
M38]EM2FG.+R.3TU!Q9,;^33I97<VBX*N47V4'P6XZU0?14@07K"J*?YXO/K_
MQC@HR:Q3-(%>+X5B2$U;/);:IL;BZ#IF-345SVYDUJSW\8^"[I=H/8#R?;]G
M5A]%)F3:,<MM== YDSM[$U&@ZL!UV776J_5MY[OM\3OK*W,+LIUY0U->H7Y0
MN4NAQ\[8%BB]NRD<29:WDG*B16'[]!>AH>NWPSW<Y)@T 'B_%4*?)V:#^FZX
M_ ]02P,$%     @ <TE<5$TWGMK2 @  # D  !D   !X;"]W;W)K<VAE971S
M+W-H965T-30N>&ULG5;?;]HP$/Y73I$F==)*$D.AK0 )FE;;0S74:MW#M >3
M',3"B3/;E/+?SW9"!E42T;TD_O5]=]^=[?-X)^1&I8@:WC*>JXF7:EW<^KZ*
M4\RHZHD"<S.S$C*CVG3EVE>%1)HX4,9]$@1#/Z,L]Z9C-[:0T['8:LYR7$A0
MVRRC<C]'+G83+_0. T]LG6H[X$_'!5WC,^H?Q4*:GE^S)"S#7#&1@\35Q)N%
MM]'(KG<+7ACNU%$;K)*E$!O;^99,O, ZA!QC;1FH^;WB'7)NB8P;?RI.KS9I
M@<?M _N#TVZT+*G".\%_LD2G$^_:@P17=,OUD]A]Q4K/E>6+!5?N"[MR[>#&
M@WBKM,@JL/$@8WGYIV]5'(X X; %0"H .1?0KP#]=P#2!AA4@(&+3"G%Q2&B
MFD['4NQ VM6&S39<,!W:R&>Y3?NSEF:6&9R>/FL1;^![89.@X!(>*)/P0OD6
M8:;,7J@F+B+4E''U>>QK8]5B_;BR,"\MD!8+(8%'D>M4P7V>8')*X!MW:Y_)
MP><YZ62,,.Y!/_P")"!A@T-WY\.#!GAT-CR\Z5#3KS/0=WS]M@RD5.*EW;L)
M+.C>'"D-,REIOD;7_C5;*BW-^?C=86Q0&QLX8X,68T],;2Y7$A%8KE&BTB"I
MQJ:L=A,%O9O@4U/LNV%ACS3"HFX8Z?7?PT[D7]7RKSIY[M\*<]^80"?LE268
M)[!GR),F^=U$02]HEO]_L.C#L!/YPUK^\#SY)O497.R1RN83W4TS!(<$$D)"
M]ZHI#.<1A-=M!%$WP=6!((2LO%O(L('J)$BC.DBC\X*DW-582!8CO I.->-,
M[YO"U4UX3=HV2S=N-&C;+1_'E9'PC^I$AG+MZJV"6&QS75Z_]6A=TF>NDKT;
MGYM27U;F?S3E.^&1RC4S!8/CRE &O9'9V;*LO65'B\)5HZ70IK:Y9FJ>*RCM
M C._$D(?.M9 _0":_@502P,$%     @ <TE<5!\IOQ$ !   [P\  !D   !X
M;"]W;W)K<VAE971S+W-H965T-34N>&ULI5==<]HX%/TK&D\?VIDDMOP%=("9
M &&VG<TFDS3;9V'+H*DM>241R+]?279L D;0\@*2K7/OT;GRD33<,/Y+K#"6
M8%OD5(R<E93E5]<5R0H72-RP$E/U)F.\0%)U^=(5)<<H-: B=WW/B]T"$>J,
MA^;9(Q\/V5KFA.)'#L2Z*!!_F^"<;48.=-X?/)'E2NH'[GA8HB5^QO*E?.2J
MYS914E)@*@BC@.-LY-S"KW,_U  SXE^"-V*G#?14%HS]TIUOZ<CQ-".<XT3J
M$$C]O>(ISG,=2?'XKP[J-#DU<+?]'GUN)J\FLT "3UG^DZ1R-7+Z#DAQAM:Y
M?&*;OW ]H4C'2U@NS"_85&-[@0.2M9"LJ,&*04%H]8^VM1 [ !@> ?@UP#\7
M$-2 X%Q 6 /"<P%1#8C.!<0U(#;:5V(9I6=(HO&0LPW@>K2*IANF7 :M!"94
MKZQGR=5;HG!R_#=691'@&OR#.$>ZRN#S#$M$<O%%/7UYGH'/G[Z 3X!0\&/%
MU@+15 Q=J5+K &Y2IYE4:?PC:6Y+?@.\Z KXG@\[X%,[_/N:WH# .PJ?V>$S
MG"@X/ J_.Q_N=<#G9\/AX"/<5=5J2N8W)?--O,!:,DN@H D4F$"A+1#("5J0
MG,BW+EVK )$)H$WJ=0R#*%(BO';D#9N\X8F\4F(.6 82CE,B@3)(('"RYHJ%
MLH62"2*[V%1AXQTV8:_?<*E*&1XP#G3-N_A&#=_(RO<;53RU5.H;>'IX 4@(
MW,5O&AWF[O6#[N1QDSRV)C=>?\VRZ[4B8#(+P!;J Z4XU83P-EDANL1&Q(Q0
M1!-"ER#_4%NROUXJ/>,#/6-OL*?GX1COXXAY?##KT!]T3[K73+IGGS2F4LU,
M;9\"=Q'O'0H=#/9XW1T.\N,PW"/?,0C&1]9WOV'?M[)_*+&VTC.K,.W_QJH9
M-!0&5@KWA))B75A, GKM#N%=YC=P9[.!5EISLSYQI<N5.IGHLT\KE'*%HM/=
M[5$A>,.(VPBVU@I]NVYH>TJWUEUA<*%NK6%"NV/^J6[VJ)'1S<JPM4AH]\B'
M+".*H"A1H@A.4;'@)%VJYOWM%3!*I+8\K1O"^$)16X^!)TT&;U!^7#T[_ SU
M6L. )QRC4N]9JP?NMB6J3NZ-C. >V?*TK@ 'EZGGMZ[@>Y>H-SD!/ZV>W[J*
M;__^]_U64S*G"T8E5U>73GKVD&?0VSFNV3WE]#%K4D?XL(<.CNT!?NM _JD#
MWI\=M"9UW-U='T:](W1:%_/M?O,#*Q>3@!0E9Z^XT'L\RM755EM;)XO#LURT
M?Y1S=ZX^^BI\C_B24*%60J9 WDU/H7EUNZPZDI7F-K1@4MVM3'.E;N28ZP'J
M?<:8?._H"U9SQQ__#U!+ P04    " !S25Q4G07"+=X"  !3"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970U-BYX;6R-5EUOVC 4_2M6U(=66IL//@(5( %I
MM4JK5K7K]C#MP2078C6Q,_M2NOWZV4[(: A17XCMG'-\S[V.+Y.=D"\J!4#R
MEF=<39T4L;AV716GD%-U)0K@^LU:R)RBGLJ-JPH)-+&D/',#SQNZ.67<F4WL
MVH.<3<06,\;A01*US7,J_RP@$[NIXSO[A4>V2=$LN+-)03?P!/A</$@]<VN5
MA.7 %1.<2%A/G;E_'8T,W@*^,]BI@S$Q3E9"O)C)73)U/!,09!"C4:#Z\0I+
MR#(CI,/X76DZ]9:&>#C>J]]:[]K+BBI8BNP'2S"=.B.')+"FVPP?Q>XS5'X&
M1B\6F;*_9%=BP\ A\5:AR"NRCB!GO'S2MRH/!P1_>((05(2@2>B?(/0J0N^C
MA'Y%Z-O,E%9L'B**=#:18D>D06LU,[#)M&QMGW%3]B>4^BW3/)Q] 9TT12[)
M4N2%X,!1$;$F=IG<O.G3I9_G$2!EF;K0N.>GB)R?79 SPCCYEHJMHCQ1$Q=U
M,$;2C:N-%^7&P8F-_8#<"XZI(C<\@>2]@*M=U%:"O95%T*D807Q%>OXG$GB!
MWQ+0\N-TKX4>?9CNCSO<].K"]*Q>K[LP/^<KA5)_';\Z-/NU9M]J]D]H?BU
M4F1\0S);WU@H;*M<J3*P*N;>>)WU!EXP<5\/LWD,"L+!X#TH:@'Y0Z\&O7,Q
MJ%T,.C-SRSCE,1QXN.[(S;!6'7;F9IX+B>POM;>1_@*DN3 NQ?IRJS>A2@&V
M'O)2='A@T!^.&YEJP7A^(U''F'#0GJ:P-A1V&KKC"!(4$NVG3%7&Z(IE#!FT
M6@F/0@A&#2<MD*:1%LB)>H]J(Z-.(\?U;HM^='32_''8"+\%$S2.=72,&3<+
MX1Y<MSG(C6U;2D>VY5A>5_5JW1GGMB$TUA>Z8Y8-[K],V6[OJ=PPKK3GM9;T
MKD(=D"Q;6#E!4=A+?250MP@[3'77!VD ^OU:"-Q/S ;U_XC9/U!+ P04
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MGKO:C62U.;H\,:D.0F:Y46=5X-I W5\Q)E\V^C34GWX7OP%02P,$%     @
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MUB?X;+1=_DVF?7/NJ%HRH3'> B4'YQ=H2+5]O)T86;O.MI &^Z0;EOCT@;(
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M=I;M*;V]4>+8''0?A=+'YN:RT%\V1!H#_7XOA'J^,6?G_EMI\S]02P,$%
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MZ49GAZ7^LX P!GI_P[DZ3$RW<_^J[ =02P,$%     @ <TE<5-8!1$L@ @
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M"T>)U>NVK=L)JMJWTE:A;4P_+.U+"-H%V/V=4GB>N.[LW];L-U!+ P04
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MPENT @894?(4;70$<8C99[''%[=\<2_?39*(2J,1ID" 5(@+I*L[IHKHRRR
M8F7 .:ITAH6^P\Q&47))3/9/11$?G83#*/HL]J(8M5&,>J/X6A4K$(AG2"H-
MC+JW69KCLLE)DB-@BJA7E!$*9M56+1.- %4);?A[S_%4;*.C_ ].DX];\O$;
MR3-(06!J-J .PI8A2U\*OM:;8P#/U:;Y^)\GP^U4^ +$VC8^B1)>,547SW:U
M[:TWMJ4<K,]USZU;Y%^9NF'?8K$F.I$4,BWI7<5ZCT7=!.N)XJ7M(RNN=%>R
MPUQ_-X P!OIYQKG:3<P+VB^1V1]02P,$%     @ <TE<5%4XWE56 P  =0L
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MOUJ<T$>1TM\ZB?@6J:S9AX_R(-A$MTJK$%WO[]2=OA^\K:.JWXT+@W/ Y6\
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M\?K  @  &P@  !D   !X;"]W;W)K<VAE971S+W-H965T-C<N>&ULS5;;;MI
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MDPV]O@<ISMDR-W=R_1GK?#J6+Y&Y=D]8U[:!!\E2&UG48(J@X*)ZL^>Z#EN
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M4*MWRXRF-RIK0/=S*<UF8QTT_P=&OP%02P,$%     @ <TE<5(=#A-B)!
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M6HO47JZ 1R#-!/Q_(81^'9CW .6KJ-&_4$L#!!0    ( '-)7%2)O B[$@,
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M&^IM!'K;:+.;0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O1[V=0&]'O9U
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M<F]P<R]A<' N>&UL4$L! A0#%     @ <TE<5(C\]TON    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ <TE<
M5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !S25Q4"G.)>&\&  #M&0  &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ <TE<
M5*UE@L ? @  : 4  !@              ("!L@X  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( '-)7%1L;?S7:@4  *T5   8
M      " @0<1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !S25Q4LF!6 \,"  "K"0  &               @(&G%@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ <TE<5+FY@AHD!0  NA0  !@
M             ("!H!D  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( '-)7%0U*4O/G <   $G   8              " @?H>  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !S25Q4PV/'KUH#  #Z
M"@  &               @(',)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ <TE<5&7=8A+."   I2@  !@              ("!7"H
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( '-)7%1)*2I)
M> H  /D8   8              " @6 S  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !S25Q4BD2XAILB  !=;@  &0
M@($./@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( '-)
M7%0O8@C=RQ,  ,Y&   9              " @>!@  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ <TE<5&%P$P$- P  TP8  !D
M         ("!XG0  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !S25Q4!S,J,R8#   C!P  &0              @($F>   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( '-)7%1*7A?RD0(  ,L%
M   9              " @8-[  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ <TE<5.[L!1/$"@  -A\  !D              ("!2WX
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !S25Q4ZC6P
M.8 '  #"$P  &0              @(%&B0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( '-)7%02JY\$N0P  !$D   9
M  " @?V0  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M<TE<5),O:SK]"   ^"H  !D              ("![9T  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !S25Q4/E*Q.<D*  "H'0  &0
M            @($AIP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( '-)7%2!OUBR=0,   ,(   9              " @2&R  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ <TE<5% \"X': @
M>08  !D              ("!S;4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !S25Q4'7 %*:T&   =$   &0              @('>
MN   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( '-)7%22
MPC#W_B$  ,)Q   9              " @<*_  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ <TE<5$[(EWEF!   A@P  !D
M     ("!]^$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '-)7%019M"Y>P(  $D%   9              "
M@0#S  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ <TE<
M5+OH&,G !0  Q0\  !D              ("!LO4  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !S25Q4T?Y^F<H$   *#P  &0
M        @(&I^P  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( '-)7%0L07^F600  !@*   9              " @:H  0!X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ <TE<5/E/^C&< @  A08
M !D              ("!.@4! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !S25Q4(+:Z_ D"  !]!   &0              @($-" $
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( '-)7%1-I5\6
MNP(  +\'   9              " @4T* 0!X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ <TE<5$$?6-^\ @  O0<  !D
M ("!/PT! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !S
M25Q403R1IT8"  #Q!0  &0              @($R$ $ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( '-)7%34??V84P,  ",,   9
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M970T,BYX;6Q02P$"% ,4    " !S25Q45'QB-H0#  "U#0  &0
M    @($O*0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M '-)7%38HLK;N@(  $,(   9              " @>HL 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ <TE<5/BQTP+$!@  BR@  !D
M             ("!VR\! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !S25Q4Q4".()0"  #_!@  &0              @('6-@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( '-)7%0Y FU%GP(
M )P'   9              " @:$Y 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ <TE<5.S4&*K)!@  J"(  !D              ("!
M=SP! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !S25Q4
MU"4Q).\"  #,"@  &0              @(%W0P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( '-)7%24B^$78P<  #@E   9
M      " @9U& 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ <TE<5#<TEOJ%!   <!(  !D              ("!-TX! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !S25Q4'5F2_+P#  !_#
M&0              @('S4@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( '-)7%3?U/L'B0,  "<.   9              " @>96 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ <TE<5$TWGMK2
M @  # D  !D              ("!IEH! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " !S25Q4'RF_$0 $  #O#P  &0
M@(&O70$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( '-)
M7%2=!<(MW@(  %,(   9              " @>9A 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ <TE<5 6=!=S2 P  "0\  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( '-)7%3<>ER)JP,  #<-   9
M  " @=AU 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M<TE<5/)9F\!= @  MP8  !D              ("!NGD! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " !S25Q4U@%$2R "  !G!0  &0
M            @(%.? $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( '-)7%3E,5V4#P,  )4(   9              " @:5^ 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ <TE<5%4XWE56 P
M=0L  !D              ("!ZX$! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " !S25Q4JE3Q^L "   ;"   &0              @(%X
MA0$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( '-)7%2'
M0X38B00  )82   9              " @6^( 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ <TE<5(F\"+L2 P  ,A$   T
M     ( !+XT! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !S25Q4EXJ[',
M   3 @  "P              @ %LD $ 7W)E;',O+G)E;'-02P$"% ,4
M" !S25Q4IT]5FDH%  "L+   #P              @ %5D0$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ <TE<5!;=:Q0F @  8R@  !H
M ( !S)8! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M<TE<5.'L7A'T 0  HB<  !,              ( !*ID! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     $P 3 #+%   3YL!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>217</ContextCount>
  <ElementCount>487</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2155112 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2157113 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/CollaborationAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/PropertyandEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedexpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/StockOptions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/Leases</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2348309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.mersana.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Summary of Significant Accounting Policies - Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail</Role>
      <ShortName>Collaboration Agreements - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Collaboration Agreements - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/AccruedExpenses</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Debt - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtComponentsDetails</Role>
      <ShortName>Debt - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Debt - Future payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/DebtFuturepaymentsDetails</Role>
      <ShortName>Debt - Future payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stockholders' Equity - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Stock Options - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsNarrativeDetails</Role>
      <ShortName>Stock Options - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails</Role>
      <ShortName>Stock Options - Activity Under Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Stock Options - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails</Role>
      <ShortName>Stock Options - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Options - Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Stock Options - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails</Role>
      <ShortName>Stock Options - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Leases - Supplemental balance sheet information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails</Role>
      <ShortName>Leases - Supplemental balance sheet information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Leases - Supplemental cash flow information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails</Role>
      <ShortName>Leases - Supplemental cash flow information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Leases - Future minimum lease payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails</Role>
      <ShortName>Leases - Future minimum lease payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2449428 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Income Taxes - Components of deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails</Role>
      <ShortName>Income Taxes - Components of deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails</Role>
      <ShortName>Income Taxes - Net operating loss carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Income Taxes - Tax credit carryforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails</Role>
      <ShortName>Income Taxes - Tax credit carryforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Income Taxes - Valuation allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails</Role>
      <ShortName>Income Taxes - Valuation allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458435 - Disclosure - Commitments - License agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/CommitmentsLicenseagreementsDetails</Role>
      <ShortName>Commitments - License agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="mrsn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mersana.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.mersana.com/role/SubsequentEvents</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="mrsn-20211231.htm">mrsn-20211231.htm</File>
    <File>exhibit101410kfy2021.htm</File>
    <File>exhibit101510kfy2021.htm</File>
    <File>exhibit102810kfy2021.htm</File>
    <File>exhibit102910kfy2021.htm</File>
    <File>exhibit103010kfy2021.htm</File>
    <File>exhibit21110kfy2021q4.htm</File>
    <File>exhibit23110kfy2021q4.htm</File>
    <File>exhibit31110kfy2021q4.htm</File>
    <File>exhibit31210kfy2021q4.htm</File>
    <File>exhibit32110kfy2021q4.htm</File>
    <File>mrsn-20211231.xsd</File>
    <File>mrsn-20211231_cal.xml</File>
    <File>mrsn-20211231_def.xml</File>
    <File>mrsn-20211231_lab.xml</File>
    <File>mrsn-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mrsn-20211231_g1.jpg</File>
    <File>mrsn-20211231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="759">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrsn-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 217,
   "dts": {
    "calculationLink": {
     "local": [
      "mrsn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrsn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrsn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrsn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrsn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrsn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 605,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 8
   },
   "keyCustom": 70,
   "keyStandard": 417,
   "memberCustom": 53,
   "memberStandard": 21,
   "nsprefix": "mrsn",
   "nsuri": "http://www.mersana.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.mersana.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - Collaboration Agreements",
     "role": "http://www.mersana.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Fair Value Measurements",
     "role": "http://www.mersana.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Property and Equipment",
     "role": "http://www.mersana.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Accrued Expenses",
     "role": "http://www.mersana.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Debt",
     "role": "http://www.mersana.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Stockholders' Equity",
     "role": "http://www.mersana.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Stock Options",
     "role": "http://www.mersana.com/role/StockOptions",
     "shortName": "Stock Options",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Leases",
     "role": "http://www.mersana.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Income Taxes",
     "role": "http://www.mersana.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.mersana.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155112 - Disclosure - Employee Benefit Plan",
     "role": "http://www.mersana.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157113 - Disclosure - Commitments",
     "role": "http://www.mersana.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159114 - Disclosure - Subsequent Events",
     "role": "http://www.mersana.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.mersana.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Accrued expenses (Tables)",
     "role": "http://www.mersana.com/role/AccruedexpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Debt (Tables)",
     "role": "http://www.mersana.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.mersana.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.mersana.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Stock Options (Tables)",
     "role": "http://www.mersana.com/role/StockOptionsTables",
     "shortName": "Stock Options (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Leases (Tables)",
     "role": "http://www.mersana.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.mersana.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "role": "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:RevenueCollectionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:RevenueCollectionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "ie614b7c768c042aba10411ce72a641cd_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RetainageDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails",
     "shortName": "Summary of Significant Accounting Policies - Stock Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightOutstanding",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Net loss per share (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails",
     "shortName": "Summary of Significant Accounting Policies - Net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Risks (Details)",
     "role": "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails",
     "shortName": "Summary of Significant Accounting Policies - Risks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements - Narrative (Detail)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
     "shortName": "Collaboration Agreements - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i311ddb6991d8496f92c657e71d74c7e1_D20140601-20140630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "mrsn:CollaborativeArrangementsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements - Contract Assets and Liabilities (Details)",
     "role": "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
     "shortName": "Collaboration Agreements - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.mersana.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:AccruedManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Accrued Expenses (Details)",
     "role": "http://www.mersana.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:AccruedManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.mersana.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i46ac06dbc12246b49e2a5075fae37c0f_D20190508-20190508",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Debt - Components (Details)",
     "role": "http://www.mersana.com/role/DebtComponentsDetails",
     "shortName": "Debt - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Debt - Future payments (Details)",
     "role": "http://www.mersana.com/role/DebtFuturepaymentsDetails",
     "shortName": "Debt - Future payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "iad1a3e94cef1418c81390f9063dcd649_D20130101-20131231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mrsn:ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stockholders' Equity - Common Stock (Details)",
     "role": "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
     "shortName": "Stockholders' Equity - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "iff2b446a5705439d8204e2db3af84557_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Stock Options - Narrative (Details)",
     "role": "http://www.mersana.com/role/StockOptionsNarrativeDetails",
     "shortName": "Stock Options - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "ib6cc8ef0ee8849a18fb5d71717b6ebc4_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Stock Options - Activity Under Stock Option Plan (Details)",
     "role": "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
     "shortName": "Stock Options - Activity Under Stock Option Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i98f2c5c74ca2449d9dc01f98a02d2f87_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Stock Options - Restricted Stock Units (Details)",
     "role": "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
     "shortName": "Stock Options - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i94e42285311c41d3a7b80346455ec74e_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Stock Options - Stock Based Compensation Expense (Details)",
     "role": "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
     "shortName": "Stock Options - Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Stock Options - Fair Value Assumptions (Details)",
     "role": "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails",
     "shortName": "Stock Options - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.mersana.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "mrsn:IncreaseDecreaseInOperatingLeaseLiabilities",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i2a56f442c69248c78859ce174629ab21_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "mrsn:IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Leases - Supplemental balance sheet information (Details)",
     "role": "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails",
     "shortName": "Leases - Supplemental balance sheet information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Leases - Supplemental cash flow information (Details)",
     "role": "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails",
     "shortName": "Leases - Supplemental cash flow information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "mrsn:LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Leases - Future minimum lease payments (Details)",
     "role": "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails",
     "shortName": "Leases - Future minimum lease payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i61ec234a6d7849c5b76113ec2c8dcfb2_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449428 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Income Taxes - Reconciliation (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Income Taxes - Components of deferred tax assets (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
     "shortName": "Income Taxes - Components of deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i72c467d1b1b6423e92438fcea0715adb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Income Taxes - Net operating loss carryforwards (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
     "shortName": "Income Taxes - Net operating loss carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i72c467d1b1b6423e92438fcea0715adb_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i3a07a4efd2d24b99831852b517363a51_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Income Taxes - Tax credit carryforward (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails",
     "shortName": "Income Taxes - Tax credit carryforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i3a07a4efd2d24b99831852b517363a51_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i1b5567939ee84f85a796f7340017d974_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Income Taxes - Valuation allowance (Details)",
     "role": "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails",
     "shortName": "Income Taxes - Valuation allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:DefinedContributionPlanEligibleAgeToParticipate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Employee Benefit Plan (Details)",
     "role": "http://www.mersana.com/role/EmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrsn:DefinedContributionPlanEligibleAgeToParticipate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458435 - Disclosure - Commitments - License agreements (Details)",
     "role": "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails",
     "shortName": "Commitments - License agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "id4b54f73246540a1bdd06f88a1c2cffe_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i828ebe879492478780a584c32808e4db_D20200501-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.mersana.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i5fa034c85dbc456988299ee454032879_D20220101-20220225",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i7d5ff0c1324e41408e5e006225ac8efb_D20190101-20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "mrsn:StockIssuanceDiscountsAndCommissionsOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Nature of Business and Basis of Presentation",
     "role": "http://www.mersana.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrsn-20211231.htm",
      "contextRef": "i20946113a6b640bf91ee43d05d504400_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "localname": "AuditorLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.mersana.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrsn_A2017ESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 ESPP",
        "label": "2017 ESPP [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "A2017ESPPMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_AccruedManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Manufacturing Expenses Current",
        "terseLabel": "Accrued manufacturing expenses"
       }
      }
     },
     "localname": "AccruedManufacturingExpensesCurrent",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_AccruedPreclinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preclinical expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preclinical Expenses Current",
        "terseLabel": "Accrued preclinical expenses"
       }
      }
     },
     "localname": "AccruedPreclinicalExpensesCurrent",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_AmendedCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Facility",
        "label": "Amended Credit Facility [Member]",
        "terseLabel": "Amended Credit Facility"
       }
      }
     },
     "localname": "AmendedCreditFacilityMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended New Credit Facility, Combined Tranche Four and Five",
        "label": "Amended New Credit Facility, Combined Tranche Four and Five [Member]",
        "terseLabel": "Amended New Credit Facility, Combined Tranche Four and Five"
       }
      }
     },
     "localname": "AmendedNewCreditFacilityCombinedTrancheFourAndFiveMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AmortizedInterestExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized Interest Expense",
        "label": "Amortized Interest Expense [Member]",
        "terseLabel": "Amortized Interest Expense"
       }
      }
     },
     "localname": "AmortizedInterestExpenseMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram2018ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program to offer and sell common stock from time to time at prevailing market prices.",
        "label": "At Market Equity Offering Program (2018 ATM) [Member]",
        "terseLabel": "At market equity offering program (2018 ATM)"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram2018ATMMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgram2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Equity Offering Program (2020 ATM)",
        "label": "At Market Equity Offering Program (2020 ATM) [Member]",
        "terseLabel": "At Market Equity Offering Program (2020 ATM)"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgram2020ATMMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_AtMarketEquityOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Equity Offering Program",
        "label": "At Market Equity Offering Program [Member]",
        "terseLabel": "At Market Equity Offering Program"
       }
      }
     },
     "localname": "AtMarketEquityOfferingProgramMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CapitalizedOtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Other Assets",
        "label": "Capitalized Other Assets [Member]",
        "terseLabel": "Capitalized Other Assets"
       }
      }
     },
     "localname": "CapitalizedOtherAssetsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ChangeInContractAssetsAndLiabilitiesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract Assets And Liabilities",
        "label": "Change In Contract Assets And Liabilities [Roll Forward]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ChangeInContractAssetsAndLiabilitiesRollForward",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right issued during the period may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Securities Called by Warrants or Rights, Number Issued",
        "terseLabel": "Number of shares into which warrant issued during period may be converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsNumberIssued",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_ClassOfWarrantOrRightSharesExchangedForWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares exchanged for warrants.",
        "label": "Class of Warrant or Right, Shares Exchanged for Warrants",
        "terseLabel": "Number of common shares exchanged for warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightSharesExchangedForWarrants",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_CollaborationAgreementNonrefundableExecutionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-refundable execution fee to be paid as part of a collaboration agreement.",
        "label": "Collaboration Agreement Nonrefundable Execution Fee",
        "terseLabel": "Collaboration Agreement Nonrefundable Execution Fee"
       }
      }
     },
     "localname": "CollaborationAgreementNonrefundableExecutionFee",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Collaboration agreements",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "xbrltype": "stringItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA and the Supply Agreement with Merck KGaA.",
        "label": "Collaboration And Commercial License Agreement And Supply Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA Agreement and Merck KGaA supply agreement"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Asana BioSciences, an existing partner.",
        "label": "Collaboration And Commercial License Agreement Asana Bio Sciences [Member]",
        "terseLabel": "Asana BioSciences"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementAsanaBioSciencesMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Collaboration and Commercial License Agreement with Merck KGaA.",
        "label": "Collaboration And Commercial License Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA"
       }
      }
     },
     "localname": "CollaborationAndCommercialLicenseAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_CollaborationArrangementIndividualCommercialMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual commercial milestones per target.",
        "label": "Collaboration Arrangement Individual Commercial Milestones Target Number",
        "terseLabel": "Number of individual commercial milestones"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualCommercialMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual development milestones per target.",
        "label": "Collaboration Arrangement Individual Development Milestones Target Number",
        "terseLabel": "Number of individual development milestones per target"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualDevelopmentMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual regulatory milestones per target.",
        "label": "Collaboration Arrangement Individual Regulatory Milestones Target Number",
        "terseLabel": "Number of individual regulatory milestones per target"
       }
      }
     },
     "localname": "CollaborationArrangementIndividualRegulatoryMilestonesTargetNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement.",
        "label": "Collaboration Arrangements, Additional Payment to Obtain a Development and Commercial License",
        "terseLabel": "Amount of additional fees receivable when target is designated and commercial license to target is granted"
       }
      }
     },
     "localname": "CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsCostsBilled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs billed during the period under terms of agreement.",
        "label": "Collaboration Arrangements, Costs Billed",
        "terseLabel": "ASC 808 costs billed to Takeda"
       }
      }
     },
     "localname": "CollaborationArrangementsCostsBilled",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail": {
       "order": 1.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum development milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Development Milestones",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestones",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the next potential development milestone the company will be eligible to receive.",
        "label": "Collaboration Arrangements, Development Milestones Payment Receivable, Next Milestone",
        "terseLabel": "Next potential development milestone payment eligible to receive"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the development milestone payment received by the entity.",
        "label": "Collaboration Arrangements, Development Milestones Payment Received",
        "terseLabel": "Amount of development milestone payment received"
       }
      }
     },
     "localname": "CollaborationArrangementsDevelopmentMilestonesPaymentReceived",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsDurationToTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time before which agreement will be terminated due to counter party serving prior written notice, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Duration to Termination",
        "terseLabel": "Period of time until agreement terminated"
       }
      }
     },
     "localname": "CollaborationArrangementsDurationToTermination",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsMaximumAggregateMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone the Company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Maximum Aggregate Milestones",
        "terseLabel": "Aggregate milestones",
        "totalLabel": "Aggregate milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsMaximumAggregateMilestones",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsMilestonePaymentReceivableNextMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the next potential milestone the company will be eligible to receive.",
        "label": "Collaboration Arrangements, Milestone Payment Receivable, Next Milestone",
        "terseLabel": "Next potential milestone payment eligible to receive"
       }
      }
     },
     "localname": "CollaborationArrangementsMilestonePaymentReceivableNextMilestone",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsPriorWrittenTerminationNoticeDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time before which prior written notice needs to be served for termination of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Prior Written Termination Notice, Duration",
        "terseLabel": "Prior written notice for termination period"
       }
      }
     },
     "localname": "CollaborationArrangementsPriorWrittenTerminationNoticeDuration",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsRegulatoryMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail": {
       "order": 2.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum regulatory milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Regulatory Milestones",
        "terseLabel": "Regulatory milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsRegulatoryMilestones",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsSalesMilestones": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail": {
       "order": 3.0,
       "parentTag": "mrsn_CollaborationArrangementsMaximumAggregateMilestones",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum sales milestone amount the company is entitled to receive under terms of the agreement.",
        "label": "Collaboration Arrangements, Sales Milestones",
        "terseLabel": "Sales milestones"
       }
      }
     },
     "localname": "CollaborationArrangementsSalesMilestones",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time following effective termination date in which development costs were equally shared with counterparty under the terms of the agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Collaboration Arrangements, Shared Development Costs Effective Following Termination Date, Period",
        "terseLabel": "Period of shared development costs following effective termination date"
       }
      }
     },
     "localname": "CollaborationArrangementsSharedDevelopmentCostsEffectiveFollowingTerminationDatePeriod",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_CollaborationArrangementsTargetsDesignatedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targets designated as of balance sheet date.",
        "label": "Collaboration Arrangements, Targets Designated, Number",
        "terseLabel": "Number of targets designated"
       }
      }
     },
     "localname": "CollaborationArrangementsTargetsDesignatedNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number",
        "label": "Collaboration Arrangements, Targets Designated, Service Obligations Completed, Number",
        "terseLabel": "Number of service obligations completed of designated targets"
       }
      }
     },
     "localname": "CollaborationArrangementsTargetsDesignatedServiceObligationsCompletedNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborativeArrangementsExclusiveTargetsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of exclusive targets entity provided right to develop under terms of agreement as of balance sheet date.",
        "label": "Collaborative Arrangements, Exclusive Targets, Number",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "CollaborativeArrangementsExclusiveTargetsNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_CollaborativeArrangementsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payment received during the period.",
        "label": "Collaborative Arrangements, Upfront Payment",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementsUpfrontPayment",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ComputerEquipmentAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to computer equipment and office equipment.",
        "label": "Computer Equipment and Office Equipment [Member]",
        "terseLabel": "Computer equipment and office equipment"
       }
      }
     },
     "localname": "ComputerEquipmentAndOfficeEquipmentMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ContractWithCustomerLiabilityDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Decrease",
        "terseLabel": "Deferred revenue, deductions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDecrease",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ContractWithCustomerLiabilityIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability, Increase",
        "terseLabel": "Deferred revenue, additions"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncrease",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ContractualLifeOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The contractual life of warrants.",
        "label": "Contractual Life of Warrants",
        "terseLabel": "Contractual life of warrants"
       }
      }
     },
     "localname": "ContractualLifeOfWarrants",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_DebtCovenantPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Period",
        "label": "Debt Covenant, Period [Axis]",
        "terseLabel": "Debt Covenant, Period [Axis]"
       }
      }
     },
     "localname": "DebtCovenantPeriodAxis",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_DebtCovenantPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Period",
        "label": "Debt Covenant, Period [Domain]",
        "terseLabel": "Debt Covenant, Period [Domain]"
       }
      }
     },
     "localname": "DebtCovenantPeriodDomain",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_DebtInstrumentAdditionalRateInEventOfDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional percentage of rate in event of default under debt instrument.",
        "label": "Debt Instrument Additional Rate in Event of Default",
        "terseLabel": "Additional rate in event of default"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalRateInEventOfDefault",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_DebtInstrumentCarryingAmountNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt, classified as noncurrent. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount, Noncurrent",
        "terseLabel": "Total debt, net of current portion"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountNoncurrent",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DebtInstrumentPrepaymentFeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of prepayment fee under debt instrument.",
        "label": "Debt Instrument Prepayment Fee Percent",
        "terseLabel": "Prepayment fee percentage"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercent",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_DeferredTaxAssetsDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation.",
        "label": "Deferred Tax Assets, Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciation",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DeferredTaxAssetsLicensedTechnology": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from licensed technology.",
        "label": "Deferred Tax Assets, Licensed Technology",
        "terseLabel": "Licensed technology"
       }
      }
     },
     "localname": "DeferredTaxAssetsLicensedTechnology",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DefinedContributionPlanEligibleAgeToParticipate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age for employees to be eligible to participate in defined contribution plan.",
        "label": "Defined Contribution Plan, Eligible Age to Participate",
        "terseLabel": "Eligible age to participate"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibleAgeToParticipate",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum annual amount the employer contributes per employee to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Employer Contribution Per Employee, Amount",
        "terseLabel": "Maximum annual amount employer contributes per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualEmployerContributionPerEmployeeAmount",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_DevelopmentAndRegulatoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and Regulatory",
        "label": "Development and Regulatory [Member]",
        "terseLabel": "Development and Regulatory"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.",
        "label": "Development Collaboration And Commercial License Agreement Takeda [Member]",
        "terseLabel": "XMT-1522 agreement"
       }
      }
     },
     "localname": "DevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ExchangeWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security, two, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount with an exercise price of $0.0001 per share. Referred to as the \"Exchange Warrants\".",
        "label": "Exchange Warrants [Member]",
        "terseLabel": "Exchange Warrants"
       }
      }
     },
     "localname": "ExchangeWarrantsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ExistingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Credit Facility",
        "label": "Existing Credit Facility [Member]",
        "terseLabel": "Existing Credit Facility"
       }
      }
     },
     "localname": "ExistingCreditFacilityMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of common stock retired in exchange for issuance of common stock warrant.",
        "label": "Fair Value of Common Stock Retired in Exchange For Issuance of Common Stock Warrant",
        "terseLabel": "Fair value of common stock retired in exchange for issuance of common stock warrant"
       }
      }
     },
     "localname": "FairValueOfCommonStockRetiredInExchangeForIssuanceOfCommonStockWarrant",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_FinalPaymentAsPercentageOfOriginalPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the final payment as percentage of original principal amount.",
        "label": "Final Payment as Percentage of Original Principal Amount",
        "terseLabel": "Final payment as percentage of original principal amount"
       }
      }
     },
     "localname": "FinalPaymentAsPercentageOfOriginalPrincipalAmount",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance lease cost recognized by lessee for lease contract.",
        "label": "Finance Lease, Cost",
        "totalLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_FinanceLeaseTotalCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Total Cost",
        "label": "Finance Lease, Total Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "FinanceLeaseTotalCostAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_FinanceLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Leases",
        "label": "Finance Leases [Member]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeasesMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_IncomeTaxesNumberOfAuditsInProgress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of federal and (or) state audits in progress.",
        "label": "Income Taxes, Number of Audits in Progress",
        "terseLabel": "Number of federal or state audits in progress"
       }
      }
     },
     "localname": "IncomeTaxesNumberOfAuditsInProgress",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_IncomeTaxesNumberOfStateJurisdictions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of state jurisdictions in which entity files income tax returns.",
        "label": "Income Taxes, Number of State Jurisdictions",
        "verboseLabel": "Number of state jurisdictions in which entity files income tax returns"
       }
      }
     },
     "localname": "IncomeTaxesNumberOfStateJurisdictions",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in operating lease assets.",
        "label": "Increase (Decrease) in Operating Lease Assets",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in operating lease liabilities.",
        "label": "Increase (Decrease) in Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Increase in ROU asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_InducementAwardProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Award Program",
        "label": "Inducement Award Program [Member]",
        "terseLabel": "Inducement Award Program"
       }
      }
     },
     "localname": "InducementAwardProgramMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_JanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen",
        "label": "Janssen [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_JointResearchCommitteeServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents joint research committee services.",
        "label": "Joint Research Committee Services [Member]",
        "terseLabel": "Joint research committee services"
       }
      }
     },
     "localname": "JointResearchCommitteeServicesMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LeasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Leases [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LeasesLineItems",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LeasesSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Supplemental Cash Flow Information",
        "label": "Leases, Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "LeasesSupplementalCashFlowInformationAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LeasesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about leases.",
        "label": "Leases [Table]",
        "terseLabel": "Leases [Table]"
       }
      }
     },
     "localname": "LeasesTable",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LendersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenders",
        "label": "Lenders [Member]",
        "terseLabel": "Lenders"
       }
      }
     },
     "localname": "LendersMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LesseeFinanceLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee, Finance Leases [Abstract]",
        "terseLabel": "Finance leases:"
       }
      }
     },
     "localname": "LesseeFinanceLeasesAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental balance sheet information related to leases.",
        "label": "Lessee, Operating And Finance Lease, Supplemental Balance Sheet Information [Table Text Block]",
        "terseLabel": "Schedule of supplemental balance sheet information related to leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalBalanceSheetInformationTableTextBlock",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating And Finance Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Schedule of supplemental cash flow information related to leases"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_LesseeOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Lessee Operating Leases [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LesseeOperatingLeasesAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_LicenseAgreementMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Payments",
        "label": "License Agreement, Milestone Payments [Member]",
        "terseLabel": "License Agreement, Milestone Payments"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAgreementUpfrontPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Upfront Payments",
        "label": "License Agreement, Upfront Payments [Member]",
        "terseLabel": "License Agreement, Upfront Payments"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPaymentsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and related research and development services, including Phase 1 development and transfer certain materials and know how related to the Company's manufacturing processes.",
        "label": "License And Related Research And Development Services And Development And Transfer [Member]",
        "terseLabel": "License and related research and development services, including phase 1 development and transfer certain materials and know how"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesAndDevelopmentAndTransferMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for fifth target.",
        "label": "License And Related Research And Development Services Target Five [Member]",
        "terseLabel": "License and corresponding research and development services, fifth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetFiveMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for fourth target.",
        "label": "License And Related Research And Development Services Target Four [Member]",
        "terseLabel": "License and corresponding research and development services, fourth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetFourMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for third and sixth designated target.",
        "label": "License And Related Research And Development Services Target Three And Six [Member]",
        "terseLabel": "License and corresponding research and development services, third and sixth target"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetThreeAndSixMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the license and corresponding research and development services for the first and second designated targets.",
        "label": "License And Related Research And Development Services Targets One And Two [Member]",
        "terseLabel": "License and corresponding research and development services, first and second targets"
       }
      }
     },
     "localname": "LicenseAndRelatedResearchAndDevelopmentServicesTargetsOneAndTwoMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LimitedServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited services.",
        "label": "Limited Services [Member]",
        "terseLabel": "Limited services"
       }
      }
     },
     "localname": "LimitedServicesMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_LineOfCreditFacilityTrancheAvailabilityDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period within which the term loan tranche will be available after achieving the tranche loan milestones.",
        "label": "Line of Credit Facility, Tranche Availability Duration",
        "terseLabel": "Tranche availability duration (in days)"
       }
      }
     },
     "localname": "LineOfCreditFacilityTrancheAvailabilityDuration",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments, which had not been received, included in the estimated transaction price.",
        "label": "Milestone Payment Not Received, Included in Estimated Transaction Price",
        "terseLabel": "Milestone Payment Not Received, Included in Estimated Transaction Price"
       }
      }
     },
     "localname": "MilestonePaymentNotReceivedIncludedInEstimatedTransactionPrice",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_NewCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility",
        "label": "New Credit Facility [Member]",
        "terseLabel": "New Credit Facility"
       }
      }
     },
     "localname": "NewCreditFacilityMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche Five",
        "label": "New Credit Facility, Tranche Five [Member]",
        "terseLabel": "New Credit Facility, Tranche Five"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheFiveMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche Four",
        "label": "New Credit Facility, Tranche Four [Member]",
        "terseLabel": "New Credit Facility, Tranche Four"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheFourMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche One",
        "label": "New Credit Facility, Tranche One [Member]",
        "terseLabel": "New Credit Facility, Tranche One"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheOneMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche Six",
        "label": "New Credit Facility, Tranche Six [Member]",
        "terseLabel": "New Credit Facility, Tranche Six"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheSixMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche Three",
        "label": "New Credit Facility, Tranche Three [Member]",
        "terseLabel": "New Credit Facility, Tranche Three"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheThreeMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NewCreditFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Credit Facility, Tranche Two",
        "label": "New Credit Facility, Tranche Two [Member]",
        "terseLabel": "New Credit Facility, Tranche Two"
       }
      }
     },
     "localname": "NewCreditFacilityTrancheTwoMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_NumberOfVotesPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes for each shares held.",
        "label": "Number of Votes Per Common Share",
        "terseLabel": "Number of votes per common share"
       }
      }
     },
     "localname": "NumberOfVotesPerCommonShare",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_OfficeSpaceCambridgeMaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space in Cambridge, MA under operating lease.",
        "label": "Office Space Cambridge Ma [Member]",
        "terseLabel": "Office space, Cambridge, MA, Leased"
       }
      }
     },
     "localname": "OfficeSpaceCambridgeMaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_OfficeSpaceExpansionCambridgeMaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space Expansion Cambridge Ma",
        "label": "Office Space Expansion Cambridge Ma [Member]",
        "terseLabel": "Office Space Expansion Cambridge Ma"
       }
      }
     },
     "localname": "OfficeSpaceExpansionCambridgeMaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_OperatingLeaseTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of allowance granted and reimbursable by the landlord to a tenant to entice tenant to move into landlord's building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Operating Lease, Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "OperatingLeaseTenantImprovementAllowance",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws not subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws subject to expiration dates.",
        "label": "Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs After October 29, 2023 but Before October 1, 2026",
        "label": "Prepayment Occurs After October 29, 2023 but Before October 1, 2026 [Member]",
        "terseLabel": "Prepayment Occurs After October 29, 2023 but Before October 1, 2026"
       }
      }
     },
     "localname": "PrepaymentOccursAfterOctober292023ButBeforeOctober12026Member",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_PrepaymentOccursBetweenOctober292022AndOctober292023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs Between October 29, 2022 and October 29, 2023",
        "label": "Prepayment Occurs Between October 29, 2022 and October 29, 2023 [Member]",
        "terseLabel": "Prepayment Occurs Between October 29, 2022 and October 29, 2023"
       }
      }
     },
     "localname": "PrepaymentOccursBetweenOctober292022AndOctober292023Member",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_PrepaymentOccursPriorToOctober292022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Occurs Prior To October 29, 2022",
        "label": "Prepayment Occurs Prior To October 29, 2022 [Member]",
        "terseLabel": "Prepayment Occurs Prior To October 29, 2022"
       }
      }
     },
     "localname": "PrepaymentOccursPriorToOctober292022Member",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ProceedsFromDebtNetIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow (outflow) during the period from borrowings in aggregate debt. Includes proceeds from short-term and long-term debt and delayed cash payments of issuance costs.",
        "label": "Proceeds From Debt, Net Issuance Costs",
        "terseLabel": "Proceeds from issuance of debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetIssuanceCosts",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net proceeds from the additional capital contribution to the entity after deducting fees, commissions and other expenses.",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Stock Issuance Costs",
        "terseLabel": "Proceeds from stock issuance, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfStockIssuanceCosts",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited. Also includes the Development Collaboration and Commercial License Agreement for the development and commercialization of XMT-1522 with Takeda Pharmaceutical Company Limited.",
        "label": "Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement And Development Collaboration And Commercial License Agreement Takeda [Member]",
        "terseLabel": "2016 Restated Tokeda agreement and XMT-1522 agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementAndDevelopmentCollaborationAndCommercialLicenseAgreementTakedaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the 2016 Restated Research Collaboration and Commercial License Agreement with Takeda Pharmaceutical Company Limited.",
        "label": "Research Collaboration And Commercial License Agreement Takeda2016 Restated Agreement [Member]",
        "terseLabel": "2016 Restated Tokeda agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndCommercialLicenseAgreementTakeda2016RestatedAgreementMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_RevenueCollectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which entity receives payment upon billing.",
        "label": "Revenue, Collection Period",
        "terseLabel": "Billing term"
       }
      }
     },
     "localname": "RevenueCollectionPeriod",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrsn_RevenueRemainingPerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Revenue, Remaining Performance Obligation, Number",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationNumber",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "mrsn_RevenueTransactionPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price which represents the amount of consideration the entity expects to receive for transfer of goods and services. Amount is net of estimated fees associated with research and development activities.",
        "label": "Revenue, Transaction Price, Amount",
        "terseLabel": "Revenue, transaction price, amount"
       }
      }
     },
     "localname": "RevenueTransactionPriceAmount",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_RightsToFutureTechnologicalImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents rights to future technological improvements.",
        "label": "Rights To Future Technological Improvements [Member]",
        "terseLabel": "Rights to future technological improvements"
       }
      }
     },
     "localname": "RightsToFutureTechnologicalImprovementsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_SaleOfStockRemainingAmountUnsoldAndAvailableForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of remaining shares of common stock available for sale under the program.",
        "label": "Sale of Stock, Remaining Amount Unsold and Available for Sale",
        "terseLabel": "Value of shares available for sale"
       }
      }
     },
     "localname": "SaleOfStockRemainingAmountUnsoldAndAvailableForSale",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of estimated useful life of property and equipment"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be added annually to the plan on the first day of the fiscal year.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Maximum Annual Increase Shares",
        "terseLabel": "Maximum annual increase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAnnualIncreaseShares",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be cumulatively issued annually in accordance with the plan, as a percentage of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Outstanding Stock Maximum, Cumulative Annual Increase",
        "terseLabel": "Cumulative annual increase in number of shares issuable, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximumCumulativeAnnualIncrease",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrsn_StockIncentivePlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2007 Stock incentive plan.",
        "label": "Stock Incentive Plan 2007 [Member]",
        "terseLabel": "2007 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2007Member",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_StockIncentivePlan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2017 Stock incentive plan.",
        "label": "Stock Incentive Plan 2017 [Member]",
        "terseLabel": "2017 Plan"
       }
      }
     },
     "localname": "StockIncentivePlan2017Member",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_StockIssuanceDiscountsAndCommissionsOnTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounts and commissions deducted from cash proceeds received on stock transaction.",
        "label": "Stock issuance, Discounts And Commissions On Transaction",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "StockIssuanceDiscountsAndCommissionsOnTransaction",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockIssuanceProgramAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock shares authorized to be issued under the program.",
        "label": "Stock Issuance Program, Authorized Amount",
        "terseLabel": "Amount of shares authorized to be offered and sold"
       }
      }
     },
     "localname": "StockIssuanceProgramAuthorizedAmount",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period and exercise of common stock warrant in exchange for common stock",
        "label": "Stock Issued During Period, Shares Of Common Stock Warrants In Exchange For Common Stock Exercised",
        "terseLabel": "Exercise of common stock warrant in exchange for common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockWarrantsInExchangeForCommonStockExercised",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued as a result of the exercise of stock options and warrants.",
        "label": "Stock Issued During Period, Shares, Stock Options and Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares, Warrants Exercised",
        "terseLabel": "Common stock issued upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options and warrants.",
        "label": "Stock Issued During Period, Value, Stock Options and Warrants Exercised",
        "terseLabel": "Exercise of stock options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock that have been retired in exchange for common stock warrant.",
        "label": "Stock Retired During Period, Exchanged For Common Stock Warrant, Shares",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant (in shares)"
       }
      }
     },
     "localname": "StockRetiredDuringPeriodExchangedForCommonStockWarrantShares",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_StockRetiredDuringPeriodExchangedForCommonStockWarrantValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been retired in exchange for common stock warrant.",
        "label": "Stock Retired During Period, Exchanged for Common Stock Warrant, Value",
        "negatedLabel": "Retirement of common stock in exchange for common stock warrant"
       }
      }
     },
     "localname": "StockRetiredDuringPeriodExchangedForCommonStockWarrantValue",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrsn_SupplyAgreementMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Supply Agreement with Merck KGaA.",
        "label": "Supply Agreement Merck Kgaa [Member]",
        "terseLabel": "Merck KGaA supply agreement"
       }
      }
     },
     "localname": "SupplyAgreementMerckKgaaMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_SynaffixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Synaffix",
        "label": "Synaffix [Member]",
        "terseLabel": "Synaffix"
       }
      }
     },
     "localname": "SynaffixMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_ThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third Parties",
        "label": "Third Parties [Member]",
        "terseLabel": "Third Parties"
       }
      }
     },
     "localname": "ThirdPartiesMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_WarrantsAndShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and share-based payment awards.",
        "label": "Warrants And Share Based Payments [Member]",
        "terseLabel": "Warrants and share-based payment awards"
       }
      }
     },
     "localname": "WarrantsAndShareBasedPaymentsMember",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrsn_WarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Warrants, Exercised In Period",
        "terseLabel": "Issuance of common upon exercise of warrant (in shares)"
       }
      }
     },
     "localname": "WarrantsExercisedInPeriod",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mrsn_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrsn_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.mersana.com/20211231",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r256",
      "r313",
      "r314",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r520",
      "r522",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r256",
      "r313",
      "r314",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r520",
      "r522",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r181",
      "r294",
      "r297",
      "r476",
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r181",
      "r294",
      "r297",
      "r476",
      "r519",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r216",
      "r256",
      "r299",
      "r313",
      "r314",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r520",
      "r522",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r216",
      "r256",
      "r299",
      "r313",
      "r314",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r520",
      "r522",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r23",
      "r507",
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails",
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r53",
      "r54",
      "r62",
      "r63",
      "r64",
      "r113",
      "r114",
      "r115",
      "r410",
      "r523",
      "r524",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r352",
      "r353",
      "r354",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Vesting of restricted stock units, net of employee tax obligation"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition",
        "terseLabel": "Purchase of common stock under ESPP"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r316",
      "r318",
      "r358",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r212",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of common stock warrant in exchange for retirement of common stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r318",
      "r348",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense included in Total operating expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r92",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r108",
      "r164",
      "r173",
      "r179",
      "r186",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r404",
      "r411",
      "r422",
      "r461",
      "r463",
      "r490",
      "r508"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r51",
      "r108",
      "r186",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r404",
      "r411",
      "r422",
      "r461",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r319",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r2",
      "r112",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r31",
      "r94"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r11",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r11",
      "r95",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r87",
      "r94",
      "r100"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash per statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r87",
      "r423"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Contract with Customer, Asset and Liability [Abstract]",
        "terseLabel": "Revenue recognized in the period from:"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r105",
      "r108",
      "r129",
      "r130",
      "r135",
      "r138",
      "r140",
      "r146",
      "r147",
      "r148",
      "r186",
      "r201",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r254",
      "r255",
      "r259",
      "r263",
      "r422",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares of common stock into which warrants may be converted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r397",
      "r398",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r199",
      "r495",
      "r513"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments (Note\u00a013)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 175,000,000 shares authorized; 73,709,056 and 68,841,288\u00a0shares issued and outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r69",
      "r498",
      "r516"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r151",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Financial instruments with off-balance sheet risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r102",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of changes in the balances of our contract assets and liabilities and recognized revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r279",
      "r281",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r279",
      "r280",
      "r295"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Deferred revenue, balance at end of period",
        "periodStartLabel": "Deferred revenue, balance at beginning of period",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r295"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amounts included in the contract liability at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails",
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r230",
      "r237",
      "r238",
      "r240",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r107",
      "r111",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r243",
      "r244",
      "r245",
      "r246",
      "r436",
      "r491",
      "r493",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r17",
      "r241",
      "r493",
      "r506"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Debt outstanding",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails",
      "http://www.mersana.com/role/DebtFuturepaymentsDetails",
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r43",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44",
      "r107",
      "r111",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r243",
      "r244",
      "r245",
      "r246",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r107",
      "r111",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r239",
      "r243",
      "r244",
      "r245",
      "r246",
      "r271",
      "r274",
      "r275",
      "r276",
      "r433",
      "r434",
      "r436",
      "r437",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r226",
      "r433",
      "r437"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Accretion related to final payment"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Debt financing costs in accrued expenses"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary.",
        "label": "Deferred Compensation, Share-based Payments [Member]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedPaymentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r35",
      "r226",
      "r435"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      },
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Debt financing costs, net of accretion",
        "verboseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r18",
      "r19",
      "r376",
      "r492",
      "r505"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r382",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails",
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesComponentsofdeferredtaxassetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefit expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Percentage employer matches of the employee's percentage contribution matched"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum contribution by employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r92",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r92",
      "r162"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r70",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126",
      "r129",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r418",
      "r419",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders \u2014 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "verboseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r70",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r138",
      "r139",
      "r140",
      "r143",
      "r144",
      "r418",
      "r419",
      "r499",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders \u2014 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r109",
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax computed at federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Impact of ownership shift"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r369",
      "r391"
     ],
     "calculation": {
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "General business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average amortization period of unrecognized stock compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r145",
      "r187",
      "r270",
      "r277",
      "r352",
      "r353",
      "r354",
      "r387",
      "r388",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r523",
      "r524",
      "r525",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r441",
      "r448",
      "r456"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "mrsn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r443",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r439",
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Other liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance lease, liability, current, statement of financial position"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments on finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance lease, liability, noncurrent, statement of financial position"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r442",
      "r450"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payments under finance lease obligations",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r441",
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r441",
      "r448",
      "r456"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "mrsn_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "verboseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r92",
      "r247",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r195",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r370",
      "r374",
      "r381",
      "r389",
      "r392",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r124",
      "r125",
      "r163",
      "r368",
      "r390",
      "r393",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r366",
      "r367",
      "r374",
      "r375",
      "r380",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r91",
      "r474"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r91",
      "r450"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r66",
      "r161",
      "r432",
      "r435",
      "r500"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r75",
      "r234",
      "r242",
      "r245",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails",
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r89",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r160"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails",
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Finance lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments under operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40",
      "r108",
      "r174",
      "r186",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r405",
      "r411",
      "r412",
      "r422",
      "r461",
      "r462"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r108",
      "r186",
      "r422",
      "r463",
      "r494",
      "r511"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42",
      "r108",
      "r186",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r405",
      "r411",
      "r412",
      "r422",
      "r461",
      "r462",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: Current portion of long-term-debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r111",
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r111",
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r111",
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r111",
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r111",
      "r200",
      "r232"
     ],
     "calculation": {
      "http://www.mersana.com/role/DebtFuturepaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.mersana.com/role/DebtComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "totalLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/DebtComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Estimated future principal payments"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtFuturepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r87",
      "r90",
      "r93"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r58",
      "r64",
      "r67",
      "r93",
      "r108",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r136",
      "r164",
      "r172",
      "r175",
      "r178",
      "r180",
      "r186",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r419",
      "r422",
      "r496",
      "r514"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r126",
      "r127",
      "r137",
      "r140",
      "r164",
      "r172",
      "r175",
      "r178",
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r128",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r449",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liability",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesFutureminimumleasepaymentsDetails",
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r444",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalcashflowinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesSupplementalbalancesheetinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carry-forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r41"
     ],
     "calculation": {
      "http://www.mersana.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r402",
      "r403",
      "r409"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r62",
      "r63",
      "r65",
      "r68",
      "r270",
      "r424",
      "r429",
      "r430",
      "r497",
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Payment of employee tax obligations related to vesting of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r76",
      "r78",
      "r185"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r319",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 25,000,000 shares authorized; 0 shares issued and outstanding at December\u00a031, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r80",
      "r351"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from purchases of common stock under ESPP"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r81",
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r76",
      "r77",
      "r185"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r80",
      "r351"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from the exercise of stock options (in dollars)",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r58",
      "r64",
      "r86",
      "r108",
      "r116",
      "r124",
      "r125",
      "r164",
      "r172",
      "r175",
      "r178",
      "r180",
      "r186",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r402",
      "r407",
      "r408",
      "r413",
      "r414",
      "r419",
      "r422",
      "r501"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r193",
      "r441",
      "r448"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r52",
      "r194",
      "r448"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "totalLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r12",
      "r192",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Total property and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Leasehold improvements, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r192"
     ],
     "calculation": {
      "http://www.mersana.com/role/PropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r194",
      "r463",
      "r502",
      "r512"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r194",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r12",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r303",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r303",
      "r458",
      "r460",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedTerseLabel": "Repayment of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r83",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross": {
     "auth_ref": [
      "r362",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r361",
      "r475",
      "r535"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Investments [Abstract]",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r100",
      "r528"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash included in other assets, noncurrent"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainageDeposit": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of assets, typically cash, provided to suppliers of goods in advance of receipt and acceptance, or services (such as research facilities, lawyers or consultants), which is held by such parties until the entity either effects full payment (including applying the retainer) or obtains release from liability.",
        "label": "Retainage Deposit",
        "verboseLabel": "Held by service provider"
       }
      }
     },
     "localname": "RetainageDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r277",
      "r355",
      "r463",
      "r510",
      "r526",
      "r527"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r187",
      "r352",
      "r353",
      "r354",
      "r387",
      "r388",
      "r417",
      "r523",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r158",
      "r159",
      "r171",
      "r176",
      "r177",
      "r181",
      "r182",
      "r183",
      "r293",
      "r294",
      "r476"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r103",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Expected recognition period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r451",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for financing lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r451",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]",
        "terseLabel": "Concentration of Credit Risk and Off-balance Sheet Risk"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesRisksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/AccruedexpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense by award type"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r318",
      "r347",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r318",
      "r347",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense as reflected in the Company\u2019s condensed consolidated statements of operations and comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of estimated future payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r34",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/PropertyandEquipmentDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "verboseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CommitmentsLicenseagreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r11",
      "r100",
      "r489",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r319",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r325",
      "r336",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions for estimating fair value of option awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r105",
      "r146",
      "r147",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r259",
      "r263",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r251",
      "r252",
      "r253",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule for number of common stock reserved for exercise of outstanding stock options and warrants"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Letter of credit for security deposit"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/LeasesNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested at end of period (in shares)",
        "periodStartLabel": "Unvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested at end of period (in dollars per share)",
        "periodStartLabel": "Unvested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "verboseLabel": "Vesting of restricted stock units, net of employee tax obligation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r327",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Number of shares outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r317",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails",
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails",
      "http://www.mersana.com/role/StockOptionsStockBasedCompensationExpenseDetails",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r319",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Accounting for Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r342",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term, Options, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares sold, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r101",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesNetoperatinglosscarryforwardsDetails",
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r105",
      "r108",
      "r129",
      "r130",
      "r135",
      "r138",
      "r140",
      "r146",
      "r147",
      "r148",
      "r186",
      "r201",
      "r205",
      "r206",
      "r207",
      "r210",
      "r211",
      "r254",
      "r255",
      "r259",
      "r263",
      "r270",
      "r422",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r49",
      "r62",
      "r63",
      "r64",
      "r113",
      "r114",
      "r115",
      "r117",
      "r123",
      "r125",
      "r145",
      "r187",
      "r270",
      "r277",
      "r352",
      "r353",
      "r354",
      "r387",
      "r388",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r430",
      "r523",
      "r524",
      "r525",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r145",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r21",
      "r22",
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockOptionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r270",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares sold (in shares)",
        "verboseLabel": "Issuance of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r270",
      "r277",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockOptionsActivityUnderStockOptionPlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r270",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r108",
      "r184",
      "r186",
      "r422",
      "r463"
     ],
     "calculation": {
      "http://www.mersana.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedBalanceSheets",
      "http://www.mersana.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r255",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r431",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r431",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r431",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r431",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.mersana.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
      "http://www.mersana.com/role/StockholdersEquityNarrativeDetails",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesTaxcreditcarryforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/CollaborationAgreementsNarrativeDetail",
      "http://www.mersana.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r365",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax position"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r149",
      "r150",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/IncomeTaxesValuationallowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/StockholdersEquityCommonStockDetails",
      "http://www.mersana.com/role/SummaryofSignificantAccountingPoliciesNetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r128",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders \u2014 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r126",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders \u2014 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.mersana.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r538": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r539": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r540": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r541": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r542": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r543": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r544": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r545": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r546": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001628280-22-004101-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-004101-xbrl.zip
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MT9N3Z/#XT9,GT2[(F>=)^7$'3@DN\0[,QOD_G^_ 9(RC49: :$UV84KXG.S
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MXO\_.#P<XY7@RZ1Y,UG6C?A%I=XL^^\EZ 2XY.(&WF_UX"7F7/NW/'[LW9+
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MM]I.<DO"^ND]:TW\]NRG/T!?8K3K7788S),S('?0%='^Q/9@F/[$QN]@8/4
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MQ+J,RZH66IG1:FQ0R7@UUR UP0E*C$4DQ4[4N&2Z1%-$[VK:(\A/^@@?KGZ
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MAFS>+ZG*.FJR26IJ0!,G4D!*U%'D.WW./:W[WO=B=04_))D*N F]KI <AZM
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MQV'2E-1Q<H?@J9S:+$TA\L/=L2Q7OVVP&Q)P,8.;E?C[YVR7 8XR9G3FF+)
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M4-/8NTINA*?D@]$A/C$PV.SN7%;-2&LL\-ATW6GE0KNZ]@WN"=48G N5W6Q
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M^]FS]=GC=8_+[5B"D=(RWPEXV<](<0W+L'"_=#^UV@]3XNF7N*,3UFR(-YF
MR1H#C5IHH[>WA["WQU9-<&L<SC_#1C[W);1&L3,DR0(W$ L19L$JF-'VC^K-
MXF/(9?H["MXP];7+[ZM]!/1 IBH&[\!(5DE\LC>N[1F7(<7^P D!&)!N6!B)
MY( =<*U(-_?WR>Q:S8M(281AN/>87<<"%TNF0:H=<_LYL\TY4]H[.S)?')K,
MF6GB [.Z]E:U3:O"Q$IGZG VL3OL]N.^Q7%?12%EO8\LL* C!L P;&@6ZDJ[
MN =9/"@(Q1$@$>3FE%PW=^O2:?RHFZ?Q[ZWVXG5?>]&OB?4UD1CR\%1BQ2:[
ML216690Y3:$A@I8GVG(I^R(>I#6>X+SL5UB=Z9Z6\(NTB1&FH>:(J?4)O:60
M/P9S+$C_QD0U#KV:@9*4U4"#6-/FL\(00N#L!2W\UA;"B B6>8)ZZ?@2+YC&
M'Z68T*5D_".L,G.=8Q%.M^G:?3<*++D $/O682O%-G8>GJI*X$6*3CD@S 7!
M+^=I<!O7F7M,!$$'L:H\V@8S9XKQ,,_DWAY/4#P6#E[%EPH=!F]:/YOI=ZS&
M1AGD,F.T#RFJINYE9MS,9Q16LS0^;ET1[*VK-,G1NDQ=DE8!7D0%R<J)'%3I
M\9G3:,,#E&HXJGV'58K$.-PU&+4Q>:B&V:AG1 U=)1;#;$#MK'\:]S_TO$L<
MI:4>)(9*UIZG$[U4IR!2YP:]9G_-6:MPB0]S++T,0&I] !HXW)J8C/&=]"-8
M+Y)JM(+/X1(I.ZST&4P5AGV5"-2I7CQO@-AIVX^]JP29% *8.[;+<]L7>-["
M1L"(*294,D_7&F6.M7*5.YJKF;Y.L1C7QKEVU3OPV]RL2LC>;FQ4@MOCMMG5
MA2")=*1#3WV9"(!20,R8B0\%[TO8NURFS7U ICI-@.R/E3R$UC;,;#:"5BAB
MB$DK2VGIFZ]N03WQP:4>#9F/DB(>;94VI\$ T1H^VU6W:ZD:2:;<%#T&.[A+
MRH(HTDHN*&-P1\S;0PP"M^ZKDSS]I-_>I%^M.3O=A=FNZ1AM@9RT3C+HOO.)
MPZI2^CQ55V&6ZQ(\O%,4?E+:X1!(,R.E;Y.4619)KI/ QGB] UVF*P0RXL,$
M48S[-N7,Y+G9/_'7^B+VD"UH*XBRQ"E"P*D-K9S36I*JWJ2W9](5]=TN&+9L
M8U;$M92D-D33CMO?()Q*<LFRB.(:6ZMBE06W-Z5MF9(61>X.)5]K*'M_>  '
MS'[HMS?T)=^D(Z/OI,9TN5Z?&'LR%F4"(-TTKMI^4C$QW\2@XH+$0Q07KI%M
M_?7/[_9^_-O?X#\'/[I *_H2N6Q[0]J:(879M)#0%#@$&##LB 65TFQ/.*=V
M^.)1 3#]5-G>5&'0?1?F!_&!8D"=ZSX59LJEFE:SYU$ AJOC6=%%UXW;,F/:
ML4WL%3%1MXFWLS]@7:@4CY.K@&+U?)$F<=;WF4M),OY>N TXK5-((:Y$BEDA
M)\_@<((T@MA8F+M8&VQ:H9MU=^4M!X_4<L6<^ASC%??5VWO[ K8;'24Z5E&
MHC?>J6AYGII0]!%+!Z&\E/"H-JM]8O@(%Q_S)'-/*L?1S!5Q$"57Q/K/[<B#
M3RHN!<3L"4V"#5A!#O>H2_LYI<7TQAN$2+64*48;;.$TC78_[[<V[SE!9<OG
MN[  8-+509;[-E/:9$^2/8'!I"IT8?+D%X,;L2^_%+_,93N__\T"9*Q0J*IQ
M)&DU7F^<,G[Y(87 F#I8-X%/&FY6B&0I@EP.%0C9%$+ :9"%IA8+%3-?H&!*
M$!(#J":--PD]/-G" O@^1>*L;(:5;F#F\/ X##AKG061K>VJO@*'GY%R8(%U
M:ES+2&XKY@2RK# $6M5?]M-ON]/OH4/*=,<?8)>!I?D>_>)W8 WH5H\\*N5#
M!\QT_DW,]'Z9CWBN SM_T9]1CH)*9<'G6!214"+)NE>BX^J7KFW91%D(H@NF
MT?.G?KO!US11HPQC=:HKXV]%-ZV&IJ,NVBRB2=>X%[DJL>PRAC<#.;N8\GLL
MF 3ODDCQ)'V*^:H@RQ+XGO%XJ?E^ZNC4N2>9TE%6!A;5<#"U17;,E'CZ%7?*
M4>L+=55$HJ0N1SBB&G#1 70,W7MW<.!6"PTD XO/9B'US $63HNU5E&%GR"%
M7D6U566NDG*(&AV$9S?'2M];%CE6!1(?G> 9-<<KBJ2:\R<)WME>Y4M*=]))
MZ!E!(J7-?"#?&0V\:WPKS42(U>*'AZ0J" :BA"KQ;DY"H22D=+I[KR#8K][L
M7IR%GE"!S)GF$8DQ<F^JX*U45A9O/>0WR),<U1*YYCTD]3[BR%UX[W&)/0RC
MB$99CA0[?WGEPZ32_QON[@Y\0P"A.XN2I%4U6L/-!R8MO>D;)BX<8_<$+W'K
M!&8-OEG(E9SX%5)VR+>N6*,.:A#KUU)CTS4Q'W[K,)EI1O,\^*Q!B&56QG@S
M\9M,E]I:5*;0<*"*OB<DBTBJ2 PET#"=NL112&8$FQ0NC<P)^/BV!QMP2;6$
M@%EG"'!9)BDL"1YK(#':N\H1CU5B/"  TPTT#T5PKI''6>2@:9!K!\N^R$!R
MO&_Z(H/'%7BH0C+NIG'<^3Q@H?$XEG@GTPS2I&9P,4J;Z+5S7G!0&&\Q(W(D
M4BNGB2*+;ZK^6R B6E:?E#=+1#PR&:\O5V5Y&@K@R58@"TF374-P763 56W!
M<<EZG"@ULMX$:<X_VEDWOYZ\CR58OXV=?9+464N*[PY'9/;-7H"791,/*K5/
M L@P%N2 8'"8KVION.$2U=$GI:H1>_/H8B6Q,5F;A2PV0#<(UVU?N*:85HA6
M<F=K<7Y4C?;5WZ2]P<V;D[QF0%!Q>1/?6Q'=/JW<QG2-;T;$XJPO#_; O0[+
M,'E'=#>Q;E.*((Z7"_S&@2VT_Y#!UB)DO8:<M=J%% ET;DX.$W\ER<8"MKFH
M#J/B]ET'-VAD,Q7>R,X(#JI:,>64T$V1-J%]78L^IA=I;)5.?&;P6MD"^ADG
M)K2EU@I%PBU8D2+2;-(*..A'G"Z(5&[A]H[_0@2M*M/2Q*)[T/!2#E.6(Q;@
MZ"#0!?5I SU9:ZY3**#'][\%;/+]X7-KAT^M]-"10R<.LG2+$:%X*)21]O+)
MG\T:DHC4FB5XA_!,!+,OPL^X)\)>@=4G\)\;=<UD@5;/W%LFZ'B:;_ 1L*"%
M$4S9@65^KO(+2WS-[.&]A6_-PB].)H]*'E8AVQS#&INL8<&[@#-*RBL[''/A
M-&N)R4VDX<U+-](@!DM"\3I8T4=AMV<I6AO@$@_173 906_4DJLFV$;X;FPM
M1PB8S0]!&;!Q%BEOY+&B0SL:V,XUG(1OB/W/Y&0'R.H*CMLU<J/3O=C,IO0A
M.FH+M+CR4SA.I#)R$1<ECVBJV 6\"F)XX[D32HN"VTPSC(H !MYYE4+KB!&=
M8R-:%ZDU>.)%R4RRR>RUEQ@Y.52B_0QHMK<CP855@CI**'D+GIZ!MTBAQ8"K
MK#!5GJJV]PPP"IX)*IZ<]=0]A4Q5?JM47'80X_G]VF@93NT=X>GP*[I0>$:-
M"VAZ>X8#>66\4,H]ET0!L 7(+9JD2]WEK@LL.E?@O#$/_YK/ASQL]"ASJ\&P
M/2K2+S9?NMB$&85&3YQB]2ZL.;)-N37TI3 :&-@DA(D)9OPK^$=*(!A:\/7J
M"CW]7+G3NLA-H$*@'8%!4E0TT'&28<K@<PCG!K1X"MG^(B';R]O$^QFKUG&1
M!F<M0^-UX[C[',,=E!!5)8 H%<+@S^QF:PO*Y[2L<.-^ 9?Q'4JN[[WSRX6?
M4S[YZ]G>U!L5E0RS@_>;]=;F3R7FW)&ITU8I\[8?^6V-_/M@QNC&]YU)E=9'
MW=L?OMH)^M*H[8WZ<2<.<>21,Q1F.!EZ[Y&%@C:AM+CR1G/PL$P=L,YI@0^%
M^4>N3\?866\46S,*%F&%HS3< %.[A QPI28D$_";FF9A)Y UCP7&:^Y WIP>
MLUOLA+KE,3(0VSO&U@ND;N8ZSU=__?.KMS_^]<\OW_#_W=[>#F-UNX;+%N!T
MP6'4K\_&+"G2F1J6NZ"?DG]T2I)XV0<^1G9@OE%061]K,4YKHL0,4Y^+M*U)
M_FC&(TX'8I@-:USB_!H.(^9T#'9HSS>KB.HY9FG!)P0*[ XHJRKY-A6D48C1
M7G@DI='P!@:(CU?\HM7>CHDF"X$-4^=KS!)%2N\KBW)=/U\^<RY?I4J_,44M
M+ 6 >RZJE'+OFUO@[3 NI/Z+L"-!LR=I>$5C:U_<X9V"]B"8 L]EYED<"<*F
MA',$,45YN()N,-FEDJDX#-I8KK*FN \\6G,/X,#-4%([, E(N$>8ZK@8'A,_
MI EBD )O<AVD/3[U@29U][C.%["2TU1&>!W8;"KT?OBG46I].=Q_]3^]0[X]
MFZ@4LG3!%MB9J +7 U.)4Y&1ZM'L#VH9E@>L"[9!?H CMU)2MM>EKYOR%NUZ
MY+#<I$S_EO?@^"W;4L%QXP[511!E+<6JC;BY5Z5_,GR8Z/"EI(MGF50MPI=^
M;>2E ^]0,.'PNK8PL!LGQ3[SLS63_K=PJ,.5:3#KS"$I)G0;K=RF+'8F;:SF
M/$JDCW0RY^6RPC8Y(X$<@N,8_7E*81)",**S!>=+/'3BD1_?.534BFQQ&ND+
M$:8*D[#G@M<P[;<]3+M?:ZI-^&DT^M"1]>5*Q1C/B]8.Y)7W1,(=<% !$7,E
MY2J*/*S"V$ 55FD2PX]FR@1B\)*1O=,'>Z?#! N5]"5+>(49>'HGF@T3OQ'5
M$&C,!R34G.D[!;%(9Q)E-C^K_?'O&?IL10VQ(;I2RK0CK0C).K>>KMTO-#LY
MXQ:GBE/B-QPY@140;)VD1' \U94.\SA\[=RCR0)<":$TK_FNNOJ+V$\MTD93
M%X3IK%ABUGZF,B=;/Y<<O>'VQB6R1X5L;[[R) $;A:XG@'0G,"%D)!:9*U,9
M8YVZE7=@=*V6LD1$R9!$%?GA +S^MR/T7=Q!Z'LWD2^C^9 */\8V$D\OS)]/
MR+O"]9 >_8EWK^JEKW VYI;FJ$P=Q'=V7]5PJ]AF\1L3RD7K;$A9B:$+-OUG
MT<Y4#$2?<M4*-U^J;6/I5AV+=NS%]])D'42L5&R\3'U_A%??AE'D0A--'03>
M4#N328K!851HR&"!44C/E.5T<US?Y8]<16IUC<% IA"$C^8)L@5Z<;"DYT=!
MN.370I0D11(Y4A1\1MXLKKO--&#(?B]<A?!ELC)VZS2.G5RPVHAJ-6A9#XQ*
M\]IH-(<,-4=XHN@I",Z0M3VLX:\$"+FC1XW+H*CWT"92*V9R"YTV\)V"8H0_
MSL(R6+T!\_Y)K5%9WC>MA+FZI*@\'0#T"97R'&FQ$LT,><C +^5([,,)96CL
MQ$U.@ %]@K6_#YEL;0]!3,)[5,;0E)]=V$+:43*J#\IO<>QO5$IU8^B+DM?8
M*9UZI*(GI"5OEE(>Z(N#&T0^K^C(93=3,7(4F W ETW.=Z7TB!V68F]R(W??
MQH*=2.H183^CLGN$GR,?%_G2O@E&8$&;51/B> ?[ZQIVCS_$-RCW,+]%3Z+W
M4!:L^[=#)AP;<->5:2J;!IWGK!EM+#<0ETQJIP/]GK1?YVG![T\?.*76TV1.
M@FA%2K, M_W(L*&4F%#49^0 H<H!+OD$-Q290V!R< #,]_X#'@ >67WT<JAJ
MW'D2)C8<,-L-426(WXN)57)F$$\MI!6UKK"L*2:6J$O?P"=:O"@]BU(N?)3L
MY]&VYA$+625=86EV2N%M!7S@23.YA#FX8<J.&N%!;Q7;M8HNK:>.XMJ"3D&Z
M6DM8?_&4:X7F,JJF,/HV&!:HB;53Q$Q73"(6*Z"*=U1SHDB?>T(B=;>(SI5]
M=<;V[*R#14T&;E>J;$*DWY3357.-&$E%U&VAB+^(A!T9\2<'8CK84T3&<.)B
M26ZXM SY-D90%=W$NLP<]W+D":/ 4E5]T[?8/_?'BO1+9U+4F5 ,E^Z"9 Y3
M>"B6IKN$'=:5@$L,N&\6K##I*S1B26EF(;?*?&#3DS6=QZR!>P8F*TJS75G:
M6W1,TK5F3>$H.K*J1&N#K%P5*5989I97"UMHPLQX4C1T5ZXQ,5L%.?3:S>([
ML=_A]A<A?V3+,86=*&69%-&<22NFF,O,4V7*OE9*",NH=UCAT^TO'D*W\9AA
M01-)#.TO'B\HYN' '.].#L3>>S5-"^RW_5=4=O::PR/-O_JXH@CJSF6R"F?>
MVY?[ V\'']:!N3^:?.S E->,,$([1IO#U"1(%!O1_89\IZ*NQIF:\N_*EE>Y
M1666N:7-OG>KTDI\G'GN87@'S:QM>#XE@^:&N+6\J=(4*?,6Q*P'P^/M4"8=
MUC,#G4TP )RG2<!_"GFV&TJ4#G1FB[PCH:7JG=#P>)PK_1Z[S3UV&4ORDI:Y
M#DR[3360>_O#_7[XMS?\61+=$"[F0YJ@RC$L$!VQ /+?3:,DF*;%MIV3H,58
MEG&5B G"W,)L3>E#4[S#._[4?DLQ.M,/E.IR<E,.W5V#/"P[6PFECQ+#KPE_
M&65$%[1 "QABF9R?H2M@WA*!"^H35SRX(0W?%8YVHHRIBD+5(T6W/A\ZD>U@
M(#HZ"Q-N5#_.VQOG7$41["M8F_1!CF3=&7.*8#2PV,H*9@'HYAM*B_I>'N:1
M$D"#RPTVU^>*11)%R2TL,%3LN$5[0K#>(]F3.937_Q_76BL4[7N7!@]!G?*!
M<1+$)OE,^F+:VA>N/+4+R##T<AL@&BWJ6/?!;7R*D]L7UPG*5YG3#KPF3+QG
MU>^S>_4[EPN#JS!7FU_^>P,>O^N!QUVSZ/F]+'I.VK!Z&6 XJ :<HE"6!H3:
MO>SYS'EUKQYB8!@='A@$14A=,$ *!P=9[AM".&;1)<KL,%ZDH3C\&N)4Y?=T
M!!)E_Y\61-+/B&<31_$9":DX7$7Z#N3\Z" 1-XKUR<*Y5S#LK-H"O&>CWV0
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M7F%]2V?F((5!"N2P62BE@Q_<1$R/4QVE^Z'K QN5)DY?Z8,53N$B?Y$L7JS
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M\K12=YH)1AC55&5%1+8!3@BL>VBV4EN+61!'FP0NG:GP9N.*6'-W2DOD-FE
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M?BJ6WN&U5,N='W?D=&S-V*52BV'$D(M.%V0XQ"2XZ J1J.:;$"4V<C_U%RZ
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M5)3T92$GB2I!^<&?J*Y4 (.8%Z"*2OA1$41Y-N;ABG0 JJT:I1(NP4>I#RJ
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M%@5"&22@"R35-)2+H)R"&HG YQ#PS1V-FC"(R0;B,_I?(JM$L0B.\(0>OG@
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M<5 P1.M7_Y%B+ ;N@;<$VPFG"KZ:S?+,7,$#I& "#6P0!*_@ZGE5S',E=0@
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M.\47F15O64)V^U*\.Z7,S21P57U>P;FD5J.\>OAZ#U__B^'K6ZJLIFVR6B^
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M($(B<_P';(TR.6 >6+ $#DS#ZS 8,\J):^P9Q <;)$KX5QD%Q2@(CTVQJ10
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MEWKOTQ@4#X&VC>T"-,M524H)!&G=H'EJO+3-VI'1B I>/']0@^#<..Y:*IR
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M)=5'N\ST<,KM*>_J^&PS;VJ@C ?^\82VI\1&4!D%@?'^KZ@Y@[[3K_A6ILO
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M$?+/FB,PX7'+@ZZYCX,]7D3S^0S./4./P V>S4G;-AO(]<,F--DV*$]E 7=
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MA'&IOC;*=3VL]%-6E'?XW,6@$LK\T+TC6M5?S%V+)8Q$?@0-2#RTVLBAM&\
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M^:R:+K :* *)+<K]F,-$8P7G8=HW6214]I#H*^&@/9%_FX\J/-KYL ;O;E&
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MP;/&<72#S'GP$1W9BG71D*3-;2M<BI)9I6:7_JJ*M!RG(SV^73)(O ]YCB.
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M>^.7)3A/]Y[K-C@83DYPZ=,_HY.SBXO^173Y6^\2 =X?3^"K\[/W42]Z<TX
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MH^[2X* P? ?$S+5.YP%U3FLOL4:JE&Y8:SM1MX:HWXJSEFT33#_C3+YEV.5
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MPHP#(A1([/XDN4(4Y6@$9@7I.=>-T".">6$=V0S#5?A4!#IL:?-=>*&7W0T
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M_6\O7G]G+R7_A@&*,&A8_D075>#+^V6CA9TPBG#E3+JFH<I25Z7WF S?%UX
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MW]OUW-=WI.:+MN\T+ZY@2[/4N!<M*VD_CB,BF8!9UP4*<!Q-F&05A7G+E,@
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M1%-X'Y9[98>+M"G1B\M0@4;B@2_SMG A;$A*NCDFU^_],;GZ X_M6>KH,"2
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ME+G9M$-[E"##XK.1@VY+J*2%Q)8CKJ7*31GMQS![_%_[WC#L'Y?:0)K2)ZI
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MW;6#8B7]>55=8X?"==HXCJ;Y#?+$MFF3V>:BHP*U''%$=>M_6SC'I7@$^GM
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M'@ZO0/WT21>8YB0M8BEP&M6$PMDCJ>;@Y[Y\RO<*&W?/OZV%%6H<(P'-*P+
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M-Q0W;!"I+_XL<YX3.Q9<?$V'-_R%BO0#/&,&L$@[;OB:"UP!A8])C'B&;]'
MBR2-:0DL*M0D'.J(@%"V=#J.#!;ZCCH^QE@D ?G*Q908ASPC17;>LG*6E:>K
MU+>MJCEFF)5.ZC94&(6O2?(V9P:B-1HP3!>,#N6:"6WZXC:US_H:J\/V_AWK
M).$XV!]LP=>.8.=\BNV#@H(V!)/N3!Y,/765,(_]J5TVSWTG6 6HPN[:2+&U
MPYE71-QS:VLNUXN]^D^@XK *E"I_'JR2="VP66J^G9D,"1T2\U1LO$<$A_/Q
MMVDF0DS68DL%]ZHYP Q1?C@T$;5?IG%OULT$'957D+[AR/J&HX(:CG!M5;"
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M/@86:CMD)XB-:_T58KZ'AO=02P,$%     @ <TE<5&SOF<45!   &Q@  !D
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M9#UD[U=3 :PM6P?/ZZ/E?=]"9UC62G-[RU8G;CSKL7DUP!_] U!+ P04
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M=BA57E+E*MUJD-S!K%;1)52:-153H4#:1%^,DB)QVTU3148D@FM! Q!>ZYT
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M0%PJN6ORF5?4V\_ZA;E^=7_\#U!+ P04    " !S25Q4:TI%:74U!  +\B$
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M#]H$0H/'#N8[<F\N-CZ3?/K'(I+TTJK!W:G;-I^"?QI[B=S-7KK2]$?LI:A
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M\!@5&1^NM" @/.\$G@U$,^.0I-Y)2L%08D$3&F/@2E'$7*1FV2#Z=>B%TG2
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MWWF>3:I7E]E5(<U:_>?_O(U?KN7BZ*_DXGS'O'UOT^]GYA3[_2(>SU5.RM/
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M7L\42V; PB>)/9W\7 L.&VR-8]+F07&=,Q]DKF@2)VVLP89HK178J^!@MLS
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M5% (C,%4L[+:N34T/6]*/\A2D<K"WYX>FF'ZB_GGK8&JQR]@7D=N'V.Q;)+
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M-AHGEU7<,FG]E9V0:1_9])ET$../Y2/,3(PW@BU!R,[&,$AX)<_DV4U_Z/R
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M[;UL?;6]6NN,I=(9B?JZ+HA0P\_,MM9S-E$:NE8:BT6UM3]66Z\;J39[I2O
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MF0,<YCR-INUA-3@U16&%PLD>MK4,5309*12^7)4?*Z$ /$SI[SRE2R04O8E
M-%5N-4LBL2L"5T5&#",7G[)!\ ,VN^Y8AA'2#2N.A9Y&,\4IZ#OKADV3XV+1
M*I)#;-$\K(+?>14T]4KC]>UU,\!LG-Z>I8Y<<<ZF.YZ<A9-$D25E??1OE?S<
MGP0'<G/!O17P91_./CU]L%35ETG.EJ4F? :>(A3C,5VE6*/":7Y9TS1=/!BI
MWWMYTKQ@CJXH0H9W&XHKY>1)*A<'II*](?5>!ACT4M.F:3I7B9.M8;G,#!;S
MJFGAW3XL@]]S&;QL=Q?AT-GGD#D"VT*1P(]<954> 5/9K<W=$)X:V(0T[3AU
M9-(K8*K%CNZMO%+#:PI.D4]:A;K5?#&@/[H<-8$3CS5) M/#D+W*+ \2##AR
M9\V"/L/+T?/^8W>!FE4LR;.7+Z;AY'Q8:K_G4GN]A!N"&>?8:(OJWJUBZFQ%
MNK*NX,,4=7%1KHVU^*'<3SJN'J"C<HYJ[ZZIZW(U-?!_!NH6Q\5<R>5\'RLO
M&#X2IP;6IZ9.[1(3-YS'58Y<Y6$-_<ZG%J:\K)E,0CX&.&'@H#$@2VN(%X_E
MW2[:YGI[:78*4Z8?./J07S /<_E[SB405%]G&TL1K'"A-3H0GR&7)3)8<V20
M])AHF?=L.;8]_=]]@[]M:&Y#!O@")UNMYP/HT8+#(&!BI"['Y&;,OPI@+G/(
M^(!3)P=(255?-:LK/*H\U&2NU]M6=#ZV[4ZQ0TY4;=KJ"CDU3N^5\UV+X%[,
M"TY2<92W0HY$=AL:&1$?XL-W+R- OA4R:3!U^)[Z[C&&] $G'<O%2@86;]<J
ML7)!L<8%_MB6FYU03>FOET6[!F>1CO6JNRP7@6TNS[D#^+ RX(@QB)U5N6K$
M$7?4PR;ZG0TB4Q-V&UH\ )OK1%]DN/R']?LXAM.5)\4^,1*;_'W@:/7?/73=
MJ2'@>@5)]C*07=5++!I35#GX=!9&/BRHW]TJC^2U-']%_X,)#-SK9K=E/F G
M6DY,R(P4UG)3,4N5R3U&64VL_2!G>'S2_QN9F4]_%=G#9P^RA_^%=,Z#1O*K
MX5*"U$CB2Y]).1 ]%$0;\>18_K?_?Y__\N[U3]^]&^?&W('2B>&W^YD\4W #
M[_*3C]9LP0\O0MA\1([G13F95<T&SF0Q9^4^37P(672^4^S7I35&H)K.L)I.
MJX4:KOR)MR./9UT6-5T"<)!6QTHV7I0A0@C CG-'(P;T '5045 BEDNMZ(E:
M>GYZ//K'Y/2)K*Q]68@H86">K>@ON*N5.] C3I95N5I(.E;@!G@R;55N"P/4
MN&Z)BXA #(Q^%K)[6Q#J%#4KQ=>RY*Y<#:- _X%7$%*?T!?6RD!@;04*+^C$
M+9:E1A;;9D7OH^6_=C!*-%-UG"K$@V]98K'Z-<ER=XY6]O>,G2C.:]U<R9"$
M"? .R<MF57#R5*I-\)_=OJ;10D1'%Y/TG.%!<:HI( )9DWZ&G_R(VB&*2%<-
MY @=I>SU>KVKFW!%20;J=3LIQ&U0HN.O#0JK(.RR'.FDIB5%>PD\4=DM[] S
ME&YTT5 ,M]6[I ^Q;2Y*+<6AY5.AW,XJEH)$1X"X2OCI.FJ7<.1X<0+!;1MR
M$+<.-=Y4FQ)#SQMP%PN*K:Q<RNYX(5?U;?6T @=X6;4=#J.C.<U#-UG3VI[O
M5J7N&5'<FZP! 6T0J.S6R#SL-Z7!!L";9=.O47U%-Y#-SYXNZT#"SPVK0P:?
M'Q8!#.\V3JN&#(7?:;;]Q,ZULD/YZ]!.,%:(WW:=[6SZ[DX\:7Y!8?P*S?X6
M.;$_PLX4XD/7E6M=60[ZW9;%6B8P(C""%9.QAAU'YJ%%K7OI]R[D*Q@GAH'S
M7^%PA18]+8[KIOV @CLRYOR;P1-+F*$2P[RI*$JMZVJWGIPGWU5EVNGD??&A
M7!1CGSXO]K3ISFAWOB^[HFWL[_^;XMWR8_XK_?#%;H9]//SA<YB:9C5YLX?-
M>/?/736;3>$5=HBH916-/,R[HFZ6U>3=\1G]Q_>KXF/S;DW#_#?>P)O5G"X#
M%35R5>T'9$>N!BX8U8'?-)BRD=>?J*^@&FO"C!_6"1:(+&+]Q>*JZI!4Y*_"
M5#;J"4A*BN]*'\=YAGU9'$QI)::8?[B%(:3?S7;52M8#$];C.ICF*8D0'[OK
M\GOVCAJUKID'X$Z=8))YJ;. &2_\?'-,@V8+#"P_OZ7@KU0(RQR&5;4LC[BD
M)5B<9>,\HB4V8154LNYTR?$(.5Z$2_9W^<G'6<-@ O*) ZR9)02+8(J:>BZ>
MH;G-*'@2Y]2@DEB/'F0/@SLSX&VRHV?GB1VU7'L;-XWFNC:H]IA795#,S,WQ
MV(HCEV$MH!#N-L 5$)\TRZ>II[YU0M]:2+U8L(9G_] 6$$ESQ-ZIMP@ ,*6N
M\^/)WTH9QZ8NZR@#JJHW>T_09/8ESPM'-9W2MP]0L__=X_<!HOR4K3X,4=+V
MUW#F.4SV!&RIR:-!*M5CT3PJ)J^:7;VP=,<;+"D<=V3U?U9%P1=B##]K"2:L
M RQ!?PN-,,5<&5Q0\J?5BP&9"G<C<YY=:,.&@9UG;-R?BO/J= ;HGF-R<D8G
MLY:"AM7>Q*957:4OP*C5_?R'+ASW*CR$WT-I00BJ/%,( >"BU+OU$5V810:V
M^841>X&/?[$JC\BI0/*MXITK,\@APMC;G__X^M7[*1]ZX0LBK1(2:F3I**!I
M:9<+S46B><DE0@P!J66R%Z=/3D_#&Y%'TQAE@+$+^#OD.IS\Y72R6\]:.%ZX
M^@S4:W;C#S[D]V_/7GXG.A4\2<E/K^66]-2T\AAOZ+270_P./1^/ITA)%.VL
MD6&=8N1H3!=PKVRD)_/+<MV(K=V'J=TY>1D653 :39B@#JZW:)(G$Q121/*(
M9=!X",\7)"&T6@$_B+/02MT/1[+5VE7TZ<#8C[L2(T[.T&H9)^1U\EDV7]-T
MNE4K.I]NBF)IA.C8^I?X8_-RUAQQHI2^1'^2J7UZPQP>_?3=__-^RL"*+/)2
MIJ3H=.U2.(X;LM9L60NY+HQS56<PU8VC;M'XE2B-Z*YU<O"TGM2AG"95DJPE
M+V&U\%$31P+/WZ$'5=5=*C.S'^#:<BOF;0-.*#TR'<(M*J<'E%GMQ:;V! T]
M ?SW0EHEY-L?M[HLBRLRJ@ (CGB4))J6W])@E45+[C692#C?H:Q?%4#Z16,/
M1_7=.ZI_WFT9=SDWQ(AF\0>)D5ZS/ _@7#F*PRD=X<G/4K"(QU5+$Q J=RX[
M@C8VA>S((SU9U?]V'CP\4 <HAE!0X*C@FTIX8+8U2)5#3:%&(3<JVPW3M4.5
ME8_'%)$+6J$-'1(TH#0FD8?MP3@?.4B!MQ[E V?>9(%-*0_H3KN^3?LDQ68&
M,G]Z]^+'%].#1_>AP^$L%&.M]E,[2$7&%F_ 8_GLV1.<DGXB4G?H^5='/WR1
M>$-!-C/QB/#> !SYL*,;B<;#".3H8"ID7-&WH,095,K0L2^5C%:7'9KA+"N
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M.IOV].4U!8;S8F-Y&[0MG5N;U2.Q(?IMO@V7B Y"5R"K1VD:]W/['2Z?#JF
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M_FB&]5.GEQN#-]VN980_'$A0*Q1>,C,\Y2A412OAP6A7^\ /YD8[\P/4W3O
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M@;.0;6S.\ERZ#?O?[(11)R$-6=NR,,#:4@-D?C;DI#"]E8Y^0__\R_7AK0&
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ML"KG/WWQQ%*(QY,7NH/RO>$&?PW&!"K6.K<#9RRZP<YPM$YA,05P92-5@8E
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M_'!AZC4/AR#Y)$4=0EJDM [)?WJ2AM$'0F=/FU\7'\HA2C5]%%XH5@G["F+
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M(;18"]V8:WWZ9 )I&+4*K*"WV;J(+W2&UOR:@%Z@V]G-VZ+JN&,!M%TE/R]
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M$IBNETBTE\$ZU,SL@E/;>-"N.376HP%G0/4%P91-E[NH836)'%9C0@#)",;
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MAK8&U2X9"BU+ULD/+JFR/#,>'$F)N*J;$?$Z^AM(RX[.&U'78*R<5C?YX6E
M'<=$YI>.YT8M>=Q*<LHD-I,%H+//"^#BU2@T6I6YS,QEMIQ'>)C'-4=;Z:NP
M)!T9$2R7H">$\G#$\SL)"?]--(RL@[GJ_[F!;[4UH'!'2WHII@L8W#-TV,36
M3'"[SYP(+4_E2A%5]#TNIO&#UADEH\/G-YR1.'VLNT%OI,&:M$H?=Q$ H]<E
M+X#^BKRAY""RLILO(-EQ?P:2K=$OD=/YF"F4QULJJ6OG']=%;37,WAW9LQM1
MTI99MSLG'&=:H76;;5:045:VUX>@EH!4D]=5+KJ:NH"(V[;@YEUV 7YY]^;]
M:]/RC@7IO"OLK0C4?O/!OTJ89"<2_4<*J"Z89Y).69$MRHKH2N]A+UNX@,ZW
M"]K29R>GCZ-7+1(YS*A+BHR@-V$Q[9VF.;KL=RR-O%YSNK,%A*ZS=;[=N  (
M&^SW8A\?U&P(3F!=_7[MI__UOY3#--U;P41 @M[%6+HN8Z><:WV58\,3I0^B
MZY7@+FB^VS3,5X.H09;5EJE'WQ54*,%TYTPAGE,S>5;FC-'H*+CG0K?(RF76
M!-BS%<SP1WV,<]L\\IM*L!.STOTOQL)S+3%3^3?+J!^ &1Z8\?@ S#@ ,^[P
M+:5@>PJ11;IZ%EF@%8DO61N^J2XS HJ'GX/Q5--CJ."8I0 <#!VPX09\TKD!
ML]&L#ML]WH'V"":Z+$@[5X'(8IUZ#-SAJKO]5:?&NA*EOE0RL3KR\6&*:;V/
MN&!RN\GWBCL,78 ACE@2+_I()+OW391&8ZOL0^ZP[E'TG+SQ5J8RD2WPN-U9
M@9BK!==@"2=M]@'8X(J$<Q9*!L]#(8JU)<%6"XZV5NMEM1,0OK3QF7!"&J++
MJU JOPNH5*<#F<3D;4G?4%ZK\]I12$CKN@QUL?1Q=R;WOW5"Z ^))UT 2Y;X
MC/G+UA0]YP^_^!BFQ5AZ7CY_,?:2%<>NFM;2[!YP=5H4Z9XT&(F&YR_2Y^]Q
M(Y%N[G<5LR3[R5E@R>^&/RU8F1<,[6O0"FW0ND2>I20_+-(<CX*K=!F# ,&*
MZ\,TJ4M5T?8FH\_LE*B>_P2P0<./[,0DFFM)I\ "?<K!M*8^SD:L_> $=E3:
M9CDQ_MMO\&!(B5YDR2 ;T7A\L<$+/9$]!I$D9Y8A/,?6P#OQ)XZ8_N+YBZ,[
MG]B],=Q<U\72X2+\71MK:;8*J8)+;#ETG.YB/I*<890>F.\SG4UKR[I@A85\
MYC$'XSHLJY(F;+%SI3RT';A^>ZGUV'M,M@4Q1VZIS=E*>>LJK"5E-!=9;;+K
M-PV=NY0H=$NNC3B;:+03/H;"Z=Q0HF@[9\W?#9L*J_59HT_/5"G 28@$E$9?
M&N1-K7!15]OU4*@_'GR\F4M_.7S3Q]LO\6B9K52SX7:_[%$#3NQ5/(817\!G
M)W&MH"8P,Q"8K!*FE97:^>_36WL"C!YU5VLD'=5(.EN/]BHE^$QER'.[4-J>
MO$EL*0\M40%TMJTD7"=8CHD= ,9<I/LH=M0@;._94?$Q8(W'YN'VE"S1SG"'
M)3.,82JT9W?NWBUB!Z@W+?3 K]BR4+%'U^'6][T'S<.']] D_N)\AXOS\2%(
MZ 8);J<FLC-]6YEU'N569U#M*I]Q%S>;_*$F3P/":6;,X$"I3)Y@![C.JD1N
M(EJQ,9A65U^-V[0'Y/22(0H.BCO.X\66RL.G(C,L8HE/F$:#Y<Q2#=6%B'-)
M(4C.5TLR;^Q$8%$ 6I Z013-2R7UQM*YV=7A$Y))3.G*_M-K27@)4<)<(GS(
MZ)(4-UFQ8F-O0^F%37>"WOJHK#:1NCMB?GJG(85"6/W&<6/XM[B'1N6]O9IU
MT%&JQ.*$@Y&Y7=(]R?9(HX34] I$&,0-(_T,AKSQ4)$84!-)W$14?W+=_/%<
MAAWXYM4YT2B0PVDY]0YAX%!^R7Z('9KP+&TA]283X1XN5W4PO3GII;QHU90%
MDB,MJYZFA^*X#<7D$+\)CQ :E> A!(.7U\= 8Z+DC6;GNEA4P1]HG,V2IW:
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MEM$;+V%74>8WFJ28?\ _N<FVT8SM"ZA:Q%'2]Z^E]A(.PA'%V_0:<G6R*LQ
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M%,;OL&<C7=5LI[J7*ADE;E?-%4]5<57H'VAX=>;6#/%8Q,RVRZPF/)>&\J!
M @T&)<W9H] ;P1G^F$:_A3F.'G'6;[G26VL^.OVV:[')5A_!;-_1Y/$M6R\9
M$7Q=&1^Q0"^#GR^BYN:E]]4 BTCS&;Q'QW88?<&8%)OC/B+,M:#]J2V^^TQN
M,0:3H!2.<:%-@T]KR8R^J_F'@W[G%XB[;Z_H^;P_]/O]A$?_ZW\%=Z[1I/M
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MZ=Q<?+1=ZW5E[>/K>.N-/8D;87WD;>2V25[J&2FM4WPL2?SP"6/%;1NVIIV
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M#3LPU^O#N7DL?<<*M53-U@?0-E=N%MV!YJ0(%E^PZ)R^(%UD/J'RGE:TIEX
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MT2=6C;))^ EJD>_]Q;Z=TFX(M]3S3X7P:I,%89&%F*6#,AG=-_9##'5+?J>
MH%A1<IH\3Q\0.]A)HY2IRZU5U*JER5!7?"R$6RV=/K"HS;>NE=/@/S0LKB>F
MG7!C064KI_%$@$-TU6U,4/B?VX(98U:H-)$2IU6?*E_E#3.EBKS(#3<Q,]ZS
MHOJC\@CPCG>04$BU1C-U_PH\[]'-VU]QD;2.IGM:Z#'[JWYT& !EI=0 PL&I
MYO;7728H%M\E[58054_R975]/'I'FXC3M,3/:FDFX9L>!1=XAS+PCDJLB]R
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ML[ES$ *I(+=Z$#MI>&/PQ?;1U+363F)FRA 8+;X=*=)&N27E&Q@BM6JK@4$
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MZ[=)]V;1[&9#RE^<YG%D\L&EPIX0JN]YO9+%U4@=;! .5LND156]R,KB7PI
M"#]R\?:U5.7[*.<.^^"K[@.5TA*XL8?^BWO^,BJAH-6*LD>C'RO0>5#@]O9'
M_.^+S27I5EP$>UYL(%1&?WDQ=HT#&XX1>U;]L.A?<]&GU"&::^F@12;)5S
MG<HP88@WT-_4)JK6 R3G2]\@D76!1*>+'($:,B'R].O#N^ _$=+Q^.0 Z3A
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M5#8C=%/UP$"'Z;+'@FF\_RF?<B[!&(KRG-@B7M!LZ*P<^Z(7\$B]H+,G,F
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MVZ[F/$NABKULWC5L7" +A<^Z=:/,"P#S.0*GVZUF^''NH?O['XM-"\82LX\
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M;!JF$XQ&($;>44AO&7&CM%6.0#00]7\P&7]"&2UW"XKPEGB:P(3L,.EKI+O
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M:#(0E&5&Z3MM)<2I_9^LNTER%9#A-U]X\M2P4=EN-6/Z62X"(I8G+@$"DT<
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MG6Z*%+UP*1"I+5'U,ZB/: _ G7 6F;S<7.Y7@ZISY!5SWN,\UO=NV \- *7
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M[^5D@/1^JQRW6*RJ,PSRR47\$/US EY)%#,)I,J65NQTRQB*(9[&;.^AI'5
MSF3 YFR"+!HV[2+#K!Z);SBI8*&.B*54%?&7E.(&D@":6:GJ =_^%!QY)'3
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M9Z#AD )][BUBMKL[" 69F(-4!FDEG(3"1(P6_!RPY?ZO* .ES"(0_YP[7NG
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MK$O, %"6G X<^:8T^:J9,W7G2$U]Z4'\]S[ORW_5WKB]]O_V1A&[]3X S7E
M-VX30)O*?3);EXO5!GB($ '#_05A$,4-=:H*H6L:K3!JT\OQ.R?6-^<8U:D
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M.!Q<H &W_]E\*'#H^8JNRKQV86!%I:7I" 5G?4^1R@+4OG\@1!9\)NH5YQ!
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M1 M@,C]LNUOC^%?"'_B/CO8# 4C*TI5TDHR-"R8"6VCC9N<5\9ILK?67SY&
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M&REECZY0LRX2#,.AU2"[F4PR7.EY[7=5.]9\&9)"$LRN7-ZBIGR3'2VJ%EO
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MD"=<RY^\%R[REL-7[Q:]/'E_3.6_E%J54C?J"FID.?3D1J24M.=R#!"C^9'
M1\%%\(3>16]BQ)L7#J>>O\"W]PN/_7M81.$$0V=7O>P84(<32O7LIGZN;=*/
M3BJIL:4%'1Q,ILPN4(PHJ MH*E42-Z3!&*M^_7)(Z*LZ,)@L>Z2.I=WT_$P/
MR^L.QP%BAH]P("I-'#-UFTOB6KXRMN\YE\8'Y8"+FP[#@:N$+#M")P:%SOEA
M(#JMS>!!("D 58+D#KH0#;LQ\PARRHDG%0<XX;P,@014,G&\<R) ("OKQKD5
MN+/\G*0+8'/>M?( LUQX!\/3N(7?\P]=J/@V6.[Q)O*=6-*K 5*[";&9,L\
MD!0)UB$X#IHAH46^U3ULBX98YV2Y*:R>\_9.<05Z(> (O]Y)/.5ERG!DSAHH
MRU:,]5)P,O>KC&$IAR.,*@%!/%V"J03H['#R"@RVT@$A=XZ'JJP>1^[US V2
M>(HWY1K$\*G7P0U0Z+5]ZF'?(!G ;L.(SBC/!B@18]K8,GE[8&5[P7<L=1-:
M1UT;.[.&XS&F&IN"/B?,7=]5<X$N>2MU4=1E?]\P+<LE2=JVLZ:8ZB).^;V2
MP;2OQ22 >A1UL?=[FE!0&.QK.'<R#*#?H(SF$\@,8&/^/PV0"SQS^1PP6&)O
M X56O%@ SP:<V8(F#:'8LFYXK65Q9;C/_N9("\"(H]$8R']AY%*(2Q;P+290
MNPHH\T687O+7"H'+R>)Q>4,=(K\_F.\MH>HG0SKRTBV+5M:W5!4CAYO15."3
M)'0RF"Z(-$._NQ7\@3-^77<8CXA'D%]' F9ZF"6J$THN&D4T!$MO$/P)[T^8
MJ8ND( >::-$;DOP)$]CJ+R.9>3R&L0O;;>N=8-/'M0/:)[P$H3=DI.7QB@XF
M[#]B0X^T<T(8';V47K0O+51I_Q1O>S"MMX D5=NT9"G"V@$4/B)-0)U 1$8P
M$WYY/8;$#X]@)WN 8*Q B+4BWGLZI<6"A[[V>BU L B>SX3+0WL:0&7=%-Z\
MUG!;_<E I&O>8J/O$"^><E;/Z\OJDC0,"9W+WGJEZ5OOX>[Q5A9O]=T>;[7'
M6]VC \&2L&BKN#:F!+8 -5]P1--C-#6HD)COJH1]0)LY*(Z>>7^FU^D\TT[G
MV-@L3<\/V^.Y[AA^0XJ'!,A]E$W>>\.)PM7DW=3[EL@W8,3\<4(1!1G3]XR]
M]9]-DM?'%)C-,=8G9/^1RZ1LDY^=>61W$,C9B>*[3_ULL2^E%^#SBY##%4%T
MY8]T-2V$7*"/QU_L^.2XU^/+QY ]^/50CUY#.._9Y^>CR"^"F=.+3B[]@PM:
M&3<X[I:D$>$'Z8A3!W_NYM2(01NMJ4L%QO'?QUP")DJ<Q^.0EG9+U!QTW#9.
M^L5;&B9_T24=8$22_!?(IIPQS\%)O?(K>.-PKKUPH'?R R7?]0^6MY^T(8H@
MT*N57#_W?_)!"O,E\]?"+1&C02W)O^ ?C@X?$R-,62HO/+WLUD<++;W<$_^C
M/XV7M%P>^S>E88K<#%PB"V2<RQJ8 ?AL4TA7+)<N-$H;+SKJ]W3^-,T)QQ6?
M#O#KBSYV0,.A()(1Y",17?MI72[)BP.%2!A;?ZW06Q @YNPH"0Z1"'C7]*O'
M?Z1ZF8_R6LH8T@!DP5T"B0[E']CK\N;DV#L8)0^04=58D4]5!-V>.'1/C@RU
M]XGW;[R=*AKOY!P7WJ/\X,K"+3C)>>HW04UZ=V=:B-02 ;YZ_.'TC'ZCPQ#>
MKO63X$!C;%X_[H"VP](C8+T\%-0\D$L,]N#QX\/)2XI>]>T>/PX?_TM7.?R&
MJA1'?S3WFW6;P,4?WCV+?=N@#_&C2Y\C7V\E"\(O'G(PF';]>.47"FD(?,P_
M^XGRE^5!,?OL\?@^P^NZ^?@\ZT)*<:<:O\V9BH&S*@@?0KJ@M33?/707%CZ\
M4\@YC:\KH1\AW0S*^9%=PJ9*.A!3]]?XM68.3>[ 9 R,VTU=9H%?+M+MZ!)T
M"E.3DU8\__$.4 &>#9*=2>Q@KC+*Y\8#MB"S  4IH5L 1+/:IFRXE%QK0GZ(
M"0#F7W,4?(93!R>-.C%R!-TDV,THUG4(C[PY33AL!1;+!PFOHCQ:P<:MG>2\
M_#]1/T[Q/9*MZVM@TM0-'M;OT<E))R'E7^II+&-^//G+<2;=/M]EX7'D]K+A
M!*ACNM"X@.(.%:GS$:EZ/#%NB54B3SL QZTHXZ+VHQ5U35J0$TJ'K:@60B0-
M$2GAGT_0[YD?TIEW5PRQ%C_[#T%5)>.3=^:08CAZFDDC4S[YY?#L</*BD,C]
MQ.^BS>17<A(TR'U;XPI5_)!_A(]^;/UX=#P8(K0S'(H)H?;DK%87I6!-N+:5
MKFHV96SBD.3U#H<4K/0KP"P%JFIZV4[25GH?.M##[)"4)Q@U99XQFUPW60G!
MS'#5X#X-O00H)#5%P'8=@W36K4F^6<;(3T(SYTE%WMJ_Y%MO1WE\']'X/G[$
MQJSB4X=6$GL?\P+@*R=?S\479>V>HI($C@RJ7^4%X;$6+7%_4'8=.PLU.$'V
MA]VCDAO>,FPZML%"EQ:<SM?>-C/8C=O'3$X01X$=BMAXKMM7ME)7B2X*)HP1
M(%HGY(/@@2=;KY6J^=ATJ_7DV.3=:4"I6+:IZT_:^''AK/&"Z^2_X&)^K0@L
M=;U=8LO/W!:+_@[%89'2"9=FJ"YD::AA&:%AQ^RH],OHL]',^B>YS NJPLVI
M,S%CY2%ZY-6:GY4[>RT_S/ Y)2?'F\CN(0Z'&93!^,I<O=%4C<)'P'.BMJZX
M(H[*A]J/ *3< :^$Z7.-EJU-59QZ+).J.7\FI>8^G+SSF])_CPHBC[_7?7E>
M7Y(5LM'DG^D_Q"U2?\)V!5ZTB2X8D=G.*7?KE]9IF/1W](E0$Z?9:X=S)_Y7
M17=J8$IM.]$:[=2:?F3IX7 Z2. !FJK6-"=-@GL5KAO6'Z:%_%L!)0@6H?%V
MP]^PDD(5+GCX[\&-W(Q4</+;@5;^X__Z179*T?(L9\-IHQ'F.=7VW@/R,_RE
M_M2;M+C?;2<9>!9<[?<3[]XU+D!D_E:,-8%T1N0#7<"T%JM,]H]&OHEKFQ3,
MT29O=/<GY;IDK[+W3M%'S%6K?AJ>GIUO+>/%Q[JLFT_JOR!T^''G )@$2NS9
M>V-0@*&2RZE\'J:^G]._/FFZ$CT;$NZA@,45=J*-C4%'^MX_<O4DN9:,0)[D
M<J"%$(<D0F>86UGXX<* +& S$:!67_4)V*NM,"?CH(3R[ZZS_'.!9G9=G2:#
M40^T$,X;_WE-NAM:N[IQ_48SQ-=EAY67C=-,XNRGR6+3R))<31P13E.-7ILB
M7IK"R;01MY&WVF%,Q&'PTOOA,03806DI3F$:)=(8E>OS7!4X)S$Z'^TV:HZO
M0='S<;4U^;1A^9F\E##5P8",)-OZZV;2LJ)F>O60 &'D@V#^F*#M$ W%**T2
M/0EB_[#(BX6F7%4=;3=39&12#(QE>K]Q\ED5QMG%V;XKI3%2N54!%U-TQ9KW
M^S-:MMB1QS ;0VH96/!3GOBOKOQ_2Z3%Q[@+H.B+!<WPR;XG.D8RIK,XA WT
M96K4IV,VO1Y$8!AQY$%G;W2[F@3:D%&8W =R"OT(N*K]J@M)MY@^WM84Y"&O
MQ02X/#WP%,ST$/"VX_ZJL4E'5B%)DFF*EZRH-UU(.,R2-%A1 =7KTF,UJ0DI
M3PU#C&WGCHWS64$$'N1X+II/"!R/Z!1;^X5(AIPRPRDBF09.&)\@+<A)%L/B
M&I#,_$&Q03%@4T(<XV!R" MO;"/BDJ-AG?5K>YQ+O]\ YE6%Q),-83E5(9&J
M+K-H+B2:)<@E%U;J2>GCX*8W^,F^"">X:6 T&;4@%B_7WN-7+'[E^SU^98]?
MN4<'8#R#?"1;-^N:95]1*;80ZM^M3>5*IP5U*Q\/2 @IZ%K!@RZ1Q8O)4D8P
MH+"SR"]JPA94 K^MYZ+SJ>0;,6OJS\-XJKVG.L:?36Q"[K=:7(T%#VS<-#@G
MA9R C'HK9!]@WH2@#E,72;&>=4_F%Y37@.]8;=C?B'4E39H><<Z4_!A*GG14
M90OIT_.\U7)]<%YS>?7+ CQ&CHGW&D(A_]I5 8V3UJD>_Z"I6: &F,:=AB",
MS__*5^L?8Y+G3#J\4,4[>7.6Q0RMF2 L[-;[(WX,?/S[=XI/Z7-1;Z!HY9W\
M-=B;DC)7(4E4]WE=UB#H]4'Z.J3XS0XB);+.\39*IF\PM[WY0EYYA>A=.*'\
M'-,\_&^3[U7=]H,I  !TO:_81T^04G[9OIMM:JP/N#H__WP6LGM$#PT:#O0/
M)+/NIPKTM5)N&*'NLF%N3L@5K,KO'SV=O%I1(9/W[GOV5+'$SEZ]9[+254)/
MDGA+1-0D2863O,KG.:^)\9@@L2.MHI8%-6:"#>^T0U2M#.4\X7]60%1;?-87
M_>9OKO%>_H8*V7Z^\KEW^U_Z?_A@/9N\\<_KUSE-U!OWN9C5[(#3SS_[O>6=
M^,9]RW'*.D?-DOMK=# 56%*8$2(I^,%+!R -/$VK%T^7\0/9"K$* @DALN3$
M111E_?T>0K:.'^K,CZ7.S'L 2\=?DM:]8?YOW*H&%R_TM[RQF=9)9VHXA6P6
ME7-2UU!+42/L!+7&.M098-1>!-I>2_"K&"RY[#8PWOD+>W>7RGM=5<+ A=2I
MR= 9N>SIED$>'T=+DPA":0.%<PB%S CEY*)>GA9O\<;I\?:87C+]U1/.0^*E
M67IHL!'YL<3DM"HUW4J1T$["Z,A[M[/DXI("  A)>5 O#DA!)HG]QZ\8.^L_
MD[*X<VE;8:^W>#@+@QB=L9 C \UYQUY6Y"9C[1V+HNR/[%=\?E&UN?.;(+@S
M_0*S)&3Z%>2CIX^>/U&DT**>$6W0!(I (UF;N&F&R9+?K]VDO8@T1"C$TSB]
M(#GN  :3RB2M^Y\[?\?4C?2F-;.2\6SVZ#CSF^SIL\F<VME9]F3JMZS PMQG
M<M70C2FIK^NRBYS .X<3.B?Z9\(3]TRPZ&W-SOT&;S-V9$.F3$()^/:R^W:P
MES%V,;T_G_M&B)YS>=HWY0\,'^.N^"UHD2V]+?>OI6"WW^T">T?+9;WA SEL
M<#J/?9##\%QJ8<6BB?,UDD=UO_-=^LEM%?LGH#RB_Z%ART&Q]Z?)-_FW7/,?
M'3U.6.>QFP,;RGL,C%)#F;2,'$:MQ SP2:C)NL]<(#V3TRUV'>$8"3<X<F>J
MC-:;(C<<A,GQ^>/DF^FWO]NIU5!6&E97]<8E1%&]&;C"1$(2POL0V]Z<B&:?
MME)@W1A@4\]FZC-,BUK*P"*ZY=T@/YL<N60)P#ZI@C!XY)O9MWY%H7&@G15,
MF#?S7ZA\P!)YI.5.CMB6+03!AOBRY'K+#$R2,F9<B";=%C0XL'OVB<E\E49"
MQH!0V14Y$&VX.QA;H2G@]Q3E),+>X&P"VO[)CPP2 U\S<N5X$YHE!&-A88<A
M-0 <,":?]6[0E</'.9 "+>1%;%%-IC0F_FR^T%3<F :A+L?(4/V2)'R),%4%
M;EX4V!(V(@9,:>DLA44$@<X-LSPP76]LSN[37 ;L">>6>'4I=@ T #W6OJ0D
MJ.B=C)-WU*%(;?"$B*;;F_>&RB@ -C95P%!3^+$AW\ACT96?C)1+KUO.#ZY0
M1L1-53?+O!+>&VV0"1,;N&"'<\OR1=-B+J-;S_P1W6@V:",(MDN<1GWK;^I@
M[*2+3F33FEXBZ>SBJEC1#+-#XSBE?JM8 $JIAEYP_$@\=<6:V2O%A*0U_9J<
M2H4$P:M==YL$K61[^F71#7KH#>)I6&&^ MFE0[$#U9502/'+,=Z5/N0C'=!-
MXP&&/)31L97;K/.MP0[J0,9I:H-K;^\7P4':AS4^E#TQ3C,@ZN7KF'[-1E0H
M,$Z[IEX[?_M?*FQ*1541L!(;) N5A3Z+A=$;;?N8I'$BB!1S=%,-7463*LN5
M9(>& )RQ]TGM:I]N37"!["6VI(VX397_Z$AGF[;5E,K6&#FD30IIU0!.#P38
MKBA!;T.P>+_SX%8D"W@#+?#B]QPM8&+M8-KC43#ZB]$IU3#Y)O%XT=KZ54+P
MI&=X]**PVACT8)Y*;S4,$%+R+=/ 0<VC&XIQ$CB1M^].&H0D+'?^J>D51G!^
MB'1TT?C38P=]CR0?4SU[/;_C.UPZE6<>*H=/7<S)LFO#KH35K2)0H?#.K,AK
M: .PY""4%4%CT".6H=PJCL1(A1"7_K^"10$&'*<+U.<6831HXAU**5W5^DEK
M%V#;W@H8]G?"OG!+%.3?71^N2.ZF#\B0.[(<F99J.M!4\Y\22NN S]?^424/
MLWSMIAGB&N7BT&@?)59WW##;>3>F'.T+'>_A31;>],,>WK2'-]UK4Q5UEFWS
MDACRE.34TM:".)%3,I%?,=(-<QDLG (CV'][;&2CD'OF,*3V69QG7PESX76M
M1+US8V#'>RS*?6[/24JQN>D)#UBM"R)HKI&#0,\R^XDJ+U!N#T3Z8LN$S.&8
MNDJ92WI<8_>S65%6?6US8S&.,;F#?C=@X\Y=A724":HT%!F7,D]=8=Q9/O%7
M?]5YO>*Z]174@Z7_N9WE:Z>%ZS!#,F5AFK1=7*!*8*4M^MT-EW53S@D.EL7^
M_EBR![1.LS1<^YP8;8JQNP+JU4:@211NIZI6##!U#QY.7@[.<FZH#LRO[3B=
M["!KD%#G"IAM2?GF#2A?38L@LZ]2\K?PLZRN*^L>;0V[/18^9X%GS!><*<\Y
MV@R90!7TY7@S9]-=@?@57G37&)I5[OJOV=\F.63*FHSF8/X%!BT;-V?"S@+5
MFH=IVQY D,P-)B!75ZX5-)7<3%'&.M;&=*5^]0YCA5B8F8/]Y9J4YIG*$EVY
M9 $Z'[UU.5,109AIXEK*]A3M^?@- _&\[8I'!E24"U.^^]O(&F63B(IR\]$/
M\!"QZMX.4H2$AUEEQV2P_97/JY#@#TI-2KBT,3Q'>'/D)W8_C^ %I 2$?,&"
MWQ&D'QEP=LMPRD@H'/J:0<S6U!6GEW;>Y7#R0E+@Z/@^=TQ.<-5S!1/N(ZYY
MR0&WH>OO4YGKZ\:Y138<^8;Q*(Q2)%,N(I;N<VAK3 FU$>\%807B$H_@K)[F
ME_8<QV<BSX_2(%(REMQ"I&F/)+95?<G:]2:C_2 MV@TS;PO*!Y%1B>QYU('F
MHXKMZ"(>V(LK=]BEB^F40,W._0G@Z'/IPF@-O5&!)Z/@?'":#]>:)B+T5#8?
M83MTM?4Q#[H@\@)0LG.605G90XAP""A(WS^XH.O1.HXN1#P^_48Q2L8C#.F&
MY(5=+ 0S.^\AB(<DF,&NX,[YU@\I.%&2"IL4>#;>\ZO<MN7R.%DR.E0X7_D_
M?#QPMZ",@?AVK7,H4 L*-&+\<?:K\]*#4@;V_59I!8"XJOI6D1]-$70MRE3^
MI8@:"3: W,CZ4MPW>_;$DIR8!*J%R;!Q_SF*=W/UFDP 9@='ST3OP7TR^GQS
MI1D;3(,FL:)#:DV;3C=KH])M!5+JHF*$7<_PIU%^'CNW!30Z<LJ#4$!L':5?
MRVURHNE=5_4\*,6U.A(Q-6;JH[@VQQP/O./[&JH[+FMI'PV-^GB(M0DNE]UJ
M@Y E27K:Z-5?E:,T4Q .F?C?;[GGX]52@A+B@\HJL$!@F3)*PWJI-/X)ED+_
M(*<1_SW2Z)N0RCL_-;.BU;/<5+%#7!TH3X^]V0I4IZ>GQR&^O>JIQ.3EGQRP
M@K- OX<+%$$K*B*K?Q*+_(*^;3B-/P1K@(?XZ<7[#U=1P+[Q%H&X  V(@7,:
M[4 8-8KS0@,&UA'/228B@+/ZFJ37O;@.SLQ'A.W!E,&Z.J5!MHH^RAD*>J'X
MB!6'-OD,&R4XN$F)(*AAT>VD=E<J E >K>:6!N('1"(G!SE7,X_"K)INT!>Q
M'$)17T;@ C[Z(15A)>J*XF.1S$S_%DZVIF<>(N7RB%>ST9&P&:<=XC*V2<CD
M<XKJ@D#&2ZU_V).+]$)9*4T'CQ.B7$;!W2_]?2XY]!I,Z'\R6Y*SQ,2/)BNA
M9Z8M T> __+TCUJNW=14#@V)(7^EBDY([U17S%.[4(R@/X,DG2).DV$ZIB9$
MVC'GWH:043 =$P >HJA'ZYG3*3M3*$IX(WD8!%4#;XR#*W.T:VXE1@L$+I1$
MRU<<&H2M">O5#O!F5V[Q= $)Z7"_?,];0/$3L$&(#=CQ<Y6$#&(>PW=!/L[9
M5?)FH%"7S_VZ!F*JET,TD+ZH.SALU?L]G\7BXJB_2&SW/I1H215+,+P)?9H1
M= \SOFNZ?XE5_[W?0S 7= UQAQ\ZH,$\ZX?U+[359SMA+DJS_I?37S(EM)4>
M9AKE R0"W\NY<W9>N!*-U^%Z*T=VOFB]=>Q:X03Q&V/C/>'_8>-_D\U[>JS'
M_W[S!!-)<S*9NQGSIJ)M;MZX2_;*P$5?B+$L_0X[H-R;#XS-CJ)^B!+!.\XF
M[R0PAS$[D<$3%I0S$A9)N.E/O0[@7'3NRN?;_3S>IF9Y7A![)_U/M$M;5RX.
MJ ;H@SXW-X2[_4T&:H%T#9"_5KI\+OP!0NG?SIIN4U!5IDJGMKU^9C19(Q%^
M:&/@W)DP^O13LDG9-4&V&PY'>X$ :E, F?^R5<1-(3A+4G<5F.Z&B0 O7#6O
M&X5[JYBD>,Z[/:7?(ZKFNT=[5,T>5?,PHH1;HG%>CV4Q&1ZK7*:2K):HR]21
M)=H5*+4IP>#7%":"IJ<3FQGY)C+3H:>Q/$D-PJ%-&V-N ![7%&J7,HC8CB#-
MN!JK&_L[OMZ@D.M%"R[24"^)UO8L&&"7 C6R&<C95TX@GJ#.H;J$I?Z5 D8_
M0P(G5V760SYOQTK2)-1H3IT 'J009?$K],LH0RFI,*2$I-%7?L<YJY<G[ZFH
M5)\74]:SW?+CF0ZEVA0817MWBY6*B!69LR947I"[E X$2CF%CX"8']@D;?=#
MKC22<- =^2>TC].3*/FH@D^RV,&!XWC+VLS291$87]9=LQ:H?5$M2N+Z#>3#
M,]$0G27R $$RG/AVD.Z63$ MA-K"#S,Z)O1IP-AE**BBRS]$/$\8:OC5D@1T
MK8E"+]$=(&Z)TKF71)TU'TWJ]Q>5&@?)-_:D1&*VC"OR#.JQ:<5I77_2!4;I
M1<W_S_P#^?N)Q[;("RJH"A4(:M!P_[2\)N,I-[ )[72!DQ)X,6?V*&WO)PD$
M04O$9&<5,R+2]HQ9E1JA>5G)GC((:==N^IHMVDG/;=[HDO-^/?7*,2J/L2A"
M2)\9, Q7>6(6*U@1OQB:;JU,-YQ]7E:HL0KU0J] NXEFQ;5PK.-=K)Z2K.J=
MK=0BIE,,>VK2GDFQ9R&_9B@E\+;U;*/.O+0RRM<GSH]8O76RV;2OQ<T'AL<O
MG!,]?(T:67P.#%U52:Z.-V32:6+O#WF"2&XXI_@C:+VO&+60W,>\48K#PT5*
M_C*&? CW^ZK7_-^\ 8%65[]GHL<\K<(H9'R#%G0/GM4Z D@P8.HJOTH.F=8O
M6R"/K/&MZHI36&I[J'"^2$!(LY).% 3C9*FB1=2 5$ZOE$QYX/H%W!:KQU"(
MG()ZZ32)VJX!C2(UKZB.(R1+TC5ZD7N[N^33Q3#Z(P& KEX2+PO]TGU:A&P2
M-#(E4<V!--9CIDW3+A/F@TQ.65:E0\\8N5$,4S'M4NJ>C)0VD5;DX_7V;U7(
MBN#M%0U(F!/BQ/=A:S%UC=3$_:5/#W\YG+QA5A5U!Y-\_.%?#R=_EB^1NB+I
MP)*)7*#KR.B\*8:WC]FEPW&3<]$F8OLM,O=P\E[-PRJ?N_Y[Q1[ZX<-.5B2[
M.M7:$9'V<\&:&E/?>+M7@RFSGQ8QEZ\7!'W1RVQ2^C__C+2JZTV :HPRYH7+
M!:52L<5$T@F-FPGGVHF.0UA^%H%PW#;4:U&/NP^C6J+I7)1M;-RWX; H_"Z!
MR1N)I[#TPN)0J)8<5[-Z[A0_')]4?KN('8@1T*5K>>19=L"_-\-''':)FS(@
MX8 R!6O[OS0%M8Z394G@H+9M1&JC3;K<OMX3A.- $_^QTT*6[JI#( M\J_T0
M^Q9Q8 _&OTEU2V^1)$ 1?T>.0) $ XZ *]XN&V$\H*%9-O4EF8)041[D<$WW
M/*=C?[^I>#J2AAV9F'=,<4PDI<%*S#=3783IHQ*1&'LZ7(7OY-019(E;:>&:
MNRGU_ZI$C7$KM0X#<@UZ]+/3$SX<6>,%XL:(>O.&VUE"NK_)$=^9R-7?#$Z0
M^ZR]K>3I&!"E+#KR6*-2]5C<^K -SQ<T*HL1VIP7S?R 4QPZ-3V64YR_"?JR
MNBB:6CKW@QXA%D&^< KJZV60LAV=PV/V:=AFY,TFN9G#CD0IQ3060OJPY_+:
M5L&1F4LGK-=,&'I?OG#>^KP2T9X$*H1M'Q,K$4\F93AVT<U3 KSH@Z-IIU!K
M]"1FW#"!@R=P<9&O3^YZ]/'\=_UR8$GA\_Q_\F9.KZ==6BK]U\+!^3G\?7;N
M5D+S:)K1RGRU"G1@AGTJ7"U325QJX9M;ES?G[JU^;P2O],L R!:>]XT+B&F.
MU'[M&DXK^EG/0T08*IO_JN&#.;[%@ FS#0ESJ::/>;RZD2<'PF+'=O["A69;
M'\X='()(6UCIR<0H1D;/P^%7(?+8,Z V8^:D6X)8NS=!&5;!_G_7^^'X\6O"
M?W)H6_K@=CX):=[T(!SIBL8S[QB=P+W0'X&OV&X=^P4 XFN4JR3E2MDI P)-
M@(E!\))'C^",G4@_\*P@ZT*?=Z$&QC,X9X5UK%(!7=$2B!FXN(SL7MNQ-02N
M$!\',H#U1J.UF#0.XHG:]6KPD.9LHE4G(M9A(.+5%\AZF-UC5C6%GO5G'U]M
MP+//R,U$,=*O\@:LV:'O=BQ=2*.A/> ]VQ#M7V8&@RH-WO6J<]:_"&/SKU^O
MOTM<P]$>U[#'-=PC6WWZ):<WG*0IY60YT#3DDN D#DQ(,(#16B<Q)BR[+8DF
M94=AX::#E0$.7^1F:/IM>+G1UUJQ0GU>-$(BP RT69* J /I%AE9Z5D[G+SK
M=OH 5P0\(1:^(DV;&4\C]/OX.9]][7Y$J"Z,==A80,7BAM$MTFN4^:^%!I@E
MCI VV(:N$]/G<T4;]Q>M1UD\W#[,9S$L![OC ^\SY32]M<=,!02@_X=-'#7
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MY9-%61-3VJ(@>+H/T\N:73B_A#;G_^C\IJ!?^YVS(I;BG'G)M//0#Q]9)EI
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M-5,';WJZY<8%;+IVC2[:BEK9TV8+[!?:B/0E!N7X^43?!-@8IF5HG) JL+]
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M5<P/@BO5HS*$RN&H="B](#75)7GB>DU^0U=Q&9 .<N)*P\#&@)L"[2" 0=G
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M\F<I1X] ]6+XW?U,]50ZQ[CVD0G4*43RDV^6)5MJR5BC!HV/5RD@54-;@:J
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M1->1[ &7=(G838L]LA'@V<.P 36R[@RG L<>T"$0>B!='5^I8C-!]I!Y4'-
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M'HJN>G?S$:65&1'U_.JV0;A!Y)R%_IPT#(%V*V8'Q ^? J\"LAM=X9<B,@2
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M!=MS%S^U5-5Q;YH[#^(R)#'MF+&[X[7TM[%,E1%FR]'4HU!QAEA40EB0PA[
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M%7(^(971.*:\(UNA6QHG5<,Q_AKZ\Q OA5Y.LJ+&+GY/HV)&"M&!;AF6LS.
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MKUG9X'/Y6V5/N8$%<S7*R^D@EGZ*>N!5?@H6RN48IPQ%9B>O$.KA9I?Y,'7
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M=1+H[/\L.V6N!_5BP*H)G5]& ]R\U$NOT&L'^.P5^J$5NN5GV&9J1T[DZ<Q
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MJ#_1Z_ #Z'#+B4CCE()]U2/+,ID..Y8.G*=ZZCNFY7D^]:'0R]%"?XNJ0YY
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M']0R4X^&D>Y'L:$[J1GJ810YNAW;0&$5F8Z?O'@3, -@/[?JQ=X /$[8TAN
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M+8OHCA.D>N!8GNY9/C/626I$00)=DH9F>/.@*[?.)VV,JW9#-KBW=[V]NX<
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MX7#"U7G[AYZ!Y]E;)[Q)NG2U%,99IK(4$@(J5LWR-^!U62I^#K$4=TX*$;S
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M)[UQ;Y)>I=''7DA3GG^9PO#=H#<]&5B-S._MBM&PMO:>1G""Z)R!%#U-O+!
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M.M'$(D@J7;!><Y#">1Z=M9[2;U!2'5S=+H)ZOSS 2G*C@W24H-KQ1$:ND9_
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MK<!&'Y:/55"AHTZ99*H%LE&.Q$>7B @H62&M1UK:VI8WH:(:X6POD._2H:A
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M%M9:'B3*5:#*4TW0.*5$:FL([G!*4%=%YT$(9*ZU.2OUM$QK ;Y^9Z4"_'X
MON"1<(%F2?%#F+=HEL14S!)IT#<104E()BE> ;ZA +_C'.X:$5Z]CYO!?,G[
M4"S9,FC(L^B)#,"(MRX1I;/Q J1446YM*]'5ZZCX:MTIN UR/(Y'I9!U<MJ!
M0>PD!,YQ0='C2I[<<;GJ-WCKQ4PB+_HPF#P9Q&=SH5166HF5ED>4ABP,@Y#*
ML1E%I$N...<#23[(!(JAT8&LI.5-**F&0=N+W=OW*BIVUX;=!<<A<I93X)I
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MZ]0V%"N-AY5*/8<8IN4#^F5;"?J>$N16K;9+QB7&2>"2<;]OAQKXM%C%N*Y
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M.S[0L%VWSP>YP]!1!.<N8-(<-4%O/>@3H*4J:^S(F5F@;Q/P1X,&JYWXRVK
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M%$?WSBJWQB:QUN;H3Z>B[]Q(;T1XC52BEA@JX^Z)@DM384(?_CJ=+3ROUM+
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M?)>[>34IH6-5")XIDN2"H[\6$P9+3:1.HY)+E@JL[LZ^?#?_*$?]'TCHBMT
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MJ_%J^/78>^9GLSEZ.N_!=L;A3ETP"\==X];P_.N!X7[-*MC7\PA)\(JM]_C
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M?:611H"LO+>TZ ,%*U(>4IS8D[Y;G-Z4Y*W#@Q1N5#U-MTW31BRJ$-3S]-,
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MZM =Y#,I0U5^L_F#3S]!BXVL2T2O<CFX&EU?&EUWICD63D$9YY#UA.>L;(;
MF61(6FN<(HXS)XJ,'3EGAY 7T,97#E_5N%SC\L\6[ZMQ^;5P>3+]B@B!M97
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M\_K\7E%J5RYA?AM&W4_Y*;N=W%NN9SNK^1Z#WGC:0J[MX< Q ,<],_&3_?R
M\#S'L;>?75& *^MA &7Q(OA(II? E]L!A+EXNW!H2ZH=VOFYW*#Z:!7G^ Y/
M6XQ^-8>^\RIUVC&_WX^YB6CA!)0!BYR87[),?V!/RH%D'.QUBZ&7?HBW_7AM
M8[U:@6L\/Q:T>!EY_O:,51T!P]BNVY4C-TN%"Y=LC+9['SO5)DBYIUQX"!EG
M>K%R!_JG8"]2._=R_3[<.0DQV4'G;"+1?+7 E7R+["9TVL?M,K"U.N.J-H>9
M8";*M!R0J#BVMK,DV(&'5@IC=[1M4UC-*R6%7RK7;IA3 ?A2>,O]:U[/#0\*
M:UH\X=@#%@\SC/:-OE:%8_X??.JXD,^L]P?9H2V/V5W?:KB6#=2K\/A% SBW
MF?GUT=ARF'/SY/WW:L.S>/ZW;/ _7;0NU_<X$TX[01'EDB*N&$6YE0J*(C=U
M]839Y',D>9;!O]I:&@9Q; X*#Z[.[%P))4AJH5G#?<RRXM1P,_/ZYF+>NR\0
M\!C,:F&"BF-)Y4;CT&K<B@/%W3(G *-2W':B>M*L8GAON-X=N[G>75VY;C'&
M4E>NJRO7+=.SW5&Y;G9]L)^CWM=M)LYW@/<#V_1V/*^Q]%FK"#48K&+APW"O
M=?A&_R#&L\(X.MN_>OL,>&B9:@:D#@:3$V[ W8VSV/,2^@6;A2MT$DL>61"!
M!^0KG=KVG(7/GCRE>)0>6A#4?CXJ[>,?W?Y9_RUGWN5BSWN!*\G #4)6&XFX
M,!'9"$PTNJ@)X<QQ[U;6C)B1;5?PQ'[VL1^4!VQQM$11:PUW7$NN&>$I6"6$
MMXJ9NS9DZF5^4 ;+]N:>E\KG[%:D.,\%[8C,]<@D2L1+'ZWT*O*5-4IFI/IF
M!"ST&91_F#F07=1YUMT9;"+X/C27&?5!.HZ#-SA7I@N!.E:O^[.LN]_3"EOG
M$T<L=[G@(H*J6ZJ15<I+$S"U OQ--:/%][5U/SMH]T*Q3=N._7>-/X:QL#S?
M986B,@D[YZ>"=,!O8>#'3:ZWO=Y%MB%#5_7D>O"Z#,P==^$&E^5%IK)T<\!F
M_WI* 9I(*1@&D/+0LSO;:Q>&>[ZC4H)'++ /D0?#!0=W/7GN6" *[)*_<P>O
MEM5[FB+6NORT1Q/''AN/P":Q?$ 4<$EHCW"BWH#,&JO!P2*"W'@$H93!*T&-
M#P8IR8TVAAF5P-4SRFAE:&*&@2BPR/U=N9;UPC\(I XW]R2Q(:CD$6.$(B[S
MN4RG@9X0G8 8.D(E\!&JV+V%X!I:E5LA>:<E TCYT3DQP1''&*<8<TUS]3?+
M:/0B<4N<38GH6C2>)?/6[T6FM3!.@D!0C+C+_46\!9!PH)F!VJ@"\!;!9HA&
M89:\/6V?@5]U651JJN+YU5Y0$62<VBC]?_!&]H?RRU6UI+& NZWB_Y,G*H?;
M#)4O>-V:P96FK-DH^0U&$;_G,DZA9\^'2:L@C3D6UK-Y)"A[:=D);4\ZE,];
MZ/T??P!FO!-+&2V"7&^[VOL1F"N*B; .I?P79\8BRX!&8T&9M=X[QL5D]?89
M;G\5O2X\_XE(P&NE_=VU6P!"G5G5/*"I30(<I#1@\.1Y,CK)9 6FD3&E*:%U
M(=-G%]H?S8WW>X83SP.85T\8<*Q\PDY''! C%MB7<A&$^>:CP==V.F_?##X)
MQ7MYI[^(L>8<B3!*(2G.%>362W<%Q6[1CMEQLJ(3T]7.4-']J<A&..W'WX8_
M_#NT^Z<=>_%;^Z00_^)+_[Y^R[P'-='YJ;AA^?;5YLH[7&ZP5,U*JSM7;[\K
MWIKH9E6^I]4[BOF-;^-WY,;W;KLLP>^$D?>Z[!T]5N]L?SS]T1F=^JK0^(MT
MI--WA<?Q>(PX'^<L]L(RKEUK//;8YK,SIJ$2T(7JS+?=/2O*D>2&(@]JN_;6
MFS>^I=Z,3]7K]GJ*R!]5*&AXG.=G-MU5>T;1@NLV+]_SW8VC'UO?FKBU_>ER
MY]OG@ZWM3=*Z_'#<.OP$W_MPM#/5GO&(PC-<-K</CK:VWXN=?!9UHW6P^^?[
M?&_6_+9#6QM@\N%:_[E\/]7N5F.A8@[Z:2F*HT(>N9" M.K$.,'@$N2C0C>8
M_D>U9WSF[HOS(/7L%N6+CM1_QW[_MT;5Q+21TT6K<&JG>[*/<N 4S8+QT8S0
M^69D)FK7Z)4K7L%\;\-T9Q2;V5,VM7_$@"YCKUOCU5QXM3F%5]Z)Z*@3*,;H
M$;<<H]P.&''/L$A>,ZO8REJ1Q$G__5C FHT++X-)R\X>5QLGL<AL]=<!ZD%P
M]"0,\TUCU8Q,W.LTJ]4]\<O5#WL9 *PY!6"4!R]S91"L<WZOP 19(N'7W/XI
M9SI(1VK"M9#@EM5GF TXW"<:P5QYL/VA +>\?.N75W$74P2H"A^*M2@WQ5IQ
M^0NFO2PV?9K")A*%E%1)Q)A-0*YT+A:)<2Y_FUSD+NF45M;XC!R@7VM.]6P:
MMCY$EO']R&N%-1[#J980<EX]0/7E9+1U^[$7C]N#XQIZYH*>+]-QJ(B--XDA
MJ65 /,!/CBJ%%,T=Q+B*)+J5-2:?B!+5K.?^8:9A-.G*K9L7["L"6NVA,9CO
MT!WD';GAZ-_LUL'33U -W;=$YVHG]SG0?&<*S26U@1&M$=$8T)SIA!Q.&CDO
M8L[+<EP"D:1\5=)'(_J3J]"C[,&_BJR!\7.M5_E7+Y>.5=77:.<$F''YKU.T
MMM?W@A1)))P;*#"../<T"V=$S"NN&14B,O.X%*W%.:QU]QGO",,[+L\Y5J?4
MIHMX%B?(>\5)N#))IU^GZ"QNBLY#_-Z%HU"YW=)C2/W/1A1G/6)-]6ZA>E<F
M<+P3R*A4[.9)"VZ_?1X[WV,SER_N_^Q;MI<[Q[L'6W]^.-[=WF$[E^MX=^,]
MVSD$6WFXSIHPMM;VYF4+*.$T&6RU=X_?\YUONYW683AL;GP^:FZ'=A.>L[GA
M+[:VOY#F89,")00RN#Y%!@5FS)O<<\:[HELT6%Z>/%(D<&<Y$]+S)]NR76S_
M?N$ *#<2>V,;%HN.2SO1]K;/NS4</0D<36>\8<$M#H+E;O6 2<%II,%?1390
MZ3SGQ)OX1C)(%A&.>+V9L7APE-OVOHF(V0NATG1>6S!18P> I)BWB!N%D;/$
MY#2WZ*T3%#,)^K&*]?1!QIHB/3,FB9HB+1PF?>@.>C4D/1TD36>J*1:)RY47
MG H2<4<T,EH)0"AE#4^1 ":MK!$ZL_]CS9.>&9/DC9CTN&>MT>A!:-3^7A.D
M)T2C\=RT_1_-(HH4:'34(VE$/E@?)1 DS%$*CF"C#6=.%ZW9.5%3:/2X@YS+
MF;?Q@(.<C]Y*_:E#\$\\.S7HUH= 7QU;JY"8I=%Z09$C"9B>9 X9)G,A.!>U
MH-8"N#[5F82GU:)GS-58AEJL&X-12Y(9K:FO;_<7U3=R&97KA5AS6;[]DZ(*
MT3RE6QZ4KG*;]@_;G;XORQ^]\0;H7RZ;A^_WB+.&&DZ0%V4:542:.H5HTI)Q
MGT)R8F5-F6G",W=INXA#,C$XF[SB2@<7G#,&>Q*(<$;'JA1/M9ZX7L_YUW-_
M3R</2T;RK@- +.?&(>NX1$$H"9KCI<XX"Y9S:CUS]YW<%R77M.Q<%+5UIPJ&
M350KN[F9^\SBS':\:])$%;'9[1F*);RS^CVA?&4QRUO/KI.NWS6>.TWOK.N/
M#KJ=7!7N_?\.8/9SW?F-=M]WNOU!;W'R\PX_55K293MTYW('V,?NX3IO77["
M6]M'YUL;7T#R0[MU^>%HY]L78";P^A\36@)L9/>P== \;!TW-_99:^.3V-J&
M:VR_YRVZR7("Z>YVD^YN?.+_N6RRUN7F7HP**PGTP\2$04LD 2WQ FDB$N.!
M:(#%$KV*<O;KF13Z@ T56&KB!8@A,8D;H2,-X"P:1_QD/M_X&E0=?QKE6DSQ
M@,EZ>M-E\N^^^<1@>>#420 #J3DGVECXF@V8&2PQ#K/3#1=/4S[VJF-X<&.8
MS>6K9'__!C@'-MS<0:E_8 &'G\0IVFQ]F"YI5\UR(;+_%/=:'YP=='N9L]W/
M+\)O#DG\CSW*D[0X$<1\((@KH9')A:VC%(I0+S3@R="IF5W8KES8XG#O:,)S
M>\1QJ7^W2'*1J\1.RL2,S)&W)PY Q?;W;,),,":04GF+U4:);+)@7+QGW(6\
M&B;W@+E-$"96'X#A>VRX&,$2%'._T/T\9L/X^AD"J$,POJ,(9+(P@O"HJ>SH
M<=KK[O?L\2(_UHUM2OX:="X S(F^#N; F8'CMOL'N8S\2<->>_Y?UK>;O]XT
M"XU?\G7R%1O%QTX'O5R6N:@$7#4FS'4M!YU0?K5LU)>;2PY.\V?F<<C@^Y%B
M1S@AFHO '78F82T3\\ 8G,E 0316-P)%4?&C (=A\>B/Y5-<68^EBJV]/!O%
MK4][,/DPQPJC"%8#<2H2LI9$E%3 RE-MM$O@@M]4&C55;6&/C[LG%624A:%!
MU M'+?_?GF5<^6[!$P-9JP3Q%,AGKDU^>XBG4?&5B:!.'YCMG(;)8">,E>"V
M!:#<'EMNO#,2*T5I8/*N , ,"S62O1C*A_A8E*XN315H>?%6OV8PLZ7OT^76
M]OYY:V.'-(OH[?Z>,B80&1,BEO@<I97(*&.1#-;G"LK$IECL@!D@-,*8V^S8
M-8DL^RC[V/X.DG52R%Y91GG>(OC>>,EM(F!?&6>::XE9],E9R0BP+CQW$&F\
MGO,0Q;;2'\7@"_&JL>MNZ3FZ;&TT]Y+D.&)ED&2, ON1!KQJF1#EAG$?K%82
MV(^DJT9-'\D$<.EU!_L'C7'[]ZX!-K9I+V;@3SXNWCXIHU%CWR@D[9KY!7$[
M+]ZYP^)2?(O%;>=VTV6K[P<:6^ISCQ$N% V))\&<C.#!ITB<3U$35[!RC$5M
M;)]+8/=Y:WTO.L$,R J2/&#$8Q+($DJ1#6!G&0%@R;T<R$W^VA-8V_E" @\P
ML]AI8KPG4EL%$&Z=LMHY+8D!)Y!J64&DN&'?I#:SSVEF\SWVF!7$*BH06-N(
MN!,:::(<<L1&34E@WH>5-;9J)%G%BK^\E=54YSY\RG!#N=)*8RLT]XQJK",/
M[@X1JJWLTWD(O+4!S[.]SN!9?F0KRPV63N"(C.6YG#)Q2'OL4* TL4B8E%JN
MK'&VBO6,3;NK[@E#BW>OC9BWVR>;3TQ/W2>[[I.]>*V7ZS[92_1L#^F3_9-L
MZ'TH:GN@HHA\Z88M:=CW)#Y-3(PIS& !15(JGU./6E,6#(:E%HX[.B3KLHIG
M8,EP3=:?<QOGO'6YOB>"2LH*G!M5)01.4T*&$0M\W3JN<"#"X)4ULTKOWM<;
M)^BKN4.?/2E)V'FO?08&J'$Z<)VV'P]+@)\XS+ 9O7D[?8<E+M9W,N:03#1*
M*>ZD!6%2+A@6-;-6*,.$YU7,X1XR-;;W]S&/[^J&;U=2?K2VO^S!;'+PJP/R
M*O>T9B(@QZ- 5@F8>PRS3'+O6/-NEI2< A4O).4=8-.8MW:]&62CH)2P0$4[
M8Y"0%&-_M1"L=K\/%RJ[S)9M):M,K:G&DB/Q*CI2SN,+/A*A)NK#W^D(PD1L
MI6MAKJHA:>T?SI3"B];ET9Y-*GE#00JM "F,#B-GJ$,J!WZ8L$EGAD D6S5F
M6@Z7<$?YF^WU[&WD;P%&?B-[ /4ZB:7>G;?/#AHV1Z]9XQ^X8.R7I'T=D<95
M\E.A#L7V?]:'ZYQC/\]#J>>^ZHC>/OD>P=[T^HWS:IKRNZ>#GC^P_3@G0;&!
M6 ;.DX^) ._TF@#E3, Z60 NRDU6?\*J#1?";HDF%OK_1\?V^UNI6K^MWN<\
M-?]$7YU_^\-V.C'\?C%<W^H#_=8@!TMG)9_4U&4$!;BY[?<$%]PDCQ$F/ >X
M24).@FFR1DO,8W!8A'RDUJQR,Z.A^6SB4O:O'DE3D9)B'T1)&-.>2.^#\H&3
MF#3!6BBBI&/>&5Y0DENE:$A)9@K2^Q^QY]O]6'"4T9LC*2)O6CI:AY_VC&0L
M8JD1]H*C'$I$3BB-&&,<"$:BP&=6UO [+&YA*T RRFFNN&K1:+I8YOS9 7CG
MG78J8BRWI3D_"%C&D>3J?G_#[:Y6^QH^ $S[W\*@EQ,;WMZ:D^;V_E[$CKH4
M(N! ;KW+;4(:; QRGAC"@N,,9XJ*)].2BV20JG5]LNU>X[OM#&+52K<_!@>Y
M)W,^X]/+:2,YR3]CQVGW)+=D@D]7^Z[VK+!;Q099WD:KK-GM&V*C$T7#]L]E
M#^A'6S4'$*1CPA'H+#>6Z)1;?!'XU\GHAI[10V%HZZI=<6VL;A!-VCK<V>,T
M  8%"K+(%<K>!+(6.V1YU)Y9;UT^??1*Z:_UTCYF:56.2K+(D2-2  _Q%!FC
M* (@%TP'@!Y-5M88T) 9&YSWYR7S'$]<'0>1^83JD6<1;TSCF!6C&]JQ(9FI
MLZUGR!AK7J[O&6<DR7V$(G$1+)L.R% ;D'82:XY!U"RXO2<STJV'#*:0J)$]
M =\I_@!S<K*?6\7W;A*Z178Z9[O+[X=/=;ZT?O/62:/5_5YFI%*9%9J8B:3K
MXK1BR*<6NSG*.EI*N]^+Q5Y1Z6[##X6OV; IM3OM(DI6O/%[NWL6_<$)/-'^
M1>-KP78^#$[":N/O=Q_?E7EBU4QFS!D_X/7KZHR\L5L^/QI<F1^^#R/<AX&,
M<>9[ I/P,E 9O1?><D.52T3A" 8/<R5)&9T#K(6?T/"'^=WSXL9#&0H?NKV9
M5+LV@2-XVLSI/GL.4(EC&I%.*>=#)H^L2 1Y&[W 6 ?E>"ZX)V[*[;XAS2=#
MTPBSQJ4R-H8+\^LU;OPX$5,!X\2DB %L'I=."QT2F#T-YL]%HPN7_3;)NI50
ME9&=K71W#*@6MAN$[4?STN^%),$ 1@;^?-+ MP0%L2,,#*(DT;$8M)0/$;9?
M^@-W&'T!:S9D&U @*9C*HK7#]\K)*[8_BR^ ,6D'H&'EKD3_M-/.+2Q[\,E>
M/U:?*5Y=;8"?N0]P#N)\M<L/8UEM5-)<C 6\_&XG7Z#;V[<G[<MR4SQ;YS:8
M&:!\9R E_?(IBC/F(?9]K^T*2]"8K1VK5>#U9#*4\<"-MN=5D3JJ=;/L8WB&
M/6E"X,)RI*G*LF^  K(H$$U&">OA;1F*J!;X@+?MPBT?*]H\R5UAN[V00RFE
M4*__\T=CNWO:]@V!Q6IC^$S/-+KBBK^USV R_#W&.SP _ZQCNG4$TZ5IBK!5
M?C&WP.R51+$,<EU'PC'*EF-<O7(_MDAE&7VPPM"K(,$H.-K+U36ZY6LANG8%
MJ*%(B"PZX;0# AGS]C3/YC!<-A5XFT:S1K>$N6%$K9%SI=XUOAVT<Z+;U5!6
M;_AZX0[[##SMU"Z?K@K9M6^3+J[QHDG71KN?-\@'[?Y!GN:_V];ETB.9ZQ=)
M^HL@?5D>[KNP,P*K94V5F:+3&(D.W*+=;YQTSQICQCM+MLW%/[* EU'=H1:$
M6)ZF*?1@#L&#F\ -LGR=M8&T75R9Y.X-URA5+(P498;D%JV@J@N<Q'T V7;.
MV)PPU)D#SQS4N\96/C($S+=!Q\\MWNR(55&6FY[QI)$&G4X>JBURZKWM'W1B
M_^J;#6?[[8+B] >=(D&C/?%8<U-N3SS.6:M$T,2-<TXFFH@36N$4@J)5S@7#
M% U_N,VKFXHH;9Z4 :>:4M^0=7^YM?UESQB5CT5[E/DSX@++3"LTLM1K3KVS
M(9^&S)2:KQIU_\W41:89L^-'97Y.J3B+//K9H)NA;JCNLPQ[L:69@T*=,H_B
M1EW]WCV;9/[6&1EQ),%RS(W73E++F7$T&*W=W('AH3?\-:<_@XY6B5&ERS&Y
MK0GZ>@ZVH1]/WK*JXJV-YEY,U,; +/(Z!<0MN &:"8Q4M)@[%[GT=F6M>Q*G
ME30O:F%.H@6;46YP'\1.>-?X8TQ(AO*3W\V&=5Q>JB-75Y[O*HA,82)@H<$<
MPJ?<12%VOW=M+Q2[G6 %?9&B4PGDT!3_,OK8KPN-$_.7.YJYE3N?6921.FFD
M"]09+J4&%>/@VCD2G(W.^_MO[5WE&_Y1DJ8RQODYPH-_+T*<'XI6E<,<Q-I0
MWJ!]M+7=W*.2I4 $1P%'C[A*%(&!U @;3902( 78YW1I8LRJ('1V*<EY18&Q
M0'6(242N(M=,2=!Z3)FB!L3D_AOXM2@\F2@<KN]9H8)-7B*I<T<'(BURUAB$
M+?:$A*0)ERMK<E5+$ =][P(2D\4I>]7JC/R $1F'+XZ[WZ6%[YZ>C?*DAY'S
M1\+K2_59+B3S]XLB,/BVRS:^WP.6Y2V8<A0T-H S,B"3C_%C%QB))@;!U%1;
MY:7I^JOX.Z74\W3]%0^Z[.WO"7;S31\U6/T4+8J');QQ+N ]=KU;/CJCET!U
M</!%RN;KNURQ0JS&RS(5)X4SA-RC4<M;F@_\N&8<,SK8J'=*5'7@EZ OQS_C
M1N\QS0YOK) _621_V;N.S>28*5''N01*@P7X]$%3S",-CMFDN1"J=C<>1@/*
M7A2GG=;Q^_/=X\V+G6.XQK;'NQOA>&MC$\-U16MCD^P>?S[8N?QR,?K.L!?%
M\1>ZL_W[\<[A7^V=XP^=UN7GHQ;=@7%_NFAM','WOQ[O_OGAL+6]R6>U9Z74
M4.9L0. U<,1%PL@RR5%2!K-@+!$).*I>99RN<CK-41_6#/'>NO30AA,/A+<;
M#4*-#W<EA6HFO<?@Z+A,Z[EV4@M.1%0\)L-M[8,N"3Y<7,>'Y(1T47ADE<7@
M9GB+K+04Q<1)LI(PGGCV80'Z5PW7RX(/3]&4;+EX$.C/&7CG9Z-:REF?'T:(
M?L).J[,/QOADHV).2> XQE,78TB ;"P%%H*C->=9!DR;;OXL*;!8EA22--<I
M<(DC*ZQ FC-- L>,V<QYB%J5^-&,YPE;K3X0JQY$:MZ*CK,8%#.1:QHT=X:X
MX&.(E@1E+1.AYBW+HN,3O,41[[WV"4G ;<2Q]TACHU"T@@1/HR"$K:PI(E>5
MG"X-N-SME)>+F$R5KWB [_73PQ1XXM0QK2P/@8<H+.<2*VY8=)$F5>_V+@5,
M33=]9SI)+Z@ ?\KG/G6"(*TE1XPE$1,#?]J$&T^&/LRW6M+PRD^OXMYJFL,E
ME(%BAQ1RWI0@7C@2L05/I&8B2Z+B$TR$1TJ)L1P)+"SBR3FDHPR(>:-4L#1R
MYQ=0Q1\;(7F,UW%KM^+'M$-?=HQXNGH.-4:\'D9\F:(!@4AB#*,H.D\1![Q
MQGJ1"VVZ*$G2UM';DL:>H2GX,W<$KU%E<5#EZ0H U:CRJJ@RP3R,%LY;XY$G
M7B'N@T>:.8V<(LPR M1#X]OR#Y</50K2\J\B86UMLH37DS375O=HKOU*YU+,
MLW?2ONJ9752IS<5UBRG\7);7+6K3%@K_N^W'\-%>%#7I%R=1TP^[T+=;=!>T
M=9-O;7\]!FV"S\.]#]?9[I]?>/Y.\\\O>.O;#MYM3W:AWV2@R:QYN"]:WW9
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M.B$F@J.Y!<=SVY_U44VSVA+=TQ)=]18_;%ZVMC?WA%*88FM1%#@A;@A!X/:
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M-N9!C5*64;16W.+,37KVFT>*22NESC:#><0Q#4A;[Q F(0B#:?2.K6U.DQR
MJ-G$AR1F@8QKJT7D1">;L=DZ@74P*GKQ='/DYB,^KQY\3MX?:9RH$I8BPRV
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M?>1<4A*<TUS#TE-?^.!4::^X=37C7P[EK3)^&PPKVG(D[PSB.#)D-3C=.L8
M*R<\46!Y*9LQZ+6*G<:?-S_NSI*;<?I_J],HJB#'*?V=+^//_""O;K'=&%=G
M:W5^S^'%(/>#ZJ7JX.DRP?ID/TF!D]?@"2.<9RMQ;CG2V@ID5%(\[[^Z4(R(
M6^<SMY-<TJZ1/THJJ1&P1L!;$##BD$P,SB:@JDH'!R36&.Q)(,(9'>OMHU5
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MR-IFMQ,G!>ZL7)\Q@RLE*?]U"[AVK]9PA)!C-EBP.I=;G\5^?\SV6J? L%M
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M]Q0+RI2PA&JL?>)28VM5WO=PP 04 >EX0(E7+1;S%HLO1]9+95D$?%(FC08
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MG>V1K/ID^2?V9L9K\JY,&ZWQ9B:\.9C<01=:$.HDDBJ7<E%#D0:+@31)F+M
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MP0DGY5Z^R<LA B_3WB_4T[B>J5J;_!F5M.)L"&M!';%#TN&4&T0XI/,X/Y9
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M>FOYVB;;>'0?^I<2S:LW"%Z&TUJ#R"- I.*J!@\K)KQ$DKK<2MXQI(T/2(3
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M1[870E)P%KBLL#S5XC3P)(T1 .LS2VW-&;D4)G%?^HW 5Y*QI(I$.+C#;R/
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M>Y;KVN9U$.ZN]Y2(_-2,G<-FZ9(O0M+R?,^M?)>E(S^G5-3>Y.G9''Q*QQA
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M87_,RBFOB@!:C0"[AP!&S0]>/ (HAFU8B "*;EO:>Z)INJ;9SB]Z*QN7.3U
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M:#F)_"ZA/>EW,@IA<J:]76==9W<66.[-3>K(]V9 15-J4'D=H')'',W9$)[
MO,19=RSM[TG'\0V(SX2L"$Q9(W3VHH]-O!Q,F:LW7V/*J\04D7L##I M>DX
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M=LWC?SP^O(JB1U%9EW@_4Z4_QM2-R_>/^>LQ"G!<?$X#+U5\#MV(//3%]N=
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M,4J\:97OEM/4P'->L,OO\GJ!D8:H/8,G-_@-N[Y(X?**Z1N4#-)/X=<(A#
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MCK*U2M4C*,Q["RJI#*%$#Q*-J05FM=5]VAH<=IR=3KELND3EDY 226\54X.
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M_OV;\G!^C%\/KB?0_?ESZY\%&6.@.0*8B#'*!?+/<G2062'9B9)*XKLXS[N
M.TWR'84JEW"S[5G%W4#!7<C"6N,R<.81E(\:H@Y8K4V5N;5>^X8G6QMA/4TR
M[DEW2^C6]$!C!6(O4@DQ@I)<DX"<@*"SAAP%TSZA3\+ODVVKH;Y(LG6DN25<
MV_K48V,?/"[ZX$_ZV3,;-EF.3OH *CE/7[2$J)@#AS)HITHFE^FP(9LM1W;:
M3#XJ7BPA_M:G,O?28QX$EEY5D^3C-%WKQV^W'WD;OM5?O:IBG<GY]6 \&4VS
MWL=O)I]P]($,F/GD_B\<3Y"D-!MX3Y:@T4L+,DLR7DJJ!^-<@N=*62XRDRJV
M69OW-,+3G@A'R9,E$V+G Z4[,_X=7M3TV0_##^'K/_J33U6PM)F1.)=+HR?1
M$4Q!?F,I@K[H#(%Y3O:Z4\Y*GY4OK1?Y34&?-FWWI<TE3-SY=&DZ42JB$7ZJ
M^?Y?2%)I>(F_#<?C/W#RIM! >C(7+2T*FB2%3'-C%#BI&&B/F2<AL#0Z"EH'
MW6ESJW/]+"'1UJ<LUR )R"VJ7K"%1Z/(QM"1>&UL!%>R !=-S/1CL*Q-TO$]
M&*=-B^TEOD3_6Y^'/);^S!6Y[@*$DX[<>N;!D?$)V0=$Q8-DL5$&X..)YYUD
M4G/I8G+5A<2:XQ13 9=2!)9$4H$'U++-<OA4)O4.%VL^A'B!/8':%9D]&'1$
M),W)0V9U72G.6JDU2[K-S9+[.#J<NW=N1C:_+K*#,)== ?AN=L_M;^EB2%;#
MW[\GVQ9O?SD<3/#KY)>+Z0O__OT8/]9O.N/#C%YUXQD.JF'SZFM_W"N>9Z>E
M![)5:AH[DT#3.0,+.CK%Z\6&W)8>RV!UR)9'[JP^PIXMU+V*.3N+O<%=D@5,
M/T]WP[5 ]19NT7;*B:6PNMSU5]T%?H0)NZMOV$KV>R.&U5YS5MEO,ZV@-I-9
M@\D#<FM+P1@$MHF/[Y$0]RY;'YX/FXB\ 0_NG"/^/K61>TYES:)AP*1EM(LZ
M#3X7L@&Y0B&<T%ZVN4GT ,K^W8 .5#3L4KX-+IJNB%'/P0F,0@29P3-%0Y4A
MDU^C:$NM5\EU4LAS&R/R45BG0(3NY-Y@%7B5TM7EU33\M2IH,0<J%187K"%W
M59+CJ\G:]LZ&F@AC)/*H4VB46;PNQ),@2Q-]-+B=^@XG-%;,OX31@!SV\1Q5
MB45$X1PX4VB-XTE!<,@A6MHV/0^&^S8AA.5X3H$2'4BZQ9W2JSCNYWX8?7L?
M+O#-K'K(U%+*1;*<44,4BNC(10''ZO6+PE3B(?NDVYQGKX1T"KYF)^)N<4O]
M%LX?X9*^_3 *@W%(5;YS\J^#L*G3^33& WF@W2AUD2IM--*BWL732#WGCFP@
MK*%Q<KN2(4.IFM"*K*403<B*-\H-.!!GGG)2#T693131(56F&;.O)K^'T3]Q
M[IB_H0USFCDVN\TD&'>O/OP^WQ5M#H*Y*('3EDNV4(G@K8S3<PQC1<R2+625
MKLAI7O^=!RB8U+&ZANUEW:$_.X7Y]BI>]-,L8W".<8XJ:%T,9Q82.@FJ1 /.
MZ0+*9S+!9-UG[5H,6/F*TU)X-Y+<\Y07[):&QEH4ELPJ;K'> ;(20A&>AA]K
MA,YJLV9MB?7?>5H,:"3KE<;FO_^P(+;?Z,?F]1_?AA']Z1-.^BFL47=UEV*0
M]U^US\J0CPQRH4PDRR5(AL[K7%06RL60BL?L,WIO,6U0)O+^2SNO&4E^K!:"
M,="9/";%<@#ON0'FR%]2.LK,5!L3L+.:D??O_=2JQC_WQVEX50\7!C6U[+(_
MKN;?^,W@SKSN!6^C"X'<1%G(I'->0G0:(?G,:!8ZM%:LM;)M_.JC* *YB>*7
MW[!J(ND6-2 WOX*CE8F12P5.I$0K<2[@42%(P9D22DMM]GJAY:BN3W5$ICVI
MIU4ER8VNV63)@PXF O.FAI-9I!G@!* MPH7BE$ZMLD2._H+4?NC4D7*:5**\
M%\<LW!:>T #WW %9E0Z"DI9^E,X+'@PY!J>=;[:;]K<6YM'DFZT,0G'O?'0Q
M@4[U.FBAS30:M+2MHBDH:4OEC5:1(X_];Z3FM6/_FXC[,/';=1">8__;*W7S
M0.XV&CD,=S09WS%Y1L*TKAKE$8+)%E@*/DE=;?-&!XG/+?;?F#*;*.* L?^4
M'*VPAD-1TRK+V4-(M$F+@"6[&*1WZ]5I>N:Q_XW4M67L?Q-9[S/VGW.47H--
MC-QX[3PX%CGPD)PTK(10UBL'^[QB_ULKO!M)'C#V[W,R@;L,)9 QI83FX&V5
M =:K5-Q(GDH74_[88_^MIORVLF[IA"Y-SU96"E?'7K*L=6@*;7X9%=AB&3G-
M&&PR+_:2RT[.1V=B;\")Y<EVZX Z7W+96'UK76K81O9[N^2B@HP24P%E2EW!
MLIPUT*0)H*S)/IG2I@C#<[GDTH /&XA\+Y=<@B^HI*.]B]>J.D(@Q$"NDM$N
M6I,8][%-A.IH+[ELI*(G+[EL(M^]7W+1@K:\& 0(3Q:2<M.Z'=*!)WY'BXXE
MU:H*RS.XY+(+$;J3^\I58!]I(S^%\:=?+X9_C;M,$+E]:+M4D!7 %Y(^LG4Q
M.LRJKNK<%V=*%,4Y,@"3BD6L3/JX?7SGZ1U":4S2%F *$W&C$"U"RH ^94Q*
M)\0V<[+[EJ!_X*0*BKRG+WT2^H_?_AS7\E5OR'(/$W*K7I'+]H5TCN-7<3P9
MD0?7XQYU=DR#-XF6RZ@9>"8E2(S,9NV$L6W\ELVQ'L6YZR9L65)^I:5Z&NQF
M!+7T)]-J,:[XDK/G0+X:^7 J)Z"WU\XF7AF3"\?8)AA^BV'_!&BML6$GXFYQ
M+?-N<<E:&7*0^A=XKW[0A^&FHL',+$HOH$A&<R>CA%AKYQ>?B]52Z1S:F+XM
M1G/R9#PX!1K$:W[&SR-,_6D1/?K^ J<:&^17E\/1I/\_L^)Z64;NN<A@<U*$
MD2CE@]: G->B^TKQU.;*SSKH]D^[P_-@V%B);:ZUCV:X[H!Z4^[F@KX=X67_
MZG+\>O %Y_+MH956YA+!"IG)NB W-N9D@1FKK,_&JT85,+;#>R;C/A3=XBQC
M>5E1*T(D/RP22ZJIX3FA$ED32)N\X39+UJA$W9'4?STZ>G6@J 9W[Z>5(?X@
MX9 D9I+YY6L%AST?&1>)+(SD$$&)@A!82:1R+QTCTP-UF_(+*R&=2=21NCIL
MZ'P-[&'MTQL1S.-WMY:L$K:>#D! +\F2-0:<=!JB-#R46H]>MLGY71_CF6FM
M%-IAR^?52&DGG^[8)$?L?YF>6RMN@RO90 B&IH<*$2*&#"6'%#0JX\N^2/<0
MW3&4*NY&NT^2:$?5-+#O'V(D*^]SZ.>?L>!HA'F^PI+Y-UU]7XW'2&9?+*X4
MY1B8& /MVTCXF;.00V 8O<I6[8M0Z^!]013K7'T-K/8EPJG@;A?S&4JF>;*"
M9H4S]7)((KR$M(#PS(64K6.NS8'&>OA>$*EV5D\#VWWUZOHV?)LNK;QX;J>)
M=:Y6!#3U5BHG#T/9(A47,3#;)@CQ)+071)U=E+(72[T&/JXP_]8/L7\QM2![
MVO)@:!DD/C-9,6;:G0ER0E84.1HAQCT29P'=R^+.+JKIT-J>IO@^(H??ZL_S
M=5%X[[6H,3!>>]I$9.!\UL!#K5JG#1.+'8I6I%*O][Z3XT,K63^DP\Z-K)Y"
M><W<;SWF=?2I!/(^ P.E,8,OBLRN*#$+[C1'W)<MLQSBR?&HK9(>LFGG9E0/
M@?XT'$S'7WMI_70UG@PO<70+UWDMG4L<@A<&% &$&(4"&9EV,:+WV*;3T(9
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MGN[NG<\>6ZEOG*(T_#CH_P_FGLI.BU0<:"071^7"P&.P@%@O0#-MG#W 3OL
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M1!'1VS:VXW[I\$1Z[K[8L(FTNT["^X5&54->"X'S6?800T'V*H]0HJFIH\5
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MW]4^FE/NRIK6*Y(&5VH,UQ!M?2TS)H4IN92H1>ZN!>G-:Y_[AKV]##N,I-V
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MG9O4\^TH%MJZ LO 0TB@5"+OCXD"6G&;4G%<R#9U,1YBV;\/O+N.'KFJOH6
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M:*=: ]S^_80.U?DPZ-*I+AJ8_/^) QR%"T+X*E^2J.L%H]JL]C[(XK(43@M
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M-8(+&TJ $P1N>SP0ZV@F4>8@N4_,T#:&8%PZ'' "QF+#,=*N751U=;TJ>/T
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M'(=[CSU'CX-A0NZJ2*BVG_?K]YG/>?KM%@K52B<E!3&6EWQ<5,3ER$G$L$:
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M,LSMWIC95P?5^YUGN!1565U=>UD?.T3H]I_+'\$OX!__]_]02P,$%     @
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M+0R&Z?KR&L;* Y-\#HOW=SF;U$<N/JC""UXM/99H[^MD@O[RX;C?(QA>7WT
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M'-8R?]R?@YO8"V[2>JYRH^#JSI"@V"B0">0 M'OD[W$V-WOJ#TF&I5=B-?]
M6B""60+=!BB;:4*-9^?:'!;.F02WN722Z5.G"',R!]B<@T,&Z4X#[)>6BUWA
M5NT*\,XP$&MJ<I#*6%J>P09\DR3'Z,J,I4VL057-U#[I3Z6#A[4X,;P)<9/B
MS5^I&MC%0U5&T<!$[ABL1O]O<<.K VLIP8I>V@[AFLBUU*F89FI!SU8M^.V>
M%Y J)AD22=T>@3=E;?OEB0S.M"EI'/%W&4F=L6A:66C ;62A_@QPWNH>*_["
M_%;/XY_326*NQ$^9YZ^]L"LH(L-!R \W^9,/(B5,.0YTU]W+IAYP]O H=@4
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M_]CU*CD[I' ,3@8%S\U>&5R]\?9@[?X@=Y.Y0( ZT2879:9LD-GI%5<DQQ5
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MT];ZQ1L5?_FL28=-^.1>!4]UEE;R"Y(3&(\HUZ.XQAZ)-UQ^U5U>U/J@]<I
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MU*^#]!)PZV<;$)7LUZ%XDO7C%S3KAR.G]8KTSZ:A+>FC;#*] R0):,V1>-X
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M^MM\":0$2,>3XNB]!L0\XIQ>JZ<(K%[:1UC-R:/QT[W)%178Q6/5:,<PYQU
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M/Q25BXH+/1 W%'00+L])J'U(KZ*OGJSE,2H6$$4E_^LIWHB,=?-N;_*[[:O
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M485]C9($QZ^0'_8WW?%ZQHB :XXLFL7&WT_,R:&*:\5EG&,6+;6UJ)$T.X'
MI>GFTK2F%AU/;[7HZ^$B0W/NL@&_'E(;8:A76RG,S4V6MF<MQ&_"Q[TM'4N6
M%N:6U7N,O-4V#:P$:QV6PWSEWTYG46*94'%1XHI^1=LUGM_F!?*--7:C#!S
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MR-=?WCL.61EQ3!XQ#IJT=01;\$9;S$2..N%!RGNB3IR'Z%1^)3N^OZ7>US>
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MG(FY?(<<^8E+-ZQH>A8</D)^3Y["S"(@9]%^6819HMAXQH:R#N\.$2U>XSF
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MT6-C<HS8>*<*RHV),Y$PN%U!EY<+7T% _LW4-"HS,7ABAOUR5,KCO,B</4T
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M?9+]^4/J1#G1JW5?EM\(D'^:O^P#IH"00URL^S$<.!X.QQ,1'>R;F'E^UW.
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M@.'>PHJ/J_P-6!F.?](32N5@<I]OU##Y,>#;K$/M)2-APN<:+:SXF2N,/06
MA[^/$,A5?Z9Q^-U\\W7J]0;A3ZE&)\[,6JM93@\RGRFWM@ZR/JNW).O-[Z@P
M5B_O<I-+2B*L"Y]DMXF61HBIB#TG^;R0J4L(_6W,^Q5%5JW"%=$9AAC"D@48
M?T>JX[4 ^@W54)KF%7P:.G[!6BP4Q!^<)-AV';_H]T'VM(&2$-MX1G6RM@WY
MZ!D ZD_HV_7*T*E2R0RM5U&A9+._!/D5 <>OE.^W1,[)50UYGA((^5,C"61J
MXNB61B V06L\&<&[GZUBGUA+RQWTKEKB2[QSTOK0D&PPM!]537MURLC1$"68
MD2+OF>LB33Z=#FC]/<4!1 L#'V'?UAF2+==,A&J@X$,I?<=:%;IH9<#"NWQW
M-7PBGL,= T_*8+_O3853L^\TE4=-3N2MJL=$_$MV:)\S\R#<*9T7=[,I(&?T
M$3\W[CI/0M"V4N< .M5?F:\6.B/?2&,7&8=?3,[16KP^<_/]TO$C!*T_WG[#
MCP^X/3D"ZT$'[NA@="*V1+R$V$]4QX4O.[PWGMNI"B@2X7A#J+08)-K+38L7
M_*L7>;_:-C@3 FM/MS4#Q_9/!#.DMX"3X+S*S+XE >]+_/R)ZT3<F7Z3RB@(
M'I0&G->*X(LA>!<WEY=M\L4XK4\UV;I2-D5?DZWIN7HVA>;OO?+71#L9HULB
MEB=XFD<D&(4*C$2X1G?N7P@)[4M? *W2BX#T'1;D3;\1+"K  D1F?_SNM63I
M9>_1INKJC]<DQ>BX@[YX+X6F"1UD4PK_/KS"]Y!S]:@XS8YT?_ITB3S-W![?
MPQBS#N;I$ ^)OELGYX YJZQQH/QEU[(#&&#&R8^B(,]R#E8Z_\V1W8:XX[MH
MY=;EV]<YK2]D2=]O)SA#IT40GE38=PQ.Y@GZ=#O-<>CSU_+1&>,\[2^ONK_]
MX&'L"/&S3GYT,Q  #MF=F/PZMB_+IKW-)=&<X!-X]? QMV D)O;5>F!=-H7=
M[VD$BJ)]C#&2R;XE+/VWU:H^P24-=4K-,MSP@S-K# O5+,VRWFW0=)^1C/GC
MP][=UK?G2>RN5+Y;EF6CWSWO-89I:ULGT@! ?VNG%HY?9(^@?'E R;21[KYQ
MCZ7@PX=1VZ?7DIXV3N4?/#9SF\D*<()T^)V%84(P<*D2L*'JD)?@FR49[YP<
MTPR7Y!NICU^Y*Y6TL9ZQ9^.'_#Z_6BC ._?1@:%.3D[(N_+FD_EOSV;EZAV%
MN:]04'/ISKB-O9J<C%7%Y"F/5EG2*YY"GS9HFANU^7@5"F[3>\@LYQ[V$+%5
M?M,E_)LC?ZMCSEC+'@3'2[BL'4%1F/B6CUFZ@=/409^>&Z,92CQ,R:U'7_7A
M?/06"$B#[,1F2,P<JU5_J!QJJ07M\R0O1P<$O:%\+O;%;6>459?HS>]#P^Z]
MHXE.YR!@XS@)"])$G\%R@&)YJ^@?HOV7$SZ4EOL^>>X#N3&&3H@%2E> \S31
M6:\6R,5.[M5-@7C'MUIP#R*YCY*94N)G_/M[%&3B6]G=?IO3IL>64?#;Z-.#
MSIJA+:#F^YBC\ D7"ZZ[Z28EG+=T.SP^[L1:YZQ?Z Z&LOTU\9\'+GH?WVV)
MJ&8S&?[>."H4:/2::)KU/;25U9U(6W97C4CVMQ;-NFCQ1G]/A:@RP//W<_17
M/04V^=\.H@>M+I'._P[ O$@QFMV.;1$Q7E]#L[R8(G&UAJ9(#L3#[CFFAMA9
M1X[IU">XP\E646Z$@A0^]M66Q6-E0& 83A8;7(!31^/\RM\LD6VESSWP36SQ
M JV^B%[?6!294NVL=)"_&I[*>IKQ*'C1?J][7W]]7A<_ 4L7D/'_WSEH8,,$
MG&PQN'U1?Q1NC@X9[#ZBKAJV/]X*G>)Q4^3S;QITDYDQ58.[VBOMYHQ"$U_
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M'(98?["P/W<%MD4;<_?+['1O ;@AX$:O4FNB.L&^H!?'%R!\)YXI2J5[Y)'
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M_N2>PG<U:*#>N)C[6UW&E'W+B$ Y.2#:=Z)<_'!4&+8M7%:^>3_7-OJ%;Y;
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MVO=N5;I/I(F:C?VWPE<"^HIM;3W<T1%GS*'MT'T*#/\9R?(YX K@\(I@SSD
M60P4. <H[%R%+&19HO/^W/3GIC\W_;^_"?W",BSP6DQKX#7)PSX'5(;EU77$
M1&+"\QQAZW1?M:@I]2O)RESZE#>,C6*+80E81\HKD"'93BB6/^WGB__P;'31
M*3Y<_1P0X@MI#[KE>;%J3%/ 6BY 2,')R"YH E >A#QA,=VZ=MM.:+P )QK4
M-?'=MC95#D!646_L=\NY3$:D79[:P8+U;&1$_-N^\7X+]3N((CJN"_7#H.8[
M/EF-[1#\^8\0]9F;MGEQ[Q1X/<SY<1)$8?*K;"@='$W?&2VD0Q?\\"QXCN=B
M<@>V(!68CP,;%Z$,X%)U$F3ISF6L=W]6@(K64R>!;9'=^!+0E>G^6\IDCQ$J
MMJ!7CQ7).I_X4V=TSM&B+8(73NV0ARV.$^N'>^M0IU&+844?V3/32@$SZA'@
MR>/?>7X#_!3$[B^"]F0G^X#6FH\J&!G=E-&N9\]QH(M-75P.WKZ?5#;\21@_
M$I4L*_9V-M@'Y1,"M$3MO#P6">5I=M$^>I0ZT=-ILMS0@:>I%][PEAN4)O(A
M6Q>6<#N%DQGTSRZSZG0.!LF)C$F43H[ E4O [_R5D2<ME.M2S)/?GF@J$&4X
M<)F"N82S[-ZR6)D'O5EXPNP3!R=9M(QK>-?ITTR1W)8Z"I;2&S;9T6VN>=L\
M)9Y:5A+CRQ;+T> L11;HG^O?V*CS&^^!1P^QJN^QT'8+KGCYB+-KH_Z*YP#B
M_D,HR ,EPJQ9(E"7Q1G.8C2W;;/[K?AKT@\>EX1EX-;ZV4U_KDE@@%>AL5$'
M074M[II,80+O>(= -&E46,7KLJ#M&_Y%O;H*^#-VEK\$KOQ?XSJ;PJGK8@EN
MCGFO>30FS@2DZD6RG!*0;\U<S8@IS2.YF:74>_)R5Z9Y4K;G\RVG#P$>*/JF
M!9CW0$?;/#IZ0_)879/D0/#$^'[:B9K>U?NVEM>IB'TU,E.^@@=N_$*VZE^'
M F\IBQ.KO BB,7=,,SACQ-P(R&MG;D[AF1/ \$BE23&,1FJD1 FSSQ%_*\5;
M=C8+N7+MO=TW?RWDK(\B)B($9UQH_Q ;+B2BT3 BO)_!M!"/DI?][)4J+Z.V
M*&LR[W1I ;E[._:1/'J,G?8<D.T3)8_6$?GYUH%<$:ES3 1./@=<WCT'A $\
M((Q HD7Y*/KG<T41UC7-T+:&N7="KTU>ZD>ZE@<.+MVS<0F.HJXQ(L\.D:(.
M<<49897*P<<;_X6]]XQJZMOVAC>B@-*D-P&5JC2E*TVDBP@"THN"="$B'0)!
M>D= 0$!Z5;I4Z;V(]":A)J'7A!H@)$_^Y]P/I]USSAWCO<][QOOZ8>TQV&/M
MF=^><ZY9V&O-J?ZM,H34QQRMZ*;!IEX<HD/+0$-J?L>08$[W5#,^RY_AW^"[
M0B^6#%7>[2!C?6Q.,@P[+X80;1IQTGM())6=G"0_Y@B#/C!4Y%M^._;1P@2<
M2]1\2?/*I@V\T/_(K=)\>X='OJ6J/LW;;]6.>=PB>.B9HO:[K/<QFAP/%O_E
M*SN3+IFSV;K73FG;GEU,AZY.'C4.[,AU0)M+H[=7C1$":=([HL\J/MIP*@G+
MJI*1_)C.\1MJH9S"4")W-?BZZ 4*-^6@#<&]\:#!D]V5AGC5X8RNIA0]=A'8
ML!XP*?0O]%TF( *?3/R>]!\WJ<4:/7A^?VXS-;WG.XP1(2#%Q#,V$P!>*U;4
M9)1QC[\_.^+QKU<3^(LS,K.GMDI4$R9C^^TS#6M066O@W0^0:[%_>T+97!\'
M_'/[L/]O%.3Q-?\[#.Q_#5*+^,??'9G^VS(;1Y!_[B78>?]5Y8'I21SPKYF3
M_2]KN_SFRF^N_/^"*PZ0CM:JDQCIYZYQT=2^@I?>GC"G?J(C+IMBB5TB][WU
MKS&]0+;"8M*0K9U;A;^P6+@V9T-3W".OS#/>;2E?-;%9_=A_Q9QMVM]S?L_Y
M/><_;8X2X'.%5I\=Q=&KB=Q2JIM:&^^>BJ:;L/LZ5])MU#,3,^Y2P0'2Y5*/
M*IN8FY%Z^TCJ&E\WEM-OA,&/<@2L7V*[P "BLCNC&RQ+OY'I="XW6YZ?PN%I
M<3%+7GD:GB(2<)[ SD=5AXB-IF^AJT'>.-8C--"DVZ2O'84O*2T;_]1EB6WP
M"+:S,&VR^7DC CB$\O76"(4O4KGB %:[# 8<$,33L6]FKU>G7WL Z=!YQT'5
MAN(#X<VSNP+[@WL 1^#PT[,\D2<-8!>S//%QDLZARA]FDK-,+V]\3=)RZ7\>
M-T3\!&A4\I(+@M@Z4G9G,*.&P^E[SH;ED5UYOCEPXAB'/J5JE],OI%^_A5"#
M_2]@-?7S[RVQ]$-5L'HWOF$FM$:UJ>#BDV3]B'/U!M_'<H+2#"$6KR)_? [1
M+I(H?H7$ 4(WV;*5O#Y"Z-RB"<18RIG0NNM&IBV)XA6I,6GN)\B2Y\#KB'?X
M)S(=[NBR=+Y"+@H)(D'=Y.:ZJ!<AH7 0>2=LH-3XJ:.^NH.OXL)52V5Y?NU5
M7LSW#^I4=QLG0B1=:OUE!"-XLR[]W> ;QM[T/#!!+D9(WX?A ,IU=^:AW-+2
M\9")&HG*$+KWSV-_)AW0\T T<@N-@,-K?(-@.11-U\+MV"[H:S/F<4>,>=9<
MY^4I&@>AXZMZNH;4B@W&%NA?\\R QZ6'K[[(,H!5IS$NY>CB9Y-@F8*-#[82
M=UZ[D0OIQY\Q[;J')'$M.E[]^>K#_7:6-%;Y-N+\49//LI(2[+1"F%O' JU6
M8P)'YK6GW^=7!T7-S :;+/N'=N9V>XB$[=8A-"5'Q*CEU*CG&_1L-!/,0_!]
MPQ.^GMJ*.='"%1: ABK&;]=E""!V5GJ+S\NQG+&1;.1L-TWO(I1U?-QL^7=G
M1802I+J3&5D,MOO-83Q,DH,>_]YFAS^/_TE1ZZ,G?,,MU&"]0+A^X*&I]OX4
M*Z'^1/!X-+UZ=ZK5]6<C?;HP=?_'R\%M"\0%SE@.OU$V-C3(/=:#JWGW0X-U
M+D3LJ'D9PED;KT!CS"O'ISHL_I/ALO!..X\_I6%.?:D0/"FXJ$?HV?<L[EBN
M]-()?8?BGI]/A_JRDPD>TVL5P8:.Y^JO>.7"*:.@Y.6!^ET9K"WC8%,+:'Y&
MTNMQ,9+E<#.?L.P'<1)111_%%S 4(JG X4.^](1>+&-LMSK, \4=G\$%21&U
M;@DSNP<UO\TZ._R#U'5=9*S:[<)^MM.;+??K CV]._V^Z=/G'N)=VH/OYY:8
M@=&<ID9%= +\O& $Y 8B5 %E.6@P*SCGV<<6F1IY139(- 09Y^18AGBN?."@
MFGR'^(9?H&N=$.1'2 <^RKE*D8B_<"^*G+/O5/I6.<W/-J7/HNH^(PI%"5J5
MO'# >S_>3!:3R^?BF84X('_3/4.Q(<8I<SM95B7EAIG!0F@Q:^>KU^SBVV&N
MYM$9;"B;+@&Y3C/6"=%A*N,YNVF/,7LCZUS6#GE.:N/"^!\I+&'UY .7Q \?
M] &']GP#+7Q@951HYZ=GV:]@C@P&HQF;8_W<]=.K-?7"P\*/OX<9]F4K] DK
M!BW11*%,;4+=MD[)Q,VX(E7&Q,[?<U9L-+@736>\N5,M&O$ZA%Y2D*#CI977
MJO]#([[$B19NM)Q2C4.Z>K<W:_"W%-U!ER\*S-8/+FL'&/J?<EHI'UH#2Y]U
M'/WNH.^>:X_S"S299YN8V\==+1&PF%BR<T)(5:!XW_2U\KW[SG[G,(OB6T3;
MO\DV,2WP4Z174TL-&_\(=+/GJE/9$G8LU+?I_G<USC@/*RI&.FM)((!2E&#R
MN0$;'6HX!./A((:_RN>C Z#$^RMI3YIC5CC>V#@P_O)_*]]>>O8WWS6:\)$A
M9:Q;*SDZMY.9./10BMQ&:ZK[OTP(UY]-"/4S;)K*LVJ"=5I]4A@EF[UW<K@0
M1@QN2L%*:E9;I[Z>-'2X8&0Z*^*X2%M*^]3PAJ.;[;33\LT/;1/,)ST@"F,T
M37<&)_*X-!]=A:6:?5#FY.@ZJ'SG7E]4A\3KQ96$ZA@5R_9NP)N<KG>3G5Z:
M/6O>;LIH,<)5@T:W.>1!]O@1^3-&F[<8P0EWLK;/_H^6(RK+P>K(V."C-$=V
M Y1>9)X#@_Q3>@9HU#U-7NN[^1S69#,O'[4M1VD1/U=Z+1%^Z%;5VN1HU/UF
MF],6)$C^@V1GV<1)C452F8F)^/)K/2UT[M+T],W15IC@2$RE5(-28?0S]FK5
MOI]E]#*SX7HJQ(0!490*CUBMZ.#'K34\06+JIH(X0+.Y(NU)_;23JW%COQOO
M<_XDQL*$'0IY*Y*.N<0!P1>=-C7>K*U=FM?,/,TTJ=OAOFP@"J5,$8-8K?"2
M<?+JU9>S1"PQS9Y9%$D1*]-PS2!C^=IIE8AJG1Q3T4BB/#$2O\$[C[9AK^=K
M:L.6>8C]HS-"JJ4EX-'L/<Q&]MX4Y9:E&]]$[IK93=]Q)KW^]I$K)S4E<2KP
MZR\+>96Y])@]' 43YU^T&K4:JZK-,ENZQM?E%"UGCGB4SD:&[3BNI%I?I;4W
M_75XC4BM?+@U?$&V&1T''V@VVOCTV""_Y#**[!'FJ\QYIK8&X+/[Y=S*[L-/
MQ#/D_.3<2TRIR[N*!/05L)^;"I9%'9NWA_D*.4X]C8\ SD!_<4,.5MVZ^0P'
M_, O=;OR%-XLR@(<\)?W<G\__?=/N\K5!EE5"@4QT4R*7>_=WP\&=RL!OKW(
MD^,P9%WL'D>%(?>8VQT*:B@:X)0-6_J@6=DN$^R=[F?%1_?RA^K-92IHR_S%
M9^RM.?1YFX_;U:?0C#2>F8*XV,';2[0NNRI,N[IXOQ;QO]UT][\;2WX"YIL'
MMA\\71Y7IB)T4&2AFN<V,T]KH6"RPN'Z3W%5*QJS5+%#*_J7G7I]E0!P);S\
MJH,9+1KR!7SOVTB-AHKFV%$TW_.1O=*2E72N"L<G=S@CU.A4#[)?<>_TNBB_
M&/)[)V#J*=6E;U1EK)FSF,9.MG5FEI;7?VP!GE7XPC41G_W\IQI)353=HY?@
M0\0&E)=P4%H^?V$0==#N'>2>3&UW?,963#;M0,.8ZY'T,Z<* 50HM_'PV/4J
MF(J59D8D=XT/NY384:/=JE8,E/)^)#NT]6P%ONN;6\OCD)UWR,_QEP6C&#KG
M7;K]V-&G>48S\\;S#A*HEM1=HU^F.Q4U@,H=QG;/&0D*@N'L,LUN<_+QWBGO
M[LS.6-)-,_J8M<[I#UMR;\:MQ]BU6X0(H7GQ/R.FJ0.2F>I9V@X8DT]/SUHB
M@%-S,[0;"#$+N6Z'C_G  A"8@P,.(+77,QH^#HD3_^1&NJ$(>6UHYJKC<K?B
M<TH/4J+69&^M&;ES=-*%#Z6N3^LH3(GZ"%&LU\69RQ:_$LL\L^JONT32%=%B
M^YPLJ"\M][S>,LYL^N_+H/\QZ&"+;**-#N5A[)1";NIR-.HY1@5Y@DY@(?J\
M\8[A&X_O#;Z4GB23/Y9<;>Z) )"9P>(29E3UZ(026_&,VYD='E2=D$(CSP"6
MV@F>5E4FIVNE(^<Z'"0[B8HI7(';I\ZF$IWFQ.C 3KDK8)E\NV3W5)5PLRFI
MQJUH8TV?/ D==O'E)C51@?J^/8PE&[I<*\=?^JYFB$0+#WK%Q0/N5:.OVL1G
M13 I+><!R34:EFQL$ SLK^^_94C1$]<W1^G=A5QK3_?SR63>\-;+%XPL5$"(
M3B#P?CAU;.N%AC9G1?5,@YJ@99*B8;([N.=*]C7/*PX;UW@)^W" #3EI5RIE
M8$V8M/J*;X[F=?L$Q<J-,</X: \^K[37B?WZ/-Y4HX;*QGOL)O^#'05\RQ>$
M[68\51$.DM4"\@(8#;BOL?JD!/1#Y8QXCA,][(3@O IH4'(*FN,623WKP(L^
ML^/X8:Q_S=X5=*CN2$WY=J,-2B"Q]Y=K<>3W+)]H175"T>NYZI5CW+<Z$E?>
M*<,R[B+:,NY,-TE](<'<+X8.>^6B?W$U3^9R%,\M*!^C*IFTQ@2?1&%^2?:M
MM@SB5?<!>I"LH3NFKF005JI]H-PTAN%SXM^KWA!(W1C72QBLG7E8.!P"%%N&
M:GN^="A$%<06H=<,40SAH@+$AK5C@F5-8O8W&\8*JS/V\:F,FEAOW.V2]Y;A
MH^K?@,?B%!.#OI1P3=*-#/Y*8U:CV1WW8F?RL=Y580N#/$/+-U^(0Y4DUYT#
MX[K?:!'WIU+Z@V#?FY"M8:"66]%/-.GZOPJ41>="Q3/?:BQ";S4Q!\[ :+D'
M?YQ<DJ_,U?)[(:>Y->A!%%JD]NH5VQ?OVGW&-]:?'B=3T.Y$?=>[QHB*)V':
M,/JH1?RSP2RA +JP'HT<Z/2[CU0),W\1X'-![\!W+D/-2/K>\YL*[_E5-K-M
ML1;#SQRW.+A3+@*_BL<1!ZB$U*AB##(>,,],*D4-6COB@&K9,9 L5/\'S_9B
MP_[ :<JI.+PE_0\.3OHQHAM-*R<.S\D9M"(V-P=ZWO98!R^I2# ':5QC8KQB
M_H#0D=-?GO.MB%G*TOD6B![LC1RJRT=+F8Z^V9'F\"B<,[=/Y3\F9;G(&<VM
MOH +/B&X==F*PMA2G(7M2 GP*NP=Y#XQ0 J4MF3:.?N^;5A(X%,"T:BV4V.)
MW=LNPUZHTXP :B4X(.Q  Y89Z4>*>M&3_M5LO1;JE%LXIY&W,;[83_:MIJJW
M@9%J&=K!1+24=PG@?&TSM9Y%F8RE0JOHIL$E@MQ\-3N-DC)9FQ;N-NA-\,^0
M%YN8=XTZ27^MZC$'R=V;CXJ(7VQC@$+:2Q]/37<FW[,7!C_&CE]7>CUP)\KA
M2<<2K\G.]2*I7A8BEXBS=WBUC3PGUG6\37D%TB'V505>C>J;&OK*;^V@ +K(
M/D[P.AYK>2YG?3&=9/YSN+^.K@:?RE[N!2%=NHZAM9'EQDQ-QKY?)8Z54FOV
MZ29^5LSG:=\Y>/Q5^?RQJJG^M=@/A>L/>0E[9<D6'*"%$35;Z4]XID37=[(#
MQKO."D/R1\4,<8"/"(O=F)*"<$\I$S7G<V7U6@:IRFW7OVF.Y,70[; Z(LN+
M>3AM,W[D,R@\)/-$*KPZG7M+ZUYU7!?-.^.>;8*;2W$Q?-.V6909&+<<AU:F
M0I13<9:=46+P9S_JIE'1GLE;:4]3L9NPR>5+#Q[W,_.&B%&L?Q<6%R9R^(P.
M?N6!HM&<V@/?APDX/*FM0!+EYPX[NN1IVG F#*RP^$A:N.I()*^H'RCCI4(7
MLWF6@><<,8*N-<(-1(E1',D:PZB\DAD,Z+3,1WMT# AO0=:=5QT&3E\E4HPQ
M7;8?^9$C4]P<<6V]R1'TU=:#&0=@.*:PM[$S4[=CU#,IMMBH?8T5IF_,Y-UE
ML_W XMM-Q3)4KZ0192106G_Q .]H-^!"Y.8*J(0GR-+:S[5G#)',XUT//VO=
MV]]9'N\(UV>?CPO)^$QV/79+-[G-.[BU_>()HRMI]20W.O2BR-)8XB"=J+I$
M\'[4SKZN.#8-+_B36:%K&[6R-UNG;\=83^P]MXBWV[7Z>%M(,9HUHBMO7_&5
M MLS3;&Z1^Q"ZUCZEJ:))KX\,T\?;?=1+,>F4>* 9N%3@2FF*X>U)Z1W-&)2
M/%NL./GHB"^_U\6X+9E?KXL1F[<@]?7N5?B&:F+.&[.MO2K3J0S5U8HLNIG$
MI(<8^(29M71GM&@5=CZRHB78OXCU[\F'"UVSKT5Z=IK6?$=]V_3P,.,=@]=(
MY8X71#OI+4C>NE=P%.ZASDSO=MGF[N!F)IFHSR!?KSEM?FJ/@Y3QO#M+I$T\
M=;CD^95OU6&JG>0_VBIV\]SH-C[^U68V(J&HDH():8XR(^, )Y[*#%[4M(MR
MFU]!ZP.64K_4Z=Y%]A;"1;2'0>/T(8M^XZ@3XP#_O3O6U2X#5BI(#^(ZA5\?
M**_]MZ5Y_YM17M1JR?<@01.E,4/<%V_L^>%X+GO +Z;FX"0 ?*44\V@R07.T
M9 '6S_:ZBXJ6XWQH'KC0?#,];TZ.(;9!(CK<O06R#YYZ>961M"?IG'S" ;?6
M 5J"R=%_^_\I_X\. H1$:W5W8O1*=R62(:;@7M]HRNW1R;@*U1^9(A^<NY5P
M +G:*QR@>-Z[B.8RQTK]$:=X%F+$N$(O:/;8(4N)$/0..W(BB?U0L\D7!P2\
MP &(FAU7+>((2*>V 614%G6"O:J/ V)&?U/Z3>DWI=^4?E/Z3>E_GY*)39=Y
MA#=[IX"8H)AA2F&RK,9G0/0;8L3F_:YG%B5O"[I_*5T;5MB,%H-']L_N:<@%
M+[G+:9N+$6,$A$);#Q7_V*(8E-[Z1V=3;.FYI<.[ISA@QILHTY$!>5&Y8'V6
MGL\GA64A[8$<DHVT(ME 6)E'K+%_]ZS*WU/SP(@S_+''@2D;LB2]B/&.1;\1
M^F/[@LAC'-#FU8H^ MSED-4M;#A@E I%C*5VQ\>5?_0)_YL[SHO(7W\T4LJR
M#L8!_@<0U*8<K*+)!@<\&B3% 02K>%9-$/S" 1UC:!\\8U2ZV-%JLW^NYO@W
M=U[T0CI?>0YCWZ<R8 D'<4!O$0X(Z4!E7A"*"F&(TW! K!:Q)0X@58?M75"Q
M7X? >$#_5:3QK^_HL^*E$(R0.R.R-4=32N  MMS?#/K_)H/&T;Y_NF/^WS#H
MJX_F+$WW'6ZG:E^VU\/SP5Q16*O94RWB/ /L6*ILFE/M,80<[&)WZ>)7ULAS
M6E\@@<X2RQS?B0T_B6U%/FG%N)=CA"YR187"DI]O3%.)AY?(706)OL_]>,:Q
M]!H'?'LDFU)NDD5)BQ=#7@4.R/%%[&&HRW$ :^Y?4VDNBP!0FFA[=<HSG@59
M'-!^%P\6*@?[PB^WGNEYCL]ZB_%@':#KOVG]IO6;UF]:?T6+#__LI7H<$,[V
M$!)J)-!2)YLA6&U;EJNAMV)]=TK\IWM:^GL6[^R[)E;N!:O]LX&_] E1]CA
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M0LPA?R'F#^))0^T-!57H_IQ%VS-'C/LT7'W'S)>*WTB4@6JN8[^D?=KO4E&
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MX&4SQ]YV-;4J,VW$:X.RYNOR==F?\$E*#LZI>^OR&C.U17:G*C/I8B]K[ ?
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MR34*A*HX:[:&(;G20.W%<T#\Q61_M+\$>A^]KJC7>D/G"6;'W7LTXP .IK[
M$=.^^U0@O3V<16WN4;#G5%OMDV2O5^9@CR[*3[UETB'*C7S2F"FJCE>@SLI]
M^%@9_P@'KRU;#R;_K@4);OQ?M4<$)E6JC/^F/;)Z!$E;3ECP16U"O%9]+2V)
M,E/T 6Q3L^C,Z4BUR8196]R+:2-=,4(;[ZF!)4C SN?8FKE'QOVCAR%MQSF
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MW','%;H&>,NSR32[.#K<A5P [G%Q;^^M]2L^P$;V$ 6:)EW+X&(8FU/=L(/
MV\LXX^@7\,:&MH_W#4JU7AUBU;M-: 5?+E]])F7PE:)!8)MVT524<52*YI%V
M8^ZI6EG3#Y]5(+Z:)&F4C*5)]=++D4B2H)?>^\:S2_9O5*H\RYZA])HGGD\J
MHJJ!ZTT6\_.SQZ"Z9Z!/T9_OL054-%[LN0$D"S$=!\OHN\4LD$Y.=4-J/,LN
M$(<PH/73#_G..C%,<G+7M/I#+\HIQAWO$22F/+=)04=OI$Z;SP';H-?.@0\Z
M@[AC>O5KXE=Q!='!CI@8S<S[<J9\+N+JK/S',<'^A>$!I@7X<8U8_='RP?D\
M"75M=1S\M2 #>!G:#IXWN?JU73PQE!PTS8;]@NJ6)M(&@SLW@"T6A9F3Y0\O
MH(611G?SB?=+^0WCOE3%@;[*"A1O%?TM9:&<UQ*7>9B"T^_D9(D1]'A1:K(A
M(]''4Y5B-C>[=>G!<](UZ=>T]^)\MC>'E'D=TN'*PMCL.$D+#O@]Z9AZ[WI6
M%Z9K"'<^I@MW+>D%A5SZ1V\@=X*+7:15R2Y\+L.E#W0J*^% D=&N99(55QRF
M6'4Z+6M?,^U7"#3\VO[PNO[( VPSSW7'RSLA URP7E,?RE"M!>Z%GV.J6G[*
M?\[TLG6_FLS#PYTNF4CHO/QY4N$[R#Q+<##@*1;5K2R?W-7*DX;8<YPVJ\M#
MX[=_^C?'>C?$#/5@M862KR=^ZMOG?_YEQ_O+.> :4CC  &^%@5P%GUI,_X3*
M"W;5PT;*2W/35WB!ZZ45A0VI*+ZDN*=ISG>I&M,$ &])@@8.0^JGX%88_TMN
MN6.2F3<E;4UA2IPXD53,WJI#.@MHKI>'D9*QTX!\_T'F9LP6/WX&305ZOKZ'
MFB^?;:NLRSU+\_9<:9BOZ9=I-9Y!N!W?M4$3=5NZ?76C%1F6W#C!&=UF?5AS
MY'6F,;R-V0-??X=I\8*L7+YI4=$4P4\IZF2 [939L.9;3<:6UW#>V4LWW2@=
MLGBQ*7/IQ>E[:*D2(.J*Q6Q+_X!$AF.^XR>?>P(G43P\IB9,ML=?*3YKX#PZ
MD\%5 9+I[Z#%4N,FT8Q#'DZNAM105Y$Z7^57>EH)0;BP'N=,;%LOFRA>P^RT
M*V'%<J!LP\\V,S7YA8>/^ZO4:?$>EN?1-HF5B1'>I X"*K>X#;AHM@* 6.+J
M4F<;-D8+\D*D,?!7N$K),L$=/[U53]_GGI01M^HE[NNOF!/IH/R<H1^LWQXD
MBO>O^ [^$" A4K^R  Y%!HKT8V9<NYC2,*N42XZVFE$\-ZGC-MIE%]^J ?R@
M:SVBE,AU>?4"QCSWXGLEZF,S:ODFYJBYQS&J/GO<T.7+;\)?&I"_9*C4O-Y'
ME (K"S,]F9A^UM 43W04WBX3JMW,R)A.4CPN O%""XT2*,"W+D,8!0?R\,!2
M1TOJ,6,];!W,OU1;N00\S7EE>JQ7;XQS[\?<)0-X9;>DM6"S1_5Q8L7.O):@
MKA[>>BGS@1XV+491U[D<_V5CC$:]<[578RI9:S*W/LLK=29+V[&L;-G+9$SN
MJ?D-65M4/1_I]*ZR./[1N/KH@5C1G*5:R>XI0VMVX=S\_$#-F=N)Y-/:@94L
MKM<TT'!0/B87+XB[Z!9C29K0]0Q6(H0,/X.+VC$_Q")\)<5D!]A3-2>2/](]
M ; ;9X(A:"(,N]G%R8:SA"XJS.0X6SP:UQNQGGYV^C1DQS[&JT%BOK]HJX?]
MT2?]"'=8/B!Y@4"&/82A$R*U[#$T(AQ,^LGZ$^4+/0LVZ;*ISC,KJN7P:U43
M/RFR5.4 I&-_5;A'<+B5"[]W#NA69L6IY_G0P#W6_7J*"SLK2\@=M@N39 =L
MXTW>L'20RK4S_)#"O%HGBF(9VN(4E?+!TFO !),V>-NX5RQPTP 67O[A8VQ!
MJD&*M.8WW13VQL?74ON#J3CIS_+@*C*A!"D?#-N'Y"Z_R,BM@]E!!8VQ"E'J
MISHL_*IO>WDOA0F&=F6VB2SMB_AQ72.\QL:'?9XUIP%N0WT+(4Y &/3C46)9
M,8MV=/KU%]0"1#_-IV#7(/UX9W1%9Z!&>]"M= F7&L?45IJQ6D'_2:^SK:G5
M1<U<K;F+G!)) (6FC^SN;5?@%$O9X7XZ.>> -W)P-9$2M+"*9M8"VZ:!?.!*
M=7^S@+@FJ6IGP$[LM^=/B0\2WU[9;%=A+Y-RHUCW0T4=^+/)K6(7/I1:K$_5
MT>_&:)=U!-3-$=W>+[V\'V/3OR1DH>:9FLVJ>,.K<.,H:<.8]9GCW;+N9?F>
M3(_".0UZNFM=,M?RXTK;OZ0\8PEYFMSM2_$FZ"H^06OD>:P9-M:IJGL11;M>
M;0+<Z'.409;=3%DUX8?N5?<VLK#YW7Z>HPFOK!% H*)8CR*]2AS&+1(T:IK'
M8<*\]W&IN8X>?N.SEF>?3=2^T=Z^VW1I25^Q6GEE.7SY5\AT&S_OH,BE7('^
M9-\$FZH]N[,Q;%396)M.6VNN"FVE-)*[?NSA^DS]RKUE=PLF@@@MY3F@T_ L
MY*Q08+9U^I!69LOC+&$;Z!.8O0U43%#@VAL((N#B<.9I\=L$($ZFX_7LK]]S
MN.<JRB^D*+64'9S5S&M3R[P:4(RO4G@88@ATH&N6'N_\^$?9]\Y6G+\#%GP)
M#P&]L11B7<0]]+DJ7#AS,?=PZQ)A6-'<_LAD[]!^%14#^!E-E ;?GS:1#T@[
M<J[;W1(N@MC.9\K9_S'+?A*MB4#M/>]#$++]8])UXRSIK>@AS\\!#D-NRE.2
MAPU JM1J[4_BW,Y57&^K]RA2;6@:PGLPY+ZPM3<!%H7X/F"GO$ 4X:87_Y=Q
MB[G/,&=_]$"S3Z.IG7==NGJZ@"<M\=.EJ%0C\ID@C\A<PC7XF)M(@%()6,$*
M1U.;3FAZ8U8;)-8 &T52-,D(\M5]VGSU@?(TUK5_*,8'T/V.%(Z//+V_KLS1
M5#/NJ1W>.FG5Q<@J5"$5/F"ZD[HJNQ8M<C_*S%/#8R6:ZK;Z7)L@R9;4OF%O
M:(!;(?YU;\=5O!B,RE^4Y4$I[;7 N@F@4N)$]Y+FM7QZWXWR_GZ]V\@5B^HO
MJ$?_O#BJ)01'T=N$BB \14-)$2<<$35%SB_7$4YF&=\1=.U%O:O:OM$"$)V\
M0K.?E_=$8Z8'<P*>XKW*AW_=LNFV'_W>^= [RNM,Y;QPY(WB7ZZ'?K]PKX.7
M78]" TW+Z>27%BU*D,)87.&@LJRKU_Z1.O1SP<QB5@*$NEYV_;$I.\C+8=IU
MF?MM^P3K48_;%2">OCN+#WM85H"O(5Z;E2MW!7D.JM^^^S6N4\8&M9)<&Z]A
MW='MNQ9?J^.S)$D4GO2D$7Q669/0:9S._QZ9+^&8;#5O+@\/UKAERJMVM2=W
MGHE?O4=UT"/[:JD(D<?Q9'XW0O%FF:/1%"=@HM9WN]PS>FLYR3<@S\V>^DF,
MW1ZA.,@!P3UWH6I>E7.W*, $&Q3F56CJ''1[5%+GV2'S:J3NA)3LBTP$MOGI
M=XD+KTE(D^[TM.!$.Y69ID"U@=;=9B*)I1;D=TVLG.YV*.:^__(.^E["-H24
M-$G,2I+PLA[WI.Q7O!^5?IW5*FI+H+'2Q,6S[0K>U,["[>R*XJ O1$@\%_F
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M0<D9^!(U-0UC^=\:QUYWVJ'&Q,4EP/MR-!6W(E]#DJ7.80>M:S=E];4L#][
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MK<KXI^0O[)%B-/D4>N98'0) TK;M:HZ[^9P 1&91C?WSET&H/CPU <C*:"(
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M9E,"LR(R G(-.?8)2S#XAD[8J *7]*\.'M&1+_O)(NHDLR9K)N?FW<8V/02
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M(7M\XO.?/$QJSD3(U1;NFI&C:WX9S$H]7\"&F02S\']._QHK_5E?7$>+/ L
M5H&[\IR5RM -5-,:<U2Y# BA2?,8=6S&/W,#99U4MFR7VEN'Z;04=RHIP3\:
MGDB.XHH/'7J=0OP6%\ I(<H&N8(G1S5,+>!IL1)#!*#.#FR5,"_".*S=R?2
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M\==_]08<TW]O0W$[_]N)]X]H K MD!VP^F@%9QTH(Q+Y2PMKN<)" +YK*1*
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M:L03MFV'\)?RNG6&5.T@ *Q8K2<)RU2J)N.'-6?>9?/)# F&GQD:]%XQ\]H
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MJ=&<&*6K\@<XN@R0;WC(.:9KU0V9KNLI$D:<GMTH(!=6K3M"DN;O->--7TB
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M75VKUJIZJM_5W0_+#UL OK*\DCR @(  @!\/X &"?R$'!MD"@*HJP H  #J
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M=-T:S)_@-"V=Y(BWH>G\>F=7JIFBPPB/@,1:+\U)J'- AC@J\!HF[A-1?SX
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MT,5(9VB/UM?C"Q-1#C65,I6-DD+V2950CRT7D9NE"K@#CN72@"XW//>$<LJ
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MYV=L%>]R.^@&Y.-J*\"X33C[27Y_[%Y$YBGO$/4)/'V'QR=E(S)M6EIK>/4
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M"6()'X&HY4$.=\,EK%2:8@S6OS<K\-)I\<7_=#*'';@GLR!-WG.#E8\F( _
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M6?[^_6Y;6Z(R%EEC<LO^Y[\84G,@"52W"4F<\=F!%.)N:NS'_>%R5PKX?+5
MU^;AET1VJ;EMR^?OW..6Y*46>3]&;'(F-_DNMW9T[":(A9&/^3E"RB?97[4E
M#7X\J2+&^RKQK1LS]JLLYX&Z12#_<7B)C9^5:#M)Z1BC[:9J,^:WA[#O3-N)
MQ!LAU6VT(A@+?T=&IV49D4RU4>^=N&#A?B"P0'%C*ZP%GQV>0?*CNK$^%^^=
M3J(29F;6/PL->\S__V4U_P^OED!:R$EOC]""899Q-5!WF@5<FF.=59*.F[87
M]B97_7-K;1S;M.?-*2Y$VPOLS\^TB%#873*0E7W#B]G+W)OKFCF%" QGZ:6G
MU$MO+9EM\&_9R;Q&#DM)K3<M[UEN$W+G$PN^08C'.M^Q#E<?GAV8L4V^L3'F
MY[P\/LZ'$]/)VO>15T4,LU-SY0Q^V?-[.=&NC!M;!:.>.)?A['Z_.'K"RZ2B
M_BHI(9.I'+P%*'+"W!U@=W8X_J]-V.())G%,G; E+]0D%=HX>@[88#&6+\OO
ME;$3^T8C2!Z8'C$334/U?3:8&/K$99G@P;DRY)>S;_GT-7=\WK"R-ND(XRP:
MXWU6EWLBI_1&GAF[#**JAZ3I2: ;\VT-FXM%*Q&ZKPQZE@$=DCY(%<%COT=7
MR6-!BV/7K8,>PJKV%[LBI=]60 :&U::U!Y9T)VK(5QW5'^=Z- V_UJ/6VG/.
M"![\H=NT%WN30XG1BQ:9.MGXPT7R=-N:FF$Q!G-<K;#H7<YH)3Q=92\5C,0Z
M19>OC%:SK2042\,"P8&/S33Q2XI+BN3#K'\#32IDE\F,_YX%B& 4_;<SPO_)
M"J% 9#$S$:*US>$9:,Y[,L;/+X,B,&EE9R&TS2%$OAN[J=87\#,CI,*6%2"D
M+L,;/"-Z<\HR/UR&%IH#@R<)QAH<?$L'K!Z$#9T]7_SI:\U(TD=?L)%CW!](
MYL1W6NHH(]YS@)ONX[B3GGGWEGG!ZMTZ[1:A.B,.&VA_V9<ZM7C>WM=$TBL)
M1)633=#TW,+T<Q'ZZE0>)Z=D\2"I:Z$P5E.,?M.5OG+Y.<#9+=_)$M>HY2^I
M9O9L\]9.K0,%JYA?1'&R,!V^ :6Y\.'0YDJ)&0H8R9]]PXM-8@\T[\E9[[![
M 8PQ\H]$6 ?@SLC5US[.G%Y2)E\1UG@_\=N-]8$)WL[Q !' C_\?J7/^O?JU
MG_WGZ6@<)^Z_LP1+13GG=7G63=6'5.;H_>U2U/R6%\P/4SCTJF0D_IH[$U6-
M&NA]&7_'0+HX4&V#E]$8@V,H8*B!C6OKAF-@G1N:"=CGY=5&JD04'8JET>=6
M@L ^?CS]SL[L13^2/JT#.GR1N:G#)@=FPLC14+O;DG+@NIM-RK%>)C1*^JQ/
M?N'F]+=M;_8Z_?Y/-%/^PF'=8=?"^+)#):%+CLH&5CHQF6*X@,]*\-"A/2;^
M5+\L)U)YMM*J".7T2R&$UA3L&6<*('K*"N"_0[[]Q;0PR"31_PZT1M*N:[%)
MYTGD?2,X,,8\6]<\*[B*Z=!'\G20?.E;11IF$3,I\T/1PW,M7*Z-8_$^O3O!
M:1C3ZV&-NKII5I4T!JG? G0U;W?(H>,J.%8]N<#KQJUJSX]_7I3+&@74T+_P
MX-*()EQQ:-,TX*UC687<H8JLSU@]<4#SN>C27XI[Z)\4=\8_*6XS&\0L%S(]
M&N8<1;._JCPD1D^O)C>SR/;N&\:^:;!<GI4\?0 C2F&CBP14UX_IH'A1J-O>
MT30C4)V+[+9=XTI]'"[A-> F_WQ$=3/O@Z1 5PE\H4:4&^;GR5]FON*0KJ\R
M:OJ]^Z,&&T9R3+9[L%FP,L!UC0AJX;K91:)!W$ +GSO/B$NK<,(1^]XU@'ME
MX";EB5GB);JS^LP<)7_'?2 K^L''UZQ>7WTV:)V7Y8(BKX!!_2> Z6C:_K]<
M*:[Z.\]1-?THD@0=(UEVZS-\#\BG!TS\=U6PBVWQ2SX% 8;8STMJI9#BD>^0
MLBW5D"?5M8\FJGX:7HQ8/FG/JP\IZ+-_F=.??AI8KPF <%P6U*(:WB)*(L)4
M2@+]72V<D*LF1^+:3UMT<79M?JRU:2THNN!^6W)SC5_;2$O86L-'Z;8#"PU
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M)!L&Y@_;5=TW23"ZJ:O49D4RS#6GWR3\X(P\'KIB UVGF,)\0@+[:9"_4TY
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MOSW=I#D,V2H!50KX/B]!A_/>DQ+CD_3#2E1>KW,95'U.\W?R3^#V >MB'ZF
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MY-\D/JQ5_#?*,+^ T>9(":1WL#1/E]"JP]HB#;Y4__NV;[)]>9,= NU3FO>
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MWK@/$,^$8),LC*=TVL.,K=O*/)0&NO(98:-!=B+?+Y/#D_"Q$W9DW+[>((B
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MJVW.\YY  X*0>L9/08HQ9,+H;E;TSR!#CR96VJ($Q=5[YM#:%V$O]2CD688
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MF,ISG0A;:1R=HBL'#=X(Q:8EG56+T1<JK#"4L[X]+JB)U5@ZO2-9]W@UKM)
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MH(!X&1=/+OA(:=SIUR2*,1?LFS]9A@8XY&WK'(1+N8"T03M#KF6@M<"V%AE
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MGYQ6KB3"^^DB**M"8,:2Q/#S!P(:^D,,UY</@P;G?*8<W*MVG'SYHN-H&]Z
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M7C)@A3S%6H7<1T>.D-SZX_!N)GU09U8AS9ZEHW6F G'L\WYH-.*\R<X"$_!
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M9N7?GMOD_..3QK*SN&'&Y=A[^^Z"*U@?^[GZ5'TK=T=NIG<]R:-!?C"7BT+
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M>E!ND5*Y40H"F 5Q#),894F01)[/0QNFO=SEU(AU(S%XDB)#2:JT$=J.$0W
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M5UEWW->+?$LJV2*O\R9YW^N\HHM"I?*SK#YCT>*$"&8C)OB9+[G(ZV'JT/1
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M?B:70'8=RW"ZHQX'M.^6M%0^MZ]Y\_/=<A,HK_YN,N;-*:%IDB88<D$2B/R
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M:%Y7NW)=[,KMHV#&V],=X(%9WZ1,5G6A3E8+P0RL0=!N7AJ&&>B  "T2ZZN
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M=K65LRH?*;)R_OKKO$A5PU7%Z^K/95%5<\%BRK*$0S_P!$0101!'.(/$3Z(
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M*@H>Q1*)!(-$Z%!IQ#) (PQ!S#!A(8T82IV*@E\89VI$HL5T#8@^#Z =57B
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M\$<P_8#S2C^.(HQ*3OW@.::NGD_I1VR_K9:KQN=6I4LVG7QAG,B,"0HB01"
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M+O>-&[F@,6(A 1*E.8 RD0!'C(,HE#S,XS0)F7#O@7EIN*D10?\VF!<!M2,
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M*8"0$D H1$!("BGC2&:A4WK^]>&F1DU'I;#:A5CZAH*=13FE3.8B3P".PQQ
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MJKHG1X/7K^X3C%@LQ6=Y6#2Q+I9X5W7E,#]ZOZU<I7,4Y@FEN0113@F ,F.
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M\1CXX[>'PCVQ^YS*?O.Y#T88-XW[G'(GV=MG+^I9L_%L=;!VW<B?7_?7U!L
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M[40YDYB(,". ARP"D*89P!$*02Q%EL9I)E&$W=PBGG >U5,R!M)V>R6_;^G
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M ,9IOPB7FV_H//.I++>"OS<A0I6]:JS:\GQ+'/6.E?.42YE'RM+D2&( 980
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MQ(,#X%RNN&NBEV.GJ'/LU.W#P\I$_WQ:K%?%HBR8R:;YVW+Q(LJUX#.,<)3
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M7_3&923MUJTW')^!5R3[<C>[03P50K%5,MAJ^4:5;GJ,P^AE;EQDG%R-FQX
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M'[KSA2.O:+,?\U:7*\+4I-NZ?/Y*UIN5^O-@SM(X8B+C0H=3*J*-%,>2!&8
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M[-'?!#PO^Z-DYW-Y1?O]#K=LJO=\4Q-&!^-_5I_6?/N<*&<9130B$H$\P0Q
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MZ__9P^25.RRZ'954[&$X9!N'-_O14&54&#M#-ZL-#9.;?/E$BL4L#F5*(D9
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M 2??:=ELNAX[/YL#'"<2M;F\W<,EQ*2S+7>GB(E(DD2F.6!AF@(8L@Q0QE/
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M/.&1#$5DE</2ML.I$:,^DA#&.%B)>54K<6E,D7GP7+D/7>,]< )P.[KS">/
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MP)D,3VKLE;+V>QB56$XJ=SC]3S_4LZ;Y<O%P+U9/^A2QG;8M3'$64PPR2"F
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MC"'EH_Z_[N.%S/6,U9;JJM#!Z_H7JO_]'[2>G,6)(CJ>A8"A) $P903@"%*
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MJ,R2,$4"1QFUCH[K[FMJ$[J]2:GNTQMY'<*@+L#;/<T]@S;PG#^/5Y_XL0O
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ME+QREE7'HQ*5"Q2'[.3T[I7^Y#K/NYI:FU7KLIWD,&,PC %.TAA F!- $ZA
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MZS,.U 4J(QJE:1)1P G- ,1, LS"$(0T@F'$&62"]$TW,,U*GX=A]+U*?9Y
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MY%]_^U/WB?P'Y/O;G_X#4$L#!!0    ( '-)7%1/"=J_TZ@  &+/!P 5
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MA&GFB*0^$4\-)PP8-QF#<*G40*#904(ON+C6X3*$?)L RK.44 6K[7_>3.?
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M),8V$/!JNCQ_G28Q:\N]"$2)&,I11O$02H:HQ+UA(ID\G-G:+#E>WZ*AM7^
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MP9<G5+Y.D>Y]6L:]7JL$HB-%WD!.X$=!R41G].\8TV7JH$!+BXZ?RT$1HV2
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MZY2P-C+B'==$(D,D!"Z)"%39$, YJ--%=T]"6YLF?R)4#J>\)K%Y.VZZZ4V
M\2HZ[@DWB9>N&+1TQ5#$A80;TE(I=)W7('L0V=I$^%&"W4.5U@ >^]=33:+1
M0@#@UJ*T-)WB&-5G$0A8;W0)N)QG5>#8G\9QO<?F;E8J*?=PV"YP1]:$[:;*
MXV%!JI2EEUH0S:)'#KTG@69'3.0E4*&"Y3H5:OO3VLB+AC<U"\V'4E4#-A19
M0P&DU2L4Y:]^?;'LN.E2]-UTP:[[C)_-5N_RLZ]^.BM9JC*.S<_@(\3MCT]
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M33[SW^Y=#^9LM4<6G$2 R"@".J 10R7\-MIQS[FKD]W;15$_@#VU.XQ!Y-\
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MS-<0DGS2IJGXPOZ>2US=/#V^[.E,U![LUS=32F7I ,]?%3F"SH72@U8K0DV
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M<(X1>P/A9S?F<HYRN"@BZ>Z5)]*+0%7FQ"HI2EMG11Q*@8 $*H,.45;*=3Q
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M_/EBM5Z]A?5$FP2N#.DU1AG< XZ2@/L(8P'GM+&:FUBGX>@.@EJR/0<J^QZ
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M.RY"+_#L7&+<<+4J6(81:P-'VQOP*_B\F*77YU^6BZ^;B;N7K4*RCH)R1+?
MZ%P&S8CWW)$83%(L.<MRG=>JCQ U[KU*+4P-K8T&@+535-=YH.1CEDY3DF+B
MN%5X),YQ10R#(".W)IDZ3<Y_3%LK185C^.F'*:AER%T/V)L$EDP0I;F)+6T<
M'<7PV@M!O!2*9<>,TG6:D_4@KE'GZD \](7;@<II&6\O5^OIN5]#NN3M*ZPF
M47)JM5($N MX+@2TY/@_!(4*40AKK:[SR' O,AOUV2IC\&B%-8#&KD4V^@U^
MNBPL/?_LEY^0"V]$2C10HGQY31&-)A8#%:(<5<E#\B)5JJ1YD)Y&_;=A\#6
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M,@Q%G*^4R'N$J'%O!FMA:FAMC&UU2E?-"_RL:S]TGM[E/(UP=[N(E&V0O%Q
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MM7*X!]-$![!ZP,-ZN7%. F(<ZY1'LIM:"$!'GJ-2/-(677BP;6I+GR1G[#S
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M R"N9;<F/F3EM$P*8A"U>%_5F5R<D4TOCA$KUAG>!&GWR!CG=LU)H'2XN#O
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MF0(NNP1%4E#J6 BAT5CY4W%XI@6+KVDI'@&Y8WNC?SJ#%4G**WFZ*:%L!?*
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M,AM0,K$:GFI0)7+,3B V.HD9>K^AIU5O;26Y.XC&PCFWD9.#)F1M6,L@:*8
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M35>7=P_!PL"2[,!9O1<6WO?0WWR=+RZG_[/2ST2+Y+@Q"F1F]>28./+>(Y3
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MND0.;@Z!K#S)C%98 I^#A5A*IO^4=F4\<SA^BKLC'.ZMKG.!8<V'TKM5<$Y
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M# M/@15&>VT2R8 2%%MXMIJ1J(U*R3C+VYR^-S0L?\8O.5U=Y/?EEU)RO*1
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MFLX^KZM=Y[/ED[[CK6R,3B*&M(IOR6L4.H$S)!O+M$7N.<I&WO] #'1LUO9
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M.(=2/'ZNK 7N'OI9)]'G^9BX(XZ2MCRMD<%K>6RT#_XRR[258FV_+@D*.B=
MAP(TNB3)S\>8VQVF-+9[-P,,IK.<ZG3BQ31<U==5^?]R,?T\#1?YS>?\:?X!
M%Y?3./U&KN2D"..D9;3?ZYA!H680!$;0/(E<IR*;M-LEP3U??#XF:Q_(/)PE
MT4P5'>0NGF'O#_Q[^O7JZYO9[ HO-G^X_) 7-Y:!/HTD[8D*CGNFB$>4Y-FF
M&,'++" Y%XQCU@K?YMQI .+'#SU;(G@L+?<+[#57BS_PDG0S^WSOY]><OB^K
M'TZ8S=9I+,"$C.3E) ?.4(1N>2I><XPV-6NC>QSIXX?#(X*ZD8;/&M(3XTR0
M# ,$2>PJ93F@+ DL^<Y%8>U&W*P+^8$TCYME[A_$>^ET[*SS+AO0#<\/>+W9
MA];GBZSP;% X2%C/AHH@86O:AG3A+FLE%(L[3V@<AJ1QYSB.Z00W5E^_)O?M
M?'GY\?:X:&)*%";E O^ONBMK;N/(P>_[7U#5]_&R54IB;67+QU;D/*OZ0,NJ
MR!R'%.WHWR^:(BV:(F5J.*T9O>A!)&?0P =T XW#("--E#& 2X@@%2,%99S+
M\*('X!_)&W<0Y,B&] 1)332(1 S]?'U[/[FC1]1H^^=#A(D.DC-<7&CS?()/
M%2]MASA+U[C8@Z HL@P^TQ&.,5:S3Q2$8!&RM%Y*G95H--SG660.D'*\>=F^
M2"G&PJU.$<@C(S6204(TA@%S:)+U7'KK6S-ABO'M1CC:DW8\E'2F;X+6\YW#
MU1SO9^F<$- ^YK$#FZSCR!_%E.50"&N*@U'6@THUF44Y 2P9II,M.K:[W'LY
M4W:1/F%>WN"'LBEXI'?^AE_QIOM22=@:T[3:VD/MS$;'RM+-/Y]W\]4=TKHK
M*N.HK4P<.*^9AY(E.CW81'KF-<8Z&46V*98?;@VOR40^!Y^/&CB,(_51$V=V
M"WM[K/B7NX_TDE5E>M0I6:D%H*_UP$G)FO!1H"A7=,UV(\DT ?L@Y(^+\['0
M=Z#"^^6 , &'^A2.TRO6A?692XFE3C=EI3J*(H&W!J&@-3ES)DULT]9Y$/+'
M1?\(L!L.^#TQ,';X<WW,/-L<,__\0G*9W?XOW*UVVW6/!^641[(<D+'XVB"[
MC@27%I(35L<LBMD=%7H@M'G4ZUXM"OMBH&LJD*E![-WU#2YNNQGNK*F4)*))
MQ*-4YP_6)%&GI0%=,@O<."5+[ 6R R\<]X)]8C ;0BBO>Q-_^[WY1#8U\LJQ
M5G9+4$IEB%Q$B(9)S9DC-Z)-J&X(ZL=%]>L_P/:#P6OWW^IE1*TH6E;"_S/O
M%HM+9H50V:\F3ZN:+N; H\S D3F9A=)>M*DS''09K_8LT1.'PRG"B9"8:(#X
M8AD7^/>2GO3F:]^+JD?/&"+T^S1A \5Y=U_R$#+C460?,A@1Z3QI23&]+:'>
M=$;-;; LMLG".431R=';G><^W'(HZTTL!%TCTJK;=(0@O 9A58ST+RE#HVZX
MAT@:.>8T!"8>A5$'8?\KL2$G7"P=>E0+B]+R ND@B,@!<4(+7R<Q)Q*WD^!]
ML%"X4$FBUSJ]C+8U,BSW9U5+WGB)QM,671/>8E80>+8@'**3)D5EVXR*V$?-
M1,W)<Y#P$W/R?*9/P#7=7<-#O+*&;&3E"Y*'S:N9326"]N1@NV*#2VT&*A\@
M:%+PZ2'IGT"G#]NGB9YU"(CV9+121Q!"9](K:\$E*\!F87Q1*7/9YL;A($G3
M0E O@?\<1#VX/ST8;4;X)FUS8@R*4K7;:C$0F4$0ND9<#%/)M:DGV4O.Y.#3
M1]1/ Z@'WR< GONNNN<A7=]L1O<(%HTQ"B'5U%55PW5.9/(1#&>2&))C:=,"
M[3$M(P<^A]ZW3F3VY."R5B+R?1(7(D.4=!14/B-XQFT=_:1#]8MRHT:-^Z@9
M.:GI1 D_"9@>[)X 9&K0\T.Y7\GF LKJC$HE*$98LI%!@P](-I(%[229R"C:
M .8Q+5."2Q_Y=H,R>P)P^0WC[>\S\B^7JZAVU: BG3<2Z\3Y6CC)G -?LP"U
MC3KX&*/);>[N'M,R;JWKX!O2B<R>'%RVIJ$P*X5TL9[GHB0M$A&<9P62*E&)
MD+EEK;H'[Z=H7$MSJJ2?!$Y/MH^=Q'+V>14F?8_??K3#OW:?8ZWN^C@/L_0)
MS[OE_&R6SZ^_XMJDYDA+]#7*S1W69&1&6[JN610L^!#0Q[1S0CZ0U=*7@BEA
MJ:_PNY>6Q 2L5?4\/Y2MJ]J5(BKFHTF!CH2Y#B=DT4,PLH N)K.<0G*-XNE[
MR1FW$G[P+>YTED\ -UODUV*)]]TL//RG*L<BW'?V7*N%+9JCT@F\U[0\SAP$
M%0Q$[704:%7$-L4ISR1TY'E%IT.C>SDYC;U;;N>:U,KJJ^5-_?IFOJ[2F2P_
M>N!9UU+[5/M#) 7<9IZ521[%<3U\GW[/N(AI*M^N#;/'QDVM\\)YN@XWF^&"
MQBA1\TU%- Z4,@@NF%33CF(HV= "RE%(V7WRN-'"%\/&20R=P&;V!Q*6,=<V
M=G?;?/GE;ON3>Q>%%>^+)N/K"ZW,AVJ+,9/'DM 64WC:[30X6+[BL32.VX]E
M\.-2(^%,#'9K?R4R+-PY6X?96%(<GR FP\!(KFT("J-N<_!^3,O8.:UMI/X$
MN'J(8.R=[+_$&!++VNJBMAEM"K3I:D;V6VD(+BHPSD:4SH4B^%';V ^/G0X.
M^@BH&X1;8\OYXFX62KG^9TTZ,]IDK218)VI4(VGP)0E(Y S(.OLC6GN4H']\
M[MBE2L-)^@1^36!?6(W'J&>T-W\O[T-.Z_$**W.',7N#-:0E2\4MU^ P,-I+
MK9,^9 RJS=W#DV2-VV1K^'RNP40P 3SMK&&M7"H'9S5J4#9E(%T*$#"3.40;
ME6=":6PS'V O.2.GXPPG[FYHWD\ 0-6_ZV87MUWZ:V-1&0J=HX3$!)VY:H)2
M;>P-(7$>6<Q6NS9NT"-2Q@7. .+=TSVK/Z\G )9JBZ_S=9C?781:HKE:RDJ/
MG.62)V$A^5AKB3T#VN'9JI>VP.!XU&W:1!XDZ2CPV->S:PW"^BE@Z('\>IGW
MH6RY@&L=,\B+RRH"2\0=93,#.K@GR$K2>GQ!*=O<IO^<MO%32P< P2ZTAI7(
MV [5V>V[,/\+U_O]AT(47,^N5N/$PF<2/#O[^&X3%17$&Z-4G;Y)O"+' 8+4
M!K)-A>5LN=]-/CUTM7[T.T<&T,"B[MKS?0HFZT=C_O9[8;4IR03#2==JNR#2
M.@.1]!"<)]Y));35+Y+V_O99O1O<J]KT3F;\! !$2I 0\^*<6/9K=T/?Z.;U
M)[00HI9LLX52/)*V&04N^ +!(R<&"6M8F]J;@R2-O\.=+O'=N6R#L'_L?>V!
M\I4L'N[_-JWJKZ[F>$7.[O=./(M+G5DLP4BP(GAR;^E8X#0O(-!ZSF(D0YN.
MVN!ZO'Q2Y12G >E%^#\M?&W:.KWO9D3,<I:K,7_S#Z95^_ESQ$N6F,TY9.!2
MDF'WZ"#JFN!98F N<.[]<8/9GOGB265%#XZK8?D^@;WO[5:1P";3<JTQOW3S
M>?>MCH )7^B3V[O+H +W*04P1 DH]!Z"M0$"2TZAX%')-K&GYU YJ9S%87;(
M9D(:VZCM6]@ZO_?L:[BFK]\7PRSOU>\R\J2#JNWIM'8U'FPA!M3@M8BR6,O8
M;N3\8 O!9[UX4HD= QBUEGR?@%%;>="_+Q9+S+2$ZN:2L]OEBT_$[L5[_+;Z
M:'%I'<80R;M5A9:F<C'@L[/DYVI1C#9"BE;W><?0-ZF+O6$,60/!3 !NVPY,
M70'I4=6NA^N$RV"L2)K<%^VE!B5*!&=JNE_.+@@C(Y8V2/LI:9.*PP_O3YXN
MCK&WR*V8X!]80X"D-?<3S?Z<+;J;?#;+:Y-]@^?=O'[],FFN,N<.K)?D-S/%
MZ C@. 2E38ZVWJD>EW_=X^63BG$-L%6VYG_['FCK#^J?&!;X[W_]'U!+ 0(4
M Q0    ( '-)7%0!L4P3I>   (O]!0 8              "  0    !E>&AI
M8FET,3 Q-#$P:V9Y,C R,2YH=&U02P$"% ,4    " !S25Q4>I&/(JO$  !@
M= 8 &               @ ';X   97AH:6)I=#$P,34Q,&MF>3(P,C$N:'1M
M4$L! A0#%     @ <TE<5*E:RB;4-P  %W ! !@              ( !O*4!
M &5X:&EB:70Q,#(X,3!K9GDR,#(Q+FAT;5!+ 0(4 Q0    ( '-)7%0/BLR=
M/1$  -]I   8              "  <;= 0!E>&AI8FET,3 R.3$P:V9Y,C R
M,2YH=&U02P$"% ,4    " !S25Q4#2HA=+ 1  #:<@  &
M@ $Y[P$ 97AH:6)I=#$P,S Q,&MF>3(P,C$N:'1M4$L! A0#%     @ <TE<
M5*'TP9K3 @  :@T  !D              ( !'P$" &5X:&EB:70R,3$Q,&MF
M>3(P,C%Q-"YH=&U02P$"% ,4    " !S25Q4;.^9Q14$   ;&   &0
M        @ $I! ( 97AH:6)I=#(S,3$P:V9Y,C R,7$T+FAT;5!+ 0(4 Q0
M   ( '-)7%1J&!"R^0<   LF   9              "  74( @!E>&AI8FET
M,S$Q,3!K9GDR,#(Q<30N:'1M4$L! A0#%     @ <TE<5'2?$28&"   "28
M !D              ( !I1 " &5X:&EB:70S,3(Q,&MF>3(P,C%Q-"YH=&U0
M2P$"% ,4    " !S25Q4.!B'+T,%   5&   &0              @ 'B& (
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M,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ <TE<5 46#(BKL $ >=X" !0
M             ( !>>X& &UR<VXM,C R,3$R,S%?9S$N:G!G4$L! A0#%
M  @ <TE<5+O?LU/XY   %QL! !0              ( !5I\( &UR<VXM,C R
M,3$R,S%?9S(N:G!G4$L! A0#%     @ <TE<5#S#7)Z=+P$ )68, !4
M         ( !@(0) &UR<VXM,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M '-)7%1/"=J_TZ@  &+/!P 5              "  5"T"@!M<G-N+3(P,C$Q
A,C,Q7W!R92YX;6Q02P4&     !( $@#/!   5ET+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
